cluster,concept,cuis
2944,age group ( ≥ nmbr years ) — no . ( % ),C0027362;C0439234;C0441833;C0687744;C1257890;C1510829;C1519504;C1705428;C1705429;C2348001
2944,age group ( ≥ nmbr ) — no . ( % ),C0027362;C2348001
2944,age cohort,C2348001
2943,mean — yr age group — no . ( % ),C0027362;C0439234;C0444504;C2347634;C2348001;C2348143
2943,age — yr age group — no . ( % ),C0027362;C0439234;C2348001
2943,age groups,C0027362
2943,age group 一 ％,C0027362;C2348001
2943,age group — no . ( % ),C0027362;C2348001
2943,age group nmbr,C0027362;C2348001
2943,age group,C0027362;C2348001
2942,azathioprine monotherapy,C0004482
2942,azathioprine ( n = nmbr ),C0004482
2942,azathioprine,C0004482
2942,aza ( n = nmbr ),C0004482
2941,angiography — no . ( % ),C0002978
2941,angiography and revascularization,C0002978
2941,angiography,C0002978
2941,angiographic findings | |,C0002978;C2607943;C2926606;C3539655
2941,angiographic features,C0002978;C1521970;C1706388;C2346469;C2348519
2941,angiographic data and treatment :,C0002978;C1511726;C3245479;C3714741
2941,angiographic data,C0002978;C1511726;C3245479;C3714741
2941,angiographic complications,C0002978;C0009566;C1171258
2941,angiographic characteristics,C0002978;C1521970
2940,diagnostic angiography,C0002978
2940,contrast angiography,C0002978;C0009924;C1979874
2940,additional angiography,C0002978;C1524062
2940,> nmbr ( ml ) additional angiography,C0002978;C0439526;C1524062;C1705224;C3887665
2939,aged ≥ nmbr years,C0001779;C0001792;C0439234;C1999167
2939,aged nmbr y or older,C0001779;C0001792;C1999167
2939,aged a nmbr years,C0001779;C0001792;C1999167
2939,aged ^nmbr years,C0001779;C0001792;C0439234;C1999167
2939,aged < nmbr years,C0001779;C0001792;C0439234;C1999167
2939,age\\yr,C0001779;C0439234
2939,age ≥ nmbr yearsa,C0001779
2939,age — yrf,C0001779
2939,age — yr,C0001779;C0439234
2939,age — y £,C0001779
2939,age — y,C0001779
2939,age   ≥ nmbr   y,C0001779
2939,age ± sd ( yrs ),C0001779;C2699239
2939,age £ nmbr,C0001779
2939,age yrs,C0001779
2939,age yr,C0001779;C0439234
2939,age y,C0001779
2939,age snmbr,C0001779
2939,age s * nmbr yr,C0001779;C0439234
2939,age nmbr y,C0001779
2939,age nmbr nmbr y,C0001779
2939,age nmbr - nmbr yr,C0001779;C0439234
2939,age nmbr - nmbr y ( n = nmbr ),C0001779
2939,age nmbr - nmbr,C0001779
2939,age nmbr + yrs,C0001779
2939,age nmbr + y,C0001779
2939,age nmbr +,C0001779
2939,age nmbr * nmbr yr,C0001779;C0439234
2939,age nmbr,C0001779
2939,age is > nmbr vrs,C0001779
2939,age group ( y ),C0001779;C0441858
2939,age bnmbr y ( n = nmbr ),C0001779
2939,age a nmbr,C0001779
2939,age ^nmbr yrs,C0001779
2939,age ^nmbr,C0001779
2939,age [year],C0001779;C0439234;C0439508
2939,age > nmbr yrs *,C0001779
2939,age > nmbr yrs,C0001779
2939,age > nmbr yr 十,C0001779;C0439234
2939,age > nmbr yr ( % ),C0001779;C0439234
2939,age > nmbr yr,C0001779;C0439234
2939,age > nmbr y * *,C0001779
2939,age > nmbr y *,C0001779
2939,age > nmbr y ( n = nmbr ),C0001779
2939,age > nmbr y ( % ),C0001779
2939,age > nmbr y,C0001779
2939,age > nmbr vears n = nmbr,C0001779
2939,age > nmbr,C0001779
2939,age > = nmbr yrs,C0001779
2939,age > = nmbr,C0001779
2939,age > : nmbr,C0001779
2939,age >,C0001779
2939,age < nmbryrs,C0001779
2939,age < nmbr yrs,C0001779
2939,age < nmbr yr or > nmbr yr,C0001779;C0439234
2939,age < nmbr yr,C0001779;C0439234
2939,age < nmbr y ( n = nmbr ),C0001779
2939,age < nmbr y,C0001779
2939,age < nmbr vears n = nmbr,C0001779
2939,age < nmbr,C0001779
2939,age :,C0001779
2939,age . y,C0001779
2939,age . . . . . . . . y ( n = nmbr ),C0001779
2939,age *,C0001779
2939,age ( yrs ) nmbr - nmbr,C0001779
2939,age ( yrs ) < nmbr,C0001779
2939,age ( yrs ),C0001779
2939,age ( yr ) *,C0001779;C0439234
2939,age ( yr ),C0001779;C0439234
2939,age ( yij,C0001779
2939,age ( year ),C0001779;C0439234;C0439508
2939,age ( y ) ∗,C0001779
2939,age ( y ),C0001779
2939,age ( sd ),C0001779;C2699239
2939,age ( p = o - nmbr ),C0001779
2939,age ' nmbr y ( n nmbr ),C0001779
2939,age ' ^nmbr yrs,C0001779
2939,age & nmbr,C0001779
2939,age $ nmbr yrs,C0001779
2939,age # nmbr yrs,C0001779
2939,age,C0001779
2939,> nmbr yrs of age ( n = nmbr,C0001779
2939,< nmbr yrs of age ( n = nmbr,C0001779
2938,age subgroups,C0001779;C1079230
2938,age subgroup,C0001779;C1079230;C1515021
2938,( b ) age subgroups,C0001779;C1304659
2937,age when diabetes first diagnosed — yr,C0001779
2937,age when diabetes first diagnosed ( years ),C0001779
2937,age at time of first seizure,C0001779;C0036572;C0040223;C0205435;C1279901;C1959629;C3541383;C4553401
2937,age at first seizure,C0001779;C0036572;C0205435;C1279901;C1959629;C4553401
2936,dd ( n = nmbr ),C3538867;C3814791
2936,dd,C3538867;C3814791
2935,id ( n = nmbr ),C0009450;C0600091;C1441613
2935,id,C0009450;C0600091;C1441613
2935,( id,C0009450;C0600091;C1441613
2934,nmbr fnmbrq % ),C0016327
2934,nmbr fnmbrl % nmbr,C0016327
2934,nmbr . nmbrfnmbr . nmbr,C0016327
2934,nmbr . nmbr - nmbr . nmbr % f,C0016327
2934,natalizumab ( n = nmbr ) f,C0016327;C1172734
2934,fnmbr vs placebo,C0016327
2934,f emale,C0016327
2934,f - plasma glucose,C0016327;C0202042;C0455280
2934,f * >,C0016327
2934,f,C0016327
2934,ancestry ( % ) f,C0016327
2934,? f ? n,C0016327
2933,trough fevi l,C0429706;C0444506;C0849974;C1561566;C4528367
2933,nmbr ( fevi nmbr - < nmbr % pred ),C0849974;C1561566;C4528367
2933,nmbr ( fevi ^nmbr % pred ),C0849974;C1561566;C4528367
2933,fevinmbr l,C0429706;C0849974;C1561566;C4528367
2933,fevi percent predicted ( % ),C0429706;C0439165;C0849974;C1561566;C4528367
2933,fevi aucnmbr - nmbrl,C0376690;C0429706;C0849974;C1561566;C4528367
2933,fevi,C0849974;C1561566;C4528367
2932,fp versus other ics,C0016704;C1419068;C1419906;C3541238;C3541412
2932,fp versus no ics,C0016704;C1419068;C1419906;C3541238;C3541412
2932,fp ( n[nmbr ),C0016704;C1419068;C1419906;C3541238;C3541412
2932,fp ( n   = nmbr,C0016704;C1419068;C1419906;C3541238;C3541412
2932,fp ( n [nmbr ),C0016704;C1419068;C1419906;C3541238;C3541412
2932,fp ( n = nmbr ),C0016704;C1419068;C1419906;C3541238;C3541412
2932,fp,C0016704;C1419068;C1419906;C3541238;C3541412
2931,gm,C0017480;C3854019
2931,baseline upgr > nmbr gm / gm ( nmbr mg / mmole ),C0017480;C0168634;C0567349;C1442488;C2348885;C3854019
2931,( gm ),C0017480;C3854019
2930,germany,C0017480
2930,denmbr n = nmbr,C0011198;C0017480;C3541240
2930,de ( n = nmbr ),C0011198;C0017480;C3541240
2930,de,C0011198;C0017480;C3541240
2929,nmbr . nmbr ± l . ot,C0439394;C1318464;C1418208;C1705587;C1706495;C3642217
2929,lnmbr - nmbr vs placebo,C0439394;C1706495;C3642217
2929,lnmbr - nmbr vs lnmbr - nmbr - nmbr,C0439394;C1706495;C3642217
2929,lnmbr,C0439394;C1706495;C3642217
2929,l vs . c,C0439394;C1706495;C3642217
2929,l compared wit,C0439394;C1706495;C3642217
2929,l compared wi,C0043193;C0439394;C1520135;C1706495;C1707455;C3642217
2929,l / ll,C0439394;C1706495;C3642217
2929,l / c,C0439394;C1706495;C3642217
2929,l ( % ),C0439394;C1706495;C3642217
2929,l,C0439394;C1706495;C3642217
2929,( l ) t,C0439394;C1706495;C3642217
2928,enoxaparin only,C0205171;C0206460;C1720467
2928,enoxaparin nmbr mg ( n = nmbr,C0024671;C0026410;C0206460;C0439269;C1960952;C2346927;C4321396;C4521761
2928,enoxaparin / vka n / n ( % ) nmbr / nmbr ( nmbr . nmbr ),C0206460
2928,enoxaparin / vka,C0206460
2928,enoxaparin ( n = nmbr ),C0206460
2928,enoxaparin ( n = nmbr,C0206460
2928,enoxaparin,C0206460
2927,enalapril lcznmbr ( n = nmbr ) ( n = nmbr ),C0014025
2927,enalapril dm = nmbr non - dm = nmbr,C0011816;C0014025;C3250443
2927,enalapril + aliskiren ( n = nmbr ),C0014025;C1120110
2927,enalapril ( n = nmbr ),C0014025
2927,enalapril,C0014025
2926,not - japan n = nmbr,C0022341;C1518422
2926,not - japan,C0022341;C1518422
2926,japan n = nmbr,C0022341
2926,japan and south korea,C0022341
2926,japan,C0022341
2926,calima japan ( n = nmbr ),C0022341
2925,lansoprazole nmbr mg qd,C0024671;C0026410;C0050940;C0332173;C0439269;C1960952;C2346927;C4321396;C4521761
2925,lansoprazole ( n = nmbr ),C0050940
2924,menopause and ht,C0025320;C0567312
2924,menopause and hrt,C0025320;C0567312
2923,ease - nmbr,C1331418
2922,uae ( p,C1519789
2921,plaque ( n,C0011389;C0241148;C0332461;C0333463;C4316797
2920,open — no . ( % ),C0175566
2920,open triple ( n = nmbr ),C0175566
2920,open,C0175566
2919,nyha lll - iv,C0022326;C1261077;C1275491;C4265176
2919,lll / iv,C0022326;C1261077;C4265176
2919,lll - iv,C0022326;C1261077;C4265176
2919,iv nitrates,C0022326;C4265176
2919,iv ( nmbr ),C0022326;C4265176
2919,iv ( n z nmbr ),C0022326;C4265176
2919,iv,C0022326;C4265176
2919,dyspnea at rest ( nyha iv ),C0022326;C0743330;C1275491;C4265176
2919,dual iv,C0022326;C0205173;C1554184;C4265176
2919,class iv / iv - v,C0022326;C0457166;C1880098;C4265176
2918,cyclosporine ( n = nmbr ),C0010592;C0010594
2918,cyclosporin,C0010592;C0010594
2917,ticlopidine ( n = nmbr ),C0040207
2917,ticlopidine,C0040207
2916,current drinker,C0556297
2916,alcohol users,C0556297
2916,alcohol use ( > nmbr drink / wk ),C0001948;C0042153;C0332174;C0439230;C0452428;C0457083;C0556297;C1947944
2916,alcohol consumption ( % ) < nmbr drink / dav,C0001948;C0009830;C0452428;C0556297;C1947907
2916,alcohol > nmbr drinks per week,C0332174;C0439230;C0556297
2915,clopidogrel plus aspirin ( n = nmbr ),C0004057;C0070166;C0332287
2915,clopidogrel plus aspirin % / yr,C0004057;C0070166;C0332287;C0439234
2915,clopidogrel plus aspirin,C0004057;C0070166;C0332287
2915,clopidogrel n / n { % ),C0070166
2915,clopidogrel n / n ( % ),C0070166
2915,clopidogrel + aspirin ( n = nmbr ),C0004057;C0070166
2915,clopidogrel ( n = nmbr nmbr ),C0070166
2915,clopidogrel ( n = nmbr ) n / n ( % ),C0070166
2915,clopidogrel ( n = nmbr ),C0070166
2915,clopidogrel ( n = nmbr,C0070166
2915,aspirin plus clopidogrel ( n = nmbr ),C0004057;C0070166;C0332287
2915,aspirin nmbr clopidogrel,C0004057;C0070166
2915,aspirin i clopidogrel ( n = nmbr,C0004057;C0021966;C0070166;C0221138
2915,aspirin - erdp clopidogrel no . of patients / total no .,C0004057;C0070166
2915,aspirin + clopidogrel ( n = nmbr ) nmbr . nmbr,C0004057;C0070166
2914,timing of clopidogrel loading dose,C0070166;C0449243;C1704250;C3714444
2914,loading dose of clopidogrel or ticlopidine,C0070166;C3714444
2914,hours from clopidogrel loading,C0070166;C0439227;C1708715
2913,clopidogrel or ticlopidine,C0070166
2913,clopidogrel no . of patients % ),C0070166
2913,clopidogrel given before procedure,C0070166
2913,clopidogrel dose on / before pci,C0070166;C0178602;C0869039;C1114758;C4049621
2913,clopidogrel dose,C0070166;C0178602;C0869039;C1114758
2913,clopidogrel / total no . of patients % %,C0070166;C0439175;C0439810
2913,clopidogrel / ticlopidine,C0040207;C0070166
2913,clopidogrel %,C0070166
2913,clopidogrel,C0070166
2912,el,C1416870;C1447747;C1823249;C3811107;C3811848;C3815598
2911,adl,C0001288;C1420005
2910,cyclo,C1172566
2909,chlor,C0308648
2908,chl,C0019829
2907,laa ostium,C0444567
2906,alaska native,C0682125
2905,laci ( n = nmbr ),C1420705;C3273314;C4281721
2905,laci,C1420705;C3273314;C4281721
2904,lama +,C0999593;C1416775
2904,lama ( tiotropium ),C0213771;C0999593;C1416775
2904,lama,C0999593;C1416775
2904,laba / lama,C0999593;C1416775
2903,lipc,C1416867
2902,lis,C2247545
2902,lips,C0023759
2901,limb ( sd ),C0015385;C2699239
2901,limb,C0015385
2900,late load,C0205087
2899,atm - locus,C1708726;C3711796
2899,atm - locm,C3711796
2898,ltg subgroup,C1079230;C1420817;C1515021;C4521367;C4521846
2898,ltg - naive,C1420817;C4521367;C4521846
2898,ltg - exposed,C1420817;C4521367;C4521846
2897,lmnmbr nmbr,C1261082;C1551056
2897,lmnmbr bid ( n = nmbr ),C1261082;C1551056
2897,lm bifurcation treated,C0184906;C1261082;C1551056;C3146289
2897,lm bifurcation not treated,C0184906;C1261082;C1551056;C3146289
2897,left main coronary artery,C1261082
2896,lvh by echo or ecg,C0058928;C0149721;C1655045
2896,lvh - n = nmbr,C0149721
2896,lvh + n = nmbr,C0149721
2896,lvh,C0149721
2896,lv hypertrophy,C0149721
2896,left ventricular hypertrophy — no . ( % ),C0149721;C3484363
2896,left ventricular hypertrophy on echo,C0058928;C0149721;C1655045;C3484363
2896,left ventricular hypertrophy * *,C0149721;C3484363
2896,left ventricular hypertrophy ( % ),C0149721;C3484363
2896,left ventricular hypertrophy,C0149721;C3484363
2895,lvh by echocardiography,C0013516;C0149721
2895,lvh by echocardiogram,C0013516;C0149721;C2243117
2895,lvh ( from echocardiogram ),C0013516;C0149721;C2243117
2894,serum haemoglobin anmbrc concentration ( % ),C0019016;C0683149
2894,qualifying hbanmbrc ( % ),C0019016;C1514624;C1825777;C3538758
2894,nmbr % < hbanmbrc < = nmbr % ( n nmbr nmbr ),C0019016;C1825777;C3538758
2894,nmbr % < hbanmbrc < = nmbr %,C0019016;C1825777;C3538758
2894,mean hbanmbrc,C0019016;C0444504;C1825777;C2347634;C2348143;C3538758
2894,hemoglobin a,C0019016
2894,hbanmbrca,C0019016;C1825777;C3538758;C3887642
2894,hbanmbrc ≤ nmbr . nmbr % without gi adverse reactions,C0019016;C0559546;C1708130;C1825777;C3538758;C3539617;C4050121
2894,hbanmbrc ≤ nmbr . nmbr %,C0019016;C1825777;C3538758
2894,hbanmbrc   baseline ( % ),C0019016;C0168634;C1442488;C1825777;C3538758
2894,hbanmbrc   at randomization,C0019016;C0034656;C1825777;C3538758
2894,hbanmbrc   ( % ),C0019016;C1825777;C3538758
2894,hbanmbrc subgroups,C0019016;C1079230;C1825777;C3538758
2894,hbanmbrc strata,C0019016;C1825777;C3538758
2894,hbanmbrc nmbr - < = nmbr %,C0019016;C1825777;C3538758
2894,hbanmbrc nmbr % - < nmbr % ( n - nmbr ),C0019016;C1825777;C3538758
2894,hbanmbrc levels,C0019016;C0441889;C1825777;C3538758
2894,hbanmbrc category,C0019016;C0683312;C1825777;C3538758;C3889287
2894,hbanmbrc categories,C0019016;C0683312;C1825777;C3538758
2894,hbanmbrc at baseline :,C0019016;C0168634;C1442488;C1825777;C3538758
2894,hbanmbrc at baseline,C0019016;C0168634;C1442488;C1825777;C3538758
2894,hbanmbrc \n ,C0019016;C1825777;C3538758
2894,hbanmbrc > nmbr · nmbr %,C0019016;C1825777;C3538758
2894,hbanmbrc > nmbr . nmbr %,C0019016;C1825777;C3538758
2894,hbanmbrc > nmbr % level,C0019016;C0441889;C0456079;C1547707;C1825777;C2946261;C3538758
2894,hbanmbrc > nmbr % ( n nmbr nmbr ),C0019016;C1825777;C3538758
2894,hbanmbrc > nmbr %,C0019016;C1825777;C3538758
2894,hbanmbrc > = nmbr %,C0019016;C1825777;C3538758
2894,hbanmbrc < nmbr . nmbr %,C0019016;C1825777;C3538758
2894,hbanmbrc < nmbr % level,C0019016;C0441889;C0456079;C1547707;C1825777;C2946261;C3538758
2894,hbanmbrc < nmbr % ( n - nmbr ),C0019016;C1825777;C3538758
2894,hbanmbrc < nmbr %,C0019016;C1825777;C3538758
2894,hbanmbrc < = nmbr % ( n nmbr nmbr ),C0019016;C1825777;C3538758
2894,hbanmbrc < = nmbr %,C0019016;C1825777;C3538758
2894,hbanmbrc ( sd ),C0019016;C1825777;C2699239;C3538758
2894,hbanmbrc ( n ),C0019016;C1825777;C3538758
2894,hbanmbrc ( % ) *,C0019016;C1825777;C3538758
2894,hbanmbrc ( % ),C0019016;C1825777;C3538758
2894,hbanmbrc,C0019016;C1825777;C3538758
2894,hba „ ( % ),C0019016;C1825777;C3538758
2894,hba,C0019016;C1825777;C3538758
2894,any hbanmbrc,C0019016;C1825777;C3538758
2893,mg daily ),C0024671;C0026410;C0332173;C0439269;C1960952;C2346927;C4321396;C4521761
2893,daily exercise ( % ),C0332173
2893,daily bowel movements,C0011135;C0332173
2893,daily,C0332173
2892,qd,C0332173
2892,dnmbr vs warfarin rr ( nmbr % ci,C0073187;C0332173;C4484261
2892,dnmbr vs warfarin,C0073187;C0332173;C4484261
2892,dnmbr % ( n / n ),C0073187;C0332173;C4484261
2892,d nmbr mg vs . warfarin,C0024671;C0026410;C0073187;C0332173;C0439269;C1960952;C2346927;C4321396;C4484261;C4521761
2892,d includes cardiac glycosides,C0073187;C0332173;C4484261
2892,d / mi / idr / st,C0036056;C0073187;C0332173;C3272372;C3810814;C4484261
2892,d / mi / idfvst,C0073187;C0332173;C3810814;C4484261
2892,d,C0073187;C0332173;C4484261
2891,ldl : hdl ratio,C0428621
2891,ldl - to - hdl cholesterol ratio,C0008377;C0428621;C1171408
2891,ldl - c : hdl - c ratio,C0428621
2891,ldl - c / hdl - c ratio,C0428621
2890,ldl - c goal attainment,C0680230
2890,dual bp / ldl - c goal attainment,C0037623;C0205173;C0680230;C1415692;C1554184;C1708288;C4318478
2889,fluticasone propionate / salmeterol fdc,C0340427;C1413520;C1622832;C3539652
2889,fdc nmbr / nmbr   μ g ( n   =   nmbr ),C0340427;C0439267;C1413520;C3539652
2889,fdc nmbr / nmbr pg vs placebo,C0030827;C0072225;C0340427;C1266240;C1413520;C3539652
2889,fdc nmbr / nmbr pg vs formoterol nmbr pg,C0030827;C0072225;C0340427;C1266240;C1413520;C3539652
2889,fdc nmbr / nmbr pg vs aclidinium nmbr pg,C0030827;C0072225;C0340427;C1266240;C1413520;C3539652
2889,fdc nmbr / nmbr pg,C0030827;C0072225;C0340427;C1266240;C1413520;C3539652
2888,rsg nmbr mg / day,C0439422
2888,no . of nmbr - mg acetaminophen tablets / day,C0439422;C1243102
2888,nmbr mg / day,C0439422
2888,nmbr mg / d ( n = nmbr ),C0439422
2888,mg / day,C0439422
2888,itca nmbr nmbr mg / day ( n = nmbr ),C0165330;C0439422
2888,ind nmbr mg q . d . n = nmbr,C0439422;C4049864
2888,i - nmbr mg / d ( n = nmbr ),C0021966;C0024671;C0026410;C0152277;C0221138;C0439269;C0439422;C1960952;C2346927;C4321396;C4521761
2888,dose ( mg / day ),C0178602;C0439422;C0869039;C1114758
2888,brv nmbr   mg / day,C0155502;C0439422
2888,brv nmbr mg / day ( n = nmbr ),C0155502;C0439422
2888,brv nmbr mg / day ( n =,C0155502;C0439422
2888,brv > nmbr mg / day,C0155502;C0439422
2888,> nmbr mg / day,C0439422
2888,> nmbr mg / d peq,C0439422
2888,> nmbr . nmbr mg / day,C0439422
2888,< nmbr mg / day,C0439422
2888,< nmbr mg / d peq,C0439422
2887,nmbr mg / day early - start - delayed start,C0439422
2887,nmbr mg / day early - start - delayed - start,C0439422
2887,nmbr mg / day early - start,C0439422
2887,nmbr mg / day delayed - start,C0439422
2887,nmbr mg / day - placebo,C0032042;C0439422;C1696465;C1706408
2886,ff nmbr   µ g,C0439267;C4554348
2886,ff nmbr pgod,C4554348
2886,ff nmbr % ( - nmbr %,C4554348
2886,ff / vi nmbr mg / nmbr mg ( n = nmbr ),C0205999;C1319635;C4554348
2886,ff / vi nmbr / nmbr   µ g,C0205999;C0439267;C4554348
2886,ff / vi nmbr . nmbr,C0205999;C4554348
2886,ff / vi nmbr % ( nmbr %,C0205999;C4554348
2886,ff / vi nmbr % ( - nmbr %,C0205999;C4554348
2886,ff / vi,C0205999;C4554348
2886,ff - nmbr % ( - nmbr %,C4554348
2886,ff - blocker,C4554348
2886,difference ff / vi versus uc,C0205999;C1705241;C1705242;C4554348
2885,nmbr - nmbr hours,C0439227
2885,nmbr - hour ppg,C0439227;C0564385;C1418888
2885,nmbr - hour masbp,C0439227;C0564385
2885,nmbr - hour madbp,C0439227;C0564385
2885,aspirin < nmbr hours,C0004057;C0439227
2884,^nmbr hrs,C1568891
2884,> nmbr hrs,C1568891
2884,> nmbr : nmbr hrs : min ( n = nmbr ),C0702093;C1524029;C1568891;C3813700
2884,< nmbr hrs,C1568891
2883,high titre ( > nmbr times of uln ),C0040223;C0205250;C0475208;C1299351;C1519815;C1632851;C2700149;C3887512;C3889660;C4321237;C4522209
2883,crp   ≤   uln,C1519815;C3890735;C4048285
2883,crp   >   uln,C1519815;C3890735;C4048285
2883,cpk > nmbr times uln,C0040223;C1519815;C1632851
2883,> nmbruln,C1519815
2882,anemia — no . ( % ) | |,C0002871;C1000483;C4554633
2882,anemia ( % ),C0002871;C1000483;C4554633
2882,anemia,C0002871;C1000483;C4554633
2881,albumin ( mg / dl ),C0001924;C0439269
2881,albumin,C0001924
2880,minority,C0026192
2879,algorithm nmbr,C0002045;C1553907
2878,abnormal angiogram,C0002978;C0205161;C1548816;C2347472;C2699333;C3891555;C4255126
2878,abnormal,C0205161;C2347472;C2699333
2877,hemoglobin 一 g / dl,C0019046;C0439267;C1319312;C3642216
2877,hemoglobin — g / dl,C0019046;C0439267;C1319312;C3642216
2877,hemoglobin ale *,C0019046;C0678386;C2632076
2877,hemoglobin ale,C0019046;C0678386;C2632076
2877,hemoglobin aj^ ( % ),C0004486;C0019046;C0230613
2877,hemoglobin ( gm / dl ),C0017480;C0019046;C3642216;C3854019
2877,hemoglobin ( gl ' ),C0018229;C0019046;C1423073;C1427674
2877,hemoglobin ( g / dl ),C0019046;C0439267;C1319312;C3642216
2877,hemoglobin ( < nmbr men,C0019046;C0025266
2877,hemoglobin,C0019046
2877,haemoglobin ( mg / dl ),C0019046;C0439269
2877,haemoglobin ( g / dl ),C0019046;C0439267;C1319312;C3642216
2877,haemoglobin,C0019046
2877,glyeated haemoglobin,C0019046
2877,for combined hemoglobin groups,C0019046;C0205195
2876,mean body - mass indexj,C0444504;C0518010;C2347634;C2348143
2876,body mass indext,C0518010
2876,body mass indexf  < nmbr,C0518010
2876,body mass indexf,C0518010
2876,body mass indexc,C0518010
2876,body mass indexb,C0518010
2876,body mass indexa,C0518010
2876,body mass,C0518010
2876,body - mass indexj,C0518010
2876,body - mass indexf,C0518010
2875,body weiqht,C0242821;C0460148;C1268086;C4082212
2875,body weighta,C0242821;C0460148;C1268086;C4082212
2875,body massindex,C0242821;C0460148;C1268086;C4082212
2874,systolic blood pressurea,C0005767;C0005768;C0039155;C0229664
2874,diastolic blood pressurea,C0005767;C0005768;C0012000;C0229664
2874,blood oxygenation,C0005767;C0005768;C0229664;C0231940;C0282636
2874,blood bilirubin increased,C0005437;C0005767;C0005768;C0229664
2874,baseline diastolic blood,C0005767;C0005768;C0012000;C0168634;C0229664;C1442488
2874,any blood,C0005767;C0005768;C0229664
2873,normalized womac score,C0449820;C1882115;C4050231
2873,normalized,C1882115
2872,losmapimod ( n = nmbr ),C3272847
2872,losmapimod,C3272847
2871,nontraumatic leg or foot amputation,C0023216;C1140621
2871,lower limbs,C0023216
2871,lower limb fractures,C0023216
2871,lower limb fracture,C0016658;C0023216;C0441994;C0596838;C1548802;C2003888
2871,lower - limb arterial — no . ( % ),C0023216
2870,obese ( bmi £ nmbr ),C0028754;C0578022
2870,nmbr < bmi < nmbr,C0578022
2870,bmi nmbr nmbr - nmbr nmbr,C0578022
2870,bmi nmbr - nmbr - nmbr nmbr,C0578022
2870,bmi nmbr - nmbr - nmbr - nmbr,C0578022
2870,bmi > nmbr — no . { % ) $,C0578022
2870,bmi > nmbr — no . ( % ) f,C0578022
2870,bmi > nmbr obese,C0578022
2870,bmi > nmbr ( % ),C0578022
2870,bmi > = nmbr,C0578022
2870,bmi < = nmbr,C0578022
2870,bmi ( sd ),C0578022;C2699239
2870,bmi ( nmbr . nmbr  nmbr . nmbr ),C0578022
2870,bmi ( kg / rrr ),C0022718;C0439209;C0578022;C4054209
2869,nmbr bmi,C0578022
2869,bmi^,C0578022
2869,bmi nmbr,C0578022
2869,bmi distribution,C0520511;C0578022;C1704711
2869,bmi anmbr,C0578022
2869,bmi > nmbr,C0578022
2869,bmi < nmbr,C0578022
2869,bmi,C0578022
2868,mean body - mass index ( kg / mq,C0005893;C0022718;C0024853;C0439209;C0444504;C0578022;C1305855;C2347634;C2348143;C4054209
2868,bodymass index ( kg / mnmbr ),C0005893;C0578022;C1305855;C1532718
2868,body mass indexnmbr,C0005893;C0578022;C1305855
2868,body mass index^,C0005893;C0578022;C1305855
2868,body mass index subgroups,C0005893;C0578022;C1079230;C1305855
2868,body mass index group ( ≥ nmbr kg / mnmbr ) — no . ( % ),C0005893;C0022718;C0439209;C0441833;C0441847;C0578022;C0687744;C1257890;C1305855;C1519504;C1532718;C1705428;C1705429;C4054209
2868,body mass index group ( kg / mnmbr ) ≥ nmbr kg / mnmbr — no . ( % ),C0005893;C0022718;C0439209;C0441833;C0578022;C0687744;C1257890;C1305855;C1519504;C1705428;C1705429;C1709500;C4054209
2868,body mass index category,C0005893;C0578022;C0683312;C1305855;C3889287
2868,body mass index [kg / mnmbr],C0005893;C0578022;C1305855;C1532718
2868,body mass index > nmbrt,C0005893;C0578022;C1305855
2868,body mass index > nmbr — no . ( % ) f,C0005893;C0578022;C1305855
2868,body mass index > nmbr kg / mnmbr *,C0005893;C0578022;C1305855;C1532718
2868,body mass index > nmbr kg / mnmbr,C0005893;C0578022;C1305855;C1532718
2868,body mass index > nmbr kg / m,C0005893;C0578022;C1305855;C1532718
2868,body mass index > nmbr,C0005893;C0578022;C1305855
2868,body mass index < nmbr kg / mnmbr,C0005893;C0578022;C1305855;C1532718
2868,body mass index :,C0005893;C0578022;C1305855
2868,body mass index - kg / mnmbrt,C0005893;C0578022;C1305855;C1532718
2868,body mass index +,C0005893;C0578022;C1305855
2868,body mass index *,C0005893;C0578022;C1305855
2868,body mass index ( range ) ( kg / mnmbr ),C0005893;C0578022;C1305855;C1514721;C1532718;C2348147;C3542016
2868,body mass index ( kgm _nmbr ),C0005893;C0578022;C1305855
2868,body mass index ( kg / nr ),C0005893;C0022718;C0027496;C0439209;C0578022;C1305855;C3844738;C4054209
2868,body mass index ( kg / mnmbr ) ∗,C0005893;C0578022;C1305855;C1532718
2868,body mass index ( kg / mnmbr ) baseline systolic blood,C0005767;C0005768;C0005893;C0039155;C0168634;C0229664;C0578022;C1305855;C1442488;C1532718
2868,body mass index ( kg / mnmbr ) - mean ± sd,C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239
2868,body mass index ( kg / mnmbr ) * ',C0005893;C0578022;C1305855;C1532718
2868,body mass index ( kg / mnmbr ),C0005893;C0578022;C1305855;C1532718
2868,body mass index ( kg / ma ),C0005893;C0022718;C0024443;C0439209;C0578022;C1305855;C3887485;C4054209
2868,body mass index ( kg / m^ ) ^,C0005893;C0578022;C1305855;C1532718
2868,body mass index ( kg / m^ ),C0005893;C0578022;C1305855;C1532718
2868,body mass index ( kg / m “ ) ^,C0005893;C0578022;C1305855;C1532718
2868,body mass index ( kg / m ’ ) ^,C0005893;C0578022;C1305855;C1532718
2868,body mass index ( kg / m ),C0005893;C0578022;C1305855;C1532718
2868,body mass index ( bmi ),C0005893;C0578022;C1305855
2868,body mass index ( bmi  kg / mnmbr )  n ( % ) < nmbr kg / mnmbr,C0005893;C0022718;C0439209;C0578022;C1305855;C1709500;C4054209
2868,body mass index  mean ± sd ( kg / mnmbr ),C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239
2868,body mass index  mean + sd ( kg / m ),C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239
2868,body mass index,C0005893;C0578022;C1305855
2868,body - mass index^ :,C0005893;C0578022;C1305855
2868,body - mass index^ ,C0005893;C0578022;C1305855
2868,body - mass index^,C0005893;C0578022;C1305855
2868,body - mass index ”,C0005893;C0578022;C1305855
2868,body - mass index — no . ( % ) : i :,C0005893;C0578022;C1305855
2868,body - mass index — no . ( % ) $,C0005893;C0578022;C1305855
2868,body - mass index §,C0005893;C0578022;C1305855
2868,body - mass index categories — no . ( % ) : c,C0005893;C0578022;C0683312;C1305855
2868,body - mass index \ kg / mnmbr,C0005893;C0578022;C1305855;C1532718
2868,body - mass index > nmbr kg / nrn,C0005893;C0022718;C0439209;C0578022;C1305855;C1425210;C4054209
2868,body - mass index > nmbr,C0005893;C0578022;C1305855
2868,body - mass index : ! :,C0005893;C0578022;C1305855
2868,body - mass index - kg / mnmbr,C0005893;C0578022;C1305855;C1532718
2868,body - mass index - ! ',C0005893;C0578022;C1305855
2868,body - mass index *,C0005893;C0578022;C1305855
2868,body - mass index ) -,C0005893;C0578022;C1305855
2868,body - mass index ) ',C0005893;C0578022;C1305855
2868,"body - mass index ) """,C0005893;C0578022;C1305855
2868,body - mass index ),C0005893;C0578022;C1305855
2868,body - mass index ( kg / mq,C0005893;C0022718;C0024853;C0439209;C0578022;C1305855;C4054209
2868,body - mass index ( kg / mnmbr ) t,C0005893;C0578022;C1305855;C1532718
2868,body - mass index ( kg / mnmbr ) *,C0005893;C0578022;C1305855;C1532718
2868,body - mass index ( kg / mnmbr ) ( mean,C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143
2868,body - mass index ( kg / mnmbr ),C0005893;C0578022;C1305855;C1532718
2868,body - mass index ( kg / mj ) previous diagnosis,C0005893;C0022718;C0332132;C0439209;C0439254;C0578022;C1305855;C4054209;C4284025
2868,body - mass index ( kg / m ’ ),C0005893;C0578022;C1305855;C1532718
2868,body - mass index ( kg / m   nmbr ),C0005893;C0578022;C1305855;C1532718
2868,body - mass index ( kg / m - ) !,C0005893;C0578022;C1305855;C1532718
2868,body - mass index ( kg / m - ),C0005893;C0578022;C1305855;C1532718
2868,body - mass index ( kg / m ' ),C0005893;C0578022;C1305855;C1532718
2868,body - mass index ( kg / cmnmbr ),C0005893;C0578022;C1305855;C4054689
2868,body - mass index $,C0005893;C0578022;C1305855
2868,body - mass index  !  waist - to - hip ratio,C0005893;C0205682;C0578022;C1305855
2868,body - mass index  ! ,C0005893;C0578022;C1305855
2868,body - mass index,C0005893;C0578022;C1305855
2868,( a ) bmi subgroups,C0578022;C1079230
2867,mean qmax score by bmi ( < nmbr / < nmbr to < nmbr / < nmbr kg / mnmbr ),C0578022;C3533236
2867,mean iief ef score mean iief domain score by bmi ( < nmbr / < nmbr to < nmbr / < nmbr kg / mnmbr ),C0578022;C1880389;C1883221;C3533236;C3541951;C3641331
2867,bmi indicates body mass index  sbp  systolic blood pressure  dbp  lipoprotein ( a ) . ldl - c was calculated with the friedewald formula . ' hypertension and diabetes were based on physician diagnosis . ! smoker includes current and past smokers .,C0578022
2866,olodaterol nmbr gg ( n = nmbr ),C0017454;C0018370;C2934193
2866,indacaterol nmbr gg qd,C0017454;C0018370;C0332173;C1722260
2866,ind nmbr gg q . d . n / n ( % ),C0017454;C0018370;C4049864
2866,gly nmbr . nmbr gg b . i . d n / n ( % ),C0017454;C0018370;C0152277;C1415124
2866,gg,C0017454;C0018370
2866,formoterol nmbr gg bid,C0017454;C0018370;C0060657
2866,formoterol nmbr gg ( n = nmbr ),C0017454;C0018370;C0060657
2866,ff nmbr gg ( n = nmbr,C0017454;C0018370;C4554348
2866,ff / vi nmbr / nmbr gg ( n = nmbr,C0017454;C0018370;C0205999;C4554348
2866,ag + gg,C0002037;C0017454;C0018370;C0051080;C0152305;C3888235
2865,tg ’,C0337445
2865,tg §,C0337445
2865,tg > nmbr . nmbr,C0337445
2865,tg > nmbr . hdl < nmbr ( mg / dl ) ( / ? = nmbr ),C0337445;C0439269;C3715113
2865,tg < nmbr,C0337445
2865,tg < = nmbr . nmbr,C0337445
2865,tg +,C0337445
2865,tg *,C0337445
2865,tg,C0337445
2864,stemi ( % ),C1536220;C3538872
2864,stemi,C1536220;C3538872
2864,st - elevation myocardial infarction,C1536220;C3538872
2864,prior stemi,C0332152;C1536220;C2826257;C3538872
2864,no prior stemi,C0332152;C1536220;C2826257;C3538872
2864,myocardial infarction without st - segment elevation — no . ( % ),C1536220
2863,st - segment — elevation myocardial infarction,C1536220
2863,st - segment elevation myocardial infarction,C1536220
2863,st - segment - elevation myocardial infarction — no . ( % ),C1536220
2863,non — st - segment — elevation myocardial infarction,C0441635;C1518422;C1536220;C1536221;C1536222;C3537184;C4255010
2863,non - st - segment elevation myocardial infarction,C0441635;C1518422;C1536220;C1536221;C1536222;C3537184;C4255010
2862,qualifying nstemi,C1514624;C3537184;C4255010
2862,nstemi ( n = nmbr,C3537184;C4255010
2862,nstemi ( % ),C3537184;C4255010
2862,nstemi,C3537184;C4255010
2862,nste - mi,C3537184;C4255010
2862,non - stemi,C3537184
2862,non - st - elevation myocardial infarction,C1536221;C1536222;C3537184;C4255010
2861,plus metformin,C0025598;C0332287
2861,on non ‐ metformin aha,C0025598;C0050451;C0772110;C1518422
2861,on metformin ir or metformin xr nmbr   mg / d,C0022065;C0022071;C0025598;C1448132
2861,not on metformin,C0025598;C1518422
2861,no metformin,C0025598
2861,metformin ± other oral anti - dm drugs,C0025598
2861,metformin,C0025598
2860,metformin dose,C0025598;C0178602;C0869039;C1114758
2860,metformin alone,C0025598
2860,metformin - dose,C0025598;C0178602;C0869039;C1114758
2860,mean ( s . d . ) metformin dose †,C0025598;C0178602;C0444504;C0869039;C1114758;C2347634;C2348143
2860,distribution of metformin dose at randomization,C0025598;C0178602;C0520511;C0869039;C1114758;C1704711
2859,metformin 一 no . ( % ),C0025598
2859,metformin — no . ( % ),C0025598
2859,metformin open - label *,C0025598
2859,metformin only,C0025598;C0205171;C1720467
2859,metformin monotherapy,C0025598
2859,metformin ? su,C0025598;C0038642;C1705534
2859,metformin : no / yes,C0025598
2859,metformin + sulphonylureas,C0025598;C0038766
2859,metformin + su + tzd,C0025598;C0038642;C1705534
2859,metformin + su,C0025598;C0038642;C1705534
2859,metformin ( n nmbr nmbr ),C0025598
2859,metformin ( n = nmbr ),C0025598
2859,metformin ( hdm ),C0025598
2859,insulin + metformin + sulphonylureas,C0021641;C0025598;C0038766;C1533581;C1579433;C3714501
2858,total cholesterol / hdl - c,C0023822;C0201950;C0439175;C0439810;C0543421;C3715113
2858,total - c : hdl - c,C0439175;C0439810;C3715113
2858,non - hdl choleslerol,C1518422;C3715113
2858,ldl - c : hdl - c,C3715113
2858,ldl - c / hdl - cx,C3715113
2858,ldl - c / hdl - c,C3715113
2858,hdl choleslerol,C3715113
2857,hdlnmbr - c,C3715113
2857,hdlnmbr,C3715113
2857,hdl - cy,C0010622;C0332298;C2239193;C3715113
2857,hdl - cd,C0007928;C0034283;C3715113;C4552032
2857,hdl - c,C3715113
2857,hdl *,C3715113
2857,hdl,C3715113
2856,overall dlqi scorenmbr,C0282416;C1561607;C3899393
2856,overall dlqi score,C0282416;C1561607;C3899393
2856,mean dlqi score ( nmbr % ci ),C0444504;C2347634;C2348143;C3899393
2856,dlqi §,C3899393
2856,dlqi score,C3899393
2856,dlqi ( nmbr - nmbr ),C3899393
2856,dlqi,C3899393
2855,without p blockers,C0369773;C2603361
2855,with p blockers,C0369773;C2603361
2855,pnmbrznmbr ( n = nmbr ),C0369773;C2603361
2855,pnmbrynmbr antagonists,C0243076;C0369773;C2603361
2855,pnmbr vs usual care,C0369773;C2603361
2855,pnmbr vs placebo,C0369773;C2603361
2855,pnmbr vs no treatment nmbr,C0369773;C2603361
2855,p   vs . placebo,C0369773;C2603361
2855,p vs placebo,C0369773;C2603361
2855,p valuey,C0369773;C2603361
2855,p valuer,C0369773;C0401806;C2603361
2855,p valuej ',C0369773;C2603361
2855,p valued,C0369773;C2603361
2855,p valuec,C0369773;C2603361
2855,p valueb,C0369773;C2603361
2855,p valuea,C0369773;C2603361
2855,p vaiue,C0369773;C2603361
2855,p nmbr interaction women vs men,C0043210;C0369773;C1704675;C2603361
2855,p nmbr interaction,C0369773;C1704675;C2603361
2855,p interaction women vs men,C0043210;C0369773;C1704675;C2603361
2855,p inter,C0369773;C2603361
2855,p int . f,C0016327;C0369773;C2603361;C3272375
2855,p inleraclion,C0369773;C2603361
2855,p for interaction *,C0369773;C1704675;C2603361
2855,p for interaction,C0369773;C1704675;C2603361
2855,p for inter - act,C0369773;C2603361
2855,p blockersubgroup,C0369773;C2603361
2855,p blockers ( % ),C0369773;C2603361
2855,p blockers,C0369773;C2603361
2855,p blocker *,C0369773;C2603361
2855,p blocker,C0369773;C2603361
2855,p between age groups,C0001779;C0027362;C0369773;C0441849;C1959644;C2603361
2855,p [int],C0369773;C2603361;C3272375
2855,p < nmbr . nmbr ) between the study groups in any of the baseline characteristics . ace,C0369773;C0441849;C0557651;C0681848;C1959644;C2603343;C2603361
2855,p : interaction,C0369773;C1704675;C2603361
2855,p / interaction,C0369773;C1704675;C2603361
2855,p . o ),C0369773;C2603361
2855,p . interaction,C0369773;C1704675;C2603361
2855,p - valuec,C0369773;C2603361
2855,p - valueb,C0369773;C2603361
2855,p - valuea,C0369773;C2603361
2855,p - val . ( nmbr ),C0042285;C0369773;C0523975;C2603361
2855,p - sitosterol / total c ( | imol / mmol ),C0037215;C0220914;C0369773;C0439175;C0439190;C0439810;C2603361
2855,p - sitosterol / lathosterol,C0037215;C0064673;C0220914;C0369773;C2603361
2855,p - interaction,C0369773;C1704675;C2603361
2855,p - interactio n,C0369773;C2603361
2855,p - inter,C0369773;C2603361
2855,p - inte faction,C0369773;C2603361
2855,p - int .,C0369773;C2603361;C3272375
2855,p - int,C0369773;C2603361;C3272375
2855,p - heterogeneity,C0019409;C0242960;C0369773;C2603361
2855,p - gp use,C0042153;C0369773;C0457083;C1705010;C1947944;C2603361;C3811116
2855,p - for interaetion,C0369773;C2603361
2855,p - blockers ( % ),C0369773;C2603361
2855,p - blockers,C0369773;C2603361
2855,p - blocker yes,C0369773;C1549445;C1705108;C1710701;C2603361
2855,p - blocker use,C0042153;C0369773;C0457083;C1947944;C2603361
2855,p - blocker intake at randomisation ( n = nmbro ),C0034656;C0369773;C1512806;C2603361
2855,p - blocker intake at randomisation ( n = nmbr ),C0034656;C0369773;C1512806;C2603361
2855,p - blocker ( % ),C0369773;C2603361
2855,p - blocker,C0369773;C2603361
2855,p +,C0369773;C2603361
2855,p *,C0369773;C2603361
2855,p ) atients with > nmbr exacerbations resulting in emergency department visit,C0369773;C2603361;C4086268
2855,p ( women vs men ),C0043210;C0369773;C2603361
2855,p ( losartan versus placebo ),C0126174;C0369773;C2603361
2855,p ( inter - action ),C0205103;C0369773;C0441472;C1548610;C2603361;C3266814
2855,p ( inter ),C0369773;C2603361
2855,p,C0369773;C2603361
2855,no p - blocker intake at randomisation ( n = nmbr ),C0034656;C0369773;C1512806;C2603361
2855,* p for heterogeneity of treatment effect between tertiles > nmbr . nmbr .,C0019409;C0242960;C0369773;C1518681;C2603361
2855,* p < nmbr . nmbr for eze / simva ( pooled across doses ) vs . simva ( pooled across doses ) for the entire cohort data are presented as least squares mean ± standard error ( † median ± se for tg ) for the entire cohort and also for each selected subgroup simva = simvastatin  eze = ezetimibe  tc = total cholesterol  tg = triglycerides  hdl - c = high - density lipoprotein - cholesterol  non - hdl - c = non - high - density lipoprotein cholesterol  apo = apolipoprotein,C0369773;C2603361
2855,* p < nmbr . nmbr for between - treatment difference with same dose of simvastatin for entire cohort data are expressed as least squares mean ± standard error simva = simvastatin  eze = ezetimibe  chd = coronary heart disease,C0369773;C2603361
2854,total score on the sgrq - c  i ,C0021966;C0221138;C2964552;C3826872
2854,stratum i,C0021966;C0221138
2854,period i,C0021966;C0221138;C0439531;C1948053
2854,pde - nmbri monotherapy,C0021966;C0221138
2854,pde - nmbri,C0021966;C0221138
2854,p for i,C0021966;C0221138;C0369773;C2603361
2854,other ' i ',C0021966;C0221138
2854,no ace - i / arb,C0021966;C0221138;C1452534;C3888198;C4284014
2854,nmbrinmbr ( nmbri . nmbr ),C0021966;C0221138
2854,nmbr — — bh — i,C0004684;C0004952;C0021966;C0221138;C1412800;C2986890;C4284594;C4321407
2854,nmbr t i,C0021966;C0221138;C2603360
2854,nmbr i - nmbr - nmbrai,C0003504;C0021966;C0221138;C4551710
2854,nmbr . nmbrto . nmbr . i . iot,C0006196;C0021966;C0221138
2854,nmbr . nmbrinmbr . nmbr ( n = nmbr ) a,C0021966;C0221138
2854,nmbr . nmbrinmbr . nmbr ( n = nmbr ),C0021966;C0221138
2854,nmbr . nmbr ( nmbr . nmbr - nmbr . inmbri ),C0021966;C0221138
2854,nmbr . nmbr ( io . i ),C0021966;C0221138;C1046794;C3146236
2854,nmbr . nmbr ( inmbr . s ),C0021966;C0221138
2854,nmbr . inmbr ( nmbr . nmbri - nmbr . nmbr ),C0021966;C0221138
2854,nmbr . i ± ii . nmbr,C0021966;C0221138;C1710602;C4082587
2854,nmbr - nmbr fo - nmbr - o - q^i,C0021966;C0221138
2854,nmbr - i,C0021966;C0221138
2854,nmbr ( nmbri . i ),C0021966;C0221138
2854,neither ace - i nor arb use,C0021966;C0221138;C1452534;C4284014
2854,l . i ( nmbr . nmbr ),C0021966;C0221138;C0439394;C1706495;C3642217
2854,inmbrinmbr ± nmbr,C0021966;C0221138
2854,inmbri ± inmbr,C0021966;C0221138
2854,inmbri ( inmbr . nmbr ),C0021966;C0221138
2854,inmbri,C0021966;C0221138
2854,inmbr ± nmbrii,C0021966;C0221138;C1710602;C4082587
2854,inmbr ± nmbri,C0021966;C0221138
2854,inmbr ± inmbr,C0021966;C0221138
2854,inmbr ( inmbr . nmbr ),C0021966;C0221138
2854,inmbr ( inmbr . i ),C0021966;C0221138
2854,infliiimab i,C0021966;C0221138
2854,iinmbr ( inmbr . nmbr ),C0021966;C0221138;C1710602;C4082587
2854,i u - uj,C0021966;C0221138;C0439148
2854,i or ii,C0021966;C0221138
2854,i no . of events,C0021966;C0221138
2854,i nmbr . nmbr vs nmbr . nmbr,C0021966;C0221138
2854,i idl cholesterol ( mg / dl ),C0021966;C0123167;C0221138;C0439269;C0523559;C0619865
2854,i / ii,C0021966;C0221138;C1710602;C4082587
2854,i . nmbri ( nmbr . nmbr - i . nmbr ),C0021966;C0221138
2854,i . nmbr ( nmbr . nmbr - i . nmbr ),C0021966;C0221138
2854,i - ^w « - i - nmbr,C0021966;C0221138
2854,i ( nmbr . i ),C0021966;C0221138
2854,i & ii : fevnmbr > nmbr % predicted,C0021966;C0221138;C1710602;C3714541;C4082587
2854,i % nmbr,C0021966;C0221138
2854,i,C0021966;C0221138
2854,ffa / i,C0015688;C0021966;C0221138
2854,ciass i,C0021966;C0221138
2854,aqe inmbr,C0021966;C0221138
2854,antithrombotic ! i,C0021966;C0221138
2854,antidiabetic drug ‘ i “ j ‘,C0021966;C0221138;C0935929
2854,ace ‐ i or arb,C0021966;C0221138;C1452534;C4284014
2854,ace - i or arb use at baseline,C0021966;C0221138;C1452534;C4284014
2854,ace - i or arb use,C0021966;C0221138;C1452534;C4284014
2854,ace - i or arb,C0021966;C0221138;C1452534;C4284014
2854,ace - i or angiotensin receptor blocker,C0021966;C0221138;C1452534;C4284014
2854,ace - i ( n,C0021966;C0221138;C1452534;C4284014
2854,> i,C0021966;C0221138
2854,< nmbr kg ' i ',C0021966;C0022718;C0221138;C0439209;C4054209
2854,- fnmbr . nmbr ( - i - nmbr . nmbr ),C0016327;C0021966;C0221138
2854,- b - i —,C0021966;C0221138
2854,- b - i -,C0021966;C0221138
2854,( i - blocker,C0021966;C0221138
2853,eczema,C0013595;C4553957
2852,czech repumc,C0337799
2851,ankle edema,C0235439
2850,pedal edema,C0574002
2849,peripheral edema,C0085649
2848,physical exam oedema,C0013604;C0031809;C1717255
2848,edema peripheral,C0013604;C1717255
2848,edema,C0013604;C1717255
2847,overweight ( bmi £ nmbr to < nmbr ),C0497406;C0578022
2847,overweight ( bmi = nmbr - nmbr . nmbr ),C0497406;C0578022
2847,overweight,C0497406
2847,nmbr - nmbr . nmbr : overweight,C0497406
2847,bmi nmbr – nmbr overweight,C0497406;C0578022
2846,normal left ventricular ejection fraction — no . ( % ) j,C0205091;C0205307;C0231683;C0428772;C0439166;C0443246;C0488728;C1535947;C1552822;C2347086;C4553972
2846,mean lvef,C0428772;C0444504;C0488728;C2347634;C2348143
2846,lvef^nmbr . nmbr and nyha class ii,C0428772;C0488728
2846,lvef ≤ nmbr %,C0428772;C0488728
2846,lvef — no . ( % )  i ,C0428772;C0488728
2846,lvef within nmbr months,C0428772;C0439231;C0488728
2846,lvef within nmbr mo,C0026544;C0332177;C0428772;C0488728
2846,lvef > nmbr %,C0428772;C0488728
2846,lvef < nmbr . nmbr,C0428772;C0488728
2846,lvef < nmbr %,C0428772;C0488728
2846,lvef ( u ),C0428772;C0439148;C0488728
2846,lvef ( % ),C0428772;C0488728
2846,lvef,C0428772;C0488728
2846,left ventricular ejection fraction — no . / total no . ( % ),C0428772;C0488728
2846,left ventricular ejection fraction — % §,C0428772;C0488728
2846,left ventricular ejection fraction — %,C0428772;C0488728
2846,left ventricular ejection fraction within previous nmbr mo — no . / total no . ( % ) nmbr,C0026544;C0205156;C0332177;C0428772;C0488728;C1552607
2846,left ventricular ejection fraction within previous nmbr mo |,C0026544;C0205156;C0332177;C0428772;C0488728;C1552607
2846,left ventricular ejection fraction < nmbr %,C0428772;C0488728
2846,left ventricular ejection fraction ( % ),C0428772;C0488728
2846,left ventricular ejection fraction,C0428772;C0488728
2845,apolipoprotein,C0003591
2844,naproxen,C0027396
2843,ibuprofen,C0020740
2842,improved,C0184511;C0332272;C1561611;C4084203
2841,pfor trend,C1151635;C1521798;C4554533
2841,pfor,C1151635
2840,ipf - related,C0034069;C1800706
2840,ipf,C0034069;C1800706
2839,paracetamol,C0000970
2839,acetaminophen,C0000970;C2917659
2838,anacetrapib nmbrmg ( n = nmbr ),C0024671;C0026410;C0439269;C1960952;C2346927;C2604745;C4321396;C4521761
2838,anacetrapib nmbr mg ( n = nmbr ),C0024671;C0026410;C0439269;C1960952;C2346927;C2604745;C4321396;C4521761
2838,anacetrapib nmbr mg ( n - nmbr ),C0024671;C0026410;C0439269;C1960952;C2346927;C2604745;C4321396;C4521761
2838,anacetrapib nmbr mg,C0024671;C0026410;C0439269;C1960952;C2346927;C2604745;C4321396;C4521761
2838,anacetrapib ( n = nmbr ),C2604745
2838,anacetrapib ( n = nmbr,C2604745
2837,anakinra,C0245109
2836,canakinumab nmbr mg,C0024671;C0026410;C0439269;C1960952;C2346927;C2718773;C4321396;C4521761
2836,canakinumab,C2718773
2836,all canakinumab,C2718773
2835,noncomplex anatomy ( n - nmbr,C0002808;C0700276;C1384516
2835,complex anatomy ( n - nmbr,C0002808;C0439855;C0700276;C1384516;C1704241
2835,anatomy,C0002808;C0700276;C1384516
2834,favors dabigatran,C0309049;C2348066
2834,factors dabigatran,C1521761;C2348066;C2827422
2833,nmbr mg dabigatran ( n = nmbr ),C0024671;C0026410;C0439269;C1960952;C2346927;C2348066;C4321396;C4521761
2833,nmbr mg dabigatran,C0024671;C0026410;C0439269;C1960952;C2346927;C2348066;C4321396;C4521761
2833,dabigatrannmbr vs . warfarin p ( inter ),C2348066
2833,dabigatran nmbrmg bid,C0024671;C0026410;C0439269;C1960952;C2346927;C2348066;C4321396;C4521761
2833,dabigatran nmbr   mg b . i . d .,C0021966;C0024671;C0026410;C0152277;C0221138;C0439269;C0439422;C1960952;C2346927;C2348066;C4321396;C4521761
2833,dabigatran nmbr vs dabigatran nmbr mg bid,C2348066
2833,dabigatran nmbr mg bid events / n ( % / y ),C0024671;C0026410;C0439269;C0441471;C1960952;C2346927;C2348066;C3541888;C4321396;C4521761
2833,dabigatran nmbr mg bid ( n = nmbr ),C0024671;C0026410;C0439269;C1960952;C2346927;C2348066;C4321396;C4521761
2833,dabigatran nmbr mg bid,C0024671;C0026410;C0439269;C1960952;C2346927;C2348066;C4321396;C4521761
2833,dabigatran nmbr mg ( n = nmbr ),C0024671;C0026410;C0439269;C1960952;C2346927;C2348066;C4321396;C4521761
2833,dabigatran nmbr mg ( n = nmbr,C0024671;C0026410;C0439269;C1960952;C2346927;C2348066;C4321396;C4521761
2833,dabigatran nmbr mg,C0024671;C0026410;C0439269;C1960952;C2346927;C2348066;C4321396;C4521761
2833,dabigatran ( n = nmbr ),C2348066
2833,dabigatran,C2348066
2832,physician global assessment of disease activity ( vas nmbr - nmbr mm ),C0042815;C3536884;C3827561;C4050369;C4330985;C4554674
2832,physician global assessment of disease activity ( nmbr - nmbr cm,C4050369
2832,physician global assessment of disease activity,C4050369
2832,physician global assessment of disease,C0012634;C4050369
2832,physician ' s global assessment of dis -,C0451119;C1444662;C1970187;C4050369
2832,physician ' s global assessment ( vas ),C0042815;C3536884;C3827561;C4050369
2832,physician ' s global assessment !,C4050369
2832,physician ' s global assessment,C4050369
2831,pga subscore,C0016410;C3541266;C4050369
2831,pga score ( range ),C0016410;C0449820;C1514721;C2348147;C3541266;C3542016;C4050231;C4050369
2831,pga score,C0016410;C0449820;C3541266;C4050231;C4050369
2831,pga,C0016410;C3541266;C4050369
2831,mean pga score ± sd,C0016410;C2699239;C3533236;C3541266;C4050369
2830,lateral,C0205093
2829,vilanterol,C2935023
2828,olodaterol sgg,C2934193
2828,olodaterol nmbrpg,C0030827;C0072225;C1266240;C2934193
2828,olodaterol nmbr mg,C0024671;C0026410;C0439269;C1960952;C2346927;C2934193;C4321396;C4521761
2828,olodaterol nmbr m g,C0456715;C2934193
2828,olodaterol nmbr jig,C2934193
2828,olodaterol,C2934193
2827,sotalol,C0037707
2826,cilostazol,C0055729
2825,platelet count,C0032181;C1287267
2824,mean platelet volume,C0200665;C0344388
2823,platelets xlooo / mm^,C0005821;C0443116;C1963076;C4330985;C4554674
2823,platelet,C0005821
2823,other anti - platelet agents,C0005821;C0040616
2823,anti ‐ platelet agents,C0005821;C0040616
2822,alt or ast > nmbr x ulnnmbr,C1266129;C4553172
2822,alt increased,C1266129;C4553172
2822,alt and / or ast > nmbr times uln consecutive #,C1266129;C4553172
2822,alt ( units / l ),C0439339;C1266129;C4553172
2822,alt,C1266129;C4553172
2821,skull,C0037303;C2951888
2820,fistula at baseline,C0016169;C0168634;C1442488
2820,fistula,C0016169
2819,nsclc,C0007131
2819,non – small - cell lung cancer,C0007131;C2984258;C3539721
2818,less than nmbr year,C0439092;C0439234;C0439508
2818,less than nmbr kg / mnmbr,C0439092;C1532718
2818,less than nmbr . nmbr %,C0439092
2818,less than nmbr %,C0439092
2818,less than nmbr,C0439092
2818,less than high school,C0439092;C0599395;C0683862;C0870649
2817,bosentan use :,C0042153;C0252643;C0457083;C1947944
2817,bosentan ( n = nmbr ),C0252643
2817,bosentan,C0252643
2816,losartan plus lisinopril ( n = nmbr ),C0065374;C0126174;C0332287
2816,losartan n = nmbr,C0126174
2816,losartan + placebo,C0032042;C0126174;C1696465;C1706408
2816,losartan + lisinopril,C0065374;C0126174
2816,losartan ( n = nmbr ),C0126174
2816,losartan ( n = nmbr,C0126174
2816,losartan,C0126174
2815,hospital stay ( days ),C0439228;C3489408
2815,hospital stay,C3489408
2814,hospitalized hf !,C0018488;C0701159;C1313497;C1538440;C3273279
2814,hospitalized hf,C0018488;C0701159;C1313497;C1538440;C3273279
2814,hospitalized !,C0701159
2814,hospitalized,C0701159
2813,lost bmd,C0745777;C3815882
2812,post - dose,C0439568
2811,post - mi,C0856742
2810,nordic,C0331873
2809,non - frail,C0871754;C1518422
2809,frail,C0871754
2808,indomethacin,C0021246
2807,romania,C0035826
2806,coumadin,C0699129
2805,patient demographics age — yr,C0011298;C0439234;C1704791;C4698447
2805,demography,C0011298
2805,demographics and clinical characteristics,C0011298;C1704791
2805,demographics age ( years ),C0011298;C1510829;C1704791
2805,demographics age,C0001779;C0011298;C1704791
2805,demographics,C0011298;C1704791
2805,demographic nmbr . nmbr ( nmbr . nmbr ),C0011298
2805,demographic factors,C0011292;C0011298
2805,demographic characteristic,C0011298;C1521970
2805,demographic and medical variables,C0011298
2805,demographic and clinical characteristics,C0011298
2805,demographic and clinical,C0011298
2805,demographic,C0011298
2805,baseline demographics,C0011298;C0168634;C1442488;C1704791
2805,( a ) demographics,C0011298;C1704791
2804,pra,C0633231;C1141951;C1419788;C3274822;C3669212;C4283900
2804,normal - high renin ( pra > nmbr . nmbr ng / ml / h ) ( n = nmbr ),C0205307;C0231683;C0439166;C0633231;C0855390;C1141951;C1419788;C1533072;C2347086;C3274822;C3669212;C4050009;C4283900;C4553972
2804,low renin ( pra < nmbr . nmbr ng / ml / h ) ( n = nmbr ),C0633231;C0855389;C1141951;C1419788;C1533072;C3274822;C3669212;C4050009;C4283900
2803,responders of three - item end point at nmbr weeks *,C0205449;C1551338;C2349179;C2826544;C4554251
2803,item,C1551338;C4554251
2802,prediabetes — no . ( % ) nmbr,C0362046
2802,prediabetes,C0362046
2802,pre – diabetes mellitus,C0362046
2802,ifg / prediabetes^,C0362046;C1334085;C1708411
2801,biguanides ¶,C0005382;C0360396;C3540012
2801,biguanides ( metformin ),C0005382;C0025598;C0360396;C3540012
2801,biguanides,C0005382;C0360396;C3540012
2801,biguanide ( metformin ),C0005382;C0025598;C3537187;C4317165
2801,biguanide,C0005382;C3537187;C4317165
2800,st ( arc definite only ),C0036056;C0205171;C0439544;C1704787;C1720467;C3272372
2800,nmbr days definite st,C0036056;C0439228;C0439544;C1704787;C3272372
2800,definite,C0439544;C1704787
2799,evening mealb,C0587117
2799,evening,C0587117
2798,ezetimibe use,C0042153;C0457083;C1142985;C1947944
2798,ezetimibe,C1142985
2797,patients with ascvd but no prior ml hr ( nmbr % cl ),C0030705;C3665365
2797,other ascvd,C3665365
2797,no ascvd,C3665365
2797,ascvd no prior ml,C3665365
2797,ascvd including tia,C3665365
2797,ascvd as per protocol,C1698058;C3665365
2797,ascvd * . n ( % ),C3665365
2797,"ascvd """,C3665365
2797,ascvd,C3665365
2796,previous ischemic heart disease — no . ( % ),C0010054;C0151744;C0205156;C1552607
2796,myocardial ischaemia,C0010054;C0151744
2796,ischemic heart disease *,C0010054;C0151744
2796,ischemic heart disease ( % ),C0010054;C0151744
2796,ischemic heart disease,C0010054;C0151744
2796,ischaemic heart disease or cerebrovascular disorder,C0010054;C0151744
2796,ischaemic heart disease,C0010054;C0151744
2796,ihd,C0151744
2796,combined ischaemic heart disease and / or cerebrovascular disorder *,C0010054;C0151744;C0205195
2795,nmbr baricitinib nmbr mg ■ baricitinib nmbr mg,C1319635;C4044947
2795,baricitinib nmbr mg qd,C0024671;C0026410;C0332173;C0439269;C1960952;C2346927;C4044947;C4321396;C4521761
2795,baricitinib nmbr mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4044947;C4321396;C4521761
2795,baricitinib nmbr / nmbr mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4044947;C4321396;C4521761
2795,baricitinib,C4044947
2794,tofacitinib nmbr mg bid,C0024671;C0026410;C0439269;C1960952;C2346927;C2930696;C4321396;C4521761
2794,tofacitinib,C2930696
2793,previous oral antidiabetic medication use,C0205156;C0935929;C1527415;C1552607
2793,oral antidiabetic drugs,C0029167;C0175795;C0304289;C0442027;C0935929;C4521986
2793,no oral antidiabetic medication,C0175795;C0442027;C0935929;C4521986
2793,no antidiabetic drug,C0935929
2793,nmbr oral antidiabetic medication,C0175795;C0442027;C0935929;C4521986
2793,insulin + oral antidiabetic medication ( s ),C0021641;C0175795;C0442027;C0935929;C1533581;C1579433;C3714501;C4521986
2793,antidiabetic medications,C0935929
2793,antidiabetic medication | |,C0935929
2793,antidiabetic medication,C0935929
2793,antidiabetic drug,C0935929
2793,antidiabetic agents,C0935929
2793,antidiabetic agent,C0935929
2793,antidiabetic,C0935929
2793,> nmbr oral antidiabetic medication,C0175795;C0442027;C0935929;C4521986
2792,ankle / brachial index,C1328319;C3888326
2792,ankle - brachial index £ nmbr . nmbr,C1328319;C3888326
2792,ankle - brachial index < nmbr . nmbr — no . ( % ),C1328319;C3888326
2792,ankle - brachial index < nmbr . nmbr,C1328319;C3888326
2792,abi > nmbr . nmbr,C1328319;C3888326
2792,abi < nmbr . nmbr,C1328319;C3888326
2792,abi # nmbr . nmbr,C1328319;C3888326
2792,abi,C1328319;C3888326
2791,cabg — no . { % ),C0010055
2791,cabg — no . ( % ),C0010055
2791,cabg or valve,C0010055
2791,cabg or ptca / pci,C0010055
2791,cabg or ptca ( % ),C0010055
2791,cabg or pci,C0010055
2791,cabg or angioplasty,C0010055
2791,cabg only,C0010055;C0205171;C1720467
2791,cabg > nmbr month ago,C0010055;C0332177;C0439231
2791,cabg ( % ),C0010055
2790,hx cabg,C0010055;C0262926;C3814444
2790,cabg :,C0010055
2790,cabg,C0010055
2789,prior aortocoronary bypass surgery 一 no . ( % ),C0010055;C0455610
2789,prior aortocoronary bypass surgery — no . ( % ),C0010055;C0455610
2789,prior aortocoronary bypass surgery,C0010055;C0455610
2789,need for urgent coronary - artery bypass grafting,C0010055;C0027552;C0439609;C0686904;C3272275
2789,multivessel coronary - artery bypass grafting,C0010055
2789,coronary bypass surgery,C0010055
2789,coronary bypass,C0010055
2789,coronary artery bypass surgery,C0010055
2789,coronary artery bypass grafting n ( % ),C0010055
2789,coronary artery bypass grafting,C0010055
2789,coronary artery bypass graft — no . ( % ),C0010055;C1260596
2789,coronary artery bypass graft,C0010055;C1260596
2789,coronary artery bypass,C0010055
2789,coronary - artery bypass grafting §,C0010055
2789,coronary - artery bypass grafting,C0010055
2788,cabg surgery by no . of vessels nmbr,C0010055;C0042381;C3714645
2788,cabg performed during index hospitalization,C0010055
2787,pci = percutaneous coronary intervention . cabg = coronary - artery bypass graft . for hope > nmbr mg / l  for europa > nmbr mg / l or on a lipid - lowering treatment  for peace  data are mean ( sd ) . data are mean ( sd ) unless otherwise indicated .,C0010055;C0184661;C0189695;C0392347;C0439268;C0522523;C0545743;C0886296;C1273869;C4049621
2787,ace = angiotensin - converting enzyme  cabg = coronary artery bypass graft  ccsc = canadian cardiovascular society classification  mi = myocardial infarction  pci = percutaneous coronary,C0010055;C0022709;C0027051;C0189695;C0545743;C3640258
2786,never used lev,C0023556;C1273517;C2003901
2786,never took alendronate,C2003901
2786,never smoking,C2003901
2786,never smoked — no . ( % ),C2003901
2786,never smoked,C2003901
2786,never or past,C2003901
2786,never drink,C2003901
2786,never been on a vka,C2003901
2786,never / rarely,C0522498;C2003901
2786,never,C2003901
2785,prior lev use,C0023556;C0332152;C2826257
2785,prior lev,C0023556;C0332152;C2826257
2785,lev - naive,C0023556
2785,lev - exposed,C0023556
2785,lev ( n   =   nmbr ),C0023556
2784,mtx average weekly dose,C0332174;C0366550;C1510992;C2825518
2784,average daily dose ( % of target ) *,C1510992;C1521840;C2348070;C2825518;C2986546
2784,average daily dose,C1510992;C2348070;C2825518
2783,predose fvc ( l ) *,C0439565;C3714541;C3812758
2783,predose fvc ( l ),C0439565;C3714541;C3812758
2783,predose fevnmbr ( l ) *,C0439565;C3714541;C3812758
2783,predose fev / fvc,C0439565;C3714541;C3812758
2783,predose fev -,C0439565;C3714541;C3812758
2783,pre - dose,C0439565;C3812758
2782,qrs interval > nmbr msec — no . ( % ),C0439223;C0520880
2782,qrs > nmbr msec nmbr - min walk test,C0439223;C0702093;C1524029;C3813700;C4277740
2782,qrs < nmbr msec,C0439223
2781,brv overalla ( n = nmbr ),C0155502
2781,brv overall ( n = nmbr ),C0155502;C0282416;C1561607
2781,brv overall,C0155502
2780,hyperkalemia * ’,C0020461;C4552983
2780,hyperkalemia ( > nmbr . nmbr meq / l ),C0020461;C0439375;C4552983
2780,hyperkalemia,C0020461;C4552983
2780,hyperkalaemia ( investigator reported ),C0020461;C0035173;C4552983
2780,hyperkalaemia,C0020461;C4552983
2779,hyperlipidemia^,C0020473;C0428465;C4555212
2779,hyperlipidemia — no . / total no . ( % ),C0020473;C0428465;C4555212
2779,hyperlipidemia — no . ( % ),C0020473;C0428465;C4555212
2779,hyperlipidemia § yes,C0020473;C0428465;C1549445;C1705108;C1710701;C4555212
2779,hyperlipidemia §,C0020473;C0428465;C4555212
2779,hyperlipidemia | | yes,C0020473;C0428465;C1549445;C1705108;C1710701;C4555212
2779,hyperlipidemia | |,C0020473;C0428465;C4555212
2779,hyperlipidemia ( % ) §,C0020473;C0428465;C4555212
2779,hyperlipidemia ( % ),C0020473;C0428465;C4555212
2779,hyperlipidemia,C0020473;C0428465;C4555212
2779,hyperlipidaemia therapy use,C0020473;C0039798;C0042153;C0087111;C0428465;C0457083;C1363945;C1947944;C4555212
2779,hyperlipidaemia ( % ),C0020473;C0428465;C4555212
2779,hyperlipidaemia,C0020473;C0428465;C4555212
2778,dyslipidemianmbr,C0242339
2778,dyslipidemia — no . { % ),C0242339
2778,dyslipidemia — no . ( % ) |,C0242339
2778,dyslipidemia — no . ( % ),C0242339
2778,dyslipidemia,C0242339
2778,dyslipidaemia 本,C0242339
2778,dyslipidaemia — no . ( % ),C0242339
2778,dyslipidaemia including hypercholesterol — no . ( % ),C0242339
2778,dyslipidaemia and hypertensiont,C0242339
2778,dyslipidaemia and hypertension,C0242339
2778,dyslipidaemia,C0242339
2778,baseline dyslipidemia,C0168634;C0242339;C1442488
2777,belgium,C0004950
2776,jejunum,C0022378
2775,pump,C0182537
2775,off pump,C0182537;C1518543
2775,off - pump,C0182537;C1518543
2774,on pump,C3842462
2774,on - pump,C3842462
2773,era monotherapy,C1521863;C3495919
2773,era and pdenmbr inhibitors,C1521863;C3495919
2773,era and pde - nmbri,C1521863;C3495919
2773,era,C1521863;C3495919
2772,vein graft stented,C0042449;C0181074;C0332835;C1961139
2772,graft occlusionsa,C0181074;C0332835;C1961139
2772,graft,C0181074;C0332835;C1961139
2771,ra ndosii zat ion,C0022023;C1700702;C3538806;C4048756
2771,ra - beam,C0338248;C2347880;C3538806;C4048756;C4521565
2771,ra,C3538806;C4048756
2771,all - baricitinib ra ( n = nmbr ) *,C3538806;C4044947;C4048756
2770,mras,C1335594;C1367476
2769,mca,C0149566
2768,eda,C0162359;C1539327;C3539920;C3887494
2767,lda,C4553195
2766,bladder,C0005682;C4319531
2765,plac,C0048838
2764,b lack,C0332268
2763,pm pef ( sd ),C0030266;C0030771;C1518922;C1542834;C2699239;C4049155
2763,pef !,C0030771;C1518922;C1542834
2763,pef,C0030771;C1518922;C1542834
2762,ref §,C1425988
2762,ref .,C1425988
2762,nmbr . nmbr ( ref . ),C1425988
2762,nmbr ( ref ),C1425988
2762,( ref ),C1425988
2761,patients with only mrf hr ( nmbr % cl ),C0030705;C0205171;C0312443;C0596019;C1412879;C1720467
2761,mrf subjects,C0312443;C1412879
2761,mrf,C0312443;C1412879
2760,ischemic stroke without hemorrhagic conversior,C0333275;C0475224;C0553692;C0948008
2760,ischemic stroke with hemnrrhnaic cnnversinn,C0948008
2760,ischemic stroke subtype,C0449560;C0948008
2760,ischemic stroke or see,C0948008
2760,ischemic stroke ( vs . tia ),C0948008
2760,ischemic stroke ( incl . uncertain ),C0948008
2760,ischemic stroke ( % ),C0948008
2759,• ischemic stroke,C0948008
2759,prior ischemic stroke,C0332152;C0948008;C2826257
2759,primary ischemic stroke,C0205225;C0439612;C0439631;C0948008
2759,nonfatal ischemic stroke,C0948008
2759,minor ischaemic stroke,C0026193;C0205165;C0948008
2759,ischemic stroke,C0948008
2759,ischaemic stroke,C0948008
2759,all ischemic stroke,C0948008
2758,non - ischaemic ( n = nmbronmbr ),C0475224;C1518422
2758,non - ischaemic ( n = nmbr ),C0475224;C1518422
2758,ischemic tvr,C0475224
2758,ischemic hf,C0018488;C0475224;C1313497;C1538440;C3273279
2758,ischemic,C0475224
2758,ischaemic skin lesions,C0037284;C0475224
2758,ischaemic or unknown stroke,C0475224
2758,ischaemic ( n = nmbrlnmbr ),C0475224
2758,ischaemic ( n = nmbr ),C0475224
2758,ischaemic,C0475224
2757,change in bp,C1268766
2756,chinese subgroup,C0008120;C0152035;C1079230;C1515021
2756,chinese,C0008120;C0152035
2755,china / tjapan,C0008115
2755,china / japan,C0008115;C0022341
2755,china,C0008115
2754,relative risk comparing icd therapy and placebo,C0021122;C0039798;C0087111;C0242492;C1363945;C1707455
2754,relative risk ( nmbr % cl ) comparing icd therapy and placebo using a linear interaction term in the model ( shfmxicd ) *,C0021122;C0039798;C0087111;C0242492;C0596019;C1363945;C1707455
2754,icd vs . placebo,C0021122
2754,icd therapy vs . placebo no . hazard ratio ( nmbr . nmbr % cl ),C0021122;C0039798;C0087111;C1363945
2754,icd therapy ( n =,C0021122;C0039798;C0087111;C1363945
2754,icd or crt - d,C0021122
2754,icd / crt - d,C0021122
2754,icd,C0021122
2753,group b,C4522078
2753,gold group b,C0018026;C1304897;C4522078
2752,group a,C0441835;C4522145
2752,gold group a,C0018026;C0441835;C1304897;C4522145
2751,group c,C0441837
2751,gold group c,C0018026;C0441837;C1304897
2750,group d ( high risk,C0441838
2750,group d,C0441838
2750,gold group d,C0018026;C0441838;C1304897
2749,good / moderate response,C0205170;C4085643
2749,good,C0205170
2748,row §,C1552840;C1552846
2748,row * n = nmbr,C1552840;C1552846
2748,row,C1552840;C1552846
2747,onmbro ( oonmbr - o - nmbro ),C0483204
2747,onmbr,C0483204
2747,o - oonmbr ( - nmbr - nmbr to nmbr - nmbr ),C0483204
2747,o - oinmbr ( - nmbr - nmbr to nmbr - nmbr ),C0029118;C0029434;C0483204
2747,o,C0483204
2747,nmbro / nmbronmbr ( nmbr - nmbr % ),C0483204
2747,nmbr nmbr ( o - nmbr - i - onmbr ),C0021966;C0221138;C0483204
2747,nmbr . nmbr ( nmbr . o - nmbr . o ),C0483204
2747,nmbr - nmbr { o - nmbr - nmbr - onmbr ),C0483204
2747,nmbr - nmbr ( onmbro - i - inmbr ),C0021966;C0221138;C0483204
2747,nmbr - nmbr ( onmbr - o - nmbr ),C0483204
2747,nmbr - nmbr ( o - nmbrs - o - nmbr ),C0483204
2747,nmbr - nmbr ( o - nmbrs - i - nmbr ),C0021966;C0221138;C0483204
2747,nmbr - nmbr ( o - nmbro - o - nmbr ),C0483204
2747,nmbr - nmbr ( o - nmbri - o - nmbr ),C0021966;C0221138;C0483204
2747,nmbr - nmbr ( o - nmbr - o - nmbro ),C0483204
2747,nmbr - nmbr ( o - nmbr - o - nmbr ),C0483204
2747,nmbr - nmbr ( o - nmbr - nmbr - oo ),C0483204
2747,nmbr - nmbr ( o - nmbr - i - onmbr ),C0021966;C0221138;C0483204
2747,nmbr - nmbr ( o - nmbr - i - nmbr ),C0021966;C0221138;C0483204
2747,nmbr ( o - onmbr - o - nmbr ),C0483204
2747,nmbr ( o - nmbr - o - nmbr ),C0483204
2747,> o - nmbr - ii,C0483204;C1710602;C4082587
2747,> o - nmbr - i - i,C0021966;C0221138;C0483204
2747,- onmbro ( - nmbr - loto - nmbr - nmbr ),C0483204
2747,- o - oonmbr ( - nmbr - nmbr to nmbr - nmbr ),C0483204
2746,= sia,C1225105;C1551538
2745,ebria,C1917247
2744,pyrexia,C0015967
2743,dyspepsia,C0013395;C4552968
2742,paresthesia,C0030554;C4553220
2741,east asia,C0015631
2740,aphasia,C0003537
2739,austria,C0004348
2738,australasia,C0282279;C1257882
2737,myalgia,C0231528;C4552646
2736,malaysia,C0024552
2735,antimalarial,C0003374;C3536844;C4552582
2734,arthralgia,C0003862;C4551938
2733,lira,C1555441
2732,ultra,C0728475
2731,saudi arabia,C0036243
2731,sa,C0036243;C0038702;C1539696;C1825840;C3539736;C4521691
2730,ptca or pci,C2936173
2730,ptca only,C0205171;C1720467;C2936173
2730,ptca / cabg,C0010055;C2936173
2730,ptca,C2936173
2730,prior ptca or pci,C0332152;C2826257;C2936173
2730,prior ptca or cabg,C0332152;C2826257;C2936173
2730,prior ptca / pci,C0332152;C2826257;C2936173;C4049621
2730,percutaneous transluminal coronary angioplasty,C2936173
2730,both ptca and cabg,C2936173
2729,pooled pah - mctd and pah,C0026272;C0030123;C1709595;C2349200;C3203102;C4284467;C4522255
2729,pah therapy at baseline,C0030123;C0039798;C0087111;C0168634;C1363945;C1442488;C3203102;C4284467
2729,pah - ssc,C0030123;C3203102;C3897657;C4284467
2729,pah - sle,C0024141;C0030123;C3203102;C4284467
2729,pah - mctd / ctd - other,C0026272;C0030123;C1335071;C1442905;C3203102;C4284467
2729,pah - ctd,C0030123;C1335071;C1442905;C3203102;C4284467
2729,no pah therapy,C0030123;C0039798;C0087111;C1363945;C3203102;C4284467
2729,no pah - specific therapy,C0030123;C0039798;C0087111;C0205369;C1363945;C1552740;C3203102;C4284467
2728,sf - nmbr physical component summaryjj,C0031809;C0037712;C0205485;C0449432;C1509143;C1705248
2728,role physical,C0031809;C0035820;C0205485;C1509143;C1705810;C3871154
2728,physical role,C0031809;C0035820;C0205485;C1509143;C1705810;C3871154
2728,physical examinations,C0031809
2728,physical examination,C0031809;C1744699
2728,physical component,C0031809;C0205485;C0449432;C1509143;C1705248
2728,physical characteristics,C0031809;C0205485;C1509143;C1521970
2728,physical and cognitive examination : ! :,C0031809;C0205485;C1509143
2727,proximal to the splenic flexure,C0205107;C0227387;C4489236
2727,proximal gl tract,C0018229;C0205107;C1185740;C1423073;C1427674;C4489236
2727,proximal gi tract,C0017189;C0205107;C4489236
2727,proximal gastrointestinal tract,C0017189;C0205107;C0521362;C4489236
2727,proximal - mainleft,C0205107;C4489236
2727,proximal,C0205107;C4489236
2726,inappropriate,C1548788;C3537135;C3542467
2725,valproate,C0080356
2724,scalp psoriasis,C0406326
2724,facial psoriasis,C1276112
2723,bisphosphonates,C0012544;C3541401
2722,phosphatase,C0031678;C1149880;C4522024
2721,phosphorus,C0031705;C0080014;C3714498
2720,screening prebronchodilator fevnmbr,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164;C2599602;C3714541
2720,prebronchodilator fevnmbr,C2599602;C3714541
2720,prebronchodilator,C2599602
2720,pre - bronchodilator fevnmbr,C2599602;C3714541
2720,pre - bronchodilator fevj,C2599602
2720,pre - bronchodilator fev,C2599602;C3714541
2720,pre - bronchodilator,C2599602
2720,fevnmbr prebronchodilator [l],C2599602;C3714541
2720,fevnmbr prebronchodilator [ % pn],C0219433;C1549735;C2599602;C3541307;C3714541;C4049640;C4049767
2720,fevnmbr pre - bronchodilator ( l ),C2599602;C3714541
2719,prebronchodilator fevj ( % predicted ),C2599602
2719,prebronchodilator fevi — liters,C0429706;C0475211;C0849974;C1561566;C2599602;C4528367
2719,prebronchodilator fevi ( % predicted ),C0849974;C1561566;C2599602;C4528367
2719,pre - bronchodilator fevr l,C1708033;C2599602
2719,pre - bronchodilator fevr % pred,C1708033;C2599602
2719,pre - bronchodilator fevi change,C0849974;C1561566;C2599602;C4528367
2719,a prebronchodilator fevl ( % predicted ),C2599602
2718,postbronchodilator nmbr . nmbr ( nmbr . nmbr ),C2599594
2718,postbronchodilator fevnmbr reversibility,C0449261;C2599594;C3714541
2718,postbronchodilator fevnmbr / fvc,C2599594;C3714541
2718,postbronchodilator fevnmbr,C2599594;C3714541
2718,postbronchodilator fevj ( % predicted ),C2599594
2718,postbronchodilator,C2599594
2718,post - bronchodilator ratio of fevnmbr to fvc — %,C0456603;C1547037;C2599594;C3714541
2718,post - bronchodilator percent of predicted fevnmbr,C1882327;C2599594;C3714541
2718,post - bronchodilator fvc ( l ) a,C2599594;C3714541
2718,post - bronchodilator fevx ( l ),C2599594
2718,post - bronchodilator fevnmbr — liters,C0475211;C2599594;C3714541
2718,post - bronchodilator fevnmbr — % of predicted value,C0681842;C1522609;C1882327;C2599594;C3714541
2718,post - bronchodilator fevnmbr reversibility,C0449261;C2599594;C3714541
2718,post - bronchodilator fevnmbr ml,C0439526;C1705224;C2599594;C3714541;C3887665
2718,post - bronchodilator fevnmbr / fvc ratio,C0456603;C1547037;C2599594;C3714541
2718,post - bronchodilator fevnmbr / fvc ( % ) a,C2599594;C3714541
2718,post - bronchodilator fevnmbr / fvc,C2599594;C3714541
2718,post - bronchodilator fevnmbr ( l ) a,C2599594;C3714541
2718,post - bronchodilator fevnmbr ( l ) *,C2599594;C3714541
2718,post - bronchodilator fevnmbr ( l ),C2599594;C3714541
2718,post - bronchodilator fevnmbr ( % predicted normal ) a,C2599594;C3714541
2718,post - bronchodilator fevnmbr ( % predicted * ),C2599594;C3714541
2718,post - bronchodilator fevnmbr % predictedb,C2599594;C3714541
2718,post - bronchodilator fevnmbr  % predicted,C2599594;C3714541
2718,post - bronchodilator fevnmbr,C2599594;C3714541
2718,post - bronchodilator fevinmbr % predicted,C0849974;C1561566;C2599594;C4528367
2718,post - bronchodilator fevi,C0849974;C1561566;C2599594;C4528367
2718,post - bronchodilator fev i reversibility,C0021966;C0221138;C0449261;C2599594;C3714541
2718,post - bronchodilator fev,C2599594;C3714541
2718,post - bronchodilator,C2599594
2718,b postbronchodilator fevl ( % predicted ),C2599594
2717,kccq score,C3476798
2717,kccq ( nmbr months ),C0439231;C3476798
2716,lvh by minnesota code,C0009219;C0026183;C0149721;C0805701;C3889831
2716,lvh by ecg ( minnesota code ),C0009219;C0026183;C0232306;C0805701;C3889831
2715,knees ( n ),C0022742
2715,knee,C0022742;C0022745;C1963703
2715,below - knee popliteal crural,C0022742;C0022745;C0023216;C0442037;C0542339;C1140621;C1552829;C1963703
2715,below - knee popliteal,C0022742;C0022745;C0442037;C0542339;C1552829;C1963703
2714,triple therapy use at screening,C0039798;C0042153;C0087111;C0205174;C0220908;C0220909;C0457083;C1363945;C1698960;C1710031;C1710032;C1710477;C1947944;C2348164
2714,theophylline use at screening,C0220908;C0220909;C0241361;C1698960;C1710031;C1710032;C1710477;C2348164
2714,smoking status at screening,C0037369;C0220908;C0220909;C0421330;C0453996;C1519386;C1698960;C1710031;C1710032;C1710477;C1881674;C2348164
2714,screening visit,C0220908;C0220909;C0545082;C1512346;C1698960;C1710031;C1710032;C1710477;C2348164;C2826704
2714,screening hbanmbrc ( % ),C0019016;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C1825777;C2348164;C3538758
2714,screening fevnmbr   % predicted,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164;C3714541
2714,screening bmi ( kg / mnmbr ),C0220908;C0220909;C0578022;C1532718;C1698960;C1710031;C1710032;C1710477;C2348164
2714,screening and baseline lung function characteristics,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
2714,screening absolute reversibility fevnmbr,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
2714,screening ( visit nmbr ),C0220908;C0220909;C0545082;C1512346;C1698960;C1710031;C1710032;C1710477;C2348164;C2826704
2714,screening % reversibility fevnmbr,C0220908;C0220909;C0449261;C1698960;C1710031;C1710032;C1710477;C2348164;C3714541
2714,screening,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
2714,present at screening,C0150312;C0220908;C0220909;C0449450;C1698960;C1710031;C1710032;C1710477;C2348164
2714,predose fev^ at screening,C0220908;C0220909;C0439565;C1698960;C1710031;C1710032;C1710477;C2348164;C3714541;C3812758
2714,pre - bronchodilator screening fevnmbr ml,C0220908;C0220909;C0439526;C1698960;C1705224;C1710031;C1710032;C1710477;C2348164;C2599602;C3714541;C3887665
2714,pre - bronchodilator screening,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164;C2599602
2714,postdose fev / fvc at screening,C0220908;C0220909;C0439568;C1698960;C1710031;C1710032;C1710477;C2348164;C3714541
2714,postbronchodilator lung function at screening,C0035245;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164;C2599594
2714,post - bronchodilator screening fevnmbr ml,C0220908;C0220909;C0439526;C1698960;C1705224;C1710031;C1710032;C1710477;C2348164;C2599594;C3714541;C3887665
2714,post - bronchodilator screening,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164;C2599594
2714,post - bronchodilator fevnmbr at screening,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164;C2599594;C3714541
2714,oad at screening,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
2714,mean blood pressure at screening visit ( mm hg ),C0220908;C0220909;C0428886;C0439475;C0488053;C0545082;C1512346;C1698960;C1710031;C1710032;C1710477;C2348164;C2826704
2714,long - acting bronchodilator use at screening,C0006280;C0042153;C0079613;C0205166;C0220908;C0220909;C0457083;C1698960;C1704930;C1706317;C1710031;C1710032;C1710477;C1869853;C1947944;C2348164;C3890007;C4048375
2714,lama use at screening,C0042153;C0220908;C0220909;C0457083;C0999593;C1416775;C1698960;C1710031;C1710032;C1710477;C1947944;C2348164
2714,laba use at screening,C0042153;C0220908;C0220909;C0457083;C1698960;C1710031;C1710032;C1710477;C1947944;C2348164
2714,insulin glargine dose at screening visit,C0178602;C0220908;C0220909;C0366513;C0869039;C0907402;C1114758;C1698960;C1710031;C1710032;C1710477;C2348164
2714,high - dose statin use at screening *,C0042153;C0220908;C0220909;C0360714;C0444956;C0457083;C1698960;C1710031;C1710032;C1710477;C1947944;C2348164
2714,fevnmbr   at screening ∗,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164;C3714541
2714,at screening,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
2714,age at screening,C0001779;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
2714,> nmbr per pl at screening,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164;C3897966;C4049765
2714,> nmbr at screening,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
2713,« snmbr - nmbr,C0565930;C2603362
2713,| : s blocker,C0565930;C2603362
2713,snmbr vs placebo,C0032042;C0565930;C1696465;C1706408;C2603362
2713,snmbr gallop,C0565930;C2603362
2713,snmbr - nmbr vs placebo,C0032042;C0565930;C1696465;C1706408;C2603362
2713,snmbr - nmbr - snmbr . nmbr %,C0565930;C2603362
2713,snmbr ( nmbr . s ),C0565930;C2603362
2713,snmbr %,C0565930;C2603362
2713,snmbr,C0565930;C2603362
2713,s £ nmbr,C0565930;C2603362
2713,s nmbr yrs,C0565930;C2603362
2713,s fs nmbr,C0565930;C1517317;C2603362;C3814419
2713,s / se,C0036919;C0565930;C2603362
2713,s . e .,C0565930;C2603362
2713,s ( snmbr,C0565930;C2603362
2713,s,C0565930;C2603362
2713,nmbrs fnmbr ),C0016327;C0565930;C2603362
2713,nmbrs . nmbr ± s . nmbr,C0565930;C2603362
2713,nmbr ( nmbrs . s ),C0565930;C2603362
2713,= snmbr,C0565930;C2603362
2712,second year !,C0205436;C0439234;C0439508;C0457385;C0565930;C1561503;C1705190
2712,second serum creatinine,C0201976;C0205436;C0457385;C0565930;C0600061;C1561503;C1705190
2712,second prior mi,C0205436;C0332152;C0457385;C0565930;C1561503;C1705190;C2826257;C3810814
2712,second mi,C0205436;C0457385;C0565930;C1561503;C1705190;C3810814
2712,second loading dose,C0205436;C0457385;C0565930;C1561503;C1705190;C3714444
2712,second co - primary,C0205436;C0457385;C0565930;C1561503;C1705190;C3245499
2712,second - generation stent,C0038257;C0079411;C0205436;C0457385;C0565930;C1561503;C1705190;C3146294
2712,second ( n = nmbr ),C0205436;C0457385;C0565930;C1561503;C1705190
2712,no second mi,C0205436;C0457385;C0565930;C1561503;C1705190;C3810814
2711,glinide 一 no . ( % ),C2266929
2711,glinide,C2266929
2710,lixisenatide ( n = nmbro ),C2973895
2710,lixisenatide ( n = nmbr ),C2973895
2710,lixisenatide,C2973895
2709,glipizide ( n = nmbr ),C0017642
2709,glipizide,C0017642
2708,delighted,C3830544
2707,whitea,C1021495
2706,limited i -,C0021966;C0221138;C0439801;C2674459;C3542948;C4050251
2706,limited,C0439801;C2674459;C3542948;C4050251
2705,glycemic indexes,C1136206
2704,glycemic status f,C0016327;C1320980
2704,glycemic status,C1320980
2703,glyburide dose duringthe study ( mg ),C0017628;C0024671;C0026410;C0178602;C0439269;C0557651;C0869039;C1114758;C1960952;C2346927;C2603343;C4321396;C4521761
2703,glyburide ( n = nmbr ),C0017628
2703,glyburide,C0017628
2702,glycosylated hemoglobin,C0017853
2702,glycated hemoglobin — % -,C0017853
2702,glycated hemoglobin — %,C0017853
2702,glycated hemoglobin | |,C0017853
2702,glycated hemoglobin < median,C0017853;C0549183;C0876920;C2347635;C2348144;C2939193
2702,glycated hemoglobin - % ’,C0017853
2702,glycated hemoglobin ( % ),C0017853
2702,glycated hemoglobin,C0017853
2702,glycated haemoglobin ( % ),C0017853
2702,glycated haemoglobin,C0017853
2701,glycohemoglobin,C0202054;C0696092
2701,glycated hemoglobin level,C0202054
2700,dulaglutide nmbr . nmbr mgf,C1366394;C3179549;C3712803;C3887684
2699,liraglutide nmbr . nmbr mg / day ( n = nmbr ),C0439422;C1456408
2699,liraglutide n ( % ),C1456408
2699,liraglutide ( « = nmbr ),C1456408
2699,liraglutide ( n = nmbr ),C1456408
2699,liraglutide ( n = nmbr,C1456408
2699,liraglutide,C1456408
2698,semaglutide exposure,C0274281;C0332157;C3885068
2698,semaglutide ( n = nmbr ),C3885068
2698,semaglutide,C3885068
2697,nmbr hr after glucose challenge,C3840385
2696,serum glucose ( mmol / l ),C0202041;C1532563;C3534430
2696,serum glucose ( mg / dl ),C0202041;C0439269;C3534430
2696,fasting serum glucose — mg / dl * *,C0015663;C0202041;C0439269;C3534430
2696,fasting serum glucose ( mg / dl ),C0015663;C0202041;C0439269;C3534430
2695,intensive blood glucose control,C0162425;C0522510;C1283828;C1550453;C3267174
2695,blood - glucose control,C3267174
2694,high density lipoprotein ( mg / dl ),C0023821;C0439269
2694,high - density lipoprotein],C0023821
2694,high - density lipoprotein,C0023821
2693,low - density lipoprotein^,C0023823
2693,low - density lipoprotein choles -,C0023823
2693,low - density lipoprotein,C0023823
2692,highly sensitive responders ( n = nmbr ),C0439822
2692,highly sensitive responder ( n = nmbr ),C0439822
2692,highly sensitive,C0439822
2691,id genotype,C0009450;C0017431;C0600091;C1441613
2691,genotype,C0017431
2690,genotyping,C1285573
2690,by genotyping,C1285573
2689,secukinumab pooled †   ( n   = nmbr ),C1709595;C2349200;C3179547;C4522255
2689,pooled secukinumab,C1709595;C2349200;C3179547;C4522255
2689,any secukinumab ( n   = nmbr ),C3179547
2688,secukinumab nmbr   mg,C0024671;C0026410;C0439269;C1960952;C2346927;C3179547;C4321396;C4521761
2688,secukinumab nmbr mg,C0024671;C0026410;C0439269;C1960952;C2346927;C3179547;C4321396;C4521761
2688,secukinumab,C3179547
2687,minimum — maximum,C0806909;C1524031;C1552614;C1552615;C2826545;C2826546
2687,minimum — maxim um,C0024968;C1524031;C1552614;C2826545
2687,minimum : maximum,C0806909;C1524031;C1552614;C1552615;C2826545;C2826546
2687,minimum / maximum,C0806909;C1524031;C1552614;C1552615;C2826545;C2826546
2687,minimum - maximum,C0806909;C1524031;C1552614;C1552615;C2826545;C2826546
2687,minimum,C1524031;C1552614;C2826545
2687,median ( minimum – maximum ) focal seizure frequency / nmbr   days at baseline,C0149775;C0168634;C0205234;C0376249;C0439228;C0439603;C0549183;C0751495;C0806909;C0871396;C0876920;C1442488;C1524031;C1552614;C1552615;C1561548;C1705502;C2347635;C2348144;C2826545;C2826546;C2939193;C3898838;C4321352
2687,( minimum - maximum ) focal seizure fre - quency / nmbr days at baseline,C0168634;C0439228;C0751495;C0806909;C1414819;C1442488;C1524031;C1552614;C1552615;C2826545;C2826546
2686,eos serum k +,C0302353;C1623465;C1861303
2685,serum potassium 一 mmol / liter,C0302353;C0439190;C0475211;C0543465
2685,serum potassium — mmol / liter,C0302353;C0439190;C0475211;C0543465
2685,serum potassium level,C0302353;C0543465
2685,serum potassium : < nmbr . nmbrmmol / l ( n = nmbr ),C0302353;C0543465;C1532563
2685,serum potassium ( mmol / l ),C0302353;C0543465;C1532563
2685,serum potassium,C0302353;C0543465
2685,serum biochemistry potassium,C0005477;C0302353;C0543465
2685,mean serum potassium,C0302353;C0444504;C0543465;C2347634;C2348143
2685,hyperkalaemia ( serum potassium > nmbr . nmbr mmol / l ),C0020461;C0302353;C0543465;C1532563;C4552983
2684,potassium — mmol / liter,C0032821;C0202194;C0304475;C0439190;C0475211;C0597277;C3714637
2684,potassium — mg / dl,C0032821;C0202194;C0304475;C0439269;C0597277;C3714637
2684,potassium supplement,C0304475
2684,potassium at admission,C0032821;C0184666;C0202194;C0304475;C0597277;C0809949;C3714637
2684,potassium - sparing at last follow - up,C0032821;C0202194;C0304475;C0589120;C0597277;C1522577;C1704685;C3274571;C3714637
2684,potassium - sparing at enrollment,C0032821;C0202194;C0304475;C0597277;C1516879;C1696073;C3714637;C3888021
2684,potassium ( mmol / l ),C0032821;C0202194;C0304475;C0597277;C1532563;C3714637
2684,potassium ( mg / dl ),C0032821;C0202194;C0304475;C0439269;C0597277;C3714637
2684,potassium ( meql ),C0032821;C0202194;C0304475;C0597277;C3714637
2684,potassium ( meq / l ),C0032821;C0202194;C0304475;C0439375;C0597277;C3714637
2684,potassium,C0032821;C0202194;C0304475;C0597277;C3714637
2684,hypokalemia ‡   ( potassium < nmbr . nmbr mmol / l ),C0020621;C0032821;C0202194;C0304475;C0597277;C1532563;C3714637;C4553966
2684,hyperkalemia ‡   ( potassium ≥ nmbr . nmbr mmol / l ),C0020461;C0032821;C0202194;C0304475;C0597277;C1532563;C3714637;C4552983
2683,prior therapy with omalizumab : yes,C0966225;C1514463;C1549445;C1705108;C1710701
2683,omalizumab ( lsm ),C0966225
2683,omalizumab,C0966225
2682,golimumab nmbr mg / kg + mtx,C0025677;C0439272;C1417487;C2353893
2682,golimumab,C2353893
2681,maximum cimt a med an,C0806909;C1552615;C2826546
2681,maximum cimt < median,C0549183;C0806909;C0876920;C1552615;C2347635;C2348144;C2826546;C2939193
2681,maximum,C0806909;C1552615;C2826546
2681,average of maximum far wall cimt ( mm ),C0205108;C0677535;C0806909;C1510992;C1552615;C2825518;C2826546;C4330985;C4554674
2681,average of maximum common carotid cimt ( mm ),C0205214;C0741968;C0806909;C1510992;C1522138;C1552615;C2825518;C2826546;C3245511;C4330985;C4554674
2681,average maximum common and bifurcation cimt ( mm ),C0806909;C1510992;C1552615;C2825518;C2826546
2681,average maximum cimt ( mm ),C0806909;C1510992;C1552615;C2825518;C2826546;C4330985;C4554674
2680,ses - cd,C0007928;C0034283;C4552032
2680,previous cd related surgery ( ref ) a,C0007928;C0034283;C0205156;C1552607;C4552032
2680,patients with eligible ses - cd score,C0007928;C0030705;C0034283;C0449820;C1548635;C4050231;C4552032
2680,patients with early cd ( n = nmbr ),C0007928;C0030705;C0034283;C1279919;C4552032
2680,no previous cd related surgerynmbr,C0007928;C0034283;C0205156;C1552607;C4552032
2680,ileum ses - cd score,C0007928;C0020885;C0034283;C0449820;C4050231;C4552032
2680,colon ' ses - cd score,C0007928;C0009368;C0034283;C0449820;C3888384;C4050231;C4552032
2680,cd complications,C0007928;C0009566;C0034283;C1171258;C4552032
2680,cd [gemini nmbr] * ’,C0007928;C0034283;C4552032
2680,( total ses - cd score at,C0007928;C0034283;C2964552;C4552032
2679,chadsnmbrscoref,C0007928;C1413373
2679,chadsnmbr^,C0007928;C1413373
2679,chadsnmbr   score,C0007928;C1413373
2679,chadsnmbr scoret,C0007928;C1413373
2679,chadsnmbr scoreb,C0007928;C1413373
2679,chadsnmbr score per outcome stroke or systemic embolism,C0007928;C1413373
2679,chadsnmbr score nmbr - nmbr,C0007928;C1413373
2679,chadsnmbr score nmbr,C0007928;C1413373
2679,chadsnmbr score > nmbr,C0007928;C1413373
2679,chadsnmbr score *,C0007928;C1413373
2679,chadsnmbr score,C0007928;C1413373
2679,chadsnmbr < nmbr,C0007928;C1413373
2679,chadsnmbr,C0007928;C1413373
2679,chads score,C0007928;C1413373
2679,chads - nmbr score,C0007928;C1413373
2679,chadnmbr > nmbr,C0007928;C1413373
2679,baseline chadsnmbra,C0007928;C0168634;C1413373;C1442488
2678,no cs and is,C0010182;C0271160;C3540510;C4085345
2678,no cs and imm,C0010182;C0271160;C3540510;C4085345
2678,neither cs nor imm,C0010182;C0271160;C3540510;C4085345
2678,glycopyrrolate / glycopyrrolate / eflow cs nmbr meg eflow cs nmbr meg ( n = nmbr ) ( n = nmbr ),C0010182;C0017970;C0024489;C0025175;C0072225;C0271160;C3540510;C4085345
2678,glycopyrrolate / eflow cs nmbr meg ( n = nmbr ),C0010182;C0017970;C0024489;C0025175;C0072225;C0271160;C3540510;C4085345
2678,cs use : no,C0010182;C0271160;C3540510;C4085345
2678,cs only,C0010182;C0205171;C0271160;C1720467;C3540510;C4085345
2678,cs and is,C0010182;C0271160;C3540510;C4085345
2678,cs and imm,C0010182;C0271160;C3540510;C4085345
2678,cs and im,C0010182;C0271160;C3540510;C4085345
2678,cs,C0010182;C0271160;C3540510;C4085345
2677,treatment by egfr stage,C0815181;C1739039;C3811844;C3812682
2677,stage nmbrb : egfr > = nmbr and < nmbr ml / min per nmbr . nmbr mnmbr,C0441781;C1739039;C3811844;C3812682
2677,severe impairment ( egfr < nmbr ml / min / m^ ),C0205082;C0221099;C0369637;C0439445;C0441923;C0684336;C1739039;C3811844;C3812682;C4050465;C4050466
2677,prevalent kidney disease ( egfr < nmbr ml / min / usm^ or maeroalbuminuria uacr > nmbr mg / g ),C0022658;C0033105;C0220900;C0439445;C1739039;C3811844;C3812682
2677,patients with egfr nmbr > nmbr to < nmbr ml / min / nmbr . nmbrmnmbr,C0030705;C1739039;C3811844;C3812682
2677,patients with egfr > nmbr ml / min / nmbr . nmbrmnmbr at baseline,C0030705;C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
2677,patients with egfr > nmbr ml / min / nmbr . nmbrmnmbr,C0030705;C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
2677,patients with egfr < nmbr ml / min / nmbr . nmbrmnmbr at baseline,C0030705;C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
2677,moderate impairment ( egfr nmbr – nmbr ),C0205081;C0221099;C0684336;C1739039;C1881878;C3811844;C3812682;C4049705;C4049706;C4085643;C4321335
2677,moderate impairment ( egfr nmbr - nmbr ml / min / m^ ),C0205081;C0221099;C0369637;C0439445;C0441923;C0684336;C1739039;C1881878;C3811844;C3812682;C4049705;C4049706;C4085643;C4321335
2677,moderate impairment ( egfr nmbr - nmbr ),C0205081;C0221099;C0684336;C1739039;C1881878;C3811844;C3812682;C4049705;C4049706;C4085643;C4321335
2677,mild impairment ( egfr nmbr – nmbr ),C0221099;C0684336;C1739039;C2945599;C3811844;C3812682
2677,mild impairment ( egfr nmbr - nmbr ml / min / m^ ),C0221099;C0369637;C0439445;C0441923;C0684336;C1739039;C2945599;C3811844;C3812682
2677,mild impairment ( egfr nmbr - nmbr ),C0221099;C0684336;C1739039;C2945599;C3811844;C3812682
2677,mdrd egfr,C1739039;C3811844;C3812682;C3839656
2677,mdrd - egfr ( ml / min per nmbr . nmbr mnmbr ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682;C3839656
2677,fgf - nmbr low / egfr > nmbr,C0016026;C0205251;C0919505;C1550472;C1739039;C3811844;C3812682;C3890211;C4048187;C4321351;C4522223
2677,fgf - nmbr low / egfr < nmbr,C0016026;C0205251;C0919505;C1550472;C1739039;C3811844;C3812682;C3890211;C4048187;C4321351;C4522223
2677,fgf - nmbr high / egfr > nmbr,C0016026;C0205250;C0919505;C1299351;C1739039;C2700149;C3811844;C3812682;C3887512;C3889660;C4321237;C4522209
2677,fgf - nmbr high / egfr < nmbr,C0016026;C0205250;C0919505;C1299351;C1739039;C2700149;C3811844;C3812682;C3887512;C3889660;C4321237;C4522209
2677,established renal disease ( egfr nmbr - < nmbr ml / min / nmbr . nmbr m^ with any uacr mg / g or egfr > nmbr - nmbr ml / inin / lnmbr mnmbr with an uacr > nmbr mg / g ) without previous maerovaseular and albuminuria disease,C0022658;C0369637;C0441923;C0443211;C1272684;C1739039;C3811844;C3812682;C3829050
2677,egfr_p_interaction,C1704675;C1739039;C3811844;C3812682
2677,egfr using cg / mdrd formulae,C1739039;C3811844;C3812682
2677,egfr nmbr . nmbr - nmbr . nmbr ( vs egfr > nmbr ),C1739039;C3811844;C3812682
2677,egfr nmbr - nmbr,C1739039;C3811844;C3812682
2677,egfr from the mdrd equation ( sd ),C0552449;C1739039;C2699239;C3811844;C3812682;C3839656
2677,egfr category,C0683312;C1739039;C3811844;C3812682;C3889287
2677,egfr and albuminuria,C1739039;C3811844;C3812682
2677,egfr > nmbr,C1739039;C3811844;C3812682
2677,egfr < nmbr . nmbr ( vs egfr > nmbr ),C1739039;C3811844;C3812682
2677,egfr < nmbr,C1739039;C3811844;C3812682
2677,egfr -,C1739039;C3811844;C3812682
2677,egfr +,C1739039;C3811844;C3812682
2677,egfr ( mumin / nmbr . nmbr mnmbr ),C0369637;C0441923;C1739039;C3811844;C3812682
2677,egfr ( ml / min per nmbr - nmbr kg / m^ ),C0369637;C0439402;C0441923;C1739039;C3811844;C3812682
2677,egfr ( ml / min / nmbr . nmbr mnmbr [mdrdequation] ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
2677,egfr ( mdrd ),C1739039;C3811844;C3812682;C3839656
2677,egfr,C1739039;C3811844;C3812682
2677,ct  calcitonin  cv  cardiovascular  egfr  estimated glomerular filtration rate  hbalc  glycated hemoglobin  hnmbr  histamine nmbr  iqr  interquartile range  n  number of patients  sd  standard deviation .,C0006668;C0007226;C1739039;C3538987;C3811844;C3812682;C3887460;C4048877;C4318503
2677,ckd ( egfr < nmbrb ),C1561643;C1739039;C3811844;C3812682
2677,ckd ( egfr < nmbr ),C1561643;C1739039;C3811844;C3812682
2677,bp = blood pressure  egfr = estimated glomerular filtration rate ( men : nmbr en : nmbr x cr nmbr . nmbr x age nmbr . nmbr x nmbr . nmbr )  hdl = high - density lipoprotein .,C0005823;C1739039;C3811844;C3812682
2677,baseline egfr ≥ nmbr to < nmbr,C0168634;C1442488;C1739039;C3811844;C3812682
2677,baseline egfr < nmbr,C0168634;C1442488;C1739039;C3811844;C3812682
2677,baseline egfr ( ml / min per nmbr « nmbr m ’ ),C0168634;C0369637;C0439445;C0441923;C1442488;C1739039;C3811844;C3812682
2677,baseline egfr,C0168634;C1442488;C1739039;C3811844;C3812682
2677,aceis  angiotensin - converting enzyme inhibitors  c  candesartan  des  drug - eluting stent  egfr  estimated glomerular filtration rate  hdl  high - density lipoprotein  ldl  low - density lipoprotein  nc  non - candesartan .,C0003015;C0011702;C0717550;C1322815;C1739039;C2757044;C3811844;C3812682;C4551552
2677,> nmbr egfr,C1739039;C3811844;C3812682
2676,estimated glomerular filtration rate^,C3811844
2676,estimated glomerular filtration rate — no . ( % ),C3811844
2676,estimated glomerular filtration rate — ml / min / nmbr . nmbr mnmbr of body - surface area §,C0017446;C0205146;C0369637;C0439445;C0441923;C0489451;C3811844
2676,estimated glomerular filtration rate — ml / min / nmbr . nmbr mnmbr,C0369637;C0439445;C0441923;C3811844
2676,estimated glomerular filtration rate — ml / min / nmbr . nmbr m^,C0369637;C0439445;C0441923;C3811844
2676,estimated glomerular filtration rate §,C3811844
2676,estimated glomerular filtration rate | |,C3811844
2676,estimated glomerular filtration rate < nmbr ml / min per nmbr . nmbr mnmbr,C0369637;C0439445;C0441923;C3811844
2676,estimated glomerular filtration rate < nmbr ml / min / nmbr . nmbr mnmbr — no . / total no . ( % ) §,C0369637;C0439445;C0441923;C3811844
2676,estimated glomerular filtration rate < nmbr ml / min / nmbr . nmbr mnmbr : i : §,C0021966;C0023806;C0221138;C0369637;C0439445;C0441923;C0702093;C1524029;C3811844;C3813700
2676,estimated glomerular filtration rate < nmbr,C3811844
2676,estimated glomerular filtration rate - no . ( % ) : :,C3811844
2676,estimated glomerular filtration rate - ml / min / nmbr . nmbrmnmbrtt,C0369637;C0439445;C0441923;C1452561;C3811844;C4554543
2676,estimated glomerular filtration rate - ml / min,C0439445;C3811844
2676,estimated glomerular filtration rate ( ml / min / nmbr . nmbrmnmbr ),C0369637;C0439445;C0441923;C3811844
2676,estimated glomerular filtration rate ( mdrd ),C3811844;C3839656
2676,estimated glomerular filtration rate,C3811844
2675,cutoffs,C1442160
2674,orthopnea,C0085619
2673,orthopaedic,C0029355
2672,neutropenia,C0023530;C0027947;C0853697
2672,leukopenia,C0023530;C0750394
2671,osteoprotegerin decreased,C0538161;C1308614;C1336645
2670,opg,C1262886;C1336645;C1412836;C1710303
2669,atonic,C0541791
2668,estonia,C0014908
2667,hematologic,C0018943;C0205488
2667,haematological,C0018943;C0200627
2666,somnolence,C0013144;C2830004;C4553740
2665,psycholeptics,C3653516
2664,psychogenic,C0458006
2663,flex ain ' ’,C0347129
2663,ain,C0347129
2662,spain ( n = nmbr ),C0037747
2662,spain,C0037747
2661,stratum ii,C1710602;C4082587
2661,period ii,C0439531;C1710602;C1948053;C4082587
2661,nyha ii,C1275491;C1710602;C4082587
2661,lor ii,C1416897;C1416899;C1710602;C2986770;C4082587
2661,lavolta ii,C1710602;C4082587
2661,iinmbr ( ii . nmbr ),C1710602;C4082587
2661,ii chiorthaiidone amiodipine,C1710602;C4082587
2661,ii - iv ( % ),C0022326;C1710602;C4082587;C4265176
2661,ii - iv,C0022326;C1710602;C4082587;C4265176
2661,ii ( n = nmbr ),C1710602;C4082587
2661,dual ii,C0205173;C1554184;C1710602;C4082587
2661,asteria i / ii,C0021966;C0221138;C1093020;C1710602;C4082587
2660,dpi ( other than diskus ),C1553480
2660,diskus only,C0205171;C1553480;C1720467
2659,sita nmbr + pio nmbr,C0030800;C2347712
2659,sita / pio nmbr / nmbr,C0030800;C2347712
2659,pio nmbr,C0030800;C2347712
2658,spinal,C0521329
2657,spine *,C0037949;C2752558
2657,spine,C0037949;C2752558
2656,pint,C0560012;C3811619;C3890014;C3890556
2655,pin /,C0175718;C1168556;C1704584
2654,dpp ‐ nmbr inhibitors,C0243077;C1414174
2654,dpp - nmbr inhibitors,C0243077;C1414174
2654,dpp - nmbr inhibitor therapy,C0039798;C0087111;C1363945;C1414174;C1999216
2654,dpp - nmbr inhibitor,C1414174;C1999216
2654,dpp - nmbr,C1414174
2653,other lipid - modifying drug 一 no . ( % ),C0013227;C0023779;C0392747;C1254351
2653,other lipid - modifying drug use at study entry,C0013175;C0013227;C0023779;C0042153;C0242510;C0392747;C0457083;C0557651;C0869040;C1254351;C1705654;C1947944;C2603343
2653,lipid - modulating drug,C0013227;C0023779;C0443264;C1254351
2653,lipid - lowerinq druq,C0023779
2652,mean lipid difference ( mg / dl ) hdl - c,C0023779;C0439269;C0444504;C1705241;C1705242;C2347634;C2348143;C3715113
2652,lipids — mg / dl,C0023779;C0439269
2652,lipid measures at baseline — mg / dl,C0023779
2652,lipid difference ( mg / dl ),C0023779;C0439269;C1705241;C1705242
2652,lipid and lipoprotein values ( mg / dl ),C0023779
2651,mean lipid values,C0023779;C0042295;C0444504;C2347634;C2348143
2651,lipids,C0023779
2651,lipid values,C0023779;C0042295
2651,lipid trial participantss,C0008976;C0023779
2651,lipid trial participantsk,C0008976;C0023779
2651,lipid profile,C0023779;C1979963;C2003903
2651,lipid modifiers,C0023779;C4284280
2651,lipid concentrations,C0023779;C0086045
2651,lipid,C0023779
2650,other bph - luts therapy,C0005001;C0039798;C0087111;C0574785;C1363945;C1704272
2650,bph - related health status,C0005001;C1704272
2650,benign prostatic hyperplasia,C1704272
2649,luts = lower urinary tract symptoms  is =,C0574785
2649,luts / bph characteristics,C0005001;C0574785;C1521970;C1704272
2648,no nasal polyps,C0027430
2648,nasal polyps,C0027430
2648,nasal polyposis or chronic rhinosinusitis — no . { % ),C0027430
2648,baseline presence of nasal polyps,C0027430;C0150312;C0168634;C0392148;C1442488;C3854307
2647,smokinq status,C0449438
2647,other glucose status,C0017725;C0449438
2647,lev status,C0023556;C0449438
2647,ish status,C0449438
2647,hormonal status,C0449438;C0458083
2647,h . pylori status,C0079488;C0449438
2647,frailty status,C0424594;C0449438
2647,emotional status,C0013987;C0449438;C0849912
2647,cortteosterom relrsclory status,C0449438
2647,aed inducer status,C0449438;C0887457;C3898767
2646,status ( spmsq > nmbr,C0449438
2646,status ( spmsq < nmbr,C0449438
2646,aha status at screeningb,C0050451;C0449438;C0772110
2645,severe ( ipss > nmbr ) age group,C0027362;C0205082;C1019118;C1998280;C2348001;C2827405;C3811063;C4050465;C4050466
2645,severe ( ipss > nmbr ) ( n = nmbr ),C0205082;C1019118;C1998280;C2827405;C3811063;C4050465;C4050466
2645,severe ( ipss > nmbr ),C0205082;C1019118;C1998280;C2827405;C3811063;C4050465;C4050466
2645,moderate ( ipss < nmbr ) ( n = nmbr ),C0205081;C1019118;C1881878;C1998280;C2827405;C3811063;C4049705;C4049706;C4085643;C4321335
2645,mean ipss,C0444504;C1019118;C1998280;C2347634;C2348143;C2827405;C3811063
2645,ipss voiding subscore,C1019118;C1998280;C2827405;C3811063
2645,ipss total score,C1019118;C1998280;C2827405;C2964552;C3811063
2645,ipss qol ( ls,C0023668;C0518214;C1019118;C1998280;C2827405;C3811063
2645,ipss qol,C0518214;C1019118;C1998280;C2827405;C3811063
2645,ipss hrql,C1019118;C1998280;C2827405;C3811063
2645,ipss categories,C0683312;C1019118;C1998280;C2827405;C3811063
2645,ipss - v,C1019118;C1998280;C2827405;C3811063
2645,ipss - s,C1019118;C1998280;C2827405;C3811063
2645,ipss ( mean ± sd ),C0444504;C1019118;C1998280;C2347634;C2348143;C2699239;C2827405;C3811063
2645,ipss ( ls mean ± se ),C0023668;C0036919;C0444504;C1019118;C1998280;C2347634;C2348143;C2827405;C3811063
2645,ipss,C1019118;C1998280;C2827405;C3811063
2645,= international prostate symptom score ,C1998280
2645,( ngml ' ' ) total mean ipss score,C0439175;C0439810;C0444504;C1019118;C1998280;C2347634;C2348143;C2827405;C2964552;C3533236;C3811063
2644,alleles,C0002085
2643,all mis *,C0687670;C1333208;C1412384;C3538735
2643,all mis,C0687670;C1333208;C1412384;C3538735
2642,sample size ( n ),C0242618
2642,sample size,C0242618
2641,icsa plus laba,C0332287
2641,basal plus bolus,C0205112;C0332287;C1186706;C1511237;C1705509;C3812160
2640,dasnmbr score,C0051767;C0057671
2640,dasnmbr - nmbr ( esr ) nmbr,C0051767;C0057671;C3811131
2640,dasnmbr - nmbr ( esr ) < nmbr . nmbrt,C0051767;C0057671;C3811131
2640,dasnmbr - nmbr ( esr ) < nmbr . nmbr *,C0051767;C0057671;C3811131
2640,dasnmbr - nmbr ( esr ),C0051767;C0057671;C3811131
2640,dasnmbr - hscrp,C0051767;C0057671
2640,dasnmbr - esr lda,C0051767;C0057671;C3811131;C4553195
2640,dasnmbr - esr,C0051767;C0057671;C3811131
2640,dasnmbr ( esr ),C0051767;C0057671;C3811131
2640,dasnmbr,C0051767;C0057671
2639,subsets,C1515021
2639,other climate subset,C0008946;C1515021
2639,ics subset,C0815320;C1515021;C4551720
2639,ics / laba subset,C0815320;C1515021;C4551720
2639,hot climate subset,C0178683;C1515021
2638,ast increased,C1415181;C3891303
2638,ast,C1415181;C3891303
2637,sitting pulse,C0232117;C0277814;C0391850;C1947910;C2584297;C4050224
2637,pulse — beats / min,C0232117;C0391850;C1947910
2637,pulse rate,C0232117
2637,pulse in beats / minute,C0232117;C0391850;C0439385;C1947910
2637,pulse ( beats / min ) cholesterol ( mmol / l ),C0232117;C0391850;C1947910
2637,pulse,C0232117;C0391850;C1947910
2636,pulse rate ( mean nmbr h ),C0033727;C0232117;C0369286;C0441932;C0444504;C0564385;C2347634;C2348143;C4528284
2636,pulse rate ( bpm ),C0232117
2635,no . japanese,C0376247;C1556094
2635,japanese subpopulation,C0376247;C1257890;C1556094
2635,japanese subgroup ( n = nmbr ),C0376247;C1079230;C1515021;C1556094
2635,japanese,C0376247;C1556094
2634,urgent cor revasc,C0018787;C0056331;C0378365;C0439609;C3272275
2634,symptomatic heart fail,C0018787;C0231220
2634,hospitaiization for heart faiiure,C0018787
2634,cor revasc,C0018787;C0056331;C0378365
2634,congestive heart,C0018787;C0742742
2633,lv heart structure,C0018787;C0023128;C0731033;C1881413
2633,heart failurea,C0018787
2632,pre - operative cardiac medications *,C0018787;C1522601;C1882154;C2347660
2632,ns cardiac cisease,C0018787;C0038944;C1112705;C1522601;C1705982
2632,cardiac stretch,C0018787;C0600080;C1522601
2632,cardiac risk,C0018787;C0035647;C1522601;C4552904
2632,cardiac parameters,C0018787;C0449381;C1522601
2632,cardiac mediations,C0018787;C0680727;C1522601
2632,cardiac failurec,C0018787;C1522601
2632,cardiac enzyates raised,C0018787;C1522601
2632,cardiac diseasec,C0018787;C1522601
2632,cardiac and echocardiography parameters,C0018787;C1522601
2632,cardiac,C0018787;C1522601
2632,bmi ( kg / mnmbr ) cardiac parameters,C0018787;C0449381;C0578022;C1522601;C1532718
2631,native coronary,C0018787;C0302891
2631,coronary,C0018787
2631,cardio - renal risk,C0018787;C0022646;C0035647;C4552904
2630,qmax category,C0683312;C3889287
2630,mean ± sd age ( y ) mean bmi category ( % ),C0001779;C0444504;C0578022;C0683312;C2347634;C2348143;C2699239;C3889287
2630,mace category,C0349381;C0683312;C0949745;C1445339;C3889287
2630,hemoglobin category,C0019046;C0683312;C3889287
2630,glycatedhemoglobin category,C0683312;C3889287
2630,creatinine clearance category,C0683312;C0812399;C3889287
2630,category — no . / total no . ( % ),C0683312;C3889287
2630,category nmbr and nmbr,C0683312;C3889287
2630,category nmbr,C0683312;C3889287
2630,category,C0683312;C3889287
2630,categorical variables . no . ( % ) * ’,C0439828;C0683312;C3889287
2630,categorical variables,C0439828;C0683312;C3889287
2630,cardiovascular disease risk category,C0683312;C1113685;C3889287
2630,bmi category ( kg / mnmbr ),C0578022;C0683312;C1532718;C3889287
2630,bmi category ( % ),C0578022;C0683312;C3889287
2630,bmi category,C0578022;C0683312;C3889287
2630,bmi categories,C0578022;C0683312
2630,background csdmard category,C0683312;C1706907;C3889287
2630,age category >,C0001779;C0683312;C3889287
2630,age category ( years ),C0683312;C1510829;C3889287
2630,age category ( % ),C0001779;C0683312;C3889287
2630,age category,C0001779;C0683312;C3889287
2630,/ \ge category,C0683312;C1292300;C3538705;C3889287
2629,rankin scale ≥ nmbr,C0451405
2628,karnofsky score 竺 nmbr,C0206065
2628,karnofsky score < nmbr,C0206065
2627,paroxysmal ( n,C0205311
2627,paroxysmal !,C0205311
2627,paroxysmal,C0205311
2626,paroxysmal atrial fibrillation — no . ( % ),C0235480;C4050122
2626,paroxysmal af,C0235480
2626,no history of paroxysmal af,C0019664;C0019665;C0235480;C0262512;C0262926;C1705255;C2004062
2626,history of paroxysmal af,C0019664;C0019665;C0235480;C0262512;C0262926;C1705255;C2004062
2625,no . of coronary vessels with > nmbr % diameter stenosis,C0010075
2624,urgent coronary revascularization,C0439609;C0877341;C3272275
2624,prior coronary revascularization — no . { % ),C0332152;C0877341;C2826257
2624,prior coronary revascularization ( pci or cabg ),C0332152;C0877341;C2826257;C4049621
2624,prior coronary revascularization,C0332152;C0877341;C2826257
2624,coronary revascularization procedure,C0877341
2624,coronary revascularization,C0877341
2624,coronary revascularisation §,C0877341
2624,coronary revascularisation,C0877341
2624,any coronary revascularization,C0877341
2623,nice secondary prevention onlyb,C0679699;C4087029
2623,nice primary prevention onlyb,C0033144;C4087029
2622,coronary eventsnmbr,C0741923
2622,acute coronary event,C0205178;C0741923
2621,pulmonary disease — no . ( % ),C0024115
2621,pulmonary disease,C0024115
2620,pulmonary embolism only,C0034065;C0205171;C1720467
2620,pulmonary embolism,C0034065
2619,pulmonary function tests ( post - bronchodilator ),C0024119;C2598152
2619,pulmonary function tests,C0024119;C2598152
2618,focal,C0205234
2617,hmgcoa rl,C0047420;C1419337;C3539667
2616,phenobarbital,C0031412
2615,premenopausal,C0279752
2614,medal,C0524670
2613,dermal,C0221928;C1522447
2612,not at goal,C0018017;C1518422;C1571704
2612,goal,C0018017;C1571704
2612,distance to ldl - c goal,C0012751;C0018017;C1571704
2612,bp goal,C0018017;C0037623;C1415692;C1571704;C1708288;C4318478
2612,at goal,C0018017;C1571704
2612,% to goal,C0018017;C1571704
2611,other oral hypoglycemic drug ( s ),C0359086
2611,oral hypoglycemics hormone replacement,C0282402;C0359086
2611,oral hypoglycemics,C0359086
2611,oral hypoglycemic drugs only,C0205171;C0359086;C1720467
2611,oral hypoglycemic drug,C0359086
2611,oral hypoglycemic agentsj,C0359086
2611,oral hypoglycemic agents,C0359086
2611,oral hypoglycemic agent,C0359086
2611,oral hypoglycemic,C0359086
2611,oral hypoglycaemics only,C0205171;C0359086;C1720467
2611,oral antihyperglycaemic,C0359086
2611,combined insulin / oral hypoglycaemic agent use,C0205195;C0240016;C0359086
2611,any oral hypoglycemic drug 一 no . ( % ),C0359086
2610,other hypoglycemic agent,C0020616
2610,other antihyperglycemic agents,C0020616
2610,naive to antihyperglycemic agent therapy,C0020616;C0039798;C0087111;C0450442;C1254351;C1363945;C1521826
2610,hypoglycemic agent,C0020616
2610,hypoglycaemic therapy,C0020616;C0039798;C0087111;C1363945
2610,hypoglycaemic agents,C0020616
2610,antihyperglycemic oral agent therapy,C0020616;C0039798;C0087111;C0442027;C0450442;C1254351;C1363945;C1521826;C4521986
2610,antihyperglycemic,C0020616
2609,hypovolaemia,C0546884
2608,hyponatremia,C0020625;C4553967
2608,hypokalemia,C0020621;C4553966
2608,hypokalaemia,C0020621;C4553966
2607,symptomatic hypoglycaemia,C0020615;C0231220;C4553659
2607,severe hypoglycemia,C0020615;C0205082;C4050465;C4050466;C4553659
2607,nonsevere hypoglycemia,C0020615;C4553659
2607,non - severe hypoglycaemia,C0020615;C0205082;C1518422;C4050465;C4050466;C4553659
2607,no severe hypoglycemia,C0020615;C0205082;C4050465;C4050466;C4553659
2607,no nonsevere hypoglycemia,C0020615;C4553659
2607,major hypoglycemia,C0020615;C0205082;C0205164;C4318856;C4521762;C4553659
2607,hypoglycemia^,C0020615;C4553659
2607,hypoglycemia,C0020615;C4553659
2607,b nonsevere hypoglycemia,C0020615;C4553659
2607,a severe hypoglycemia,C0020615;C0205082;C4050465;C4050466;C4553659
2606,normoglycemicnmbr,C0580545
2606,normoglycemic^,C0580545
2606,normoglycemic {,C0580545
2606,normoglycemic,C0580545
2606,normoglycemia^,C0580545
2606,normoglycemia,C0580545
2606,normoglycaemic individuals,C0027361;C0237401;C0580545
2606,individuals with normoglycaemia,C0027361;C0237401;C0580545
2605,no dysglycaemia or mets pbo ( n = nmbr ) vs evomab ( n = nmbr ),C1960636
2605,no dysglycaemia or mets,C1960636
2605,dysglycemic categories,C0683312;C1960636
2605,dysglycaemia or mets,C1960636
2604,americas * *,C0002454;C0596070
2604,americas ( n = nmbr ),C0002454;C0596070
2604,americas,C0002454;C0596070
2604,american,C0596070
2603,n america,C0002454;C0369718;C0441922
2603,america,C0002454
2602,mexican,C0240339
2601,mexico,C0025885
2600,symptomatic ich,C0019191;C0231220;C3272597;C3281105
2600,ich,C0019191;C3272597;C3281105
2599,severe recurrent ischemia,C0022116;C0205082;C1455761;C2945760;C4050465;C4050466;C4321499
2599,recurrent ischemia - urgent revascularization,C0022116;C0439609;C0581603;C1455761;C2945760;C3272275;C4321499
2599,recurrent ischemia,C0022116;C1455761;C2945760;C4321499
2599,rec . ischemia requiring revasc,C0022116;C0378365;C1424025;C2606415;C4321499
2599,rec . ischemia leading to hosp,C0022116;C1424025;C2606415;C4321499
2599,rec . ischemia leading to hasp,C0022116;C1424025;C2606415;C4321499
2599,rec . ischemia due worsening angina,C0002965;C0022116;C0678226;C1424025;C2606415;C3146286;C4321499
2599,rec . ischemia due to ecg changes,C0022116;C0678226;C1424025;C1623258;C2606415;C4321499
2599,rec . ischemia,C0022116;C1424025;C2606415;C4321499
2599,no ischemia ( n = nmbr,C0022116;C4321499
2599,ischemia on cecg ( n = nmbr,C0022116;C4321499
2599,ischemia on cecg ( % ),C0022116;C4321499
2599,ischemia driven revascularization,C0022116;C4321499
2599,ischemia - driven revascularization,C0022116;C4321499
2599,ischemia,C0022116;C4321499
2599,global ischemia ( % ) * *,C0022116;C0205246;C2348867;C4321499
2599,global ischemia,C0022116;C0205246;C2348867;C4321499
2599,anti - ischaemia agents *,C0022116;C0040616;C4321499
2598,serious teaes,C0205404
2598,serious aes,C0205404;C1412268;C2699274
2598,serious ae,C0205404;C3887670
2598,serious,C0205404
2598,any serious teaes,C0205404
2598,any serious ae,C0205404;C3887670
2598,> nmbr serious aes,C0205404;C1412268;C2699274
2597,syncope — no . ( % ),C0039070;C3541349;C4554644
2597,syncope,C0039070;C3541349;C4554644
2596,ppg post - meal test,C0022885;C0039593;C0376674;C0392366;C0456984;C1418888;C1515976;C3831328;C4318744
2596,positive orthostatic test },C0022885;C0039593;C0231472;C0392366;C0439178;C0456984;C1446409;C1514241;C1515976;C2825490;C3812269;C3831328;C4318744
2596,orthostatic test *,C0022885;C0039593;C0231472;C0392366;C0456984;C1515976;C3831328;C4318744
2596,likelihood test,C0022885;C0033204;C0039593;C0392366;C0456984;C1515976;C3831328;C4318744
2596,laboratory tests,C0022885
2596,laboratory testing,C0022885
2596,dfisher ' s exact test .,C0022885;C0039593;C0392366;C0456984;C1515976;C2828393;C3831328;C4050514;C4318744
2596,cfisher ' s exact test .,C0022885;C0039593;C0392366;C0456984;C1515976;C2828393;C3831328;C4050514;C4318744
2595,leukocytes,C0023516
2595,blood leukocyte count ( nmbr cells per l ),C0023508;C0023516;C0347983;C0427512
2594,sexy,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
2594,sex :,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
2594,sex,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
2594,gender n ( % ),C0079399;C1522384
2594,gender male,C0079399;C0086582;C1522384;C1706180;C1706428;C1706429
2594,gender [n ( % ) ],C0079399;C1522384
2594,gender : male,C0079399;C0086582;C1522384;C1706180;C1706428;C1706429
2594,gender :,C0079399;C1522384
2594,gender - n ( % ),C0079399;C1522384
2594,gender - male,C0079399;C0086582;C1522384;C1706180;C1706428;C1706429
2594,gender ( male ),C0079399;C0086582;C1522384;C1706180;C1706428;C1706429
2594,gender ( m / f ),C0079399;C1306057;C1522384
2594,gender,C0079399;C1522384
2594,eze / simva gender,C0079399;C1522384
2594,> nmbr yrs sex :,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
2594,> nmbr yr sex,C0009253;C0036864;C0079399;C0439234;C0804628;C1314687;C1522384
2593,tnmbrd,C2603360
2593,t - jj ( nmbr - nmbr ),C2603360
2593,t,C2603360
2593,other ( nmbr . nmbr % ) t,C2603360
2593,nmbr . nmbr - nmbr . nmbr % t,C2603360
2593,nmbr . ' ^ / nmbrtnmbrc } u,C0439148;C2603360
2592,alcohol abuse,C0085762;C4050601
2591,alcohol^,C0001962;C0001975
2591,alcohol usef,C0001962;C0001975
2591,alcohol useb,C0001962;C0001975
2591,alcohol drinker,C0001962;C0001975;C0556338
2591,alcohol > nmbr / wk,C0001962;C0001975;C0332174;C0439230
2591,alcohol < = nmbr / wk,C0001962;C0001975;C0332174;C0439230
2591,alcohol,C0001962;C0001975
2590,reduced hdl cholesterol,C0151691
2590,low hdl cholesterol * |,C0151691
2590,low hdl cholesterol,C0151691
2590,low hdl - c,C0151691
2589,colon or rectum,C0009368;C3888384
2589,colon only,C0009368;C0205171;C1720467;C3888384
2589,colon,C0009368;C3888384
2589,all of the colon,C0009368;C3888384
2588,t - score at femoral neck,C0015815;C3854607
2588,mean femoral neck t score,C0015815;C3533236
2588,femoral neck bmd ( g / cmnmbr ),C0015815;C0439267
2588,femoral neck ( n = nmbr,C0015815
2588,femoral neck,C0015815
2588,at femoral neck,C0015815
2587,femoral neckc,C0015811
2587,femoral access — no . / total no . ( % ),C0015811
2587,femoral access,C0015811;C0444454;C1554204
2587,femoral,C0015811
2586,rate of oral or systemic corticosteroid,C0442027;C0871208;C1521828;C4521986
2586,previous oral glucose - lowering agents,C0017725;C0205156;C0441994;C0442027;C0450442;C1254351;C1521826;C1552607;C2003888;C4521986
2586,oral β - adrenergics,C0001637;C0442027;C4521986
2586,oral treprostinil ( n = nmbr ),C0442027;C1145760;C4521986
2586,oral study drug administered — no . / total no . ( % ),C0013175;C0442027;C4521986
2586,oral or other systemic corticosteroid,C0442027;C4521986
2586,oral glucocorticoid dose,C0017710;C0178602;C0442027;C0869039;C1114758;C4521986
2586,oral fi - blockers,C0442027;C4050619;C4521986
2586,oral blood glucose - lowering drug nmbr ( nmbr . nmbr ),C0005802;C0013227;C0017725;C0018938;C0441994;C0442027;C1254351;C2003888;C4521986
2586,oral blood glucose - lowering,C0005802;C0441994;C0442027;C2003888;C4521986
2586,oral antidiabetes monotherapya,C0442027;C4521986
2586,oral antidiabetes combination therapy without insulina,C0009429;C0442027;C0556895;C4521986
2586,oral ( % ),C0442027;C4521986
2586,oral,C0442027;C4521986
2586,no po,C0032729;C0442027
2586,day nmbr oral glucocorticoid use — no . { % ),C0017710;C0332173;C0439228;C0439505;C0442027;C4521986
2586,concomitant oral glucose - lowering agents,C0017725;C0441994;C0442027;C2003888;C2347852;C4521986
2585,furosemide equivalent,C0016860;C0205163;C0439185
2585,furosemide,C0016860
2584,euroscore logistic,C3164744
2584,euroscore additive,C0442796;C1550602;C3164744
2583,musculoskeletal stiffness,C0427008;C0497254;C2707260
2583,musculoskeletal,C0497254;C2707260
2582,other / multiple,C0439064
2582,multiple tnfi and other bdmards §,C0439064
2582,multiple tnfi *,C0439064
2582,multiple diagnoses,C0011900;C0439064
2582,multiple ( nmbr + ) chd risk,C0439064;C1282512
2582,multiple,C0439064
2582,multi - racial,C0034510;C0439064;C1706779;C3266262;C3669213;C3853635
2581,tc level,C0039411;C0040642;C0041405;C0041698;C0441889;C0456079;C1547707;C1824670;C2946261;C3272447;C4522122
2581,systolic pressure at ankle level ( mmhg ),C0003086;C0003087;C0439475;C0441889;C0456079;C0871470;C1547707;C2946261
2581,serum k + level and drug treatment,C0302353;C0441889;C0456079;C1547707;C2946261
2581,patients with level > nmbr pg / ml,C0030705;C0439297;C0441889;C0456079;C1547707;C2946261
2581,outcome according to renal function level ( in ml / min ),C0022646;C0232804;C0441889;C0456079;C0680240;C0935587;C1274040;C1547707;C2946261
2581,no active cancer center - level inr percent time,C0040223;C0205177;C0439165;C0441889;C0456079;C0525032;C1513817;C1547707;C1704538;C2946261;C3541383;C3853793;C3888249
2581,mean — mm hg level — no . ( % ),C0439475;C0441889;C0444504;C0456079;C1547707;C2347634;C2348143;C2946261
2581,mean — mg / dl level — no . ( % ),C0439269;C0441889;C0444504;C0456079;C1547707;C2347634;C2348143;C2946261
2581,mean crp level,C0441889;C0444504;C0456079;C1547707;C2347634;C2348143;C2946261;C3890735;C4048285
2581,level — no . ( % ),C0441889;C0456079;C1547707;C2946261
2581,level of thyroperoxidase antibody at baseline,C0021965;C0428536;C0441889;C0456079;C0487652;C1318460;C1364508;C1429427;C1547707;C2946261;C3272921
2581,level nmbr immobility^,C0231441;C0441889;C0456079;C1547707;C2946261
2581,level nmbr immobility § | |,C0231441;C0441889;C0456079;C1547707;C2946261
2581,level nmbr,C0441889;C0456079;C1547707;C2946261
2581,ldl cholesterol level,C0023824;C0201950;C0202117;C0428466;C0441889;C0456079;C1547707;C2946261
2581,ldl - c level,C0441889;C0456079;C1547707;C2946261
2581,hscrp level,C0441889;C0456079;C1547707;C2946261
2581,hdl cholesterol level,C0023822;C0201950;C0392885;C0428466;C0441889;C0456079;C1547707;C2946261;C3715113
2581,hdl - c level,C0441889;C0456079;C1547707;C2946261;C3715113
2581,geometric anti - dsdna antibody binding level,C0441889;C0449829;C0456079;C1145667;C1167622;C1547707;C2355607;C2746079;C2946261
2581,european quality of life - nmbr dimensions - nmbr level ( eq - nmbrd ),C0034380;C0205163;C0239307;C0439185;C0439534;C0441889;C0456079;C0518214;C1535514;C1547707;C2946261
2581,elevated natriuretic peptide level ( n = nmbr ),C0205250;C0441889;C0456079;C1144709;C1547707;C2709270;C2946261;C3163633;C3537020
2581,crp level,C0441889;C0456079;C1547707;C2946261;C3890735;C4048285
2581,characteristic_level,C0441889;C0456079;C1521970;C1547707;C2946261
2581,cardiac troponin t level > nmbr . nmbr pg / l,C0439278;C0441889;C0456079;C1547707;C2946261;C3538889
2581,cardiac troponin t level,C0441889;C0456079;C1547707;C2946261;C3538889
2581,blood pressure at target level ( % ) §,C0005823;C0441889;C0456079;C1271104;C1272641;C1521840;C1547707;C2946261;C2986546
2581,baseline total pcsknmbr level by median,C0168634;C0439175;C0439810;C0441889;C0456079;C0549183;C0876920;C1442488;C1547707;C2347635;C2348144;C2939193;C2946261
2581,baseline total pcsknmbr level,C0168634;C0439175;C0439810;C0441889;C0456079;C1442488;C1547707;C2946261
2581,baseline tg level { n = nmbr,C0168634;C0337445;C0441889;C0456079;C1442488;C1547707;C2946261
2581,baseline tg level ( n = nmbr . nmbr ) > nmbr . nmbr mg / dl,C0168634;C0337445;C0439269;C0441889;C0456079;C1442488;C1547707;C2946261
2581,baseline tg level ( n = nmbr,C0168634;C0337445;C0441889;C0456079;C1442488;C1547707;C2946261
2581,baseline ldlc level ( n = nmbr . nmbr ) > nmbr . nmbr mg / dl,C0168634;C0439269;C0441889;C0456079;C1416822;C1442488;C1547707;C2946261
2581,baseline ldlc level ( n = nmbr,C0168634;C0441889;C0456079;C1416822;C1442488;C1547707;C2946261
2581,baseline hdl - c level ( n = snmbr,C0168634;C0441889;C0456079;C1442488;C1547707;C2946261;C3715113
2581,baseline hdl - c level ( n = nmbr » nmbr ) > nmbr . nmbr mg / dl,C0168634;C0439269;C0441889;C0456079;C1442488;C1547707;C2946261;C3715113
2581,baseline hdl - c level ( n = nmbr . nmbr ) > nmbr . nmbr mg / dl,C0168634;C0439269;C0441889;C0456079;C1442488;C1547707;C2946261;C3715113
2581,baseline hdl - c level ( n = nmbr,C0168634;C0441889;C0456079;C1442488;C1547707;C2946261;C3715113
2581,baseline free pcsknmbr level by median,C0168634;C0332296;C0441889;C0456079;C0549183;C0876920;C1442488;C1547707;C1880497;C1996904;C2347635;C2348144;C2939193;C2946261
2581,baseline free pcsknmbr level,C0168634;C0332296;C0441889;C0456079;C1442488;C1547707;C1880497;C1996904;C2946261
2581,atrial fibrillation ldl cholesterol level,C0004238;C0023824;C0202117;C0344434;C0441889;C0456079;C1547707;C1963067;C2946261
2581,antibody binding level at baseline,C0168634;C0428536;C0441889;C0456079;C1145667;C1149306;C1167622;C1442488;C1547707;C2946261
2581,> nmbr . nmbr hdl cholesterol level,C0023822;C0201950;C0392885;C0428466;C0441889;C0456079;C1547707;C2946261;C3715113
2580,undetermined etiology,C0478157
2579,metformin • pioglitazone,C1635037
2579,metformin ? pioglitazone,C1635037
2578,thienopyridine + dipyridamole,C0012582;C1120149
2578,dipyridamole alone,C0012582
2578,dipyridamole,C0012582
2577,no depression,C0011570;C0011581;C0344315;C0460137;C4049644;C4084909;C4085311;C4553827
2577,depression^,C0011570;C0011581;C0344315;C0460137;C4049644;C4084909;C4085311;C4553827
2577,depression ®,C0011570;C0011581;C0344315;C0460137;C4049644;C4084909;C4085311;C4553827
2577,depression,C0011570;C0011581;C0344315;C0460137;C4049644;C4084909;C4085311;C4553827
2577,depressed only,C0344315;C0549249
2577,depressed and low perceived social support,C0344315;C0549249
2576,poland,C0032356
2575,probenecid,C0033209
2574,provoked,C1444748
2573,pnd,C1417807;C1956415;C4552608
2573,paroxysmal nocturnal dyspnea,C1956415
2572,oropharyngeal pain,C2363731;C4554669
2571,pharyngitis,C0031350;C4553308
2570,nasopharyngitis,C0027441
2569,chondroitin,C0008454
2568,phenytoin,C0031507;C0202454
2567,triglycerides nmbrst third,C0036056;C0041004;C0205437;C3272372
2567,triglycerides nmbrnd third,C0041004;C0205437
2567,third yeart,C0205437
2567,slowest third,C0205437;C0439834
2566,nyha iv,C0022326;C1275491;C4265176
2566,nyha,C1275491
2566,( nyha grade iii or iv ),C0205617;C0450094;C0475271;C0687697;C1275491;C3889290;C4050000;C4283820;C4283821;C4283822
2565,nyha ll / lll patients with lvef < nmbr . nmbr at baseline,C1275491
2565,nyha functional classification — no . ( % ) i,C0205245;C0542341;C1275491;C2700217
2565,nyha functional classification — no . ( % ),C0205245;C0542341;C1275491;C2700217
2564,± sd .,C2699239
2564,sd or %,C2699239
2564,sd of sbp,C0085805;C2699239
2564,sd,C2699239
2564,sbp ( sd ),C0085805;C2699239
2564,mssbp ± sd,C2699239
2564,msdbp ± sd,C2699239
2564,dbp ( sd ),C0536221;C2699239;C3813197;C4281799
2564,[sd],C2699239
2564,( sd ),C2699239
2563,symptom score ( sd ),C2699239;C3476546
2563,selena - sledai mean score ( sd ),C0451528;C2699239;C3533236
2563,mean ucsd - sobq score * ( sd ),C2699239;C3533236
2563,mean bdi focal score ( sd ),C0006448;C0205234;C0451022;C2699239;C3533236;C3714938;C3889415
2562,sustained esrd,C0022661;C0035078;C0443318;C2316810
2562,esrd or nmbr % dedine in gfr,C0022661;C0035078;C2316810
2562,esrd or nmbr % decline in gfr,C0022661;C0035078;C2316810
2562,esrd or death,C0022661;C0035078;C2316810
2562,esrd on losartan ( % ),C0022661;C0035078;C0126174;C2316810
2562,esrd *,C0022661;C0035078;C2316810
2562,esrd ',C0022661;C0035078;C2316810
2562,esrd,C0022661;C0035078;C2316810
2562,end - stage renal disease,C0022661;C2316810
2561,this study,C0557651;C2603343
2561,study nmbr . nmbr,C0557651;C2603343
2561,study nmbr,C0557651;C2603343
2561,study medication,C0013227;C0557651;C2603343;C3244316;C4284232
2561,study druga,C0557651;C2603343
2561,study,C0557651;C2603343
2561,six - study placebo - controlled set,C0036849;C0205452;C0557651;C1442518;C1705195;C1706408;C2603343
2561,permanently stopped study drug because of adverse events,C0041755;C0557651;C1272691;C2603343
2561,intravenous study drug administered — no . ( % ),C0013175;C0348016;C0557651;C0683092;C2603343
2561,in extension study,C0231448;C0557651;C1880641;C2603343
2561,administration of study drug ( % ),C0001554;C0013175;C0013227;C0150270;C0262754;C0557651;C1254351;C1533734;C2603343;C3161471;C3469597
2561,administration of study - drug bolus — no . / total no . ( % ),C0001554;C0013175;C0013227;C0150270;C0262754;C0557651;C1186706;C1254351;C1511237;C1533734;C1705509;C2603343;C3161471;C3469597;C3812160
2561,acute dvt study,C0149871;C0205178;C0557651;C2603343;C2926618;C3899446
2561, l = lovastatin . p = pravastatin . f = ﬂ uvastatin . a = atorvastatin . * mean duration of follow - up based on survival times within each trial . overall mean is weighted by trial - speci ﬁ c variances of logrank ( o – e ) for major vascular events . † all trials included dietary intervention : woscops  gissi prevention  lipid  nmbrs  lips  and hps provided dietary advice  afcaps / texcaps  post - cabg  care  allhat  alert  cards  and prosper used american heart association ( aha ) step nmbr diet and care intensi ﬁ ed to step nmbr diet if ldl cholesterol nmbr · nmbr mmol / l ( nmbr mg / dl ) . ‡ other chd includes patients with a history of other symptomatic chd but excludes those with a history of mi ( as already counted in mi column ) . § other vascular includes history of intracerebral bleed  transient ischaemic attack  ischaemic stroke  unknown stroke  and peripheral artery disease . ¶ none includes individuals without a history of mi  symptomatic chd  intracerebral bleed  transient ischaemic attack  ischaemic stroke  unknown stroke  or peripheral artery disease,C0008377;C0036453;C0038952;C0074554;C0150158;C0220921;C0240951;C0489835;C0557651;C0565930;C1705493;C1706420;C1947933;C2603343;C2603362
2560,smoking status current smoker ( n = nmbr ),C1519386;C3173209;C3241966
2560,former / current smoker,C0205156;C0337671;C0521116;C0750523;C1705970;C3173209;C3241966
2560,ex - / current smoker,C0337671;C0521116;C1704625;C1705970;C3173209;C3241966;C4555205
2560,current smokers *,C3173209;C3241966
2560,current smokers ( n = nmbr ),C3173209;C3241966
2560,current smokers ( itt ) ( n = nmbr ),C3173209;C3241966
2560,current smokers ( % ),C3173209;C3241966
2560,current smokers,C3173209;C3241966
2560,current smoker 一 no . ( % ),C3173209;C3241966
2560,current smoker — no . { % ),C3173209;C3241966
2560,current smoker — no . of patients ( % ),C3173209;C3241966
2560,current smoker — no . / total no . ( % ),C3173209;C3241966
2560,current smoker — no . ( % ) blood pressure — mm hg,C3173209;C3241966
2560,current smoker — no . ( % ),C3173209;C3241966
2560,current smoker »,C3173209;C3241966
2560,current smoker yes,C1549445;C1705108;C1710701;C3173209;C3241966
2560,current smoker at screeninga,C3173209;C3241966
2560,current smoker at screening,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164;C3173209;C3241966
2560,current smoker at baseline,C0168634;C1442488;C3173209;C3241966
2560,current smoker : ex - smoker ( % ),C3173209;C3241966
2560,current smoker ( n z nmbr ),C3173209;C3241966
2560,current smoker ( n = nmbr ),C3173209;C3241966
2560,current smoker ( n = nmbr,C3173209;C3241966
2560,current smoker ( > nmbr cigarettes / day ) — no . ( % ),C0332173;C0439228;C0439505;C0677453;C3173209;C3241966
2560,current smoker ( % ),C3173209;C3241966
2560,current smoker,C3173209;C3241966
2560,> nmbr . nmbr bpm current smoker,C3173209;C3241966
2559,nmbr coenzyme qnmbr subgroups for time to first hospitalization ( number of patients variable ) .,C0040223;C0041536;C1079230;C3541383
2559,coenzyme qnmbr p,C0041536
2559,coenzyme qnmbr,C0041536
2559,all with coenzyme qnmbr ( n = nmbr,C0041536
2558,thromboembolism,C0040038
2557,systemic embolism,C0013922;C0205373;C1704212
2557,non cns embolism,C0013922;C1518422;C1704212;C3714787
2557,embolism,C0013922;C1704212
2557,cns systemic embolism,C0013922;C0205373;C1704212;C3714787
2556,stent thrombosis or mi,C3897493
2556,stent thrombosis - related mi,C3897493
2556,stent thrombosis *,C3897493
2556,stent thrombosis,C3897493
2556,non stent thrombosis - related mi,C1518422;C3897493
2556,definite stent thrombosis,C0439544;C1704787;C3897493
2556,definite acute stent thrombosis,C0205178;C0439544;C1704787;C3897493
2556,any risk factor for stent thrombosis,C0035648;C3897493
2556,acute stent thrombosis ( definite or probable ),C0205178;C3897493
2556,acute stent thrombosis,C0205178;C3897493
2555,tocilizumab ( n = nmbr ),C1609165
2555,tocilizumab,C1609165
2555,p value for mra vs no mra,C0243032;C1609165;C1709380;C3891069
2555,mra use,C0243032;C1609165;C3891069
2555,mra,C0243032;C1609165;C3891069
2554,notes :,C1317574
2553,not severe,C4316743
2552,not assessable,C1883425
2551,not available,C0686905
2550,non - extensive,C0205231;C1518422
2550,no extensive colitis,C0009319;C0205231;C1963084
2550,extensive colitisy,C0205231
2550,extensive colitis or pancolitis,C0009319;C0205231;C1963084
2550,extensive colitis,C0009319;C0205231;C1963084
2550,extensive,C0205231
2549,second primary composite outcome,C0205199;C0205225;C0205436;C0439612;C0439631;C0457385;C0565930;C1274040;C1547335;C1561503;C1705190
2549,renal composite *,C0022646;C0205199;C1547335
2549,primary composite^,C0205199;C0205225;C0439612;C0439631;C1547335
2549,primary composite outcome,C0205199;C0205225;C0439612;C0439631;C1274040;C1547335
2549,primary composite endpoint ‡,C0205199;C1547335;C2986535
2549,primary composite end points,C0205199;C0205225;C0439612;C0439631;C1547335;C2349179
2549,primary composite end point ‡,C0205199;C1547335;C2986535
2549,primary composite end point,C0205199;C1547335;C2986535
2549,net composite,C0205199;C1456447;C1547335;C3853572;C3887809;C3890893
2549,first primary composite outcome,C0205199;C0205225;C0205435;C0439612;C0439631;C1274040;C1279901;C1547335
2549,composite vascular endpoint,C0005847;C0205199;C1547335;C1558950;C1801960;C2349179;C2826544
2549,composite ocular end point^,C0015392;C0042789;C0205199;C0700042;C1299003;C1547335;C2349179;C2826544;C4521296
2549,composite microvascular end point *,C0205199;C0443258;C1547335;C2349179;C2826544
2549,composite endpoint ( anmbrc < nmbr . nmbr %,C0205199;C1547335;C2349179;C2826544
2549,composite endpoint,C0205199;C1547335;C2349179;C2826544
2549,composite,C0205199;C1547335
2549,components of primary composite end point — secondary end points,C0205199;C1547335;C1882460;C4528314
2549,a . primary composite outcome,C0205199;C0205225;C0439612;C0439631;C1274040;C1547335
2549,( composite endpoint ),C0205199;C1547335;C2349179;C2826544
2548,arthritis mutilans,C0702102
2547,prothrombin mutation ( % ),C1610621
2546,direct thrombin inhibitors,C0003440;C3541936
2546,antithrombin,C0003438;C0003440;C4521254
2545,thrombus aspiration done per lesion †,C0087086;C0220787;C0302148;C0349707;C0700198;C2712334;C2827071;C3146237
2545,thrombus aspiration,C0087086;C0220787;C0302148;C0349707;C0700198;C2712334;C2827071;C3146237
2545,thrombus - containing lesion,C0087086;C0221198;C0302148;C0332256;C1546698;C2700400;C3146237
2544,increased - risk for thrombotic cardiovascular,C0007226;C0087086;C3887460;C4699158
2544,anti - thrombotics,C0087086
2543,criteria for subcortical vad ( by mri ),C0077973;C0243161;C0815275
2543,by who / simon broome criteria,C0243161;C0443058
2542,no longer met study criteria,C0205166;C0243161;C0428210;C0557651;C1550543;C1706317;C2603343;C4317104
2542,met criterion at finalt,C0243161;C0428210;C1550543;C4317104
2542,met criterion at final ( n [ % ] ),C0205088;C0243161;C0428210;C1546485;C1550543;C3853528;C4317104
2542,met criterion at blt ( n [ % ] ),C0243161;C0428210;C1550543;C1563149;C1708627;C4317104
2542,met criterion at bl ( n [ % ] ),C0005918;C0006413;C0243161;C0428210;C1550543;C1552663;C2827109;C4317104
2542,criterion reached first,C0243161
2542,criterion,C0243161
2541,mild thrombocytopenia ( < nmbrx nmbr / l ),C1856453
2540,thrombocytopenia,C0040034;C0392386
2540,profound thrombocytopenia ( < nmbrxnmbr / l ),C0040034;C0392386;C0439808
2539,antithrombotic agents,C1704311
2538,antithrombotic / coagulant,C0009117
2537,thrombophilia,C0398623
2537,known thrombophilic condition — no . ( % ),C0012634;C0205309;C0348080;C0398623;C1705253;C3864998
2537,known thrombophilia — no . ( % ),C0205309;C0398623
2537,known thrombophilia,C0205309;C0398623
2536,no family history of chd ( n = nmbr,C0241889;C0280604;C3542407
2536,family history^,C0241889
2536,family history ot chd,C0241889;C0280604;C1318464;C1418208;C1705587;C3542407
2536,family history of vte,C0241889;C0630906
2536,family history of premature chdj,C0151526;C0205252;C0241889;C4018905
2536,family history of premature chd * *,C0151526;C0205252;C0241889;C0280604;C3542407;C4018905
2536,family history of premature chd,C0151526;C0205252;C0241889;C0280604;C3542407;C4018905
2536,family history of premature,C0151526;C0205252;C0241889;C4018905
2536,family history of chd ( n = nmbr,C0241889;C0280604;C3542407
2536,family history of cancerf,C0241889
2536,family history of cancera,C0241889
2536,family history,C0241889
2535,positive family history of type nmbr diabetes ( % ),C0332307;C0439178;C1313937;C1446409;C1514241;C1547052;C2825490;C3812269
2535,family history ol diabetes ?,C1313937
2535,family history of diabetes — no . ( % ),C1313937
2535,family history of diabetes mellitus — no . { % ),C0260526;C1313937
2535,family history of diabetes mellitus — no . ( % ),C0260526;C1313937
2535,family history of diabetes ( - ),C1313937
2535,family history of diabetes ( + ),C1313937
2535,family history of diabetes ( % ) *,C1313937
2534,smoking history — no . ( % ),C1519384
2534,smoking history : current smoker,C1519384;C3173209;C3241966
2534,smoking history ( pack - yr ),C0439234;C1519384;C1968515;C2825051;C2828395
2534,smoking history ( ever ),C1519384;C3887636
2534,smoking history,C1519384
2534,history of smoking,C1519384
2533,study drug,C0013175
2533,interval study drug to pci,C0013175;C1272706;C1552654;C1552713;C4049621
2532,median duration of study - drug administration ( iqr ) — days,C0013175;C0439228;C0549183;C0876920;C2347635;C2348144;C2348354;C2939193
2532,median duration of study - drug administration,C0013175;C0549183;C0876920;C2347635;C2348144;C2348354;C2939193
2532,duration of study - drug administration — hr,C0013175;C2348354
2531,time from study drug administration to coronary revascularization,C0013175;C0040227;C0150270;C0206209;C2349982;C3469597
2531,time from randomization to study - drug initiation — hr,C0013175;C0013227;C0034656;C0040223;C0040227;C0589507;C1158830;C1254351;C1704686;C2349982;C3541383
2531,time from randomization to study - drug administration — hr,C0013175;C0034656;C0040227;C0150270;C0206209;C2349982;C3469597
2531,time from fibrinolytic therapy to study - drug administration — no . / total no . ( % ),C0013175;C0013216;C0040044;C0040223;C0040227;C0150270;C0206209;C0557651;C1611232;C2349982;C2603343;C3469597;C3541383;C3665478
2530,fasting triglycerides — mg / dl,C0015663;C0041004;C0439269
2530,fasting triglycerides > nmbr mg / dl *,C0015663;C0041004;C0439269
2530,fasting triglycerides,C0015663;C0041004
2530,fasting serum glucose,C0015663;C0202041;C3534430
2530,fasting plasma insulin — mu / liter,C0015663;C0028971;C0347978;C0475211;C0857690;C3714918
2530,fasting lipids ( mmol / nmbr ),C0015663;C0023779;C0439190
2530,fasting lipid levels,C0015663;C0428460
2530,fasting indices,C0015663;C4033634
2530,fasting glucose *,C0015663;C0017725
2530,fasting glucose ( mmol / l ),C0015663;C0017725;C1532563
2530,fasting glucose,C0015663;C0017725
2530,fasting free fatty acids ( ^mol / liter ),C0015663
2530,fasting c - peptide ( nmol / l ) c,C0006558;C0015663;C0439282
2530,fasting c - peptide ( ng / ml ),C0006558;C0015663;C0439275
2530,fasting c - peptide,C0006558;C0015663
2529,fasting tgs §,C0015663;C1156212;C1537574
2529,fasting tgs,C0015663;C1156212;C1537574
2529,fasting,C0015663
2529,baseline fasting tgs,C0015663;C0168634;C1156212;C1442488;C1537574
2528,fastest third,C0015663;C0205437;C0456962;C2985769
2528,faster aspart   +   basal,C0015663;C0123677;C0205112;C0456962;C2985769
2528,faster aspart ( mealtime ),C0015663;C0123677;C0456962;C0587119;C2985769
2528,faster aspart,C0015663;C0123677;C0456962;C2985769
2527,risk factor for venous thromboembolism,C1521761;C2827422;C3495424;C3496592
2527,factors that confer a,C1521761;C2827422
2527,factor present,C0150312;C0449450;C1521761;C2827422
2527,factor at baseline,C0168634;C1442488;C1521761;C2827422
2527,factor absent,C1521761;C2827422
2527,factor *,C1521761;C2827422
2527,factor,C1521761;C2827422
2527,baseline factor,C0168634;C1442488;C1521761;C2827422
2526,glucosamine + chondroitin sulfate ( n = nmbr ),C0008454;C0008466;C0017718;C0017720;C0038720;C0474702;C0475337;C0876712;C3536965
2526,glucosamine + chondroitin sulfate,C0008454;C0008466;C0017718;C0017720;C0038720;C0474702;C0475337;C0876712;C3536965
2526,chondroitin sulfate ( n = nmbr ),C0008466
2526,chondroitin sulfate,C0008466
2525,dronedarone ( n = nmbr ) nmbr . nmbr ± nmbr . nmbr,C0766326
2525,dronedarone ( n = nmbr ),C0766326
2525,dronedarone,C0766326
2524,epilepsy with grand mal seizures on awakening,C0014549;C0494475
2523,more than nmbr vessels stented,C0005847;C0205172
2523,more than nmbr lesions per vessel,C0205172
2522,number of hospitalizations in last year prior to baseline,C4086639
2521,draining cutaneous fistula at baseline,C0013103;C0180499;C4265177
2520,abdominal or perianal fistula at baseline,C0000726
2519,non - early crohn ' s disease,C0010346;C1279919;C1518422
2519,median crohn ' s disease duration,C0010346;C0449238;C0549183;C0876920;C2347635;C2348144;C2926735;C2939193
2519,history of crohn ' s disease surgery,C0010346;C0455610
2519,early crohn ' s disease *,C0010346;C1279919
2519,duration of crohn ’ s disease ( yrs ),C0010346;C0449238;C2926735
2519,duration of crohn ' s disease ( yrs ),C0010346;C0449238;C2926735
2519,crohn ’ s disease related surgery,C0010346
2519,crohn ' s disease duration,C0010346;C0449238;C2926735
2519,crohn ' s disease - related medication at baseline,C0010346
2519,crohn ' s disease,C0010346
2518,morning,C0332170
2518,duration of morning,C0332170;C0449238;C2926735
2517,doxazosin group,C0114873;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
2517,doxazosin,C0114873
2516,pro / pro homozygotes,C0019904;C1120626
2515,progression to diabetes,C1735364
2514,proctosigmoiditis,C0033252
2513,hormones,C0019932
2513,estrogen - containing hormones,C0014939;C0019932;C0332256;C2700400;C2936882;C4542544
2512,tobacco user,C3853727
2512,tobacco use — no . ( % ),C0040335;C0543414;C0841002;C3853727
2512,tobacco use ( % ),C0040335;C0543414;C0841002;C3853727
2512,tobacco use,C0040335;C0543414;C0841002;C3853727
2512,prior tobacco use,C0040335;C0332152;C0543414;C0841002;C2826257;C3853727
2512,no current tobacco use,C0040335;C0521116;C0543414;C0841002;C1705970;C3853727
2512,current tobacco use,C0040335;C0521116;C0543414;C0841002;C1705970;C3853727
2512,baseline tobacco use,C0040335;C0168634;C0543414;C0841002;C1442488;C3853727
2511,stent thrombosis arc definite / probable,C0033204;C0332148;C0439544;C1704787;C3897493
2511,probable stent thrombosis,C0033204;C0332148;C3897493
2511,probable,C0033204;C0332148
2511,definite / probable stent thrombosis,C0033204;C0332148;C0439544;C1704787;C3897493
2510,regions,C0017446;C0205147
2510,region 一 no . ( % ),C0017446;C0205147
2510,region — no . { % ),C0017446;C0205147
2510,region — no . ( % ),C0017446;C0205147
2510,region united states,C0017446;C0041703;C0205147
2510,region ofthe world,C0017446;C0205147;C2700280
2510,region ofenrollment — %,C0017446;C0205147
2510,region of world — no . ( % ),C0017446;C0205147;C2700280
2510,region of the world,C0017446;C0205147;C2700280
2510,region of residence ( p = nmbr nmbr ),C0017446;C0205147;C0237096
2510,region of enrollment — no . ( % ),C0017446;C0205147;C1516879;C1696073;C3888021
2510,region of enrollment,C0017446;C0205147;C1516879;C1696073;C3888021
2510,region north america,C0017446;C0028405;C0205147
2510,region n ( % ),C0017446;C0205147
2510,region latin american,C0017446;C0205147
2510,region :,C0017446;C0205147
2510,region - north america,C0017446;C0028405;C0205147
2510,region - no . ( % ),C0017446;C0205147
2510,region - n ( % ),C0017446;C0205147
2510,region *,C0017446;C0205147
2510,region ( us ),C0017446;C0205147
2510,region ( pooled ),C0017446;C0205147
2510,region ( % ),C0017446;C0205147
2510,region,C0017446;C0205147
2510,other ® region — no . ( % ),C0017446;C0205147
2510,grouped region,C0017446;C0205147;C0439745;C4319846
2510,age years geographic region,C0017446;C1510829
2509,geographical region ( % ),C0017446
2509,geographical region,C0017446
2509,geographic site,C0017446
2509,geographic region^,C0017446
2509,geographic region — number ( % ),C0017446;C0237753;C0449788
2509,geographic region — no . ( % ),C0017446
2509,geographic region ?,C0017446
2509,geographic region - other,C0017446
2509,geographic region - north america,C0017446;C0028405
2509,geographic region - europe,C0015176;C0017446
2509,geographic region,C0017446
2509,geographic location,C0017446
2509,geo graphic region : asia,C0003980;C0017446;C0017454;C0205147
2508,eo severity by la classification at baseline ( baseline of the healing study ),C0332120;C0439793;C0522510;C1881447
2508,eo,C0332120
2507,smoking habit,C4505437
2506,abdominal obesity *,C0311277
2506,abdominal obesity,C0311277
2505,topical therapy,C0039798;C0087111;C0332237;C1363945
2505,topical prescription,C0033080;C0332237;C1521941
2505,topical non - prescription,C0033080;C0332237;C1518422;C1521941
2505,topical,C0332237
2504,colonoscopy,C0009378;C1548837
2503,autonomic neuropathy,C0259749
2502,tonic – clonic,C3543842
2502,tonic,C3543842
2501,elevated vs normalb,C0205250;C3163633
2501,elevated vs . normalc,C0205250;C3163633
2501,elevated vs . normalb,C0205250;C3163633
2501,elevated troponin — %,C0041199;C0205250;C3163633
2501,elevated troponin ( > nmbr . nmbr pg / l ),C0041199;C0205250;C0439278;C3163633
2501,elevated troponin ( > nmbr . nmbr mg / l ),C0041199;C0205250;C0439268;C3163633
2501,elevated troponin,C0041199;C0205250;C3163633
2501,elevated tg,C0205250;C0337445;C3163633
2501,elevated non - hdl cholesterol,C0205250;C0729627;C1535899;C3163633
2501,elevated hscrp > nmbr mg / l,C0205250;C0439268;C3163633
2501,elevated hscrp,C0205250;C3163633
2501,elevated fasting glucose,C0205250;C3163633
2501,elevated cardiac markers — no . ( % ) : t,C0205250;C1271630;C3163633
2501,elevated cardiac markers,C0205250;C1271630;C3163633
2501,elevated bnp,C0054015;C0205250;C1095989;C1417808;C2982014;C3163633
2500,total aim ‐ high study,C0205250;C0439175;C0439810;C0557651;C1299351;C1947946;C2603343;C2700149;C2744535;C2948600;C3540471;C3540472;C3887512;C3889660;C3890193;C4321237;C4522209
2500,ige high ( > nmbr ku / l  n = nmbr  nmbr ),C0205250;C0439340;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
2500,high vs . normalc,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
2500,high vs . normalb,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
2500,high tt > nmbr . nmbr ( n = nmbr ),C0205250;C1299351;C1452561;C2700149;C3887512;C3889660;C4321237;C4522209;C4554543
2500,high trs : nmbr - nmbr ( n = nmbr,C0205250;C0266427;C0968917;C1150746;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
2500,high subgroup,C0205250;C1079230;C1299351;C1515021;C2700149;C3887512;C3889660;C4321237;C4522209
2500,high potencyc,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
2500,high periostin subgroup ( > nmbr ng / ml ) ( n = nmbr ),C0205250;C0219433;C0439275;C1079230;C1299351;C1424662;C1515021;C2700149;C3812270;C3887512;C3889660;C4321237;C4522209
2500,high nfs nfs > nmbr . nmbr ( n = nmbr ),C0205250;C1299351;C1513839;C2700149;C3887512;C3889660;C4321237;C4522209
2500,high feno subgroup ( > nmbr . nmbr ppb ) ( n = nmbr ),C0205250;C1079230;C1299351;C1415800;C1515021;C2700149;C3887512;C3889660;C4321237;C4522209
2500,high crp or esr,C0205250;C1299351;C2700149;C3887512;C3889660;C3890735;C4048285;C4321237;C4522209
2500,high crp and esr,C0205250;C1299351;C2700149;C3887512;C3889660;C3890735;C4048285;C4321237;C4522209
2500,high *,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
2500,high ( nmbr - nmbr ),C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
2500,high ( nmbr % ),C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
2500,high ( n = nmbr ),C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
2500,high ( inmbr % ) baseline hbanmbrc,C0019016;C0021966;C0168634;C0205250;C0221138;C1299351;C1442488;C1825777;C2700149;C3538758;C3887512;C3889660;C4321237;C4522209
2500,high ( >   uln and   ≤   nmbrxuln ) ( n   =   nmbr ),C0205250;C1299351;C1519815;C2700149;C3887512;C3889660;C4321237;C4522209
2500,high ( > uln ),C0205250;C1299351;C1519815;C2700149;C3887512;C3889660;C4321237;C4522209
2500,high ( > nmbr . nmbr u / ml ),C0205250;C0439340;C1299351;C1880521;C2700149;C2945590;C3887512;C3889660;C4321237;C4522209
2500,high ( > nmbr ) ( n = nmbr  nmbr  nmbr % ),C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
2500,high ( > nmbr ),C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
2500,high ( > nmbr % ) baseline hbalc,C0168634;C0205250;C1299351;C1442488;C2700149;C3887512;C3889660;C4321237;C4522209
2500,high ( > nmbr % ),C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
2500,high,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
2499,ng ( n = nmbr,C0017887;C0028074
2499,ng,C0017887;C0028074
2498,nmbr . nmbr ( ne,C0027608;C0028219;C3538705
2498,ne,C0027608;C0028219;C3538705
2498,( ne,C0027608;C0028219;C3538705
2497,years [range],C0439234;C1514721;C2348147;C3542016
2497,total scores ( total score range : nmbr - nmbr ),C1514721;C2348147;C2964552;C3542016
2497,selena - sledai ( range u - nmbrunmbr ) t,C0439148;C0451528;C1514721;C2348147;C3542016
2497,range iga modified nmbr score,C1514721;C2348147;C2825347;C3542016
2497,range,C1514721;C2348147;C3542016
2497,pain vas ( range nmbr - nmbr ),C0042815;C1514721;C2348147;C3542016
2497,nmbr . nmbr range nmbr - nmbr,C1514721;C2348147;C3542016
2497,motor subscale ( range,C1513492;C1514721;C1705994;C2348147;C3542016
2497,"median pasi score { range ) ' i "" i '",C0021966;C0221138;C0449820;C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016;C4050231;C4528685
2497,mean daily dose ( range ) — mg  i ,C0021966;C0024671;C0026410;C0221138;C0439269;C0444504;C1514721;C1960952;C2346927;C2347634;C2348070;C2348143;C2348147;C3542016;C4321396;C4521761
2497,il - nmbr range,C0020898;C0021764;C0022271;C1514721;C2348147;C3542016
2497,hscrp range,C1514721;C2348147;C3542016
2497,health assessment questionnaire ( nmbr - nmbr range ),C0451208;C1514721;C2348147;C3542016
2497,hbanmbrc % ( range ),C0019016;C1514721;C1825777;C2348147;C3538758;C3542016
2497,haq di score ( range nmbr - nmbr ),C0449820;C1514721;C2348147;C3542016;C3826998;C4050231;C4321476
2497,haq di ( range nmbr - nmbr ),C1514721;C2348147;C3542016;C3826998;C4321476
2497,haq - di ( range nmbr - nmbr ),C1514721;C2348147;C3542016;C3826998;C4321476
2497,fpg ( range ) ( mmol / l ),C1514721;C1532563;C2348147;C3542016
2497,age range,C0001779;C1514721;C2348147;C3542016
2497,adl subscale ( range,C0001288;C1420005;C1514721;C2348147;C3542016
2497,( range ),C1514721;C2348147;C3542016
2496,dilatative,C0002940;C0012359;C0700124;C1322279
2495,digitalis,C0012252;C0304520
2494,digitalis glycoside,C0012253
2493,digital clubbing,C0009080;C0149651
2492,medial - distal - diag,C0205098;C0205108;C0348026;C4522154
2492,distal lower,C0205108;C0441994;C1548802;C2003888;C4522154
2492,distal,C0205108;C4522154
2491,non - diabetic patients,C0241863;C1829939
2491,diabetics • no ( n = nmbr,C0241863
2491,diabetics - yes ( n = nmbr,C0241863;C1549445;C1705108;C1710701
2491,diabetics - no ( n = nmbr,C0241863
2491,diabetics ( n = nmbr ),C0241863
2491,diabetic treatments !,C0087111;C0241863
2491,diabetic therapy use,C0039798;C0042153;C0087111;C0241863;C0457083;C1363945;C1947944
2491,diabetic patients,C0030705;C0241863
2491,diabetic ( yes ),C0241863;C1549445;C1705108;C1710701
2491,diabetic ( no ),C0241863
2490,total ! by baseline diabetic status,C0168634;C0241863;C0439175;C0439810;C0449438;C1442488
2490,diabetics,C0241863
2490,diabeticnmbr,C0241863
2490,diabetic status,C0241863;C0449438
2490,diabetic no,C0241863
2490,diabetic,C0241863
2490,by baseline diabetic status,C0168634;C0241863;C0449438;C1442488
2489,perindopril - indapamide,C1273169
2488,pctindopnl - indapamide ( n = nmbr ),C0021186
2487,insulin detemir,C0537270
2487,detemir / insulin glargine,C0537270;C0907402
2486,indian subpopulation,C1257890;C1524069
2486,indian ( american ) or alaskan native,C0596070;C1524069
2486,indian ( american ) or alaska native,C0596070;C1524069
2486,indian,C1524069
2485,india,C0021201;C2700456
2484,fluindione,C0117899
2483,pci indication,C0392360;C3146298;C4049621
2483,indication for stent,C0038257;C0392360;C3146298
2483,indication for pci,C0392360;C3146298;C4049621
2483,indication,C0392360;C3146298
2482,stomach,C0038351;C3714551
2481,source,C0449416;C1705919;C4521696
2480,so nmbr %,C0037640
2480,so,C0037640
2479,su monotherapy,C0038642;C1705534
2479,su / tzd,C0038642;C1705534
2479,su / met,C0038642;C1705534
2479,su,C0038642;C1705534
2478,tpm subgroup,C0076829;C1079230;C1515021
2478,subgroups,C1079230
2478,subgroup_level,C0441889;C0456079;C1079230;C1515021;C1547707;C2946261
2478,subgroup sex,C0009253;C0036864;C0079399;C0804628;C1079230;C1314687;C1515021;C1522384
2478,subgroup p valuef,C1079230;C1515021
2478,subgroup p value 本,C1079230;C1515021;C1709380
2478,subgroup p value !,C1079230;C1515021;C1709380
2478,subgroup p - valuenmbr,C1079230;C1515021;C1709380
2478,subgroup overall,C0282416;C1079230;C1515021;C1561607
2478,subgroup no .,C1079230;C1515021
2478,subgroup nmbr,C1079230;C1515021
2478,subgroup name / level,C0027365;C0441889;C0456079;C1079230;C1515021;C1547383;C1547707;C2946261;C4522128
2478,subgroup levels,C0441889;C1079230;C1515021
2478,subgroup level,C0441889;C0456079;C1079230;C1515021;C1547707;C2946261
2478,subgroup based on :,C1079230;C1515021
2478,subgroup,C1079230;C1515021
2478,secondary prevention subgroup,C0679699;C1079230;C1515021
2478,primary prevention subgroup,C0033144;C1079230;C1515021
2478,prespecified subgroups,C1079230
2478,planned conservative therapy subgroup,C0459914;C1079230;C1301732;C1515021
2478,outcome_subgroup,C1079230;C1274040;C1515021
2478,mnmbr subgroup,C0369637;C0441923;C1079230;C1515021
2478,high eosinophil subgroup ( > nmbr / ml ) ( n = nmbr ),C0014457;C0439526;C1079230;C1515021;C1705224;C3887665
2478,genetic subgroup,C0017296;C0314603;C1079230;C1515021
2478,diuretic subgroup,C0012798;C1079230;C1515021
2478,ctd population subgroup,C0032659;C1079230;C1257890;C1335071;C1442905;C1515021
2478,baseline subgroup,C0168634;C1079230;C1442488;C1515021
2478,baseline mtss subgroup,C0168634;C1079230;C1442488;C1515021
2478,baseline hbanmbrc subgroup,C0019016;C0168634;C1079230;C1442488;C1515021;C1825777;C3538758
2478,asubset of the ≥ nmbr years subgroup .,C0439234;C1079230;C1515021
2478,additional antihypertensive subgroup,C0003364;C1079230;C1515021;C1524062
2478,* subgroups were defined on the basis of variables assessed before randomization . the lipid levels represent the averages of the values measured four weeks before randomization and those measured at randomization . to convert values for cholesterol to millimoles per liter  multiply by nmbr . nmbr  to convert values for triglycerides to millimoles per liter  multiply by nmbr . nmbr . ci denotes confidence interval  ldl low - density lipoprotein  and hdl high - density lipoprotein . tests for heterogeneity of treatment effect were undertaken across each of the subgroups . in addition  we performed tests for interaction between treatment and the following continuous base - line variables : age  total  ldl  and hdl cholesterol  and triglyceride levels . there was no evidence of significant heterogeneity of treat - ment effect in any prespecified subgroup ( p » nmbr . nmbr ) . † data were missing for three patients  two in the placebo group and one in the pravastatin group .,C1079230
2478,( subgroup ),C1079230;C1515021
2477,impacts,C1825598;C4049986
2476,empty,C1880497
2475,empa,C2699863
2474,emphysema ( n = nmbr ),C0013990;C0034067
2474,emphysema ( itt ) ( n = nmbr ),C0013990;C0034067
2474,emphysema ( % ),C0013990;C0034067
2474,emphysema,C0013990;C0034067
2473,tr jet velocity ( m / sec ),C0108801;C0336862;C0439493;C0439830;C1539482;C1547053;C1705610;C1872943;C3811249;C3811250;C3814152
2473,mnmbrs,C0439493;C1513009
2472,rituximab,C0393022
2471,piroxicam,C0031990
2470,meloxicam,C0083381
2469,systolic bp,C0871470
2469,mean systolic bp,C0444504;C0871470;C2347634;C2348143
2468,mean diastolic bp,C0428883;C0444504;C2347634;C2348143
2468,diastolic bp,C0428883
2467,hip + other nonvertebral fractures,C0019552;C0022122;C1505163;C3538851;C4284725
2467,hip + nonvertebral + vertebral,C0019552;C0022122;C0549207;C1505163;C3538851;C4284725
2467,hip + nmbr vertebral fractures,C0019552;C0019557;C0022122;C0080179;C0549207;C1505163;C3538851;C4284725
2467,hip,C0019552;C0022122;C1505163;C3538851;C4284725
2466,systolic — mm hg,C0039155;C0439475
2466,systolic ( mmhg ),C0039155;C0439475
2466,systolic ( mm hg ),C0039155;C0439475
2466,systolic ( mean,C0039155;C0444504;C2347634;C2348143
2466,systolic,C0039155
2466,peak systolic pressure gradient,C0039155;C4687747
2466,mean systolic pressure gradient,C0039155;C4687744
2465,diastolic — mm hg,C0012000;C0439475
2465,diastolic fmmhff ' ),C0012000
2465,diastolic ( mmhg ),C0012000;C0439475
2465,diastolic ( mm hg ),C0012000;C0439475
2465,diastolic ( mean,C0012000;C0444504;C2347634;C2348143
2465,diastolic,C0012000
2464,transient ischemic attack ( % ) type of lacunar syndrome ( % ),C0007787;C0332307;C0917805;C1547052;C3178801
2464,transient ischemic attack,C0007787;C0917805
2464,transient ischaemic attack — no . ( % ),C0007787;C0917805
2464,transient ischaemic attack,C0007787;C0917805
2464,tia,C0007787;C0917805;C1054154
2464,prior transient ischemic attack,C0007787;C0332152;C0917805;C2826257
2464,prior tia,C0007787;C0332152;C0917805;C1054154;C2826257
2464,hemispheric tia n = nmbr,C0007787;C0205139;C0917805;C1054154
2463,age ≥ nmbr years,C1510829
2463,age years,C1510829
2463,age range ( years ),C1510829;C1514721;C2348147;C3542016
2463,age nmbryears,C1510829
2463,age nmbr + years,C1510829
2463,age in years,C1510829
2463,age group ( years ),C0027362;C0439234;C0441833;C0687744;C1257890;C1510829;C1519504;C1705428;C1705429;C2348001
2463,age groiro : < nmbr years,C1510829
2463,age at entry ( years ),C1510829;C1705654
2463,age [years],C1510829
2463,age > nmbr yearsnmbr,C1510829
2463,age > nmbr years,C1510829
2463,age > nmbr ( years ) t,C1510829
2463,age > = nmbr years old,C1510829
2463,age > = nmbr years,C1510829
2463,age < nmbryears,C1510829
2463,age < nmbr yearsnmbr,C1510829
2463,age < nmbr years old,C1510829
2463,age < nmbr years,C1510829
2463,age : > nmbr years,C1510829
2463,age : < nmbr years,C1510829
2463,age . years,C1510829
2463,age - years,C1510829
2463,age ( years ) a,C1510829
2463,age ( years ) :,C1510829
2463,age ( years ) +,C1510829
2463,age ( years ) *,C1510829
2463,age ( years ),C1510829
2463,age ( years  sd ),C1510829;C2699239
2463,age ( range ) ( years ),C1510829;C1514721;C2348147;C3542016
2463,age ( per nmbr years ),C1510829
2463,age $ nmbr years § *,C1510829
2462,mean age ± sd ( years ),C0444504;C1510829;C2347634;C2348143;C2699239
2462,mean age ( years ) race,C0444504;C1510829;C2347634;C2348143
2462,mean age ( years ) ( s . d . ),C0444504;C1510829;C2347634;C2348143
2462,mean age ( years ),C0444504;C1510829;C2347634;C2348143
2462,mean age ( years,C0444504;C1510829;C2347634;C2348143
2462,age ≥ nmbr years and bmi ≥ nmbr kg / mnmbr,C1510829
2462,age ≥ nmbr years and bmi < nmbr kg / mnmbr,C1510829
2462,age £ nmbr years ( itt ) ( n = nmbr ),C1510829
2462,age snmbr years ( n = nmbr,C1510829
2462,age nmbr years or more,C1510829
2462,age nmbr years ( n = nmbr ),C1510829
2462,age nmbr - nmbr years ( n = nmbr ),C1510829
2462,age nmbr - nmbr years ( itt ) ( n = nmbr ),C1510829
2462,age > nmbr years ( n = nmbr ),C1510829
2462,age > nmbr years ( median ),C1510829
2462,age > nmbr years ( itt ) ( n = nmbr ),C1510829
2462,age < nmbr years — no . ( % ),C1510829
2462,age < nmbr years and bmi ≥ nmbr kg / mnmbr,C1510829
2462,age < nmbr years and bmi < nmbr kg / mnmbr,C1510829
2462,age < nmbr years ( n = nmbr ),C1510829
2462,age < nmbr years ( n = nmbr,C1510829
2462,age < nmbr years ( n =,C1510829
2462,age < nmbr years ( median ),C1510829
2462,age < nmbr years ( itt ) ( n = nmbr ),C1510829
2462,age : < nmbr years ( n = nmbr ),C1510829
2462,age ( years ) mean ± sd,C0444504;C1510829;C2347634;C2348143;C2699239
2462,age ( years ) mean ( sd ),C0444504;C1510829;C2347634;C2348143;C2699239
2462,age ( years ) : nmbr - < nmbr,C1510829
2462,age ( years ) : mean ± sd,C0444504;C1510829;C2347634;C2348143;C2699239
2462,age ( years ) : > nmbr,C1510829
2462,age ( years ) : < nmbr,C1510829
2462,age ( years ) - mean ± sd,C0444504;C1510829;C2347634;C2348143;C2699239
2462,age ( years ) ( mean ± sd ),C0444504;C1510829;C2347634;C2348143;C2699239
2462,age ( years ) ( mean,C0444504;C1510829;C2347634;C2348143
2462,age ( years ( s . d . ) ),C1510829
2462,age  years  mean ( sd ),C0444504;C1510829;C2347634;C2348143;C2699239
2461,inmbr years of age,C0021966;C0221138;C1510829
2461,> nmbr years of age,C1510829
2461,< nmbr years of age,C1510829
2460,≥ nmbr ae,C3887670
2460,due to ae,C3887670
2460,because of ae,C3887670
2460,any ae leading to discontinuation,C3887670
2460,any ae,C3887670
2460,any adverse event ( ae ),C0877248;C3887670
2460,ae / e ' ratio ( per nmbr unit ),C0439148;C0439453;C0456603;C1509845;C1519795;C1547037;C1704753;C1880519;C3853603;C3887670
2460,ae / a ratio ( per nmbr . nmbr unit ),C3887670
2460,ae ' ( per cm / s ),C0439392;C3887670
2459,sex : female,C0086287
2459,sex ( female ),C0086287
2459,nmbr ( except for female alone ),C0043210;C0086287;C1705497;C1705498
2459,hdl — female,C0043210;C0086287;C1705497;C1705498;C3715113
2459,gender female,C0043210;C0079399;C0086287;C1522384;C1705497;C1705498
2459,gender ( male / female ) ( number ),C0043210;C0079399;C0086287;C0086582;C0237753;C0449788;C1522384;C1705497;C1705498;C1706180;C1706428;C1706429
2459,gender ( female : male,C0043210;C0079399;C0086287;C0086582;C1522384;C1705497;C1705498;C1706180;C1706428;C1706429
2459,gender ( % ) male / female,C0043210;C0079399;C0086287;C0086582;C1522384;C1705497;C1705498;C1706180;C1706428;C1706429
2459,females ( n = nmbr ),C0086287
2459,females ( itt ) ( n = nmbr ),C0086287
2459,females,C0086287
2459,femalenmbr,C0043210;C0086287;C1705497;C1705498
2459,female — no . ( % ),C0043210;C0086287;C1705497;C1705498
2459,female subjects ( n = nmbr ),C0043210;C0086287;C1705497;C1705498
2459,female subgroup,C0043210;C0086287;C1079230;C1515021;C1705497;C1705498
2459,female simva ( „ = nmbr },C0043210;C0086287;C1705497;C1705498
2459,female simva ( n = nmbr ),C0043210;C0086287;C1705497;C1705498
2459,female simva,C0043210;C0086287;C1705497;C1705498
2459,female sex — no . { % ),C0086287
2459,female sex — no . ( % ),C0086287
2459,female sex,C0086287
2459,female race white,C0007457;C0034510;C0043157;C0043210;C0086287;C0220938;C1705497;C1705498;C1706779;C3853635
2459,female race / ethnicity,C0015031;C0034510;C0043210;C0086287;C0243103;C1705497;C1705498;C1706779;C3853635
2459,female participants who are ≥ nmbr years postmenopausal,C0043210;C0086287;C0679646;C1705497;C1705498
2459,female nmbr,C0043210;C0086287;C1705497;C1705498
2459,female n ( % ),C0043210;C0086287;C1705497;C1705498
2459,female eze / simva ( „ = nmbr },C0043210;C0086287;C1705497;C1705498
2459,female eze / simva ( n = nmbr ),C0043210;C0086287;C1705497;C1705498
2459,female eze / simva,C0043210;C0086287;C1705497;C1705498
2459,female : ≥ nmbr years postmenopausal,C0043210;C0086287;C0439234;C1705497;C1705498
2459,female : premenopausal,C0043210;C0086287;C1705497;C1705498
2459,female : perimenopausal or < nmbr years postmenopausal,C0043210;C0086287;C1705497;C1705498
2459,female / male ( % ),C0043210;C0086287;C0086582;C1705497;C1705498;C1706180;C1706428;C1706429
2459,female - n ( % ),C0043210;C0086287;C1705497;C1705498
2459,female ( n — nmbr ),C0043210;C0086287;C1705497;C1705498
2459,female ( n   = nmbr,C0043210;C0086287;C1705497;C1705498
2459,female ( n z nmbr ),C0043210;C0086287;C1705497;C1705498
2459,female ( n = nmbr ),C0043210;C0086287;C1705497;C1705498
2459,female ( n = nmbr,C0043210;C0086287;C1705497;C1705498
2459,female ( n = lllnmbr ),C0043210;C0086287;C1261077;C1705497;C1705498
2459,female ( % ),C0043210;C0086287;C1705497;C1705498
2459,female,C0043210;C0086287;C1705497;C1705498
2458,number of females n ( % ),C0086287;C0237753;C0449788
2458,number of ( % ) females,C0086287;C0237753;C0449788
2458,female sex — number ( % ),C0086287;C0237753;C0449788
2458,female sex — no . ( % ) race — no . ( % ) f,C0086287
2458,female sex — %,C0086287
2458,female sex ( % ),C0086287
2458,female gender n ( % ),C0086287
2458,female gender ( % ),C0086287
2458,female gender,C0086287
2457,early death,C1836407
2456,mental health,C0025353
2455,sudden death,C0011071;C1964022;C4554103
2454,sudden cardiac death §,C0085298
2453,sexually activenmbr ( % ),C0241028
2453,sexually active with female,C0043210;C0086287;C0241028;C1705497;C1705498
2453,sexually active,C0241028
2452,delayed reaction,C0205421;C0443286;C1545665;C3272602
2452,delayed eptifibatide,C0205421;C0253563;C1545665;C3272602
2452,delayed - start group ( n = nmbr ),C0205421;C0439659;C0441848;C1545665;C3272602
2452,delayed - eptifibatide group ( n = nmbr ),C0205421;C0253563;C0441848;C1545665;C3272602
2452,delayed,C0205421;C1545665;C3272602
2451,phospholipid omega - nmbr levels : < nmbr % ( n = nmbr ),C0031676;C0202177;C0441889;C1719844
2450,omega - nmbr fatty acids,C0015684;C1719844
2450,omega - nmbr fatty acid vs placebo least - squares mean ( nmbr % cl ),C0015684;C1719844
2450,omega - nmbr fatty acid ( n = nmbr ),C0015684;C1719844
2450,omega - nmbr fatty acid,C0015684;C1719844
2450,omega - nmbr fa intake nmbrst third,C0036056;C0205437;C1512806;C1719844;C3272372
2450,omega - nmbr fa intake nmbrnd third,C0205437;C1512806;C1719844
2450,omega - nmbr fa intake nmbr,C1512806;C1719844
2450,omega - nmbr fa ( n = nmbr ),C1719844
2450,omega - nmbr fa,C1719844
2450,number omega - nmbr number placeb fatty acid,C0015684;C0237753;C0449788;C1719844
2449,unstable angina ( biomarker negative ),C0002965;C0005516;C0205160;C1513916;C2825415;C2825491;C3853545
2449,troponin negative ( n = nmbr ),C0041199;C0205160;C1513916;C2825415;C2825491;C3853545
2449,negative ctnl ( n = nmbr,C0205160;C1513916;C2825415;C2825491;C3853545
2449,negative ( < nmbr . nmbr ),C0205160;C1513916;C2825415;C2825491;C3853545
2449,negative,C0205160;C1513916;C2825415;C2825491;C3853545
2449,anti - gad negative ( n = nmbr ),C0205160;C0270549;C0432633;C1414925;C1513916;C2825415;C2825491;C3853545
2449,anti - gad negative,C0205160;C0270549;C1414925;C1513916;C2825415;C2825491;C3853545
2448,pre fvc % pred,C0332152;C0740175;C2257086;C3669034;C3714541
2448,pre fevnmbr   % pred,C0332152;C0740175;C2257086;C3669034;C3714541
2448,fevnmbr ( pre - albuterol ),C0001927;C0332152;C0740175;C2257086;C3669034;C3714541
2448,fevnmbr ( post - albuterol ),C3714541
2448,fevnmbr % pred,C3714541
2447,trough fevnmbr,C0444506;C3714541
2447,trough fev,C0444506;C3714541
2447,cnmbr ml decrease in trough fevnmbr,C0392756;C0439526;C0444506;C0547047;C1705224;C3714541;C3887665
2446,nmbr ( fevnmbr < nmbr % pred ),C3714541
2446,iv : fevnmbr < nmbr % predicted,C0022326;C3714541;C4265176
2446,fvc ∗,C3714541
2446,fvc — liters,C0475211;C3714541
2446,fvc ( liters ),C0475211;C3714541
2446,fvc ( l ) *,C3714541
2446,fvc ( l ) ,C3714541
2446,fvc ( l ),C3714541
2446,fvc,C3714541
2446,fevnmbr — liters,C0475211;C3714541
2446,fevnmbr aucnmbrminenmbrh,C0376690;C3714541
2446,fevnmbr ( liters ),C0475211;C3714541
2446,fevnmbr ( l ),C3714541
2446,fevnmbr,C3714541
2446,fev_ ( l ) :,C3714541
2446,fev auc i nmbrh,C0021966;C0033727;C0221138;C0369286;C0376690;C0441932;C0564385;C3714541;C4528284
2446,fev,C3714541
2445,ratio of fevnmbrto fvc ( % ),C0456603;C1547037;C3714541
2445,ratio of fevnmbr to fvc,C0456603;C1547037;C3714541
2445,fevt : fvc ratio — % |,C0016529;C0456603;C1547037;C3714541
2445,fevnmbr : fvc ratio ,C0456603;C1547037;C3714541
2445,fevnmbr : fvc ratio,C0456603;C1547037;C3714541
2445,fevnmbr / fvc ratio *,C0456603;C1547037;C3714541
2445,fevnmbr / fvc ratio,C0456603;C1547037;C3714541
2445,fevnmbr / fvc %,C3714541
2445,fevnmbr / fvc,C3714541
2444,prebronchodilator fevnmbr / fvc,C2599602;C3714541
2444,prebronchodilator fevnmbr ( l ) t,C2599602;C3714541
2444,prebronchodilator fevnmbr ( l ),C2599602;C3714541
2444,prebronchodilator fevnmbr ( % predicted normal ) t,C2599602;C3714541
2444,prebronchodilator fevnmbr ( %,C2599602;C3714541
2444,pre - bronchodilator fvc ’ % pred,C2599602;C3714541
2444,pre - bronchodilator fvc ( l ),C2599602;C3714541
2444,pre - bronchodilator fevnmbr / fvc ratio *,C0456603;C1547037;C2599602;C3714541
2444,pre - bronchodilator fevnmbr / fvc ( % ),C2599602;C3714541
2444,pre - bronchodilator fevnmbr ( l ),C2599602;C3714541
2444,pre - bronchodilator fevnmbr ( % predicted normal ),C2599602;C3714541
2444,pre - bronchodilator fev^ ( l ),C2599602;C3714541
2444,pre - bronchodilator fev i ( l ),C0021966;C0221138;C2599602;C3714541
2444,pre - bronchodilation fvc,C0439566;C3714541
2444,pre - bronchodilation fevnmbr,C0439566;C3714541
2444,post - bronchodilation fvc,C0439576;C3714541
2444,post - bronchodilation fevnmbr,C0439576;C3714541
2444,fvc pre - bronchodilator,C2599602;C3714541
2444,fvc post - bronchodilator,C3714541
2444,fevnmbr pre - bronchodilator ( % predicted normal ),C2599602;C3714541
2444,fevnmbr pre - bronchodilator,C2599602;C3714541
2444,fevnmbr post - bronchodilator,C3714541
2444,fevnmbr / fvc prebronchodilatort,C3714541
2444,fevnmbr / fvc prebronchodilator,C2599602;C3714541
2444,fevnmbr ( l ) pre - bronchodilator,C2599602;C3714541
2444,baseline pre - bronchodilator fevnmbr,C0168634;C1442488;C2599602;C3714541
2443,screening % predicted fevnmbr,C0220908;C0220909;C0681842;C1698960;C1710031;C1710032;C1710477;C1882327;C2348164;C3714541
2443,percent of predicted fevnmbr,C1882327;C3714541
2443,fvc > nmbr % predicted,C3714541
2443,fvc < nmbr % predicted,C3714541
2443,fvc ( % predicted ),C3714541
2443,fvc % predicted !,C3714541
2443,fevnmbr — % of predicted value,C0681842;C1522609;C1882327;C3714541
2443,fevnmbr percent predicted ( sd ),C0439165;C3714541
2443,fevnmbr ( % predicted normal ),C3714541
2443,fevnmbr ( % predicted ),C3714541
2443,fevnmbr ( % of predicted value ),C0681842;C1522609;C1882327;C3714541
2443,fevnmbr % predicted ≥ nmbr %,C3714541
2443,fevnmbr % predicted normal,C3714541
2443,fevnmbr % predicted at baseline,C3714541
2443,fevnmbr % predicted < nmbr %,C3714541
2443,fevnmbr % predicted ( sd ),C0681842;C1882327;C2699239;C3714541
2443,fevnmbr % predicted,C3714541
2443,% predicted ” fev,C0681842;C1882327;C3714541
2443,% predicted fevnmbr,C0681842;C1882327;C3714541
2443,% predicted fev^,C0681842;C1882327;C3714541
2443,% predicted fev,C0681842;C1882327;C3714541
2442,post fvc % pred,C0687676;C1704687;C3469826;C3714541
2442,post fvc,C0687676;C1704687;C3469826;C3714541
2442,post fevnmbr   % pred,C0687676;C1704687;C3469826;C3714541
2442,post fevnmbr,C0687676;C1704687;C3469826;C3714541
2442,fevnmbr reversibilityz ( pre / post salbutamol ),C0001927;C0332152;C0687676;C0740175;C1704687;C2257086;C3469826;C3669034;C3714541
2442,fevnmbr reversibilityz ( pre / post ipratropium ),C0027235;C0332152;C0687676;C0740175;C1704687;C2257086;C3469826;C3669034;C3714541
2442,fevnmbr / fvc ( post salbutamol ),C0001927;C0687676;C1704687;C3469826;C3714541
2442,fevnmbr / fvc ( post - albuterol ),C3714541
2442,fevnmbr % predicted ( post salbutamol ),C3714541
2442,fevnmbr % pred . ( post - albuterol ),C0001927;C0032952;C0044955;C0687676;C1704687;C3469826;C3714541
2441,anmbrs - hydroxy -,C0700307
2440,nmbr ( mono ),C1551432;C1551969
2439,nmbr % ( ito nmbr ),C0022283
2439,nmbr % ( - ito nmbr ),C0022283
2438,use nmbr - asa compounds,C0004057;C0042153;C0205198;C0457083;C1706082;C1947944;C3853627
2438,no use of nmbr - asa compounds,C0004057;C0205198;C1524063;C1706082;C3853627
2438,nmbr - asa compounds,C0004057;C0205198;C1706082;C3853627
2438,nmbr - aminosalicylic compounds — no . ( % ),C0205198;C1706082
2437,angina symptoms^,C0858277
2436,duration of symptoms > nmbr min,C0436359;C0702093;C1524029;C3813700
2436,duration of symptoms,C0436359
2436,duration of dementia symptoms,C0011265;C0436359;C0497327
2435,presenting signs and symptoms,C0220912;C0220913;C0311392;C0449450
2435,no . of ' signs or symptoms of chff,C0220912;C0220913;C0311392
2435,hf signs and symptoms,C0018488;C0220912;C0220913;C0311392;C1313497;C1538440;C3273279
2434,trough fvc response ( l ) !,C0444506;C0871261;C1704632;C1706817;C2911692;C3714541
2434,trough fvc response ( l ),C0444506;C0871261;C1704632;C1706817;C2911692;C3714541
2434,trough fevnmbr   response,C0444506;C0871261;C1704632;C1706817;C2911692;C3714541
2434,trough fev | response ( l ),C0444506;C0871261;C1704632;C1706817;C2911692;C3714541
2434,stratum nmbr : inadequate response or intolerance to nmbr - nmbr bdmards of same moa,C0205412;C0439856;C0871261;C1704632;C1706817;C2911692
2434,stratum nmbr : inadequate response or intolerance to > nmbr bdmards of same moa or > nmbr of multiple moa,C0205412;C0439856;C0871261;C1704632;C1706817;C2911692
2434,sri response,C0871261;C1420401;C1704632;C1706817;C2911692
2434,previous loss of response to infliximab,C0205156;C0871261;C1517945;C1552607;C1704632;C1706817;C2911692
2434,previous loss of response to and intolerance of infliximab,C0205156;C0871261;C1517945;C1552607;C1704632;C1706817;C2911692
2434,peak fevnmbr ( nmbr - nmbrh )   response,C0033727;C0369286;C0441932;C0444505;C0564385;C0871261;C1704632;C1706817;C2911692;C3714541;C4528284
2434,patients with weekly iss mid response,C0030705;C0332174;C0871261;C1704632;C1706817;C1740819;C1845118;C2911692
2434,patients with previous loss of response to infliximab,C0030705;C0205156;C0871261;C1517945;C1552607;C1704632;C1706817;C2911692
2434,patients with previous loss of response to and intolerance of infliximab *,C0030705;C0205156;C0871261;C1517945;C1552607;C1704632;C1706817;C2911692
2434,patient ' s global assessment of response to therapy score,C0871261;C1704632;C1706817;C2911692;C4054229
2434,pasinmbr response },C0871261;C1704632;C1706817;C2911692;C4528685
2434,pasi response by baseline weight,C0871261;C1303013;C1704632;C1706817;C2911692;C4528685
2434,pasi response by baseline mtx use,C0025677;C0042153;C0168634;C0457083;C0871261;C1417487;C1442488;C1704632;C1706817;C1947944;C2911692;C4528685
2434,omeract - oarsi response,C0871261;C1704632;C1706817;C2911692
2434,mean eq - nmbrd response ( nmbr % ci ),C0008107;C0205163;C0439185;C0444504;C0871261;C1704632;C1706817;C2347634;C2348143;C2911692;C3259781
2434,loss of response ‘ s,C0871261;C1517945;C1704632;C1706817;C2911692
2434,loss of response ®,C0871261;C1517945;C1704632;C1706817;C2911692
2434,loss of response : ! : : ! :,C0871261;C1517945;C1704632;C1706817;C2911692
2434,loss of response,C0871261;C1517945;C1704632;C1706817;C2911692
2434,inadequate response or intolerance to > nmbr anti - tnfdrug,C0205412;C0439856;C0871261;C1704632;C1706817;C2911692
2434,inadequate response / intolerance to prior therapy,C0039798;C0087111;C0205412;C0231199;C0332152;C0439856;C0871261;C1363945;C1704632;C1706817;C1744706;C2355652;C2911692
2434,inadequate response ' ’ ',C0205412;C0439856;C0871261;C1704632;C1706817;C2911692
2434,inadequate response ' ^,C0205412;C0439856;C0871261;C1704632;C1706817;C2911692
2434,inadequate response,C0205412;C0439856;C0871261;C1704632;C1706817;C2911692
2434,eular good response,C0205170;C0871261;C1704632;C1706817;C2911692
2434,bronchodilator response,C0006280;C0871261;C1704632;C1706817;C2911692
2434,acrnmbr response at week nmbr,C0332174;C0439230;C0871261;C1412134;C1515941;C1704632;C1706817;C2911692
2434,acrnmbr response,C0871261;C1412134;C1515941;C1704632;C1706817;C2911692
2434,acr response by baseline weight,C0871261;C1303013;C1412134;C1515941;C1704632;C1706817;C2911692
2434,acr response by baseline mtx use,C0025677;C0042153;C0168634;C0457083;C0871261;C1412134;C1417487;C1442488;C1515941;C1704632;C1706817;C1947944;C2911692
2434,acr response,C0871261;C1412134;C1515941;C1704632;C1706817;C2911692
2433,time to end - of - study ivus,C0040227;C0444930;C1456025;C2746065
2432,time since last dose of,C0946444
2432,time from last dose of pnmbrynmbr inhibitor,C0946444;C1999216
2431,time of symptom onset to randomization ( hrs ),C1320528
2431,time of symptom onset to balloon inflation ( hrs ),C1320528
2431,time from symptom onset of ra,C1320528;C3538806;C4048756
2431,time from onset of symptoms to start of fibrinolytic therapy — hr,C1320528
2431,time from onset of symptoms to randomization — days,C1320528
2431,time from onset of symptoms to presentation — hr,C1320528
2430,time from sx onset to baseline ecg,C0449244;C1519428;C3539997;C3815196
2430,time from onset to randomization,C0449244
2430,time from onset to medication,C0449244
2429,symptom onset to start of reperfusion treatment : tenecteplase or arterial sheath insertion !,C4086878
2429,symptom onset to randomization,C0034656;C4086878
2429,symptom onset to pci,C4049621;C4086878
2429,symptom onset to hospitalization,C0019993;C4086878
2429,symptom onset to hospital admission,C0184666;C4086878
2429,symptom onset to first medical contact : ambulance or emergency department,C0002422;C0199168;C0205435;C0205476;C0332158;C0337611;C1279901;C1705415;C3812666;C3846685;C4086878
2429,symptom onset - to - randomization,C0034656;C4086878
2429,symptom onset - to -,C4086878
2429,symptom onset,C4086878
2428,symptomatic pe,C0070939;C0231220;C1880476;C4284304
2428,symptomatic padt,C0231220
2428,symptomatic pad,C0182158;C0231220;C0332568;C3540603;C3669270;C3814046;C4319657
2428,symptomatic,C0231220
2428,initial symptomatic pe,C0070939;C0205265;C0231220;C1279901;C1555582;C1705685;C1880476;C4284304
2427,symptomatic remissionb n / n ( % ),C0231220
2427,symptomatic hypotension with sbp < nmbr mm   hg,C0020649;C0085805;C0231220;C0439475;C3163620
2427,symptomatic hypotension ( sbp < nmbr mmhg ),C0020649;C0085805;C0231220;C0439475;C3163620
2427,symptomatic hypotension,C0020649;C0231220;C3163620
2426,teaes of special interest,C0205555;C0543488
2426,special interest categories,C0205555;C0543488;C0683312
2425,rest pain,C0234253
2425,intensity of rest pain ( mmvas ),C0035253;C0234253;C0522510;C1320357;C1622890;C4085211
2424,vasoprotectives,C0304533
2423,progestins,C0033306
2422,use of compression stockings,C0038348;C1524063
2422,compression stockings,C0038348
2421,prior use of osteoporosis medications,C0013227;C0029456;C0332152;C0802604;C1524063;C2598133;C2826257;C4284232;C4554622
2421,other osteoporosis medication,C0013227;C0029456;C3244316;C4284232;C4554622
2421,osteoporosis drug,C0013227;C0029456;C1254351;C4554622
2421,osteoporosis,C0029456;C4554622
2420,seropositivity status,C0449438;C0521143
2420,seropositivity,C0521143
2419,trough seated sbp ( mmhg ) a,C0085805;C0277814;C0439475;C0444506;C1283233
2419,trough seated hr ( bpm ) a,C0277814;C0444506;C1283233
2419,trough seated dbp ( mmhg ) a,C0277814;C0439475;C0444506;C0536221;C1283233;C3813197;C4281799
2419,seated sbp at nmbr weeks,C0085805;C0277814;C0439230;C1283233
2419,seated sbp,C0085805;C0277814;C1283233
2418,sitting systolic blood pressure ( mm hg ),C0277814;C2584297;C4050224
2418,mean sitting sbp ( mmhg ),C0085805;C0277814;C0439475;C0444504;C2347634;C2348143;C2584297;C4050224
2418,mean sitting dbp ( mmhg ),C0277814;C0439475;C0444504;C0536221;C2347634;C2348143;C2584297;C3813197;C4050224;C4281799
2417,rest ofworld,C0035253;C1622890
2417,rest ofthe world,C0035253;C1622890;C2700280
2417,rest of world n z nmbr,C0035253;C1622890;C2700280
2417,rest of world,C0035253;C1622890;C2700280
2417,rest of the world,C0035253;C1622890;C2700280
2417,rest - of - world ( n = nmbr ),C0035253;C1622890;C2700280
2417,paonmbr at rest,C0035253;C0232555;C1423784;C1427155;C1622890;C4318615
2417,heart rate at rest — beats / min,C0018810;C0035253;C1622890
2417,heart rate at rest in the supine position ( beats / min ),C0018810;C0035253;C1622890
2417,aaponmbr at rest,C0035253;C1622890
2416,long term *,C0443252
2416,long term ( n = nmbr ) +,C0443252
2416,long - term warfarin ( n = nmbr ),C0043031;C0443252
2416,long - term warfarin ( n - nmbr ),C0043031;C0443252
2416,long - term aspirin,C0004057;C0443252
2415,units per week,C0560588
2415,daily iglar dose at week nmbr ( u ),C0560588;C2348070
2414,nmbr - nmbr ( low risk ),C3272281;C3538919
2414,lower risk ( n = nmbr ),C3272281;C3538919
2414,lower risk,C3272281;C3538919
2414,low risk and more symptoms ( group b ),C3272281;C3538919
2414,low risk and fewer symptoms ( group a ),C3272281;C3538919
2414,low risk ( nmbr - nmbr ),C3272281;C3538919
2414,low risk ( n nmbr nmbr ),C3272281;C3538919
2414,low risk ( ? ics ),C0815320;C3272281;C3538919;C4551720
2414,low risk ( - ics ),C0815320;C3272281;C3538919;C4551720
2414,low risk,C3272281;C3538919
2414,group b ( low risk,C3272281;C3538919;C4522078
2413,lvh on ecg,C0232306
2413,lvh by ecg or echocardiographyd,C0232306
2413,lvh by ecg or echocardiography,C0232306
2413,lvh by ecg or echo . n ( % ),C0232306
2413,lvh by ecg / echo,C0058928;C0232306;C1655045
2413,lvh by ecg,C0232306
2413,lv hypertrophy per ecg,C0232306
2413,ecg - lvh ( sokolow - lyon ),C0232306
2413,ecg - lvh ( cornell ),C0232306
2413,baseline ecg with lvh,C0168634;C0232306;C1442488
2412,non - black race and ss > nmbr ( n = nmbr vs nmbr ),C0005680;C1518422
2412,non - black race and ss < nmbr ( n = nmbr vs nmbr ),C0005680;C1518422
2412,non - black race ( n = nmbr vs nmbr ),C0005680;C1518422
2412,non - black ( n = nmbr ),C0005680;C0027567;C0085756;C0439541;C1518422
2412,black region or country ( % ),C0005680;C0017446;C0027567;C0085756;C0205147;C0439541
2412,black race — no . / total no . ( % ) f,C0005680;C0027567;C0085756;C0439541
2412,black race and ss > nmbr ( n = nmbr vs nmbr ),C0005680
2412,black race and ss < nmbr ( n = nmbr vs nmbr ) ■ -,C0005680
2412,black race ( n = nmbr vs nmbr ),C0005680
2412,black race,C0005680
2412,black or asian,C0005680;C0027567;C0085756;C0439541
2412,black or african,C0005680;C0027567;C0085756;C0439541
2412,black and other,C0005680;C0027567;C0085756;C0439541
2412,black ( n — nmbr ),C0005680;C0027567;C0085756;C0439541
2412,black ( n   = nmbr ),C0005680;C0027567;C0085756;C0439541
2412,black ( n = nmbr ),C0005680;C0027567;C0085756;C0439541
2411,black non - hispanic - n ( % ),C0005680;C0027567;C0085756;C0439541;C1518422;C1518424;C1533017;C1533018
2411,black non - hispanic,C0005680;C0027567;C0085756;C0439541;C1518422;C1518424;C1533017;C1533018
2411,black hispanic - n ( % ),C1533017;C1533018
2411,black hispanic,C1533017;C1533018
2411,asian / black / white / hispanic / other ( % ) clinical parameters,C0005680;C0007457;C0027567;C0043157;C0078988;C0085756;C0220938;C0439541;C1533017;C1533018;C1533020;C1533021
2410,qids - srnmbr,C4331197
2409,ill -,C0231218
2408,ttf - fv,C1332112;C1705840;C4087167
2407,hla - bnmbr,C0019737;C0550853;C1415561
2406,plp - c,C0034266;C1175541;C1257874;C1705623
2405,cgi - s,C4526016
2404,ctn - l,C0917591
2404,ctn - i,C0021966;C0221138;C0917591
2403,nx *,C0445085
2402,hder *,C3898895
2401,two - sided p - value for hetero - geneity,C0205448;C0441987;C1709380
2401,p — value for interaction,C1704675;C1709380
2401,p ‐ value *,C1709380
2401,p ‐ value,C1709380
2401,p   values of interaction,C1704675;C1709380
2401,p   values for interaction,C1704675;C1709380
2401,p   value for interaction,C1704675;C1709380
2401,p   value,C1709380
2401,p values,C1709380
2401,p valuenmbr,C1709380
2401,p value 十,C1709380
2401,p value ∥,C1709380
2401,p value § ® ( w,C1709380
2401,p value within category,C0683312;C1709380;C3889287
2401,p value versus placebo,C1709380
2401,p value nmbr . nmbr,C1709380
2401,p value interaction,C1704675;C1709380
2401,p value for interactiont,C1709380
2401,p value for interaction^,C1704675;C1709380
2401,p value for interaction ®,C1704675;C1709380
2401,p value for interaction,C1704675;C1709380
2401,p value for,C1709380
2401,p value fo interactio,C1709380
2401,p value f,C0016327;C1709380
2401,p value c,C1709380
2401,p value by gt,C1435727;C1704693;C1709380;C2697657
2401,p value * nmbr,C1709380
2401,p value *,C1709380
2401,p value ( nominal ),C1709380
2401,p value ( interaction ),C1704675;C1709380
2401,p value ( inter ),C1709380
2401,p value ( int ),C1709380;C3272375
2401,p value,C1709380
2401,p - valuenmbr,C1709380
2401,p - value ‘ ’,C1709380
2401,p - value ¶,C1709380
2401,p - value },C1709380
2401,p - value vs . placebo,C1709380
2401,p - value n / n ( % ),C1709380
2401,p - value low vs . high nfs^,C1709380
2401,p - value interaction,C1704675;C1709380
2401,p - value for variance,C1709380;C1711260;C2348152
2401,p - value for interaction,C1704675;C1709380
2401,p - value for,C1709380
2401,p - value * ' ',C1709380
2401,p - value *,C1709380
2401,p - value ( ■ nt ),C0332126;C1449832;C1709380;C3889152;C4050156;C4283901;C4284038
2401,p - value ( vs placebo ),C1709380
2401,p - value ( overall ),C0282416;C1561607;C1709380
2401,p - value ( lnteraction ),C1709380
2401,p - value ( interaction ) ≠,C1704675;C1709380
2401,p - value ( int ),C1709380;C3272375
2401,p - value ( anova ),C0753802;C1709380
2401,"p - value """,C1709380
2401,p - value,C1709380
2401,p ' value,C1709380
2401,nmbr p value,C1709380
2401,adjusted p - value for interaction,C0456081;C1704675;C1709380
2401,* p value,C1709380
2400,p value § ( < nmbr vs . > = nmbr years ),C1709380
2400,p value ( vs . previous time point ),C1709380
2400,p value ( on vs off omt ),C1709380
2400,p value ( men versus women ),C0025266;C1709380
2400,p value ( cangrelor versus clopidogrel in women ),C1121991;C1709380
2400,p value ( cangrelor versus clopidogrel in men ),C1121991;C1709380
2400,p value ( aged > nmbr vs . < nmbr years ),C0001779;C0001792;C1709380;C1999167
2400,p - value for east asian versus non - east asian *,C0078988;C1707877;C1709380
2400,* the p ‐ value is from the test statistic for testing the interaction between the treatment group and diabetes group .,C1709380
2399,univariate p - value,C1709380
2399,rr ( nmbraci ) [p value],C0814206;C1510682;C1709380;C2346870;C4050575;C4554402
2399,nteraction p value,C1709380
2399,multivariate p - value,C1709380
2399,interactior p - value,C1709380
2399,heterogeneity p value,C0019409;C0242960;C1709380
2399,chi - square p value,C1552646;C1709380
2399,bonferroni - adjusted p value,C1709380;C1879894
2398,atv n ( % ),C0210243;C0674679;C1145759;C1334862
2398,"atv  atorvastatin  ldl - c  low - density lipoprotein cholesterol . * p - values pertain to treatment - by - stratum interaction test for stratum or treatment - by - subgroup interaction test for subgroups . ' multiplicity adjustments were not applied to this predefined subgroup analysis of ldl - c goal attainment  "" [expressed as number of patients reaching ldl - c goal at week nmbr / number of patients above goal at baseline  ^treatment stratum was defined by intake of atv nmbr or nmbr mg .",C0023824;C0210243;C0286651;C0674679;C1145759;C1334862;C1709380
2397,type ii diabetes,C0011860
2397,diabetes type ii,C0011860
2396,place of randomization,C0034656;C0442504;C1533810;C1704765;C1882509
2396,place !,C0442504;C1533810;C1704765;C1882509
2395,glycemic variability,C0005802;C2827666
2395,glycemic drugs,C0005802;C0013227;C3687832
2395,glycemia,C0005802
2395,blood glucose,C0005802
2395,baseline glycemic control,C0005802;C0168634;C0243148;C1442488;C1550141;C1882979;C2587213;C3274648;C4553389
2394,> nmbr : obese class iii,C1319441
2393,nmbr - nmbr . nmbr : obese class ii,C3853263
2393,nmbr - nmbr . nmbr : obese class i,C3853264
2392,nyha functional class i,C0205245;C0542341;C1882084;C2700217
2392,nyha class i,C1882084
2391,eosinophils ( cells / ll ) inclusion criteria,C0682547
2391,eosinophil counf cells pl ',C0682547;C3897966;C4049765
2391,baseline eosinophil nmbr cells / pl,C0168634;C0682547;C1442488;C3897966;C4049765
2391,baseline eosinophil < nmbr cells / pl,C0168634;C0682547;C1442488;C3897966;C4049765
2390,killip class — no . / total no . ( % ) i,C1881332
2390,killip class — no . ( % ) i,C1881332
2390,killip class at admission — no . / total no . ( % ),C0184666;C0809949;C1881332
2390,killip class ( interaction : p = nmbr . nmbr ),C1704675;C1881332
2389,killip class nmbr / nmbr,C1881332
2389,killip class nmbr,C1881332
2389,killip class > nmbr,C1881332
2389,killip class *,C1881332
2389,killip class,C1881332
2389,baseline killip class,C0168634;C1442488;C1881332
2389,< nmbr baseline killip class,C0168634;C1442488;C1881332
2388,ex - drinker,C0337679
2387,non - / ex - drinker,C0457801
2387,former / non - drinker,C0205156;C0457801;C0750523
2386,nonsmoker,C0337672;C0425293;C4554605
2386,non - smoker ( n = nmbr,C0337672;C0425293;C4554605
2386,non - smoker,C0337672;C0425293;C4554605
2386,never smoker,C0425293
2385,prior smoker,C0337671
2385,previous smokers,C0337671
2385,previous smoker,C0337671
2385,former smokers,C0337671
2385,former smoker — no . { % ),C0337671
2385,former smoker — no . ( % ),C0337671
2385,former smoker ( n = nmbr ),C0337671
2385,former smoker ( n = nmbr,C0337671
2385,former smoker,C0337671
2385,exsmoker,C0337671;C4555205
2385,ex - smokers nmbr,C0337671;C4555205
2385,ex - smokers : qvainmbr - sfc,C0337671;C4521536;C4555205
2385,ex - smokers ( n = nmbr ),C0337671;C4555205
2385,ex - smokers ( itt ) ( n = nmbr ),C0337671;C4555205
2385,ex - smokers,C0337671;C4555205
2385,ex - smoker / smoker,C0337671;C4555205
2385,ex - smoker / current,C0337671;C0521116;C1705970;C4555205
2385,ex - smoker ( n z nmbr ),C0337671;C4555205
2385,ex - smoker,C0337671;C4555205
2384,use of concomitant lipid - lowering treatment,C0023779;C0039798;C0087111;C0441994;C0521115;C1522326;C1524063;C1533734;C1705169;C2003888;C3538994;C3887704
2384,type of lipid - lowering regimen,C0023779;C0040808;C0332307;C0441994;C1547052;C2003888;C2945654
2384,prior urate lowering therapies,C0441994;C0729829;C0935936;C1514463;C2003888
2384,other lipid - lowering medication,C0013227;C0023779;C0441994;C2003888;C3244316;C4284232
2384,other glucose - lowering drugs,C0013227;C0017725;C0441994;C2003888;C3687832
2384,no glucose lowering drugs,C0013227;C0017725;C0441994;C2003888;C3687832
2384,no . of background glucose - lowering therapies,C0017725;C0087111;C0441994;C1706907;C2003888
2384,lower than normal range — % ^,C0086715;C0441994;C1548802;C2003888
2384,lower tertile : b nmbr . nmbr,C0441994;C1548802;C2003888
2384,lower,C0441994;C1548802;C2003888
2384,lipid lowering medication use,C0023779;C0240320;C0441994;C2003888
2384,lipid lowering,C0023779;C0441994;C2003888
2384,lipid - lowering medications^,C0013227;C0023779;C0441994;C0802604;C2003888;C2598133;C4284232
2384,lipid - lowering medications,C0013227;C0023779;C0441994;C0802604;C2003888;C2598133;C4284232
2384,lipid - lowering medication ( % ),C0013227;C0023779;C0441994;C2003888;C3244316;C4284232
2384,lipid - lowering medication,C0013227;C0023779;C0441994;C2003888;C3244316;C4284232
2384,lipid - lowering,C0023779;C0441994;C2003888
2384,ldl cholesterol - lowering therapy,C0023824;C0039798;C0087111;C0202117;C0441994;C1363945;C2003888
2384,iop - lowering medication,C0013227;C0441994;C0578862;C2003888;C3244316;C4284232
2384,glucose - lowering therapy - no . ( % ),C0017725;C0039798;C0087111;C0441994;C1363945;C2003888
2384,glucose - lowering therapy,C0017725;C0039798;C0087111;C0441994;C1363945;C2003888
2384,glucose - lowering therapies — no . { % ),C0017725;C0087111;C0441994;C2003888
2384,glucose - lowering therapies,C0017725;C0087111;C0441994;C2003888
2384,glucose - lowering medications,C0013227;C0017725;C0441994;C0802604;C2003888;C2598133;C4284232
2384,glucose - lowering medication,C0013227;C0017725;C0441994;C2003888;C3244316;C4284232
2384,glucose - lowering drug,C0013227;C0017725;C0441994;C1254351;C2003888
2384,blood pressure lowering medication use,C0005823;C0240320;C0441994;C1271104;C1272641;C2003888
2384,blood pressure - lowering treatment,C0005823;C0033095;C0039798;C0087111;C0441994;C0460139;C0596197;C1271104;C1272641;C1306345;C1522326;C1533734;C1705169;C2003888;C3538994;C3887704;C4284008
2384,blood glucose lowering treatment,C0005802;C0017725;C0039798;C0087111;C0441994;C0596197;C1522326;C1533734;C1705169;C2003888;C3538994;C3887704
2384,blood glucose - lowering treatments,C0005802;C0017725;C0087111;C0441994;C0596197;C2003888
2384,blood glucose - lowering drugs,C0005802;C0013227;C0017725;C0018938;C0441994;C2003888;C3687832
2384,> nmbr glucose - lowering medication . no . ( % ),C0013227;C0017725;C0441994;C2003888;C3244316;C4284232
2383,poor,C0032854;C0542537;C2700379
2382,fair or poor,C2911689
2382,fair / poor,C0032854;C0542537;C2700379;C2911689
2381,pure motor hemiparesis,C0018989;C1513492;C1705994;C2247561
2381,motor weakness,C1513492;C1705994;C3714552
2381,motor,C1513492;C1705994
2380,total mayo score $ | |,C0454788;C1077578;C2964552
2380,total mayo score,C0454788;C1077578;C2964552
2380,partial mayo clinic scored,C0002424;C0442592;C0454788;C0728938;C1077578;C1550516
2380,mean mayo score ( sd ),C0454788;C1077578;C2699239;C3533236
2380,mayo clinic scoreb,C0002424;C0442592;C0454788;C1077578
2380,mayo clinic score §,C0002424;C0442592;C0449820;C0454788;C1077578;C4050231
2380,mayo clinic score,C0002424;C0442592;C0449820;C0454788;C1077578;C4050231
2380,mayo < nmbr,C0454788;C1077578
2380,mayo $ nmbr,C0454788;C1077578
2380,complete mayo clinic score,C0002424;C0205197;C0442592;C0449820;C0454788;C0725685;C1077578;C3853530;C4050231;C4283785
2380,baseline composite mayo clinic score,C0002424;C0168634;C0442592;C0454788;C1077578;C1442488;C4055211
2379,om nmbr mg / aml nmbr mg / hctz nmbr mg,C0020261;C0023465;C0023467;C0028971;C1319635;C1705272
2379,om nmbr mg + aml nmbr mg + hctz nmbr mg ( n = nmbr ),C0020261;C0023465;C0023467;C0028971;C1319635;C1705272
2379,om nmbr mg + aml nmbr mg + hctz nmbr mg,C0020261;C0023465;C0023467;C0028971;C1319635;C1705272
2379,aml vs . lis,C0023465;C0023467
2379,aml vs . chl,C0023465;C0023467
2379,aml nmbr mg / hctz nmbr mg,C0020261;C0023465;C0023467;C1319635
2379,aml nmbr mg + hctz nmbr mg ( n = nmbr ),C0020261;C0023465;C0023467;C1319635
2379,aml nmbr mg + hctz nmbr mg,C0020261;C0023465;C0023467;C1319635
2379,aml nmbr /,C0023465;C0023467
2379,aml / val nmbr / nmbr mg,C0023465;C0023467;C0024671;C0026410;C0042285;C0439269;C0523975;C1960952;C2346927;C4321396;C4521761
2379,aml / val,C0023465;C0023467;C0042285;C0523975
2379,aml / hctz ( n = nmbr ),C0020261;C0023465;C0023467
2379,aml ( n = nmbr ),C0023465;C0023467
2379,aml,C0023465;C0023467
2379,a / aml ( n = nmbr ),C0023465;C0023467
2378,• ml without st - segment elevation,C0439526;C0520886;C1705224;C3887665
2378,• ml with st - segment elevation,C0439526;C0520886;C1705224;C3887665
2378,type of ml,C0332307;C0439526;C1547052;C1705224;C3887665
2378,quartiles of fgf - nmbr ( ru / ml ),C0016026;C0035970;C0439526;C0919505;C1425796;C1705224;C2828255;C3887665
2378,prior ml or stroke at baseline,C0332152;C0439526;C1705224;C2826257;C3887665
2378,prior ml or abnormal angiogram,C0332152;C0439526;C1705224;C2826257;C3887665
2378,prior ml,C0332152;C0439526;C1705224;C2826257;C3887665
2378,prior history ml or stroke,C0019664;C0019665;C0262512;C0262926;C0332152;C0439526;C1705224;C1705255;C2004062;C2826257;C3887665
2378,previous ml or abnormal angiogram,C0205156;C0439526;C1552607;C1705224;C3887665
2378,previous ml ( interaction : p = nmbr . nmbr ),C0205156;C0439526;C1552607;C1704675;C1705224;C3887665
2378,nontatal ml,C0439526;C1705224;C3887665
2378,nonfatal ml,C0439526;C1705224;C3887665
2378,non - st - elevation ml,C0439526;C0520886;C1518422;C1705224;C3887665
2378,non - fatal ml,C0439526;C1302234;C1518422;C1705224;C1705232;C3887665
2378,no prior ml or stroke,C0332152;C0439526;C1705224;C2826257;C3887665
2378,no prior ml,C0332152;C0439526;C1705224;C2826257;C3887665
2378,nmbr ml ( nmbr to nmbr ) ( n = nmbr / nmbr ) §,C0439526;C1705224;C3887665
2378,nmbr ml ( nmbr to nmbr ) ( n = nmbr / nmbr ),C0439526;C1705224;C3887665
2378,nmbr ml ( nmbr to nmbr ) ( n - nmbr / nmbr ),C0439526;C1705224;C3887665
2378,nmbr - nmbr ml / rain,C0034640;C0439526;C1705224;C3887665
2378,ml without st - segment elevation !,C0439526;C0520886;C1705224;C3887665
2378,ml with st - segment elevation,C0439526;C0520886;C1705224;C3887665
2378,ml c,C0439526;C1705224;C3887665
2378,ml ),C0439526;C1705224;C3887665
2378,ml,C0439526;C1705224;C3887665
2378,lvesv ( ml ),C0439526;C1705224;C3887665
2378,lvedv ( ml ),C0439526;C1705224;C3887665
2378,lav ( ml ),C0019682;C0439526;C1705224;C3887665
2378,decline #   ml · yr − nmbr,C0439234;C0439526;C1705224;C3887665
2378,alvesv ( per ml ),C0439526;C1705224;C3887665
2378,alvedv ( per ml ),C0439526;C1705224;C3887665
2378,alav ( per ml ),C0439526;C1705224;C3887665
2378,> nmbr ml,C0439526;C1705224;C3887665
2378,> = nmbr ml / mln,C0439526;C1417190;C1705224;C3815103;C3887665
2378,< nmbr ml,C0439526;C1705224;C3887665
2378,* nonfatal ml,C0439526;C1705224;C3887665
2377,prior copd medicationa,C0024117;C0332152;C1412502;C2826257;C3714496
2377,prior copd medication,C0013227;C0024117;C0332152;C1412502;C2826257;C3244316;C3714496;C4284232
2377,overall night - time copd symptom severity scorec,C0024117;C0240526;C0282416;C1319166;C1412502;C1561607;C3714496
2377,overall early - morning copd symptom severity scorec,C0024117;C0282416;C0332170;C1279919;C1319166;C1412502;C1561607;C3714496
2377,mean copd duration,C0024117;C0444504;C0449238;C1412502;C2347634;C2348143;C2926735;C3714496
2377,copd — no . ( % ) medication use,C0024117;C1412502;C3714496
2377,copd worsening,C0024117;C0332271;C1412502;C1457868;C1546960;C3714496
2377,copd type,C0024117;C0332307;C1412502;C1547052;C3714496
2377,copd severityy,C0024117;C1412502;C3714496
2377,copd severitya,C0024117;C1412502;C3714496
2377,copd severity : severe / very severe,C0024117;C0439793;C0442824;C0522510;C1412502;C2984081;C3714496
2377,copd severity : mild / moderate,C0024117;C0439793;C0522510;C1412502;C3714496
2377,copd severity ( gold stage ),C0018026;C0024117;C0205390;C0439793;C0522510;C1300072;C1304897;C1306673;C1412502;C3714496
2377,copd severity ( gold nmbr ),C0018026;C0024117;C0439793;C0522510;C1304897;C1412502;C3714496
2377,copd severity,C0024117;C0439793;C0522510;C1412502;C3714496
2377,copd or asthma,C0024117;C1412502;C3714496
2377,copd medication taken for at least nmbr months before study entry,C0013227;C0024117;C1412502;C3244316;C3714496;C4284232
2377,copd medication taken for at least nmbr months before st,C0013227;C0024117;C1412502;C3244316;C3714496;C4284232
2377,copd duration,C0024117;C0449238;C1412502;C2926735;C3714496
2377,copd - rosuvastatin ( nmbr pt ) n . ( % ),C0024117;C0032743;C0699718;C0965129;C1412502;C3714496
2377,copd - rosuvastatin ( n = nmbr ),C0024117;C0965129;C1412502;C3714496
2377,copd ( n = nmbr ),C0024117;C1412502;C3714496
2377,copd ( % ),C0024117;C1412502;C3714496
2377,copd,C0024117;C1412502;C3714496
2377,chronic obstructive pulmonary disease — no . ( % ),C0024117
2377,chronic obstructive pulmonary disease,C0024117
2377,chronic obstructive lung disease,C0024117
2376,copd assessment test ( cat ) score,C0007450;C0325090;C0449820;C0524517;C1443200;C3665481;C4050231;C4050461;C4284282
2376,comparison : cat . nmbr vs . cat . nmbr,C0007450;C0325090;C0524517;C1443200;C1707455;C3665481;C4050461;C4284282
2376,cat scoreff,C0007450;C0325090;C0524517;C1443200;C3665481;C4050461;C4284282
2376,cat score category,C0007450;C0325090;C0449820;C0524517;C0683312;C1443200;C3665481;C3889287;C4050231;C4050461;C4284282
2376,cat score,C0007450;C0325090;C0449820;C0524517;C1443200;C3665481;C4050231;C4050461;C4284282
2376,cat > nmbr,C0007450;C0325090;C0524517;C1443200;C3665481;C4050461;C4284282
2376,cat > = nmbr ( n = nmbr,C0007450;C0325090;C0524517;C1443200;C3665481;C4050461;C4284282
2376,cat > = nmbr,C0007450;C0325090;C0524517;C1443200;C3665481;C4050461;C4284282
2376,cat < nmbr,C0007450;C0325090;C0524517;C1443200;C3665481;C4050461;C4284282
2376,cat . nmbr n / n ( % ),C0007450;C0325090;C0524517;C1443200;C3665481;C4050461;C4284282
2376,b . i . d .  twice daily  cat  copd assessment test  copd  chronic obstructive pulmonary disease  fevnmbr    forced expiratory volume in nmbr   s  fvc  forced vital capacity  gold  global initiative for chronic obstructive lung disease  ics  inhaled corticosteroid  mcid  minimum clinically important difference  mmrc  modified medical research council  o . d .  once daily  sd  standard deviation  sgrq - c  st . george ’ s respiratory questionnaire for copd,C0007450;C0018026;C0024117;C0152277;C0178628;C0205246;C0231958;C0325090;C0424093;C0524517;C0585361;C1304897;C1443200;C2348867;C3665481;C4050461;C4284282
2375,types of antihypertensive medications at nmbr year   †,C0003364;C0332307
2375,types of antihypertensive medications at last visit   §,C0003364;C0332307
2375,type of stent at index procedure,C0038257;C0332307;C1547052
2375,type of hospital care,C0259945;C0332307;C1547052
2375,type of des at index procedure,C0011702;C0332307;C1547052;C4551552
2375,type of concomitant statin by daily dose - no . ( % ),C0332307;C0360714;C0521115;C1547052
2375,type of concomitant statin by daily dose,C0332307;C0360714;C0521115;C1547052
2375,type of concomitant statin,C0332307;C0360714;C0521115;C1547052
2375,type of antihypertensive medication use among patients using antihypertensive medications,C0003364;C0332307;C1524063;C1547052
2375,type of af,C0332307;C0344434;C1547052;C4049859
2375,type nmbr collagen,C0009325;C0332307;C1547052
2375,type nmbr,C0332307;C1547052
2375,type ic,C0020750;C0332307;C1547052;C4554818
2375,type ib,C0332307;C1547052;C2744579;C3890035;C4283819
2375,type ia,C0020980;C0332307;C0694634;C1547052;C1947960
2375,type / no . of valves repaired / replaced mitral,C0332307;C1547052
2375,type,C0332307;C1547052
2375,serum n - propeptide of type nmbr collagen,C0009325;C0229671;C0332307;C1546774;C1547052;C1550100;C1709708;C1875696
2375,phosphodiesterase type nmbr inhibitors,C0031638;C0332307;C1547052;C1656262;C3539996
2375,endothelin - receptor antagonists plus phosphodiesterase type nmbr inhibitors,C0031638;C0332307;C1134681;C1547052;C1656262;C2266875;C3539996
2375,barc types nmbr,C0332307
2375,any type,C0332307;C1547052
2375,af type — no . ( % ),C0332307;C0344434;C1547052;C4049859
2375,af type,C0332307;C0344434;C1547052;C4049859
2375,acs type,C0332307;C0742343;C1547052;C4318612
2375,> nmbr type,C0332307;C1547052
2374,transaminases increased,C0002594;C0919834
2373,low - trauma fracture since age nmbr,C0521170
2372,gamma glutamyltransferase,C0017040
2371,aspartate aminotransferase increased,C0004002
2371,aspartate aminotransferase,C0004002
2370,mean score,C3533236
2370,mean mmse score,C0451306;C3533236
2370,mean ( sd ) nonstudy eye e - etdrs visual acuity letter score,C0015392;C0042812;C0700042;C1096774;C2360551;C2699239;C3533236
2370,mean ( sd ) e - etdrs visual acuity letter score ( snellen equivalent ),C0042812;C0183370;C0205163;C0439185;C1096774;C2360551;C2699239;C3533236
2369,unacceptable side effects,C0001688;C0877248;C0879626;C1883420
2369,unacceptable adverse events,C0877248;C1705413;C1883420
2369,gall bladder adverse event ( n = nmbr ),C0016976;C0877248
2369,any early adverse event,C0877248;C1279919
2369,any adverse event leading to study drug discontinuation,C0877248
2369,adverse events leading to premature treatment discontinuation,C0877248;C1705413
2369,adverse events ( any grade ),C0877248;C1705413
2369,adverse event,C0877248
2368,dose of aspirin,C4696290
2368,aspirin dose at baseline,C0168634;C1442488;C4696290
2368,aspirin dose,C4696290
2368,aspirin at any dose,C4696290
2367,favors ff / vi favors placebo,C0205999;C0309049;C4554348
2367,favors favors lisinopril chlorthalidone,C0309049
2367,favors favors amlodipine chlorthalidone,C0309049
2366,sri ‐ nmbr response rate,C0237629;C1420401
2365,serum phosphate,C0036820
2364,measurements,C0242485
2364,measure,C0079809;C0242485
2364,lipid measure *,C0023779;C0079809;C0242485
2364,diff_measure ( dm added this as table had multiple headings ),C0011816;C0079809;C0242485;C3250443
2363,sbp ( office measurement ),C0085805;C0242485;C0442603
2363,dbp ( office measurement ),C0242485;C0442603;C0536221;C3813197;C4281799
2362,physiological measures,C0079809;C0205463;C1879489
2362,measures ( mmol / l ),C0079809;C0242485;C1879489
2362,measures ( % ),C0079809;C1879489
2362,measures,C0079809;C1879489
2362,ipeated - measures state examinatioi,C0079809;C1879489
2362,biochemical measures,C0079809;C0205474;C1879489
2361,timi major / minor bleeding,C0019080;C4441842
2361,timi major / minor,C4441842
2360,immunomodulatory agents,C0005525
2360,immunomodulators,C0001551;C0005525;C1527392
2359,timi minor bleeding,C0019080;C0026193;C0205165
2359,minor bleeding,C0019080;C0026193;C0205165
2359,minor bleed,C0019080;C0026193;C0205165
2359,minor / major,C0026193;C0205082;C0205164;C0205165;C4318856;C4521762
2359,minor,C0026193;C0205165
2358,unadjusted model hr,C1439367;C3161035;C3274659;C3714583;C3853906
2358,risk model endpoint,C0035647;C2349179;C2826544;C3161035;C3274659;C3714583;C3853906;C4552904
2358,model nmbrt,C3161035;C3274659;C3714583;C3853906
2358,model nmbr §,C3161035;C3274659;C3714583;C3853906
2358,model nmbr +,C3161035;C3274659;C3714583;C3853906
2358,model nmbr,C3161035;C3274659;C3714583;C3853906
2358,model,C3161035;C3274659;C3714583;C3853906
2358,crude model hr ( nmbr % ci ),C0008107;C3161035;C3259781;C3274659;C3714583;C3853906
2358,bivariate frailty model ( statin users vs non - users ),C0360714;C0424594;C1706077;C3161035;C3274659;C3714583;C3853906
2357,mean eosinophil count,C0200638;C0444504;C0750879;C2347634;C2348143
2357,local eosinophil count [cells / µ l],C0200638;C0205276;C0347983;C0750879
2357,local eosinophil count [cells / ml],C0200638;C0205276;C0750879;C2699156
2357,local eosinophil count,C0200638;C0205276;C0750879
2357,eosinophil count,C0200638;C0750879
2357,central eosinophil count,C0200638;C0205099;C0750879;C1879652
2357,blood eosinophil count — cells / mm ’,C0005773;C0200638;C0750879;C4330985;C4554674
2357,blood eosinophil count cells / mmnmbr no .,C0005773;C0200638;C0750879;C4330985;C4554674
2357,blood eosinophil count > nmbr / mmnmbr in nmbr months before screening — no . ( % ),C0005767;C0005768;C0014467;C0200638;C0229664;C0439231;C0750480;C0750879;C1705566;C4330985;C4554674
2357,blood eosinophil count > nmbr / mmnmbr at screening — no . ( % ),C0200638;C0750879;C1511226;C4330985;C4554674
2356,median blood eosinophil count ( cells per pl ) t,C0200638;C0549183;C0876920;C2347635;C2348144;C2939193;C3897966;C4049765
2356,mean blood eosinophil count ( cells per pl ),C0200638;C0444504;C2347634;C2348143;C3897966;C4049765
2356,blood eosinophil count ( nmbr cells per l ),C0200638
2355,median blood eosinophil count,C0005767;C0005768;C0014467;C0200638;C0229664;C0549183;C0750480;C0750879;C0876920;C1705566;C2347635;C2348144;C2939193
2355,eosinophils £ nmbr % ( n = nmbr ),C0014467;C0200638
2355,eosinophils £ nmbr % ( itt ) ( n = nmbr ),C0014467;C0200638
2355,eosinophils nmbr . nmbrxnmbr ' ' nmbr ( n = nmbr ),C0014467;C0200638
2355,eosinophils nmbr % ( n - nmbr ),C0014467;C0200638
2355,eosinophils nmbr % ( itt ) ( n = nmbr ),C0014467;C0200638
2355,eosinophils > nmbr nmbrxnmbr * nmbr / nmbr ( n = nmbr ),C0014467;C0200638
2355,eosinophils > nmbr . nmbrxnmbr^^ ( itt ) ( n = nmbr ),C0014467;C0200638
2355,eosinophils > nmbr . nmbrxnmbr * nmbr ( n = nmbr ),C0014467;C0200638
2355,eosinophils > nmbr . nmbrxnmbr ' ^ ( itt ) ( n = nmbr ),C0014467;C0200638
2355,eosinophils > nmbr . nmbrxnmbr ' ' nmbr ( itt ) ( n = nmbr ),C0014467;C0200638
2355,eosinophils > nmbr % ( n = nmbr ),C0014467;C0200638
2355,eosinophils > nmbr % ( itt ) ( n = nmbr ),C0014467;C0200638
2355,eosinophils < nmbr nmbrxnmbr * nmbr / l ( n = nmbr ),C0014467;C0200638
2355,eosinophils < nmbr . nmbrxnmbr * nmbr ( n = nmbr ),C0014467;C0200638
2355,eosinophils < nmbr . nmbrxnmbr * nmbr ( itt ) ( n = nmbr ),C0014467;C0200638
2355,eosinophils < nmbr . nmbrxnmbr ' ' nmbr ( n = nmbr ),C0014467;C0200638
2355,eosinophils < nmbr . nmbrxnmbr ' ' nmbr ( itt ) ( n = nmbr ),C0014467;C0200638
2355,eosinophils < nmbr % ( n = nmbr ),C0014467;C0200638
2355,eosinophils < nmbr % ( itt ) ( n = nmbr ),C0014467;C0200638
2355,eosinophils,C0014467;C0200638
2355,eosinophil low,C0014467
2355,eosinophil high,C0014467
2355,blood eosinophils count,C0014467
2355,blood eosinophils,C0014467
2355,blood eosinophil count,C0005767;C0005768;C0014467;C0200638;C0229664;C0750480;C0750879;C1705566
2355,blood eosinophil,C0014467
2354,type of end point,C0332307;C1547052;C2349179;C2826544
2354,other prespecified end points,C2349179
2354,endpoints,C2349179
2354,endpoint week nmbr,C0332174;C0439230;C2349179;C2826544
2354,endpoint rate,C0871208;C1521828;C2349179;C2826544
2354,endpoint / baselinec,C2349179;C2826544
2354,endpoint / baseline,C0168634;C1442488;C2349179;C2826544
2354,endpoint *,C2349179;C2826544
2354,endpoint,C2349179;C2826544
2354,end points,C2349179
2354,end point,C2349179;C2826544
2354,end - point ( sd ),C2349179;C2699239;C2826544
2354,coronary endpoint,C0018787;C2349179;C2826544
2354,coronary end point,C0018787;C2349179;C2826544
2354,all randomized coronary end point,C0018787;C0034656;C2349179;C2826544;C3815594
2353,primary end points,C0205225;C0439612;C0439631;C2349179
2353,other end points,C2349179
2353,bleeding end points,C0019080;C2349179
2353,additional endpoints,C1524062;C2349179
2352,adjustednmbr risk reduction losartan vs placebo ( nmbr % cl ),C0126174;C0456081;C1137094
2352,adjusted ∗   mean of difference ( se ) ( ml ),C0036919;C0439526;C0444504;C0456081;C1705224;C1705241;C1705242;C2347634;C2348143;C3887665
2352,adjusted ∗   mean ( se ) ( ml ),C0036919;C0439526;C0444504;C0456081;C1705224;C2347634;C2348143;C3887665
2352,adjusted or ( nmbr % cl ),C0456081
2352,adjusted or ( nmbr % ci ) c,C0456081
2352,adjusted or ( nmbr % ci ) b,C0456081
2352,adjusted nmbr or ( nmbr % cl ),C0456081
2352,adjusted mean ± se ( nmbr % ci ),C0008107;C0036919;C0444504;C0456081;C2347634;C2348143;C3259781
2352,adjusted mean difference ( nmbr % ci ),C0008107;C0444504;C0456081;C1705241;C1705242;C2347634;C2348143;C3259781
2352,adjusted mean change ( kg ),C0022718;C0392747;C0439209;C0443172;C0444504;C0456081;C1705241;C2347634;C2348143;C4054209;C4319952
2352,adjusted mean change,C0392747;C0443172;C0444504;C0456081;C1705241;C2347634;C2348143;C4319952
2352,adjusted mean ( se ) trough fevi,C0036919;C0444504;C0444506;C0456081;C0849974;C1561566;C2347634;C2348143;C4528367
2352,adjusted mean ( se ) fevi auco_nmbr,C0036919;C0429706;C0444504;C0456081;C0849974;C1561566;C2347634;C2348143;C4528367
2352,adjusted mean ( se ),C0036919;C0444504;C0456081;C2347634;C2348143
2352,adjusted hr losartan vs atenolol *,C0126174;C0456081
2352,adjusted hr * ( nmbr % cl ) pvalue,C0456081;C0596019
2352,adjusted hr ( nmbr % cl ),C0456081;C0596019
2352,adjusted hr ( enl vs lcz ) ( nmbr % cl ),C0456081
2352,adjusted * or ( nmbr % ci ) p value,C0456081
2351,p value for adjusted hr,C0456081;C1709380
2351,nonblack ( n = nmbr )  adjusted hazard ratio *,C0456081;C2985465
2351,black ( n = nmbr )  adjusted hazard ratio *,C0005680;C0027567;C0085756;C0439541;C0456081;C2985465
2351,adjusted modelc hr,C0456081
2351,adjusted *   hr,C0456081
2351,adjusted,C0456081
2350,unadjusted p value,C1439367;C1709380
2350,unadjusted p - value for interaction,C1439367;C1704675;C1709380
2350,unadjusted or ( nmbr % ci ) p value,C1439367
2350,unadjusted irr,C1439367;C4082285
2350,unadjusted hr .,C1439367
2350,unadjusted hr ( nmbr % ci ) for nmbr standard deviation increment,C0008107;C0871420;C1439367;C1705117;C3259781
2350,unadjusted hr ( nmbr % ci ) for nmbr sd increment,C0008107;C1439367;C1705117;C2699239;C3259781
2350,unadjusted hr ( nmbr % ci ) a,C0008107;C1439367;C3259781
2350,unadjusted hr,C1439367
2350,unadjusted,C1439367
2349,abatacept ‡,C1619966
2349,abatacept plus mtx ( n = nmbr ),C0025677;C1417487;C1619966
2349,abatacept nmbr / nmbr ( n = nmbr ),C1619966
2349,abatacept monotherapy ( n = nmbr ),C1619966
2349,abatacept ( n = nmbr * ),C1619966
2349,abatacept,C1619966
2348,placebo / open - label abatacept,C0032042;C1619966;C1696465;C1706408;C1709323
2348,abatacept / open - label abatacept,C1619966;C1709323
2347,abl - sc n / n,C0023139;C0282380;C1704928;C3890208
2347,abl - sc mean,C0023139;C0282380;C0444504;C1704928;C2347634;C2348143;C3890208
2347,abaloparatide - sc,C0282380;C4042342
2346,absent ( < nmbr mg / dl ),C0332197;C0439269;C4285062
2346,absent,C0332197;C4285062
2346,absence,C0332197;C1689985
2345,polyarticular arthritis,C0162323
2344,psoriatic arthropathy,C0003872
2344,psoriatic arthritis pain],C0003872;C0030193;C0518090;C1962977;C2984058;C4085210;C4085211;C4085212;C4317006;C4553004;C4554132
2344,psoriatic arthritis,C0003872
2343,rheumatoid arthritis,C0003873
2343,duration of rheumatoid arthritis — yr,C0003873;C0439234;C0449238;C2926735
2343,duration of rheumatoid arthritis ( years ),C0003873;C0439234;C0449238;C2926735
2343,duration of rheumatoid arthritis,C0003873;C0449238;C2926735
2342,aborted cardiac arrest,C1550015;C1609614;C4085625;C4318470
2341,history of cardiac arrhythmia,C3494593
2340,randomization to arterial sheath insertion,C0003842;C0021107;C0034656;C0221464;C0227952;C0441587;C1512796;C1883719
2340,arterial access,C0003842;C0221464;C0444454;C1554204
2339,non - lad artery,C0003842;C0226004;C1518422
2339,lad artery,C0003842;C0226004
2339,imaged artery,C0003842;C0226004;C1704254;C1704922;C3542466
2338,predominant type of heparin,C0019134;C0332307;C0770546;C1542147;C1547052
2338,heparins and fondaparinux,C0019134
2338,heparin only,C0019134;C0205171;C0770546;C1720467
2338,heparin dose regimen,C0019134;C0770546;C2348331
2338,heparin,C0019134;C0770546
2338,additional heparin,C0019134;C0770546;C1524062
2337,unfractionated heparin — no . ( % ),C0019134;C2825026
2337,unfractionated heparin within nmbr hr before randomization — no . / total no . ( % ),C0019134;C2825026
2337,unfractionated heparin or enoxaparin plus glycoprotein iib / iiia inhibitors ( n = nmbr ),C0019134;C2825026
2337,unfractionated heparin only,C0019134;C0205171;C1720467;C2825026
2337,unfractionated heparin before randomisation,C0019134;C0034656;C2825026
2337,unfractionated heparin ( n = nmbr ),C0019134;C2825026
2337,unfractionated heparin ( n = nmbr,C0019134;C2825026
2337,unfractionated heparin,C0019134;C2825026
2337,neither unfractionated heparin nor low - molecular - weight heparin,C0019134;C2825026
2337,both unfractionated heparin and low - molecular - weight heparin,C0019134;C2825026
2336,pravastatin sodium,C0700474
2335,orthostatic hypotension,C0020651
2334,propafenone,C0033429
2333,prostate biopsy,C0194804
2332,prostate cancer,C0376358;C0600139;C2984325;C3541264
2331,prior amputation,C0002688;C0332152;C0332840;C1546539;C2826257
2331,history of amputation — no . ( % ),C0002688;C0019664;C0019665;C0262512;C0262926;C0332840;C1546539;C1705255;C2004062
2331,amputations,C0002688
2331,amputation — no . ( % ),C0002688;C0332840;C1546539
2331,amputation,C0002688;C0332840;C1546539
2330,mar imputation ( random . ) ( n = nmbr ),C0034656;C0439605;C2699638;C3829202;C4255469
2330,imputed,C2699638
2330,cr imputation ( random . ) ( n = nmbr ),C0034656;C0201975;C0439605;C2699638;C3539604;C3711669;C4084730;C4553336;C4553337
2330,bocf - iike imputation ( random . ) ( n = nmbr ),C0034656;C0439605;C2699638;C2984917
2329,no . patients with,C0030705
2329,no . patients ( % ),C0030705
2329,no . of patients with ra,C0030705
2329,no . of patients with psa,C0030705
2329,no . of patients with as,C0030705
2329,no . of patients ( % ),C0030705
2329,no . of patients,C0030705
2329,n ( % of patients ),C0030705;C0369718;C0441922
2329,n ( % ) patients with risk faetors for cv disease aged > nmbr,C0030705;C0035647;C0369718;C0441922;C4552904
2328,no . of patients / no . of events ( % ) nmbr / nmbr ( nmbr ) nmbr / nmbr ( nmbr ),C0030705
2328,hbanmbrc in patients with baseline hbanmbrc > nmbr % to < nmbr % ( > nmbr to < nmbr mmol / mol ),C0019016;C0030705;C0168634;C1442488;C1825777;C3538758
2328,hbanmbrc in patients with baseline hbanmbrc > nmbr % ( > nmbr mmol / mol ),C0019016;C0030705;C0168634;C1442488;C1825777;C3538758;C3829066
2328,hbanmbrc in patients with baseline hbanmbrc < nmbr % ( < nmbr mmol / l ),C0019016;C0030705;C0168634;C1442488;C1532563;C1825777;C3538758
2328,hbanmbrc ( % patients < nmbr . nmbr % ),C0019016;C0030705;C1825777;C3538758
2328,% of patients nmbr . nmbr nmbr . nmbr,C0030705
2327,subset of patients on metformin,C0030705;C1515021
2327,subset of patients not on metformin,C0030705;C1515021
2327,patients treated with statins ( n = nmbr ),C0030705
2327,patients treated with losartan ( n = nmbr ),C0030705
2327,patients treated with insulin,C0030705
2327,patients treated with atenoloi ( n = nmbr ),C0030705
2327,patients treated for > nmbr weeks ( % ),C0030705
2327,patients treated and operated,C0030705
2327,patients randomly assigned,C0030705
2327,patients randomized,C0030705
2327,patients randomised,C0030705
2327,patients on atorvastatin,C0030705;C0286651
2327,patients on antihypertensive medications,C0003364;C0030705
2327,patients not treated with statins ( n = nmbr ),C0030705
2327,patients in analysis,C0002778;C0030705;C0936012;C1524024
2327,patients analyzed,C0030705
2327,patients ( treated set * ),C0030705
2327,patient - reported hypertension — no . { % ),C0030705
2327,no . of patients with events ( % ),C0030705
2327,no . of patients ind / gly sfc,C0017890;C0030705;C0523677;C4049864;C4521536
2327,no . of patients / total no . ( % ),C0030705
2327,no . of patients / no . of events,C0030705
2327,no . ( % ) of patients with ≥ nmbr % bsa affected,C0030705
2327,no . ( % ) of patients with stroke,C0030705
2327,no . ( % ) of patients with atrial tachyarrhythmia,C0030705
2327,antihypertensive agents ( n per patient ),C0003364;C0030705
2326,total patients n = nmbr,C0030705;C0439175;C0439810
2326,for patients using personal cgm,C0030705
2326,for patients not using personal cgm,C0030705
2326,all patients with opg n - nmbr,C0030705;C1262886;C1336645;C1412836;C1710303
2326,all patients n = nmbr nmbr,C0030705
2326,all patients n = nmbr,C0030705
2326,all patients ( « = nmbr nmbr ),C0030705
2326,all patients ( p = nmbr . nmbr ),C0030705
2326,all patients ( p < nmbr . nmbr ),C0030705
2326,all patients ( n   =   nmbr ) b,C0030705
2326,all patients ( n nmbr nmbr ),C0030705
2326,all patients ( n = nmbr ),C0030705
2326,all patients ( n = nmbr,C0030705
2326,aii patients ( n = nmbr ),C0030705;C1424250;C2698414
2326,( nmbr patients ),C0030705
2325,remaining patients,C0030705;C1527428
2325,of patients,C0030705
2325,obese patients,C0028754;C0030705
2325,no . of hospitalised patients,C0030705
2325,itt patients,C0030705
2325,anti - tnf - naive patientsnmbr,C0030705;C1448177
2325,anti - tnf - naive patients,C0030705;C1448177
2325,anti - tnf - ir patients,C0022065;C0022071;C0030705;C1448132;C1448177
2325,anti - tnf - experienced patients,C0030705;C1448177
2325,all patients,C0030705
2325,% patients,C0030705
2324,randomized patients,C0030705;C0034656;C3815594
2324,randomised patients ( n ),C0030705
2324,all randomized patients ( range ),C0030705;C0034656;C1514721;C2348147;C3542016;C3815594
2324,all randomized patients,C0030705;C0034656;C3815594
2323,vents / patients,C0030705
2323,percentages of patients with event,C0030705;C0439165;C1549488;C1561533
2323,percentage patients reaching target,C0030705;C0439165;C1549488;C1561533
2323,percentage of patients with event,C0030705;C0439165;C1549488;C1561533
2323,percentage of patients using ics or ics / laba on entry,C0030705;C0439165;C1549488;C1561533
2323,percentage of patients receiving dose adjustment,C0030705;C0439165;C1549488;C1561533
2323,percent of patients,C0030705;C0439165
2322,rates per nmbr patient - years,C0030705;C0439234;C0871208;C1521828
2322,rate per nmbr patient - years,C0030705;C0439234;C0871208;C1521828
2322,rate per nmbr - patient - years ( control vs alirocumab ) i,C0030705;C0439234;C0871208;C1521828
2322,rate per nmbr - patient - years ( control vs alirocumab ) *,C0030705;C0439234;C0871208;C1521828
2322,rate / nmbr patient - years,C0030705;C0439234;C0871208;C1521828
2322,patients per nmbr patient - years,C0030705;C0439234
2322,patients n,C0030705
2322,patients,C0030705
2322,patient years,C0030705;C0439234
2322,patient - years ) hr ( unadjusted ),C0030705;C0439234
2322,patient,C0030705
2322,number ol ( % ) patients > nmbr years,C0030705;C0237753;C0439234;C0449788
2322,event rates per nmbr patient - years ( nmbr % ci ),C0008107;C0030705;C0439234;C0441471;C0871208;C1521828;C3259781;C4019010
2322,ard per nmbr nmbr patient - years ( nmbr % ci ),C0008107;C0030705;C0439234;C1817569;C1826411;C3259781
2321,patients without a prior mi or stroke at baseline,C0030705;C0332152;C2826257;C3810814
2321,patients with prior copd - related,C0024117;C0030705;C0332152;C0439849;C0445223;C1412502;C2826257;C3714496
2321,patients with no prior cvd ( primary,C0007222;C0030705;C0332152;C2826257
2321,patients with a prior mi or stroke at baseline,C0030705;C0332152;C2826257;C3810814
2321,patients taking oral corticosteroids at baseline,C0030705
2321,patients receiving corticosteroids at baseline,C0030705
2321,patients not receiving corticosteroids at baseline,C0030705
2321,patients meeting the criteria to receive nmbr mg of,C0030705
2321,of patients meeting criterion / total no . of patients,C0030705
2320,patients with prior ml hr ( nmbr % cl ),C0030705;C0332152;C0439526;C0596019;C1705224;C2826257;C3887665
2320,patients with > nmbr % ■ nmbr ml increase in fevnmbr post - bronchodilator ( % ),C0030705;C0439526;C0442805;C1705224;C3887665
2320,patients entering pt period n = nmbr,C0030705
2319,patients without dm ( n = nmbr ),C0011816;C0030705;C3250443
2319,patients without dm ( n = nmbr,C0011816;C0030705;C3250443
2319,patients with possible new dm at randomization ( hbanmbrc > nmbr . nmbr - nmbr % ),C0011816;C0030705;C0205314;C0332149;C1705910;C2362652;C3250443
2319,patients with possible new dm at randomization ( fpg > nmbr - nmbr ),C0011816;C0030705;C0205314;C0332149;C1705910;C2362652;C3250443
2319,patients with dm vs . patients without dm,C0011816;C0030705;C3250443
2319,patients with dm ( n = nmbr ),C0011816;C0030705;C3250443
2319,patients receiving nmbr mg of edoxaban at randomization — no . ( % ) f,C0030705
2318,randomised patients with spondylitis at baseline,C0030705;C0038012
2318,randomised patients with enthesitis at baselinet,C0030705;C1282952
2318,randomised patients with dactylitis at baseline,C0030705;C0239161
2318,patients without syndesmophytes at baseline,C0030705;C0221690
2318,patients without ra,C0030705;C3538806;C4048756
2318,patients without prevalent kidney disease at baseline,C0022646;C0030705;C0227665;C0683921
2318,patients without draining fistulae at baseline[n = nmbr],C0030705;C0544791
2318,patients without diabetesb,C0030705
2318,patients without diabetes mellitus ( n = nmbr ),C0011849;C0030705
2318,patients without diabetes,C0011847;C0011849;C0030705
2318,patients without chronic,C0030705;C0205191
2318,patients without,C0030705
2318,patients with syndesmophytes at baseline,C0030705;C0221690
2318,patients with ra,C0030705;C3538806;C4048756
2318,patients with pulmonary embolism,C0030705;C0034065
2318,patients with prevalent kidney disease at baseline,C0022646;C0030705;C0227665;C0683921
2318,patients with pneumonia resulting in death,C0030705;C0032285
2318,patients with pneumonia events,C0030705;C0032285;C0441471;C3541888
2318,patients with pneumonia event,C0030705;C0032285;C0441471;C4019010
2318,patients with perianal fistulae,C0030705;C0267561
2318,patients with normoalbuminuria at baseline,C0030705
2318,patients with nmbr co - aeds,C0030705;C0180309;C3245499
2318,patients with nmbr co - aed,C0030705;C0887457;C3245499
2318,patients with negative anti - dsdna,C0030705;C0205160;C0741099;C1513916;C2825415;C2825491;C3853545
2318,patients with nail psoriasis ( mnapsi > nmbr ),C0030705;C0406322
2318,patients with mild pain ( womac pain score,C0030705;C0278138;C0449820;C0582148;C2945599;C4050231;C4522280
2318,patients with microalbuminuria at baseline,C0030705;C0730345
2318,patients with measurement,C0030705;C0242485
2318,patients with macroalbuminuria at baseline,C0030705
2318,patients with improvement $ nmbr . nmbr,C0030705;C2986411
2318,patients with glycated hemoglobin > nmbr . nmbr % and > nmbr episode ofdiabetic ketoacidosis *,C0017853;C0030705
2318,patients with glycated hemoglobin > nmbr . nmbr % and > nmbr episode of severe hypoglycemia *,C0017853;C0030705
2318,patients with glycated hemoglobin < nmbr . nmbr % and no severe hypoglycemia or diabetic ketoacidosis,C0017853;C0030705
2318,patients with fistulas at baseline,C0016169;C0030705
2318,patients with fingernail involvement,C0030705;C0222001;C1314939
2318,patients with enthesitis at week nmbr radiographic progression § change from baseline to week nmbr in psa - modified total shs score,C0030705;C1282952
2318,patients with enthesitis at week nmbr,C0030705;C1282952
2318,patients with enthesitis at baseline,C0030705;C1282952
2318,patients with enthesitis ( lei > nmbr ),C0023401;C0030705;C0428209;C1282952
2318,patients with enthesitis,C0030705;C1282952
2318,patients with endpoin t,C0030705
2318,patients with end point,C0030705;C2349179;C2826544
2318,patients with draining fistulae at baseline[n = nmbr],C0030705;C0544791
2318,patients with digits with dactylitis,C0030705;C0582802
2318,patients with diabetesb,C0030705
2318,patients with diabetes mellitus ( n = nmbr ),C0011849;C0030705
2318,patients with diabetes mellitus,C0011849;C0030705
2318,patients with diabetes,C0011847;C0011849;C0030705
2318,patients with dactylitisa,C0030705
2318,patients with dactylitis at week nmbr,C0030705;C0239161
2318,patients with dactylitis at baseline,C0030705;C0239161
2318,patients with dactylitis,C0030705;C0239161
2318,patients with chronic,C0030705;C0205191
2318,patients with cardiac disorders,C0012634;C0018799;C0030705;C0741926
2318,patients with at least one concomitant disease | |,C0030705;C0205447;C0243087
2318,patients with at least one concomitant disease *,C0030705;C0205447;C0243087
2318,patients with > nmbr co - aeds,C0030705;C0180309;C3245499
2318,patients with > nmbr % bsa,C0030705
2318,patients with $ nmbr % bsa at baseline,C0030705
2318,patients who used insulin pump,C0030705
2318,patients who received positive results on test for antibodies to infliximabt,C0030705
2318,patients who received nmbr or nmbr drugs,C0030705
2318,patients who received nmbr drug,C0030705
2318,patients who received negative results on test for antibodies to infliximabt,C0030705
2318,patients who received indeterminate results on test for antibodies to infliximabt,C0030705
2318,patients who did not use insulin pump,C0030705
2318,patients using concurrent tiotropium,C0030705
2318,patients total no .,C0030705
2318,patients receiving statin,C0030705
2318,patients receiving mtx,C0030705
2318,patients receiving lcz,C0030705
2318,patients receiving immunotherapy,C0030705
2318,patients receiving immunosuppressive agents at baseline,C0030705
2318,patients receiving enl,C0030705
2318,patients not receiving statin,C0030705
2318,patients not receiving mtx,C0030705
2318,patients not receiving immunosuppressive agents at baseline,C0030705
2318,patients included in analysis,C0030705
2318,patients aged > nmbr y,C0030705
2318,patients > nmbr y *,C0030705
2318,patients > nmbr y,C0030705
2318,patients > nmbr %,C0030705
2318,patients < nmbr y *,C0030705
2318,patients < nmbr y,C0030705
2318,patients < nmbr %,C0030705
2318,patients ( n ),C0030705
2318,patients ( ft ),C0030705
2318,no . ( % ) of patients with fingernail involvement,C0030705
2318,all patients with fistulas ( n = nmbr ),C0016169;C0030705
2317,patients who had ulcerations at,C0030705
2317,patients treated,C0030705
2317,patients taking mtx,C0030705
2317,patients receiving any uc medication,C0030705
2317,patients having exacerbation,C0030705
2317,patients assessed,C0030705
2317,patient presentation,C0030705;C0449450
2317,patient population,C0030705;C0032659;C1257890
2317,patient classification,C0008902;C0008903;C0030705;C0678229
2317,patient characteristic,C0030705
2317,patient ' s ga,C0016993;C0030705
2316,total comparators ( n = nmbr ),C0439175;C0439810;C1707454;C4553389;C4553390
2316,total comparators,C0439175;C0439810;C1707454;C4553389;C4553390
2316,favors comparator,C0309049;C1707454;C4553389;C4553390
2316,comparator,C1707454;C4553389;C4553390
2315,pairwise comparison,C1707455
2315,comparison,C1707455
2315,a compared wi,C0043193;C1520135;C1707455
2315,a compared w,C1707455
2314,other countries,C0454664
2314,hbanmbrc ( % ) all countries,C0019016;C0454664;C1825777;C3538758
2314,country,C0454664;C1511538
2314,all countries,C0454664
2313,participants taking insulin,C0679646
2313,participants randomized,C0679646
2313,participants at baseline,C0168634;C0679646;C1442488
2313,no . of participants with events ( % ),C0679646
2313,no . of participants per nmbr patient - yr,C0679646
2313,no . of participants ( % ),C0679646
2313,all participants^^ ( n = nmbr / nmbr ),C0679646
2313,all participants * ( n = nmbr / nmbr ),C0679646
2313,all participants ( n = nmbr ),C0679646
2313,aii participants ( n = nmbr ),C0679646;C1424250;C2698414
2312,participant - reported hypertension — no . { % ),C0679646;C2698741;C4554048
2312,* per nmbr participant years . composite of first occurrence death ( all cause ),C0011065;C0205199;C0205435;C0243132;C0439234;C0679646;C1279901;C1306577;C1547335;C1554210;C2698741;C2745955;C4082313;C4552775;C4554048
2311,participants n,C0679646
2311,participants,C0679646
2311,number of participants,C0237753;C0449788;C0679646
2311,nondiabetic participants !,C0679646
2311,nonblack participants,C0679646
2311,non - black participants,C0005680;C0027567;C0085756;C0439541;C0679646;C1518422
2311,no . of participants,C0679646
2311,no . ( % ) of participants,C0679646
2311,nmbr % participants,C0679646
2311,n participants,C0369718;C0441922;C0679646
2311,diabetic participants !,C0241863;C0679646
2311,diabetic participants,C0241863;C0679646
2311,black participants,C0005680;C0027567;C0085756;C0439541;C0679646
2311,all participants,C0679646
2310,snp,C0752046;C1527094
2309,nph,C0020258;C0027442
2308,unhappy,C1688635
2307,nap,C0870935;C1423800;C4283878
2306,overall quality of life,C3641830
2305,rasagiline,C0525678
2305,ras antagonist,C0034678;C0231491;C0525678
2304,basal insulin doset,C0650607
2304,basal insulin analogue dose * ( coefficient,C0178602;C0205112;C0243071;C0366513;C0650607;C0869039;C1114758;C1707429;C2825028
2304,basal insulin analogue : insulin,C0205112;C0243071;C0650607;C2825028
2304,basal insulin,C0650607
2303,normal cognitive,C2712133
2302,impaired cognitive,C0338656
2301,univariate logistic modela,C0242415
2301,multivariate logistic modelb,C0242415
2300,symptomatic localization - related,C0231220;C0475264;C1744691
2300,infarct localization,C0021308;C0475264;C1744691
2300,infarct localisation,C0021308;C0475264;C1744691
2300,disease localization ' ’,C0012634;C0475264;C1744691
2300,disease localization,C0012634;C0475264;C1744691
2299,insulin glargine   ±   oad   +   od prandial,C0229089;C0439164;C0907402;C1512019;C3273373;C3665488
2299,insulin glargine   ±   oad   +   bd prandial,C0005126;C0907402;C2344255;C4050145
2299,insulin glargine   ±   oad   +   > bd prandial,C0005126;C0907402;C2344255;C4050145
2299,insulin glargine   ±   oad,C0907402
2299,insulin glargine vs standard care least - squares mean ( nmbr % cl ),C0907402
2299,insulin glargine n ( x ),C0907402
2299,insulin glargine n ( % ) / nmbrpy,C0030428;C0907402;C3538810
2299,insulin glargine + insulin lispro ( award - nmbr  n = nmbr ),C0004446;C0293359;C0907402
2299,insulin glargine ( n = nmbrll ),C0907402
2299,insulin glargine ( n = nmbr ),C0907402
2299,glargine n ( n / loopy ),C0907402
2298,number insulin glargine,C0237753;C0449788;C0907402
2298,insulin glargine,C0907402
2298,iglar ( insulin glargine lnmbr u ),C0439148;C0907402
2298,glargine nmbr,C0907402
2298,glargine,C0907402
2297,without insulin or insulin - modifying therapy,C0021641;C1533581;C1579433;C3714501
2297,total daily insulin dose ( u / day ),C0021641;C0456683;C1533581;C1579433;C2348070;C3714501
2297,total daily insulin dose ( lu / kg ),C0021641;C0022718;C0024171;C0024176;C0439209;C1533581;C1579433;C2348070;C2697939;C3714501;C4054209
2297,total daily insulin dose,C0021641;C1533581;C1579433;C2348070;C3714501
2297,total baseline insulin dose,C0021641;C0168634;C0366513;C0439175;C0439810;C1442488;C1533581;C1579433;C2986497;C3714501
2297,premixed insulin with oads ( % ),C0021641;C1533581;C1579433;C3714501
2297,premixed insulin only ( % ),C0021641;C0205171;C1533581;C1579433;C1720467;C3714501
2297,placebo + insulin ( n   = nmbr ),C0021641;C0032042;C1533581;C1579433;C1696465;C1706408;C3714501
2297,placebo + insulin ( n = nmbr ),C0021641;C0032042;C1533581;C1579433;C1696465;C1706408;C3714501
2297,oral antidiabetic drugs / insulin ( % / % ),C0021641;C0029167;C0175795;C0304289;C0442027;C0935929;C1533581;C1579433;C3714501;C4521986
2297,oad plus insulin,C0021641;C1533581;C1579433;C3714501
2297,non - insulin treated dm,C0011816;C0021641;C1518422;C1522326;C1533581;C1579433;C3250443;C3714501
2297,nmbr - h postprandial insulin ( miu / ml ),C0021641;C0033727;C0369286;C0376674;C0439457;C0441932;C0564385;C1533581;C1579433;C3714501;C4528284
2297,insulin 一 no . ( % ),C0021641;C1533581;C1579433;C3714501
2297,insulin — iu,C0021641;C0049272;C0439453;C0694756;C1533581;C1579433;C3714501
2297,insulin — / tu / ml,C0021641;C0041400;C0439526;C1532464;C1533581;C1579433;C1705224;C2700314;C3714501;C3811255;C3887665
2297,insulin yes,C0021641;C1533581;C1549445;C1579433;C1705108;C1710701;C3714501
2297,insulin tx difference vs pbo,C0021641;C0041403;C1533581;C1579433;C1705241;C1705242;C3714501
2297,insulin treated,C0021641;C1533581;C1579433;C3714501
2297,insulin secretagogue,C0021641;C1533581;C1579433;C3714501;C4704833
2297,insulin plus oral,C0021641;C0442027;C1533581;C1579433;C3714501;C4521986
2297,insulin plus nmbr oral agent,C0021641;C0442027;C0450442;C1254351;C1521826;C1533581;C1579433;C3714501;C4521986
2297,insulin plus > nmbr oral agent,C0021641;C0442027;C0450442;C1254351;C1521826;C1533581;C1579433;C3714501;C4521986
2297,insulin only,C0021641;C0205171;C1533581;C1579433;C1720467;C3714501
2297,insulin glargin arm,C0021641;C0446516;C1533581;C1579433;C3714501;C3715044;C4553528
2297,insulin dependentc,C0021641;C1533581;C1579433;C3714501
2297,insulin based,C0021641;C1533581;C1579433;C3714501
2297,insulin and oral hypoglycemic drugs,C0021641;C1533581;C1579433;C3714501
2297,insulin alone,C0021641;C1533581;C1579433;C3714501
2297,insulin : glucose ratio,C0017725;C0021641;C0456603;C1533581;C1547037;C1579433;C3714501
2297,insulin - treated dm,C0021641;C1533581;C1579433;C3714501
2297,insulin - treated diabetes,C0021641;C1533581;C1579433;C3714501
2297,insulin - treated,C0021641;C1533581;C1579433;C3714501
2297,insulin - requiring diabetes,C0011847;C0011849;C0021641;C1533581;C1579433;C3714501
2297,insulin - requiring,C0021641;C1533581;C1579433;C3714501
2297,insulin - naive,C0021641;C1533581;C1579433;C3714501
2297,insulin - na ' ive,C0021641;C0597484;C1272460;C1533581;C1546968;C1579433;C1879645;C3435805;C3714501;C4049872;C4552882;C4554334
2297,insulin - dependent,C0021641;C0429964;C0429986;C0851827;C1533581;C1579433;C1701901;C3244310;C3714501;C4321395
2297,insulin + sulphonylureas,C0021641;C0038766;C1533581;C1579433;C3714501
2297,insulin + oad,C0021641;C1533581;C1579433;C3714501
2297,insulin + metformin,C0021641;C0025598;C1533581;C1579433;C3714501
2297,insulin ( pmol / l ) t vital signs,C0021641;C0150404;C0439284;C0518766;C1533581;C1579433;C3714501
2297,insulin ( pmol / l ),C0021641;C0439284;C1533581;C1579433;C3714501
2297,insulin ( mu / ml ),C0021641;C0439339;C1533581;C1579433;C3714501
2297,insulin ( % ),C0021641;C1533581;C1579433;C3714501
2297,insulin,C0021641;C1533581;C1579433;C3714501
2297,initiation of insulin,C0021641;C0589507;C1158830;C1533581;C1579433;C1704686;C3714501
2297,fasting insulin — pmol / liter,C0015663;C0021641;C0439192;C0475211;C1533581;C1579433;C3714501
2297,fasting insulin — / tiu / ml §,C0015663;C0021641;C0439526;C1533581;C1579433;C1705224;C3714501;C3887665
2297,fasting insulin ( pmol / l ),C0015663;C0021641;C0439284;C1533581;C1579433;C3714501
2297,fasting insulin ( miu / ml ),C0015663;C0021641;C0439457;C1533581;C1579433;C3714501
2297,fasting insulin ( giu / ml ),C0015663;C0021641;C0439526;C1533581;C1579433;C1705224;C3714501;C3887665
2297,fasting insulin,C0015663;C0021641;C1533581;C1579433;C3714501
2297,daily total dose of insulin — lu / kg,C0021641;C0022718;C0024171;C0024176;C0439209;C1533581;C1579433;C2348070;C2697939;C3714501;C4054209
2297,daily insulin dose,C0021641;C0332173;C0366513;C1533581;C1579433;C2348070;C3714501
2297,bolus insulin doseh,C0021641;C1186706;C1511237;C1533581;C1579433;C1705509;C3714501;C3812160
2297,baseline insulin daily dose / kg,C0021641;C0022718;C0168634;C0332173;C0366513;C0439209;C1442488;C1533581;C1579433;C2348070;C3714501;C4054209
2297,baseline insulin,C0021641;C0168634;C1442488;C1533581;C1579433;C3714501
2296,high - probability ventilation / perfusion lung scanning,C0024109;C0560738;C4699572
2295,systolic pulmonary arterial pressure,C0024109;C0039155;C0871470;C1168098;C2707265;C2709248;C4522268
2295,pulmonary medication during baseline ! ',C0013227;C0024109;C0168634;C1442488;C2707265;C2709248;C3244316;C4284232;C4522268
2295,pulmonary embolismb,C0024109;C2707265;C2709248;C4522268
2295,pulmonary embolisma,C0024109;C2707265;C2709248;C4522268
2295,lung,C0024109
2295,baseline pulmonary medications,C0013227;C0024109;C0168634;C0802604;C1442488;C2598133;C2707265;C2709248;C4284232;C4522268
2295,baseline pulmonary medication,C0013227;C0024109;C0168634;C1442488;C2707265;C2709248;C3244316;C4284232;C4522268
2295,any pulmonary medication,C0013227;C0024109;C2707265;C2709248;C3244316;C4284232;C4522268
2294,serious gi disorder,C0012634;C0205404;C1708130;C3539617;C4050121
2294,no gi bleed,C1708130;C3539617;C4050121
2294,nmbr - gi,C1708130;C3539617;C4050121
2294,most frequent gi disorders,C0012634;C0205393;C0332183;C1708130;C3539617;C4050121
2294,gi bleed,C1708130;C3539617;C4050121
2293,pvr,C0242852;C0456261;C1419141
2293,pulmonary vascular resistance,C0456261;C0488644
2292,updrs score,C3639721
2292,updrs,C3639721
2292,bl updrs : low,C0005918;C0006413;C1552663;C2827109;C3639721
2292,bl updrs : high,C0005918;C0006413;C1552663;C2827109;C3639721
2291,gmr,C1522544;C1704695
2290,scr,C1539487;C4050416
2289,potassium - sparing diuretic,C0304490;C3536751
2288,non - fibrin - specific,C0015982;C0205370
2288,fibrin - specilic,C0015982
2288,fibrin - specific,C0015982
2287,aspirin + dipyridamole ( n = nmbr ),C0732279
2287,aspirin + dipyridamole,C0732279
2286,nonaspirin antiplatelet agent,C0085826;C0722138
2286,nonaspirin antiplatelet,C0722138
2285,periostin low,C0219433;C1424662;C3812270
2285,periostin high,C0219433;C1424662;C3812270
2285,periostin ( ng / ml ),C0219433;C0439275;C1424662;C3812270
2285,periostin,C0219433;C1424662;C3812270
2285,biomarker low ( periostin < nmbr ng / ml or blood eosinophils < nmbr cells per pl ),C0005516;C0205251;C0219433;C0439275;C1424662;C1550472;C3812270;C3890211;C4048187;C4321351;C4522223
2285,biomarker high ( periostin > nmbrng / ml or blood eosinophils > nmbrcells per pl ),C0005516;C0205250;C0219433;C0439275;C1299351;C1424662;C2700149;C3812270;C3887512;C3889660;C4321237;C4522209
2285,biomarker high ( periostin > nmbr ng / ml or blood eosinophils > nmbr cells per pl ) t,C0005516;C0205250;C0219433;C0439275;C1299351;C1424662;C2700149;C3812270;C3887512;C3889660;C4321237;C4522209
2284,major gastro - intestinal bleeding,C0017181;C0205082;C0205164;C4318856;C4521762
2284,gastrointestinal major bleed,C0017181;C0205082;C0205164;C4318856;C4521762
2284,gastrointestinal bleeding,C0017181
2283,upper gastrointestinal tract,C3203348
2283,upper gastrointestinal,C3203348
2283,history of upper gastrointestinal event,C0019664;C0019665;C0262512;C0262926;C0441471;C1705255;C2004062;C3203348;C4019010
2282,three - point mace,C0205449;C0349381;C0949745;C1445339;C1552961;C2347617;C3714763
2282,oct center point thickness,C0205099;C1280412;C1552961;C2347617;C3714763;C3810851;C3828732
2282,nmbr - point mace ( nmbr - point mace plus hospitalization for unstable angina ),C1552961;C2347617;C3714763
2282,nmbr - point mace,C1552961;C2347617;C3714763
2282,( points ),C1552961;C2347617;C3714763
2281,pooled trials * n = nmbr,C0008976;C1709595;C2349200;C4522255
2281,pooled simva,C1709595;C2349200;C4522255
2281,pooled placebo,C0032042;C1696465;C1706408;C1709595;C2349200;C4522255
2281,pooled non - canvas studies ( n = nmbr ) : non - cana ( n = nmbr )  cana nmbr mg ( n = nmbr )  cana nmbr mg ( n = nmbr ),C1518422;C1709595;C2349200;C3281223;C4522255
2281,pooled itt,C1709595;C2349200;C4522255
2281,pooled eze / simva,C1709595;C2349200;C4522255
2281,pooled analysis sample,C0002778;C0936012;C1303103;C1524024;C1709595;C2349200;C4522255
2281,pooled analysis,C0002778;C0936012;C1524024;C1709595;C2349200;C4522255
2281,pooled,C1709595;C2349200;C4522255
2280,pool of long term ( hefh patients only ) and high fh,C0030705;C0205171;C0337051;C0443252;C1509144;C1720467;C2349200
2280,pool of fh i and ii studies,C0337051;C1260386;C1509144;C2349200
2279,prior vka experience,C0237607;C0332152;C0596545;C2826257
2279,experienced,C0237607;C0596545
2279,experience ( n,C0237607;C0596545
2279,experience,C0237607;C0596545
2279,clinic research experience,C0008972;C0237607;C0596545
2279,cdmard experience,C0237607;C0596545
2279,> nmbr yr warfarin experience,C0043031;C0237607;C0439234;C0596545
2278,referent,C1706462
2278,reference,C1514811;C1706462
2278,no ( reference ),C1514811;C1706462
2278,nmbr . nmbr ( referent ),C1706462
2278,nmbr . nmbr ( reference ),C1514811;C1706462
2278,< nmbr mg dl ( reference ),C0439269;C1514811;C1706462
2277,prior cancer,C0006826;C0332152;C0998265;C1306459;C2826257
2277,no prior cancer,C0006826;C0332152;C0998265;C1306459;C2826257
2277,no adk / e cancer,C0006826;C0998265;C1306459;C1412243
2277,cancer — no . ( % ),C0006826;C0998265;C1306459
2277,cancer §,C0006826;C0998265;C1306459
2277,cancer n ( % ),C0006826;C0998265;C1306459
2277,cancer * *,C0006826;C0998265;C1306459
2277,cancer *,C0006826;C0998265;C1306459
2277,cancer ( n = nmbr ),C0006826;C0998265;C1306459
2277,cancer,C0006826;C0998265;C1306459
2277,all cancer,C0006826;C0998265;C1306459
2277,ac tve cancer,C0001246;C0003354;C0006826;C0998265;C1306459;C1412573;C2000891;C3539770
2276,panel b,C0441833;C1706365;C1999270
2276,panel a,C0441833;C1706365;C1999270
2276,device group,C1706365
2275,gene / chr / snp,C0017337;C0043459;C0752046;C1527094;C1861559;C3890034;C4050175
2275,gene,C0017337
2274,upper tertile : > nmbr . nmbr,C1282910
2274,upper,C1282910
2274,none of the above,C1282910;C1552828
2274,any of the above,C1282910;C1552828
2274,all of the above,C1282910;C1552828
2273,physical component score ( pcs ),C0449432;C1705248;C1864389;C1882368;C4483112
2273,pcs score ( nmbr – nmbr scale ),C1864389;C1882368
2273,pcs score,C1864389;C1882368
2272,baseline acq - nmbr score,C0168634;C1442488;C2919686
2272,acqnmbr score,C2919686
2272,acq score,C2919686
2272,acq - nmbr scoret,C2919686
2272,acq - nmbr score 本,C2919686
2272,acq - nmbr score *,C2919686
2272,acq - nmbr score ' ! ',C2919686
2272,acq - nmbr score,C2919686
2271,gds score *,C0451184;C1149049;C1418244
2270,midas score,C1309950;C1423498;C4049617
2269,bii score,C1413059
2268,ups score,C0334463;C3542434
2268,sss score,C0037052;C0723181
2267,nihss score,C1697238
2267,nih stroke scale,C1697238;C3484372
2266,aqlq score,C4055434
2266,aqlq ( si + nmbr score ’,C0449820;C4050231;C4055434
2266,aqlq ( s ) score,C0449820;C4050231;C4055434
2266,aqlq ( s ) + nmbr scorets,C4055434
2266,aqlq ( s ) + nmbr scored,C4055434
2266,aqlq ( s ) + nmbr score : §,C0449820;C4050231;C4055434
2266,aqlq ( s ) + nmbr score,C0449820;C4050231;C4055434
2265,total vdh - s score,C2964552
2265,total periventricular wml score,C2964552
2265,total hip bmi ) t - score,C0019552;C0022122;C0578022;C1505163;C2964552;C3538851;C4284725
2265,total hip bmd t - score,C0019552;C0022122;C1505163;C2964552;C3538851;C4284725
2265,total feet score,C0016504;C0347981;C2964552
2265,total - hip bmd t - score,C0019552;C0022122;C1505163;C2964552;C3538851;C4284725
2264,total vdh - s score ( nmbr - nmbr ) ( n ),C2964552
2264,total score ( nmbr – nmbr scale ),C0175659;C0349674;C1947916;C2964552
2264,total back pain score ( nmbr – nmbr   mm scale ),C0004604;C0175659;C0349674;C1947916;C1963071;C2964552;C4330985;C4553945;C4554674
2263,total score §,C2964552
2263,total score > nmbr,C2964552
2263,total score < nmbr,C2964552
2263,total score,C2964552
2263,tdi total score ( week nmbr,C0205976;C0332174;C0439230;C2674784;C2964552;C3714807
2263,sgrq total scorenmbr,C2964552
2263,sgrq total score * *,C2964552
2263,sgrq total score ( week,C0332174;C0439230;C2964552
2263,sgrq total score,C2964552
2263,in ibdq total score at week nmbr,C0332174;C0439230;C2964552
2263,ibdq total score,C2964552
2263,eacit - e total score ) |,C2964552
2263,ccq total score,C2964552
2263,cat total scorenmbr,C0007450;C0325090;C0524517;C1443200;C2964552;C3665481;C4050461;C4284282
2263,cat total score,C0007450;C0325090;C0524517;C1443200;C2964552;C3665481;C4050461;C4284282
2263,acq - nmbr total score ∗,C2919686;C2964552
2262,peak creatine kinase - mb,C0010290;C0444505;C0523584
2262,ck - mb,C0010290
2261,chanmbrdsnmbr - vasc nmbr nmbr,C1420648;C3714751
2261,chanmbrdsnmbr - vasc nmbr - nmbr,C1420648;C3714751
2261,chanmbrdsnmbr - vasc > nmbr,C1420648;C3714751
2261,chanmbrdsnmbr - vasc < nmbr,C1420648;C3714751
2261,chanmbrdsnmbr - vasc $ nmbr,C1420648;C3714751
2261,chanmbrdsnmbr - vasc # nmbr,C1420648;C3714751
2261,chanmbrdsnmbr - vasc,C1420648;C3714751
2261,baseline chanmbrdsnmbr - vascb,C0168634;C1420648;C1442488;C3714751
2260,mtss cfb mean ± sd,C0009002;C0444504;C1824728;C2347634;C2348143;C2699239
2260,mtss cfb,C0009002;C1824728
2259,mean score on dasnmbr - nmbr ( crp ) ^,C0051767;C0057671;C3533236;C3890735;C4048285
2259,hs - crp < nmbr . nmbr nlg l,C3890735;C4048285
2259,hs - crp < nmbr . nmbr g / l,C0439294;C0456615;C3890735;C4048285
2259,hs - crp,C3890735;C4048285
2259,dasnmbr ‐ crp,C0051767;C0057671;C3890735;C4048285
2259,dasnmbr - crp §,C0051767;C0057671;C3890735;C4048285
2259,dasnmbr - crp,C0051767;C0057671;C3890735;C4048285
2259,dasnmbr ( crp ),C0051767;C0057671;C3890735;C4048285
2259,das - nmbr ( crp ) < nmbr . nmbr,C0051767;C0057671;C3890735;C4048285
2259,das - nmbr ( crp ),C0051767;C0057671;C3890735;C4048285
2259,crp ( normal range : nmbr - nmbr . nmbr ),C0086715;C3890735;C4048285
2259,crp ( ng / ml ),C0439275;C3890735;C4048285
2259,crp,C3890735;C4048285
2259,c . dasnmbr - crp < nmbr . nmbr,C0051767;C0057671;C3890735;C4048285
2259,asdas - crp   <   nmbr . nmbr,C3890735;C4048285
2259,asdas - crp δ   ≥   nmbr . nmbr,C3890735;C4048285
2259,asdas - crp *,C3890735;C4048285
2258,median c - reactive protein — mg / liter,C0006560;C0024671;C0026410;C0439269;C0475211;C0549183;C0876920;C1413716;C1960952;C2346927;C2347635;C2348144;C2939193;C4048285;C4321396;C4521761
2258,median c - reactive protein — mg / dl^,C0006560;C0439269;C0549183;C0876920;C1413716;C2347635;C2348144;C2939193;C4048285
2258,high sensitivity c - reactive protein ( mg / l ),C0006560;C0439268;C1413716;C1441604;C4048285
2258,high - sensitivity c - reactive protein — mg / liter |,C0006560;C0024671;C0026410;C0439269;C0475211;C1413716;C1441604;C1960952;C2346927;C4048285;C4321396;C4521761
2258,high - sensitivity c - reactive protein stratification,C0006560;C1413716;C1441604;C1514983;C4048285
2258,high - sensitivity c - reactive protein ( mg / l ),C0006560;C0439268;C1413716;C1441604;C4048285
2258,high - sensitivity c - reactive protein,C0006560;C1413716;C1441604;C4048285
2258,dasnmbr ( c - reactive protein ),C0006560;C0051767;C0057671;C1413716;C4048285
2258,c - reactive protein — mg / literj,C0006560;C0024671;C0026410;C0439269;C1413716;C1960952;C2346927;C4048285;C4321396;C4521761
2258,c - reactive protein — mg / liter * *,C0006560;C0024671;C0026410;C0439269;C0475211;C1413716;C1960952;C2346927;C4048285;C4321396;C4521761
2258,c - reactive protein concentration ( mg / l ),C0006560;C0086045;C0439268;C1413716;C1446561;C3827302;C4048285
2258,c - reactive protein ( mg / l ),C0006560;C0439268;C1413716;C4048285
2258,c - reactive protein ( mg / dl_ ),C0006560;C0439269;C1413716;C4048285
2258,c - reactive protein ( mg / dl ),C0006560;C0439269;C1413716;C4048285
2258,c - reactive protein ( high - sensitivity assay )  mitt = modified intent - to - treat  pbo cholesterol  cl = confidence intervals  hdl - c = high - density lipoprotein cholest = national cholesterol education program adult treatment panel y patients with diabetes ( fc > _ nmbr mg / dl [ > nmbr . nmbr mmol / l] ) . to qualify as having acteristics described in methods ( ncep atp iii definition )  + baseline values are rr d hs - crr for which medians are presented  * * p < nmbr . nmbr  § p = nmbr . nmbr  * p = nmbr . nmbr . nteractions were not statistically significant ( p > nmbr . nmbr ) .,C0005507;C0006560;C0243073;C1413716;C1441604;C1510438;C4048285
2258,c - reactive protein,C0006560;C1413716;C4048285
2257,mean pulmonary artery pressure,C3854605
2256,left main coronary artery bifurcation,C3898614
2255,ischemic coronary artery disease,C0852149
2254,single vessel coronary artery diseasenmbr,C0581374
2254,single vessel coronary artery disease †,C0581374
2254,single vessel coronary artery disease *,C0581374
2254,multi - vessel coronary artery disease,C1299432
2253,duration of coronary artery disease — yr,C0018787;C0439234;C0449238;C0852949;C2926735
2253,coronar y artery disease,C0852949
2253,coronaiy artery disease,C0852949
2252,history of coronary artery disease — no . { % ),C1881055
2252,history of coronary artery disease - n ( % ),C1881055
2252,history of coronary artery disease,C1881055
2251,coronary bypass graft,C1260596
2250,previous coronary artery bypass surgery,C2144990
2250,previous coronary artery bypass grafting,C2144990
2250,previous coronary artery bypass graft,C2144990
2250,previous coronary - artery bypass grafting,C2144990
2249,coronary artery treated,C0205042
2249,coronary artery osteochondrosis,C0029376;C0029429;C0205042;C0729346
2249,coronary artery,C0205042
2248,urinary protein : creatinine ratioa ( mg / mg ),C0042027;C0369901;C0428627;C1319635;C1524119
2248,urinary acr,C0042027;C1412134;C1515941;C1524119
2248,categories of urinary acr,C0042027;C0683312;C1412134;C1515941;C1524119
2247,medications at study entry — no . / total no . ( % ),C0013175;C1705654
2247,diagnosis at study entry — no . ( % ),C1704656;C1705654;C4068481
2247,copd medication at study entry,C0013175;C0024117;C1412502;C1705654;C3714496
2246,total ics dose at entry,C0815320;C1705654;C2986497;C4551720
2246,controllertreatment before entry *,C1705654
2245,udy entry,C1705654
2245,entry hip fracture location,C1705654;C3260017
2245,entry criteria ( % ),C0243161;C1705654
2245,entry criteria,C0243161;C1705654
2245,entry category,C0683312;C1705654;C3889287
2245,cv entry criteria,C0243161;C1705654;C3538987;C4048877;C4318503
2245,at entry,C1705654
2244,eligibility stratum,C0013893;C1548635
2244,eligibility strata,C0013893;C1548635
2244,eligibility risk factorsa,C0013893;C0035647;C1548635;C4552904
2244,eligibility risk factors ’ ),C0013893;C0035648;C1548635;C1553898
2244,eligibility risk factors — n ( % ) :,C0013893;C0035648;C1548635;C1553898
2244,eligibility risk factors :,C0013893;C0035648;C1548635;C1553898
2244,eligibility risk factors /,C0013893;C0035648;C1548635;C1553898
2244,eligibility risk factors !,C0013893;C0035648;C1548635;C1553898
2244,eligibility risk factors,C0013893;C0035648;C1548635;C1553898
2244,* eligibility risk factors,C0013893;C0035648;C1548635;C1553898
2243,ecg abnormality at entry,C0522055;C1705654
2243,any electrocardiographic abnormality — no . ( % ),C0522055
2242,migraine — no . ( % ) $,C0149931
2242,migraine severity score,C0149931;C0457451
2242,migraine occurrence ( days / month ),C0149931;C0243132;C0556971;C1554210;C2745955
2242,migraine duration ( h ),C0033727;C0149931;C0369286;C0441932;C0449238;C0564385;C2926735;C4528284
2241,migraine without aura,C0338480
2241,migraine with aura,C0154723
2240,cigarette users,C0677453;C1704760;C1706077;C3890423
2239,cigarette smoker *,C0337667
2239,cigarette smoker,C0337667
2238,cigarette smoking status,C0239059;C0449438;C0677453;C0700219;C1519386;C1704760;C3890423
2238,cigarette smoking in the past year,C0239059;C0700219;C4086728
2238,cigarette smoking,C0239059;C0700219
2238,cigarette - smoking status — no . ( % ),C0239059;C0449438;C0677453;C0700219;C1519386;C1704760;C3890423
2238,cigarette - smoking status ( % ),C0239059;C0449438;C0677453;C0700219;C1519386;C1704760;C3890423
2237,mra regimen ( n - nmbr ),C0040808;C0243032;C1609165;C2945654;C3891069
2237,magnetic resonance angiography,C0243032
2236,relative risk ( nmbr % confidence interval ),C0009667;C0242492
2236,nmbr % confidence interval,C0009667
2235,missing data — no . / total no . ( % ),C4684714
2235,missing data initial diagnosis — no .,C0011900;C0205265;C1279901;C1555582;C1704338;C1704656;C1705685;C4684714
2235,missing data,C4684714
2234,stratified log - rank   p   value,C0205363;C0667477;C0699794;C1708728;C1709380;C2986775
2234,stratified log - rank p value,C0205363;C0667477;C0699794;C1708728;C1709380;C2986775
2234,rank based on treatment   =   placebo,C0667477;C0699794
2234,log rank p - value,C0667477;C0699794;C1708728;C1709380;C2986775
2234,log - rank p value,C0667477;C0699794;C1708728;C1709380;C2986775
2234,log - rank,C0667477;C0699794;C1708728;C2986775
2234,cmann whitney u test / wilcoxon sum rank test .,C0439148;C0667477;C0683443;C0699794;C1515051
2234,amann whitney u test / wilcoxon sum rank test .,C0439148;C0667477;C0683443;C0699794;C1515051
2233,other asian,C0078988
2233,oriental,C0078988;C0699027
2233,non - asian ( n = nmbr nmbr ),C0078988;C1518422
2233,non - asian,C0078988;C1518422
2233,east asian,C0078988;C1707877
2233,asians ( n = nmbr ),C0078988
2233,asian or pacific islander,C0078988
2233,asian or oriental,C0078988
2233,asian / pacific islander,C0078988;C0242191
2233,asian / oriental,C0078988;C0699027
2233,asian *,C0078988
2233,asian ( nmbr . nmbr % ),C0078988
2233,asian ( n — nmbr ),C0078988
2233,asian ( n   = nmbr ),C0078988
2233,asian ( n = nmbr ),C0078988
2233,asian ( n = nmbr,C0078988
2233,asian,C0078988
2232,ovary,C0029939;C0227898
2231,avr,C0449217
2230,puva,C0853073;C1704892
2229,uvb,C0454530;C0564461
2228,urine acr geometric mean ( cv % ),C0042036;C0042037;C1412134;C1515941;C2963137;C2986759;C3538987;C4048877;C4318503
2228,prior cv history,C0019664;C0019665;C0262512;C0262926;C0332152;C1705255;C2004062;C2826257;C3538987;C4048877;C4318503
2228,prior cv event at randomization !,C0034656;C0332152;C0441471;C2826257;C3538987;C4019010;C4048877;C4318503
2228,previous cv events,C0205156;C0441471;C1552607;C3538987;C3541888;C4048877;C4318503
2228,previous cv event,C0205156;C0441471;C1552607;C3538987;C4019010;C4048877;C4318503
2228,no previous cv event,C0205156;C0441471;C1552607;C3538987;C4019010;C4048877;C4318503
2228,no cv event ( n = nmbr,C0441471;C3538987;C4019010;C4048877;C4318503
2228,nmbr - nmbr with cv risk but not disease ( n = nmbr ),C0035647;C3538987;C4048877;C4318503;C4552904
2228,mdrd egfr geometric mean ( cv % ),C1739039;C2986759;C3538987;C3811844;C3812682;C3839656;C4048877;C4318503
2228,incidence rate of cv events,C0441471;C1708485;C3538987;C3541888;C4048877;C4318503
2228,first cv hospitalization,C0019993;C0205435;C1279901;C3538987;C4048877;C4318503
2228,expanded cv endpoint,C0205229;C2349179;C2826544;C3538987;C4048877;C4318503
2228,cv risk factors,C0035648;C1553898;C3538987;C4048877;C4318503
2228,cv risk factor - no . ( % ),C0035648;C3538987;C4048877;C4318503
2228,cv risk factor,C0035648;C3538987;C4048877;C4318503
2228,cv historya,C3538987;C4048877;C4318503
2228,cv endpoints n ( % ),C2349179;C3538987;C4048877;C4318503
2228,cv,C3538987;C4048877;C4318503
2227,gained bmd,C1517378
2226,urine qmax,C0042036;C0042037;C2963137
2226,urine p / cr,C0042036;C0042037;C0201975;C2963137;C3539604;C3711669;C4084730;C4553336;C4553337
2225,stiffness subscale,C0427008
2225,stiffness ( min ),C0427008;C0702093;C1524029;C3813700
2224,ugt induction status : per aeda,C0205263;C0449438;C0857127;C1420188;C4284131
2224,ugt induction status : as randomizeda,C0205263;C0449438;C0857127;C1420188;C4284131
2224,octave induction nmbr and nmbr,C0205263;C0857127
2224,octave induction nmbr,C0205263;C0857127
2224,induction - trial group assignment — no . ( % ),C0205263;C0857127;C1320290;C1516050
2224,inducing,C0205263
2224,baseline of induction ),C0168634;C0205263;C0857127;C1442488
2224,baseline of induction,C0168634;C0205263;C0857127;C1442488
2223,body height ( cm ),C0005890;C0487985
2222,height loss ( cm ),C0424641
2222,height loss,C0424641
2221,rectum and sigmoid colon only,C0034896
2221,rectum,C0034896
2220,risk difference,C0035647;C1705241;C1705242;C4552904
2220,percentage difference ( nmbr % cl ),C0439165;C0596019;C1549488;C1561533;C1705241;C1705242
2220,nmbr % ci for difference,C0008107;C1705241;C1705242;C3259781
2220,mean difference ( nmbr % cl ),C0444504;C0596019;C1705241;C1705242;C2347634;C2348143
2220,lsms difference ( nmbr % ci ) nmbr,C0008107;C1705241;C1705242;C3259781
2220,lsm difference ( nmbr % cl ),C0596019;C1705241;C1705242
2220,lsm difference,C1705241;C1705242
2220,ls means difference ( nmbr % ci ) nmbr,C0008107;C0023668;C1704970;C1705241;C1705242;C3259781
2220,ls means difference ( nmbr % ci ) a,C0008107;C0023668;C1704970;C1705241;C1705242;C3259781
2220,ls mean difference vs placebo ( nmbr % ci ),C0023668;C0444504;C1705241;C1705242;C2347634;C2348143
2220,ls mean difference ( se ) vs placebo,C0023668;C0036919;C0444504;C1705241;C1705242;C2347634;C2348143
2220,ls mean difference ( nmbr % cl ),C0023668;C0444504;C0596019;C1705241;C1705242;C2347634;C2348143
2220,ls mean difference ( nmbr % ci ),C0008107;C0023668;C0444504;C1705241;C1705242;C2347634;C2348143;C3259781
2220,ls - mean difference ® ( nmbr % cl ),C0023668;C0444504;C0596019;C1705241;C1705242;C2347634;C2348143
2220,ls - mean difference between treatment groups ( nmbr % ci ),C0008107;C0023668;C0039798;C0087111;C0374505;C0444504;C1522326;C1533734;C1705169;C1705241;C1705242;C2347634;C2348143;C3259781;C3538994;C3887704
2220,ls - mean between - group difference ( nmbr % ci ),C0008107;C0023668;C1705241;C1705242;C2347634;C3259781
2220,least squares mean between - treatment difference ( nmbr % ci ),C0008107;C0023189;C0039798;C0087111;C0444504;C1522326;C1533734;C1705169;C1705241;C1705242;C2347634;C2348143;C3259781;C3538994;C3887704
2220,estimated difference ( nmbr % ci ),C0008107;C0750572;C1705241;C1705242;C3259781
2220,estimated difference %,C0750572;C1705241;C1705242
2220,estimated difference,C0750572;C1705241;C1705242
2220,differencenmbr,C1705241;C1705242
2220,difference vs placebo * *,C1705241;C1705242
2220,difference vs placebo ( nmbr % ci ),C1705241;C1705242
2220,difference vs placebo ',C1705241;C1705242
2220,difference vs placebo,C1705241;C1705242
2220,difference vs pbo ( nmbr % ci ),C1705241;C1705242
2220,difference vs pbo,C1705241;C1705242
2220,difference vs ff nmbr pg ( nmbr % ci ),C1705241;C1705242
2220,difference vs . placebo,C1705241;C1705242
2220,difference vs . pbof mean ( s . e . ) t,C1705241;C1705242
2220,difference nmbr years - baseline *,C0168634;C0439234;C1442488;C1705241;C1705242
2220,difference nmbr years - baseline,C0168634;C0439234;C1442488;C1705241;C1705242
2220,difference mepo - pbo ( nmbr % ci ),C0008107;C0031962;C1705241;C1705242;C3259781
2220,difference in sbp between treatment,C0085805;C1705241;C1705242
2220,difference in means ( nmbr % cl ),C0596019;C1704970;C1705241;C1705242
2220,difference in means,C1704970;C1705241;C1705242
2220,difference in ls means ( nmbr % ci ) versus placebo,C0008107;C0023668;C1704970;C1705241;C1705242;C3259781
2220,difference in ls means ( nmbr % ci ) nmbr,C0008107;C0023668;C1704970;C1705241;C1705242;C3259781
2220,difference in ls means ( nmbr % ci ) a,C0008107;C0023668;C1704970;C1705241;C1705242;C3259781
2220,difference in ls means ( nmbr % ci ),C0008107;C0023668;C1704970;C1705241;C1705242;C3259781
2220,difference in ls meannmbr ( nmbr % cl ),C0023668;C0444504;C0596019;C1705241;C1705242;C2347634;C2348143
2220,difference in ls mean vs placebo ( nmbr % ci ),C0023668;C0444504;C1705241;C1705242;C2347634;C2348143
2220,difference in change,C0392747;C0443172;C1705241;C1705242;C4319952
2220,difference from placeboa,C1705241;C1705242
2220,difference from placebo ¥,C0032042;C1696465;C1705241;C1705242;C1706408
2220,difference from placebo * ( nmbr % ci ),C0008107;C0032042;C1696465;C1705241;C1705242;C1706408;C3259781
2220,difference from placebo ( nmbr % cl ),C0032042;C0596019;C1696465;C1705241;C1705242;C1706408
2220,difference from placebo ( nmbr % ci ),C0008107;C0032042;C1696465;C1705241;C1705242;C1706408;C3259781
2220,difference from placebo,C0032042;C1696465;C1705241;C1705242;C1706408
2220,difference from baselinea,C1705241;C1705242
2220,difference ( tiotropium - placebo ) ml ( nmbr % ci ),C0008107;C0032042;C0213771;C0439526;C1696465;C1705224;C1705241;C1705242;C1706408;C3259781;C3887665
2220,difference ( se ),C0036919;C1705241;C1705242
2220,difference ( nmbr % cl ),C0596019;C1705241;C1705242
2220,difference ( nmbr % ci ) *,C0008107;C1705241;C1705242;C3259781
2220,difference ( nmbr % ci  p value ),C0008107;C1705241;C1705242;C1709380;C3259781
2220,difference ( a ) vs placebo ( nmbr % cl ),C1705241;C1705242
2220,difference ( % ),C1705241;C1705242
2220,difference,C1705241;C1705242
2220,atorvastatin ls means difference nmbr mg ( nmbr % ci ) a ( n = nmbr ),C0008107;C0023668;C0024671;C0026410;C0286651;C0439269;C1704970;C1705241;C1705242;C1960952;C2346927;C3259781;C4321396;C4521761
2220,% difference,C1705241;C1705242
2220,% - point difference ( nmbr % ci ) c,C0008107;C1552961;C1705241;C1705242;C2347617;C3259781;C3714763
2219,≥ nmbra ( n = nmbr ),C0369718;C0441922
2219,without ( n = nmbr nmbr ),C0369718;C0441922
2219,with ( n = nmbr ),C0369718;C0441922
2219,us n = nmbr,C0369718;C0441922
2219,us ( n = nmbr ),C0369718;C0441922
2219,other { n = nmbr ),C0369718;C0441922
2219,other n ( % ),C0369718;C0441922
2219,other * ( n = nmbr ),C0369718;C0441922
2219,other ( n — nmbr ),C0369718;C0441922
2219,other ( n   = nmbr ),C0369718;C0441922
2219,other ( n = nmbr ),C0369718;C0441922
2219,other ( n = nmbr,C0369718;C0441922
2219,other ( n,C0369718;C0441922
2219,none ( n = nmbr ),C0369718;C0441922
2219,no ( n = nmbr ),C0369718;C0441922
2219,no ( n = nmbr,C0369718;C0441922
2219,nnmbr yrs,C0369718;C0441922
2219,nnmbr / nnmbr,C0369718;C0441922
2219,nnmbr,C0369718;C0441922
2219,nmbr to < nmbr ( n z nmbr ),C0369718;C0441922
2219,nmbr to < nmbr ( n = nmbr ),C0369718;C0441922
2219,nmbr n qi,C0369718;C0376586;C0441922
2219,nmbr n / n,C0369718;C0441922
2219,nmbr - nmbr ( n = nmbr ),C0369718;C0441922
2219,nmbr - nmbr ( n = nmbr,C0369718;C0441922
2219,nmbr ( n nmbr nmbr ),C0369718;C0441922
2219,nmbr ( n = nmbr ),C0369718;C0441922
2219,nmbr ( n = nmbr,C0369718;C0441922
2219,neither n = nmbr,C0369718;C0441922
2219,n_,C0369718;C0441922
2219,n t % ),C0369718;C0441922
2219,n observed,C0369718;C0441922
2219,n o,C0369718;C0441922
2219,n nt,C0332126;C0369718;C0441922;C1449832;C3889152;C4050156;C4283901;C4284038
2219,n nmbr,C0369718;C0441922
2219,n analysed,C0369718;C0441922
2219,n = nmbrt,C0369718;C0441922
2219,n = nmbr lesions,C0369718;C0441922
2219,n = nmbr,C0369718;C0441922
2219,n =,C0369718;C0441922
2219,n / r,C0205090;C0369718;C0441922;C0684010;C2603358
2219,n / pyr,C0369718;C0441922
2219,n / n   ( % ),C0369718;C0441922
2219,n / n nmbr / nmbr,C0369718;C0441922
2219,n / n ( % / yr ),C0369718;C0439234;C0441922
2219,n / n ( % ),C0369718;C0441922
2219,n / n,C0369718;C0441922
2219,n .,C0369718;C0441922
2219,n - nmbr pufa ( n = nmbr ),C0032615;C0369718;C0441922
2219,n - nmbr pufa,C0032615;C0369718;C0441922
2219,n - nmbr fatty acit,C0369718;C0441922
2219,n - nmbr fatty acids slope lsm ± se ( mm / year ),C0015684;C0369718;C0441922
2219,n - nmbr fatty acids - placebo lsm ( nmbr % cl ),C0015684;C0032042;C0369718;C0441922;C0596019;C1696465;C1706408
2219,n - nmbr fatty acids ( n = nmbr ),C0015684;C0369718;C0441922
2219,n - nmbr fatty acids,C0015684;C0369718;C0441922
2219,n - nmbr allocation,C0369718;C0441922;C1706778
2219,n - nmbr - pufa ( n = nmbr ),C0032615;C0369718;C0441922
2219,n + v ( n = nmbr ),C0369718;C0441922
2219,n *,C0369718;C0441922
2219,n ( stented lesions ),C0369718;C0441922
2219,n ( lesions ),C0369718;C0441922
2219,n ( iqr ),C0369718;C0441922
2219,n ( % ) unless otherwise specified,C0369718;C0441922
2219,n ( % ) responders,C0369718;C0441922
2219,n ( % ) liraglutide nmbr placebo,C0032042;C0369718;C0441922;C1456408;C1696465;C1706408
2219,n ( % ) blood pressure - mean ( sd ) mm hg,C0369718;C0428886;C0439475;C0441922;C2699239
2219,n ( % ),C0369718;C0441922
2219,n %,C0369718;C0441922
2219,n,C0369718;C0441922
2219,anmbr n = nmbr,C0369718;C0441922
2219,anmbr / nmbr ( n = nmbr ),C0369718;C0441922
2219,all n = nmbr nmbr,C0369718;C0441922
2219,all n = nmbr,C0369718;C0441922
2219,all ( n = nmbrf ),C0016327;C0369718;C0441922
2219,all ( n = nmbr * ),C0369718;C0441922
2219,all ( n = nmbr ) nmbr . nmbr ± nmbr . nmbr,C0369718;C0441922
2219,all ( n = nmbr ),C0369718;C0441922
2219,all ( n = nmbr,C0369718;C0441922
2219,> nmbr . nmbr ( n — nmbr ),C0369718;C0441922
2219,> nmbr ( n — nmbr ),C0369718;C0441922
2219,> nmbr ( n = nmbrlnmbr ),C0369718;C0441922
2219,> nmbr ( n = nmbr ),C0369718;C0441922
2219,> nmbr ( n,C0369718;C0441922
2219,> nmbr % ( n = nmbr ),C0369718;C0441922
2219,< nmbr . nmbr ( n — nmbr ),C0369718;C0441922
2219,< nmbr ( n — nmbr ),C0369718;C0441922
2219,< nmbr ( n z nmbr ),C0369718;C0441922
2219,< nmbr ( n = nmbr ),C0369718;C0441922
2219,< nmbr % ( n = nmbr ),C0369718;C0441922
2219,( n nmbr nmbr ),C0369718;C0441922
2219,( n = nmbrlnmbr ),C0369718;C0441922
2219,( n = nmbr ) ( n = nmbr ),C0369718;C0441922
2219,"( n = nmbr ) "" ' ( n = nmbr )",C0369718;C0441922
2219,( n = nmbr ),C0369718;C0441922
2219,( n = nmbr,C0369718;C0441922
2219,( n = ms ),C0369718;C0441922;C2349943;C3539704;C3713294
2219,( n = lnmbr ),C0369718;C0441922
2219,$ nmbr ( n = nmbr ),C0369718;C0441922
2218,muscle twitching,C0015644;C0231530
2217,muscle spasms,C0037763
2216,mucolytics,C0026698
2216,mucolytic agent,C0026698
2215,glucose in urine,C0004076
2214,glucose metabolism,C0596620
2213,glucose test,C0337438;C0595310
2212,glucosamine ( n = nmbr ),C0017718
2212,glucosamine,C0017718
2211,subcutaneous unfractionated heparin,C0353681
2210,subcutaneous injections,C0021499
2209,subcutaneous ( n = nmbr ),C0443315
2208,sustain nmbr : semaglutide vs . sitagliptin nmbr mg,C0443318;C2732140
2208,sustain nmbr : semaglutide vs . placebo,C0443318;C2732140
2208,sustain nmbr : semaglutide vs . iglar,C0443318;C2732140
2208,sustain nmbr : semaglutide vs . exenatide er nmbr . nmbr mg,C0443318;C2732140
2208,sustain nmbr : semaglutide add ‐ on to insulin vs . placebo,C0443318;C2732140
2208,sustain nmbr,C0443318;C2732140
2208,sustain,C0443318;C2732140
2207,sustained mucosal healingc n / n ( % ),C0026724;C0443318
2207,sustained mucosal healingc,C0026724;C0443318
2207,mucosal healingf,C0026724
2207,mucosal healingc n / n ( % ),C0026724
2206,inguinal hernia repair,C0021446
2205,insulin aspart ( mealtime ),C0123677;C0587119;C1708521
2205,insulin aspart,C0123677;C1708521
2204,insulin dose — lu / day,C0024171;C0024176;C0332173;C0366513;C0439228;C0439505;C2697939
2204,insulin dose ( u ),C0366513;C0439148
2204,insulin dose ( lu / day ),C0024171;C0024176;C0332173;C0366513;C0439228;C0439505;C2697939
2204,insulin dose ( iu / day ),C0366513;C0439465
2204,insulin dose,C0366513
2203,insulin use at baseline,C0168634;C0240016;C1442488
2203,insulin use,C0240016
2202,insulins and analogs,C0021641;C3537244;C4049919
2202,insulins,C0021641;C3537244;C4049919
2201,insulin sensitivity — % §,C0920563;C4049919
2201,composite index of insulin sensitivity ( isi ),C0205199;C0600653;C0918012;C0920563;C1547335;C1552854;C1637833;C2986546;C4049919
2200,prior immunosuppressive exposure,C0021081;C0274281;C0332152;C0332157;C2826257
2200,prior immunosuppressant failurec,C0021081;C0332152;C2826257
2200,"prior immunosuppressant failure """,C0021081;C0231174;C0332152;C0680095;C2826257
2200,prior immunosuppressant failure,C0021081;C0231174;C0332152;C0680095;C2826257
2200,no immunosuppressive agents at baseline,C0021081;C0168634;C1442488
2200,no baseline immunosuppressant use,C0021081;C0042153;C0168634;C0457083;C1442488;C1947944
2200,immunosuppressive use,C0021081;C0042153;C0457083;C1947944
2200,immunosuppressive agents only,C0021081;C0205171;C1720467
2200,immunosuppressive agents at baseline,C0021081;C0168634;C1442488
2200,immunosuppressants onlyff,C0021081
2200,immunosuppressants only,C0021081;C0205171;C1720467
2200,immunosuppressants,C0021081
2200,immunosuppressant^^,C0021081
2200,immunosuppressant^,C0021081
2200,immunosuppressant use,C0021081;C0042153;C0457083;C1947944
2200,immunosuppressant ( with or without corticosteroid ),C0021081
2200,any immunosuppressive agent,C0021081
2199,no concomitant immunosuppressive and / or prior anti - tnf use,C0021081;C0521115
2199,immunosuppressants and antimalarials only,C0021081
2199,corticosteroids . immunosuppressants . and antimalarials,C0001617;C0021081;C3539185;C3540725;C3540726;C3540727
2199,concomitant immunosuppressive and / or prior anti - tnf use,C0021081;C0521115
2198,doubling of creatinine level,C0205173;C0428279;C1705764
2198,creatinine level,C0428279
2197,triglycerides level,C0428475
2197,triglyceride level,C0428475
2197,fasting triglyceride level,C0015663;C0428475
2196,psa level,C4086720
2195,calcium level,C0201925;C0428302
2194,pharmaco - invasive n = nmbr,C0205281;C1334278
2194,pharmaco - invasive ( n = nmbr ),C0205281;C1334278
2194,invasive,C0205281;C1334278
2194,"early invasivenmbr """,C0205281;C1279919;C1334278
2194,early invasive *,C0205281;C1279919;C1334278
2193,us site,C0205145;C1515974;C2825164
2193,u . s . sites,C0041703;C0205145
2193,u . s . site,C0041703;C0205145;C1515974;C2825164
2193,sites,C0205145
2193,site,C0205145;C1515974;C2825164
2193,critical site,C0205145;C1511545;C1515974;C2825164
2193,any site,C0205145;C1515974;C2825164
2192,nmbr carotid artery sites,C0007272;C0162859;C0205145
2192,internal carotid artery sites,C0007276;C0205145
2192,common carotid artery sites,C0007272;C0162859;C0205145
2192,carotid bulb sites,C0007281;C0205145
2191,hypotension,C0020649;C3163620
2190,hypertensive,C0857121
2189,antihypertensive therapy — no . ( % ),C0585941
2189,antihypertensive therapy,C0585941
2189,anti - hypertensive therapy - no . ( % ),C0585941
2189,anti - hypertensive therapy,C0585941
2188,hypertrophy per ecg ( n = nmbr nmbr ),C0020564;C1623258
2188,hypertrophy,C0020564
2187,use of antihypertensive drugs,C0003364;C1524063
2187,use of anti - hypertensive agents,C0003364;C1524063
2187,total antihypertensive use,C0003364;C0042153;C0439175;C0439810;C0457083;C1947944
2187,prior antihypertensive medication,C0003364;C0332152;C2826257
2187,previous antihypertensive treatment,C0003364;C0039798;C0087111;C0205156;C1522326;C1533734;C1552607;C1705169;C3538994;C3887704
2187,other antihypertensive medications,C0003364
2187,other antihypertensive drug,C0003364
2187,other antihypertensive agents,C0003364
2187,other antihypertensive,C0003364
2187,other anti - hypertensives,C0003364
2187,other anti - hypertensive,C0003364
2187,one antihypertensive medication,C0003364;C0205447
2187,on antihypertensive treatment,C0003364;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
2187,no antihypertensive medication,C0003364
2187,nmbr antihypertensive medication,C0003364
2187,any antihypertensive drug,C0003364
2187,any antihypertensive agent,C0003364
2187,any anti - hypertensive agent,C0003364
2187,antihypertensives ' *,C0003364
2187,antihypertensives,C0003364
2187,antihypertensive use,C0003364;C0042153;C0457083;C1947944
2187,antihypertensive treatments,C0003364;C0087111
2187,antihypertensive treatment,C0003364;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
2187,antihypertensive randomization,C0003364;C0034656
2187,antihypertensive medicationnmbr ',C0003364
2187,antihypertensive medication use,C0003364;C0042153;C0457083;C1947944
2187,antihypertensive medication or,C0003364
2187,antihypertensive medication ),C0003364
2187,antihypertensive medication,C0003364
2187,antihypertensive drugs,C0003364
2187,antihypertensive drug,C0003364
2187,antihypertensive agents *,C0003364
2187,antihypertensive agents,C0003364
2187,antihypertensive agent use,C0003364;C0042153;C0457083;C1947944
2187,antihypertensive,C0003364
2187,anti - hypertensives,C0003364
2187,anti - hypertensive,C0003364
2187,> nmbr antihypertensive medications,C0003364
2187,> nmbr antihypertensive medication,C0003364
2186,other blood pressure - lowering drugs,C0003364
2186,other blood - pressure drug,C0003364
2186,number of antihypertensive medications used,C0003364;C1718138
2186,number of antihypertensive medications at study entry,C0003364;C1718138
2186,number of antihypertensive medications,C0003364;C1718138
2186,mean number of antihypertensive medications at nmbr year   *,C0003364;C0444504;C1718138;C2347634;C2348143
2186,mean number of antihypertensive medication at last visit   ‡,C0003364;C0237753;C0444504;C0449788;C2347634;C2348143
2186,any blood - pressure - lowering drug 一 no . ( % ),C0003364
2185,inhaled anticholinergic §,C0004048;C0242896;C3537004
2185,anticholinergics,C0242896;C3537307;C3540711
2185,anticholinergic use,C0042153;C0242896;C0457083;C1947944;C3537004
2185,anticholinergic drug,C0242896
2185,anticholinergic,C0242896;C3537004
2185,anti - cholinergics ( short - acting ) a,C0242896
2185,anti - cholinergics ( long - acting ),C0242896
2184,previous intolerance of infliximab,C0205156;C0231199;C0666743;C1552607;C1744706;C2355652
2184,patients with previous intolerance of infliximab,C0030705;C0205156;C0231199;C0666743;C1552607;C1744706;C2355652
2184,intolerance ®,C0231199;C1744706;C2355652
2184,intolerance ',C0231199;C1744706;C2355652
2184,intolerance,C0231199;C1744706;C2355652
2183,post erior - anterior spine,C0037949;C0205094;C0687676;C1704687;C2752558;C3469826
2183,not anterior,C0205094;C1518422
2183,non - anterior,C0205094;C1518422
2183,anterior { % ),C0205094
2183,anterior or non - anterior ml,C0205094
2183,anterior circulation,C0005775;C0205094;C1516559
2183,anterior ( n,C0205094
2183,anterior,C0205094
2182,nesiritide ( n = nmbr ),C0054015
2182,nesiritide,C0054015
2182,bnp — pg / ml  i ,C0021966;C0023806;C0030827;C0054015;C0072225;C0221138;C0439297;C1095989;C1266240;C1417808;C2982014
2182,bnp — pg / ml,C0054015;C0439297;C1095989;C1417808;C2982014
2182,bnp indicates brain natriuretic peptide  and nyha  new york heart association .,C0054015;C1095989;C1417808;C2982014
2182,bnp > nmbr pg / ml n = nmbr,C0054015;C0439297;C1095989;C1417808;C2982014
2182,bnp > nmbr pg / ml,C0054015;C0439297;C1095989;C1417808;C2982014
2182,bnp < nmbr pg / ml n = nmbr,C0054015;C0439297;C1095989;C1417808;C2982014
2182,bnp / ntbnp ( n = nmbr ),C0054015;C1095989;C1417808;C2982014
2182,bnp / nt - probnp,C0054015;C0669479;C0754710;C1095989;C1417808;C2982014
2182,bnp ( pg / ml ) h,C0030827;C0033727;C0054015;C0072225;C0369286;C0439297;C0439391;C0439526;C0441932;C0564385;C1095989;C1266240;C1417808;C1705224;C2827929;C2982014;C3887665;C4528284
2182,bnp ( pg / ml ),C0054015;C0439297;C1095989;C1417808;C2982014
2182,bnp ( n = nmbr ),C0054015;C1095989;C1417808;C2982014
2182,bnp,C0054015;C1095989;C1417808;C2982014
2181,fixed triple ( n = nmbr ),C0205174;C0443218;C2827483;C3714578
2181,adhere,C3714578
2180,etn,C0014758;C0717758
2180,etanercept ( n = nmbr ),C0717758
2180,etanercept,C0717758
2179,characteristics of pulmonary embolism at inclusion,C0034065;C1521970
2179,characteristics no . of participants,C1521970
2179,characteristics *,C1521970
2179,characteristics,C1521970
2179,characteristic_name,C0027365;C1521970;C1547383;C4522128
2179,characteristic^,C1521970
2179,characteristic †,C1521970
2179,characteristic at baseline,C0168634;C1442488;C1521970
2179,characteristic and treatment,C1521970
2179,characteristic age — yr,C0001779;C0439234;C1521970
2179,characteristic age mean ± sd — yr,C0001779;C0439234;C0444504;C1521970;C2347634;C2348143;C2699239
2179,characteristic age,C0001779;C1521970
2179,characteristic / outcome,C1274040;C1521970
2179,characteristic *,C1521970
2179,characteristic ( a ),C1521970
2179,characteristic,C1521970
2178,psoriasis characteristics,C0033860;C1521970
2178,infarct characteristics,C0021308;C1521970
2178,glycemic characteristics,C0005802;C1521970
2178,ed characteristics,C1521970;C3538926
2178,e ( characteristic n,C1521970
2178,arthritis characteristics,C0003864;C1521970;C4552845
2178,anthropometric characteristics,C0003188;C1521970
2177,number ( s ) of features present,C0237753;C0449788;C1521970;C1706388;C2346469;C2348519
2177,feature,C1521970;C1706388;C2346469;C2348519
2177,baseline feature,C0168634;C1442488;C1521970;C1706388;C2346469;C2348519
2176,disseminated tuberculosis,C0152915
2175,ulcerative colitis,C0009324
2175,duration of ulcerative colitis,C0009324;C0449238;C2926735
2174,hematocrit,C0018935;C0518014
2174,baseline hematocrit,C0018935;C0168634;C0518014;C1442488
2173,documented symptomatic chdb,C0231220;C1301725;C1609436
2173,documented mi,C1301725;C1609436;C3810814
2173,documented hypoglycaemiac,C1301725;C1609436
2173,documented asymptomatic cardiac ischemiac,C0018787;C0231221;C1301725;C1522601;C1609436
2172,treatment   ×   lipid interaction,C0023779;C0039798;C0087111;C1522326;C1533734;C1704675;C1705169;C3538994;C3887704
2172,treatment with sulphonylurea + biguanide,C0005382;C0038766;C0039798;C0087111;C1522326;C1533734;C1705169;C3536898;C3537187;C3538994;C3887704;C4317165
2172,treatment with sulphonylurea,C0038766;C0039798;C0087111;C1522326;C1533734;C1705169;C3536898;C3538994;C3887704
2172,treatment with statins,C0039798;C0087111;C0360714;C1522326;C1533734;C1705169;C3538994;C3887704
2172,treatment with drugeluting stent,C0039798;C0087111;C1322815;C1522326;C1533734;C1705169;C3538994;C3887704
2172,treatment with candesartan,C0039798;C0087111;C0717550;C1522326;C1533734;C1705169;C3538994;C3887704
2172,treatment with any blood - pressure -,C0005823;C0033095;C0039798;C0087111;C0460139;C0596197;C1271104;C1272641;C1306345;C1522326;C1533734;C1705169;C3538994;C3887704;C4284008
2172,treatment with anti - platelet drugs,C0039798;C0087111;C1522326;C1533734;C1705169;C2963157;C3538994;C3887704
2172,treatment stratum^ :,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
2172,treatment groups [n / nb ( % ) ],C0028101;C0039798;C0087111;C0441848;C0919442;C1522326;C1533734;C1705169;C1705347;C3538994;C3887704;C4553907
2172,treatment groups,C0039798;C0087111;C0441833;C0687744;C1257890;C1519504;C1522326;C1533734;C1552839;C1705169;C1705428;C1705429;C3538994;C3887704
2172,treatment group,C0039798;C0087111;C0441833;C0687744;C1257890;C1519504;C1522326;C1533734;C1705169;C1705428;C1705429;C3538994;C3887704
2172,treatment glargine,C0039798;C0087111;C0907402;C1522326;C1533734;C1705169;C3538994;C3887704
2172,treatment for latent tuberculosis^,C0039798;C0087111;C0205275;C0749724;C1522326;C1533734;C1609538;C1705169;C3538994;C3887704
2172,treatment during or after catheterization,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
2172,treatment difference ( nmbr % cl ),C0039798;C0087111;C0596019;C1522326;C1533734;C1705169;C1705241;C1705242;C3538994;C3887704
2172,treatment difference ( nmbr % ci ),C0008107;C0039798;C0087111;C1522326;C1533734;C1705169;C1705241;C1705242;C3259781;C3538994;C3887704
2172,treatment difference % ( nmbr % cl ),C0039798;C0087111;C0596019;C1522326;C1533734;C1705169;C1705241;C1705242;C3538994;C3887704
2172,treatment diff . vs tio ( nmbr % ci ),C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
2172,treatment comparison ( mg / day ) t,C0039798;C0087111;C0439422;C1522326;C1533734;C1705169;C1707455;C3538994;C3887704
2172,treatment comparison,C0039798;C0087111;C1522326;C1533734;C1705169;C1707455;C3538994;C3887704
2172,treatment characteristics,C0039798;C0087111;C1521970;C1522326;C1533734;C1705169;C3538994;C3887704
2172,treatment by subgroup interaction,C0039798;C0087111;C1079230;C1515021;C1522326;C1533734;C1704675;C1705169;C3538994;C3887704
2172,treatment before randomization — days,C0034656;C0039798;C0087111;C0439228;C1522326;C1533734;C1705169;C3538994;C3887704
2172,treatment before catheterization,C0007430;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
2172,treatment before admission ( % ),C0039798;C0087111;C0184666;C0809949;C1522326;C1533734;C1705169;C3538994;C3887704
2172,treatment at randomization — no . ( % ),C0034656;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
2172,treatment and parameter,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
2172,treatment after admission,C0039798;C0087111;C0184666;C0809949;C1522326;C1533734;C1705169;C3538994;C3887704
2172,treatment - by - subgroup interaction,C0039798;C0087111;C1079230;C1515021;C1522326;C1533734;C1704675;C1705169;C3538994;C3887704
2172,treatment ( de vs warfarin ) by thrombophilia interaction,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
2172,treatment,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
2172,treated,C1522326
2171,nmbr - y incidence rate ( se ) per nmbr participants,C0036919;C0679646;C1708485
2171,incidence rate per nmbr person years,C0027361;C0439234;C1708485;C2347489
2171,incidence rate per nmbr person - years,C0027361;C0439234;C1708485;C2347489
2171,incidence rate no . ( / nmbrperson - years ),C1708485
2171,incidence rate difference,C1705241;C1705242;C1708485
2171,incidence rate *,C1708485
2171,incidence rate ( per nmbr person - yr ),C0027361;C0439234;C1708485;C2347489
2171,incidence rate ( n ) a,C1708485
2171,incidence rate ( n ),C1708485
2171,incidence rate,C1708485
2171,incidence [n / n ( rate per nmbr person - years ) ],C0027361;C0439234;C1708485;C2347489
2170,no incident dm or change in fg > nmbr,C0011816;C1551358;C3250443
2170,incident or worsening nephropathy,C1551358
2170,incident dm or change in,C0011816;C1551358;C3250443
2169,remission at maintenance - trial entry — no . ( % ),C0008976;C0024501;C0544452;C0687702;C1705654
2169,maintenance use — no . ( % ),C0024501
2169,maintenance ocs use,C0024501
2168,arb = angiotensin ii receptor blocker  ccb,C0006684;C0521942;C3536793;C3888198
2168,angiotensin receptor blockers,C0521942;C0815017
2168,angiotensin ii receptor blockers,C0521942;C2757003
2168,angiotensin ii receptor blocker,C0521942;C3536793
2167,angiotensin receptor blocker yes,C0034787;C1549445;C1622222;C1705108;C1710701
2167,angiotensin receptor blocker and / or ace,C0034787;C1622222
2167,angiotensin receptor blocker,C0034787;C1622222
2167,angiotensin receptor,C0034787;C1622222
2167,angiotensin - receptor blocker,C0034787;C1622222
2167,angiotensin - receptor,C0034787;C1622222
2166,angiotensin receptive blocker,C0003018;C0544683;C4521302
2166,angiotensin ll - receptor blocker,C0003018;C4521302
2166,angiotensin ll - receptor antagonist — no . ( % ),C0003018;C4521302
2166,angiotensin il - receptor blocker,C0003018;C0020898;C0021764;C0022271;C0034787;C1149183;C1622222;C4521302
2166,angiotensin - eonverting enzyme inhibitors / angiotensin reeeptor bloekers,C0003018;C0014432;C1152555;C2756995;C4521302
2166,angiotensin - eonverting enzyme inhibitors,C0003018;C0014432;C1152555;C2756995;C4521302
2166,angiotensin -,C0003018;C4521302
2165,functional assessment of chronic illness,C0008679;C0278372
2164,patient global assessment of disease activity ( vas nmbr - nmbr mm ),C0042815;C3536884;C3827561;C4054228;C4330985;C4554674
2164,patient global assessment of disease activity ( nmbr - nmbr cm,C4054228
2164,patient global assessment of disease activity,C4054228
2164,patient ' s global assessment of disease activity,C4054228
2163,main effect baseline hormone,C0019932;C0168634;C0205225;C1280500;C1442488;C1518681;C1542147;C2348382;C4521914
2163,effect of ranolazine compared with placebo on angina and recurrent ischemia,C0073633;C1280500;C1518681;C2348382
2163,effect of covariates on slopes,C1280500;C1518681;C2348382
2163,consistency of effect,C0332529;C1280500;C1518681;C1547017;C2348382
2162,treatment effect ( hr ),C1518681
2162,genotype - specific treatment effect hazard ratio ( nmbr % ci ),C0008107;C0017431;C0205369;C1518681;C1552740;C2985465;C3259781
2161,use of antiplatelet agents^,C0085826;C1524063
2161,use of antiplatelet agents — no . / total no . ( % ),C0085826;C1524063
2161,use of antiplatelet agents,C0085826;C1524063
2161,previous use of antiplatelet drugs,C0085826;C0205156;C1524063;C1552607;C2963157
2161,previous chronic use of antiplatelet drugs,C0085826;C0205156;C0205191;C1524063;C1552607;C2963157
2161,other antiplatelet agents,C0085826
2161,other antiplatelet agent 一 no . ( % ),C0085826
2161,antiplatelets agents,C0085826
2161,antiplatelet drugs,C0085826;C2963157
2161,antiplatelet drug,C0085826
2161,antiplatelet agents ( % ),C0085826
2161,antiplatelet agents,C0085826
2161,antiplatelet agent or anticoagulant,C0085826
2161,antiplatelet agent n ( % ),C0085826
2161,antiplatelet agent,C0085826
2160,no history of hypertension ( n = nmbr ),C0455527
2160,medical history of hypertension,C0020538;C0199168;C0205476;C0262926;C0455527;C1963138
2160,history of systemic hypertension,C0205373;C0455527
2160,history of hypertension^,C0455527
2160,history of hypertension — no . ( % ),C0455527
2160,history of hypertension for nmbr mo or more,C0455527
2160,history of hypertension . no . ( % ),C0455527
2160,history of hypertension - n ( % ),C0455527
2160,history of hypertension *,C0455527
2160,history of hypertension ( n = nmbr ),C0455527
2160,history of hypertension ( a ) c,C0455527
2160,history of hypertension ( % ),C0455527
2160,history of hypertension,C0455527
2160,history of diagnosed hypertension prior to randomization,C0011900;C0455527
2160,history of diagnosed hypertension n ( % ),C0011900;C0455527
2160,history of currently treated hypertension,C0455527;C0521116;C1522326
2159,extent of disease — no . / total no . ( % ) § ^ |,C0449279;C4553144
2159,extent of disease,C0449279;C4553144
2159,angiographic extent of disease,C0002978;C0449279;C4553144
2158,history of percutaneous coronary intervention,C1320647;C4554713
2157,history of paroxysmal atrial fibrillation,C0205311;C0729790
2157,history of atrial fibrillation or flutter treatment at randomisation,C0729790
2157,history of atrial fibrillation or flutter,C0729790
2157,history of atrial fibrillation or fl utter,C0729790
2157,history of atrial fibrillation and / or flutter,C0729790
2157,history of atrial fibrillation / flutter,C0016385;C0232197;C0729790;C1998417;C2242390
2157,history of atrial fibrillation,C0729790
2156,history of gestational diabetes mellitus — no . ( % of women ),C2183115
2155,history of asthma - related intubation — no . ( % ),C0455544
2154,history of microalbuminuria — no . ( % ),C3532606
2153,history of intermittent claudication and abi < nmbr - nmbr or substantial peripheral arterial stenosis > nmbr %,C0205267;C2315493
2153,history of claudication,C2315493
2152,left side only,C3842976
2152,left - sided disease only,C0012634;C3842976
2151,left sided colitis,C2887821
2151,left - sided colitis,C2887821
2150,limited to left side of colon,C0227388;C0439801;C2674459;C3542948;C4050251
2150,left side of colon,C0227388
2149,size of left atrium normal — no . ( % ) £,C0225860;C0456389
2149,left atrial diameter : < nmbr mm ( n = nmbr ),C0225860;C0225861;C1301886;C4330985;C4554674
2149,left atrial diameter,C0225860;C0225861;C1301886
2149,left atrial anteroposterior diameter — mm,C0225860;C0225861;C1301886;C4330985;C4554674
2148,estradiol quartiles,C0014912;C2828255
2148,estradiol ( pmol / l ),C0014912;C0439284
2148,estradiol ( enmbr ) ( pmol / l ),C0014912;C0439284
2147,stratified by,C0205363
2147,stratified analyses,C0002778;C0205363;C0936012;C1524024
2146,use of diuretics,C0012798;C1524063
2146,other diuretic,C0012798
2146,non diuretics,C0012798;C1518422
2146,diuretics^,C0012798
2146,diuretics * *,C0012798
2146,diuretics ( % ),C0012798
2146,diuretics,C0012798
2146,diuretic use,C0012798;C0042153;C0457083;C1947944
2146,diuretic n ( % ),C0012798
2146,diuretic drugs ( excluding antialdosterone ),C0012798;C0013227;C3687832
2146,diuretic drugs,C0012798;C0013227;C3687832
2146,diuretic ( any ),C0012798
2146,diuretic,C0012798
2145,total diuretic dose ( iv + oral ) on day nmbr,C0012798;C0022326;C2986497;C4265176
2145,diuretic — no . / total no . ( % ),C0012798
2145,diuretic — no . ( % ) surgery,C0012798
2144,seropositive ( rf + ve and / or acpa + ve ) subgroup,C0035448;C0042469;C0201660;C0521143;C0748398;C1547111;C3714652;C4321495
2144,seronegative ( rf - ve and acpa - ve ) subgroup,C0035448;C0042469;C0201660;C0521144;C0748398;C1547111;C3714652;C4321495
2144,rheumatoid factor positive §,C0035448;C0201660;C0439178;C1446409;C1514241;C2825490;C3812269
2144,rheumatoid factor positive,C0035448;C0201660;C0439178;C1446409;C1514241;C2825490;C3812269
2144,rheumatoid factor or acpa positive,C0035448;C0201660
2144,rheumatoid factor and acpa positive,C0035448;C0201660
2144,rheumatoid factor - positive,C0035448;C0201660;C0439178;C1446409;C1514241;C2825490;C3812269
2144,rheumatoid factor !,C0035448;C0201660
2144,rf positive — number ( % ),C0035448;C0201660;C0748398;C1547111;C3812269
2144,rf positive and acpa negative,C0035448;C0201660;C0439178;C0748398;C1446409;C1514241;C1547111;C2825490;C3812269
2144,rf or acpa positive,C0035448;C0201660;C0748398;C1547111
2144,rf negative and acpa positive,C0035448;C0201660;C0205160;C0748398;C1513916;C1547111;C2825415;C2825491;C3853545
2144,rf and acpa positive,C0035448;C0201660;C0748398;C1547111
2144,rf and acpa negativenmbr,C0035448;C0201660;C0748398;C1547111
2144,rf and acpa negative,C0035448;C0201660;C0748398;C1547111
2144,rf ( iu / ml ),C0035448;C0201660;C0439458;C0748398;C1547111
2144,rf,C0035448;C0201660;C0748398;C1547111
2144,% rf +,C0035448;C0201660;C0748398;C1547111
2143,used,C1273517
2142,torsemide,C0076840
2141,us resident,C1320928;C1549439;C2347958;C3835651
2140,observation,C0302523;C0700325;C1964257;C3889687
2139,observed case,C0868928;C1441672;C1706255;C1706256
2139,observed,C1441672
2138,qrs > nmbr ms *,C2349943;C3539704;C3713294
2138,qrs > nmbr ms,C2349943;C3539704;C3713294
2138,no prior ms therapies,C1514463;C2349943;C3539704;C3713294
2138,ms nmbr - nmbr,C2349943;C3539704;C3713294
2138,ms < nmbr,C2349943;C3539704;C3713294
2138,ms & ng,C0017887;C0028074;C2349943;C3539704;C3713294
2138,ms,C2349943;C3539704;C3713294
2137,diastolic pressure,C0428883
2137,diastolic blood pressure — mm hg,C0428883;C0439475;C1305849
2137,diastolic blood pressure subgroups,C0428883;C1079230;C1305849
2137,diastolic blood pressure mmhg,C0428883;C0439475;C1305849
2137,diastolic blood pressure > nmbr mm hg,C0428883;C0439475;C1305849
2137,diastolic blood pressure - mmhg,C0428883;C0439475;C1305849
2137,diastolic blood pressure ( mmhg ),C0428883;C0439475;C1305849
2137,diastolic blood pressure ( mm hg ) medications,C0013227;C0428883;C0439475;C0802604;C1305849;C2598133;C4284232
2137,diastolic blood pressure ( mm hg ) :,C0428883;C0439475;C1305849
2137,diastolic blood pressure ( mm hg ),C0428883;C0439475;C1305849
2137,diastolic blood pressure  and lp ( a ) ,C0428883;C1305849
2137,diastolic blood pressure,C0428883;C1305849
2137,< nmbr . nmbr mm hg diastolic blood pressure,C0428883;C0439475;C1305849
2136,systolic pressure,C0871470
2136,systolic blood pressure^,C0488055;C0871470;C1306620
2136,systolic blood pressure — mmhg,C0439475;C0488055;C0871470;C1306620
2136,systolic blood pressure — mm hg,C0439475;C0488055;C0871470;C1306620
2136,systolic blood pressure subgroups,C0488055;C0871470;C1079230;C1306620
2136,systolic blood pressure mmhg,C0439475;C0488055;C0871470;C1306620
2136,systolic blood pressure [mmhg] ( interaction : p = nmbr . nmbr ),C0439475;C0488055;C0871470;C1306620;C1704675
2136,systolic blood pressure > nmbr mm hg — no . ( % ),C0439475;C0488055;C0871470;C1306620
2136,systolic blood pressure > nmbr mm hg or diastolic blood pressure > nmbr mm hg,C0439475;C0488055;C0871470;C1306620
2136,systolic blood pressure > nmbr mm hg or diastolic,C0439475;C0488055;C0871470;C1306620
2136,systolic blood pressure > nmbr mm hg,C0439475;C0488055;C0871470;C1306620
2136,systolic blood pressure < nmbr mm hg and diastolic blood pressure < nmbr mm hg,C0439475;C0488055;C0871470;C1306620
2136,systolic blood pressure < nmbr mm hg and diastolic,C0439475;C0488055;C0871470;C1306620
2136,systolic blood pressure - mmhg,C0439475;C0488055;C0871470;C1306620
2136,systolic blood pressure ( mmhg ),C0439475;C0488055;C0871470;C1306620
2136,systolic blood pressure ( mm hg ),C0439475;C0488055;C0871470;C1306620
2136,systolic blood pressure,C0488055;C0871470;C1306620
2136,nonglycemic cardiovascular risk factors systolic blood pressure — mmhg,C0439475;C0488055;C0850624;C0871470;C1306620
2136,nob systolic blood pressure ( mm hg ),C0439475;C0488055;C0871470;C1306620
2135,triglyceride ( mmol / l ) * blood pressure,C0005823;C0041004;C1271104;C1272641;C1532563
2135,preoperative blood pressure ( mm hg ) patients fulfilling eligibility criteria,C0005823;C0030705;C0439475;C0445204;C1271104;C1272641
2135,lvh by ecgt blood pressure,C0005823;C0149721;C1271104;C1272641
2135,body mass index blood pressure — mmhg,C0005823;C0005893;C0439475;C0578022;C1271104;C1272641;C1305855
2135,body - mass index : ! : blood pressure — mm hg,C0005823;C0005893;C0439475;C0578022;C1271104;C1272641;C1305855
2135,bloodpressure,C0005823;C1271104;C1272641
2135,blood pressure — mmhg,C0005823;C0439475;C1271104;C1272641
2135,blood pressure — mm hg,C0005823;C0439475;C1271104;C1272641
2135,blood pressure while seated — mm hg,C0005823;C1271104;C1272641
2135,blood pressure systolic,C0005823;C1271104;C1272641
2135,blood pressure in mm hg,C0005823;C0439475;C1271104;C1272641
2135,blood pressure eontrolt,C0005823;C1271104;C1272641
2135,blood pressure control *,C0005823;C0243148;C1271104;C1272641;C1550141;C1882979;C2587213;C3274648;C4553389
2135,blood pressure control,C0005823;C0243148;C1271104;C1272641;C1550141;C1882979;C2587213;C3274648;C4553389
2135,blood pressure at entry ( mm   hg ),C0005823;C0439475;C1271104;C1272641;C1705654
2135,blood pressure at baseline :,C0005767;C0005768;C0005823;C0168634;C0229664;C0443150;C1271104;C1272641;C1442488
2135,blood pressure > nmbr mm hg,C0005823;C0439475;C1271104;C1272641
2135,blood pressure < nmbr mm hg,C0005823;C0439475;C1271104;C1272641
2135,blood pressure < nmbr / nmbr mmhg,C0005823;C0439475;C1271104;C1272641
2135,blood pressure ( mmhg ),C0005823;C0439475;C1271104;C1272641
2135,blood pressure ( mm hg ) systolic,C0005823;C0439475;C1271104;C1272641
2135,blood pressure ( mm hg ) *,C0005823;C0439475;C1271104;C1272641
2135,blood pressure ( mm hg ),C0005823;C0439475;C1271104;C1272641
2135,blood pressure ( % ),C0005823;C1271104;C1272641
2135,blood pressure  pbo y patients with diabe teristics ( ncep atp i,C0005823;C0021966;C0030705;C0031962;C0221138;C1271104;C1272641;C2744579;C4552600
2135,blood pressure,C0005823;C1271104;C1272641
2134,sulphonylureas only,C0038766;C0205171;C1720467
2134,sulphonylureas,C0038766
2134,sulphonylurea,C0038766;C3536898
2134,sulfonylureas,C0038766;C3653359
2134,sulfonylurea — no . ( % ),C0038766;C3536898
2134,sulfonylurea derivatives,C0038766
2134,sulfonylurea based,C0038766;C3536898
2134,sulfonylurea,C0038766;C3536898
2134,other sulfonylurea 一 no . ( % ),C0038766;C3536898
2134,on sulfonylurea,C0038766;C3536898
2134,non - sulfonylurea secretagogues,C0038766;C1518422;C3536898;C4704833
2134,duration of sulphonylurea use ( months ),C0038766;C0439231;C1881378;C2826775;C3536898
2134,any sulfonylurea,C0038766;C3536898
2133,user,C1548600;C1706077
2133,non - user nmbr,C1518422;C1548600;C1706077
2133,laba users,C1706077
2133,laba non - users,C1518422;C1706077
2133,"esr ( mm / hour ) git config - - global user . name "" your name """,C0205246;C0439227;C0564385;C1418224;C1548600;C1706077;C2348867;C2827597;C3811131;C4330985;C4554674
2132,threatened abrupt vessel closure,C0005847;C0185003;C1276802;C1521802
2132,pfo closure group ( n = nmbr ),C0185003;C0441848;C1521802
2132,pfo closure,C0185003;C1521802
2132,laa closure ( n = nmbr ),C0185003;C1521802
2132,laa closure ( n - nmbr ),C0185003;C1521802
2132,laa closure,C0185003;C1521802
2132,closure,C0185003;C1521802
2132,abrupt vessel closure,C0005847;C0185003;C1276802;C1521802
2131,sodium - glucose cotransporter nmbr inhibitor,C0017725;C0037473;C0597484;C1999216;C3541959;C3714642
2131,sodium,C0037473;C0597484;C3541959;C3714642
2130,ustekinumab ® ( n = nmbr ),C1608841
2130,ustekinumab nmbr mg ( n = nmbr ),C0024671;C0026410;C0439269;C1608841;C1960952;C2346927;C4321396;C4521761
2130,ustekinumab combined,C1608841
2130,ustekinumab ' ’ ( n = nmbr ),C1608841
2130,ustekinumab,C1608841
2129,nmbr drinks / wk,C0452428
2129,nmbr drinks,C0452428
2129,nmbr - nmbr drinks / wk,C0452428
2129,nmbr - nmbr drinks / dav,C0452428
2129,nmbr - nmbr drinks,C0452428
2129,nmbr + drinks / wk,C0452428
2129,> nmbr drinks / wk,C0452428
2129,> nmbr drinks / week,C0452428
2129,> nmbr drinks / dav,C0452428
2129,> nmbr drinks,C0452428
2129,> nmbr ( nmbr ) drinks / day if male ( female ),C0452428
2128,gastroenteritis,C0017160
2127,tendonitis,C0039503
2126,synovitis,C0039103
2125,sinusitis,C0037199;C4553555
2124,rhinitis,C0035455
2123,bronchitis,C0006277
2122,cystitis,C0010692;C0600041;C1963088
2121,osteitis,C0029400
2120,uveitis,C0042164;C1963266
2119,bursitis,C0006444
2118,pancolitis,C0868908
2118,extensive / pancolitis,C0205231;C0868908
2117,spondylitis,C0038012
2117,non - spondylitis,C0038012;C1518422
2116,pts,C1419129;C2698747
2116,pioglitazone pts / n ( % ),C0071097;C1419129;C2698747
2116,no . pts,C1419129;C2698747
2116,# pts,C1419129;C2698747
2115,lv mass,C0455825
2114,y es,C0013754;C0205944
2113,no cases,C0868928;C1533148
2113,cases,C0868928;C1533148
2112,ramus,C3538818
2111,fibrous,C0016059;C0439709
2110,fibrates,C1449704;C3540783
2109,valdecoxib,C0913246
2108,rofecoxib,C0762662
2107,celecoxib ( n = nmbr ),C0538927
2107,celecoxib,C0538927
2106,etoricoxib nmbr mg ( n nmbr nmbr ),C0024671;C0026410;C0439269;C0972314;C1960952;C2346927;C4321396;C4521761
2106,etoricoxib nmbr mg,C0024671;C0026410;C0439269;C0972314;C1960952;C2346927;C4321396;C4521761
2106,etoricoxib ( n = nmbr nmbr ),C0972314
2106,etoricoxib ( n = nmbr ),C0972314
2106,etoricoxib ( n = nmbr,C0972314
2106,etoricoxib,C0972314
2105,rs - cough & sputumc,C0010200;C0035970;C1961131;C3274924;C3714753;C3813325;C4084725;C4084726;C4084727
2105,cough ( leading to study drug discontinuation ),C0010200;C1961131;C3274924;C4084725;C4084726;C4084727
2105,cough ( investigator reported ),C0010200;C0035173;C1961131;C3274924;C4084725;C4084726;C4084727
2105,cough,C0010200;C1961131;C3274924;C4084725;C4084726;C4084727
2105,any cough,C0010200;C1961131;C3274924;C4084725;C4084726;C4084727
2104,alirocumab nmbr mg qnmbrw,C0024671;C0026410;C0439269;C1960952;C2346927;C3491162;C4321396;C4521761
2104,alirocumab nmbr / nmbr mg,C0024671;C0026410;C0439269;C1960952;C2346927;C3491162;C4321396;C4521761
2104,alirocumab n = nmbr,C3491162
2104,alirocumab ( n = nmbr ),C3491162
2104,alirocumab,C3491162
2103,nmbr locf ),C2825507
2103,locf ),C2825507
2102,evolocumab nmbr mg monthly ( n = nmbr ),C0024671;C0026410;C0332177;C0439269;C1960952;C2346927;C3529352;C4321396;C4521761
2102,evolocumab + soc ( n = nmbr ),C3529352
2102,evolocumab ( nmbr mg ),C0024671;C0026410;C0439269;C1960952;C2346927;C3529352;C4321396;C4521761
2102,evolocumab ( n = nmbr ),C3529352
2102,evolocumab,C3529352
2101,native hawaiian or other pacific islander,C0337920
2101,native hawaiian or other pacific,C0337920
2101,native hawaiian or,C0337920
2101,native hawaiian / pacific islander,C0242191;C0337920
2101,native hawaiian / other,C0337920
2101,hawaiian pacific islander,C0242191;C0337920
2101,hawaiian / pacific islander,C0242191;C0337920
2101,hawaiian / pacific,C0337920
2100,watchman ( n = nmbr ),C0335390
2100,device = watchman filter,C0180860;C0335390
2099,apixaban vs . placebo,C1831808
2099,apixaban dose ( or matching placebo ),C0178602;C0869039;C1114758;C1831808
2099,apixaban ( n = nmbr ),C1831808
2099,apixaban,C1831808
2098,valsartan n / n,C0216784
2098,valsartan ( n = nmbr ),C0216784
2098,valsartan,C0216784
2097,irbesartan ( n = nmbr ),C0288171
2097,irbesartan,C0288171
2096,telmisartan group ( n = nmbr ),C0248719;C0441848
2096,telmisartan ( n = nmbr ),C0248719
2096,telmisartan ( n = nmbr,C0248719
2096,telmisartan,C0248719
2095,vein bypass graft stented,C0398147
2094,prior bypass graft surgery,C0185098;C0455610
2094,bypass graft §,C0185098
2094,bypass graft,C0185098
2093,coronar y - artery bypass grafting,C0450140;C0741847
2093,arterial graft,C0450140
2092,r - tpa,C0032143
2092,alteplase group ( n = nmbr ),C0032143;C0441848
2092,alteplase ( n = nmbr ),C0032143
2092,alteplase,C0032143
2091,temporal data and management strategy,C0442043;C1511726;C2362314;C3245479;C3714741
2091,pci data,C1511726;C3245479;C3714741;C4049621
2091,no ef data | |,C1511726;C3245479;C3714741
2091,imaging data,C0011923;C0079595;C1511726;C3245479;C3714741
2091,fpg data ',C1511726;C3245479;C3714741
2091,data presented as mean   ±   sd  unless otherwise specified    acopd severity is based on the gold nmbr criteria [nmbr]  gold nmbr [nmbr]    bon a scale of nmbr – nmbr  with higher scores indicating worse health status  the mcid is a change of nmbr   units  on a scale of nmbr – nmbr  with higher scores indicating more severe dyspnea  on a scale of nmbr – nmbr  with higher scores indicating worse health status,C1511726;C3245479;C3714741
2091,data missing or no drug given,C1511726;C1551393;C1705492;C3245479;C3272743;C3714741
2091,data missing,C1511726;C3245479;C3714741
2091,data are reported as percentage or mean ± standard deviation  unless otherwise indicated . ng  normoglycemia  igm  impaired glucose metabolism  ldl  low - density lipoprotein  hdl  high - density lipoprotein  fpg  fasting plasma glucose . a median ( interquartile range ) . ‡ p < nmbr . nmbr vs . non - epa . § p < nmbr . nmbr vs . non - epa,C1511726;C3245479;C3714741
2091,data are reported as percentage or mean ± standard deviation  unless otherwise indicated . ng  normoglycemia  igm  impaired glucose metabolism  ldl  low - density lipoprotein  hdl  high - density lipoprotein  fpg  fasting plasma glucose . a median ( interquartile range ) . * p < nmbr . nmbr vs . ng . † p < nmbr . nmbr vs . ng .,C1511726;C3245479;C3714741
2091,data are reported as n ( % ) . event rates in parentheses are kaplan - meier estimates ( % ) at nmbr year . * cardiovascular ( cv ) death,C1511726;C3245479;C3714741
2091,data are number of patients ( % ) or mean ( sd ),C1511726;C3245479;C3714741
2091,data are number of patients ( % ) or hazard ratio ( nmbr % cl ),C1511726;C3245479;C3714741
2091,data are mean ± standard deviation for continuous variables and number ( % ) for categoric variables . p,C1511726;C3245479;C3714741
2091,data are mean ( sd ) or number ( % ) . pufa = polyunsaturated fatty acids,C1511726;C3245479;C3714741
2091,data are expressed as n / total ( % ) unless otherwise specified . systeme international unit conversion : to convert creatinine clearance to ml / s  multiply by nmbr . nmbr . * estimated with cockroft - gault equation ,C1511726;C3245479;C3714741
2091,data,C1511726;C3245479;C3714741
2091,available data,C0470187;C1511726;C3245479;C3714741
2091,at c data,C1511726;C3245479;C3714741
2091,* data reported as n ( % ) or median ( quartiles nmbr,C1511726;C3245479;C3714741
2091,* data are given as percentage of subjects unless otherwise specified . ptca indicates percutaneous transluminal coronary angioplasty  cabg  coronary artery bypass graft  ace  angiotensin - converting enzyme  bmi  body mass index ( calculated as weight in kilograms divided by square of height in meters )  hdl - c  high - density lipoprotein cholesterol  ldl - c  low - density lipoprotein cholesterol  fpg  fasting plasma glucose  and fpi  fasting plasma insulin . tto convert cholesterol values to micromoles per liter  multiply by nmbr . nmbr . to convert triglycerides to micromoles per liter  multiply by nmbr . nmbr . to convert fpg to micromoles per liter  multiply by nmbr . nmbr . to convert fpi to picomoles per liter  multiply by nmbr . nmbr .,C1511726;C3245479;C3714741
2091,* data are expressed as median ± sd,C1511726;C3245479;C3714741
2091,* data are expr,C1511726;C3245479;C3714741
2091, signi ﬁ cantly different from baseline values by repeated measures ( analysis of variance )  p nmbr . nmbr .,C1511726;C3245479;C3714741
2091, median ( interquartile range ) . ldl  low - density lipoprotein  hdl  high - density lipoprotein  tg  triglyceride .,C1511726;C3245479;C3714741
2091, hf = heart failure . ami = acute myocardial infarction . cabg = coronary artery bypass graft . pci = percutaneous coronary intervention . icd = implantable cardioverter de ﬁ brillator . copd = chronic obstructive pulmonary disease . ace = angiotensin - converting enzyme . arbs = angiotensin receptor blockers . * available for nmbr patients ( nmbr rosuvastatin  nmbr placebo ) .,C1511726;C3245479;C3714741
2091, chf = congestive heart failure . * any use in nmbr h before surgery except for aspirin which only required any use in the nmbr days before surgery .,C1511726;C3245479;C3714741
2091, ace angiotensin - converting enzyme  cabg coronary artery bypass graft  ccsc canadian cardiovascular society classi ﬁ cation  mi myocardial infarction  pci percutaneous coronary intervention .,C1511726;C3245479;C3714741
2090,rivaroxaban plus aspirin ( nmbr % cl ),C0004057;C0332287;C0596019;C1739768
2090,rivaroxaban plus aspirin ( n = nmbr ) nmbr . nmbr ± nmbr . nmbr,C0004057;C0332287;C1739768
2090,rivaroxaban plus aspirin ( n = nmbr ),C0004057;C0332287;C1739768
2090,rivaroxaban nmbr . nmbr mg bid + aspirin nmbr mg od,C0004057;C0229089;C0439164;C1319635;C1512019;C1739768;C3273373;C3665488
2090,rivaroxaban alone ( n = nmbr ) nmbr . nmbr ± nmbr . nmbr,C0205171;C0439044;C0679994;C1739768
2090,rivaroxaban alone ( n = nmbr ),C0205171;C0439044;C0679994;C1739768
2090,rivaroxaban + aspirin,C0004057;C1739768
2090,rivaroxaban ( n   = nmbr ),C1739768
2090,rivaroxaban ( n = nmbr ),C1739768
2090,low - dose rivaroxaban plus aspirin ( n = nmbr ),C0332287;C1739768;C2608320
2090,low - dose rivaroxaban + aspirin ( n / n ),C1739768;C2608320
2089,rivaroxaban plus,C1739768
2089,rivaroxaban nmbr mg,C0024671;C0026410;C0439269;C1739768;C1960952;C2346927;C4321396;C4521761
2089,rivaroxaban +,C1739768
2089,rivaroxaban,C1739768
2088,ranolazine vs . placebo km failure rate,C0073633
2088,ranolazine n = nmbr,C0073633
2088,ranolazine ( n nmbr nmbr ),C0073633
2088,ranolazine ( n = nmbr ) placebo ( n = nmbr ),C0032042;C0073633;C1696465;C1706408
2088,ranolazine ( n = nmbr ),C0073633
2088,ranolazine ( n = nmbr,C0073633
2088,ranolazine,C0073633
2087,hazard ratio vs . placebo,C2985465
2087,hazard ratio for event ( nmbr % ci ),C0008107;C0441471;C2985465;C3259781;C4019010
2087,hazard ratio [nmbr % ci],C0008107;C2985465;C3259781
2087,hazard ratio * ( nmbr % ci ),C0008107;C2985465;C3259781
2087,hazard ratio * ( and nmbr % ci ),C2985465
2087,hazard ratio ( nmbr % confidence interval ) *,C0009667;C2985465
2087,hazard ratio ( nmbr % confidence interval ),C0009667;C2985465
2087,hazard ratio ( nmbr % ci ) vs . placebo,C0008107;C2985465;C3259781
2087,hazard ratio ( nmbr % ci ) - j -,C0008107;C2985465;C3259781
2087,hazard ratio ( nmbr % ci ) *,C0008107;C2985465;C3259781
2087,hazard ratio ( nmbr % ci ),C0008107;C2985465;C3259781
2087,coronary syndrome . ci = confidence interval  hr = hazard ratio .,C0008107;C0009667;C0018787;C0039082;C2985465;C3259781
2087, pre - specified analysis and adjusted for time - varying bp,C0005823;C0008107;C0009667;C0022661;C2985465;C3259781
2086,unadjusted hazard ratio ( nmbr % cl ),C0596019;C1439367;C2985465
2086,unadjusted hazard ratio ( nmbr % ci ),C0008107;C1439367;C2985465;C3259781
2086,adjusted hazard ratio *,C0456081;C2985465
2086,adjusted hazard ratio ( nmbr % cl ) *,C0456081;C0596019;C2985465
2086,adiusted hazard ratio *,C2985465
2085,hazard rationmbr,C2985465
2085,hazard ratio with low ( nmbr % cl ),C0205251;C0596019;C1550472;C2985465;C3890211;C4048187;C4321351;C4522223
2085,hazard ratio with high ( nmbr % cl ),C0205250;C0596019;C1299351;C2700149;C2985465;C3887512;C3889660;C4321237;C4522209
2085,hazard ratio with dabigatran,C2348066;C2985465
2085,hazard ratio with,C2985465
2085,hazard ratio or differencenmbr * ( nmbr % cl ) p - value,C2985465
2085,hazard ratio or differencenmbr ( nmbr % cl ) p - value,C2985465
2085,hazard ratio nmbr ),C2985465
2085,hazard ratio and nmbr % confidence interval,C2985465
2085,hazard ratio [nmbr % cl],C0596019;C2985465
2085,hazard ratio ( nmbr % confi dence interval ),C1272706;C1552654;C1552713;C2985465
2085,hazard ratio ( nmbr % cl],C0596019;C2985465
2085,hazard ratio ( nmbr % cl ) valsartan vs . placebo,C0216784;C0596019;C2985465
2085,hazard ratio ( nmbr % cl ) nmbr . nmbr ( nmbr . nmbr,C0596019;C2985465
2085,hazard ratio ( nmbr % cl ) nateglinide vs . placebo,C0596019;C0903898;C2985465
2085,hazard ratio ( nmbr % cl ) *,C0596019;C2985465
2085,"hazard ratio ( nmbr % cl ) """,C0596019;C2985465
2085,hazard ratio ( nmbr % cl ),C0596019;C2985465
2085,hazard ratio ( nmbr % c,C2985465
2085,hazard ratio,C2985465
2084,fondaparinux — no . ( % ),C1098510
2084,fondaparinux ( n = nmbr ),C1098510
2084,fondaparinux ( n = nmbr,C1098510
2084,fondaparinux,C1098510
2084,commercially available fondaparinux,C0470187;C1098510
2083,tadalafil nmbr mg n = nmbr,C0024671;C0026410;C0439269;C1176316;C1960952;C2346927;C4321396;C4521761
2083,tadalafil nmbr mg ( n = nmbr ),C0024671;C0026410;C0439269;C1176316;C1960952;C2346927;C4321396;C4521761
2083,tadalafil nmbr mg,C0024671;C0026410;C0439269;C1176316;C1960952;C2346927;C4321396;C4521761
2083,tadalafil nmbr . nmbr mg n = nmbr,C0024671;C0026410;C0439269;C1176316;C1960952;C2346927;C4321396;C4521761
2083,tadalafil nmbr . nmbr mg ( n = nmbr ),C0024671;C0026410;C0439269;C1176316;C1960952;C2346927;C4321396;C4521761
2083,tadalafil nmbr . nmbr mg,C0024671;C0026410;C0439269;C1176316;C1960952;C2346927;C4321396;C4521761
2083,tadalafil,C1176316
2082,both adalimumab groups ( n = nmbr ) no baseline cd - related antibiotic use,C1122087
2082,both adalimumab groups ( n = nmbr ) baseline immunosuppressant use,C1122087
2082,both adalimumab groups ( n = nmbr ) baseline cd - related antibiotic use,C1122087
2082,both adalimumab groups ( n = nmbr ),C1122087
2082,adalimumab group ( n = nmbr ) t,C0036669;C1122087
2082,adalimumab croup,C0010380;C1122087
2082,adalimumab ( n = nmbr ),C1122087
2082,adalimumab,C1122087
2081,oral aminosalicylates,C0368663;C0442027;C4521986
2081,no aminosalicylates,C0368663
2081,"nmbr - aminosalicylates ’ i "" i ‘",C0021966;C0221138;C0368663
2081,nmbr - aminosalicylates | | | |,C0368663
2081,nmbr - aminosalicylates {,C0368663
2081,aminosalicylates * *,C0368663
2081,aminosalicylates,C0368663
2081,aminosalicylate,C0368663;C2825094
2080,familial,C0015576;C0241888
2080,diagnosis of heterozygous familial hypercholester,C0011900;C0015576;C0019425;C0241888;C1704338;C1704656
2079,fema le,C0023190;C0439090;C1423767;C2697858
2078,terminal ileum,C0227327
2077,terrible,C3827840
2076,heritable,C0439660
2075,variablesnmbr,C0439828
2075,variables .,C0439828
2075,variables *,C0439828
2075,variables,C0439828
2075,variable_level,C0439828;C0441889;C0456079;C1547707;C2946261;C4553760
2075,variable ' ! ',C0439828;C4553760
2075,variable,C0439828;C4553760
2075,stratification variables,C0439828;C1514983
2075,efficacy variable,C0439828;C1280519;C1707887;C4553760
2075,diary variables,C0376660;C0439828
2075,demographic variable,C0011298;C0439828;C4553760
2074,nationality,C0027473
2073,paternal history,C0424909
2073,maternal history,C0559473
2072,haq alternative disability score,C0102923;C0231170;C0449820;C0451208;C1523987;C4050231
2072,alternative disability,C0231170;C1523987
2071,strategy,C0679199
2071,planned treatment strategy,C0599880;C0679199
2071,early invasive strategy ( n = nmbr,C0205281;C0679199;C1279919;C1334278
2071,conservative strategy ( n = nmbr,C0679199
2070,vasodilator,C0042402;C3537240
2070,other vasodilators §,C0042402
2070,other vasodilator,C0042402;C3537240
2070,iv vasodilator,C0022326;C0042402;C3537240;C4265176
2070,both iv vasodilator and inotrope,C0022326;C0042402;C3537240;C4265176
2069,clinically relevant non,C1518422;C2347946
2069,any relevant infarct,C0021308;C2347946
2068,country : argentina ( n = nmbr ),C0003761;C0454664;C1504311;C1511538
2068,argentina,C0003761;C1504311
2067,st segment elevation,C0520886
2067,st elevation,C0520886
2067,st - segment elevation mi,C0520886;C3810814
2067,st - segment elevation,C0520886
2067,st - elevation mi,C0520886;C3810814
2067,non - st — elevation mi,C0520886;C1518422;C3810814
2067,non - st - segment elevation mi,C0520886;C1518422;C3810814
2067,non - st - segment elevation acs,C0520886;C0742343;C1518422;C4318612
2067,non - st - segment elevation,C0520886;C1518422
2067,non - st - elevation mi,C0520886;C1518422;C3810814
2066,gt + tt,C1435727;C1452561;C1704693;C2697657;C4554543
2066,gt,C1435727;C1704693;C2697657
2065,ga / a,C0016993
2065,ga,C0016993
2065,a / ga,C0016993
2064,proton pump inhibitors,C0358591;C1384478;C3540020
2064,proton pump inhibitor use,C0042153;C0358591;C0457083;C1947944;C3536754;C4521480
2064,proton pump inhibitor ( n,C0358591;C3536754;C4521480
2064,proton pump inhibitor,C0358591;C3536754;C4521480
2064,proton - pump inhibitors,C0358591;C1384478;C3540020
2064,proton - pump inhibitor,C0358591;C3536754;C4521480
2063,regular ppi use,C0205272;C0358591;C0871125;C3811894
2063,ppi use within nmbr months of randomization,C0358591;C0871125;C3811894
2063,ppi use at baseline,C0358591;C0871125;C3811894
2063,ppi use ( p = nmbr . nmbrt ),C0358591;C0871125;C3811894
2063,ppi use ( p = nmbr - nmbrt ),C0358591;C0871125;C3811894
2063,ppi use,C0358591;C0871125;C3811894
2063,ppi or hnmbr receptor antagonist,C0358591;C0871125;C3811894
2063,ppi but no aspirin,C0358591;C0871125;C3811894
2063,ppi,C0358591;C0871125;C3811894
2063,nontrial ppi,C0358591;C0871125;C3811894
2063,non - study ppi use,C0358591;C0557651;C0871125;C1518422;C2603343;C3811894
2063,no regular ppi use,C0205272;C0358591;C0871125;C3811894
2063,no ppi,C0358591;C0871125;C3811894
2062,pt,C0032743;C0699718
2062,event / patients ( nmbr / pt - y ),C0030705;C0032743;C0441471;C0699718;C4019010
2062,diet diet + pravastatin event / patients ( nmbrooo / pt - y ),C0012155;C0012159;C0030705;C0032743;C0085542;C0441471;C0699718;C1519433;C2983588;C3668949;C4019010
2061,vdz / pbo [n = nmbr],C0031962
2061,pbo n = nmbr,C0031962
2061,pbo n ( % ),C0031962
2061,pbo - sc every other week ( n = nmbr ),C0031962;C0282380
2061,pbo + mtx^mtx,C0025677;C0031962;C1417487
2061,pbo + mtx to mtx,C0025677;C0031962;C1417487
2061,pbo + mtx n = nmbr,C0025677;C0031962;C1417487
2061,pbo + mtx,C0025677;C0031962;C1417487
2061,pbo ( nnmbr nmbr ),C0031962
2061,pbo ( nnmbr ),C0031962
2061,pbo ( n   =   nmbr ),C0031962
2061,pbo ( n nmbr nmbr ),C0031962
2061,pbo ( n = nmbr ) vs,C0031962
2061,pbo ( n = nmbr ),C0031962
2061,pbo ( n - nmbr ),C0031962
2061,pbo,C0031962
2061,ind + pbo ( n = nmbr ),C0031962;C4049864
2061,flex pbo ®,C0031962
2060,study period fatal pe,C0070939;C0439531;C0557651;C1302234;C1705232;C1880476;C1948053;C2603343;C4284304
2060,pe ± dvt,C0070939;C0149871;C1880476;C2926618;C3899446;C4284304
2060,pe with / without dvt,C0070939;C1880476;C4284304
2060,pe only,C0070939;C0205171;C1720467;C1880476;C4284304
2060,pe associated with dvt at diagnosis,C0070939;C1880476;C4284304
2060,pe and dvt,C0070939;C1880476;C4284304
2060,pe ( with or without dvt ),C0070939;C1880476;C4284304
2060,pe,C0070939;C1880476;C4284304
2060,neither pe nor dvt,C0070939;C1880476;C4284304
2059,dupilumab nmbr,C3660996
2058,mepolizumab,C0969324
2057,vedolizumab n = nmbr,C2742797
2057,vedolizumab cohort nmbr ( n = nmbr ),C0009247;C0599755;C2742797
2057,vedolizumab,C2742797
2056,benralizumab qnmbrw ( n = nmbr ),C2982078
2056,benralizumab qnmbrw ( n - nmbr ),C2982078
2056,benralizumab nmbr mg qnmbrw ( n = nmbr ),C0024671;C0026410;C0439269;C1960952;C2346927;C2982078;C4321396;C4521761
2056,benralizumab nmbr mg qnmbrw,C0024671;C0026410;C0439269;C1960952;C2346927;C2982078;C4321396;C4521761
2056,benralizumab,C2982078
2056,"b . benralizumab nmbr mg qnmbrw """,C0024671;C0026410;C0439269;C1960952;C2346927;C2982078;C4321396;C4521761
2055,lebrikizumab nmbr mg ( n = nmbr ),C0024671;C0026410;C0439269;C1960952;C2346927;C2981360;C4321396;C4521761
2055,lebrikizumab nmbr mg,C0024671;C0026410;C0439269;C1960952;C2346927;C2981360;C4321396;C4521761
2055,lebrikizumab nmbr - nmbr mg ( n = nmbr ),C0024671;C0026410;C0439269;C1960952;C2346927;C2981360;C4321396;C4521761
2055,lebrikizumab nmbr - nmbr mg,C0024671;C0026410;C0439269;C1960952;C2346927;C2981360;C4321396;C4521761
2055,lebrikizumab ( n = nmbr ),C2981360
2054,reslizumab nmbr . nmbr   mg / kg ( n   = nmbr ),C0439272;C1869620
2054,reslizumab nmbr . nmbr mg / kg ( n = nmbr ),C0439272;C1869620
2054,reslizumab ( n = nmbr ),C1869620
2054,reslizumab,C1869620
2054,b reslizumab nmbr . nmbr mg / kg n / n,C0439272;C1869620
2054,a reslizumab nmbr . nmbr mg / kg n / n,C0439272;C1869620
2053,low molecular weight heparin,C0019139;C3536766
2053,low molecular weight ( lmw ) heparin before randomisation,C0019139;C0034656;C3536766
2053,low - molecular weight heparin or intravenous unfractionated heparin,C0019139;C3536766
2053,low - molecular - weight heparin — no . ( % ),C0019139;C3536766
2053,low - molecular - weight heparin only,C0019139;C0205171;C1720467;C3536766
2053,low - molecular - weight heparin,C0019139;C3536766
2053,lmwh,C0019139;C3536766
2053,enrollment in lmwh substudy,C0019139;C1516879;C1696073;C3536766;C3888021
2053,enrollment in lmwh,C0019139;C1516879;C1696073;C3536766;C3888021
2052,other atherosclerotic event,C0333482;C0441471;C4019010
2052,other atherosclerotic cvdd,C0333482;C1859330
2052,other atherosclerotic cvd st depression on,C0007222;C0333482;C0520887
2052,other atherosclerotic cvd * *,C0007222;C0333482
2052,other atherosclerotic cvd,C0007222;C0333482
2052,other atherosclerotic,C0333482
2052,clinical atherosclerotic disease *,C0012634;C0205210;C0333482
2052,atherosclerotic disease *,C0012634;C0333482
2052,atherosclerotic disease ( % ),C0012634;C0333482
2052,atherosclerotic cvdj,C0333482
2052,atherosclerotic cvd §,C0007222;C0333482
2052,atherosclerotic cvd,C0007222;C0333482
2051,previous aorta - femoral or lower extremity bypass surgery,C0003483;C0205156;C1552607
2051,aortic,C0003483
2050,non ‐ haemorrhagic stroke — no . ( % ),C0333275;C1518422
2050,hemorrhagic,C0333275
2050,haemorrhagic,C0333275
2049,• hemorrhagic stroke,C0553692
2049,primary hemorrhagic stroke,C0205225;C0439612;C0439631;C0553692
2049,hemorrhagic stroke ( n = nmbr ),C0553692
2049,hemorrhagic stroke,C0553692
2049,haemorrhagic stroke — no . ( % ),C0553692
2049,haemorrhagic stroke,C0553692
2048,mestizos,C0682082
2047,omeprazole,C0028978
2046,role emotional,C0013987;C0035820;C0849912;C1705810;C3871154
2046,emotional role,C0013987;C0035820;C0849912;C1705810;C3871154
2045,gemfibrozil ( n = nmbr,C0017245
2045,gemfibrozil,C0017245
2044,lesion characteristics,C1286326
2043,subject characteristics,C0681884;C1519021;C1706465
2043,study eye characteristics,C0015392;C0700042;C1568011
2042,patients ' characteristics age ( years ),C0815172;C1510829
2042,patients ' characteristics,C0815172
2042,patient characteristics,C0815172
2041,disease characteristics *,C0599878
2041,disease characteristics,C0599878
2041,demographic / disease characteristics at baseline,C0011298;C0012634;C0168634;C0599878;C0683970;C1442488;C4684572
2040,radiographic characteristics at baseline and randomization,C0444708;C4684572
2040,no baseline characteristics,C4684572
2040,baseline characteristics,C4684572
2039,selected clinical characteristics — no . / total no . ( % ),C0683325;C1707391
2039,selected clinical characteristics,C0683325;C1707391
2039,other clinical characteristics,C0683325
2039,clinical characteristics ( % ),C0683325
2039,clinical characteristics,C0683325
2038,geographical location,C4545686
2037,demographic data,C4684639
2036,variable demographic characteristics,C0439828;C0683970;C4553760
2036,demographic features,C0683970
2036,demographic feature,C0683970
2036,demographic characteristics,C0683970
2035,potential predictor,C2698872;C3245505
2034,postprandial indices,C0376674;C4033634
2033,reported in ecrf,C0684224;C0700287;C4319718;C4551412
2033,reported diabetes mellitus,C0011849;C0684224;C0700287;C4319718
2032,prevalent vertebral fracture status,C0033105;C0080179;C0220900;C0449438
2032,prevalent vertebral fracture,C0033105;C0080179;C0220900
2032,prevalent cvd,C0007222;C0033105;C0220900
2032,number of prevalent vertebral fractures,C0033105;C0080179;C0220900;C0237753;C0449788
2032,fracture status prevalent vertebral fractured,C0016658;C0033105;C0220900;C0449438;C0549207;C4554413
2031,mycophenolate ( any derivative ),C0883242
2030,propionic acid derivatives,C0033482;C0695274;C3540752
2029,dopa and dopa derivativese,C0013023
2028,adamantane derivatives,C3653470
2027,verifynow pru - defined hpr ( % patients ),C0030705;C1337105;C1704788;C3539106
2027,other defined,C1704788;C3539106
2026,nmbr μ g bid ( n = nmbr ),C0439267
2026,nmbr μ g ( n = nmbr ),C0439267
2026,formoterol nmbr   μ g ( n   =   nmbr ),C0060657;C0439267
2026,bone mineral density ( g / cmnmbr ),C0005938;C0177804;C0439267
2026,bdp / ff / g ( n = nmbr ),C0004906;C0439267;C1422585;C1538710;C4554348
2026,aclidinium nmbr   μ g bid ( n   =   nmbr ),C0439267;C2699757
2026,aclidinium nmbr   μ g ( n   =   nmbr ) b,C0439267;C2699757
2026,aclidinium nmbr   μ g ( n   =   nmbr ) a,C0439267;C2699757
2026,aclidinium nmbr   μ g ( n   =   nmbr ),C0439267;C2699757
2025,nosnmbr glunmbrasp g . t,C0125690;C0326287;C0439267;C1518425
2025,glunmbrasp g . t,C0125690;C0439267
2024,very g ood / ex cellent,C0439267;C0442824;C2984081;C4267693
2024,g - blockers,C0439267
2024,g + c,C0439267
2023,nmbr a . g,C0439267
2023,g,C0439267
2023,aa / g,C0282379;C0439267;C1235746;C1882141;C4554792
2022,qrs width,C0487742
2021,qrs duration > nmbr ms,C0429025;C0488377;C2349943;C3539704;C3713294
2021,qrs duration,C0429025;C0488377
2020,persistent wrf ( n = nmbr ),C0205322;C0332996
2020,persistent or permanent immobilization,C0205322;C0332996
2020,persistent or paroxysmal,C0205322;C0332996
2020,persistent faol ( n [ nmbr ),C0205322;C0332996
2020,persistent faod ( n [ nmbr ),C0205322;C0332996
2020,persistent af,C0205322;C0332996;C0344434;C4049859
2020,persistent / permanent,C0205322;C0205355;C0332996
2020,persistent *,C0205322;C0332996
2020,persistent ( n,C0205322;C0332996
2020,persistent,C0205322;C0332996
2020,no persistent wrf ( n = nmbr,C0205322;C0332996
2020,long - standing persistent,C0205166;C0205322;C0231472;C0332996;C1706317
2019,very high vs . normalb,C0442804;C4321397
2019,very high vs . normal,C0442804;C4321397
2019,very high ( >   nmbrxuln ) n   =   nmbr,C0442804;C4321397
2019,very high,C0442804;C4321397
2018,the netherlands,C0027778
2017,erysipelas,C0014733
2016,predictive factor,C0683956
2015,heart disease risk factors,C0741920
2014,repaired s - p shunts,C0205340
2014,repaired chd,C0205340;C0280604;C3542407
2013,pre - specified trial endpoints,C2826245
2013,pre - specified hr ( nmbr % cl ),C2826245
2012,preferred term,C1709637;C2347664
2011,any recurrent stroke,C2242682
2011,all recurrent strokes,C1836785
2010,requiring assistance,C0018896;C1269765
2010,nmbr = help needed  still independent,C1269765;C1552861
2009,extreme tortuosity,C0205403;C0333076;C3641272;C4085555
2008,very severe n z nmbr,C3641272;C4050419
2008,very severe copd,C0024117;C1412502;C3641272;C3714496;C4050419
2008,very severe ( itt ) ( n = nmbr ),C3641272;C4050419
2008,very severe ( gold nmbr ),C0018026;C1304897;C3641272;C4050419
2008,very severe,C3641272;C4050419
2008,nmbr - nmbr ( very severe ),C3641272;C4050419
2007,esr — mm / hr,C3811131;C4330985;C4554674
2007,esr ( mm / hour ),C0439227;C0564385;C3811131;C4330985;C4554674
2007,esr ( mm / hour  per unit ),C0456685;C3811131;C4330985;C4554674
2007,esr ( mm / h ),C0456680;C3811131
2006,esr,C3811131
2006,er visit,C0545082;C1512346;C2826704;C3810541;C3811131
2005,trend / het . test,C1521798;C4554533
2005,test for trend,C0022885;C0039593;C0392366;C0456984;C1515976;C1521798;C3831328;C4318744;C4554533
2005,pvaluefor trend,C1521798;C4554533
2005,p value for trend across tertiles,C1521798;C1709380;C4554533
2005,p value for trend *,C1521798;C1709380;C4554533
2005,p value for trend,C1521798;C1709380;C4554533
2005,p trend,C0369773;C1521798;C2603361;C4554533
2005,p j nmbr * trend,C1518835;C1521798;C4554533
2005,p for trend -,C0369773;C1521798;C2603361;C4554533
2005,p for trend,C0369773;C1521798;C2603361;C4554533
2005,p - value for trend across categories,C1521798;C1709380;C4554533
2005,p - value for trend *,C1521798;C1709380;C4554533
2005,p - value ( trend ),C1521798;C1709380;C4554533
2004,systoiic biood pressure,C0033095;C0460139;C1306345;C4284008
2004,pressure ( mm hg ),C0033095;C0439475;C0460139;C1306345;C4284008
2004,pressure,C0033095;C0460139;C1306345;C4284008
2004,diastoiic biood pressure,C0033095;C0460139;C1306345;C4284008
2003,other / mixed ( n = nmbr ),C0205430;C3160715
2003,mixed ( n = nmbr ),C0205430;C3160715
2003,mixed ( itt ) ( n = nmbr ),C0205430;C3160715
2003,mixed,C0205430;C3160715
2003,insulin lispro mix nmbr,C0205430;C0293359;C1421951;C1720722;C4553942
2002,other / missing,C1551393;C1705492;C3272743
2002,missing hb at yr nmbr,C0019046;C0439234;C1551393;C1705492;C3272743
2002,missing ed duration ( y ),C0449238;C1551393;C1705492;C2926735;C3272743;C3538926
2002,missing *,C1551393;C1705492;C3272743
2002,missing,C1551393;C1705492;C3272743
2001,vitamins,C0042890;C3540032;C3714649
2001,other plain vitamin preparations,C0042890
2000,vitamin e,C0042874;C3714803
2000,nmbr vitamin e ( n = nmbr nmbr ),C0042874;C3714803
2000,nmbr vitamin e,C0042874;C3714803
2000,i vitamin e ( n = nmbr ),C0021966;C0042874;C0042890;C0221138;C0683454;C3714803
2000,i vitamin e,C0021966;C0042874;C0042890;C0221138;C0683454;C3714803
1999,vitamin d §,C0014695;C0042866;C2936842;C3537249;C3714503
1999,serum vitamin d ( nmol / l ),C0014695;C0042866;C0229671;C0439282;C1546774;C1550100;C2936842;C3537249;C3714503
1999,nmbr ( oh ) vitamin d ( ng / ml ),C0014695;C0042866;C0220853;C0439275;C2936842;C3537249;C3714503
1999,daily dose of vitamin d ( iu / day ),C0014695;C0042866;C0439465;C2348070;C2936842;C3537249;C3714503
1999,baseline vitamin - d,C0014695;C0042866;C0168634;C1442488;C2936842;C3537249;C3714503
1998,verapamil ( n,C0042523
1998,use of verapamil or quinidine,C0042523;C1524063
1997,verapamil sr strategy ( n = nmbr,C0679199;C1527129
1997,verapamil sr n = nmbr no . ( % ),C1527129
1997,verapamil sr n = nmbr,C1527129
1997,verapamil sr ( no . = nmbr ),C1527129
1997,verapamil sr,C1527129
1997,verapamil - sr strategy,C0679199;C1527129
1997,verapamil - sr ( « = nmbr nmbr ),C1527129
1996,vldl cholesterol,C0023826;C0523560
1996,vldl - c,C0523560
1996,vldl,C0523560
1995,ldlc : hdlc,C1416822;C1704429
1995,ldlc,C1416822
1994,ld,C0694649
1994,cg / ld,C0043444;C0694649;C1567075;C3540479
1994,< nmbr . nmbr ld,C0694649
1993,severity ofcopd ( goldnmbr ),C0018026;C0439793;C0522510;C1304897
1993,severity of the disease ( gold nmbr ),C0018026;C0521117;C1304897
1993,gold stage — no . ( % ) * *,C0018026;C1304897
1993,gold stage iv,C0018026;C0022326;C0205390;C1300072;C1304897;C1306673;C4265176
1993,gold stage [n ( % ) ],C0018026;C0205390;C1300072;C1304897;C1306673
1993,gold stage ( % ) f,C0016327;C0018026;C0205390;C1300072;C1304897;C1306673
1993,gold stage ( % ) : c,C0018026;C0441785;C1304897
1993,gold stage #,C0018026;C0205390;C1300072;C1304897;C1306673
1993,gold stage,C0018026;C0205390;C1300072;C1304897;C1306673
1993,gold nmbr - nmbr ( « = nmbr ),C0018026;C1304897
1993,gold nmbr - nmbr ( n = nmbr ),C0018026;C1304897
1993,gold nmbr - nmbr,C0018026;C1304897
1993,gold nmbr ( « = nmbr ),C0018026;C1304897
1993,gold nmbr,C0018026;C1304897
1993,gold ii,C0018026;C1304897;C1710602;C4082587
1993,gold groups a - d using mmrcb,C0018026;C1304897
1993,gold group d — no . ( % ) | |,C0018026;C0441838;C1304897
1993,gold grades nmbr - nmbr ( percent - predicted fev ( ),C0018026;C1304897
1993,gold grade nmbr and ics users at screening,C0018026;C0441800;C0919553;C1304897;C3244287
1993,gold grade nmbr and ics non - users at screening,C0018026;C0441800;C0919553;C1304897;C3244287
1993,gold d,C0018026;C1304897
1993,gold c,C0018026;C1304897
1993,gold b,C0018026;C1304897
1993,gold a,C0018026;C1304897
1993,gold,C0018026;C1304897
1993,copd severity stage ( gold ),C0018026;C0024117;C0205390;C0439793;C0522510;C1300072;C1304897;C1306673;C1412502;C3714496
1992,ind / glynmbr / nmbr pg o . d . n = nmbr,C0017890;C0523677;C2827928;C4049864
1992,ind / gly n = nmbr,C0017890;C0523677;C4049864
1992,ind / gly ( n = nmbr ),C0017890;C0523677;C4049864
1992,ind / gly,C0017890;C0523677;C4049864
1992,ind + gly ( n = nmbr ),C0017890;C0523677;C4049864
1992,gly nmbr μ g bid,C0017890;C0439267;C0523677
1992,gly,C0017890;C0523677
1992,annualized rate ind / gly sfc,C0017890;C0523677;C0871208;C1521828;C4049864;C4521536
1992,abbreviations :   teae  treatment - emergent adverse event  gly  glycopyrrolate inhalation solution  bid  twice daily .,C0000723;C0017890;C0017970;C0523677;C0585361;C1154181;C4684800
1991,charm,C0849759
1990,three arm,C0205449;C0446516;C3715044;C4553528
1990,s arm,C0446516;C0565930;C2603362;C3715044;C4553528
1990,arm,C0446516;C3715044;C4553528
1989,hungary,C0020174
1988,voluntary,C0439656;C3543419
1987,sedentary,C0205254
1986,pregnancy,C0032961
1985,organic,C0747055
1984,lrg,C1428862
1983,hrg,C1437978;C1705020
1982,other cardiovascular risk factors,C0850624
1982,nonglycemic cardiovascular risk factors,C0850624
1982,cardiovascular risk factors — no . { % ),C0850624
1982,cardiovascular risk factors — no . / total no . ( % ),C0850624
1982,cardiovascular risk factors and medical history,C0850624
1982,cardiovascular risk factors and history — no . ( % ),C0850624
1982,cardiovascular risk factors and history ( % ),C0850624
1982,cardiovascular risk factors and history,C0850624
1982,cardiovascular risk factors alone ( n = nmbr ),C0205171;C0439044;C0679994;C0850624
1982,cardiovascular risk factors,C0850624
1982,cardiovascular risk factor — no . { % ),C0850624
1982,at least two cardiovascular risk factors,C0205448;C0850624
1981,smoking ( % ) laboratory parameters,C0022877;C0037369;C0449381;C0453996;C1881674;C3244292;C4283904
1981,laboratory variables at baseline,C0022877;C0168634;C0439828;C1442488;C3244292;C4283904
1981,laboratory variables,C0022877;C0439828;C3244292;C4283904
1981,laboratory values,C0022877;C0042295;C3244292;C4283904
1981,laboratory parameters,C0022877;C0449381;C3244292;C4283904
1981,laboratory measures,C0022877;C3244292;C4283904
1981,laboratory evaluations,C0022877;C0220825;C3244292;C4283904
1981,laboratory determinations,C0022877;C0680730;C3244292;C4283904
1981,laboratory data,C0022877;C1511726;C3244292;C3245479;C3714741;C4283904
1981,laboratory ae,C0022877;C3244292;C3887670;C4283904
1981,baseline laboratory values,C0022877;C0042295;C0168634;C1442488;C3244292;C4283904
1980,peri - op amiodarone : no ( n = nmbr ),C0002598;C0347985
1980,no amiodarone,C0002598
1980,i amiodarone,C0002598;C0021966;C0221138
1980,amiodarone vs . placebo no . hazard ratio ( nmbr . nmbr % cl ),C0002598
1980,amiodarone vs . placebo,C0002598
1980,amiodarone use at baseline yes nmbr,C0002598;C0042153;C0168634;C0457083;C1442488;C1549445;C1705108;C1710701;C1947944
1980,amiodarone use at baseline,C0002598;C0042153;C0168634;C0457083;C1442488;C1947944
1980,amiodarone ote at baseline,C0002598;C0168634;C1442488
1980,amiodarone ( n = nmbr ),C0002598
1980,amiodarone ( n,C0002598
1980,amiodarone,C0002598
1979,vorapaxar placebo nmbr - yr . km % rate,C0032042;C0439234;C0871208;C1521828;C1696465;C1706408;C2974521;C3887676
1979,vorapaxar placebo nmbr - yr . km %,C0032042;C0439234;C1696465;C1706408;C2974521;C3887676
1979,vorapaxar placebo nmbr - yr %,C0032042;C0439234;C1696465;C1706408;C2974521
1979,vorapaxar placebo,C0032042;C1696465;C1706408;C2974521
1979,vorapaxar no . ( nmbr - y km % ),C2974521
1979,vorapaxar nmbr - y,C2974521
1979,vorapaxar n = nmbr,C2974521
1979,vorapaxar group ( n = nmbr ),C0441848;C2974521
1979,vorapaxar ( n = nmbr nmbr ),C2974521
1979,vorapaxar ( n = nmbr . nmbr ),C2974521
1979,vorapaxar ( n = nmbr ),C2974521
1979,vorapaxar ( n = nmbr,C2974521
1979,vorapaxar,C2974521
1978,inspiratory capacity ( l ),C0021610;C0802663
1977,respiratory rate ( breaths / min ),C0231832;C0439386;C0489258
1977,respiratory rate,C0231832;C0489258
1976,upper respiratory tract inflammation,C0877266
1975,upper respiratory tract infection nmbr ( nmbr . nmbr ),C0041912
1975,upper respiratory tract infection,C0041912
1974,respiratory medication taken at baseline,C0418986
1974,respiratory medication ( % ),C0418986
1974,( b ) concomitant respiratory medications [n ( % ) ],C0418986;C0521115
1973,spironolactone ( n = nmbr ),C0037982
1973,spironolactone,C0037982
1973,outcomes by treatment ( spironolactone vs placebo ),C0037982;C0085415
1973,mra ( spironolactone or eplerenone ),C0037982;C0243032;C1609165;C3891069
1972,gaviscon da ( n = nmbr ),C0011318;C0061146;C3668815
1972,> nmbr da of capillary nonperfusion in the eyec,C0006901;C0011318;C0935624;C3668815
1971,oral contraceptives,C0009905
1971,oral contraceptive pills — no . / total no . ( % ),C0009905;C0009906;C0029151
1970,pdqol scale,C0175659;C0349674;C1947916
1970,pasi score ( nmbr – nmbr scale ),C0175659;C0349674;C0449820;C1947916;C4050231;C4528685
1970,mmrc dyspnea scale,C0013404;C0175659;C0349674;C1947916;C1963100;C3826977
1970,mean ( sd on loge scale ) u / ml,C0175659;C0349674;C0439340;C0444504;C1880521;C1947916;C2347634;C2348143;C2697934;C2699239;C2945590
1970,jsn score ( nmbr – nmbr scale ),C0175659;C0349674;C0449820;C1947916;C4050231
1970,haq score ( nmbr – nmbr scale ),C0102923;C0175659;C0349674;C0449820;C0451208;C1947916;C4050231
1970,geometric mean ige on loge scale — u / ml,C0175659;C0349674;C0439340;C1880521;C1947916;C2697934;C2945590;C2986759
1970,geometric mean blood eosinophil count on loge scale — cells / ^ljj,C0175659;C0200638;C0349674;C1947916;C2697934;C2986759
1970,geometric mean blood eosinophil count ( sd on a loge scale ) — cells / mmnmbr,C0175659;C0200638;C0349674;C1947916;C2697934;C2699239;C2986759;C4330985;C4554674
1970,( scale obesity and prediabetes ),C0028754;C0175659;C0349674;C1947916;C1963185
1970,( scale diabetes ),C0011847;C0011849;C0175659;C0349674;C1947916
1969,nmbr - minute walk distance — m,C0369637;C0429886;C0439232;C0441923;C0700321;C0702093;C1282918;C2347166
1969,nmbr - min walk distance m,C0369637;C0429886;C0441923;C0702093;C1524029;C3813700
1969,nmbr - min walk distance ( m ),C0369637;C0429886;C0441923;C0702093;C1524029;C3813700
1969,nmbr - min walk distance,C0429886;C0702093;C1524029;C3813700
1968,£ nmbr ml / minute,C0439232;C0439526;C0700321;C0702093;C1282918;C1705224;C2347166;C3887665
1968,supine after nmbr minutes change from baseline,C0038846;C0439232;C0700321;C0702093;C1282918;C2347166
1968,standing after nmbr minutes change from baseline,C0231472;C0439232;C0700321;C0702093;C1282918;C2347166
1968,standing after nmbr minute change from baseline,C0231472;C0392747;C0439232;C0443172;C0700321;C0702093;C1282918;C1705241;C2347166;C4319952
1968,nmbr to < nmbr ml / minute,C0439232;C0439526;C0700321;C0702093;C1282918;C1705224;C2347166;C3887665
1968,minutes from symptom onset to prehospital ecg,C0439232;C0700321;C0702093;C1282918;C2347166;C4086878
1968,minutes from prehospital ecg to pci,C0439232;C0700321;C0702093;C1282918;C1623258;C2347166
1968,minutes from pre - pci angiography to post - pci angiography,C0002978;C0332152;C0439232;C0700321;C0702093;C0740175;C1282918;C2257086;C2347166;C3669034;C4049621
1968,< nmbr ml / minute ),C0439232;C0439526;C0700321;C0702093;C1282918;C1705224;C2347166;C3887665
1968,< nmbr ml / minute,C0439232;C0439526;C0700321;C0702093;C1282918;C1705224;C2347166;C3887665
1968,( < nmbr ml / minute ) *,C0439232;C0439526;C0700321;C0702093;C1282918;C1705224;C2347166;C3887665
1967,£ nmbr min,C0702093;C1524029;C3813700
1967,£ nmbr . nmbr min,C0702093;C1524029;C3813700
1967,range : min,C0702093;C1514721;C1524029;C2348147;C3542016;C3813700
1967,range ( min,C0702093;C1514721;C1524029;C2348147;C3542016;C3813700
1967,pnmbr min twice / week,C0332174;C0369773;C0439230;C0702093;C1524029;C1720725;C1948050;C2603361;C3813700
1967,pifr l / min,C0702093;C1524029;C3813700
1967,pefpm   ( l / min ) ∗,C0702093;C1524029;C3813700
1967,pefam   ( l / min ) ∗,C0702093;C1524029;C3813700
1967,on - pump time : < l : nmbrhrs : min ( n = nmbr ),C0040223;C0702093;C1524029;C1568891;C3541383;C3813700;C3842462
1967,nmbr min twice / week,C0332174;C0439230;C0702093;C1524029;C1720725;C1948050;C3813700
1967,nmbr min / time ),C0040223;C0702093;C1524029;C3541383;C3813700
1967,nmbr min,C0702093;C1524029;C3813700
1967,nmbr . nmbr min,C0702093;C1524029;C3813700
1967,nmbr - nmbr min,C0702093;C1524029;C3813700
1967,morning peak expiratory flow — liters / min,C0332170;C0475211;C0702093;C1518922;C1524029;C3813700
1967,min – max,C0702093;C1524029;C3813700
1967,min - ’,C0702093;C1524029;C3813700
1967,min - max age,C0001779;C0702093;C1524029;C3813700
1967,min - max,C0702093;C1524029;C3813700
1967,min,C0702093;C1524029;C3813700
1967,mean score ( min,C0702093;C1524029;C3533236;C3813700
1967,iduration of symptoms > nmbr min,C0683368;C0702093;C1457887;C1524029;C3813700
1967,cross - damp time : < l : llhrs : min ( n = nmbr ),C0040223;C0205381;C0702093;C1524029;C2828360;C3541383;C3813700;C3891560
1967,baseline in - check * ’ pifr ( l / min ),C0168634;C0702093;C1283174;C1442488;C1524029;C1555524;C3813700;C4321547
1967,baseline heart rate ( beat / min ),C0168634;C0425583;C0702093;C0871208;C1442488;C1521828;C1524029;C3813700
1967,[min,C0702093;C1524029;C3813700
1967,> nmbr to < nmbr ml / min / lnmbrnr,C0027496;C0702093;C1524029;C1635169;C3813700;C3844738
1967,> nmbr min,C0702093;C1524029;C3813700
1967,> nmbr mi / min,C0702093;C1524029;C3810814;C3813700
1967,> nmbr . nmbr min,C0702093;C1524029;C3813700
1967,< nmbr min,C0702093;C1524029;C3813700
1967,< nmbr mi / min,C0702093;C1524029;C3810814;C3813700
1967,< nmbr . nmbr min,C0702093;C1524029;C3813700
1967,( sd ) l / min acq - nmbr score,C0702093;C1524029;C2699239;C2919686;C3813700
1967,( min ) *,C0702093;C1524029;C3813700
1966,£ nmbr ( men ) / £ nmbr ( women ),C0025266;C0043210
1966,waist circumference women : > nmbr in ( nmbr cm ) men : > nmbr in ( nmbr cm ) tc nmbrc nmbr mg / dl,C0025266;C0043210;C0455829
1966,waist circumference snmbr ( men ) or > nmbr cm ( women ),C0025266;C0455829
1966,sex ( men / women ),C0009253;C0025266;C0036864;C0043210;C0079399;C0804628;C1314687;C1522384
1966,nmbr - nmbr ( men ),C0025266
1966,men : qvainmbr - sfc,C0025266;C4521536
1966,men ( n 二 nmbr ),C0025266
1966,men ( n [ % ] ),C0025266
1966,men ( n = nmbr vs nmbr ),C0025266
1966,men ( n = nmbr nmbr ),C0025266
1966,men ( n = nmbr ),C0025266
1966,men ( n,C0025266
1966,men ( % ),C0025266
1966,gmi ( men ),C0025266
1966,< nmbr ( men ) / < nmbr ( women ),C0025266;C0043210
1965,men without ed ( n = nmbr ) nmbr . nmbr ± nmbr . nmbr,C0025266;C3538926
1965,men with ed ( n = nmbr ) nmbr . nmbr ± nmbr . nmbr,C0025266;C3538926
1965,low hdl - c ( for men < nmbr   mg / dl / for women < nmbr   mg / dl ),C0025266;C0151691;C0439269
1965,high hdl - c ( for men ≥ nmbr   mg / dl / for women ≥ nmbr   mg / dl ),C0025266;C0205250;C0439269;C1299351;C2700149;C3715113;C3887512;C3889660;C4321237;C4522209
1964,no . men,C0025266
1964,men,C0025266
1964,chd men,C0025266;C0280604;C3542407
1964,all men,C0025266
1963,renal fmclicn : creatntoe clearance,C0232813;C0699829
1962,renal insufficiencynmbr,C0035078;C1565489
1962,renal insufficiency — no . ( % ),C0035078;C1565489
1962,renal insufficiency or failure,C0035078;C1565489
1962,renal insufficiency / failure,C0035078;C0231174;C0231179;C0680095;C1565489;C1963154
1962,renal insufficiency *,C0035078;C1565489
1962,renal insufficiency,C0035078;C1565489
1962,renal failure,C0035078;C1963154
1961,previous treatment failure — no . ( % ) § * *,C0162643;C0205156;C0235828;C0521983;C1547544;C1552607
1961,lack of efficacy with > nmbr bdmard,C0235828
1961,lack of efficacy with > nmbr anti - interleukin nmbr,C0235828
1961,lack of efficacy,C0235828
1961,lack of effectiveness,C0235828
1960,hip circumference — cm,C0562350
1959,waist circumference — cmj,C0455829
1959,waist circumference — cm,C0455829
1959,waist circumference .,C0455829
1959,waist circumference ( cm ) : mean ± sd,C0444504;C0455829;C2347634;C2348143;C2699239
1959,waist circumference ( cm ),C0455829
1959,waist circumference,C0455829
1958,left circumflex,C0205091;C0443246;C1552822;C1880089
1958,circumflex,C1880089
1957,nonsustained ventricular tachycardia — no . ( % ) - j -,C0750194;C2919575
1956,other supraventricular tachycardia,C0039240;C1963244;C3815188
1955,supraventricular tachyarrhythmias ( incl . atrial,C1698480;C3853833
1954,ventricular tachycardia or fibrillation,C0042514;C0344428;C1963247;C4554446
1953,injectable anti ‐ hyperglycaemic,C1272883
1952,anti ‐ hyperglycaemic agent,C1321567
1951,use of antiarrhythmic agent,C0003195;C0301380;C1524063
1951,other antiarrhythmics^,C0003195
1951,any prerandomization failure of an antiarrhythmic drug — no . ( % ),C0003195;C0231174;C0301380;C0680095
1951,antiarrhythmics,C0003195
1951,antiarrhythmic drugs,C0003195
1951,antiarrhythmic drug,C0003195;C0301380
1951,antiarrhythmic agent,C0003195;C0301380
1951,antiarrhythmic,C0003195;C3537142
1951,anti arrhythmic,C0003195;C3537142
1950,tachyarrhythmias,C0080203
1949,ventricular tachyarrhythmias,C3827656
1948,prior arrhythmias,C0003811;C0332152;C2826257
1948,cardiac arrhythmia,C0003811;C0264886;C1560249
1948,arrhythmias,C0003811
1948,arrhythmia !,C0003811
1948,arrhythmia,C0003811
1947,conversion to sinus rhythm in < nmbr days,C1321500
1946,sinus rhythm at baseline,C0168634;C0232201;C1442488
1946,sinus rhythm,C0232201
1945,waist - to - hip,C0019552;C0022122;C0230097;C1505163;C3538851;C4284725
1945,waist ( cm ),C0230097
1944,waisthip ratio,C0205682;C0456603;C1547037
1944,waist : hip ratio,C0205682
1944,waist - to - hip ratio,C0205682
1944,waist - hip ratio,C0205682
1943,within last nmbr d,C1517741
1943,last study visit,C1517741
1942,basdainmbr,C1998004
1942,basdai ⁎ ⁎,C1998004
1942,basdai score ( nmbr - nmbr ),C1998004
1942,basdai score,C1998004
1942,basdai responses at week nmbr,C0332174;C0439230;C0871261;C1998004
1942,basdai question nmbr score ( nmbr - nmbr ),C1998004
1942,basdai,C1998004
1941,residence in asia,C0003980;C0237096
1941,getgoal - l - asia,C0003980
1941,asia pacific or other,C0003980
1941,asia pacific and south africa,C0003980
1941,asia pacific and other,C0003980
1941,asia pacific and africa,C0003980
1941,asia pacific ( n = nmbr ),C0003980
1941,asia pacific,C0003980
1941,asia and pacific islands,C0003980
1941,asia / pacific / other,C0003980
1941,asia / pacific ( % ),C0003980
1941,asia / pacific,C0003980
1941,asia - pacific region and south africa,C0003980;C0017446;C0205147
1941,asia - pacific hr ( nmbr % cl ),C0003980;C0596019
1941,asia - pacific and south africa,C0003980
1941,asia - pacific,C0003980
1941,asia ( n = nmbr ),C0003980
1941,asia ( n = nmbr,C0003980
1941,asia ( excluding japan ),C0003980;C0022341;C0332196;C2828389
1941,asia #,C0003980
1941,asia,C0003980
1940,total body ( without head ),C0018670;C0229960;C1706305
1940,total body,C0229960
1939,total bilirubin > nmbr x ulnnmbr,C0005437;C0368753;C1519815
1939,total bilirubin,C0005437;C0368753
1938,upper abdominal pain,C0232492
1937,sf - nmbr bodily pain,C0037712;C3890602
1937,bodily pain,C3890602
1936,persistent anemia bsl hb < nmbrg i - nmbr  yr nmbr < nmbrg i nmbr,C0019046;C0021966;C0221138;C0439234;C0741008;C1319635;C1549954
1936,no anemia bsl hb > nmbrg i - nmbr  yr nmbr > nmbrg i - nmbr,C0002871;C0019046;C0021966;C0221138;C0439234;C1000483;C1319635;C1549954;C4554633
1936,new anemia bsl hb > nmbrg i - nmbr  yr nmbr < nmbrg i - nmbr,C0002871;C0019046;C0021966;C0205314;C0221138;C0439234;C1000483;C1319635;C1549954;C4554633
1936,improving anemia bsl hb < nmbrg i - nmbr  yr nmbr > nmbrg i - nmbr,C0002871;C0019046;C0021966;C0221138;C0439234;C1000483;C1272745;C1319635;C1549954;C4554633
1936,cox bsl onlyc,C1549954;C1565830
1936,cox bsl + yr nmbr hbd,C0439234;C1549954;C1565830
1936,bsl hb,C0019046;C1549954
1935,nmbr - mercaptopurine / azathioprine,C0000618;C0004482
1935,nmbr - mercaptopurine,C0000618
1935,mercaptopurine,C0000618
1935,azathioprine / nmbr - mercaptopurine,C0000618;C0004482
1934,placebo + glimepiride,C0032042;C0061323;C1696465;C1706408
1934,glimepiride,C0061323
1933,scores for global and pain assessments §,C0205246;C0449820;C2348867
1932,generalized,C0205246
1932,general andthoracic epidural,C0205246;C0228134;C0812144;C3812897;C3891294;C4521767
1932,general and lumbar epidural,C0205246;C3812897;C3891294;C4521767
1932,general alone,C0205171;C0205246;C0439044;C0679994;C3812897;C3891294;C4521767
1932,general allergic events,C0205246;C0441471;C0700624;C3541888;C3812897;C3891294;C4521767
1932,general,C0205246;C3812897;C3891294;C4521767
1931,walk for exercise ( % ),C0015259;C0080331;C1522704
1931,walk for exercise,C0015259;C0080331;C1522704
1931,exercise times per week,C0015259;C0456698;C1522704
1931,exercise status,C0015259;C0449438;C1522704
1931,exercise at least weekly ( a ),C0015259;C1522704
1931,exercise > once weekly ?,C0015259;C1522704
1931,exercise > once weekly,C0015259;C1522704
1931,exercise ( % ),C0015259;C1522704
1931,exercise,C0015259;C1522704
1930,some physical activity,C0015259;C0026606
1930,physical activity §,C0015259;C0026606
1930,physical activity ( hours walking / wk ),C0015259;C0026606;C0439227
1930,physical activity,C0015259;C0026606
1930,intense physical activity,C0015259;C0026606;C0522510
1929,stage i ( gfr > nmbr ml / min per nmbr . nmbr mnmbr ) and stage v ( gfr < nmbr ml / min per nmbr . nmbr mnmbr ) were not considered because they included only nmbr and nmbr patient,C0007591;C0017654;C0021966;C0023806;C0221138;C0369637;C0439445;C0441766;C0441923;C0456533;C0702093;C1424601;C1524029;C3813700
1929,glomerular filtration rate §,C0017654;C1561549
1929,glomerular filtration rate ( ml / min / nmbr . nmbrma,C0017654;C0024443;C0439445;C1561549;C3887485
1929,glomerular filtration rate,C0017654;C1561549
1929,gfr nmbr nmbr,C0017654;C1424601
1929,gfr nmbr - nmbr,C0017654;C1424601
1929,gfr as assessed by mdrd,C0017654;C1424601
1929,gfr > nmbr,C0017654;C1424601
1929,gfr < nmbr,C0017654;C1424601
1929,gfr ( ml / min per nmbr . nmbr nr ),C0017654;C0027496;C0439445;C1424601;C3844738
1929,gfr ( mdrd ) ( ml / min / nmbr - nmbr mnmbr ),C0017654;C0369637;C0439445;C0441923;C1424601;C3839656
1929,estimated gfr — ml / min / nmbr . nmbr mnmbr,C0017654;C0369637;C0439445;C0441923;C0750572;C1424601
1929,estimated gfr — ml / min / nmbr . nmbr m^ |,C0017654;C0369637;C0439445;C0441923;C0750572;C1424601
1929,estimated gfr > nmbr ml / min / nmbr . nmbr mnmbr,C0017654;C0369637;C0439445;C0441923;C0750572;C1424601
1929,estimated gfr < nmbr ml / min / nmbr . nmbr mnmbr,C0017654;C0369637;C0439445;C0441923;C0750572;C1424601
1929,estimated gfr < nmbr ml / min / nmbr . nmbr m^ — no . ( % ),C0017654;C0369637;C0439445;C0441923;C0750572;C1424601
1929,estimated gfr ( ml / min per nmbr . nmbr mnmbr ),C0017654;C0369637;C0439445;C0441923;C0750572;C1424601
1929,estimated gfr ( ml / min / nmbr . nmbrmnmbr ),C0017654;C0369637;C0439445;C0441923;C0750572;C1424601
1929,estimated gfr ( ml / min / nmbr . nmbr mnmbr ) ^ |,C0017654;C0369637;C0439445;C0441923;C0750572;C1424601
1929,estimated gfr ( ml / min / nmbr . nmbr mnmbr ),C0017654;C0369637;C0439445;C0441923;C0750572;C1424601
1928,estimated gfr^,C0017654;C0750572;C1424601
1928,estimated gfr — no . ( % ) nmbr,C0017654;C0750572;C1424601
1928,estimated gfr — no . ( % ) ^ |,C0017654;C0750572;C1424601
1928,estimated gfr renal function stage,C0017654;C0205390;C0232804;C0750572;C1300072;C1306673;C1424601
1928,estimated gfr at baseline,C0017654;C0168634;C0750572;C1424601;C1442488
1928,estimated gfr,C0017654;C0750572;C1424601
1928,by gfr stratum tor diabetic participants,C0017654;C0076836;C0241863;C0679646;C1199517;C1419603;C1424601;C3539732
1928,by gfr stratum tor all participants,C0017654;C0076836;C1199517;C1419603;C1424601;C3539732
1928,by gfr stratum for diabetic participants,C0017654;C0241863;C0679646;C1424601
1928,by gfr stratum for all participants,C0017654;C0679646;C1424601
1927,sotagliflozin ( n = nmbr ),C3896939
1927,sotagliflozin,C3896939
1926,canagliflozin dose,C0178602;C0869039;C1114758;C2974540
1926,canagliflozin ( n = nmbr ),C2974540
1926,canagliflozin,C2974540
1925,ertugliflozin nmbrmg,C0024671;C0026410;C0439269;C1960952;C2346927;C4079805;C4321396;C4521761
1925,ertugliflozin nmbr   mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4079805;C4321396;C4521761
1925,ertugliflozin nmbr mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4079805;C4321396;C4521761
1925,ertugliflozin,C4079805
1924,dapagliflozin nmbr mg / day ( n = nmbr ),C0439422;C2353951
1924,dapagliflozin ( n = nmbr ),C2353951
1924,dapagliflozin,C2353951
1923,pooled empagliflozin ( n = nmbr ),C1709595;C2349200;C3490348;C4522255
1923,empagliflozin pooled ( n = nmbr ),C1709595;C2349200;C3490348;C4522255
1923,empagliflozin nmbr mg / day ( n = nmbr ),C0439422;C3490348
1923,empagliflozin ( n   =   nmbr ),C3490348
1923,empagliflozin ( n = nmbr ) nmbr . nmbr ± nmbr . nmbr,C3490348
1923,empagliflozin ( n = nmbr ),C3490348
1922,nmbr mg empagliflozin,C0024671;C0026410;C0439269;C1960952;C2346927;C3490348;C4321396;C4521761
1922,empagliflozin,C3490348
1921,who / idf ifg,C1334085;C1708411
1921,igt / ifg,C1334085;C1708411
1921,ifg pbo ( n = nmbr ) vs evomab ( n = nmbr ),C0031962;C1334085;C1708411
1921,ifg and igt,C1334085;C1708411
1921,ifg / igt,C1334085;C1708411
1921,ifg,C1334085;C1708411
1920,rolofylline rx,C0166128;C1425688;C1521941;C2709207
1920,rolofylline nmbr mg ( n = nmbr ),C0024671;C0026410;C0166128;C0439269;C1960952;C2346927;C4321396;C4521761
1920,rolofylline n,C0166128
1920,rolofylline ( n = nmbr ),C0166128
1920,rolofylline ( n = nmbr,C0166128
1920,rolofylline,C0166128
1919,theophyllines,C0039771
1919,theophylline compound,C0039771;C0205198;C1706082
1918,walking,C0080331;C4283795;C4321241;C4321242
1917,coping,C0009967
1916,vomiting,C0042963;C1963281;C3898969;C4084766;C4084767;C4084768;C4084769
1915,hong kong,C0019907;C2987742
1914,no smo king,C1311076;C1364142;C1423784
1913,headache,C0018681;C4553197
1912,hazard ratiof,C0598697
1912,hazard interaction,C0598697;C1704675
1912,hazard inleraction,C0598697
1912,hazard,C0598697
1911,haplotype,C0018591
1910,radiate,C0332301
1909,pramlintide,C0537551
1908,total hands score,C0018563;C0439175;C0439810;C1552914
1908,hands,C0018563;C1552914
1908,hand,C0018563;C1552914
1907,haq score,C0102923;C0451208
1907,haq pain scale,C0102923;C0451208;C1504479
1907,haq,C0102923;C0451208
1906,war,C0043027
1905,ainmbr,C0003504;C4551710
1904,ag,C0002037;C0051080;C0152305;C3888235
1903,base,C0002055;C0178499;C1880279
1902,mae,C0286540;C4085238
1901,racec,C4287599
1900,pace,C0287990;C1552930;C4048252
1899,stage ii,C0441767
1899,gold stage ii,C0018026;C0441767;C1304897
1898,stage iii,C0441771
1898,gold stage iii,C0018026;C0441771;C1304897
1897,q wave mi,C0861151
1897,q - wave mi,C0861151
1896,tass ’,C0559483
1895,class iii,C0441887;C2698969
1894,alpha glucosidase inhibitors,C1299007;C2756986;C3539108
1894,alpha - glucosidase inhibitors,C1299007;C2756986;C3539108
1894,agi,C1299007
1893,rash,C0015230
1892,asp,C0206293;C0206298;C1332656;C1528298;C3541260;C3890396;C4048238;C4321307;C4553371
1891,aa,C0282379;C1235746;C1882141;C4554792
1890,samanmbr,C1075468
1890,sama,C1075468
1889,trait,C0599883
1888,gait,C0016928
1887,paci ( n = nmbr ),C1165245
1887,paci,C1165245
1886,pasinmbra,C4528685
1886,pasinmbr,C4528685
1886,pasi^i,C0021966;C0221138;C4528685
1886,pasi nmbr,C4528685
1886,pasi [c],C4528685
1886,pasi < nmbr *,C4528685
1886,pasi *,C4528685
1886,pasi,C4528685
1885,taci ( n = nmbr ),C0666480;C1425349;C4284230
1885,taci,C0666480;C1425349;C4284230
1884,warfarin naive,C0043031
1884,warfarin n = nmbr n / n ( % ),C0043031
1884,warfarin n = nmbr,C0043031
1884,warfarin n / n  rate ( % ),C0043031;C0871208;C1521828
1884,warfarin ( snmbr % cl ),C0043031;C0596019
1884,warfarin ( n = nmbr ),C0043031
1884,warfarin ( n - nmbr,C0043031
1884,warfarin ( % ),C0043031
1884,warfarin % ( n / n ),C0043031
1884,warfarin,C0043031
1884,warf,C0043031
1884,> nmbr days warfarin,C0043031;C0439228
1883,intravenous vasoactive drugs,C0683092;C1980011
1882,intravenous vasodilators ( % ),C0443081
1881,non - pci intravenous unfractionated heparin,C0354566;C1518422;C4049621
1881,intravenous heparin,C0354566
1880,jugular venous distention > nmbr cm,C0425687
1880,jugular venous distension,C0425687
1879,total intravenous loop diuretics,C0348016;C0354100;C0439175;C0439810
1879,total intravenous loop diuretic ( mg ) median,C0024671;C0026410;C0348016;C0354100;C0439175;C0439269;C0439810;C0549183;C0876920;C1960952;C2346927;C2347635;C2348144;C2939193;C3536704;C4321396;C4521761
1879,intravenous nitrates,C0028125;C0348016
1879,intravenous loop diuretics !,C0348016;C0354100
1879,intravenous inotropes or vasopressors ( % ),C0348016;C1258199
1879,intravenous dobutamine,C0012963;C0348016
1879,intravenous ( n = nmbr ),C0348016
1878,tender and swollen joints — mean no . : :,C0234234
1878,tender - or painful - joint count ( of nmbr joints assessed ) — no .,C0234234
1878,tender,C0234234
1878,number of tender joints ( nmbr assessed ),C0234234;C0449813
1878,number of tender joints ( nmbr - nmbr ),C0234234;C0449813
1877,bpearson ' s chi ‐ square test .,C0008041
1876,pneumonia in past year,C0032285;C4086728
1876,over past nmbr years,C4086728
1875,bone erosion score,C0449820;C0587240;C4050231
1875,bone erosion ( judged by physician ),C0587240
1874,lower - limb angioplasty or bypass surgery,C0745788
1873,previous bypass surgery,C0205156;C1536078;C1552607
1873,bypass surgery,C1536078
1872,renal disease ),C0022658
1872,renal disease,C0022658
1872,previous renal disease,C0022658;C0205156;C1552607
1872,kidney disease ( usrds ),C0022658
1872,duration of chronic kidney disease * ( years ),C0022658;C0205191;C0439234;C0449238;C2926735
1871,nephropathy,C0022658
1871,contrast nephropathy risk score,C0009924;C0022658;C0035647;C0449820;C1979874;C4050231;C4552904
1870,week nmbr overall population,C0032659;C0282416;C0332174;C0439230;C1257890;C1561607
1870,remission in overall population,C0032659;C0282416;C0544452;C0687702;C1257890;C1561607
1870,overall ® nmbr . nmbr,C0282416;C1561607
1870,overall vero population,C0032659;C0282416;C1257890;C1561607
1870,overall treatment effect,C0282416;C1518681;C1561607
1870,overall study population,C0282416;C1561607;C2348561
1870,overall study period,C0282416;C1561607
1870,overall population ( n = nmbr ),C0032659;C0282416;C1257890;C1561607
1870,overall population ( n - nmbr ),C0032659;C0282416;C1257890;C1561607
1870,overall population,C0032659;C0282416;C1257890;C1561607
1870,overall pea population,C0030738;C0032659;C0069964;C0070939;C0282416;C1257890;C1262903;C1561607;C3257529
1870,overall pad,C0282416;C1561607
1870,overall nmbr,C0282416;C1561607
1870,overall n = nmbr,C0282416;C1561607
1870,overall n ( n / loopy ),C0282416;C1561607
1870,overall hr ( nmbr % cl ),C0282416;C0596019;C1561607
1870,overall freedom population ( n = nmbr ),C0016694;C0032659;C0282416;C1257890;C1561607
1870,overall effect,C0282416;C1280500;C1518681;C1561607;C2348382
1870,overall ctd,C0282416;C1335071;C1442905;C1561607
1870,overall cohort ( primary analysis ),C0086027;C0205225;C0282416;C0439612;C0439631;C1561607
1870,overall cohort ( post hoc analysis excluding metformin users ),C0025598;C0086027;C0282416;C0332196;C0687676;C1561607;C1704687;C1706077;C2828389;C3469826
1870,overall a phase population,C0282416;C1561607
1870,overall ( w = nmbr ),C0282416;C1561607
1870,overall ( pp ) ( n = nmbr ),C0030375;C0063017;C0282416;C1561607;C4319755
1870,overall ( per protocol ) ( n = nmbr ),C0282416;C1561607;C1698058
1870,overall ( nmbr,C0282416;C1561607
1870,overall ( n = unmbr ),C0282416;C0439148;C1561607
1870,overall ( n = nmbr vs nmbr ),C0282416;C1561607
1870,overall ( n = nmbr ),C0282416;C1561607
1870,overall ( n = nmbr,C0282416;C1561607
1870,overall ( itt ) ( n = nmbr ),C0282416;C1561607
1870,overall  qvainmbr - sfc,C0282416;C1561607;C4521536
1870,overall,C0282416;C1561607
1870,during overall study period,C0282416;C0439531;C0557651;C1561607;C1948053;C2603343
1870,calima overall ( n = nmbr ),C0282416;C1561607
1870,a . overall and subgroups bv statin potency - -,C0282416;C1561607
1870,- recurrent vte during overall study period,C0282416;C0439531;C0557651;C0630906;C1455761;C1561607;C1948053;C2603343;C2945760
1869,saba reversibility,C0449261
1869,reversibility ’ ' %,C0449261
1869,reversibility — %,C0449261
1869,reversibility to salbutamolc,C0449261
1869,reversibility to,C0449261
1869,reversibility stratum *,C0449261
1869,reversibility snmbr % ( itt ) ( n = nmbr ),C0449261
1869,reversibility of fevnmbr ( % ),C0449261;C3714541
1869,reversibility [ % ],C0449261
1869,reversibility > nmbr % ( n = nmbr ),C0449261
1869,reversibility > nmbr % ( itt ) ( n = nmbr ),C0449261
1869,reversibility < nmbr % ( n = nmbr ),C0449261
1869,reversibility < nmbr % ( itt ) ( n = nmbr ),C0449261
1869,reversibility : > nmbr - < nmbr %,C0449261
1869,reversibility : > nmbr %,C0449261
1869,reversibility : < nmbr %,C0449261
1869,reversibility *,C0449261
1869,reversibility ( bnmbr - agonist ),C0449261;C2987634
1869,reversibility ( anticholinergic ),C0449261
1869,reversibility ( % predicted fevnmbr ) *,C0449261
1869,reversibility ( % ) t,C0449261
1869,reversibility ( % ),C0449261
1869,reversibility %,C0449261
1869,reversibility,C0449261
1869,fevnmbr reversibility,C0449261;C3714541
1869,fevnmbr % reversibility ( sd ),C0449261;C2699239;C3714541
1869,fevnmbr % reversibility,C0449261;C3714541
1869,bronchial reversibility %,C0205039;C0449261;C1442216
1869,albuterol reversibility,C0001927;C0449261
1869,airway reversibility,C0178987;C0449261;C0458827
1869,airflow reversibility — no . ( % ) |,C0231999;C0449261
1869,% reversibility in fev^ at,C0449261;C3714541
1869,% reversibility,C0449261
1869,% bronchial reversibility ( sd ),C0205039;C0449261;C1442216;C2699239
1868,weekly issnmbr,C0332174;C1740819;C1845118
1868,weekly iss {,C0332174;C1740819;C1845118
1868,weekly,C0332174
1868,baseline weekly iss,C0168634;C0332174;C1442488;C1740819;C1845118
1867,married,C0024841;C0555047
1866,diarrhoea,C0011991;C1963091;C3641756;C4084784;C4084802;C4085317
1866,diarrhea,C0011991;C1963091;C3641756;C4084784;C4084802;C4085317
1865,rales,C0034642;C0240859
1865,pulmonary rales,C0034642
1864,arr ( % ),C2170357;C4084934
1864,arr,C2170357;C4084934
1863,without previous surgery,C0038894;C0038895;C0205156;C0543467;C1274039;C1552607
1863,with previous surgery,C0038894;C0038895;C0205156;C0543467;C1274039;C1552607
1863,valve surgery,C0038894;C0038895;C0184252;C0543467;C1186983;C1274039;C1704414;C3888056
1863,type of surgery cabg only,C0010055;C0038894;C0038895;C0205171;C0332307;C0543467;C1274039;C1547052;C1720467
1863,type of surgery cabg,C0010055;C0038894;C0038895;C0332307;C0543467;C1274039;C1547052
1863,type of surgery,C0038894;C0038895;C0332307;C0543467;C1274039;C1547052
1863,surgery,C0038894;C0038895;C0543467;C1274039
1863,recent surgery or trauma,C0038894;C0038895;C0332185;C0543467;C1274039
1863,planned valve surgery,C0038894;C0038895;C0184252;C0543467;C1186983;C1274039;C1301732;C1704414;C3888056
1863,operative procedure,C0543467;C0677612
1863,cardiac valve surgery : no ( n = nmbr ),C0018821;C0018826;C0038894;C0038895;C0184252;C0524727;C0543467;C1186983;C1274039;C1704414;C3888056
1863,cabg surgery,C0010055;C0038894;C0038895;C0543467;C1274039
1862,weekly size of largest hives score {,C0042109;C0332174;C0443228;C0456389
1862,weekly number of hives scorenmbr,C0042109;C0237753;C0332174;C0449788
1862,weekly number of hives score {,C0042109;C0237753;C0332174;C0449788
1862,urticaria,C0042109;C1559188
1861,triglycerides — mmol / l,C0041004;C1532563
1861,triglycerides nmbr,C0041004
1861,triglycerides mean,C0041004;C0444504;C2347634;C2348143
1861,triglycerides > nmbr - nmbr mmol / l,C0041004;C1532563
1861,triglycerides < nmbr - nmbr mmol / l,C0041004;C1532563
1861,triglycerides * *,C0041004
1861,triglycerides *,C0041004
1861,triglycerides ( sd ),C0041004;C2699239
1861,triglycerides ( mmol / l ) :,C0041004;C1532563
1861,triglycerides ( mmol / l ) ( median,C0041004;C0549183;C0876920;C1532563;C2347635;C2348144;C2939193
1861,triglycerides ( mmol / l ),C0041004;C1532563
1861,triglycerides ( median,C0041004
1861,triglycerides,C0041004
1861,triglyceride a,C0041004
1861,triglyceride ( mmol / l ) t,C0041004;C1532563
1861,triglyceride ( mmol / l ),C0041004;C1532563
1861,triglyceride ( mm,C0041004;C4330985;C4554674
1861,triglyceride ( mg / dl ) d,C0041004;C0439422;C3642216
1861,triglyceride,C0041004
1861,triacylglycerol,C0041004
1861,- triglycerides,C0041004
1860,cardiac glycosides,C0007158
1859,cardiac index,C0428776
1858,cardiac death,C0376297
1857,cardiac rhythm,C0232187
1856,prior cardiac resynchronization therapy,C0332152;C1167956;C2826257
1856,cardiac resynchronization therapy n ( % ),C1167956
1856,cardiac resynchronization therapy,C1167956
1855,cardiovascu lar subg roup,C0276828;C1419115;C3814448
1854,cardiovascular medications,C0007220
1854,cardiovascular medication usage,C0007220;C0457083
1853,weight — kg cardiovascular history — no . ( % ),C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C1880008;C4054209
1853,past cardiovascular history,C0007226;C0332119;C1444637;C1880008;C3887460;C4284302
1853,cardiovascular history 一 no . ( % ),C1880008
1853,cardiovascular history — no . / total no . ( % ),C1880008
1853,cardiovascular history — no . ( % ),C1880008
1853,cardiovascular history,C1880008
1852,dilated cardiomyopathy,C0007193;C2984282
1851,non - ischaemic dilated cardiomyopathy,C1518422;C1960867
1851,ischaemic dilated cardiomyopathy,C1960867
1850,hypertrophic cardiomyopathy,C0007194;C4551472
1849,non - ischaemic cardiomyopathy,C0349782;C1518422
1849,ischemic cardiomyopathy,C0349782
1849,ischaemic cardiomyopathy,C0349782
1848,nonischemic cardiomyopathy — no . ( % ),C0878544
1848,nonischemic cardiomyopathy,C0878544
1848,cardiomyopathy,C0878544
1847,calcitonin,C0006668;C0770558;C1704385;C2825090;C4520796
1846,acitretin,C0050559
1845,fatty acid profile,C0015684;C1979963;C2003903
1845,fatty acid composition,C0015684;C0486616;C1555710
1844,lamotrigine,C0064636;C0524166
1843,carotid imt,C0334121;C0741968;C1704614;C4318736
1843,carotid,C0741968
1842,thyroid hormone,C0040135;C4522017
1841,thyroid disease,C0040128
1840,thiazide diuretics,C0012802
1840,thiazide diuretic *,C0012802;C3536861
1840,thiazide diuretic,C0012802;C3536861
1840,diuretic thiazide,C0012802
1840,any thiazide diuretic,C0012802;C3536861
1839,pain in extremity,C0030196;C4553007
1838,aerobic exercise,C0001701
1838,aerobic activity,C0001701
1837,left circumflex coronary artery,C0226037
1837,left circumflex artery,C0226037
1836,left anterior descending coronary artery,C0226032
1836,left anterior descending artery,C0226032
1836,l eft anterior descending coronary artery,C0226032;C0439394;C0451214;C1706495;C3642217
1835,laparoscopic cholecystectomy,C0162522
1834,atherectomy,C0162513
1833,carotid endarterectomy,C0014099
1832,laser or vitrectomy,C0023089;C0458142;C1023865;C1706315
1831,lifestyle modifications,C0870811;C2960841
1830,heavy calcification,C0006660;C0006663;C0175895;C0439539;C1533591;C1879982;C2242558
1830,calcification,C0006660;C0006663;C0175895;C1533591;C1879982;C2242558
1829,daily activities / social functioning,C0037395;C0871707
1829,daily activities,C0871707
1828,smoking classification,C0008902;C0008903;C0037369;C0453996;C0678229;C1881674
1828,pah classification — no . ( % ),C0008902;C0008903;C0030123;C0678229;C3203102;C4284467
1828,pah classification,C0008902;C0008903;C0030123;C0678229;C3203102;C4284467
1828,gold classification,C0008902;C0008903;C0018026;C0678229;C1304897
1828,fasting glucose mg / dl diabetes classification,C0008902;C0008903;C0011847;C0011849;C0015663;C0017725;C0439269;C0678229
1828,diabetes mellitus classification,C0008902;C0008903;C0011849;C0678229
1828,classification of epilepsy type,C0008902;C0008903;C0014544;C0332307;C0678229;C1547052
1828,classification of af,C0008902;C0008903;C0344434;C0678229;C4049859
1827,≤ median,C0549183;C0876920;C2347635;C2348144;C2939193
1827,£ median ( nmbr . nmbr ),C0549183;C0876920;C2347635;C2348144;C2939193
1827,£ median ( nmbr ),C0549183;C0876920;C2347635;C2348144;C2939193
1827,£ median,C0549183;C0876920;C2347635;C2348144;C2939193
1827,weight — kg ( median ),C0005910;C0022718;C0043100;C0439209;C0549183;C0876920;C1305866;C1705104;C2347635;C2348144;C2939193;C4054209
1827,weight ( median [iqr] ),C0005910;C0043100;C0549183;C0876920;C1305866;C1705104;C2347635;C2348144;C2939193
1827,weight ( kg / mnmbr ) [median ( nmbrth to nmbrth percentile ) ],C0039725;C0039738;C0549183;C0552346;C0876920;C1420718;C1532718;C2347635;C2348144;C2939193;C4282123;C4285344
1827,waisvhip > = median,C0549183;C0876920;C2347635;C2348144;C2939193
1827,waist / hip < median,C0019552;C0022122;C0230097;C0549183;C0876920;C1505163;C2347635;C2348144;C2939193;C3538851;C4284725
1827,urine acr > = median,C0042036;C0042037;C0549183;C0876920;C1412134;C1515941;C2347635;C2348144;C2939193;C2963137
1827,urine acr < median,C0042036;C0042037;C0549183;C0876920;C1412134;C1515941;C2347635;C2348144;C2939193;C2963137
1827,triglyceride ( median : mg / dl ) a [nmbr - nmbr percentile],C0041004;C0439269;C0549183;C0876920;C2347635;C2348144;C2939193
1827,triglyceride ( median  mg / dl ) - nmbr [nmbr - nmbr percentile |,C0041004;C0439269;C0549183;C0876920;C1264641;C2347635;C2348144;C2939193
1827,total cholesterol ( median,C0201950;C0543421;C0549183;C0876920;C2347635;C2348144;C2939193
1827,systolic blood pressure ( median nmbr . nmbr ),C0488055;C0549183;C0871470;C0876920;C1306620;C2347635;C2348144;C2939193
1827,score on nih stroke scale — median ( iqr ),C0449820;C0549183;C0876920;C1697238;C2347635;C2348144;C2939193;C3484372;C4050231
1827,score on modified rankin scale — median ( iqr ),C0449820;C0549183;C0876920;C2347635;C2348144;C2939193;C2984908;C3854213;C4050231
1827,score on modified mini - mental state examination — median ( iqr ),C0549183;C0876920;C2347635;C2348144;C2939193;C4304091
1827,sbp > median ( n = nmbr ),C0085805;C0549183;C0876920;C2347635;C2348144;C2939193
1827,sbp < median ( n = nmbronmbr ),C0085805;C0549183;C0876920;C2347635;C2348144;C2939193
1827,s median,C0549183;C0565930;C0876920;C2347635;C2348144;C2603362;C2939193
1827,pulse pressure ( median nmbr . nmbr],C0549183;C0876920;C0949236;C2347635;C2348144;C2939193
1827,proprotein convertase subtil / kexin typnmbr ( ng / ml ) - baseline - > = median ( n = nmbr,C0165249;C0168634;C0439275;C0549183;C0876920;C1100660;C1414185;C1442488;C2347635;C2348144;C2939193;C3811813
1827,proprotein convertase subtil / kexin typnmbr ( ng / ml ) - baseline - < median ( n = nmbr,C0165249;C0168634;C0439275;C0549183;C0876920;C1100660;C1414185;C1442488;C2347635;C2348144;C2939193;C3811813
1827,pci duration in min ( median,C0449238;C0549183;C0702093;C0876920;C1524029;C2347635;C2348144;C2926735;C2939193;C3813700;C4049621
1827,non - high density lipoprotein ( mg / dl ) - baseline - > = median ( n = nmbr,C0168634;C0439269;C0549183;C0876920;C1442488;C1535899;C2347635;C2348144;C2939193
1827,non - high density lipoprotein ( mg / dl ) - baseline - < median ( n = nmbr,C0168634;C0439269;C0549183;C0876920;C1442488;C1535899;C2347635;C2348144;C2939193
1827,months from mi — median ( iqr ),C0439231;C0549183;C0876920;C2347635;C2348144;C2939193;C3810814
1827,medians ( iqr ),C0549183
1827,median — yr,C0439234;C0549183;C0876920;C2347635;C2348144;C2939193
1827,median — vr,C0549183;C0876920;C2347635;C2348144;C2939193;C3476815
1827,median — ml / min / nmbr . nmbr mnmbr,C0369637;C0439445;C0441923;C0549183;C0876920;C2347635;C2348144;C2939193
1827,median — ml / min,C0439445;C0549183;C0876920;C2347635;C2348144;C2939193
1827,median §,C0549183;C0876920;C2347635;C2348144;C2939193
1827,median total cholesterol,C0201950;C0543421;C0549183;C0876920;C2347635;C2348144;C2939193
1827,median time to first exacerbation ( months [nmbr % ci] ),C0008107;C0205435;C0549183;C0556969;C0876920;C1279901;C2347635;C2348144;C2939193;C3259781;C4086268
1827,median time to event ( weeks ),C0040223;C0439230;C0441471;C0549183;C0876920;C2347635;C2348144;C2939193;C3541383;C4019010
1827,median time since diagnosis * ( range ),C0040223;C0549183;C0876920;C2347635;C2348144;C2939193;C3541383
1827,median time delay ( interquartile range ) — min,C0522486;C0549183;C0702093;C0876920;C1524029;C1711350;C2347635;C2348144;C2939193;C3813700
1827,median serum periostin ( ng / ml ) t,C0219433;C0229671;C0439275;C0549183;C0876920;C1424662;C1546774;C1550100;C2347635;C2348144;C2939193;C3812270
1827,median serum periostin,C0219433;C0229671;C0549183;C0876920;C1424662;C1546774;C1550100;C2347635;C2348144;C2939193;C3812270
1827,median seconds,C0457385;C0549183;C0876920;C2347635;C2348144;C2939193
1827,median of jsw,C0549183;C0876920;C2347635;C2348144;C2939193
1827,median nt - probnp ( iqr ) – pg / ml,C0439297;C0549183;C0669479;C0754710;C0876920;C2347635;C2348144;C2939193
1827,median n - terminal probnp ( iqr ) — pg / ml,C0439297;C0549183;C0669479;C0876920;C2347635;C2348144;C2939193
1827,median m / kgnmbr ( iqr ),C0022718;C0369637;C0439209;C0441923;C0549183;C0876920;C2347635;C2348144;C2939193;C4054209
1827,median infusions — no . ( range ),C0549183;C0574032;C0876920;C2347635;C2348144;C2939193
1827,median feno ( ppb ) f,C0016327;C0549183;C0876920;C1415800;C2347635;C2348144;C2939193
1827,median feno,C0549183;C0876920;C2347635;C2348144;C2939193
1827,median fasting insulin ( iqr ) — pu per milliliter,C0015663;C0018387;C0021641;C0439242;C0549183;C0876920;C1533581;C1579433;C2347635;C2348144;C2939193;C3714501
1827,median egfr ( interquartile range ),C0549183;C0876920;C1711350;C1739039;C2347635;C2348144;C2939193;C3811844;C3812682
1827,median duration of symptoms ( range ),C0436359;C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
1827,median duration of chf — mo,C0018802;C0026544;C0332177;C0449238;C0549183;C0876920;C2347635;C2348144;C2926735;C2939193
1827,median dose ( range ) b,C0178602;C0549183;C0869039;C0876920;C1114758;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
1827,median dose ( range ) ' ’,C0178602;C0549183;C0869039;C0876920;C1114758;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
1827,median delay ( h ) §,C0033727;C0205421;C0369286;C0441932;C0549183;C0564385;C0876920;C2347635;C2348144;C2939193;C4528284
1827,median daily dose - iu ™,C0049272;C0439453;C0549183;C0694756;C0876920;C2347635;C2348070;C2348144;C2939193
1827,median crcl — ml / min,C0439445;C0549183;C0876920;C1846718;C2347635;C2348144;C2939193
1827,median cardiac troponin t ( iqr ) 一 pg / ml,C0439297;C0549183;C0876920;C2347635;C2348144;C2939193;C3538889
1827,median cardiac troponin t ( iqr ) — pg / ml,C0439297;C0549183;C0876920;C2347635;C2348144;C2939193;C3538889
1827,median body weight — kg,C0005910;C0022718;C0043100;C0439209;C0549183;C0876920;C1305866;C1705104;C2347635;C2348144;C2939193;C3821165;C4054209
1827,median body weight ( kg ),C0005910;C0022718;C0043100;C0439209;C0549183;C0876920;C1305866;C1705104;C2347635;C2348144;C2939193;C3821165;C4054209
1827,median body mass index,C0005893;C0549183;C0578022;C0876920;C1305855;C2347635;C2348144;C2939193
1827,median bnp ( iqr ) – pg / ml,C0054015;C0439297;C0549183;C0876920;C1095989;C1417808;C2347635;C2348144;C2939193;C2982014
1827,median albumin / creatinine ratio ( g / mg ),C0024671;C0026410;C0439267;C0439269;C0486293;C0549183;C0876920;C1318293;C1960952;C2346927;C2347635;C2348144;C2939193;C4321396;C4521761
1827,median albumin - to - creatinine ratio ( interquartile range ),C0486293;C0549183;C0876920;C1318293;C1711350;C2347635;C2348144;C2939193
1827,median age — yr §,C0001779;C0439234;C0549183;C0876920;C2347635;C2348144;C2939193
1827,median age — yr,C0001779;C0439234;C0549183;C0876920;C2347635;C2348144;C2939193
1827,median age [interquartile range] — yr,C0001779;C0439234;C0549183;C0876920;C1711350;C2347635;C2348144;C2939193
1827,median age ( nmbr %,C0001779;C0549183;C0876920;C2347635;C2348144;C2939193
1827,median age ( iqr  years ),C0549183;C0876920;C1510829;C2347635;C2348144;C2939193
1827,median age,C0001779;C0549183;C0876920;C2347635;C2348144;C2939193
1827,median ( sd ),C0549183;C0876920;C2347635;C2348144;C2699239;C2939193
1827,median ( range ) treatment duration,C0444921;C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3259042;C3542016
1827,median ( range ) total ige level ( iuml ~ ’ ) nmbr,C0439175;C0439810;C0441889;C0456079;C0549183;C0876920;C1514721;C1547707;C2347635;C2348144;C2348147;C2939193;C2946261;C3542016
1827,median ( range ) duration of hospital stayi,C0019994;C0449238;C0549183;C0876920;C1510665;C1514721;C2347635;C2348144;C2348147;C2926735;C2939193;C3542016
1827,median ( range ) duration of asthma ( years ),C0004096;C0439234;C0449238;C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2926735;C2939193;C2984299;C3542016
1827,median ( range ) duration of asthma ( y ),C0004096;C0449238;C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2926735;C2939193;C2984299;C3542016
1827,median ( range ),C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
1827,median ( qnmbr – qnmbr ),C0549183;C0876920;C2347635;C2348144;C2939193
1827,median ( qnmbr : qnmbr ) total daily insulin dosenmbr,C0021641;C0549183;C0876920;C1533581;C1579433;C2347635;C2348070;C2348144;C2939193;C3714501
1827,median ( qnmbr : qnmbr ) tgs,C0549183;C0876920;C1156212;C1537574;C2347635;C2348144;C2939193
1827,median ( qnmbr : qnmbr ) tg - rich lipoprotein cholesterol,C0065055;C0337445;C0549183;C0699759;C0876920;C2347635;C2348144;C2939193
1827,median ( qnmbr : qnmbr ) lp ( a ),C0065058;C0549183;C0876920;C1439335;C2347635;C2348144;C2939193;C4553379
1827,median ( qnmbr : qnmbr ) duration of insulin use,C0021641;C0549183;C0876920;C1533581;C1579433;C1881378;C2347635;C2348144;C2826775;C2939193;C3714501
1827,median ( qnmbr : qnmbr ),C0549183;C0876920;C2347635;C2348144;C2939193
1827,median ( qnmbr,C0549183;C0876920;C2347635;C2348144;C2939193
1827,median ( nmbrth,C0039725;C0039738;C0549183;C0876920;C1420718;C2347635;C2348144;C2939193;C4282123;C4285344
1827,median ( nmbr % ci ) time to weekly iss mid response up to week nmbr ( wk ) f,C0008107;C0034746;C0332174;C0549183;C0876920;C1740819;C1845118;C2347635;C2348144;C2939193;C3259781
1827,median ( min,C0549183;C0702093;C0876920;C1524029;C2347635;C2348144;C2939193;C3813700
1827,median ( iqr ) — yr,C0439234;C0549183;C0876920;C2347635;C2348144;C2939193
1827,median ( iqr ) meannmbrsdchange from baseline to week nmbr by weight group and mtx use : weight,C0168634;C0444504;C0549183;C0876920;C1442488;C2347634;C2347635;C2348143;C2348144;C2939193
1827,median ( iqr ) cholesterol,C0008377;C0549183;C0876920;C2347635;C2348144;C2939193
1827,median ( iqr ) change from baseline to week nmbr in psa - modified total shs score,C0168634;C0392747;C0443172;C0549183;C0876920;C1442488;C1705241;C2347635;C2348144;C2939193;C4319952
1827,median ( iqr ) age,C0001779;C0549183;C0876920;C2347635;C2348144;C2939193
1827,median ( iqr ) admission data,C0184666;C0549183;C0809949;C0876920;C1511726;C2347635;C2348144;C2939193;C3245479;C3714741
1827,median ( iqr ),C0549183;C0876920;C2347635;C2348144;C2939193
1827,median ( iq range ),C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
1827,median ( interquartile range ) — yr,C0439234;C0549183;C0876920;C1711350;C2347635;C2348144;C2939193
1827,median ( interquartile range ),C0549183;C0876920;C1711350;C2347635;C2348144;C2939193
1827,median,C0549183;C0876920;C2347635;C2348144;C2939193
1827,less than the median,C0439092;C0549183;C0876920;C2347635;C2348144;C2939193
1827,less than median,C0439092;C0549183;C0876920;C2347635;C2348144;C2939193
1827,length of stent > median,C0449462;C0549183;C0876920;C2347635;C2348144;C2939193
1827,length of stent < median,C0449462;C0549183;C0876920;C2347635;C2348144;C2939193
1827,ldl cholesterol ( mmol / l ) ( median,C0023824;C0202117;C0549183;C0876920;C1532563;C2347635;C2348144;C2939193
1827,ldl - c > median,C0549183;C0876920;C2347635;C2348144;C2939193
1827,ldl - c ( median,C0549183;C0876920;C2347635;C2348144;C2939193
1827,hs - crp ( median,C0549183;C0876920;C2347635;C2348144;C2939193;C3890735;C4048285
1827,homa > median,C0549183;C0876920;C2347635;C2348144;C2939193
1827,homa - ir index — median ( iqr ),C0022065;C0022071;C0549183;C0600653;C0876920;C0918012;C1448132;C1552854;C1637833;C2347635;C2348144;C2939193;C2986546
1827,heart rate ( median nmbr . nmbr },C0018810;C0549183;C0876920;C2347635;C2348144;C2939193
1827,hdl cholesterol ( mmol / l ) ( median,C0023822;C0392885;C0549183;C0876920;C1532563;C2347635;C2348144;C2939193
1827,hdl - c ( median,C0549183;C0876920;C2347635;C2348144;C2939193;C3715113
1827,hbanmbrc in % ( median ( qnmbr,C0019016;C0549183;C0876920;C1825777;C2347635;C2348144;C2939193;C3538758
1827,hbanmbrc ( % ) ( median ( iqr ),C0019016;C0549183;C0876920;C1825777;C2347635;C2348144;C2939193;C3538758
1827,hbalca median,C0549183;C0876920;C2347635;C2348144;C2939193
1827,hbalc > median,C0549183;C0876920;C2347635;C2348144;C2939193
1827,hbalc < median,C0549183;C0876920;C2347635;C2348144;C2939193
1827,hbak > median,C0549183;C0876920;C2347635;C2348144;C2939193
1827,hbak < median,C0549183;C0876920;C2347635;C2348144;C2939193
1827,hba < median,C0019016;C0549183;C0876920;C1825777;C2347635;C2348144;C2939193;C3538758
1827,final median,C0205088;C0549183;C0876920;C1546485;C2347635;C2348144;C2939193;C3853528
1827,fastng plasma glucose < median,C0202042;C0455280;C0549183;C0876920;C2347635;C2348144;C2939193
1827,fasting plasma glucose in mmol / l ( median ( qnmbr,C0549183;C0583513;C0876920;C1532563;C2347635;C2348144;C2939193
1827,fasting plasma glucose < median,C0015663;C0202042;C0455280;C0549183;C0876920;C2347635;C2348144;C2939193
1827,egfr ( median,C0549183;C0876920;C1739039;C2347635;C2348144;C2939193;C3811844;C3812682
1827,crp median ( se ),C0036919;C0549183;C0876920;C2347635;C2348144;C2939193;C3890735;C4048285
1827,body mass indexa < median,C0518010;C0549183;C0876920;C2347635;C2348144;C2939193
1827,body mass index ( median,C0005893;C0549183;C0578022;C0876920;C1305855;C2347635;C2348144;C2939193
1827,bmi ( median,C0549183;C0578022;C0876920;C2347635;C2348144;C2939193
1827,bmi ( kg / mnmbr ) [median ( nmbrth to nmbrth percentile ) ],C0039725;C0039738;C0549183;C0876920;C1420718;C1532718;C2347635;C2348144;C2923536;C2939193;C4282123;C4285344
1827,bmi  kg / mnmbr  median ( iqr ),C0549183;C0578022;C0876920;C1532718;C2347635;C2348144;C2939193
1827,below median,C0549183;C0876920;C2347635;C2348144;C2939193
1827,baseline tav - > = median ( n = nmbr,C0168634;C0279686;C0549183;C0876920;C1442488;C2347635;C2348144;C2939193
1827,baseline tav - < median ( n = nmbr,C0168634;C0279686;C0549183;C0876920;C1442488;C2347635;C2348144;C2939193
1827,baseline pav - > = median ( n = nmbr,C0058890;C0168634;C0549183;C0876920;C1442488;C2347635;C2348144;C2939193
1827,baseline pav - < median ( n = nmbr,C0058890;C0168634;C0549183;C0876920;C1442488;C2347635;C2348144;C2939193
1827,baseline median [mg / l],C0168634;C0439268;C0549183;C0876920;C1442488;C2347635;C2348144;C2939193
1827,baseline median ( iq range ),C0168634;C0549183;C0876920;C1442488;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
1827,baseline median,C0168634;C0549183;C0876920;C1442488;C2347635;C2348144;C2939193
1827,anmbrc > = median,C0549183;C0876920;C2347635;C2348144;C2939193
1827,anmbrc < nmbr . nmbr % ( median ),C0549183;C0876920;C2347635;C2348144;C2939193
1827,anmbrc < median,C0549183;C0876920;C2347635;C2348144;C2939193
1827,anmbr = nmbr . nmbr % ( median ),C0549183;C0876920;C2347635;C2348144;C2939193
1827,age — year ( median ),C0001779;C0439234;C0439508;C0549183;C0876920;C2347635;C2348144;C2939193
1827,age > - median,C0001779;C0549183;C0876920;C2347635;C2348144;C2939193
1827,age < median,C0001779;C0549183;C0876920;C2347635;C2348144;C2939193
1827,age ( years ) [median ( nmbrth to nmbrth percentile ) ],C0039725;C0039738;C0549183;C0876920;C1264641;C1420718;C1510829;C2347635;C2348144;C2939193;C4282123;C4285344
1827,age ( years ) - > = median ( n = nmbr,C0549183;C0876920;C1510829;C2347635;C2348144;C2939193
1827,age ( years ) - < median ( n = nmbr,C0549183;C0876920;C1510829;C2347635;C2348144;C2939193
1827,age ( median [iqr] ),C0001779;C0549183;C0876920;C2347635;C2348144;C2939193
1827,age ( median,C0001779;C0549183;C0876920;C2347635;C2348144;C2939193
1827,age  y  median ( qnmbr – qnmbr ),C0001779;C0549183;C0876920;C2347635;C2348144;C2939193
1827,a median,C0549183;C0876920;C2347635;C2348144;C2939193
1827,^median > median,C0549183;C0876920;C2347635;C2348144;C2939193
1827,^median,C0549183;C0876920;C2347635;C2348144;C2939193
1827,> median nmbr . nmbr,C0549183;C0876920;C2347635;C2348144;C2939193
1827,> median ( nmbr mm ),C0549183;C0876920;C2347635;C2348144;C2939193;C4330985;C4554674
1827,> median ( nmbr kg ),C0022718;C0439209;C0549183;C0876920;C2347635;C2348144;C2939193;C4054209
1827,> median ( nmbr . nmbr ),C0549183;C0876920;C2347635;C2348144;C2939193
1827,> median ( nmbr ),C0549183;C0876920;C2347635;C2348144;C2939193
1827,> median ( nmbr % ),C0549183;C0876920;C2347635;C2348144;C2939193
1827,> median,C0549183;C0876920;C2347635;C2348144;C2939193
1827,> = median,C0549183;C0876920;C2347635;C2348144;C2939193
1827,< median nmbr . nmbr,C0549183;C0876920;C2347635;C2348144;C2939193
1827,< median ( nmbr kg ),C0022718;C0439209;C0549183;C0876920;C2347635;C2348144;C2939193;C4054209
1827,< median ( nmbr . nmbr ),C0549183;C0876920;C2347635;C2348144;C2939193
1827,< median,C0549183;C0876920;C2347635;C2348144;C2939193
1827,- median urine acr ( mg / g ) ( iqr ),C0042036;C0042037;C0549183;C0876920;C1300563;C1412134;C1515941;C2347635;C2348144;C2939193;C2963137
1827,- median tg ( iqr ),C0337445;C0549183;C0876920;C2347635;C2348144;C2939193
1827,- median pulse pressure ( mm hg ) ( iqr ),C0439475;C0549183;C0876920;C0949236;C2347635;C2348144;C2939193
1827,- median fasting serum glucose ( mg / dl ) ( iqr ),C0015663;C0202041;C0439269;C0549183;C0876920;C2347635;C2348144;C2939193;C3534430
1827,( median,C0549183;C0876920;C2347635;C2348144;C2939193
1827,& median,C0549183;C0876920;C2347635;C2348144;C2939193
1826,middle tg tertile,C0337445;C0444598;C0549183;C1552826
1826,middle tertile : > nmbr . nmbr to b nmbr . nmbr,C0444598;C0549183;C1552826
1826,middle,C0444598;C0549183;C1552826
1825,w eight ( k g ),C0205454;C0439267;C0597277;C1708601
1825,k - m % n,C0369637;C0441923;C0597277;C1708601
1825,k - m %,C0369637;C0441923;C0597277;C1708601
1825,k,C0597277;C1708601
1824,« nmbr kg,C0022718;C0439209;C4054209
1824,£ nmbr kg,C0022718;C0439209;C4054209
1824,weight at randomization ( kg ),C0022718;C0439209;C2985844;C4054209
1824,qnmbr : nmbr . nmbr to < nmbr . nmbr kg ( n = nmbr vs nmbr ),C0022718;C0439209;C4054209
1824,qnmbr : > nmbr . nmbr kg ( n = nmbrvsnmbr ),C0022718;C0439209;C4054209
1824,qnmbr : < nmbr . nmbr kg ( n = nmbrvsnmbr ),C0022718;C0439209;C4054209
1824,onmbr kg,C0022718;C0439209;C0483204;C4054209
1824,nonobese ( < nmbr kg / nr ),C0022718;C0027496;C0439209;C3844738;C4054209
1824,nmbr to < nmbrkg,C0022718;C0439209;C4054209
1824,nmbr to < nmbr kg,C0022718;C0439209;C4054209
1824,nmbr kg,C0022718;C0439209;C4054209
1824,nmbr - nmbr kg,C0022718;C0439209;C4054209
1824,nmbr - < nmbr kg,C0022718;C0439209;C4054209
1824,lu / kg,C0022718;C0024171;C0024176;C0439209;C2697939;C4054209
1824,low body weight ( < nmbr kg ),C0022718;C0041667;C0439209;C4054209
1824,kg,C0022718;C0439209;C4054209
1824,grip strength ( kg ),C0022718;C0429271;C0439209;C2598165;C4054209
1824,dose adjustment reason < nmbr kg,C0022718;C0439209;C2826286;C4054209
1824,bodyweight ( kg ),C0005910;C0022718;C0439209;C1305866;C4054209
1824,body weight — kg,C0005910;C0022718;C0439209;C1305866;C4054209
1824,body weight ( kg ) *,C0005910;C0022718;C0439209;C1305866;C4054209
1824,body weight ( kg ),C0005910;C0022718;C0439209;C1305866;C4054209
1824,bmi nmbr - < nmbr kg / ni - ( n = nmbr / nmbr ),C0022718;C0028075;C0439209;C0578022;C2348274;C3869926;C3869927;C4054209
1824,bmi : < nmbr kg / nr,C0022718;C0027496;C0439209;C0578022;C3844738;C4054209
1824,> nmbrkg,C0022718;C0439209;C4054209
1824,> nmbr kg — no . ( % ),C0022718;C0439209;C4054209
1824,> nmbr kg nr,C0022718;C0027496;C0439209;C3844738;C4054209
1824,> nmbr kg / nr,C0022718;C0027496;C0439209;C3844738;C4054209
1824,> nmbr kg,C0022718;C0439209;C4054209
1824,> nmbr . nmbr kg,C0022718;C0439209;C4054209
1824,> nmbr . nmbr - nmbr . nmbr kg,C0022718;C0439209;C4054209
1824,> nmbr - nmbr kg,C0022718;C0439209;C4054209
1824,> = nmbrkg,C0022718;C0439209;C4054209
1824,> = nmbr kg,C0022718;C0439209;C4054209
1824,< nmbrkg,C0022718;C0439209;C4054209
1824,< nmbr kg,C0022718;C0439209;C4054209
1824,< nmbr . nmbr kg,C0022718;C0439209;C4054209
1824,< = € nmbr kg,C0022718;C0439209;C4054209
1824,< = nmbr kg,C0022718;C0439209;C4054209
1824,. nmbr kg,C0022718;C0439209;C4054209
1824,# nmbr kg,C0022718;C0439209;C4054209
1823,week nmbr ( itt population ),C0032659;C0332174;C0439230;C1257890
1823,uplift ® population,C0032659;C1257890
1823,subpopulation,C1257890
1823,safety population,C0032659;C0036043;C1257890;C1705187
1823,populations :,C0032659;C1257890
1823,population,C0032659;C1257890
1823,open - label population,C0032659;C1257890;C1709323
1823,mn population,C0026327;C0026405;C0032659;C1257890;C4285072
1823,mitt population ( n = nmbr ),C0032659;C1257890
1823,mitt population,C0032659;C1257890
1823,metrex overall modified intention - to - treat population ? :,C0032659;C0087111;C0162425;C0282416;C0392747;C1257890;C1283828;C1292734;C1522326;C1561607;C3889737
1823,metreo modified intention - to - treat population §,C0032659;C0087111;C0162425;C0392747;C1257890;C1283828;C1292734;C1522326;C3889737
1823,itt population,C0032659;C1257890
1823,intent - to - treat population,C0032659;C0087111;C0162425;C1257890;C1283828;C1292734;C1522326;C1550453
1823,full population,C0032659;C0443225;C1257890
1823,disease activity outcomes ( itt population ) week nmbr,C0032659;C0205177;C0332174;C0439167;C0439230;C0441655;C0679250;C1257890;C1274040;C1292728;C1561536;C3542417;C3668946;C4049938;C4049939
1823,d population,C0032659;C0073187;C0332173;C1257890;C4484261
1823,copd population ( n = nmbr ),C0024117;C0032659;C1257890;C1412502;C3714496
1823,asian itt population total ( n = nmbr ),C0032659;C0078988;C0439175;C0439810;C1257890
1822,weight group,C0005910;C0043100;C0441833;C0687744;C1257890;C1305866;C1519504;C1705104;C1705428;C1705429
1822,warfarin group,C0043031;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
1822,vascular disease ( % of group ),C0042373;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
1822,total group,C0439175;C0439810;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
1822,table_group,C0039224;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C1706074
1822,statin group,C0360714;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
1822,salmeterol - fluticasone group,C0441833;C0687744;C0939232;C1257890;C1519504;C1705428;C1705429
1822,previous coronary procedure ( % of group ),C0018787;C0018821;C0205156;C0441833;C0687744;C1257890;C1279986;C1519504;C1552607;C1705428;C1705429;C2986530
1822,p value between groups,C0441833;C0441849;C0687744;C1257890;C1519504;C1522609;C1552839;C1705428;C1705429;C1709380
1822,no statin group,C0360714;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
1822,no epa group no . of events ( % ),C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
1822,no . of diseased vessels ( % of group ),C0005847;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
1822,nmbr - year rates in placebo groups,C0032042;C0439234;C0439508;C0441833;C0687744;C0871208;C1257890;C1519504;C1521828;C1552839;C1696465;C1705428;C1705429;C1706408
1822,mepolizumab group,C0441833;C0687744;C0969324;C1257890;C1519504;C1705428;C1705429
1822,low - dose rivaroxaban + aspirin group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C1739768;C2608320
1822,indacaterol - glycopyrronium group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C1722260;C3814772
1822,in the spironolactone group and nmbr patients in the placebo group .,C0037982;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
1822,hbaic group ( % ),C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
1822,groups,C0441833;C0687744;C1257890;C1519504;C1552839;C1705428;C1705429
1822,group — no . ( % ),C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
1822,group difference,C0441833;C0687744;C1257890;C1519504;C1705241;C1705242;C1705428;C1705429
1822,group dif . ( nmbr ),C0441833;C0687744;C0812246;C1257890;C1519504;C1705428;C1705429;C1710304
1822,group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
1822,gold nmbr groups,C0018026;C0441833;C0687744;C1257890;C1304897;C1519504;C1552839;C1705428;C1705429
1822,gold group,C0018026;C0441833;C0687744;C1257890;C1304897;C1519504;C1705428;C1705429
1822,experimental treatment group,C0441833;C0687744;C0949266;C1257890;C1519504;C1705428;C1705429;C2585119
1822,events / statin group,C0360714;C0441471;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C3541888
1822,epa group no . of events ( % ),C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
1822,ejection fraction group,C0441833;C0489482;C0687744;C1257890;C1519504;C1705428;C1705429;C2700378
1822,diet group,C0012155;C0012159;C0441833;C0687744;C1257890;C1519433;C1519504;C1705428;C1705429;C2983588;C3668949
1822,dabigatran group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C2348066
1822,coronary procedure ( % of group ),C0018787;C0018821;C0441833;C0687744;C1257890;C1279986;C1519504;C1705428;C1705429;C2986530
1822,certolizumab group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C1872109
1822,bmi group — no . ( % ),C0441833;C0578022;C0687744;C1257890;C1519504;C1705428;C1705429
1822,bmi group ( kg / m^ ),C0022718;C0439209;C0441833;C0441847;C0578022;C0687744;C1257890;C1519504;C1532718;C1705428;C1705429;C4054209
1822,aspirin group,C0004057;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
1822,alc group ( % ),C0441833;C0687744;C1257890;C1424945;C1519504;C1705428;C1705429;C3811058
1822,aga group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
1822,( % of group ),C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
1821,white race — number ( % ),C0007457;C0043157;C0237753;C0449788
1821,white race ( n = nmbr nmbr ),C0007457;C0043157
1821,caucasians ( n = nmbr ),C0007457;C0043157
1821,caucasian simva ( „ = nmbr },C0007457;C0043157
1821,caucasian simva ( n = nmbr ),C0007457;C0043157
1821,caucasian simva,C0007457;C0043157
1821,caucasian race ( % ),C0007457
1821,caucasian race,C0007457
1821,caucasian n = nmbr,C0007457;C0043157
1821,caucasian eze / simva ( „ = nmbr },C0007457;C0043157
1821,caucasian eze / simva ( n = nmbr ),C0007457;C0043157
1821,caucasian eze / simva,C0007457;C0043157
1821,caucasian ethnicity,C0007457;C0015031;C0043157;C0243103
1821,caucasian ( % ),C0007457;C0043157
1820,tanezumab nmbr mg + nsaid,C0003211;C0024671;C0026410;C0439269;C1960952;C2346819;C2346927;C3536840;C4321396;C4521761
1820,tanezumab nmbr mg,C0024671;C0026410;C0439269;C1960952;C2346819;C2346927;C4321396;C4521761
1820,tanezumab nmbr . nmbr mg + nsaid,C0003211;C0024671;C0026410;C0439269;C1960952;C2346819;C2346927;C3536840;C4321396;C4521761
1820,tanezumab nmbr . nmbr mg,C0024671;C0026410;C0439269;C1960952;C2346819;C2346927;C4321396;C4521761
1820,tanezumab ( all doses combined ) + nsaida,C2346819
1820,tanezumab ( all doses combined ),C2346819
1819,or for cana vs pbo ( nmbr % ci ) §,C1418845
1819,or for cana vs pbo ( nmbr % ci ) | |,C1418845
1819,canvas ( n = nmbr ) : placebo ( n = nmbr )  cana nmbr mg ( n = nmbr )  cana nmbr mg ( n = nmbr ),C0032042;C1319635;C1418845;C1696465;C1706408;C3281223
1819,cananmbr / met ( n = nmbr ),C1418845
1819,cananmbr ( n = nmbr ),C1418845
1819,cana,C1418845
1819,all cana,C1418845
1818,range race,C0034510;C1514721;C1706779;C2348147;C3542016;C3853635
1818,racial group,C0034510
1818,racial category *,C0034510;C0683312;C1706779;C3669213;C3853635;C3889287
1818,racial category,C0034510;C0683312;C1706779;C3669213;C3853635;C3889287
1818,racenmbr,C0034510;C1706779;C3853635
1818,race_white,C0034510;C1706779;C3853635
1818,race — no . { % ) - i -,C0034510;C1706779;C3853635
1818,race — no . { % ) ' i ',C0034510;C1706779;C3853635
1818,race — no . / total no . ( % ) f,C0034510;C1706779;C3853635
1818,race — no . ( % ) 卞,C0034510;C1706779;C3853635
1818,race — no . ( % ) |,C0034510;C1706779;C3853635
1818,race — no . ( % ) f,C0034510;C1706779;C3853635
1818,race — no . ( % ) : t,C0034510;C1706779;C3853635
1818,race — no . ( % ) : c,C0034510;C1706779;C3853635
1818,race — no . ( % ) ' (,C0034510;C1706779;C3853635
1818,race — no . ( % ),C0034510;C1706779;C3853635
1818,race §,C0034510;C1706779;C3853635
1818,race white,C0034510;C1706779;C3853635
1818,race or ethnicity,C0034510;C1706779;C3853635
1818,race or ethnic origin,C0034510;C1706779;C3853635
1818,race or ethnic group — no . { % ) ■ ' ( white,C0034510;C1706779;C3853635
1818,race or ethnic group — no . f,C0034510;C1706779;C3853635
1818,race or ethnic group — no . / total no . ( % ) f,C0034510;C1706779;C3853635
1818,race or ethnic group — no . ( % ) f,C0034510;C1706779;C3853635
1818,race or ethnic group — no . ( % ) : t,C0034510;C1706779;C3853635
1818,race or ethnic group ( % ) f,C0034510;C1706779;C3853635
1818,race or ethnic group ( % ),C0034510;C1706779;C3853635
1818,race or ethnic group,C0034510;C1706779;C3853635
1818,race or ethnic background — no . ( % ) f,C0034510;C1706779;C3853635
1818,race nonwhitet,C0034510;C1706779;C3853635
1818,race n ( % ),C0034510;C1706779;C3853635
1818,race and ss at baseline,C0034510;C1706779;C3853635
1818,race : white,C0034510;C1706779;C3853635
1818,race : non - white,C0034510;C1706779;C3853635
1818,race :,C0034510;C1706779;C3853635
1818,race / ethnicity white,C0007457;C0015031;C0034510;C0043157;C0220938;C0243103;C1706779;C3853635
1818,race / ethnicity n ( % ),C0015031;C0034510;C0243103;C1706779;C3853635
1818,race / ethnicity chinese,C0008120;C0015031;C0034510;C0152035;C0243103;C1706779;C3853635
1818,race / ethnicity,C0015031;C0034510;C0243103;C1706779;C3853635
1818,race - white ( n = nmbr,C0034510;C1706779;C3853635
1818,race - nonwhite,C0034510;C1706779;C3853635
1818,race - non - white ( n = nmbr,C0034510;C1706779;C3853635
1818,race - non - white,C0034510;C1706779;C3853635
1818,race - no . ( % ),C0034510;C1706779;C3853635
1818,race - n ( % ),C0034510;C1706779;C3853635
1818,race *,C0034510;C1706779;C3853635
1818,race ( white,C0034510;C1706779;C3853635
1818,race ( p = o - nmbr ),C0034510;C1706779;C3853635
1818,race ( non - white ) ( % ),C0034510;C1706779;C3853635
1818,race ( % white ),C0034510;C1706779;C3853635
1818,race ( % ) white,C0034510;C1706779;C3853635
1818,race ( % ) *,C0034510;C1706779;C3853635
1818,race ( % ) ) ',C0034510;C1706779;C3853635
1818,race ( % ) $,C0034510;C1706779;C3853635
1818,race ( % ),C0034510;C1706779;C3853635
1818,race,C0034510;C1706779;C3853635
1818,other race,C0034510;C1706779;C3853635
1818,nonwhite race !,C0034510;C1706779;C3853635
1818,nonwhite race,C0034510;C1706779;C3853635
1818,$ race was determined by the investigator during the patient ' s interview .,C0034510;C1706779;C3853635
1817,white tcz + mtx ( n ),C0007457;C0025677;C0043157;C0220938;C1417487
1817,white race — no . { % ) t,C0007457;C0043157;C0220938
1817,white race — no . { % ) - i -,C0007457;C0043157;C0220938
1817,white race — no . { % ) ' i ',C0007457;C0043157;C0220938
1817,white race — no . { % ) $,C0007457;C0043157;C0220938
1817,white race — no . / total no . ( % ) f,C0007457;C0043157;C0220938
1817,white race — no . / total no . ( % ) $,C0007457;C0043157;C0220938
1817,white race — no . ( % ) y left ventricular ejection fraction — %,C0007457;C0043157;C0220938
1817,white race — no . ( % ) f,C0007457;C0043157;C0220938
1817,white race — no . ( % ) : t,C0007457;C0043157;C0220938
1817,white race — no . ( % ) :,C0007457;C0043157;C0220938
1817,white race,C0007457;C0043157
1817,white or caucasian,C0007457;C0043157;C0220938
1817,white not of hispanic origin,C0007457;C0043157;C0220938
1817,white mtx ( n ),C0007457;C0025677;C0043157;C0220938;C1417487
1817,white ethnic origin,C0007457;C0015031;C0043157;C0220938
1817,white : black : other,C0005680;C0007457;C0027567;C0043157;C0085756;C0220938;C0439541
1817,white / other,C0007457;C0043157;C0220938
1817,white / european,C0007457;C0043157;C0220938;C0239307;C1535514
1817,white / caucasian,C0043157
1817,white ( nmbr . nmbr % ),C0007457;C0043157;C0220938
1817,white ( n — nmbr ),C0007457;C0043157;C0220938
1817,white ( n   = nmbr,C0007457;C0043157;C0220938
1817,white ( n = nmbr ),C0007457;C0043157;C0220938
1817,white ( n = nmbr,C0007457;C0043157;C0220938
1817,white,C0007457;C0043157;C0220938
1817,racea white,C0007457;C0043157;C0220938
1817,non white,C0007457;C0043157;C0220938;C1518422
1817,non - white raceb,C0007457;C0043157;C0220938;C1518422
1817,non - white race,C0007457;C0043157;C1518422
1817,non - white,C0007457;C0043157;C0220938;C1518422
1817,non - caucasian simva ( „ = nmbr },C0007457;C0043157;C1518422
1817,non - caucasian simva ( n = nmbr ),C0007457;C0043157;C1518422
1817,non - caucasian simva,C0007457;C0043157;C1518422
1817,non - caucasian eze / simva ( „ = nmbr },C0007457;C0043157;C1518422
1817,non - caucasian eze / simva ( n = nmbr ),C0007457;C0043157;C1518422
1817,non - caucasian eze / simva,C0007457;C0043157;C1518422
1817,non - caucasian,C0007457;C0043157;C1518422
1817,caucasians,C0007457;C0043157
1817,caucasian nmbr,C0007457;C0043157
1817,caucasian,C0007457;C0043157
1816,use of hormone replacement therapy ( a ),C0282402;C1524063
1816,pre - menopausal without hormone replacement,C0206158;C0282402
1816,pre - menopausal with hormone replacement,C0206158;C0282402
1816,hrt,C0282402
1816,hormone replacement therapy use,C0042153;C0282402;C0457083;C1947944
1816,hormone replacement therapy,C0282402
1816,hormone replacement ! !,C0282402
1816,hormone replacement,C0282402
1815,whole cohort,C0009247;C0444667;C0599755
1815,secondary - prevention cohort,C0009247;C0599755;C0679699
1815,primary - prevention cohort,C0009247;C0033144;C0599755
1815,nmbr mg cohort,C0009247;C0024671;C0026410;C0439269;C0599755;C1960952;C2346927;C4321396;C4521761
1815,itt cohort,C0009247;C0599755
1815,full cohort,C0009247;C0443225;C0599755
1815,entire evaluable cohort,C0009247;C0439751;C0444667;C0599755;C1516986
1815,entire cohort gender,C0009247;C0079399;C0439751;C0444667;C0599755;C1522384
1815,entire cohort,C0009247;C0439751;C0444667;C0599755
1815,cohort nmbr ( n = nmbr ) f,C0009247;C0016327;C0599755
1815,cohort nmbr ( n = nmbr ),C0009247;C0599755
1815,cohort,C0009247;C0599755
1814,hps,C0242994
1813,hub,C0063034;C1414372;C1708389
1812,hgb,C0019029;C0019046;C0518015;C1424337
1812,hb,C0019046
1811,ho,C0019905;C1832110;C3889614
1810,hc,C0020268;C0262499;C1413512
1809,hiv,C0019682;C0019699
1808,fh ii,C1854107
1807,cataract removal,C0007389
1806,cataract,C0086543;C4555209
1805,canada or united states,C0006823
1805,canada,C0006823
1804,carvedilol,C0054836
1803,cards,C2930619;C3275277
1802,canvas - r,C0205090;C0684010;C2603358;C3281223
1802,canvas,C3281223
1801,with ckd standard ( n = nmbr ),C1442989;C1561643;C2828392
1801,standard therapyy ( n = nmbr ),C1442989;C2828392
1801,standard care n ( % ) / nmbrpy,C0030428;C1442989;C1947933;C2828392;C3538810
1801,standard care n ( % ),C1442989;C1947933;C2828392
1801,standard care allocation,C1442989;C1706778;C1947933;C2828392
1801,standard care ( n = nmbr ),C1442989;C1947933;C2828392
1801,standard care,C1442989;C1947933;C2828392
1801,standard allocation,C1442989;C1706778;C2828392
1801,standard ( nmbr ),C1442989;C2828392
1801,standard ( n = nmbr ),C1442989;C2828392
1801,standard,C1442989;C2828392
1801,number standard care,C0237753;C0449788;C1442989;C1947933;C2828392
1801,no - ckd standard ( n = nmbr ),C1442989;C1561643;C2828392
1801,nmbr standard ( n = nmbr ),C1442989;C2828392
1800,previous cad,C0205156;C1504769;C1552607;C2239547;C3813548;C4284121
1800,premature cad among family members,C0086282;C0151526;C0205252;C1504769;C2239547;C3813548;C4018905;C4284121
1800,multivessel cad ( % ),C1504769;C2239547;C3813548;C4284121
1800,multivessel cad,C1504769;C2239547;C3813548;C4284121
1800,family history of cad ( diagnosed at < nmbr yr of age ) — no . ( % ) cigarette smoker — no . ( % ),C0241889;C1504769;C2239547;C3813548;C4284121
1800,family history of cad,C0241889;C1504769;C2239547;C3813548;C4284121
1800,familv historv of cad,C1504769;C2239547;C3813548;C4284121
1800,cad and abi < nmbr - nmbr §,C1504769;C2239547;C3813548;C4284121
1800,cad and / or crvd ( % ),C1504769;C2239547;C3813548;C4284121
1800,cad *,C1504769;C2239547;C3813548;C4284121
1800,cad,C1504769;C2239547;C3813548;C4284121
1799,with events ( % ),C0441471;C3541888
1799,warfarin events / n ( % / y ),C0043031;C0441471;C3541888
1799,total events,C0439175;C0439810;C0441471;C3541888
1799,selexipag patients / events n,C0030705;C0441471;C2000145;C3541888
1799,rosuvastatin events / patients ( % ),C0030705;C0441471;C0965129;C3541888
1799,previous events,C0205156;C0441471;C1552607;C3541888
1799,pneumonia events,C0032285;C0441471;C3541888
1799,pioglitazone events / n ( % ),C0071097;C0441471;C3541888
1799,patients with uncomplicated events ( p = o - nmbr 十 ),C0030705;C0441471;C0443334;C3541888
1799,patients with uncomplicated events,C0030705;C0441471;C0443334;C3541888
1799,patients with hospitalized pneumonia events,C0032285;C0441471;C0870668;C3541888
1799,patients with complicated events ( p = nmbr - nmbr 十 ),C0030705;C0231242;C0441471;C3541888
1799,patients with complicated events,C0030705;C0231242;C0441471;C3541888
1799,patients / events n,C0030705;C0441471;C3541888
1799,ophthalmologic events,C0029087;C0205481;C0441471;C3541888
1799,number of events / patients,C0030705;C0441471;C2360800;C3541888;C4330837
1799,no of events womenmen *,C0441471;C3541888
1799,no of events women men *,C0025266;C0043210;C0441471;C3541888
1799,no of events / total n ( % ),C0439175;C0439810;C0441471;C3541888
1799,no ckd rate ( # events ),C0441471;C0871208;C1521828;C1561643;C3541888
1799,no . of events / totol no . ( % ),C0441471;C3541888
1799,no . of events / total no . nmbr % ),C0441471;C3541888
1799,no . of events / total no . ( % ),C0441471;C3541888
1799,no . of events / total,C0441471;C3541888
1799,no . of events / sample size i i,C0441471;C3541888
1799,no . of events / sample size,C0441471;C3541888
1799,no . of events / patients % / yr,C0030705;C0439234;C0441471;C3541888
1799,no . of events / patients,C0030705;C0441471;C3541888
1799,no . of events / no . of patients,C0441471;C3541888
1799,no . of events ( rate ),C0441471;C0871208;C1521828;C3541888
1799,no . of events,C0441471;C3541888
1799,nmbr no . of events,C0441471;C3541888
1799,nmbr events[nmbr . nmbr],C0441471;C3541888
1799,nmbr events,C0441471;C3541888
1799,neurologicai events,C0441471;C3541888
1799,n events / n subjects,C0369718;C0441471;C0441922;C3541888
1799,n events / n at risk,C0369718;C0441471;C0441922;C3541888
1799,n events ( % ),C0369718;C0441471;C0441922;C3541888
1799,n - nmbr pufa events / patients ( % ),C0030705;C0032615;C0369718;C0441471;C0441922;C3541888
1799,icosapent ethyl ( events / n ( % ) ),C0058978;C0441471;C3541888
1799,hospitalized pneumonia events,C0032285;C0441471;C0701159;C3541888
1799,frequency of events,C0376249;C0439603;C0441471;C0871396;C1561548;C1705502;C3541888;C3898838;C4321352
1799,freqency of events,C0441471;C3541888
1799,events requiring assistance,C0441471;C3541888
1799,events consistent with volume depletion,C0441471;C3541888
1799,events consistent with uti,C0441471;C3541888
1799,events consistent with genital infection,C0441471;C3541888
1799,events / patient - year ( n ),C0030705;C0439234;C0439508;C0441471;C3541888
1799,events / n,C0441471;C3541888
1799,events ( % ),C0441471;C3541888
1799,events,C0441471;C3541888
1799,epa hr events ( % ),C0441471;C3541888
1799,cvd events,C0007222;C0441471;C3541888
1799,cumulative events,C0441471;C1511559;C3541888
1799,composite events,C0205199;C0441471;C1547335;C3541888
1799,ckd rate ( # events ),C0441471;C0871208;C1521828;C1561643;C3541888
1799,bleeding events during the entire study,C0019080;C0439751;C0441471;C0444667;C0557651;C2603343;C3541888
1799,bleeding events during first nmbr days of treatmen,C0019080;C0205435;C0439228;C0441471;C1279901;C3541888
1799,biochemical events,C0205474;C0441471;C3541888
1799,adjusted rate of pneumonia events ( per patient - year ),C0032285;C0441471;C0456081;C0871208;C1521828;C3541888
1799,adjusted rate of hospitalized pneumonia events ( per patient - year ),C0032285;C0441471;C0456081;C0701159;C0871208;C1521828;C3541888
1798,w event ( rate ),C0441471;C0871208;C1521828;C4019010
1798,vorapaxar event rate ( n = nmbr ),C0441471;C0871208;C1521828;C2974521;C4019010
1798,vhd event rate / year ( n ),C0439234;C0439508;C0441471;C0871208;C1521828;C4019010
1798,"probability "" of event %",C0033204;C0441471;C4019010
1798,patients with event / patients analyzed,C0030705;C0441471;C4019010
1798,patients with event / patients analysed,C0030705;C0441471;C4019010
1798,patients with event / analyzed,C0030705;C0441471;C4019010
1798,patients with event ( n,C0030705;C0441471;C4019010
1798,patients with an event per nmbr patient - years,C0030705;C0441471;C4019010
1798,participants with an event per nmbr patient - years,C0441471;C0679646;C4019010
1798,overall event rate,C0282416;C0441471;C0871208;C1521828;C1561607;C4019010
1798,overal event rate,C0441471;C0871208;C1521828;C4019010
1798,normal cognitive function ( spmsq < nmbr ) . n - nmbr . nmbr n ( % ) participants with the event of interest,C0009240;C0392335;C0441471;C0679646;C1276356;C4019010;C4050130
1798,no vhd event rate / year ( n ),C0439234;C0439508;C0441471;C0871208;C1521828;C4019010
1798,no . ( % ) with event [incidence rate per nmbr patient - y],C0030705;C0441471;C1708485;C4019010
1798,nmbr event,C0441471;C4019010
1798,n event ( rate ),C0369718;C0441471;C0441922;C0871208;C1521828;C4019010
1798,n ( nmbryr km event rate,C0369718;C0439234;C0441471;C0441922;C0871208;C1521828;C3887676;C4019010
1798,km event ( % ) at nmbr y,C0441471;C3887676;C4019010
1798,impaired cognitive function ( spmsq > nmbr ) . n - nmbr n ( % ) participants with the event of interest,C0009240;C0221099;C0392335;C0441471;C0543488;C0679646;C4019010;C4050130
1798,gastrointestinal event,C0441471;C0521362;C4019010
1798,event { n ( % ),C0441471;C4019010
1798,event rates,C0441471;C0871208;C1521828;C4019010
1798,event rate ( per nmbr,C0441471;C0871208;C1521828;C4019010
1798,event rate ( % / year ),C0439234;C0439508;C0441471;C0871208;C1521828;C4019010
1798,event rate ( % / vr ),C0441471;C0871208;C1521828;C3476815;C4019010
1798,event rate,C0441471;C0871208;C1521828;C4019010
1798,event during overall,C0282416;C0441471;C1561607;C4019010
1798,event during on -,C0441471;C4019010
1798,event ( p = nmbr . nmbro + ),C0441471;C4019010
1798,event ( % ),C0441471;C4019010
1798,event,C0441471;C4019010
1798,empagliflozin n with event / n,C0441471;C3490348;C4019010
1798,cv event,C0441471;C3538987;C4019010;C4048877;C4318503
1798,atients with event,C0441471;C4019010
1798,any event,C0441471;C4019010
1798,acs event,C0441471;C0742343;C4019010;C4318612
1797,timi flow ‡,C3272266
1797,final timi flow,C0205088;C1546485;C3272266;C3853528
1796,fish oil ( n = nmbr ),C0016157
1796,fish oil,C0016157
1795,fibrinogen ( pmol / l ) c,C0016006;C0439284;C1167394;C2587184;C3540039
1795,fibrinogen,C0016006;C1167394;C2587184;C3540039
1794,hispanic — no . ( % ),C0086409
1794,hispanic or non - hispanic ethnic group — no . ( % ) f,C0086409
1794,hispanic or latino ethnic groupf,C0086409
1794,hispanic or latino ethnic groupb,C0086409
1794,hispanic or latino ethnic group *,C0086409
1794,hispanic or latino ethnic group !,C0086409
1794,hispanic or latino ( n — nmbr ),C0086409
1794,hispanic or latino ( n = nmbr ),C0086409
1794,hispanic or latino,C0086409
1794,hispanic ethnicity,C0015031;C0086409;C0243103
1794,hispanic ethnic group — no . { % ) ’ i ',C0015031;C0086409;C1879937
1794,hispanic ethnic group — no . / total no . ( % ) ‘ j ‘,C0015031;C0086409;C1879937
1794,hispanic ethnic group — no . ( % ) f,C0015031;C0086409;C1879937
1794,hispanic ethnic group — no . ( % ) : t,C0015031;C0086409;C1879937
1794,hispanic ethnic group,C0015031;C0086409;C1879937
1794,hispanic / non - hispanic,C0086409;C1518422
1794,hispanic / latino ethnicity,C0015031;C0086409;C0086528;C0243103
1794,hispanic / latino ( n = nmbr ),C0086409;C0086528
1794,hispanic ( n = nmbrlnmbr ),C0086409
1794,hispanic ( n = nmbr ),C0086409
1794,ethnicitya hispanic or latino,C0086409
1794,ethnicity - - hispanic or latino,C0015031;C0086409;C0243103
1793,mixed hispanic,C0086409;C0205430;C3160715
1793,hispanic,C0086409
1793,biack hispanic,C0086409
1793,american hispanic ( n   = nmbr ),C0086409;C0596070
1792,non high dose statin ( n = nmbr,C0360714;C0444956;C1518422
1792,higher dose,C0444956
1792,higher - dose,C0444956
1792,high dose statin ( n = nmbr,C0360714;C0444956
1792,high dose,C0444956
1792,high - dose statin use,C0042153;C0360714;C0444956;C0457083;C1947944
1792,high - dose statin,C0360714;C0444956
1792,high - dose aspirin,C0004057;C0444956
1792,high - dose arb ( n = nmbr ),C0444956;C3888198
1791,iga nmbr / nmbr,C2825347
1791,iga mod nmbr score,C0011860;C0449820;C2825347;C4050231
1790,with highest bwa,C0006041;C1522410
1790,highest tg tertile,C0337445;C1522410
1790,highest killip classiciation pre - pci,C1522410
1790,highest,C1522410
1789,ct ratio > nmbr . nmbr,C0007673;C0456603;C1547037;C3540513;C3813556;C3888140
1789,ct ratio ( % ),C0007673;C0456603;C1547037;C3540513;C3813556;C3888140
1789,ct or mr scan of the brain *,C0007673;C3540513;C3813556;C3888140
1789,ct findings,C0007673;C2607943;C2926606;C3539655;C3540513;C3813556;C3888140
1789,ct,C0007673;C3540513;C3813556;C3888140
1788,with highest hbanmbrcc,C0008318;C0019016;C1522410;C1825777;C3538758;C3538933
1788,cc,C0008318;C3538933
1787,other chd,C0280604;C3542407
1787,no chd simva ( „ = nmbr ),C0280604;C3542407
1787,no chd simva ( n = nmbr],C0280604;C3542407
1787,no chd simva,C0280604;C3542407
1787,no chd eze / simva nmbr = nmbr },C0280604;C3542407
1787,no chd eze / simva ( n = nmbr ),C0280604;C3542407
1787,no chd eze / simva,C0280604;C3542407
1787,no chd,C0280604;C3542407
1787,known chd,C0205309;C0280604;C3542407
1787,fatal chd and nonfatal mia,C0280604;C1302234;C1705232;C3542407
1787,fatal chd + nonfatal ml,C0280604;C0439526;C1302234;C1705224;C1705232;C3542407;C3887665
1787,chd status §,C0280604;C0449438;C3542407
1787,chd status,C0280604;C0449438;C3542407
1787,chd simva nmbr = nmbr],C0280604;C3542407
1787,chd simva ( „ = nmbr ),C0280604;C3542407
1787,chd simva,C0280604;C3542407
1787,chd risk factors #,C0035648;C0280604;C1553898;C3542407
1787,chd risk - no . ( % ),C0280604;C3542407
1787,chd eze / simva ( „ = nmbr ),C0280604;C3542407
1787,chd eze / simva ( n = nmbr],C0280604;C3542407
1787,chd eze / simva,C0280604;C3542407
1787,chd disease death,C0011065;C0012634;C0280604;C1306577;C3542407;C4082313;C4552775
1787,chd deaths,C0011065;C0280604;C1306577;C3542407
1787,chd death,C0011065;C0280604;C1306577;C3542407;C4082313;C4552775
1787,chd + cl all,C0280604;C0596019;C3542407
1787,chd *,C0280604;C3542407
1787,chd,C0280604;C3542407
1787,> nmbrmg / dl chd status,C0280604;C0439269;C0449438;C3542407
1787,> nmbr chd risk factors,C0035648;C0280604;C1553898;C3542407
1786,tk,C0041405;C0220928;C4050092
1785,tc : hdlc,C0039411;C0040642;C0041405;C0041698;C1704429;C1824670;C3272447;C4522122
1785,tc / hdl - c ratio,C0039411;C0040642;C0041405;C0041698;C0456603;C1547037;C1824670;C3272447;C3715113;C4522122
1785,tc / hdl - c,C0039411;C0040642;C0041405;C0041698;C1824670;C3272447;C3715113;C4522122
1785,tc,C0039411;C0040642;C0041405;C0041698;C1824670;C3272447;C4522122
1785,key : tc = triglyceride  hs - crp = ldl - c = low - density lipoprotein fc = fasting glucose  ncep atp * this category did not include ar to have > _ nmbr of the indicated char least - square means  except tc an note : all treatment by subgroup,C0015663;C0017725;C0023823;C0039411;C0040642;C0041004;C0041405;C0041698;C1824670;C2744579;C2983605;C3272447;C3890735;C4048285;C4522122;C4552600
1785,apo  apolipoprotein  dm  diabetes mellitus  hdl - c  high - density lipoprotein cholesterol  ldl - c  low - density lipoprotein cholesterol  tc  total cholesterol  tg  triglycerides . * includes agents acting on the renin - angiotensin system  beta blocking agents  calcium channel blockers  and diuretics . † median values [standard deviation for medians calculated by ( qnmbr qnmbr ) / nmbr . nmbr] . § includes cardiac glycosides  antiarrhythmics class i and iii  vasodilators used in cardiac diseases and other cardiac preparations . ‡ expressed as g / l .,C0003591;C0003594;C0008377;C0011849;C0023824;C0039411;C0040642;C0041004;C0041405;C0041698;C0392885;C0428471;C1824670;C3272447;C4522122
1785,apo  apolipoprotein  dm  diabetes mellitus  hdl - c  high - density lipoprotein cholesterol  ldl - c  low - density lipoprotein cholesterol  tc  total cholesterol ,C0003591;C0003594;C0008377;C0011849;C0023824;C0039411;C0040642;C0041405;C0041698;C0392885;C0428471;C1824670;C3272447;C3715113;C4522122
1785,= ezetimibe  tc = triglycerides  hdl - c = lg / dl l > nmbr . nmbr mmol / l] ) . to qualify as having,C0023128;C0039411;C0040642;C0041405;C0041698;C0062152;C0439190;C0694651;C1142985;C1824670;C3272447;C3642216;C4522122
1784,with treatment,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
1784,with corticosteroid treatment > nmbr,C0001617;C0039798;C0087111;C1522326;C1533734;C1705169;C3536709;C3538994;C3887704
1784,with corticosteroid treatment < nmbr,C0001617;C0039798;C0087111;C1522326;C1533734;C1705169;C3536709;C3538994;C3887704
1784,vka therapy,C0039798;C0087111;C1363945
1784,vasodilator therapy,C0039798;C0042402;C0087111;C1363945;C3537240
1784,type of insulin therapy — no . ( % ) nmbr,C0039798;C0087111;C0457592;C1363945
1784,treatment difference,C0039798;C0087111;C1522326;C1533734;C1705169;C1705241;C1705242;C3538994;C3887704
1784,total time of fondaparinux treatment before,C0039798;C0040223;C0087111;C0439175;C0439810;C1098510;C1522326;C1533734;C1705169;C3538994;C3541383;C3887704
1784,total by treatment,C0039798;C0087111;C0439175;C0439810;C1522326;C1533734;C1705169;C3538994;C3887704
1784,time between cessation of full - dose warfarin therapy and enrollment ( mo ),C0039798;C0087111;C0178602;C0366686;C0682295;C0869039;C1114758;C1363945;C1880019;C4303340
1784,therapy use,C0039798;C0042153;C0087111;C0457083;C1363945;C1947944
1784,therapy,C0039798;C0087111;C1363945
1784,therapies,C0087111
1784,subgroup treatment,C0039798;C0087111;C1079230;C1515021;C1522326;C1533734;C1705169;C3538994;C3887704
1784,subgroup by treatment interaction p - value,C0039798;C0087111;C1079230;C1515021;C1522326;C1533734;C1704675;C1705169;C1709380;C3538994;C3887704
1784,statin treatment,C0039798;C0087111;C0360714;C1522326;C1533734;C1705169;C3538994;C3887704
1784,refractory to such therapy — no . ( % ),C0039798;C0087111;C0205269;C1363945
1784,receiving insulin therapy,C0021641;C0039798;C0087111;C1363945;C1514756;C1533581;C1579433;C3714501
1784,randomised treatment,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
1784,previous treatment with tnf antagonist — no . ( % ) §,C0039798;C0087111;C0205156;C0231491;C1448177;C1522326;C1533734;C1552607;C1705169;C3538994;C3887704
1784,previous treatment with infliximab,C0039798;C0087111;C0205156;C0666743;C1522326;C1533734;C1552607;C1705169;C3538994;C3887704
1784,previous treatment with a laba and / or lama,C0039798;C0087111;C0205156;C1522326;C1533734;C1552607;C1705169;C3538994;C3887704
1784,previous treatment ?,C0039798;C0087111;C0205156;C1522326;C1533734;C1552607;C1705169;C3538994;C3887704
1784,previous treatment,C0039798;C0087111;C0205156;C1522326;C1533734;C1552607;C1705169;C3538994;C3887704
1784,previous copd treatment,C0024117;C0039798;C0087111;C0205156;C1412502;C1522326;C1533734;C1552607;C1705169;C3538994;C3714496;C3887704
1784,prestudy treatment ( % ) a,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
1784,pinteraction for treatment and history of heart failure,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
1784,p - value ( ancova treatment difference ) a,C0039798;C0087111;C0814908;C1522326;C1533734;C1705169;C1705241;C1705242;C1709380;C3538994;C3887704
1784,other treatment assignment,C0039798;C0087111;C1516050;C1522326;C1533734;C1705169;C3538994;C3887704
1784,oab therapy,C0039798;C0087111;C1363945
1784,noninsulin therapy,C0039798;C0087111;C1363945
1784,non - trial treatment during hospital stay,C0008976;C0039798;C0087111;C1518422;C1522326;C1533734;C1705169;C3489408;C3538994;C3887704
1784,no treatment or antihistamines only,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
1784,no previous treatment with infliximab,C0039798;C0087111;C0205156;C0666743;C1522326;C1533734;C1552607;C1705169;C3538994;C3887704
1784,net clinical benefit : on - treatment vte or major bleeding,C0039798;C0087111;C0630906;C0814225;C1456447;C1516635;C1522326;C1533734;C1705169;C3538994;C3853572;C3887704;C3887809;C3890893;C4684590
1784,month nmbr subgroup x treatment interaction p - value,C0039798;C0087111;C0332177;C0439231;C1079230;C1515021;C1522326;C1533734;C1704675;C1705169;C1709380;C3538994;C3887704
1784,monitoring treatment,C0039798;C0087111;C0150369;C1283169;C1522326;C1533734;C1705169;C3538994;C3887704
1784,m o nito ring treatment,C0039798;C0087111;C0369637;C0441923;C0521164;C1260969;C1522326;C1533734;C1705169;C1882954;C3538994;C3887704
1784,ls mean treatment difference ( nmbr % ci ),C0008107;C0023668;C0039798;C0087111;C0444504;C1522326;C1533734;C1705169;C1705241;C1705242;C2347634;C2348143;C3259781;C3538994;C3887704
1784,ls mean [nmbr % ci] treatment difference vs placebo,C0008107;C0023668;C0039798;C0087111;C0444504;C1522326;C1533734;C1705169;C1705241;C1705242;C2347634;C2348143;C3259781;C3538994;C3887704
1784,long term vka therapy,C0039798;C0087111;C0443252;C1363945
1784,long - term vka therapy,C0039798;C0087111;C0443252;C1363945
1784,location of treatment center,C0039798;C0087111;C0205099;C1522326;C1533734;C1705169;C3538994;C3887704
1784,lipid treatment,C0023779;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
1784,lcznmbr treatment,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
1784,interaction between treatment and baseline bmi category,C0039798;C0087111;C1522326;C1533734;C1704675;C1705169;C3538994;C3887704
1784,insulin therapy,C0021641;C0039798;C0087111;C1363945;C1533581;C1579433;C3714501
1784,initiated use during double - blind treatment period,C0013072;C0039798;C0042153;C0087111;C0439531;C0457083;C1522326;C1533734;C1548602;C1704686;C1705169;C1947944;C1948053;C3538994;C3887704
1784,ineffective therapy,C0039798;C0087111;C1363945;C3242229
1784,ifx treatment,C0020823;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
1784,ics dose of stable maintenance treatment ( μ g ) ∗,C0039798;C0087111;C0178602;C0205360;C0439267;C0814469;C0815320;C0869039;C1114758;C1522326;C1533734;C1547311;C1705169;C3538994;C3714445;C3887704;C4551720
1784,high risk ( receiving treatment for ) :,C0039798;C0087111;C0332167;C1514756;C1522326;C1533734;C1705169;C3272283;C3538994;C3887704;C4050568;C4319571
1784,high on - treatment platelet reactivity *,C0005821;C0039798;C0087111;C0205250;C0443286;C1299351;C1522326;C1533734;C1705169;C2700149;C3538994;C3887512;C3887704;C3889660;C4321237;C4522209
1784,goncomitant treatment with age inhibitors / angiotensin,C0001779;C0003018;C0039798;C0087111;C0243077;C1522326;C1533734;C1705169;C3538994;C3887704;C4521302
1784,genotype - by - treatment interaction p values *,C0017431;C0039798;C0087111;C1522326;C1533734;C1704675;C1705169;C1709380;C3538994;C3887704
1784,events treatment ( nmbr ),C0039798;C0087111;C0441471;C1522326;C1533734;C1705169;C3538994;C3541888;C3887704
1784,estimated treatment difference ( % ),C0039798;C0087111;C0750572;C1522326;C1533734;C1705169;C1705241;C1705242;C3538994;C3887704
1784,epa treatment ( n = nmbr ),C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
1784,ed therapy,C0039798;C0087111;C1363945;C3538926
1784,dual therapy,C0039798;C0087111;C0205173;C1363945;C1554184
1784,diabetes treatment,C0011847;C0011849;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
1784,currently on aha therapy,C0039798;C0050451;C0087111;C0521116;C0772110;C1363945
1784,continuous lvef nmbr treatment interaction,C0039798;C0087111;C0428772;C0488728;C0549178;C1522326;C1533734;C1704675;C1705169;C3538994;C3887704
1784,concurrent treatment of crohn ' s disease at study entry — no . of patients ( % ) ff,C0010346;C0039798;C0087111;C0205420;C1522326;C1533734;C1705169;C3538994;C3887704
1784,concurrent treatment at study entry — no . ( % ) * *,C0009247;C0039798;C0087111;C0205420;C0557651;C0679827;C1521826;C1522326;C1533734;C1705169;C1705654;C2603343;C3161471;C3538994;C3887704
1784,concomitant treatment 一 no . ( % ),C0039798;C0087111;C0521115;C1522326;C1533734;C1705169;C3538994;C3887704
1784,concomitant treatment,C0039798;C0087111;C0521115;C1522326;C1533734;C1705169;C3538994;C3887704
1784,chronic treatment with aspirin,C0004057;C0039798;C0087111;C0205191;C1522326;C1533734;C1705169;C3538994;C3887704
1784,background treatment,C0039798;C0087111;C1522326;C1533734;C1705169;C1706907;C3538994;C3887704
1784,background therapy,C0039798;C0087111;C1363945;C1706907
1784,background lipid therapy per acc / aha definition,C0023779;C0039798;C0087111;C1363945;C1550452;C1704788;C1706907;C3539107;C3888054;C4072694
1784,background aha therapy at screening,C0039798;C0050451;C0087111;C0220908;C0220909;C0772110;C1363945;C1698960;C1706907;C1710031;C1710032;C1710477;C2348164
1784,assigned treatment by sex interaction,C0009253;C0036864;C0039798;C0079399;C0087111;C0804628;C1314687;C1516050;C1522326;C1522384;C1533734;C1552601;C1704675;C1705169;C3538994;C3887704
1784,any treatment - emergent ae,C0039798;C0087111;C0750573;C1522326;C1533734;C1705169;C3538994;C3887670;C3887704
1784,any therapy — no . ( % ),C0039798;C0087111;C1363945
1784,antithrombotic therapy,C0039798;C0087111;C1363945
1784,antiarrhythmic therapy,C0003195;C0039798;C0087111;C1363945;C3537142
1784,anti platelet therapy,C0005821;C0039798;C0087111;C1363945
1784,anti - platelet therapy,C0005821;C0039798;C0087111;C1363945
1784,all treatments,C0087111
1784,actual treatment strategy,C0039798;C0087111;C0237400;C0679199;C1522326;C1533734;C1705169;C3538994;C3887704
1784,acs treatment,C0039798;C0087111;C0742343;C1522326;C1533734;C1705169;C3538994;C3887704;C4318612
1784,( e ) aza treatment ( ref ),C0004482;C0039798;C0087111;C1425988;C1522326;C1533734;C1705169;C3538994;C3887704
1784,( d ) aza treatment ( ref ),C0004482;C0039798;C0073187;C0087111;C0332173;C1425988;C1522326;C1533734;C1705169;C3538994;C3887704;C4484261
1784,( c ) ' ' kza treatment ( ref ),C0039798;C0087111;C1425988;C1522326;C1533734;C1705169;C3538994;C3887704
1784,( b ) aza treatment ( ref ),C0004482;C0039798;C0087111;C1425988;C1522326;C1533734;C1705169;C3538994;C3887704
1784,( a ) aza treatment ( ref ),C0004482;C0039798;C0087111;C1425988;C1522326;C1533734;C1705169;C3538994;C3887704
1783,thrombolysis,C0520997
1783,pci / thrombolysis at randomization,C0034656;C0520997;C4049621
1782,rhabdomyolysis or myopathy,C0035410;C4552660
1782,rhabdomyolysis ( n = nmbr ),C0035410;C4552660
1782,rhabdomyolysis,C0035410;C4552660
1781,trandolapril ( n = nmbr ),C0076891
1781,trandolapril,C0076891
1780,hrqol,C4279947;C4300252
1780,health - related quality of life,C4279947
1779,withdrew consent,C2349954
1779,withdrawals,C1710677;C2349954;C2825032;C3812880;C4049634
1778,brazil,C0006137
1777,brachial,C0445456
1776,basal only,C0205112;C0205171;C1720467
1776,basal,C0205112
1775,quality of life,C0034380;C0518214
1775,qol,C0518214
1774,aspirin orother antiplatelet drug,C0004057;C0013227;C0085826;C1254351
1774,aspirin or other antiplatelet or anticoagulant agent,C0004057
1774,aspirin or other antiplatelet drug,C0004057
1774,aspirin or other antiplatelet agents,C0004057
1774,aspirin or other antiplatelet agent,C0004057
1774,aspirin and other antiplatelet,C0004057
1774,aspirin alone group no of events / total n ( % ),C0004057;C2826346
1774,aspirin / other antiplatelet agents,C0004057
1774,aspirin / antiplatelet medication,C0004057;C0013227;C0085826;C3244316;C4284232
1774,aspirin / antiplatelet,C0004057
1774,aspirin ( n = nmbr ) no . of participants with events ( % ),C0004057
1773,prior aspirin,C0004057;C0332152;C2826257
1773,no prior aspirin,C0004057;C0332152;C2826257
1773,no aspirin,C0004057
1773,baseiine aspirin,C0004057
1772,without aspirin ( n = nmbr,C0004057
1772,with aspirin ( n = nmbr,C0004057
1772,no aspirin or ppi,C0004057
1772,aspirin or thienopyridines ( % ),C0004057
1772,aspirin only ( n = nmbr,C0004057;C0205171;C1720467
1772,aspirin only,C0004057;C0205171;C1720467
1772,aspirin nmbr mg,C0004057;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
1772,aspirin nmbr,C0004057
1772,aspirin but no ppi,C0004057
1772,aspirin and thienopyridine therapy,C0004057
1772,aspirin and ppi,C0004057
1772,aspirin < nmbr day,C0004057;C0332173;C0439228;C0439505
1772,aspirin - erdp ( n = nmbr,C0004057
1772,aspirin + thienopyridine,C0004057;C1120149
1772,aspirin ( n = nmbr,C0004057
1772,aspirin ( n,C0004057
1772,aspirin ( % ),C0004057
1772,aspirin,C0004057
1771,therapy ( asa nmbr / placebo nmbr ),C0004057;C0032042;C0039798;C0087111;C1363945;C1696465;C1706408;C3853627
1771,therapy ( asa nmbr,C0004057;C0039798;C0087111;C1363945;C3853627
1771,pfo + asa,C0004057;C3853627
1771,no asa,C0004057;C3853627
1771,nmbr aspirin ( n = nmbr nmbr ),C0004057
1771,baseline nmbr - asa,C0004057;C0168634;C1442488;C3853627
1771,aspirin 一 no . ( % ),C0004057
1771,aspirin — no . ( % ),C0004057
1771,aspirin ( n = nmbr nmbr ),C0004057
1771,aspirin ( n = nmbr ),C0004057
1771,aspirin ( asa ) ( » = nmbr nmbr ),C0004057;C3853627
1771,aspirin ( any dose ),C0004057
1771,asasnmbr,C0004057;C3853627
1771,asas partial remission,C0004057;C1521726;C3853627;C4552913;C4552914
1771,asas nmbr / nmbr,C0004057;C3853627
1771,asa or antiplatelet agent,C0004057;C3853627
1771,asa,C0004057;C3853627
1771,acetylsalicylic acid,C0004057
1771,acetyl - salicylic acid,C0004057
1770,long - term treatment with aspirin — no . / total no . ( % ),C0004057;C0023977
1770,combinations of aspirin and ppi use ( p = nmbr . nmbrt ),C0004057;C0453882;C3539181;C3539182;C3539954;C3539955;C3539956;C3539957;C3539959;C3539960;C3539961;C3539962;C3539963;C3539964;C3539965;C3539966;C3539967;C3539968;C3539969;C3539970;C3539971;C3539972;C3539973;C3539974;C3539975;C3539976;C3539977;C3539978;C3539979;C3540026;C3540027;C3540028;C3540030;C3540031;C3540719;C3540720;C3540721;C3540722;C3540723;C3540724;C3540740;C3854036
1769,regular aspirin use,C0004057;C0042153;C0205272;C0457083;C1947944
1769,prior aspirin use,C0004057;C0042153;C0332152;C0457083;C1947944;C2826257
1769,no regular aspirin use,C0004057;C0042153;C0205272;C0457083;C1947944
1769,aspirin use n ( % ),C0004057;C0042153;C0457083;C1947944
1769,aspirin use before screening — no . { % ),C0004057;C0042153;C0220908;C0220909;C0457083;C1698960;C1710031;C1710032;C1710477;C1947944;C2348164
1769,aspirin use at randomization - n ( % ),C0004057;C0034656;C0042153;C0457083;C1947944
1769,aspirin use ( p = nmbr . nmbrt ),C0004057;C0042153;C0457083;C1947944
1769,aspirin use ( p = nmbr - nmbrt ),C0004057;C0042153;C0457083;C1947944
1769,aspirin use ( p = nmbr - nmbr 十 ),C0004057;C0042153;C0457083;C1947944
1769,aspirin use ( > nmbr mg ),C0004057;C0024671;C0026410;C0042153;C0439269;C0457083;C1947944;C1960952;C2346927;C4321396;C4521761
1769,aspirin use ( % ),C0004057;C0042153;C0457083;C1947944
1769,aspirin use,C0004057;C0042153;C0457083;C1947944
1769,aspirin alone,C0004057
1768,previous chronic kidney disease,C0205156;C1552607;C1561643;C4553188
1768,chronic renal insufficiency,C0403447;C1561643
1768,chronic renal failure,C0022661;C1561643;C2316810
1768,chronic renal disease — no . ( % ),C0022661;C1561643
1768,chronic renal disease,C0022661;C1561643
1768,chronic kidney disease †,C1561643;C4553188
1768,chronic kidney disease ( % ),C1561643;C4553188
1768,chronic kidney disease,C1561643;C4553188
1767,without ckd ( nmbr ),C1561643
1767,with ckd ( nmbr ),C1561643
1767,no ckd n,C1561643
1767,no ckd ( % ),C1561643
1767,no ckd,C1561643
1767,gfr ( ckd - epi ),C0017654;C0162734;C1424601;C1561643;C4281721
1767,egfr ( ckd - epi,C0162734;C1561643;C1739039;C3811844;C3812682;C4281721
1767,cgfrby ckd - epi,C0162734;C1561643;C4281721
1767,baseline - ckd - epi,C0162734;C0168634;C1442488;C1561643;C4281721
1766,ckd stages,C1306673;C1561643
1766,ckd stage nmbr ( % ),C0205390;C1300072;C1306673;C1561643
1766,ckd stage nmbr,C0205390;C1300072;C1306673;C1561643
1766,ckd prognosis by kdigo ' ',C0033325;C1561643;C3854082
1766,ckd n,C1561643
1766,ckd *,C1561643
1766,ckd,C1561643
1765,without concomitant ics,C0521115;C0815320;C4551720
1765,with ics,C0815320;C4551720
1765,with concomitant ics,C0521115;C0815320;C4551720
1765,use of ics,C0815320;C1524063;C4551720
1765,total daily dose of ics,C0815320;C2348070;C4551720
1765,other ics versus no ics,C0815320;C4551720
1765,other ics,C0815320;C4551720
1765,no ics,C0815320;C4551720
1765,neither ics nor laba,C0815320;C4551720
1765,mean ics use at enrolment ( pg ) *,C0444504;C0815320;C2347634;C2348143;C4551720
1765,mean ics ( fluticasone propionate dpi or equivalent  pg per day ),C0117996;C0444504;C0815320;C2347634;C2348143;C4551720
1765,laba   +   ics,C0815320;C4551720
1765,laba plus ics,C0815320;C4551720
1765,laba / lama / ics,C0815320;C0999593;C1416775;C4551720
1765,laba / ics use at screening,C0815320;C4551720
1765,laba / ics #,C0815320;C4551720
1765,laba + ics versus indzgly lsm difference ( nmbr % cl ),C0815320;C4551720
1765,laba + ics n = nmbr,C0815320;C4551720
1765,laba + ics ( free or fixed - dose combination ),C0815320;C4551720
1765,laba + ics,C0815320;C4551720
1765,ics users at screening,C0220908;C0220909;C0815320;C1698960;C1706077;C1710031;C1710032;C1710477;C2348164;C4551720
1765,ics users at baseline,C0168634;C0815320;C1442488;C1706077;C4551720
1765,ics users : qvainmbr - sfc,C0815320;C1706077;C4521536;C4551720
1765,ics users,C0815320;C1706077;C4551720
1765,ics use yes / no,C0815320;C4551720
1765,ics use yes,C0815320;C4551720
1765,ics use no,C0815320;C4551720
1765,ics use at screeningg,C0815320;C4551720
1765,ics use at screening,C0815320;C4551720
1765,ics use at enrollment,C0815320;C4551720
1765,ics use at baseline : yes,C0815320;C4551720
1765,ics use at baseline : no,C0815320;C4551720
1765,ics use at baseline,C0815320;C4551720
1765,ics use,C0815320;C4551720
1765,ics usage,C0457083;C0815320;C4551720
1765,ics plus laba,C0815320;C4551720
1765,ics nonusers,C0815320;C4551720
1765,ics non - users at screening,C0220908;C0220909;C0815320;C1518422;C1698960;C1706077;C1710031;C1710032;C1710477;C2348164;C4551720
1765,ics non - users : qvainmbr - sfc,C0815320;C1518422;C1706077;C4521536;C4551720
1765,ics non - users,C0815320;C1518422;C1706077;C4551720
1765,ics no laba,C0815320;C4551720
1765,ics alone,C0815320;C4551720
1765,ics ? laba ( free or fdc ),C0815320;C4551720
1765,ics : yes,C0815320;C1549445;C1705108;C1710701;C4551720
1765,ics : no,C0815320;C4551720
1765,ics / lama,C0815320;C0999593;C1416775;C4551720
1765,ics / labd,C0396059;C0815320;C4551720
1765,ics / laba therapy,C0039798;C0087111;C0815320;C1363945;C4551720
1765,ics / laba,C0815320;C4551720
1765,ics + laba,C0815320;C4551720
1765,ics # #,C0815320;C4551720
1765,ics  no laba ( tiotropium n = nmbr  placebo n = nmbr ),C0815320;C4551720
1765,ics,C0815320;C4551720
1765,baseline ics > nmbr pg per day ( fluticasone propionate dpi or equivalent ) and laba,C0117996;C0168634;C0815320;C1442488;C2827928;C4551720
1765,- ics / + laba n z nmbr,C0815320;C4551720
1765,+ ics / + laba nz nmbr,C0027978;C0815320;C4551720
1765,+ ics / + laba n z nmbr,C0815320;C4551720
1764,without tnmbrdm n = nmbr,C0011816;C2986835;C3250443
1764,without dm ( n = nmbrinmbr * ),C0011816;C3250443
1764,without dm,C0011816;C3250443
1764,with tnmbrdm n = nmbr,C0011816;C2986835;C3250443
1764,with dm,C0011816;C3250443
1764,tnmbrdm duration ( years ),C0011816;C0439234;C0449238;C2603360;C2926735;C3250443
1764,tnmbrdm duration,C0011816;C0449238;C2603360;C2926735;C3250443
1764,tnmbrdm,C0011816;C2603360;C3250443
1764,previous dm,C0011816;C0205156;C1552607;C3250443
1764,of tnmbrdm ( years ),C0011816;C0439234;C2603360;C3250443
1764,no dm ( n = nmbr ),C0011816;C3250443
1764,no dm ( n = nmbr,C0011816;C3250443
1764,no dm,C0011816;C3250443
1764,new dm,C0011816;C0205314;C3250443
1764,neither tnmbrdm nor mets,C0011816;C2603360;C3250443
1764,dm present,C0011816;C0150312;C0449450;C3250443
1764,dm or diabetic complications,C0011816;C3250443
1764,dm or ckd *,C0011816;C3250443
1764,dm duration,C0011816;C0449238;C2926735;C3250443
1764,dm absent,C0011816;C3250443
1764,dm ( n = nmbr ),C0011816;C3250443
1764,dm ( n = nmbr,C0011816;C3250443
1764,dm,C0011816;C3250443
1763,symptomatic deep - vein thrombosis,C0149871;C0231220
1763,residual deep - vein thrombosis,C0149871;C1609982
1763,pulmonary embolism ± deep vein thrombosis,C0034065;C0149871;C0226514;C0852030
1763,previous deep - vein thrombosis or pulmonary embolism,C0149871;C0205156;C1552607
1763,patients with deep - vein thrombosis only,C0030705;C0149871;C0205171;C1720467
1763,neither deep - vein thrombosis nor pulmonary embolism^,C0149871
1763,neither deep - vein thrombosis nor pulmonary embolism §,C0149871
1763,deep vein thrombosis only,C0149871;C0205171;C1720467
1763,deep - vein thrombosis or pulmonary embolism — no . ( % ),C0149871
1763,deep - vein thrombosis only,C0149871;C0205171;C1720467
1763,deep - vein thrombosis ( % ),C0149871
1763,deep - vein thrombosis,C0149871
1763,both deep - vein thrombosis and pulmonary embolism,C0149871
1762,without dvt dvt alone,C0149871;C2926618;C3899446
1762,sco . ’ ita ' rojs dvt . ' pe,C0022277;C0070939;C0149871;C1880476;C2926618;C2986561;C3899446;C4284304
1762,pre ' rtous eptscde ( s } d dvt / pe,C0070939;C0149871;C0332152;C0740175;C1880476;C2257086;C2926618;C3669034;C3899446;C4284304
1762,only dvt,C0149871;C0205171;C1720467;C2926618;C3899446
1762,dvt only,C0149871;C0205171;C1720467;C2926618;C3899446
1762,dvt,C0149871;C2926618;C3899446
1762,causes of dvt or pe — no . ( % ) ^ |,C0015127;C0149871;C1314792;C2926618;C3899446
1762,causes of dvt or pe,C0015127;C0149871;C1314792;C2926618;C3899446
1762,cause of dvt or pe — no . ( % ),C0015127;C0149871;C1524003;C2926618;C3899446
1761,seated dbp,C0277814;C0536221;C1283233;C3813197;C4281799
1761,sbp / dbp mean,C0085805;C0444504;C0536221;C2347634;C2348143;C3813197;C4281799
1761,sbp / dbp ( mmhg ),C0085805;C0439475;C0536221;C3813197;C4281799
1761,sbp / dbp $ nmbr / $ nmbr mmhg,C0085805;C0439475;C0536221;C3813197;C4281799
1761,dbp ≥ nmbr mmhg,C0439475;C0536221;C3813197;C4281799
1761,dbp > nmbr or sbp > nmbr mm hg laboratory determinations,C0536221;C3813197;C4281799
1761,dbp < nmbr mmhg,C0439475;C0536221;C3813197;C4281799
1761,dbp ( mmhg ),C0439475;C0536221;C3813197;C4281799
1761,dbp ( mmghg ),C0536221;C3813197;C4281799
1761,dbp ( mm hg ),C0439475;C0536221;C3813197;C4281799
1761,dbp,C0536221;C3813197;C4281799
1761,baseline dbp ( mm hg ),C0168634;C0439475;C0536221;C1442488;C3813197;C4281799
1760,subacute ( nmbr - nmbr days ),C0205365;C0439228
1760,median ( days ),C0439228;C0549183;C0876920;C2347635;C2348144;C2939193
1760,> = medion ( nmbr days ),C0439228
1760,> = median ( nmbr days ),C0439228;C0549183;C0876920;C2347635;C2348144;C2939193
1760,< median { nmbr days ),C0439228;C0549183;C0876920;C2347635;C2348144;C2939193
1760,< median ( nmbr days ),C0439228;C0549183;C0876920;C2347635;C2348144;C2939193
1759,slo days,C0439228;C1416602;C3539661
1759,nmbr — nmbr days,C0439228
1759,nmbr days,C0439228
1759,nmbr - nmbr days,C0439228
1759,^nmbr days,C0439228
1759,> nmbr days,C0439228
1759,> = nmbr days,C0439228
1759,< nmbr days,C0439228
1758,treatment duration before randomization — days,C0034656;C0439228;C0444921;C3259042
1758,recent cardioversion ( within nmbr days before randomization ) — no . ( % ),C0013778;C0332185;C0439228
1758,recent cardioversion ( within nmbr days before randomization ) —,C0013778;C0332185;C0439228
1758,no . of days to randomization — median ( iqr ),C0439228
1758,no . of days to homa - ir testing — median ( iqr ),C0439228
1758,lmwh within nmbr days before randomization — no . / total no . ( % ),C0019139;C0439228;C3536766
1758,index stroke > nmbr days before randomization — no . ( % ),C0034656;C0439228;C0456712
1758,coronary revascularization nmbr days after randomization,C0034656;C0439228;C0877341
1757,vte at day nmbr +,C0332173;C0439228;C0439505;C0630906
1757,saba puffs per day at baseline,C0332173;C0439228;C0439505;C1533107
1757,nmbr day l,C0332173;C0439228;C0439505
1757,nmbr / day,C0332173;C0439228;C0439505
1757,nmbr - nmbr / day,C0332173;C0439228;C0439505
1757,nmbr - day mortality,C0026565;C0026566;C0332173;C0439228;C0439505
1757,nmbr - day cce,C0332173;C0439228;C0439505
1757,every day,C0332173;C0439228;C0439505
1757,current ( nmbr + cigs / day ),C0332173;C0439228;C0439505;C0521116;C1570610;C1705970
1757,as - needed inhalations / day,C0004048;C0332173;C0354922;C0439228;C0439505;C1879745;C1883728
1757,a ngina > nmbr day s previously *,C0332173;C0439228;C0439505
1757,> nmbr / day,C0332173;C0439228;C0439505
1756,saba use in past nmbr days,C0042153;C0439228;C0457083;C1444637;C1947944;C4284302
1756,days without albuterol use,C0001927;C0042153;C0439228;C0457083;C1947944
1756,days with heartburna ( days ),C0439228
1756,( iqr ) — days,C0439228
1755,nmbr days stroke ( ischemic ),C0439228
1755,nmbr days new mi or definite acute st,C0205314;C0439228;C3810814
1755,nmbr days new mi,C0205314;C0439228;C3810814
1755,nmbr - nmbr days ( % ),C0439228
1755,> nmbr days ( % ),C0439228
1755,< nmbr days ( n = nmbr ),C0439228
1755,< nmbr days ( % ),C0439228
1754,poor outcome at nmbr months,C0439231;C3806166
1754,fall in last nmbr months ( % ),C0085639;C0238715;C0439231;C4553726
1754,duration of metformin therapy ( months ),C0025598;C0439231;C0444917
1753,months from qualifying stroke *   ( % ),C0038454;C0439231;C1514624;C4554100
1753,months ( log - transformed ),C0439231
1752,snmbr months,C0439231;C0565930;C2603362
1752,nmbrtob nmbr months,C0439231;C1420851
1752,nmbr – nmbr months,C0439231
1752,nmbr months,C0439231
1752,nmbr - nmbr months fn = nmbr . nmbr ),C0439231;C1570610
1752,nmbr - nmbr months,C0439231
1752,months since ra was first diagnosed,C0439231
1752,months since first ra symptom,C0439231
1752,intensified nmbr months ( n - nmbr ),C0439231
1752,^nmbr months,C0439231
1752,> nmbrmonths,C0439231
1752,> nmbr months,C0439231
1752,< nmbr months in - nmbr kill,C0162388;C0439231;C0681205;C1550555
1752,< nmbr months,C0439231
1751,smoking ( during the previous month ),C0332177;C0439231;C2114448
1751,nmbr week to nmbr month,C0332174;C0332177;C0439230;C0439231
1751,nmbr - nmbr months ( n = nmbr ),C0439231
1751,nmbr - nmbr / month,C0332177;C0439231
1751,nmbr - < nmbr months,C0439231
1751,hbanmbrc month nmbr ( % ),C0019016;C0332177;C0439231;C1825777;C3538758
1751,> nmbr months ( n = nmbr,C0439231
1751,> nmbr month n = nmbr,C0332177;C0439231
1751,< nmbr month n = nmbr,C0332177;C0439231
1750,without mets,C0812270;C1705694;C2939420
1750,with mets,C0812270;C1705694;C2939420
1750,mets w / o tnmbrdm,C0011816;C0812270;C1705694;C2939420;C3250443
1750,mets pbo ( n = nmbr ) vs evomab ( n = nmbr ),C0031962;C0812270;C1705694;C2939420
1750,mets,C0812270;C1705694;C2939420
1750,i without mets ( n = nmbr ),C0021966;C0221138;C0812270;C1705694;C2939420
1750,i with mets ( n = nmbr ),C0021966;C0221138;C0812270;C1705694;C2939420
1749,serum total ige,C1441420
1748,sertraline,C0074393;C0524265
1747,stating,C1301808;C1442792;C3148680
1747,state,C1301808;C1442792;C3148680
1746,parameter statistics,C0681933
1745,subgroup statistics,C0038215;C0600673;C1079230;C1515021
1745,statistics,C0038215;C0600673
1744,statistic * *,C2348149;C2828391
1744,sample statistics,C2348149
1743,total asthma symptom score :,C0004096;C2984299;C3533163
1743,total asthma symptom score,C0004096;C2984299;C3533163
1743,newly diagnosed asthma ( n ),C0004096;C0011900;C0750546;C2984299
1743,mean ( sd ) total asthma symptom scores,C0004096;C0444504;C2347634;C2348143;C2699239;C2984299;C3533163
1743,hospitalized for asthma,C0004096;C0701159;C2984299
1743,duration of asthma — yr,C0004096;C0439234;C0449238;C2926735;C2984299
1743,duration of asthma > nmbr years,C0004096;C0439234;C0449238;C2926735;C2984299
1743,duration of asthma ( years ),C0004096;C0439234;C0449238;C2926735;C2984299
1743,duration of asthma,C0004096;C0449238;C2926735;C2984299
1743,asthma population ( n = nmbr ),C0004096;C0032659;C1257890;C2984299
1743,asthma duration ( sd ),C0004096;C0449238;C2699239;C2926735;C2984299
1743,asthma - related health -,C0004096;C2984299
1743,asthma,C0004096;C2984299
1742,without psoriasis ( zi = nmbr ),C0033860;C0043476
1742,without psoriasis ( zi = nmbr,C0033860;C0043476
1742,without psoriasis ( n = nmbr ),C0033860
1742,without psoriasis ( n = nmbr,C0033860
1742,with psoriasis ( zi = nmbr ),C0033860;C0043476
1742,with psoriasis ( n = nmbr ),C0033860
1742,randomised patients with > nmbr % bsa psoriasis skin involvement at baseline,C0030705;C0033860;C0444099;C1123023;C1314939;C4520765
1742,patients without psoriasis ( n = nmbr ),C0030705;C0033860
1742,patients with psoriasis > nmbr % of body surface area,C0017446;C0030705;C0033860;C0205146;C0489451
1742,patients with psoriasis ( n = nmbr ),C0030705;C0033860
1742,patients with psoriasis ( bsa ≥   nmbr % ),C0030705;C0033860
1742,patients with > nmbr % bsa psoriasis skin involvement,C0030705;C0033860;C0444099;C1123023;C1314939;C4520765
1742,dlqi ( patients with £ nmbr % bsa psoriasis ),C0030705;C0033860;C3899393
1741,psoriasis covering > nmbr % bsa,C0033860;C0180153;C0439844
1741,psoriasis affecting > nmbr % of body - surface,C0033860;C0392760;C0489451;C1314939
1741,psoriasis > nmbr % of bsa,C0033860
1740,£ nmbr % bsa psoriasis,C0033860
1740,psoriasis duration ( years ),C0033860;C0439234;C0449238;C2926735
1740,psoriasis duration,C0033860;C0449238;C2926735
1740,psoriasis bsa > nmbr %,C0033860
1740,psoriasis ( n =,C0033860
1740,psoriasis,C0033860
1740,duration of psoriasis,C0033860;C0449238;C2926735
1739,edss stratification . no . ( % ),C0451246;C1514983;C3887783
1739,edss stratification,C0451246;C1514983;C3887783
1739,edss score,C0451246;C3887783
1738,leeds enthesitis index^ score > nmbr — no . { % ),C0451148
1738,leeds enthesitis index,C0451148
1737,odds ‐ ratio ( nmbr % ci ),C0008107;C0028873;C3259781
1737,odds ratios ( nmbr % ci ),C0008107;C0028873;C3259781
1737,odds ratio versus placebo ( nmbr % ci ),C0028873
1737,odds ratio and nmbr % cl,C0028873
1737,odds ratio adj ( nmbr % cl ),C0001552;C0028873;C0596019;C2826286
1737,odds ratio ( nmbr % cl ),C0028873;C0596019
1737,odds ratio ( nmbr % ci ),C0008107;C0028873;C3259781
1737,odds ratio,C0028873
1737,estimated odds ratio,C0028873;C0750572
1736,postmenopausal hormone use,C0019932;C0042153;C0232970;C0457083;C1947944;C4521914
1736,postmenopausal and no ht,C0232970
1736,postmenopausal and no hrt,C0232970
1736,postmenopausal and current ht,C0232970
1736,postmenopausal and current hrt,C0232970
1736,postmenopausal ( % ),C0232970
1736,postmenopausal,C0232970
1736,post - menopausal ( a ),C0232970
1736,history of postmenopausal fracture *,C0232970;C1272071
1735,surgical technique post - randomisation characteristic * *,C0034656;C0683469;C0687676;C1521970;C1704687;C3469826
1735,postoperative glucocorticoid use post - randomisation characteristic * *,C0017710;C0032790;C0034656;C0042153;C0457083;C0687676;C1521970;C1704687;C1947944;C3469826
1735,post svc,C0231957;C0687676;C1704687;C3469826
1735,post - salbutamol fevnmbr / fvcb,C0001927;C0687676;C1704687;C3469826;C3714541
1735,post - salbutamol fevnmbr ( l ) b,C0001927;C0687676;C1704687;C3469826;C3714541
1735,post - cabg,C0010055;C0687676;C1704687;C3469826
1735,post - albuterol % predicted fevnmbr mean ( sd ) e,C0001927;C0687676;C1704687;C3469826
1735,post - acute ischemic stroke,C0205178;C0475224;C0687676;C0751956;C0948008;C1704687;C3469826
1734,stricturing,C1261287
1734,stenosis > nmbr %,C0678234;C1261287;C2632116
1734,percent stenosis [investigator],C0035173;C0439165;C0678234;C1261287;C2632116
1734,percent stenosis [core lab],C0439165;C0678234;C1261287;C2632116;C4684837
1734,maximal diameter stenosis,C0205289;C0678234;C0806909;C1261287;C1301886;C2632116;C4049713
1734,ica stenosis nmbr % - nmbr % f,C0016327;C0201519;C0678234;C1261287;C2632116
1734,diameter stenosis,C0678234;C1261287;C1301886;C2632116
1734,% stenosis ( investigator ),C0035173;C0678234;C1261287;C2632116
1734,% stenosis ( core lab ),C0678234;C1261287;C2632116;C4684837
1734,% stenosis,C0678234;C1261287;C2632116
1733,time from qualifying myocardial infarction,C0027051;C0040223;C0428953;C1514624;C2926063;C3541383;C3810814;C4552959
1733,qualifying myocardial infarction,C1514624
1733,qualifying mi < nmbr yrs prior,C1514624;C3810814
1733,qualifying mi : stemi,C1514624;C1536220;C3538872;C3810814
1733,qualifying mi $ nmbr yrs prior,C1514624;C3810814
1732,qualifying risk factors — no . ( % ),C0035648;C1514624;C1553898
1732,qualifying risk factor — no . ( % ),C0035648;C1514624
1732,qualifying risk factor,C0035648;C1514624
1732,qualifying peripheral arterial disease,C1514624
1731,qualifying symptomatic event,C1514624
1731,qualifying index event as pe,C0070939;C0441471;C0600653;C0918012;C1514624;C1552854;C1637833;C1880476;C2986546;C4019010;C4284304
1731,qualifying high - risk features — %,C1514624
1731,qualifying events,C0441471;C1514624;C3541888
1731,qualifying event — no . ( % ),C0441471;C1514624;C4019010
1731,qualifying event,C0441471;C1514624;C4019010
1731,qualifying cv event,C0441471;C1514624;C3538987;C4019010;C4048877;C4318503
1731,qualifying acs event — no . ( % ),C0441471;C0742343;C1514624;C4019010;C4318612
1731,pciperformed for qualifying event,C0441471;C1514624;C4019010
1731,fibrinolytic for qualifying event,C0040044;C0441471;C1514624;C4019010
1731,at qualifying event,C0441471;C1514624;C4019010
1731,anatomical extent of qualifying event — no . ( % ) : t,C0220784;C0439792;C0441471;C1514624;C4019010
1731,anatomic extent of qualifying event,C0220784;C0439792;C0441471;C1514624;C4019010
1730,quintile nmbr ( nmbr . nmbr % - nmbr . nmbr % ) ( n = nmbr ),C1508496
1730,quintile ( n ),C1508496
1730,quintile,C1508496
1730,baseline trl - c by quintiles,C0168634;C1442488;C1508496
1730,baseline triglycerides by quintiles,C0041004;C0168634;C1442488;C1508496
1729,vital signs,C0150404;C0518766
1728,vitamin c,C0003968;C2349136;C3714687;C4522080
1727,vitality,C0424589
1726,italy ( n = nmbr ),C0022277
1726,italy,C0022277
1725,final mean,C0205088;C0444504;C1546485;C2347634;C2348143;C3853528
1725,final anmbrc ( % ),C0205088;C1546485;C3853528
1725,final ( mg / dl ),C0205088;C0439269;C1546485;C3853528
1725,final,C0205088;C1546485;C3853528
1724,vildagliptin nmbr mg qd n = nmbr,C0024671;C0026410;C0332173;C0439269;C1570906;C1960952;C2346927;C4321396;C4521761
1724,vildagliptin nmbr mg qd,C0024671;C0026410;C0332173;C0439269;C1570906;C1960952;C2346927;C4321396;C4521761
1724,vildagliptin nmbr mg daily,C0024671;C0026410;C0332173;C0439269;C1570906;C1960952;C2346927;C4321396;C4521761
1724,vildagliptin nmbr mg bid n = nmbr,C0024671;C0026410;C0439269;C1570906;C1960952;C2346927;C4321396;C4521761
1724,vildagliptin nmbr mg bid,C0024671;C0026410;C0439269;C1570906;C1960952;C2346927;C4321396;C4521761
1724,vildagliptin + metformin ( vldm ),C0025598;C1570906
1724,vildagliptin ( n = nmbr ),C1570906
1724,vildagliptin,C1570906
1723,with alogliptin nmbr mg ( n nmbr nmbr ),C0024671;C0026410;C0439269;C1958126;C1960952;C2346927;C4321396;C4521761
1723,with alogliptin nmbr mg,C0024671;C0026410;C0439269;C1958126;C1960952;C2346927;C4321396;C4521761
1723,with alogliptin nmbr . nmbr mg ( n nmbr nmbr ),C0024671;C0026410;C0439269;C1958126;C1960952;C2346927;C4321396;C4521761
1723,with alogliptin nmbr . nmbr mg,C0024671;C0026410;C0439269;C1958126;C1960952;C2346927;C4321396;C4521761
1723,alogliptin ( n = nmbr ),C1958126
1723,alogliptin,C1958126
1722,linagliptin / metformin,C3264599
1721,sitagliptin ± oad,C1565750
1721,sitagliptin no . / total no .,C1565750
1721,sitagliptin nmbrmg n = nmbr,C0024671;C0026410;C0439269;C1565750;C1960952;C2346927;C4321396;C4521761
1721,sitagliptin nmbr mg n = nmbr,C0024671;C0026410;C0439269;C1565750;C1960952;C2346927;C4321396;C4521761
1721,sitagliptin nmbr,C1565750
1721,sitagliptin n = nmbr,C1565750
1721,sitagliptin ( n = nmbr ),C1565750
1721,sitagliptin,C1565750
1720,saxagliptin nmbrmg ( n z nmbr ),C0024671;C0026410;C0439269;C1611934;C1960952;C2346927;C4321396;C4521761
1720,saxagliptin nmbrmg,C0024671;C0026410;C0439269;C1611934;C1960952;C2346927;C4321396;C4521761
1720,saxagliptin nmbr mg ( n = nmbr,C0024671;C0026410;C0439269;C1611934;C1960952;C2346927;C4321396;C4521761
1720,saxagliptin nmbr mg,C0024671;C0026410;C0439269;C1611934;C1960952;C2346927;C4321396;C4521761
1720,saxagliptin nmbr . nmbr mg ( n z nmbr ),C0024671;C0026410;C0439269;C1611934;C1960952;C2346927;C4321396;C4521761
1720,saxagliptin nmbr . nmbr mg ( n = nmbr ),C0024671;C0026410;C0439269;C1611934;C1960952;C2346927;C4321396;C4521761
1720,saxagliptin nmbr . nmbr mg ( n = nmbr,C0024671;C0026410;C0439269;C1611934;C1960952;C2346927;C4321396;C4521761
1720,saxagliptin nmbr . nmbr mg,C0024671;C0026410;C0439269;C1611934;C1960952;C2346927;C4321396;C4521761
1720,saxagliptin ( n = nmbr ),C1611934
1720,saxagliptin ( n = nmbr,C1611934
1720,saxagliptin ( % ),C1611934
1720,saxagliptin,C1611934
1719,wml load at follow - up mri stratified by baseline severity of wml load,C0024485;C0589120;C1522577;C1550025;C1704685;C1704782;C1708715;C1824234;C3274571;C3890166
1719,wml load at follow - up mri,C0024485;C0589120;C1522577;C1550025;C1704685;C1704782;C1708715;C1824234;C3274571;C3890166
1719,wml load at baseline mri,C0024485;C0168634;C1442488;C1550025;C1704782;C1708715;C1824234;C3890166
1719,mri substudy ( n = nmbr ),C0024485;C1824234;C3890166
1718,dexlansoprazole mr nmbr mg qd,C0024485;C0024671;C0026410;C0332173;C0439269;C1417249;C1960952;C2346927;C2347167;C2348248;C3254418;C4050513;C4321396;C4521761
1718,dexlansoprazole mr nmbr mg,C0024485;C0024671;C0026410;C0439269;C1417249;C1960952;C2346927;C2347167;C2348248;C3254418;C4050513;C4321396;C4521761
1718,dexlansoprazole mr ( n = nmbr ),C0024485;C1417249;C2347167;C2348248;C3254418;C4050513
1718,dexlansoprazole mr,C0024485;C1417249;C2347167;C2348248;C3254418;C4050513
1717,prior percutaneous coronary intervention — no . / total no . ( % ),C0332152;C1532338;C2826257
1717,prior percutaneous coronary intervention — no . ( % ),C0332152;C1532338;C2826257
1717,prior percutaneous coronary intervention,C0332152;C1532338;C2826257
1717,percutaneous coronary revascularization,C1532338
1717,percutaneous coronary intervention §,C1532338
1717,percutaneous coronary intervention or coronary artery bypass graft surgery,C1532338
1717,percutaneous coronary intervention or coronary - artery bypass grafting for index acute coronary syndrome — no . { % ),C1532338
1717,percutaneous coronary intervention n ( % ),C1532338
1717,percutaneous coronary intervention done *,C1532338
1717,percutaneous coronary intervention,C1532338
1717,index percutaneous coronary intervention,C0600653;C0918012;C1532338;C1552854;C1637833;C2986546
1717,graft  pci  percutaneous coronary intervention  tia  transient,C0007787;C0181074;C0332835;C0917805;C1054154;C1532338;C1961139
1716,no known frtrontxtfufoc cond aon,C0205309
1716,known tiromtcch * c ccndifeon,C0205309
1716,known t ' rc - iitoji cccndilon,C0205309;C1167159;C1419366
1716,known prothrombotic genotype,C0017431;C0205309
1715,valve replacement / repair with or without cabg,C0035139;C0043240;C0184252;C0374711;C0559956;C1186983;C1555302;C1704414;C3888056;C4319951;C4553149
1715,valve repair / replacement with or without cabg,C0035139;C0043240;C0184252;C0374711;C0559956;C1186983;C1555302;C1704414;C3888056;C4319951;C4553149
1715,valve repair / replacement only,C0035139;C0043240;C0184252;C0205171;C0374711;C0559956;C1186983;C1555302;C1704414;C1720467;C3888056;C4319951;C4553149
1715,surgical repair of vsd or pda > nmbr - year duration,C0018818;C0374711
1714,elevation of troponin levels — no . / total no . ( % ),C0041199;C0439775;C0441889;C0702240
1714,elevation of cardiac biomarker levels — no . / total no . ( % ),C0439775;C0441889;C0702240;C1271630
1714,elevation of cardiac biomarker levels or st - seg - ment deviation > nmbr mm — no . / total no . ( % ),C0439775;C0441889;C0702240;C1271630
1714,cardiac biomarker elevation,C0439775;C0702240;C1271630
1713,ultrasound carotid arteries,C0948945
1712,fluticasone furoate and vilanterol ( n = nmbr ),C1948374
1712,fluticasone furoate,C1948374
1711,intermittent claudication,C0021775
1711,claudication only,C0021775;C0205171;C0311395;C1456822;C1720467
1711,claudication ( fontaine class > nmbr ),C0021775;C0311395;C0456387;C1456822;C1518526;C1705943
1711,claudication,C0021775;C0311395;C1456822
1710,no inducer at core study entry,C0444669;C0557651;C1167518;C1705654;C1706352;C1882467;C2603343;C3274653;C3898767
1710,necrotic core,C0027540;C0444669;C1167518;C1706352;C1882467;C3274653
1710,core laboratory percent stenosis,C0022877;C0439165;C0444669;C0678234;C1167518;C1261287;C1706352;C1882467;C2632116;C3244292;C3274653;C4283904
1709,obstructive subscore,C0549186
1709,chronic obstructive pulmonary,C0024109;C0205191;C0549186;C2707265;C2709248;C4522268
1708,coexisting conditions,C0679225
1707,cognitive functioning,C0392334;C0392335
1706,nordic countries,C0036273
1705,aortic stenosis,C0003507
1704,scarring on renal biopsy,C0005558;C0008767;C0194073;C0220797;C1700247;C2004491
1703,transient monocular blindness,C0149793
1702,bifurcation per lesion ‡,C0184906;C0221198;C1546698;C3146289
1702,bifurcation lesion with side branch ≥ nmbr . nmbr mm stented,C0184906;C0205384;C0221198;C0441987;C1253959;C1546698;C1881507;C2700383;C2826234;C3146289;C4330985;C4554674
1702,bifurcation lesion with side branch $ nmbr . nmbr mm stented,C0184906;C0205384;C0221198;C0441987;C1253959;C1546698;C1881507;C2700383;C2826234;C3146289;C4330985;C4554674
1702,bifurcation lesion,C0184906;C0221198;C1546698;C3146289
1702,bifurcation,C0184906;C3146289
1701,who functional class — no . ( % ) : c,C0205245;C0456387;C0542341;C1518526;C1705943;C2700217
1701,who functional class,C0205245;C0456387;C0542341;C1518526;C1705943;C2700217
1701,nyha functional class nmbr,C0205245;C0542341;C1882083;C2700217
1701,nyha functional class at screening,C0205245;C0220908;C0220909;C0542341;C1698960;C1710031;C1710032;C1710477;C1882083;C2348164;C2700217
1701,nyha functional class at randomization,C0034656;C0205245;C0542341;C1882083;C2700217
1701,nyha functional class ( % ),C0205245;C0542341;C1882083;C2700217
1701,nyha functional class,C0205245;C0542341;C1882083;C2700217
1701,functional outcome ( mrs nmbr - nmbr ),C0205245;C0542341;C1274040;C1522706;C2349188;C2700217;C3714939;C3854213
1701,ara functional class — no . ( % ),C0205245;C0325983;C0456387;C0542341;C1518526;C1705943;C2316832;C2700217;C3890184;C4282437;C4321455
1701,ara functional class,C0205245;C0325983;C0456387;C0542341;C1518526;C1705943;C2316832;C2700217;C3890184;C4282437;C4321455
1701,acr functional class,C0205245;C0456387;C0542341;C1412134;C1515941;C1518526;C1705943;C2700217
1700,womac function score,C0031843;C0449820;C0542341;C0700205;C1705273;C4050231
1700,opaqb physical function score,C0031843;C0449820;C0516981;C0542341;C0700205;C1705273;C4049916;C4050231;C4483112
1700,lv function > nmbr . nmbr and < nmbr . nmbr,C0023128;C0031843;C0542341;C0700205;C0731033;C1705273;C1881413
1700,lv function,C0023128;C0031843;C0542341;C0700205;C0731033;C1705273;C1881413
1700,function subscale,C0031843;C0542341;C0700205;C1705273
1700,erectile function  ipss,C0030847;C0031843;C0542341;C0700205;C1019118;C1705273;C1998280;C2827405;C3811063
1700,emotional function,C0013987;C0031843;C0542341;C0700205;C0849912;C1705273
1700,dysfunction  ef = erectile function  iief = i,C0021966;C0030847;C0031843;C0031847;C0221138;C0277785;C0542341;C0700205;C1705273;C3641331;C3887504;C3887505
1699,eosinoohil count,C0750480;C1705566
1699,dactylitis count ( nmbr - nmbr ),C0239161;C0750480;C1705566
1699,dactylitis count,C0239161;C0750480;C1705566
1699,< nmbr with no historical count > nmbr,C0750480;C1552658;C1552723;C1705566;C2004062
1699,< nmbr with historical count > nmbr,C0750480;C1552658;C1552723;C1705566;C2004062
1699,< nmbr regardless of historical count,C0750480;C1552658;C1552723;C1705566;C2004062
1698,increased waist circumference,C0205217;C0442805;C0455829
1698,increased risk for thrombotic cardiovascular event^,C0087086;C0205217;C0442805;C1273410
1698,augment copd,C0205217
1697,no glucocorticoids or immunosuppressants,C0017710;C3540777;C3540778
1697,no glucocorticoids at baseline,C0017710;C0168634;C1442488;C3540777;C3540778
1697,neither glucocorticoids nor immunosuppressive agents,C0017710;C3540777;C3540778
1697,glucocorticoids plus immunosuppressive agents,C0017710;C0021081;C3540777;C3540778
1697,glucocorticoids only,C0017710;C0205171;C1720467;C3540777;C3540778
1697,glucocorticoids combined with immunosuppressive agents,C0017710;C3540777;C3540778
1697,glucocorticoids at baseline,C0017710;C0168634;C1442488;C3540777;C3540778
1697,glucocorticoids and immunosuppressants,C0017710;C3540777;C3540778
1697,glucocorticoids *,C0017710;C3540777;C3540778
1697,glucocorticoids,C0017710;C3540777;C3540778
1697,glucocorticoid],C0017710
1697,glucocorticoid,C0017710
1697,any glucocorticoid *,C0017710
1696,oral glucocorticoid use at baseline — no . ( % ) : t,C0017710;C0168634;C1442488;C1527415
1696,oral glucocorticoid use,C0017710;C1527415
1695,current oral corticosteroid use,C0001617;C0239126;C0442027;C0521116;C1527415;C1705970;C3536709;C4521986
1695,current inhaled corticosteroid use,C0004048;C0239126;C0521116;C1705970
1695,current corticosteroid use,C0239126;C0521116;C1705970
1695,corticosteroid use,C0239126
1695,concomitant corticosteroid use,C0239126;C0521115
1694,systemic corticosteroids — no . ( % ),C4053960
1694,systemic corticosteroids,C4053960
1694,systemic corticosteroid use,C0042153;C0205373;C0239126;C0457083;C1947944;C4053960
1693,placebo - control study,C0683952
1692,glycaemic control group,C0005802;C0009932
1692,events / control group,C0009932;C0441471;C3541888
1692,control group,C0009932
1691,diet controlled or no,C0743195
1691,diet - controlled ( % ),C0743195
1690,required corticosteroid and / or antibiotic ( without hospitalization ),C0001617;C1514873;C3536709
1690,prior corticosteroid treatment,C0001617;C1514463;C3536709
1690,oral corticosteroid use at enrolmentt,C0001617;C0239126;C0442027;C1527415;C3536709;C4521986
1690,oral corticosteroid use,C0001617;C0239126;C0442027;C1527415;C3536709;C4521986
1690,oral corticosteroid dose ( mg / day ),C0001617;C0178602;C0439422;C0442027;C0869039;C1114758;C3536709;C4521986
1690,oral corticosteroid,C0001617;C0442027;C3536709;C4521986
1690,no corticosteroid + no imm,C0001617;C3536709
1690,no corticosteroid,C0001617;C3536709
1690,neither corticosteroid nor immunosuppressant,C0001617;C3536709
1690,inhaled corticosteroid - yes,C0001617;C0004048;C1549445;C1705108;C1710701;C3536709
1690,inhaled corticosteroid,C0001617;C0004048;C3536709
1690,immy ( without corticosteroid ),C0001617;C3536709
1690,imm + corticosteroid,C0001617;C0205470;C3536709
1690,imm ( without corticosteroid ),C0001617;C0205470;C3536709
1690,corticosteroid or immunosuppressant,C0001617;C3536709
1690,corticosteroid or azathioprine / nmbr - mercaptopurine,C0001617;C3536709
1690,corticosteroid and immunosuppressant,C0001617;C3536709
1690,corticosteroid - free remissioni,C0001617;C0332296;C1880497;C1996904;C3536709
1690,corticosteroid - azathioprine / nmbr - mercaptopurine,C0000618;C0001617;C0004482;C3536709
1690,corticosteroid + imm,C0001617;C0205470;C3536709
1690,corticosteroid ( without imm ),C0001617;C0205470;C3536709
1690,corticosteroid ( with or without immunosuppressants ),C0001617;C3536709
1690,corticosteroid,C0001617;C3536709
1689,refractory to corticosteroids,C0001617;C0205269;C3539185;C3540725;C3540726;C3540727
1689,oral corticosteroids,C0001617;C0442027;C3539185;C3540725;C3540726;C3540727;C4521986
1689,no corticosteroids or immunosuppressants,C0001617;C3539185;C3540725;C3540726;C3540727
1689,no baseline corticosteroids,C0001617;C0168634;C1442488;C3539185;C3540725;C3540726;C3540727
1689,inhaled corticosteroids,C0001617;C0004048;C3539185;C3540725;C3540726;C3540727
1689,corticosteroids only,C0001617;C0205171;C1720467;C3539185;C3540725;C3540726;C3540727
1689,corticosteroids and immunosuppressants only,C0001617;C3539185;C3540725;C3540726;C3540727
1689,corticosteroids and immunosuppressants,C0001617;C3539185;C3540725;C3540726;C3540727
1689,corticosteroids and antimalarials only,C0001617;C3539185;C3540725;C3540726;C3540727
1689,corticosteroids ( excluding budesonide ),C0001617;C3539185;C3540725;C3540726;C3540727
1689,corticosteroids ' nmbr,C0001617;C3539185;C3540725;C3540726;C3540727
1689,corticosteroids,C0001617;C3539185;C3540725;C3540726;C3540727
1689,concomitant use of corticosteroids,C0001617;C0521115;C1524063;C3539185;C3540725;C3540726;C3540727
1689,concomitant oral corticosteroids,C0001617;C0442027;C0521115;C3539185;C3540725;C3540726;C3540727;C4521986
1689,baseline corticosteroids *,C0001617;C0168634;C1442488;C3539185;C3540725;C3540726;C3540727
1689,> nmbr corticosteroids or immunosuppressants,C0001617;C3539185;C3540725;C3540726;C3540727
1688,use of cgm interaction test p - value^ =,C0022885;C0039593;C0392366;C0456984;C1515976;C1524063;C1704675;C1709380;C3831328;C4318744
1688,test for interaction ( p value ),C0022885;C0039593;C0392366;C0456984;C1515976;C1704675;C1709380;C3831328;C4318744
1688,pvaluefor interaction nmbr - nmbr,C1704675
1688,pfor interaction,C1151635;C1704675
1688,p value for interaction ® vertebral fracture at flex baseline :,C0080179;C1704675;C1709380
1688,p value for interaction by region,C1704675;C1709380
1688,p value for interaction - dosage with dabigatran,C0178602;C1704675;C1709380;C2986497
1688,p value for interaction ( age groups ) *,C0027362;C1704675;C1709380
1688,p value for interaction ( age continuous ),C0001779;C1704675;C1709380
1688,p - value for interactionnmbr :,C1704675;C1709380
1688,p - value for interaction nmbr . nmbr,C1704675;C1709380
1688,p - value for interaction *,C1704675;C1709380
1688,interaction pf,C1704675;C3815179
1688,interaction p values are as follows : amlodipine vs . chlorthalidone : age  p = nmbr . nmbr  gender  p = nmbr . nmbr  race  p = nmbr . nmbr  history of chd  p = nmbr . nmbr  history of diabetes  p = nmbr . nmbr . lisinopril vs . chlorthalidone : age  p = nmbr . nmbr  gender  p = nmbr . nmbr  race  p = nmbr . nmbr  history of chd  p = nmbr . nmbr  history of diabetes  p = nmbr . nmbr . peripheral arterial disease refers to in - trial hospitalization or lower extremity revascularization procedure .,C1704675;C1709380
1688,interaction p value 中,C1704675;C1709380
1688,interaction p value ∗,C1704675;C1709380
1688,interaction p value §,C1704675;C1709380
1688,interaction p value nmbr . nmbr,C1704675;C1709380
1688,interaction p value *,C1704675;C1709380
1688,interaction p value !,C1704675;C1709380
1688,interaction p value,C1704675;C1709380
1688,interaction p vaiue,C1704675
1688,interaction p - valuenmbr,C1704675;C1709380
1688,interaction p - valuef,C1704675
1688,interaction p - value *,C1704675;C1709380
1688,interaction p - value,C1704675;C1709380
1688,interaction p - vaiue,C1704675
1688,interaction p,C1704675
1688,interaction jnmbr - valuet,C1704675
1688,interaction : treatment by psoriasis p valuenmbr,C1704675;C1709380;C3258078
1688,interaction : treatment by psoriasis p valueb,C1704675;C3258078
1688,interaction - p,C1704675
1688,albuminuria_p_interaction,C0001925;C1704675
1688,age [years] ( interaction : p = nmbr . nmbr ),C1510829;C1704675
1688,age - interaction,C0001779;C1704675
1688,/ ’ interaction,C1704675
1688,( nmbr % cl ) interaction,C0596019;C1704675
1687,test for interaction between treatment and race,C0022885;C0039593;C0392366;C0456984;C1515976;C1704675;C3831328;C4318744
1687,test for interaction,C0022885;C0039593;C0392366;C0456984;C1515976;C1704675;C3831328;C4318744
1687,rvalue for interaction,C1704675
1687,lue for interaction,C1704675
1686,p vaiue ( interaction ),C0369773;C1704675;C2603361
1686,p lace of randomization ( interaction : p = nmbr . nmbr ),C0034656;C0280109;C0369773;C0453991;C1704675;C2603361
1686,p interaction = nmbr . nmbr,C0369773;C1704675;C2603361
1686,p interaction ( rx arm * sex ),C0009253;C0036864;C0079399;C0369773;C0446516;C0804628;C1314687;C1425688;C1521941;C1522384;C1704675;C2603361;C2709207;C3715044;C4553528
1686,p interaction,C0369773;C1704675;C2603361
1686,p for interaction between rhtn and no rhtn and treatmenta,C0369773;C1704675;C2603361
1686,interactionnmbr,C1704675
1686,interaction p = nmbr . nmbr,C1704675
1686,interaction,C1704675
1685,women  qvanmbr - sfc,C0043210;C4521536
1685,sfc nmbr mg / nmbr mg,C1319635;C4521536
1685,sfc ( n[nmbr ),C4521536
1685,sfc ( n   = nmbr,C4521536
1685,sfc ( n [nmbr ),C4521536
1685,sfc ( n = nmbr ),C4521536
1685,sfc,C4521536
1685,severe cord * : qvainmbr - sfc,C0205082;C1550235;C1706500;C3489532;C4050465;C4050466;C4521536
1685,moderate cord * : qvanmbr - sfc,C0205081;C1550235;C1706500;C1881878;C3489532;C4049705;C4049706;C4085643;C4321335;C4521536
1685,age > nmbr : qvainmbr - sfc,C0001779;C4521536
1685,age < nmbr : qvainmbr - sfc,C0001779;C4521536
1684,density lipoprotein  csf =,C0023820;C0178587;C3540512;C3889436
1684,csf nmbrs - hydroxy -,C3540512;C3889436
1684,csf a ( nmbr ( pm ),C3540512;C3889436
1684,csf,C3540512;C3889436
1683,se,C0036919
1683,( se]tf total - c,C0036919;C0439175;C0439810;C4048299;C4048587
1683,( se]tf hdl - c,C0036919;C3715113;C4048299;C4048587
1683,( se]tf,C0036919;C4048299;C4048587
1683,( se]t *,C0036919
1683,( se]t,C0036919
1683,( se] +,C0036919
1683,( se ) t *,C0036919
1682,unadjusteda beta ( se ),C0036919;C0330390;C0439096;C2004068
1682,( se ),C0036919
1682,% ( se ),C0036919
1681,nc,C0027964;C0028407;C0067895;C0265987
1680,lcl,C3658298
1679,lce,C1423759;C3273355
1678,aicd,C0972395;C2611803;C3537205;C3546309
1677,acm,C0001143;C1549040
1676,acid,C0001128;C0202406
1676,acd,C4554601
1675,ocn,C1412791;C2347392
1674,concern,C2699424
1673,black / african american *,C0085756
1673,black / african american,C0085756
1673,black / african - american ( nmbr . nmbr % ),C0085756
1673,black / african - american,C0085756
1673,black / af rican american,C0085756;C0344434;C4049859
1673,african - american / african heritage ( n = nmbr ),C0085756;C2986513
1672,worldwide non - black patients,C0005680;C0027567;C0085756;C0439541;C1829939
1672,worldwide black patients,C0005680;C0027567;C0030705;C0085756;C0439541
1672,u . s . non - black patients,C0005680;C0027567;C0041703;C0085756;C0439541;C1829939
1672,u . s . black patients,C0005680;C0027567;C0030705;C0041703;C0085756;C0439541
1672,non - hispanic black or african - american,C0005680;C0027567;C0085756;C0439541;C1518424
1672,non - hispanic black,C0005680;C0027567;C0085756;C0439541;C1518424
1672,non - black,C0005680;C0027567;C0085756;C0439541;C1518422
1672,nmbrfe black *,C0005680;C0027567;C0085756;C0439541;C3848561
1672,hispanic black,C0005680;C0027567;C0085756;C0086409;C0439541
1672,black or african ‐ american,C0005680;C0027567;C0085756;C0439541
1672,black or african heritage,C0005680;C0027567;C0085756;C0439541
1672,black or african american,C0005680;C0027567;C0085756;C0439541
1672,black or african america,C0005680;C0027567;C0085756;C0439541
1672,black or african - american,C0005680;C0027567;C0085756;C0439541
1672,black / non - black,C0005680;C0027567;C0085756;C0439541;C1518422
1672,black /,C0005680;C0027567;C0085756;C0439541
1672,black *,C0005680;C0027567;C0085756;C0439541
1672,black,C0005680;C0027567;C0085756;C0439541
1672,b : u . s . black and non - black patients,C0005680;C0027567;C0041703;C0085756;C0439541
1672,african americans,C0085756
1672,african american n = nmbr,C0085756
1672,african american / black,C0005680;C0027567;C0085756;C0439541
1672,african american,C0085756
1672,african america,C0085756
1672,african - latin american,C0085756
1672,african - american,C0085756
1672,a : worldwide black and non - black patients,C0005680;C0027567;C0085756;C0439541
1672,* non - black *,C0005680;C0027567;C0085756;C0439541;C1518422
1671,extracranial carotid stenosis,C0007282;C0580586
1671,carotid stenosis,C0007282
1671,carotid artery stenosis,C0007282
1670,nmbr degree of ica stenosis 丰,C0201519;C4034225
1670,degree of stenosis,C4034225
1669,> nmbr y pathogenesis,C0543483;C0699748
1668,angiogenesis,C0302600;C1519670
1667,qualifying type of atherosclerosis — no . ( % ),C0003850;C0004153;C0332307;C1514624;C1547052
1667,qualifying type of atherosclerosis,C0003850;C0004153;C0332307;C1514624;C1547052
1667,qualifying atherosclerosis,C0003850;C0004153;C1514624
1667,large vessel atherosclerosis,C0003850;C0004153;C0225990
1667,large - artery atherosclerosis,C0003850;C0004153;C0226003
1667,atherosclerosis^,C0003850;C0004153
1667,atherosclerosis,C0003850;C0004153
1667,arteriosclerosis,C0003850
1666,age at diagnosis snmbr years,C0439234;C1828181;C3173302
1666,age at diagnosis of sle,C0024141;C1828181;C3173302
1666,age at diagnosis of ln,C0861352;C1428884;C1828181;C3173302;C3714709
1666,age at diagnosis < nmbr years,C0439234;C1828181;C3173302
1666,age at diagnosis,C1828181;C3173302
1666,age at asthma diagnosis years,C0004096;C0439234;C1828181;C2984299;C3173302
1665,age categories ( y ),C2916832
1665,age categories,C2916832
1664,pnmbrynmbr antagonist,C0231491;C0369773;C2603361
1664,miami k antagonist received,C0231491;C0597277;C1551421;C1708601
1664,antagonist,C0231491
1664,adp antagonist,C0231491;C0523452
1663,wrist,C0043262;C1322271
1662,grs,C1412761;C3539564
1661,serms,C0732611
1660,elms,C0330531;C2980688
1659,wt,C1883559;C2700323
1658,tgt,C1421391;C1428265;C4321338
1657,tt,C1452561;C4554543
1657,ct + tt,C0007673;C1452561;C3540513;C3813556;C3888140;C4554543
1656,st ‐ str ≥ nmbr % post pci,C0036056;C0687676;C1704687;C3272372;C3469826;C4049621
1656,st / t wave,C0036056;C0429103;C3272372
1656,st - t wavett,C0036056;C3272372
1656,st - t waveft,C0036056;C3272372
1656,st - t wave changes,C0036056;C0429103;C3272372
1656,st - t wave abnormality d,C0036056;C1839341;C3272372
1656,st - t wave,C0036056;C0429103;C3272372
1656,st - nmbr ( ng / ml ),C0036056;C0439275;C3272372
1656,st -,C0036056;C3272372
1656,st +,C0036056;C3272372
1656,st,C0036056;C3272372
1656,nmbrst : nmbr - nmbr . nmbr pmol / l,C0036056;C0439284;C3272372
1656,nmbr st < nmbr . nmbr,C0036056;C3272372
1656,> nmbrst and < nmbrnd quartile,C0036056;C3272372
1656,< nmbrst quartile,C0036056;C2828255;C3272372
1655,czp combined arms ( n = nmbr ),C0054841;C0205195;C0206655;C0446516;C1861828;C1872109;C2681631;C3715044;C4553528
1655,czp + mtx^mtx,C0025677;C0054841;C1417487;C1861828;C1872109
1655,czp + mtx to mtx,C0025677;C0054841;C1417487;C1861828;C1872109
1655,czp + mtx n = nmbr,C0025677;C0054841;C1417487;C1861828;C1872109
1655,czp + mtx,C0025677;C0054841;C1417487;C1861828;C1872109
1655,certolizumab pegol ( n = nmbr ),C1872109
1655,certolizumab group ( n = nmbr ),C0441848;C1872109
1654,x cr nmbr . nmbr x age,C0001779;C0201975;C3539604;C3711669;C4084730;C4553336;C4553337
1654,cr + mh + crpnorr,C0026514;C0201975;C2930980;C3539604;C3711669;C4084730;C4553336;C4553337
1654,cr + mh,C0026514;C0201975;C2930980;C3539604;C3711669;C4084730;C4553336;C4553337
1654,cr + crpnorr,C0201975;C3539604;C3711669;C4084730;C4553336;C4553337
1653,ldl - cz,C0206578
1653,ez / simva nmbr mg,C0024671;C0026410;C0206578;C0439269;C1960952;C2346927;C4321396;C4521761
1653,ez / simva nmbr / nmbr mg,C0024671;C0026410;C0206578;C0439269;C1960952;C2346927;C4321396;C4521761
1653,ez / simva n = nmbr n ( % ),C0206578
1653,ez / simva < % >,C0206578
1653,ez / simva,C0206578
1653,czech republic,C0206578
1653,anmbr + eznmbr anmbr ( n = nmbr ) ( n = nmbr ),C0206578
1653,anmbr + eznmbr,C0206578
1653,anmbr + ez n = nmbr anmbr n = nmbr,C0206578
1653,anmbr + ez n = nmbr,C0206578
1653,all ez / simva,C0206578
1652,vi – nmbr % ( nmbr % ci – nmbr – nmbr % ),C0008107;C0205999;C3259781
1652,vi nmbr % ( nmbr % ci – nmbr – nmbr % ),C0008107;C0205999;C3259781
1652,vi nmbr % ( nmbr % ci nmbr – nmbr % ),C0008107;C0205999;C3259781
1652,stratified hazard ratio ( nmbr % ci ),C0008107;C0205363;C2985465;C3259781
1652,rr^ ( nmbr % ci ),C0008107;C3259781;C4554402
1652,rr ( nmbr % ci ) c,C0008107;C3259781;C4554402
1652,rr ( nmbr % ci ) *,C0008107;C3259781;C4554402
1652,rr ( nmbr % ci ),C0008107;C3259781;C4554402
1652,relative risk { nmbr % ci ),C0008107;C0242492;C3259781
1652,relative risk ( nmbr % ci ) ofprimary end point,C0008107;C0242492;C2349179;C2826544;C3259781
1652,relative risk ( nmbr % ci ),C0008107;C0242492;C3259781
1652,reduction in risk % ( nmbr % ci ),C0008107;C0035647;C0520870;C1137094;C3259781;C4552904
1652,ratio of hrs ( nmbr % ci ),C0008107;C0456603;C1547037;C1568891;C3259781
1652,ratio mepo / pbo ( nmbr % ci ),C0008107;C0031962;C0456603;C1547037;C3259781
1652,ratio fp / sal : sal ( nmbr % ci ),C0008107;C0016704;C0036140;C0037494;C0206136;C0456603;C1419068;C1419906;C1547037;C3259781;C3541238;C3541412
1652,ratio ( nmbr % ci ) *,C0008107;C0456603;C1547037;C3259781
1652,rate ratio mepo / pbo ( nmbr % ci ),C0008107;C0031962;C0456603;C0871208;C1521828;C1547037;C3259781
1652,r elative risk ( nmbr % ci ),C0008107;C0035647;C0205090;C0233492;C0684010;C2603358;C3259781;C4552904
1652,proportion ( nmbr % ci ) adjusted for baseline hbanmbrc,C0008107;C1709707;C3259781
1652,oradj ( nmbr % ci ),C0008107;C3259781
1652,no p value for ischemia ischemia hr ( nmbr % ci ) interaction,C0008107;C0022116;C1704675;C1709380;C3259781;C4321499
1652,nmbr . nmbr nmbr % ci : nmbr . nmbr - nmbr . nmbr p = nmbr . nmbr,C0008107;C3259781
1652,nmbr . nmbr ( nmbr % ci nmbr . nmbr to nmbr . nmbr ) p = nmbr . nmbr,C0008107;C3259781
1652,nmbr . nmbr ( nmbr % ci nmbr . nmbr to nmbr . nmbr ),C0008107;C3259781
1652,nmbr . nmbr ( nmbr % ci : nmbr . nmbr,C0008107;C3259781
1652,nmbr % cinmbr,C0008107;C3259781
1652,nmbr % ci nmbr . nmbr - nmbr . nmbr,C0008107;C3259781
1652,nmbr % ci,C0008107;C3259781
1652,multivariable adjusted model hr ( nmbr % ci ),C0008107;C0456081;C3161035;C3259781;C3274659;C3714583;C3853906
1652,multivariable adjusted hr ( nmbr % ci ),C0008107;C0456081;C3259781
1652,mean sfnmbr score ( nmbr % ci ),C0008107;C0037712;C3259781;C3533236
1652,mean pasi score ( nmbr % ci ),C0008107;C3259781;C3533236;C4528685
1652,mean ham - d score ( nmbr % ci ),C0008107;C1570167;C3259781;C3533236;C3853311
1652,lsm ( nmbr % ci ),C0008107;C3259781
1652,hradjusted ( nmbr % ci ) b,C0008107;C3259781
1652,hradj ( nmbr % ci ),C0008107;C3259781
1652,hr with edoxaban ( nmbr % ci ),C0008107;C2975435;C3259781
1652,hr nmbr % ci,C0008107;C3259781
1652,hr [nmbr % ci ),C0008107;C3259781
1652,hr ( nmbrs % ci ),C0008107;C3259781
1652,hr ( nmbr % ci ) “,C0008107;C3259781
1652,hr ( nmbr % ci ) p   value,C0008107;C1709380;C3259781
1652,hr ( nmbr % ci ) p value for interaction *,C0008107;C1704675;C1709380;C3259781
1652,hr ( nmbr % ci ) *,C0008107;C3259781
1652,hr ( nmbr % ci ),C0008107;C3259781
1652,heart failure  ci  confidence interval .,C0008107;C0009667;C0018801;C0018802;C3259781;C4554158
1652,hazard ratiof ( nmbr % ci ),C0008107;C0598697;C3259781
1652,hazard ratio ( nmbr % ci ) nmbr with vs . without psoriasis,C0008107;C2985465;C3259781
1652,hazard ratio ( nmbr % ci ) for adjudicated type nmbr diabetes,C0008107;C1320657;C2985465;C3259781
1652,hazard . ratio . ( nmbr % ci ) . . . . . . . . . .,C0008107;C2985465;C3259781
1652,harzard ratio ( nmbr % ci ),C0008107;C0456603;C1547037;C3259781
1652,harzar ratio ( nmbr % ci ),C0008107;C0456603;C1547037;C3259781
1652,from baseline ( nmbr % ci ),C0008107;C0168634;C1442488;C3259781
1652,ff – nmbr % ( nmbr % ci – nmbr – nmbr % ),C0008107;C3259781;C4554348
1652,ff nmbr % ( nmbr % ci – nmbr – nmbr % ),C0008107;C3259781;C4554348
1652,ff / vi – nmbr % ( nmbr % ci – nmbr – nmbr % ),C0008107;C0205999;C3259781;C4554348
1652,ff / vi nmbr % ( nmbr % ci nmbr – nmbr % ),C0008107;C0205999;C3259781;C4554348
1652,etr : nmbr . nmbr [nmbr . nmbr  nmbr . nmbr]nmbr % ci  p     =   nmbr . nmbr,C0008107;C3259781
1652,etd : − nmbr . nmbr [ − nmbr . nmbr  − nmbr . nmbr]nmbr % ci  p     <   nmbr . nmbr,C0008107;C1180255;C3259781
1652,etd : − nmbr . nmbr [ − nmbr . nmbr  − nmbr . nmbr]nmbr % ci  p     <   nmbr . nmbr,C0008107;C1180255;C3259781
1652,etd : − nmbr . nmbr [ − nmbr . nmbr  nmbr . nmbr]nmbr % ci  p     =   nmbr . nmbr,C0008107;C1180255;C3259781
1652,etd ( nmbr % ci ),C0008107;C1180255;C3259781
1652,etd ( % ) [nmbr % ci],C0008107;C1180255;C3259781
1652,esrd only rr ( ci ) “,C0008107;C0022661;C0035078;C0205171;C1720467;C2316810;C3259781;C4554402
1652,d ( nmbr % ci ),C0008107;C0073187;C0332173;C3259781;C4484261
1652,cox hr ( nmbr % ci ),C0008107;C1565830;C3259781
1652,cochranemantelehaenszel ( repeated nmbr . nmbr % ci ) c,C0008107;C0205341;C3259781
1652,cmh rr ( nmbr % ci ),C0008107;C3259781;C4554402
1652,ci  confidence interval  esrd  end - stage renal disease  n / n  number of patients who had an event / total number of patients . aadjusted with terms including treatment ( losartan or placebo )  geographic region  genotype  and the treatment  genotype interaction . bp value for treatment  genotype interaction ( i . e .  comparison of the losartan treatment effect between the nmbr genotype groups ) .,C0008107;C0009667;C0022661;C2360800;C3259781
1652,arr ( nmbr % ci ),C0008107;C2170357;C3259781;C4084934
1652,adjusted ⁎ hazard ratio ( nmbr % ci ),C0008107;C0456081;C2985465;C3259781
1652,adjusted hr * ( nmbr % ci ),C0008107;C0456081;C3259781
1652,adjusted hr ( nmbr % ci ) * comparing idm with bl,C0005918;C0006413;C0008107;C0270221;C0456081;C1552663;C1707455;C2827109;C3259781
1652,adjusted hr ( nmbr % ci ) * compared with no diabetes at bl or at year nmbr,C0008107;C0456081;C3259781
1652,adjusted hr ( nmbr % ci ),C0008107;C0456081;C3259781
1652,adjusted hr  nmbr % ci,C0008107;C0456081;C3259781
1652,adjusted hazard ratio ≠ ( nmbr % ci ),C0008107;C0456081;C2985465;C3259781
1652,adjusted hazard ratio ‡ ( nmbr % ci ),C0008107;C0456081;C2985465;C3259781
1652,adjusted hazard ratio § ( nmbr % ci ),C0008107;C0456081;C2985465;C3259781
1652,adjusted hazard ratio ( nmbr % ci ) †,C0008107;C0456081;C2985465;C3259781
1652,[nmbr % ci] *,C0008107;C3259781
1652,- nmbr . nmbr ( nmbr % ci : - nmbr . nmbr,C0008107;C3259781
1652,* ci denotes confidence interval .,C0008107;C3259781
1652,( nmbr % ci]h,C0008107;C0033727;C0369286;C0441932;C0564385;C3259781;C4528284
1652,( nmbr % ci] nmbr,C0008107;C3259781
1652,( nmbr % ci ) p value,C0008107;C1709380;C3259781
1652,( nmbr % ci ) c,C0008107;C3259781
1652,( nmbr % ci ) b,C0008107;C3259781
1652,( nmbr % ci ) a,C0008107;C3259781
1652,( nmbr % ci ) ,C0008107;C3259781
1652,( nmbr % ci ),C0008107;C3259781
1652,( ci ) b,C0008107;C3259781
1652,% ( nmbr % ci ),C0008107;C3259781
1652, ( nmbr % ci ) %,C0008107;C0035647;C0520870;C1137094;C3259781;C4552904
1652, ( nmbr % ci ) %,C0008107;C0035647;C0520870;C1137094;C3259781;C4552904
1651,> nmbr per pl in nmbr months before screening,C0439231;C3897966;C4049765
1651,> nmbr cells / pl,C0007584;C0007634;C3897966;C4049765
1651,< nmbr cells / pl,C0007584;C0007634;C3897966;C4049765
1651,/ pl nmbr nmbr,C3897966;C4049765
1651,( cells per pl ) t,C0007584;C0007634;C3897966;C4049765
1650,itch nrs nmbr - nmbr ( v = nmbr ),C0033774;C1422257;C2240043;C4050142
1650,itch nrs nmbr - nmbr ( at = nmbr ),C0033774;C1422257;C2240043;C4050142
1650,itch nrs nmbr - nmbr ( a ' = nmbr ),C0033774;C1422257;C2240043;C4050142
1650,itch nrs nmbr - nmbr ( . \ ' = nmbr ),C0033774;C1422257;C2240043;C4050142
1650,itch nrs nmbr ( v = nmbr ),C0033774;C1422257;C2240043;C4050142
1650,itch nrs,C0033774;C1422257;C2240043;C4050142
1649,sfcnmbr / nmbr pg b . i . d . n = nmbr,C0021966;C0030827;C0072225;C0152277;C0221138;C1266240;C2827928;C4521536
1649,sfc nmbr / nmbr pg twice daily ( n = nmbr ),C0030827;C0072225;C0585361;C1266240;C4521536
1649,salmeterol / fluticasone nmbr / nmbr pg twice daily,C0030827;C0072225;C0585361;C0939232;C1266240
1649,sal nmbr pg ( n = nmbr ),C0030827;C0036140;C0037494;C0072225;C0206136;C1266240
1649,qvanmbr / nmbr pg once daily ( n = nmbr ),C0030827;C0072225;C0332173;C1266240
1649,nt - probnp pg / mla ( iqr ),C0030827;C0072225;C0599973;C0669479;C0754710;C1266240
1649,indacaterol nmbr pg,C0030827;C0072225;C1266240;C1722260
1649,gly ( nmbr . nmbr pg b . i . d . ) n = nmbr,C0030827;C0072225;C0152277;C1266240;C1415124
1649,fp / sal nmbr / nmbr pg ( n = nmbr ),C0016704;C0030827;C0036140;C0037494;C0072225;C0206136;C1266240;C1419068;C1419906;C3541238;C3541412
1649,formoterol nmbr pg vs placebo,C0030827;C0060657;C0072225;C1266240
1649,formoterol nmbr pg,C0030827;C0060657;C0072225;C1266240
1649,ff nmbr pg ( n = nmbr ),C0030827;C0072225;C1266240;C4554348
1649,aclidinium nmbr pg vs placebo,C0030827;C0072225;C1266240;C2699757
1649,aclidinium nmbr pg,C0030827;C0072225;C1266240;C2699757
1649,aclidinium / formoterol nmbr / nmbr pg twice daily,C0030827;C0060657;C0072225;C0585361;C1266240;C2699757
1649,ab nmbr pg ( n = nmbr ),C0030827;C0072225;C1266240
1649,ab / ff nmbr / nmbr pg ( n = nmbr ),C0030827;C0072225;C1266240;C4554348
1648,xi = ° - ° nmbr,C1720296
1648,xi = oo  p = o - nmbr,C1720296
1648,xi = o - nmbr  p = o - nmbr,C1720296
1648,xi = nmbr . nmbr,C1720296
1648,xi = nmbr - nmbr  p = o - l,C1720296
1648,xi = nmbr - nmbr  p = nmbr - nmbr,C1720296
1648,xi = nmbr - nmbr  p = nmbr - l,C1720296
1648,xi = nmbr - nmbr  p = nmbr,C1720296
1648,xi = nmbr - nmbr,C1720296
1648,xi = nmbr - l  p = nmbr - nmbr,C1720296
1648,xi = nmbr,C1720296
1648,xi = l ’ nmbr  p = nmbr - nmbr,C1720296
1647,feno — ppb,C1415800
1647,> nmbr to < nmbr ppb,C1415800
1647,> nmbr ppb,C1415800
1647,< nmbr ppb,C1415800
1646,ascot - lla,C0718674
1645,facit - f score,C0449820;C3272505;C4050231
1645,facit - f,C3272505
1644,exact - pro total score,C0033382;C0523852;C2828393;C2964552;C2987124;C4050514
1644,exact ( b ),C2828393;C4050514
1643,phi ( n = nmbr ),C1333690;C1704947;C1706536;C2975867;C4084801
1643,phi ( n - nmbr ),C1333690;C1704947;C1706536;C2975867;C4084801
1643,pgi - s,C0523816;C1333690;C1412792;C1704947;C2975867;C3810522;C4522133
1642,p . b “ int,C1539794;C3272375
1642,p . b * int,C1539794;C3272375
1642,int . p *,C3272375
1641,years ( mean ± sd ),C0439234;C0444504;C2347634;C2348143;C2699239
1641,weight in kg ( baseline : mean ( sd ) [n]  wk nmbr and change : mean ( se ) [n] ),C0022718;C0332174;C0439209;C0439230;C0444504;C1303013;C2347634;C2348143;C2699239;C4054209
1641,weight ( kg ) ( mean ± sd ),C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209
1641,weeko mean + sem,C0444504;C2347634;C2348143
1641,week o ( baseline ) mean 士 sd,C0168634;C0332174;C0439230;C0444504;C1442488;C2347634;C2348143;C2699239
1641,week nmbr mean 士 sd,C0332174;C0439230;C0444504;C2347634;C2348143;C2699239
1641,week nmbr mean ± sem,C0332174;C0439230;C0444504;C2347634;C2348143
1641,week nmbr mean + sem,C0332174;C0439230;C0444504;C2347634;C2348143
1641,week nmbr mean ( se ),C0036919;C0332174;C0439230;C0444504;C2347634;C2348143
1641,week nmbr mean ( sd ),C0332174;C0439230;C0444504;C2347634;C2348143;C2699239
1641,triglycerides mean ( mg / dl ± sd ),C0041004;C0439269;C0444504;C2347634;C2348143;C2699239
1641,total sgrq mean total score ( sd ),C0439175;C0439810;C0444504;C2347634;C2348143;C2699239;C2964552;C3533236
1641,total pack - years mean ( sd ),C0439175;C0439810;C0444504;C1277691;C2347634;C2348143;C2699239
1641,systolic — mean ( sd ) ( mm hg ),C0039155;C0439475;C0444504;C2347634;C2348143;C2699239
1641,symptoms mean ( sd ),C0444504;C0683368;C1457887;C2347634;C2348143;C2699239
1641,sulfasalazine ( mean dose : nmbr . nmbr g / day ),C0036078;C0178602;C0439417;C0444504;C0869039;C1114758;C2347634;C2348143
1641,standardized mean difference,C0444504;C1705241;C1705242;C2347634;C2348143
1641,size ( cmnmbr ) ( mean ± standard deviation ),C0444504;C0456389;C0871420;C1442989;C1828170;C2347634;C2348143;C2828392
1641,sesbp ( mmhg ) [mean _sd]a,C0439475;C0444504;C2347634;C2348143;C2699239
1641,sesbp ( mmhg ) [mean - sd]d,C0439475;C0444504;C2347634;C2348143;C2699239
1641,serum creatinine - mean ( sd,C0201976;C0444504;C0600061;C2347634;C2348143;C2699239
1641,sedbp ( mmhg ) [mean_ sd]a,C0439475;C0444504;C2347634;C2348143;C2699239
1641,sedbp ( mmhg ) [mean _sd]d,C0439475;C0444504;C2347634;C2348143;C2699239
1641,sbp . mean ( sd ) mm hg,C0085805;C0439475;C0444504;C2347634;C2348143;C2699239
1641,rescue use : mean no . of inhalations / d,C0042153;C0444504;C0457083;C1947944;C2347634;C2348143
1641,pre - bronchodilator mean ( sd ) fevnmbr,C0444504;C2347634;C2348143;C2599602;C2699239;C3714541
1641,post - bronchodilator reversibility fevnmbr ( % ) mean ( sd ),C0444504;C0449261;C2347634;C2348143;C2599594;C2699239;C3714541
1641,physician ' s global assessment . mean nmbr sd,C0444504;C2347634;C2348143;C2699239;C4050369
1641,non - hdl - c ( mg / dl ) - mean ± sd,C0439269;C0444504;C1518422;C2347634;C2348143;C2699239;C3715113
1641,nmbrbaseline mean,C0168634;C0444504;C1442488;C2347634;C2348143
1641,nighttime mean sbp ( abpm ) at week nmbr,C0085805;C0240526;C0332174;C0439230;C0444504;C2347634;C2348143
1641,nighttime mean dbp ( abpm ) at week nmbr,C0240526;C0332174;C0439230;C0444504;C0536221;C2347634;C2348143;C3813197;C4281799
1641,middle tertile ( range  nmbr . nmbr - nmbr . nmbr mg / dl  mean ± sd  nmbr . nmbr ± nmbr . nmbr mg / dl ),C0024671;C0026410;C0439269;C0444504;C0444598;C0549183;C1514721;C1552826;C1960952;C2346927;C2347634;C2348143;C2348147;C2699239;C3539687;C3542016;C4321396;C4521761
1641,mean_delta,C0439097;C0444504;C1705241;C2347634;C2348143;C3146239;C3538806;C3540585;C3815527
1641,mean 土 sd ( n ),C0444504;C2347634;C2348143;C2699239
1641,mean — yr,C0439234;C0444504;C2347634;C2348143
1641,mean — ml / min / nmbr . nmbrmnmbr,C0369637;C0439445;C0441923;C0444504;C2347634;C2348143
1641,mean — ml / min / nmbr . nmbr mnmbr,C0369637;C0439445;C0441923;C0444504;C2347634;C2348143
1641,mean — ml / min / nmbr . nmbr m^,C0369637;C0439445;C0441923;C0444504;C2347634;C2348143
1641,mean — ml / min,C0439445;C0444504;C2347634;C2348143
1641,mean — mg / dl,C0439269;C0444504;C2347634;C2348143
1641,mean — kg,C0022718;C0439209;C0444504;C2347634;C2348143;C4054209
1641,mean — g / dl,C0439267;C0444504;C2347634;C2348143
1641,mean — %,C0444504;C2347634;C2348143
1641,mean ±   sd,C0444504;C2347634;C2348143;C2699239
1641,mean ± se ) bii ( ls mean ± se ),C0023668;C0036919;C0444504;C1413059;C2347634;C2348143
1641,mean ± se,C0036919;C0444504;C2347634;C2348143
1641,mean ± sd waist circumference,C0444504;C0455829;C2347634;C2348143;C2699239
1641,mean ± sd unless otherwise indicated,C0444504;C2347634;C2348143;C2699239
1641,mean ± sd triglycerides,C0041004;C0444504;C2347634;C2348143;C2699239
1641,mean ± sd nmbr - h adbp,C0033727;C0168370;C0369286;C0441932;C0444504;C0564385;C2347634;C2348143;C2699239;C4528284
1641,mean ± sd msdbp,C0444504;C2347634;C2348143;C2699239
1641,mean ± sd mg ( n = nmbr,C0024671;C0026410;C0439269;C0444504;C1960952;C2346927;C2347634;C2348143;C2699239;C4321396;C4521761
1641,mean ± sd fasting insulin,C0015663;C0021641;C0444504;C1533581;C1579433;C2347634;C2348143;C2699239;C3714501
1641,mean ± sd egfr,C0444504;C1739039;C2347634;C2348143;C2699239;C3811844;C3812682
1641,mean ± sd bmi,C0444504;C0578022;C2347634;C2348143;C2699239
1641,mean ± sd ( yr ),C0439234;C0444504;C2347634;C2348143;C2699239
1641,mean ± sd ( n ),C0444504;C2347634;C2348143;C2699239
1641,mean ± sd,C0444504;C2347634;C2348143;C2699239
1641,mean ± s . d . hbanmbrc,C0019016;C0444504;C1825777;C2347634;C2348143;C3538758
1641,mean ± s . d . fpg,C0444504;C2347634;C2348143
1641,mean ± s . d . bmi,C0444504;C0578022;C2347634;C2348143
1641,mean ± s . d . age,C0001779;C0444504;C2347634;C2348143
1641,mean ± s . d .,C0444504;C2347634;C2348143
1641,mean   ±   sd,C0444504;C2347634;C2348143;C2699239
1641,mean yearly decline,C0444504;C2347634;C2348143
1641,mean weight ( sd ),C0005910;C0043100;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239
1641,mean treatment exposure,C0039798;C0087111;C0274281;C0332157;C0444504;C1522326;C1533734;C1705169;C2347634;C2348143;C3538994;C3887704
1641,mean total serum psa,C0229671;C0444504;C1546774;C1550100;C2347634;C2348143;C2986589
1641,mean total serum ige ( sd ),C0229671;C0439175;C0439810;C0444504;C1546774;C1550100;C2347634;C2348143;C2699239
1641,mean total ipss mean ipss by bmi ( < nmbr / < nmbr to < nmbr / < nmbr kg / mnmbr ),C0439175;C0439810;C0444504;C0578022;C1019118;C1998280;C2347634;C2348143;C2827405;C3811063
1641,mean total ipss ( sd ),C0439175;C0439810;C0444504;C1019118;C1998280;C2347634;C2348143;C2699239;C2827405;C3811063
1641,mean stents per lesion ( sd ) ‡,C0038257;C0221198;C0444504;C1546698;C2347634;C2348143;C2699239
1641,mean sitting systolic blood pressure,C0444504;C2347634;C2348143
1641,mean sitting diastolic blood pressure,C0444504;C1319894;C2347634;C2348143
1641,mean sgrq total score ( sd ),C0439175;C0439810;C0444504;C2347634;C2348143;C2699239;C2964552;C3533236
1641,mean sgrq total score,C0439175;C0439810;C0444504;C2347634;C2348143;C2964552;C3533236
1641,mean serum glucose,C0202041;C0444504;C2347634;C2348143;C3534430
1641,mean selena - sledai score ± sd,C0444504;C0451528;C2347634;C2348143
1641,mean sd nmbr - h asbp,C0033727;C0369286;C0441932;C0444504;C0564385;C2347634;C2348143;C2699239;C4528284
1641,mean sd mssbp,C0444504;C2347634;C2348143;C2699239
1641,mean sd ldl - c,C0444504;C2347634;C2348143;C2699239
1641,mean sd hdl - c,C0444504;C2347634;C2348143;C2699239;C3715113
1641,mean sd fpg,C0444504;C2347634;C2348143;C2699239
1641,mean reversibility ( % ),C0444504;C0449261;C2347634;C2348143
1641,mean prebronchodilator fevnmbr ( sd ),C0444504;C2347634;C2348143;C2599602;C2699239;C3714541
1641,mean prebronchodilation ( l ),C0444504;C2347634;C2348143
1641,mean postbronchodilatora fevnmbr,C0444504;C2347634;C2348143;C3714541
1641,mean percentage change from baseline to final visit,C0168634;C0392747;C0439165;C0443172;C0444504;C1442488;C1549488;C1561533;C1705241;C2347634;C2348143;C4319952
1641,mean or n,C0444504;C2347634;C2348143
1641,mean of mean cimt,C0444504;C2347634;C2348143
1641,mean of maximum cimt,C0444504;C0806909;C1552615;C2347634;C2348143;C2826546
1641,mean number of puffs per day,C0237753;C0444504;C0449788;C1533107;C2347634;C2348143
1641,mean number of exacerbations in previous y ( sd ),C0237753;C0444504;C0449788;C2347634;C2348143;C4086268
1641,mean number of exacerbations in previous nmbr months ( sd ),C0237753;C0444504;C0449788;C2347634;C2348143;C4086268
1641,mean number of exacerbations ( per patient - year [nmbr % ci] ),C0237753;C0444504;C0449788;C2347634;C2348143;C4086268
1641,mean number of combined visits / hospitalizations †,C0205195;C0444504;C0545082;C1512346;C2347634;C2348143;C4086639
1641,mean number of caes in past nmbr months ( number per patient ) ] |,C0237753;C0444504;C0449788;C2347634;C2348143
1641,mean no . agents ( sd ) other medications,C0444504;C2347634;C2348143
1641,mean nmbrmwd *,C0444504;C2347634;C2348143
1641,mean nmbr sd,C0444504;C2347634;C2348143;C2699239
1641,mean lixi dose ± sd ( lg / day ),C0023128;C0178602;C0332173;C0439228;C0439505;C0444504;C0694651;C0869039;C1114758;C2347634;C2348143;C2699239
1641,mean ipss qol ( sd ),C0444504;C0518214;C1019118;C1998280;C2347634;C2348143;C2699239;C2827405;C3811063
1641,mean involved bsa,C0444504;C2347634;C2348143
1641,mean iglar dose ± sd ( u / day ),C0178602;C0444504;C0456683;C0869039;C1114758;C2347634;C2348143;C2699239
1641,mean hscrp,C0444504;C2347634;C2348143
1641,mean hbanmbrc ± s . d .,C0019016;C0444504;C1825777;C2347634;C2348143;C3538758
1641,mean hbaic = • = s . d .,C0444504;C2347634;C2348143
1641,mean fvc ± sd,C0444504;C2347634;C2348143;C2699239;C3714541
1641,mean fpg,C0444504;C2347634;C2348143
1641,mean fevnmbr,C0444504;C2347634;C2348143;C3714541
1641,mean duration offollow - up ( years ) *,C0439234;C0444504;C0449238;C2347634;C2348143;C2926735
1641,mean duration of surgery ± sd,C0038894;C0038895;C0444504;C0449238;C0543467;C1274039;C2347634;C2348143;C2699239;C2926735
1641,mean doseb,C0444504;C2347634;C2348143
1641,mean dose ( sd ) ( mg / week ),C0024671;C0026410;C0178602;C0332174;C0439230;C0439269;C0444504;C0869039;C1114758;C1960952;C2346927;C2347634;C2348143;C2699239;C4321396;C4521761
1641,mean dose ( sd ) ( mg / day ),C0178602;C0439422;C0444504;C0869039;C1114758;C2347634;C2348143;C2699239
1641,mean dose ' ’,C0178602;C0444504;C0869039;C1114758;C2347634;C2348143
1641,mean dlco ± sd,C0444504;C1516251;C2347634;C2348143;C2699239
1641,mean difference = seb,C0059386;C0444504;C1309881;C1423585;C1705241;C1705242;C2347634;C2348143;C3815268
1641,mean change ‘ s in fasting blood glucose [mg / dl ( mmol / l ) ],C0392747;C0428568;C0443172;C0444504;C1261430;C1532563;C1705241;C2347634;C2348143;C2827883;C3642216;C4319952
1641,mean change in total updrs scores adjusted according to baseline updrs,C0392747;C0439175;C0439810;C0443172;C0444504;C1705241;C2347634;C2348143;C2964552;C3533236;C3639721;C4319952
1641,mean change in radiographic end points shs,C0392747;C0443172;C0444504;C0444708;C1705241;C2347634;C2348143;C2349179;C4319952
1641,mean change in radiographic end points,C0392747;C0443172;C0444504;C0444708;C1705241;C2347634;C2348143;C2349179;C4319952
1641,mean cdai score ( sd ),C0444504;C0683448;C1413248;C2347634;C2348143;C3273706
1641,mean cdai score,C0444504;C0683448;C1413248;C2347634;C2348143;C3273706
1641,mean body weight ( sd ),C0005910;C0444504;C1305866;C2347634;C2348143;C2699239
1641,mean body mass index ( sd ),C0005893;C0444504;C0578022;C1305855;C2347634;C2348143;C2699239
1641,mean body mass index ( kg / mnmbr ) *,C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143
1641,mean body mass index ( kg / mnmbr ),C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143
1641,mean body mass index,C0005893;C0444504;C0578022;C1305855;C2347634;C2348143
1641,mean body - mass index ( = sd ),C0005893;C0444504;C0578022;C1305855;C2347634;C2348143;C2699239
1641,mean body - mass index,C0005893;C0444504;C0578022;C1305855;C2347634;C2348143
1641,mean bmnmbr ± s . d .,C0006416;C0444504;C2347634;C2348143
1641,mean bmii 士 s . d .,C0444504;C2347634;C2348143
1641,mean bmi ± sd ( kg / mnmbr ),C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
1641,mean bmi ± s . d .,C0444504;C0578022;C2347634;C2348143
1641,mean bmi ( sd ),C0444504;C0578022;C2347634;C2348143;C2699239
1641,mean bmi ( nmbr % ci ),C0008107;C0444504;C0578022;C2347634;C2348143;C3259781
1641,mean bmi,C0444504;C0578022;C2347634;C2348143
1641,mean bmd ( = sd ),C0444504;C2347634;C2348143;C2699239
1641,mean baseline ucdai score,C0168634;C0444504;C1442488;C2347634;C2348143
1641,mean baseline ei score,C0022067;C0168634;C0444504;C1414370;C1442488;C2347634;C2348143;C2348481
1641,mean baseline bmi,C0168634;C0444504;C0578022;C1442488;C2347634;C2348143
1641,mean baseline ( n ),C0168634;C0444504;C1442488;C2347634;C2348143
1641,mean asui scored,C0444504;C2347634;C2348143
1641,mean aqlq total score t,C0439175;C0439810;C0444504;C2347634;C2348143;C2964552;C3533236;C4055434
1641,mean alc,C0444504;C1424945;C2347634;C2348143;C3811058
1641,mean age 士 s . d .,C0001779;C0444504;C2347634;C2348143
1641,mean age — yr ( range ),C0001779;C0439234;C0444504;C1514721;C2347634;C2348143;C2348147;C3542016
1641,mean age — yr,C0001779;C0439234;C0444504;C2347634;C2348143
1641,mean age ± s . d .,C0001779;C0444504;C2347634;C2348143
1641,mean age ( yrs ),C0001779;C0444504;C2347634;C2348143
1641,mean age ( yr ),C0001779;C0439234;C0444504;C2347634;C2348143
1641,mean age ( y ) ( sd ),C0001779;C0444504;C2347634;C2348143;C2699239
1641,mean age ( y ),C0001779;C0444504;C2347634;C2348143
1641,mean age ( sd ),C0001779;C0444504;C2347634;C2348143;C2699239
1641,mean age ( range ) — yr,C0001779;C0439234;C0444504;C1514721;C2347634;C2348143;C2348147;C3542016
1641,mean age,C0001779;C0444504;C2347634;C2348143
1641,mean acrn,C0444504;C2347634;C2348143
1641,mean acq - nmbr scores,C0444504;C2347634;C2348143;C2919686
1641,mean acq - nmbr score at randomization  ! ,C0444504;C2347634;C2348143;C2919686
1641,mean a ± sem ( % ),C0444504;C2347634;C2348143
1641,mean a ± sdt,C0444504;C2347634;C2348143
1641,mean a ± sd ( mmhg ),C0444504;C2347634;C2348143
1641,mean a ± sd,C0444504;C2347634;C2348143
1641,mean = sd,C0444504;C2347634;C2348143;C2699239
1641,mean - sd change in pre - bronchodilator fevnmbr,C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C2599602;C2699239;C3714541;C4319952
1641,mean *,C0444504;C2347634;C2348143
1641,mean ( ± sd ) change from,C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C2699239;C4319952
1641,mean ( ± s . d . ),C0444504;C2347634;C2348143
1641,mean ( se ) trough l,C0036919;C0444504;C0444506;C2347634;C2348143
1641,mean ( se ) trough,C0036919;C0444504;C0444506;C2347634;C2348143
1641,mean ( se ) aucnmbr - nmbr,C0036919;C0376690;C0444504;C2347634;C2348143
1641,mean ( se ) auc^p l,C0036919;C0376690;C0444504;C2347634;C2348143
1641,mean ( se ),C0036919;C0444504;C2347634;C2348143
1641,mean ( sd ) years daily ocs use,C0332173;C0439234;C0444504;C2347634;C2348143;C2699239
1641,mean ( sd ) values are presented for all variables,C0042295;C0444504;C2347634;C2348143;C2699239
1641,mean ( sd ) tender joint count *,C0444504;C0451530;C2347634;C2348143;C2699239
1641,mean ( sd ) swollen joint count *,C0444504;C0451521;C2347634;C2348143;C2699239
1641,mean ( sd ) sdai *,C0444504;C2347634;C2348143;C2699239;C3871128
1641,mean ( sd ) ptga vas *,C0042815;C0444504;C2347634;C2348143;C2699239;C3536884;C3827561
1641,mean ( sd ) pre - bronchodilator,C0444504;C2347634;C2348143;C2599602;C2699239
1641,mean ( sd ) postbronchodilator fevnmbr reversibility,C0444504;C0449261;C2347634;C2348143;C2599594;C2699239;C3714541
1641,mean ( sd ) postbronchodilator fevnmbr / fvc,C0444504;C2347634;C2348143;C2599594;C2699239;C3714541
1641,mean ( sd ) postbronchodilator fevnmbr % predicted,C0444504;C2347634;C2348143;C2599594;C2699239;C3714541
1641,mean ( sd ) post - bronchodilator fevnmbr reversibility,C0444504;C0449261;C2347634;C2348143;C2599594;C2699239;C3714541
1641,mean ( sd ) post - bronchodilator fevnmbr percentage predicted,C0439165;C0444504;C1549488;C1561533;C2347634;C2348143;C2599594;C2699239;C3714541
1641,mean ( sd ) post - bronchodilator fevnmbr / fvc,C0444504;C2347634;C2348143;C2599594;C2699239;C3714541
1641,mean ( sd ) post - bronchodilator,C0444504;C2347634;C2348143;C2699239
1641,mean ( sd ) pga vas *,C0016410;C0042815;C0444504;C2347634;C2348143;C2699239;C3536884;C3541266;C3827561;C4050369
1641,mean ( sd ) periostin,C0219433;C0444504;C1424662;C2347634;C2348143;C2699239;C3812270
1641,mean ( sd ) pain vas *,C0042815;C0444504;C2347634;C2348143;C2699239
1641,mean ( sd ) number of albuterol per day,C0001927;C0237753;C0444504;C0449788;C2347634;C2348143;C2699239
1641,mean ( sd ) nmbr . nmbr ( nmbr . nmbr ),C0444504;C2347634;C2348143;C2699239
1641,mean ( sd ) mtx dose,C0366550;C0444504;C2347634;C2348143;C2699239
1641,mean ( sd ) improvement from baseline to week nmbr in basdai questions *,C0168634;C0444504;C1442488;C2347634;C2348143;C2699239;C2986411
1641,mean ( sd ) improvement from baseline to week nmbr in basdai,C0168634;C0444504;C1442488;C2347634;C2348143;C2699239;C2986411
1641,mean ( sd ) hbanmbrc level,C0019016;C0441889;C0444504;C0456079;C1547707;C1825777;C2347634;C2348143;C2699239;C2946261;C3538758
1641,mean ( sd ) hbanmbrc,C0019016;C0444504;C1825777;C2347634;C2348143;C2699239;C3538758
1641,mean ( sd ) fevnmbr postbronchodilator,C0444504;C2347634;C2348143;C2699239;C3714541
1641,mean ( sd ) fevnmbr / fvc,C0444504;C2347634;C2348143;C2699239;C3714541
1641,mean ( sd ) fevnmbr ( l ) pre - bronchodilator,C0444504;C2347634;C2348143;C2599602;C2699239;C3714541
1641,mean ( sd ) fevnmbr ( l ) post - bronchodilator,C0444504;C2347634;C2348143;C2699239;C3714541
1641,mean ( sd ) fevnmbr,C0444504;C2347634;C2348143;C2699239;C3714541
1641,mean ( sd ) fevi / fvc,C0444504;C0802741;C2347634;C2348143;C2699239;C3815113
1641,mean ( sd ) fevi / evc,C0013903;C0429706;C0429711;C0444504;C0849974;C1414479;C1561566;C2347634;C2348143;C2699239;C4528367
1641,mean ( sd ) fevi,C0444504;C0849974;C1561566;C2347634;C2348143;C2699239;C4528367
1641,mean ( sd ) fev nmbr / fvc,C0444504;C2347634;C2348143;C2699239;C3714541
1641,mean ( sd ) fev nmbr,C0444504;C2347634;C2348143;C2699239;C3714541
1641,mean ( sd ) feno,C0444504;C2347634;C2348143;C2699239
1641,mean ( sd ) extent of exposure,C0274281;C0332157;C0439792;C0444504;C2347634;C2348143;C2699239
1641,mean ( sd ) esr,C0444504;C2347634;C2348143;C2699239;C3811131
1641,mean ( sd ) egfr,C0444504;C1739039;C2347634;C2348143;C2699239;C3811844;C3812682
1641,mean ( sd ) eevi,C0444504;C2347634;C2348143;C2699239
1641,mean ( sd ) duration of tnmbrdm,C0011816;C0444504;C0449238;C2347634;C2348143;C2699239;C2926735;C3250443
1641,mean ( sd ) duration of smoking,C0037369;C0444504;C0449238;C0453996;C1881674;C2347634;C2348143;C2699239;C2926735
1641,mean ( sd ) duration of copd,C0024117;C0444504;C0449238;C1412502;C2347634;C2348143;C2699239;C2926735;C3714496
1641,mean ( sd ) dasnmbr - nmbr ( esr ) *,C0051767;C0057671;C0444504;C2347634;C2348143;C2699239;C3811131
1641,mean ( sd ) d,C0444504;C2347634;C2348143;C2699239
1641,mean ( sd ) crp,C0444504;C2347634;C2348143;C2699239;C3890735;C4048285
1641,mean ( sd ) change from pre - to post - bronchodilator fevnmbr,C0332152;C0392747;C0443172;C0444504;C0687676;C0740175;C1704687;C1705241;C2257086;C2347634;C2348143;C2599594;C2599602;C2699239;C3469826;C3669034;C3714541;C4319952
1641,mean ( sd ) change from pre - to post - bronchodilator fevi,C0332152;C0444504;C0687676;C0740175;C1704687;C2257086;C2347634;C2348143;C2599594;C2599602;C2699239;C3469826;C3481639;C3669034
1641,mean ( sd ) cdai *,C0444504;C0683448;C1413248;C2347634;C2348143;C2699239;C3273706
1641,mean ( sd ) body mass index,C0005893;C0444504;C0578022;C1305855;C2347634;C2348143;C2699239
1641,mean ( sd ) bmi ( kg / mnmbr ),C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
1641,mean ( sd ) bmi,C0444504;C0578022;C2347634;C2348143;C2699239
1641,mean ( sd ) bmd in g / cmnmbr,C0439267;C0444504;C2347634;C2348143;C2699239
1641,mean ( sd ) baseline scores,C0168634;C0444504;C1442488;C2347634;C2348143;C2699239
1641,mean ( sd ) baseline,C0168634;C0444504;C1442488;C2347634;C2348143;C2699239
1641,mean ( sd ) aqlq,C0444504;C2347634;C2348143;C2699239;C4055434
1641,mean ( sd ) anthropometry,C0003188;C0444504;C2347634;C2348143;C2699239
1641,mean ( sd ) age in years,C0444504;C1510829;C2347634;C2348143;C2699239
1641,mean ( sd ) age ( years ),C0444504;C1510829;C2347634;C2348143;C2699239
1641,mean ( sd ) age,C0001779;C0444504;C2347634;C2348143;C2699239
1641,mean ( sd ) [range] duration of epilepsy,C0014544;C0444504;C0449238;C1514721;C2347634;C2348143;C2348147;C2699239;C2926735;C3542016
1641,mean ( sd ) [range],C0444504;C1514721;C2347634;C2348143;C2348147;C2699239;C3542016
1641,mean ( sd ) ( years ),C0439234;C0444504;C2347634;C2348143;C2699239
1641,mean ( sd ) % reversibility fevnmbr at,C0444504;C0449261;C2347634;C2348143;C2699239;C3714541
1641,mean ( sd ) % predicted normal fevnmbr,C0444504;C2347634;C2348143;C2699239
1641,mean ( sd ) % of predicted normal fevnmbr,C0444504;C0520835;C0681842;C1882327;C2347634;C2348143;C2699239
1641,mean ( sd ) % of predicted normal fevi,C0205307;C0231683;C0429706;C0439166;C0444504;C0681842;C0849974;C1561566;C1882327;C2347086;C2347634;C2348143;C2699239;C4528367;C4553972
1641,mean ( sd ) % of predicted normal eevi,C0205307;C0231683;C0439166;C0444504;C0681842;C1882327;C2347086;C2347634;C2348143;C2699239;C4553972
1641,mean ( sd ),C0444504;C2347634;C2348143;C2699239
1641,mean ( s . e . ) t,C0444504;C2347634;C2348143
1641,mean ( s . e . ),C0444504;C2347634;C2348143
1641,mean ( s . d . ) total pcsknmbr,C0439175;C0439810;C0444504;C2347634;C2348143
1641,mean ( s . d . ) non - hdl cholesterol,C0444504;C0729627;C1535899;C2347634;C2348143
1641,mean ( s . d . ) measured ldl cholesterol,C0444504;C2347634;C2348143
1641,mean ( s . d . ) ldl particle size,C0444504;C2347634;C2348143;C3641256
1641,mean ( s . d . ) ldl particle number,C0237753;C0444504;C0449788;C2347634;C2348143;C2612459
1641,mean ( s . d . ) hdl cholesterol,C0023822;C0392885;C0444504;C2347634;C2348143
1641,mean ( s . d . ) hbalc,C0444504;C2347634;C2348143
1641,mean ( s . d . ) free pcsknmbr,C0332296;C0444504;C1880497;C1996904;C2347634;C2348143
1641,mean ( s . d . ) fpg,C0444504;C2347634;C2348143
1641,mean ( s . d . ) egfr,C0444504;C1739039;C2347634;C2348143;C3811844;C3812682
1641,mean ( s . d . ) duration of tnmbrdm,C0011816;C0444504;C0449238;C2347634;C2348143;C2926735;C3250443
1641,mean ( s . d . ) calculated ldl cholesterol,C0444504;C2347634;C2348143
1641,mean ( s . d . ) bmi,C0444504;C0578022;C2347634;C2348143
1641,mean ( s . d . ) baseline hbanmbrc,C0019016;C0168634;C0444504;C1442488;C1825777;C2347634;C2348143;C3538758
1641,mean ( s . d . ) baseline fpg,C0168634;C0444504;C1442488;C2347634;C2348143
1641,mean ( s . d . ) apoc - ll nmbr,C0003594;C0444504;C2347634;C2348143
1641,mean ( s . d . ) apob,C0003593;C0444504;C2347634;C2348143;C3252643
1641,mean ( s . d . ) age,C0001779;C0444504;C2347634;C2348143
1641,mean ( s . d . ),C0444504;C2347634;C2348143
1641,mean ( nmbr % ci ) difference vs saxa + dapa + met,C0008107;C0444504;C1705241;C1705242;C2347634;C2348143;C3259781
1641,mean ( nmbr % ci ) change from nmbr . nmbr to nmbr . nmbr mg,C0008107;C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C3259781;C4319952
1641,mean ( median ) mtx dose,C0366550;C0444504;C0549183;C0876920;C2347634;C2347635;C2348143;C2348144;C2939193
1641,mean ( = sd ) days since,C0439228;C0444504;C2347634;C2348143;C2699239
1641,mean % predicted value prebronchodilation,C0444504;C2347634;C2348143
1641,mean % predicted fvc ( sd ),C0444504;C2347634;C2348143
1641,mean % predicted dlco * ( sd ),C0444504;C2347634;C2348143
1641,mean,C0444504;C2347634;C2348143
1641,mayo score ( mean ± sd ),C0444504;C0449820;C0454788;C1077578;C2347634;C2348143;C2699239;C4050231
1641,lvef ( mean ± sd ),C0428772;C0444504;C0488728;C2347634;C2348143;C2699239
1641,ls mean ± se,C0023668;C0036919;C0444504;C2347634;C2348143
1641,ls mean difference ± seb,C0023668;C0059386;C0444504;C1309881;C1423585;C1705241;C1705242;C2347634;C2348143;C3815268
1641,ls mean difference ( se ),C0023668;C0036919;C0444504;C1705241;C1705242;C2347634;C2348143
1641,ls mean ( se ),C0023668;C0036919;C0444504;C2347634;C2348143
1641,ls mean ( nmbr % ci ) a,C0008107;C0023668;C0444504;C2347634;C2348143;C3259781
1641,ls mean ( nmbr % ci ),C0008107;C0023668;C0444504;C2347634;C2348143;C3259781
1641,ls mean,C0023668;C0444504;C2347634;C2348143
1641,ls - mean change from baseline ( nmbr % ci ),C0008107;C0023668;C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C3259781;C4319952
1641,lowest tertile ( range  nmbr . nmbr - nmbr . nmbr mg / dl  mean ± sd  nmbr . nmbr ± nmbr . nmbr mg / dl ),C0024671;C0026410;C0439269;C0444504;C1514721;C1708760;C1960952;C2346927;C2347634;C2348143;C2348147;C2699239;C3539687;C3542016;C4321396;C4521761
1641,leflunomide ( mean dose : nmbr . nmbr mg / day ),C0063041;C0178602;C0439422;C0444504;C0869039;C1114758;C2347634;C2348143
1641,least square mean ( se ),C0023189;C0036919;C0444504;C2347634;C2348143
1641,least - squares mean difference ( nmbr % cl ),C0023189;C0444504;C0596019;C1705241;C1705242;C2347634;C2348143
1641,least - squares mean difference ( nmbr % ci ) *,C0008107;C0023189;C0444504;C1705241;C1705242;C2347634;C2348143;C3259781
1641,ldl - c in mmol / l ( mean ± sd for baseline [n]  mean ± se for week nmbr [n] ),C0444504;C1532563;C2347634;C2348143;C2699239
1641,ldl - c in mmol / l ( baseline : mean ( sd ) [n]  wk nmbr and change : mean ( se ) [n] ),C0168634;C0332174;C0439230;C0444504;C1442488;C1532563;C2347634;C2348143;C2699239
1641,ldl - c ( bq ) ( mg / dl ) - mean ± sd,C0439269;C0444504;C0560038;C2346983;C2347634;C2348143;C2699239;C3541236;C3642216
1641,hrql mean ( sd ),C0444504;C2347634;C2348143;C2699239
1641,highest tertile ( range  nmbr . nmbr - nmbr . nmbr mg / dl  mean ± sd  nmbr . nmbr ± nmbr . nmbr mg / dl ),C0024671;C0026410;C0439269;C0444504;C1514721;C1522410;C1960952;C2346927;C2347634;C2348143;C2348147;C2699239;C3539687;C3542016;C4321396;C4521761
1641,height ( cm ) ( mean ± sd ),C0444504;C0489786;C2347634;C2348143;C2699239
1641,hdl - c ( mg / dl ) - mean ± sd,C0439269;C0444504;C2347634;C2348143;C2699239;C3715113
1641,hbajc ( mmol / mol ) mean ± sd,C0444504;C2347634;C2348143;C2699239;C3829066
1641,hbaie ( % ) mean ± sd,C0444504;C2347634;C2348143;C2699239
1641,habnmbrc ( mean ± sem ),C0444504;C2347634;C2348143
1641,femoral neck t - score ( mean = sd ),C0015815;C0444504;C0449820;C2347634;C2348143;C2699239;C4050231
1641,estimated mean nmbr % cl,C0444504;C0596019;C0750572;C2347634;C2348143
1641,estimated mean,C0444504;C0750572;C2347634;C2348143
1641,egfr — mean ( sd,C0444504;C1739039;C2347634;C2348143;C2699239;C3811844;C3812682
1641,diastolic — mean ( sd ) ( mm hg ),C0012000;C0439475;C0444504;C2347634;C2348143;C2699239
1641,dbp . mean ( sd ) mm hg,C0439475;C0444504;C0536221;C2347634;C2348143;C2699239;C3813197;C4281799
1641,daytime mean sbp ( abpm ) at week nmbr,C0085805;C0332169;C0332174;C0439230;C0444504;C2347634;C2348143
1641,daytime mean dbp ( abpm ) at week nmbr,C0332169;C0332174;C0439230;C0444504;C0536221;C2347634;C2348143;C3813197;C4281799
1641,crp mean ( mg / dl ± sd ),C0439269;C0444504;C2347634;C2348143;C2699239;C3890735;C4048285
1641,cholesterol - mean ( sd,C0008377;C0444504;C2347634;C2348143;C2699239
1641,body mass index mean kg / mnmbr ( sd ),C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239
1641,body mass index / mean ( sd ),C0005893;C0444504;C0578022;C1305855;C2347634;C2348143;C2699239
1641,body mass index - mean ( sd ),C0005893;C0444504;C0578022;C1305855;C2347634;C2348143;C2699239
1641,bmi — mean ( sd ) ( kg / mnmbr ),C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
1641,bmi ¼ body mass index  hctz ¼ hydrochlorothiazide  msdbp ¼ mean sitting diastolic blood pressure  mssbp ¼ mean sitting systolic blood pressure  sd ¼ standard deviation,C0020261;C0444504;C1305855;C1319894;C2347634;C2348143
1641,bmi ( kg / mnmbr ) mean ± sd,C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
1641,bmi ( kg / mnmbr ) mean ( sd ),C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
1641,bmi ( kg / mnmbr ) [mean - sd],C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
1641,bmi ( kg / mnmbr ) : mean ± sd,C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
1641,bmi ( kg / mnmbr ) ( mean ± sd ),C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
1641,bl mean ( mmhg ),C0005918;C0006413;C0439475;C0444504;C1552663;C2347634;C2348143;C2827109
1641,bl mean ( cm ),C0005918;C0006413;C0444504;C1552663;C2347634;C2348143;C2827109
1641,bl mean,C0005918;C0006413;C0444504;C1552663;C2347634;C2348143;C2827109
1641,bii ( mean ± sd ),C0444504;C1413059;C2347634;C2348143;C2699239
1641,baseline nmbr - hour mean sbp,C0085805;C0168634;C0439227;C0444504;C0564385;C1442488;C2347634;C2348143
1641,baseline mean 士 sd,C0168634;C0444504;C1442488;C2347634;C2348143;C2699239
1641,baseline mean serum uric acid,C0168634;C0444504;C0455272;C0700634;C1442488;C2347634;C2348143
1641,baseline mean seated sbp,C0085805;C0168634;C0277814;C0444504;C1283233;C1442488;C2347634;C2348143
1641,baseline mean mtss,C0168634;C0444504;C1442488;C2347634;C2348143
1641,baseline mean fevnmbr ( sd ),C0168634;C0444504;C1442488;C2347634;C2348143;C2699239;C3714541
1641,baseline mean ambulatory sbp,C0085805;C0168634;C0439841;C0444504;C1442488;C2347634;C2348143
1641,baseline mean ( se ),C0036919;C0168634;C0444504;C1442488;C2347634;C2348143
1641,baseline mean ( sd ),C0168634;C0444504;C1442488;C2347634;C2348143;C2699239
1641,baseline mean ( mg / dl],C0168634;C0439269;C0444504;C1442488;C2347634;C2348143
1641,baseline mean,C0168634;C0444504;C1442488;C2347634;C2348143
1641,baseline lipids  mean ± sd ( mmol / nmbr ),C0023779;C0168634;C0439190;C0444504;C1442488;C2347634;C2348143;C2699239
1641,baseline lipids  mean ± sd ( mmol / l ),C0023779;C0168634;C0444504;C1442488;C1532563;C2347634;C2348143;C2699239
1641,baseline haq mean ( s . e . ),C0102923;C0168634;C0444504;C0451208;C1442488;C2347634;C2348143
1641,baseline corticosteroidst ( mean dose : nmbr . nmbr mg / day ),C0168634;C0178602;C0439422;C0444504;C0869039;C1114758;C1442488;C2347634;C2348143
1641,baseline . mean _ sd . mg / mg,C0168634;C0444504;C1319635;C1442488;C2347634;C2348143;C2699239
1641,baseline . mean _ sd . mg / dl,C0168634;C0439269;C0444504;C1442488;C2347634;C2348143;C2699239
1641,baseline . mean _ sd,C0168634;C0444504;C1442488;C2347634;C2348143;C2699239
1641,baseline ( mean,C0168634;C0444504;C1442488;C2347634;C2348143
1641,apo b ( mg / dl ) - mean ± sd,C0003593;C0439269;C0444504;C2347634;C2348143;C2699239;C3252643
1641,apo a - l ( mg / dl ) - mean ± sd,C0439269;C0444504;C1447574;C2347634;C2348143;C2699239;C4521365
1641,anthropometry : mean ( sd ),C0003188;C0444504;C2347634;C2348143;C2699239
1641,age — mean ( sd ) ( years ),C0444504;C1510829;C2347634;C2348143;C2699239
1641,age mean age,C0001779;C0444504;C2347634;C2348143
1641,age mean ( yrs ± sd ),C0001779;C0444504;C2347634;C2348143;C2699239
1641,age - mean ( sd ) years,C0444504;C1510829;C2347634;C2348143;C2699239
1641,age ( y ) [mean - sd],C0001779;C0444504;C2347634;C2348143;C2699239
1641,adjusted mean change from baseline ( se ),C0036919;C0168634;C0392747;C0443172;C0444504;C0456081;C1442488;C1705241;C2347634;C2348143;C4319952
1641,adjusted mean change from baseline ( nmbr % ci ),C0008107;C0168634;C0392747;C0443172;C0444504;C0456081;C1442488;C1705241;C2347634;C2348143;C3259781;C4319952
1641,adjusted change from baseline mean ( s . e . ),C0168634;C0392747;C0443172;C0444504;C0456081;C1442488;C1705241;C2347634;C2348143;C4319952
1641,> mean,C0444504;C2347634;C2348143
1641,< mean,C0444504;C2347634;C2348143
1641,( mean ± sd ),C0444504;C2347634;C2348143;C2699239
1641,( mean difference,C0444504;C1705241;C1705242;C2347634;C2348143
1641,( mean + . sd ),C0444504;C2347634;C2348143;C2699239
1641,( mean % difference,C0444504;C1705241;C1705242;C2347634;C2348143
1641,% \mean ± sd,C0444504;C2347634;C2348143;C2699239
1640,partner,C0682323;C3887537
1640,octi & matenmbr,C0682323;C1260875
1640,mate !,C0682323;C1260875
1640,mate,C0682323;C1260875
1640,companion : wake - up stroke,C0031268;C0038454;C0335343;C0682323;C1170730;C4554100
1640,companion : nmbr - nmbr hours,C0031268;C0335343;C0439227;C0682323
1639,oma / oat ( n   =   nmbr ),C0028753;C0331496;C0939905;C3539067;C3897364
1639,oma / oat,C0028753;C0331496;C0939905;C3539067;C3897364
1639,oat ( n   =   nmbr ),C0028753;C0331496;C0939905;C3539067;C3897364
1639,oat,C0028753;C0331496;C0939905;C3539067;C3897364
1638,years duration oa,C0029408;C0439234;C0449238;C2926735;C3887876
1638,severe oa symptoms at baselined,C0029408;C0436345;C3887876
1638,oa,C0029408;C3887876
1638,less severe oa symptoms at baseline,C0029408;C0168634;C0436345;C0439092;C0547044;C1442488;C3887876
1637,osteoarthritis,C0029408
1637,duration of osteoarthritis symptoms — yr,C0029408;C0436359;C0439234
1636,ze + statin,C0360714
1636,pbo + statin nmbr,C0031962;C0360714
1636,pbo + statin n = nmbr,C0031962;C0360714
1636,pbo + statin,C0031962;C0360714
1636,other statin,C0360714
1636,no statin,C0360714
1636,neither pbo + statin eze + statin,C0031962;C0360714
1636,eze + statin n = nmbr,C0360714
1636,eze + statin,C0360714
1636,baseline statin usec,C0168634;C0360714;C0439224;C1442488
1636,baseline statin,C0168634;C0360714;C1442488
1636,baseiine statin,C0360714
1636,any statin,C0360714
1635,statin with niacin,C0027996;C0360714;C1142562
1635,statin with fibrate,C0360714
1635,extended - release niacin plus statin ( n = nmbr ),C0027996;C0332287;C0360714;C1142562;C1707968
1634,statins 一 no . ( % ),C0360714
1634,statins used during follow - up,C0360714
1634,statin use — no . { % ),C0360714
1634,statin use ( % ),C0042153;C0360714;C0457083;C1947944
1634,statin use,C0042153;C0360714;C0457083;C1947944
1634,statin usage,C0360714;C0457083
1634,prior statin use,C0042153;C0332152;C0360714;C0457083;C1947944;C2826257
1634,no statin vs statin alone vs any statin plus other llt,C0360714
1634,no statin use,C0042153;C0360714;C0457083;C1947944
1634,no prior statin use,C0042153;C0332152;C0360714;C0457083;C1947944;C2826257
1634,moderate - intensity statin use,C0042153;C0360714;C0457083;C1947944;C4081855
1634,moderate - intensity statin,C0360714;C4081855
1634,all patients on maximally tolerated statin ± other llt,C0030705;C0360714
1633,statin — no . / total no . ( % ),C0360714
1633,statin users ( n = nmbr ),C0360714;C1706077
1633,statin users,C0360714;C1706077
1633,statin potency stratum,C0360714;C3245505
1633,statin potency medium ( n = nmbr ),C0009458;C0360714;C0439536;C1705217;C3244283;C3245505;C4085196;C4522282;C4522283
1633,statin non - users ( n = nmbr ),C0360714;C1518422;C1706077
1633,statin and / or other lipid - lowering agent therapy,C0360714
1633,statin + placebo ( n = nmbr ),C0032042;C0360714;C1696465;C1706408
1633,statin ( s ),C0360714
1633,statin ( open ),C0360714
1633,statin ( n = nmbr ),C0360714
1633,statin ( n - nmbr ),C0360714
1633,statin ( % ),C0360714
1633,non - statin ( n = nmbr ),C0360714;C1518422
1633,combined statin and other lipid - lowering agent use,C0205195;C0360714
1632,statin medication,C0013227;C0360714;C3244316;C4284232
1632,statin + fibrate or niacin,C0360714
1632,statin + fibrate or,C0360714
1631,statins / ezetimibe,C0360714;C1142985
1631,statins,C0360714
1631,statin with ezetimibe,C0360714;C1142985
1631,statin or ezetimibe,C0360714
1631,statin only ( n = nmbr,C0205171;C0360714;C1720467
1631,statin only,C0205171;C0360714;C1720467
1631,statin monotherapy,C0360714
1631,statin intolerant *,C0231200;C0360714
1631,statin intolerancenmbr,C0231199;C0360714;C1744706;C2355652
1631,statin intensitynmbr * nmbr,C0360714;C0522510
1631,statin intensity per acc / ahac,C0175754;C0282160;C0360714;C0522510;C3541413
1631,statin and / or ezetimibe,C0360714
1631,statin alone,C0360714
1631,statin + ezetimibe { n = nmbr,C0360714;C1142985
1631,statin + ezetimibe ( n = nmbr . nmbr ),C0360714;C1142985
1631,statin + ezetimibe,C0360714;C1142985
1631,statin,C0360714
1630,no statin ( + / - llt ),C0360714;C2347090
1630,moderate - dose statin,C0360714;C1709056
1630,ltt other than statin,C0360714
1630,low - dose statin,C0360714;C0445550;C1708745
1630,llv wlalil nmbr statin,C0360714
1630,llt other than statin at randomization,C0360714;C2347090
1630,fenofibric acid - i - moderate - dose statin,C0021966;C0060179;C0221138;C0360714;C1709056
1630,fenofibric acid + moderate - dose statin,C0060179;C0360714;C1709056
1630,any statin versus no statin at randomization,C0360714
1630,any statin + other llt,C0360714
1630,any statin ( with / without llt ),C0360714
1630,any llt other than statins,C0360714;C2347090
1629,years male gender,C0086582;C0439234;C1706180
1629,sexa male,C0086582;C1706180;C1706428;C1706429
1629,sex : male ( n = nmbr ),C0086582
1629,sex : male,C0086582
1629,sex ( male / female ) ( n ),C0043210;C0086287;C0086582;C1705497;C1705498;C1706180;C1706428;C1706429
1629,sex ( male / female ),C0043210;C0086287;C0086582;C1705497;C1705498;C1706180;C1706428;C1706429
1629,sex ( male ) - no . ( % ),C0086582
1629,sex ( male ),C0086582
1629,sex ( male,C0086582
1629,males [n ( % ) ],C0086582
1629,males ( n = nmbr ),C0086582
1629,males ( itt ) ( n = nmbr ),C0086582
1629,males ( % ),C0086582
1629,males,C0086582
1629,male vs . female,C0086582;C1706180;C1706428;C1706429
1629,male subjects ( n = nmbr,C0086582;C1706180;C1706428;C1706429
1629,male simva ( „ = nmbr },C0086582;C1706180;C1706428;C1706429
1629,male simva ( n = nmbr ),C0086582;C1706180;C1706428;C1706429
1629,male simva,C0086582;C1706180;C1706428;C1706429
1629,male sex^,C0086582
1629,male sex 一 no . ( % ),C0086582
1629,male sex — no . { % ),C0086582
1629,male sex — no . ( % ) risk factors,C0086582
1629,male sex — no . ( % ) f,C0086582
1629,male sex — no . ( % ),C0086582
1629,male sex — %,C0086582
1629,male sex \ no . ( % ),C0086582
1629,male sex ( % ),C0086582
1629,male sex,C0086582
1629,male nyha class,C0086582;C1706180;C1706428;C1706429;C1882083
1629,male gender ( % ),C0086582;C1706180
1629,male gender,C0086582;C1706180
1629,male eze / simva ( „ = nmbr },C0086582;C1706180;C1706428;C1706429
1629,male eze / simva ( n = nmbr ),C0086582;C1706180;C1706428;C1706429
1629,male eze / simva,C0086582;C1706180;C1706428;C1706429
1629,male / female,C0043210;C0086287;C0086582;C1705497;C1705498;C1706180;C1706428;C1706429
1629,male - no . ( % ),C0086582;C1706180;C1706428;C1706429
1629,male *,C0086582;C1706180;C1706428;C1706429
1629,male ( n   = nmbr,C0086582;C1706180;C1706428;C1706429
1629,male ( n z nmbr ),C0086582;C1706180;C1706428;C1706429
1629,male ( n = nmbr ),C0086582;C1706180;C1706428;C1706429
1629,male ( n = nmbr,C0086582;C1706180;C1706428;C1706429
1629,male ( n - nmbr ),C0086582;C1706180;C1706428;C1706429
1629,male ( % ),C0086582;C1706180;C1706428;C1706429
1629,male,C0086582;C1706180;C1706428;C1706429
1629,hdl — male,C0086582;C1706180;C1706428;C1706429;C3715113
1629,genital mycotic infections malenmbr,C0086582;C0740330;C1706180;C1706428;C1706429
1629,[cm { female ) / cm { male ) ],C0043210;C0086287;C0086582;C1705497;C1705498;C1706180;C1706428;C1706429
1629,[cm ( female ) / cm ( male ) ],C0043210;C0086287;C0086582;C1705497;C1705498;C1706180;C1706428;C1706429
1628,sex ( male ) ethnic origin,C0015031;C0086582
1628,male sex — no . of patients ( % ),C0086582
1628,male sex — no . / total no . ( % ),C0086582
1628,male sex — no . ( % ) weight — no . ( % ),C0086582
1628,male sex — no . ( % ) race — no . ( % ) ) :,C0086582
1628,male sex — no . ( % ) medical history — no . / total no . ( % ),C0086582
1628,male sex ( % ) race or ethnic group ( % ) f,C0034510;C0086582;C1706779;C3853635
1627,acute infection without septic shock,C0036983;C0275518
1626,measured at home with automated device,C0444706;C3541902
1626,measured at clinic visit with usual device,C0008952;C0444706;C3541902
1626,measured at clinic visit with automated device §,C0008952;C0444706;C3541902
1625,weight at baseline,C1303013
1625,baseline weight,C1303013
1625,baseline body weight quartile,C1303013;C2828255
1624,self - reported disease severity,C0521117;C0681906;C2700446
1624,self - reported descent,C0681906;C2700446
1623,insulin - dependent diabetes mellitus,C0011854
1623,insulin - dependent diabetes,C0011854
1622,selena - sledai total score,C0451528;C2964552
1622,selena - sledai activity,C0205177;C0439167;C0441655;C0451528;C1561536;C3668946;C4049938;C4049939
1622,selena - sledai > nmbr,C0451528
1621,volume depletion - related aes,C0439849;C0445223;C0546884;C1412268;C2699274
1621,respiratory - related^,C0439849;C0445223;C0521346;C1546767
1621,related to study druga,C0439849;C0445223
1621,osmotic diuresis - related aes,C0232823;C0439849;C0445223;C1412268;C2699274
1621,gallbladder - related aes,C0016976;C0439849;C0445223;C1412268;C2699274
1620,exenatide ± oad,C0167117
1620,exenatide no . of events / total no . ( % ),C0167117
1620,exenatide n = nmbr,C0167117
1620,exenatide lar,C0167117
1620,exenatide er,C0167117;C3810541;C3811131
1620,exenatide,C0167117
1619,associated with hiv infection,C0019693;C0332281
1619,associated with drug or toxin exposure,C0013227;C0332281;C1254351
1619,associated with drug / toxin,C0013221;C0332281
1619,associated with ctd,C0332281;C1335071;C1442905
1619,associated with corrected - congenital shunts,C0009678;C0205202;C0232180;C0332281;C0542331;C1442858;C1744681
1619,associated with corrected,C0205202;C0332281
1619,associated with an atrial septal defect,C0018817;C0332281
1618,treated with losartan ( n = nmbr ),C0126174;C0332293
1618,treated with laba,C0332293
1618,treated with insulin,C0021641;C0332293;C1533581;C1579433;C3714501
1618,treated with cabg — no . / total no . ( % ),C0010055;C0332293
1618,treated with atenolol ( n = nmbr ),C0004147;C0332293
1617,isolated upper gastrointestinal disease behavior,C0004927;C0205409;C0810300;C1548221;C2707008
1617,isolated pulmonary embolism,C0034065;C0205409;C1548221
1617,isolated impaired glucose tolerance — no .,C0205409;C1548221
1617,isolated igt,C0205409;C1548221
1617,isolated deep - vein thrombosis,C0149871;C0205409;C1548221
1616,elevated serum potassium,C0553704
1615,elevated symptomatic serum creatinine,C0231220;C0700225
1615,elevated serum creatinine ( > nmbr . nmbr mg / dl_ ),C0439269;C0700225
1615,elevated serum creatinine,C0700225
1615,elevated creatinine ( > nmbr pmol / l ),C0151578;C0439284;C0700225
1614,elevated high - sensitivity crp — no . { % ) * *,C0742906;C1441604
1614,elevated crp ( > ulnt ),C0742906
1614,elevated crp,C0742906
1614,elevated baseline crp,C0168634;C0742906;C1442488
1613,implantable cardioverter - defibrillator n ( % ),C0162589;C2825184
1613,implantable cardioverter - defibrillator,C0162589;C2825184
1612,implanted cardioverter defibrillator,C0021102;C0810516;C2828363
1612,implanted cardioverter - defibrillator,C0021102;C0810516;C2828363
1611,median fecal calprotectin — mg / kg gi areas involved — no . ( % ),C0015733;C0205146;C0439272;C0549183;C0876920;C0950624;C1335798;C1366582;C1708130;C2347635;C2348144;C2939193;C3539617;C4050121;C4319729
1611,mean fecal calprotectin level,C0015733;C0441889;C0444504;C0456079;C0950624;C1335798;C1366582;C1547707;C2347634;C2348143;C2946261
1611,fecal calprotectin — pg / g * *,C0015733;C0950624;C1335798;C1366582;C1638318
1610,medical therapy only ( n = nmbr ),C0205171;C0418981;C1720467
1610,medical therapy only,C0205171;C0418981;C1720467
1610,medical therapy before randomization — no . / total no . ( % ),C0034656;C0418981
1610,medical therapy alone,C0418981
1610,medical therapy ( n = nmbr ),C0418981
1610,medical therapy,C0418981
1610,medical therapies,C0418981
1609,years of education *,C0013621;C0013622;C0013658;C0039401;C0439234
1609,years of education,C0013621;C0013622;C0013658;C0039401;C0439234
1609,education — no . ( % ),C0013621;C0013622;C0013658;C0039401
1609,education nmbr to nmbr y,C0013621;C0013622;C0013658;C0039401
1609,education nmbr - nmbr years,C0013621;C0013622;C0013658;C0039401;C0439234
1609,education level,C0013621;C0013658
1609,education in years,C0013621;C0013622;C0013658;C0039401;C0439234
1609,education > nmbr yr ( % ),C0013621;C0013622;C0013658;C0039401;C0439234
1609,education > nmbr years,C0013621;C0013622;C0013658;C0039401;C0439234
1609,education > nmbr y,C0013621;C0013622;C0013658;C0039401
1609,education < nmbr years,C0013621;C0013622;C0013658;C0039401;C0439234
1609,education < nmbr y,C0013621;C0013622;C0013658;C0039401
1609,education *,C0013621;C0013622;C0013658;C0039401
1609,education ( years ),C0013621;C0013622;C0013658;C0039401;C0439234
1609,education ( % ),C0013621;C0013622;C0013658;C0039401
1609,education,C0013621;C0013622;C0013658;C0039401
1609,> nmbr years education,C0013621;C0013622;C0013658;C0039401;C0439234
1609,< nmbr yr of education — no . ( % ),C0013621;C0013622;C0013658;C0039401;C0439234
1608,no antiplatelet therapy,C1096021
1608,long - term antiplatelet therapy,C0443252;C1096021
1608,dual antiplatelet therapy,C0205173;C1096021;C1554184
1608,antiplatelet therapy §,C1096021
1608,antiplatelet therapy dual,C1096021
1608,antiplatelet therapy,C1096021
1607,statin therapy,C1278454
1607,prerandomization statin therapy,C1278454
1607,intensity of statin therapy at baseline — no . { % ),C0522510;C1278454
1607,intensity of statin therapy,C0522510;C1278454
1606,phototherapy,C0031765
1605,estrogen therapy,C0279494
1604,anticoagulant therapy,C0150457
1603,no diuretic therapy,C0948575
1603,diuretic therapy,C0948575
1602,cardiac therapy §,C3654025
1602,cardiac therapy,C3654025
1601,low dose combination therapy,C0009429;C0445550;C0556895;C1708745
1601,combination therapy * *,C0009429;C0556895
1601,combination therapy ( n = nmbr ),C0009429;C0556895
1601,combination therapy,C0009429;C0556895
1600,the square of the height in meters . patient ' s and physician ' s global assessment scores can range from nmbr to nmbr . scores for the western,C0205120;C0489786;C1552595
1599,height — cm,C0489786
1599,height ( cm ),C0489786
1599,height ',C0489786
1599,height,C0489786
1599,baseline height ( cm ),C0168634;C0489786;C1442488
1598,yes ( % ) weight [kg] ( interaction : p = nmbr . nmbr ),C0005910;C0022718;C0043100;C0439209;C1305866;C1549445;C1704675;C1705104;C1705108;C1710701;C4054209
1598,weight^ ,C0005910;C0043100;C1305866;C1705104
1598,weight 一 kg,C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
1598,weight — no . ( % ),C0005910;C0043100;C1305866;C1705104
1598,weight — kg,C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
1598,weight of < nmbr kg,C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
1598,weight nmbr - nmbr,C0005910;C0043100;C1305866;C1705104
1598,weight nmbr +,C0005910;C0043100;C1305866;C1705104
1598,weight in kg,C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
1598,weight category,C0005910;C0043100;C0683312;C1305866;C1705104;C3889287
1598,weight ab,C0005910;C0043100;C1305866;C1705104
1598,weight [kg],C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
1598,weight > nmbr kg,C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
1598,weight < nmbr kg,C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
1598,weight < nmbr . nmbr kg,C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
1598,weight < nmbr,C0005910;C0043100;C1305866;C1705104
1598,weight - kg,C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
1598,weight ( range ) ( kg ),C0005910;C0022718;C0043100;C0439209;C1305866;C1514721;C1705104;C2348147;C3542016;C4054209
1598,weight ( kg },C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
1598,weight ( kg ) 十,C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
1598,weight ( kg ) bmi ( kg / mnmbr ),C0005910;C0043100;C0369637;C0441923;C0578022;C1305866;C1319635;C1705104
1598,weight ( kg ) a,C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
1598,weight ( kg ) *,C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
1598,weight ( kg ),C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
1598,weight $ nmbr . nmbr kg,C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
1598,weight # nmbr kg,C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
1598,weight  mean ± sd ( kg ),C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209
1598,weight,C0005910;C0043100;C1305866;C1705104
1598,per body weight,C0005910;C1305866
1598,no body weight at randomization ( ixrs ),C0005910;C0034656;C0242821;C0460148;C1268086;C1305866;C2985844;C4082212
1598,median weight,C0005910;C0043100;C0549183;C0876920;C1305866;C1705104;C2347635;C2348144;C2939193
1598,mean ± s . d . weight,C0005910;C0043100;C0444504;C1305866;C1705104;C2347634;C2348143
1598,mean weight,C0005910;C0043100;C0444504;C1305866;C1705104;C2347634;C2348143
1598,mean body weight,C0005910;C0444504;C1305866;C2347634;C2348143
1598,mean ( sd ) weight,C0005910;C0043100;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239
1598,mean ( s . d . ) weight,C0005910;C0043100;C0444504;C1305866;C1705104;C2347634;C2348143
1598,healthy weight,C0005910;C0043100;C1305866;C1705104;C3898900
1598,dose / weight ( iu / kg ),C0005910;C0043100;C0178602;C0439463;C0869039;C1114758;C1305866;C1705104
1598,bodyweight,C0005910;C1305866
1598,body weight at randonization { ixrs ),C0005910;C1305866
1598,body weight at randomization,C0005910;C0034656;C0242821;C0460148;C1268086;C1305866;C2985844;C4082212
1598,body weight *,C0005910;C1305866
1598,body weight,C0005910;C1305866
1598,> nmbr kg body weight at randomization,C0005910;C0022718;C0034656;C0242821;C0439209;C0460148;C1268086;C1305866;C2985844;C4054209;C4082212
1597,patients with bw decrease of $ nmbr % in patients with baseline bmi of $ nmbr kg / mnmbr +,C0005910;C0006041;C0030705;C0392756;C0547047;C2986891
1597,bw at nmbr weeks,C0005910;C0006041;C0439230;C2986891
1597,bw,C0005910;C0006041;C2986891
1596,microalbuminuria — no . / total no . ( % ),C0730345
1596,microalbuminuria — no . ( % ),C0730345
1596,microalbuminuria or proteinuria,C0730345
1596,microalbuminuria or macroalbuminuria §,C0730345
1596,microalbuminuria or macroalbuminuria,C0730345
1596,microalbuminuria ( uacr nmbr – nmbr ),C0730345
1596,microalbuminuria,C0730345
1596,low to medium microalbuminuria ( n = nmbr ),C0009458;C0205251;C0439536;C0730345;C1550472;C1705217;C3244283;C3890211;C4048187;C4085196;C4321351;C4522223;C4522282;C4522283
1596,low - medium microalbuminuria ( n = nmbr ),C0009458;C0205251;C0439536;C0730345;C1550472;C1705217;C3244283;C3890211;C4048187;C4085196;C4321351;C4522223;C4522282;C4522283
1596,high microalbuminuria to macroalbuminuria ( n = nmbr ),C0205250;C0730345;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
1595,micro / macroalbuminuria,C0085672;C1553035;C3811161;C4049106
1595,micro / macroaibuminuria,C0085672;C1553035;C3811161;C4049106
1595,micro - or macroalbuminuria,C0085672;C1553035;C3811161;C4049106
1595,micro - albuminuria,C0001925;C0085672;C1553035;C3811161;C4049106
1595,micro - / macro - albuminuria,C0001925;C0085672;C1553035;C2984010;C3811161;C4049106
1595,combined macro + micro,C0085672;C0205195;C1553035;C2984010;C3811161;C4049106
1594,cross - clamp,C0175721;C1883710;C2828360;C3810601
1593,cromoglicate,C0010347
1592,first co - primary,C0205435;C1279901;C3245499
1592,colombia,C3245499
1591,red blood cell counting,C0014772;C1287262
1590,emotional well - being,C2984554;C3641833
1589,bdi total score ( baseline ),C0006448;C0168634;C0451022;C1442488;C2964552;C3714938;C3889415
1589,bdi focal scorenmbr,C0006448;C0205234;C0449820;C0451022;C3714938;C3889415;C4050231
1589,bdi focal score,C0006448;C0205234;C0449820;C0451022;C3714938;C3889415;C4050231
1588,hormone - refractory prostate carcinoma,C1328504
1587,squamous cell carcinoma,C0007137;C1302853
1586,other / multiracial,C1881928
1586,multiracial or other,C1881928
1586,multiracial,C1881928
1585,nutraceuticals,C1518478
1585,any llt other than nutraceuticals,C1518478;C2347090
1584,everolimus - eluting,C0541315
1584,everolimus,C0541315
1583,zotarolimus - eluting,C1700035
1583,zotarolimus,C1700035
1582,chloroquine,C0008269
1581,hydroxychloroquine treatment §,C0020336;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
1581,hydroxychloroquine,C0020336
1580,chronic sinusitis + nasal polypsd,C0028429;C0149516;C4520890
1579,mixed chronic bronchitis and emphysema,C0008677;C0205430;C3160715
1579,chronic bronchitis ( n = nmbr ),C0008677
1579,chronic bronchitis ( itt ) ( n = nmbr ),C0008677
1579,chronic bronchitis ( % ),C0008677
1579,chronic bronchitis !,C0008677
1579,chronic bronchitis,C0008677
1578,chronic respiratory failure,C0264492
1577,chronic coxnmbr inhibitors,C0085387;C0205191
1577,chronic bronchitist,C0205191
1576,ethacrynic acid,C0014963
1575,zoledronic acid arm,C0257685;C0446516;C3715044;C4553528
1575,zoledronic acid ( n = nmbr ),C0257685
1575,zoledronic acid,C0257685
1574,caffeine,C0006644;C0236734
1573,caffeine users,C3532939
1573,caffeine user,C3532939
1572,caffeine consumption *,C0948365
1572,caffeine consumption ( yes ) ( n ),C0948365;C1549445;C1705108;C1710701
1571,other - candesartan,C0717550
1571,candesartan nmbr / nmbr,C0717550
1571,candesartan group ( n = nmbr ),C0441848;C0717550
1571,candesartan,C0717550
1570,current non - smoker,C0425311
1569,current medication — no . ( % ),C0746467
1569,current medication use,C0042153;C0240320;C0457083;C0521116;C0746467;C1705970;C1947944
1569,current medication,C0746467
1568,currently smokes,C0521116
1568,currently smoker,C0337664;C0521116
1568,currently,C0521116
1568,current xanthine derivative use,C0042153;C0043314;C0043318;C0457083;C0521116;C1527240;C1705970;C1947944
1568,current use of hormone therapy,C0019932;C0279025;C0521116;C1524063;C1705970;C2827774;C4521914
1568,current tobacco smoker ( % ) qualifying event ( % ),C0040329;C0086707;C0441471;C0521116;C0740009;C1514624;C1705970;C3173209;C3241966;C4019010;C4505217
1568,current tobacco smoker,C0040329;C0086707;C0521116;C0740009;C1705970;C3173209;C3241966;C4505217
1568,current prescribed medications,C0521116;C1705970;C3166216;C3202967
1568,current other ( predefined ) medical conditions,C0521116;C1705970
1568,current or prior smoking,C0521116;C1705970
1568,current or previous atrial fibrillation,C0521116;C1705970
1568,current or former smoker,C0521116;C1705970
1568,current nonsmokers,C0337672;C0521116;C1705970;C4554605
1568,current nonsmoker,C0337672;C0425293;C0521116;C1705970;C4554605
1568,current n z nmbr,C0521116;C1705970
1568,current lra use,C0521116;C1705970
1568,current lama use,C0042153;C0457083;C0521116;C0999593;C1416775;C1705970;C1947944
1568,current laba use,C0042153;C0457083;C0521116;C1705970;C1947944
1568,current inhaler +,C0021461;C0521116;C1705970;C1881212;C4319647
1568,current enthesitis,C0521116;C1282952;C1705970
1568,current dactylitis,C0239161;C0521116;C1705970
1568,current cvd / diabetes,C0007222;C0011847;C0011849;C0521116;C1705970
1568,current cigarette use,C0521116;C0694535;C1705970
1568,current cigarette smoking,C0239059;C0521116;C0700219;C1705970
1568,current cigarette smoker or within past year,C0337667;C0521116;C0677453;C1704760;C1705970;C3173209;C3241966;C3890423
1568,current cigarette smoker,C0337667;C0521116;C0677453;C1704760;C1705970;C3173209;C3241966;C3890423
1568,current cigarette,C0521116;C0677453;C1704760;C1705970;C3890423
1568,current bone disease,C0005940;C0521116;C1705970
1568,current alcohol use — no . / total no . ( % ),C0001962;C0001975;C0521116;C1705970
1568,current alcohol,C0001962;C0001975;C0521116;C1705970
1568,current / past,C0521116;C1444637;C1705970;C4284302
1568,current ( n   = nmbr,C0521116;C1705970
1568,current ( % ),C0521116;C1705970
1568,current (,C0521116;C1705970
1568,current,C0521116;C1705970
1567,concurrent prednisolone,C0032950;C0205420
1567,concurrent illness,C0205420;C0221423
1566,concomitant therapy,C1707479
1566,concomitant therapies n ( % ),C1707479
1566,concomitant therapies at hospital discharge,C0586003;C1707479
1565,cornell voltage x duration product,C0449238;C0598352;C1514468;C1704444;C2926735
1565,cornell voltage - duration product ( mmxmsec ) *,C0449238;C0598352;C1514468;C1704444;C2926735
1565,cornell voltage - duration product,C0449238;C0598352;C1514468;C1704444;C2926735
1565,corneii product,C1514468;C1704444
1564,no concomitant antiplatelet,C0521115
1564,main concomitant treatments,C0087111;C0205225;C0521115;C1542147
1564,concomitant antiplatelet,C0521115
1564,concomitant anticoagulant,C0003280;C0521115;C0848112;C3536711
1564,concomitant aminosalicylates,C0368663;C0521115
1563,most common concomitant aeds,C0180309;C0205214;C0205393;C0521115;C1522138;C3245511
1563,concomitant oads,C0521115
1563,concomitant aedsb,C0521115
1563,concomitant aedsa,C0521115
1563,concomitant aeds,C0180309;C0521115
1562,concomitant treatments at randomization,C0034656;C0087111;C0521115
1562,concomitant medications after randomization,C0013227;C0034656;C0521115;C0802604;C2598133;C4284232
1562,concomitant medication after randomisation,C0013227;C0034656;C0521115;C3244316;C4284232
1562,concomitant drugs,C0013227;C0521115;C3687832
1562,concomitant drug therapy at discharge,C0012621;C0013216;C0013217;C0013227;C0030685;C0039798;C0087111;C0521115;C1254351;C1363945;C1707479;C2926602;C3850077
1562,concomitant drug therapies,C0013216;C0521115
1562,concomitant antihyperglycaemic drugs,C0013227;C0020616;C0521115;C3687832
1561,concomitant dvt — no . ( % ) baseline nt - probnp — no . ( % ),C0149871;C0521115;C2926618;C3899446
1561,concomitant dvt,C0149871;C0521115;C2926618;C3899446
1561,concomitant,C0521115
1560,complex lesions^,C0221198;C0439855;C1704241
1560,anatomic complexity characteristics,C0439855;C0502371;C1704241
1559,chylomicron triglycerides,C0008731;C0041004;C1325761
1559,chylomicron cholesterol,C0008377;C0008731;C1325761
1558,comorbidity score,C0009488;C0449820;C4050231
1558,comorbidity,C0009488
1558,comorbidities other than diabetes,C0009488;C0011847;C0011849
1558,comorbidities and concomitant medications,C0009488
1558,comorbidities / concomitant medications,C0009488;C0013227;C0521115;C0802604;C2598133;C4284232
1558,comorbidities ( % ),C0009488
1558,comorbidities,C0009488
1558,comorbid illnesses,C0009488;C0221423
1558,comorbid diseasesa diabetesb,C0009488
1558,comorbid conditionsb,C0009488
1558,co - morbidities,C0009488
1557,total cholesterol > nmbr - nmbr mmol / lt,C0023376;C0201950;C0230426;C0439190;C0543421;C3887647;C4521399
1557,total cholesterol > nmbr ' nmbr mmol / lt,C0023376;C0201950;C0230426;C0439190;C0543421;C3887647;C4521399
1557,total cholesterol < nmbr nmbr mmol / lt,C0023376;C0201950;C0230426;C0439190;C0543421;C3887647;C4521399
1557,total cholesterol < nmbr - nmbr mmol / lt,C0023376;C0201950;C0230426;C0439190;C0543421;C3887647;C4521399
1557,nmbr . nmbr ± o . lt,C0023376;C0230426;C0483204;C3887647;C4521399
1556,statin without other llt,C0360714;C2347090
1556,statin with other llt,C0360714;C2347090
1556,allhat - llt,C2347090
1555,fasting blood glucose > nmbr mg / dl ( > nmbr . nmbr mmol / l ),C0428568;C0439269;C1261430;C1532563
1555,fasting blood glucose > nmbr mg / dl,C0428568;C0439269;C1261430
1555,fasting blood glucose ( mg / dl ),C0428568;C0439269;C1261430
1555,fasting blood glucose,C0428568;C1261430
1554,fasting serum glucose level,C0015663;C0202045;C0229671;C0583332;C1546774;C1550100
1554,fasting glucose level,C0202045
1553,atenolol use at nmbr month,C0004147;C0042153;C0332177;C0439231;C0457083;C1947944
1553,atenolol strategy ( n = nmbr ),C0004147;C0679199
1553,atenolol strategy ( n = nmbr,C0004147;C0679199
1553,atenolol strategy,C0004147;C0679199
1553,atenolol n = nmbr no . ( % ),C0004147
1553,atenolol n = nmbr,C0004147
1553,atenolol - losartan,C0004147;C0126174
1553,atenolol *,C0004147
1553,atenolol ( « = nmbr nmbr ),C0004147
1553,atenolol ( no . = nmbr ),C0004147
1553,atenolol ( n = nmbr ),C0004147
1553,atenolol ( n = nmbr,C0004147
1553,atenolol,C0004147
1552,v total ( n = nmbr ),C0439175;C0439810
1552,total updrs score ( range,C0439175;C0439810;C3639721
1552,total updrs score ( baseline ),C0439175;C0439810;C3639721
1552,total stent length - mm,C0038257;C0439175;C0439810;C1444754;C1706316;C4330985;C4554674
1552,total stent length ( mm ),C0038257;C0439175;C0439810;C1444754;C1706316;C4330985;C4554674
1552,total stent length,C0038257;C0439175;C0439810;C1444754;C1706316
1552,total sgrq score,C0439175;C0439810
1552,total resolution of nail psoriasisd,C0027342;C0439175;C0439810;C1432728;C1514893;C1706463;C2699488;C3538766
1552,total resolution of enthesitisc,C0439175;C0439810;C1514893;C1706463;C2699488
1552,total resolution of dactylitisb,C0439175;C0439810;C1514893;C1706463;C2699488
1552,total randomized,C0439175;C0439810
1552,total randomised ( n ),C0439175;C0439810
1552,total phase nmbr pooled ( n = nmbr ),C0205390;C0439175;C0439810;C1710475
1552,total patients,C0030705;C0439175;C0439810
1552,total pack - yrs,C0439175;C0439810;C1968515;C2825051;C2828395
1552,total number of patients,C0439175;C0439810;C2360800
1552,total number of events / participants,C0439175;C0439810;C0679646;C4330837
1552,total no . of patients,C0439175;C0439810
1552,total no . of events / total no . of participants,C0439175;C0439810
1552,total no . of events / participants,C0439175;C0439810
1552,total no . of events ( % of participants ) / total no . of participants,C0439175;C0439810
1552,total no . nmbr,C0439175;C0439810
1552,total no .,C0439175;C0439810
1552,total nnmbr,C0439175;C0439810
1552,total nmbr,C0439175;C0439810
1552,total n   =   nmbr,C0439175;C0439810
1552,total n = nmbr n ( % ),C0439175;C0439810
1552,total n = nmbr,C0439175;C0439810
1552,total n,C0439175;C0439810
1552,total length of implanted stents,C0021102;C0439175;C0439810;C0449462;C2828363
1552,total ldl - c *,C0439175;C0439810
1552,total ipss,C0439175;C0439810;C1019118;C1998280;C2827405;C3811063
1552,total invasive cancer,C0439175;C0439810;C0677898
1552,total included in combined analysis,C0439175;C0439810
1552,total ige — lu / ml,C0439175;C0439810;C2697941
1552,total ige levelx ( iu / ml ),C0439175;C0439458;C0439810
1552,total ige,C0439175;C0439810
1552,total hipc,C0439175;C0439810
1552,total hip or knee replacement,C0019552;C0022122;C0439175;C0439810;C1505163;C3538851;C4284725
1552,total hip bmd ( g / cmnmbr ),C0019552;C0022122;C0439175;C0439267;C0439810;C1505163;C3538851;C4284725
1552,total hip ( n = nmbr,C0019552;C0022122;C0439175;C0439810;C1505163;C3538851;C4284725
1552,total hip,C0019552;C0022122;C0439175;C0439810;C1505163;C3538851;C4284725
1552,total haq,C0102923;C0439175;C0439810;C0451208
1552,total group ( n = nmbr ),C0439175;C0439810;C0441848
1552,total glucose mg / dl,C0017725;C0439175;C0439269;C0439810
1552,total gadolinium - enhancing lesion count . no . ( % ),C0439175;C0439810;C1333400
1552,total gadolinium - enhancing lesion count,C0439175;C0439810;C0750480;C1333400;C1705566
1552,total deaths,C0011065;C0439175;C0439810;C1306577
1552,total death,C0011065;C0439175;C0439810;C1306577;C4082313;C4552775
1552,total cohort,C0009247;C0439175;C0439810;C0599755
1552,total cigarette pack - years,C0439175;C0439810;C1303175
1552,total cholesterol : hdl - c ratio,C0439175;C0439810;C0523558
1552,total chol,C0201950;C0439175;C0439810
1552,total c / hdl - c ratio * *,C0439175;C0439810;C0456603;C1547037;C3715113
1552,total c ( mmol / l,C0439175;C0439810;C1532563
1552,total c ( mg / dl ) *,C0439175;C0439269;C0439810
1552,total c,C0439175;C0439810
1552,total basdai score,C0439175;C0439810;C1998004
1552,total basdai,C0439175;C0439810;C1998004
1552,total > atients,C0439175;C0439810
1552,total - c,C0439175;C0439810
1552,total *,C0439175;C0439810
1552,total ( v = nmbr,C0439175;C0439810
1552,total ( n   =   nmbr ),C0439175;C0439810
1552,total ( n   = nmbr ),C0439175;C0439810
1552,total ( n nmbr nmbr ),C0439175;C0439810
1552,total ( n [ nmbr ),C0439175;C0439810
1552,total ( n = nmbr nmbr ),C0439175;C0439810
1552,total ( n = nmbr ),C0439175;C0439810
1552,total ( n = nmbr,C0439175;C0439810
1552,total ( n ),C0439175;C0439810
1552,total !,C0439175;C0439810
1552,total,C0439175;C0439810
1552,standardized total hip bmd ( g / cmnmbr ),C0019552;C0022122;C0439175;C0439267;C0439810;C1505163;C3538851;C4284725
1552,sgrq - c total scoreb,C0439175;C0439810;C3826872
1552,o total randomized,C0439175;C0439810;C0483204
1552,no . with event / total no . { % ),C0439175;C0439810;C0441471;C4019010
1552,no . / total no . ( % ) t,C0439175;C0439810
1552,no . / total no . ( % ),C0439175;C0439810
1552,no . / total 	 no . ( % ),C0439175;C0439810
1552,no . / total,C0439175;C0439810
1552,nmbr — no . / total no . ( % ),C0439175;C0439810
1552,nmbr - nmbr — no . / total no . ( % ),C0439175;C0439810
1552,lathosterol / total c ( | imol / mmol ),C0064673;C0439175;C0439190;C0439810
1552,event / total,C0439175;C0439810;C0441471;C4019010
1552,duration of total exposure to study treatment,C0439175;C0439810;C2826870
1552,baseline total ipss,C0168634;C0439175;C0439810;C1019118;C1442488;C1998280;C2827405;C3811063
1551,lv ejection fraction > nmbr % and < nmbr %,C0023128;C0489482;C0731033;C1881413;C2700378
1551,lv ejection fraction ( % ),C0023128;C0489482;C0731033;C1881413;C2700378
1551,lv ejection fraction,C0023128;C0489482;C0731033;C1881413;C2700378
1551,ejection fraction — mean ± sd,C0444504;C0489482;C2347634;C2348143;C2699239;C2700378
1551,ejection fraction category,C0489482;C0683312;C2700378;C3889287
1551,ejection fraction based on local reading,C0489482;C2700378
1551,ejection fraction : < nmbr % ( n = nmbr ),C0489482;C2700378
1551,ejection fraction *,C0489482;C2700378
1551,ejection fraction ( mean ),C0444504;C0489482;C2347634;C2348143;C2700378
1551,ejection fraction ( % ),C0489482;C2700378
1551,ejection fraction,C0489482;C2700378
1550,moderate dysfunction ( crcl nmbr - nmbr ml / min  n = nmbr [nmbr . nmbr % ] ),C0439445;C1846718;C3274776
1550,moderate dysfunction,C3274776
1549,mild dysfunction or normal,C3274775
1549,mild dysfunction ( crcl > nmbr - nmbr ml / min  n = nmbr [nmbr . nmbr % ] ),C0439445;C1846718;C3274775
1548,^nmbr - cell function — % §,C0007613
1547,bowel function,C0011135
1546,social functioning,C0037395
1546,social function,C0037395
1545,physical functioning,C0516981;C4049916
1545,physical function ( nmbr - nmbr,C0516981;C4049916
1545,physical function,C0516981;C4049916
1545,assessment of physical function ( nmbr - nmbr,C0031809;C0031843;C0516981;C0542341;C0700205;C1261322;C1516048;C1705273;C4049916
1544,serious decline in kidney functionnmbr,C0205404;C0232804
1544,serious decline in kidney function *,C0205404;C0232804
1544,renal function subgroups,C0232804;C1079230
1544,renal function < nmbr egfr,C0232804;C1739039;C3811844;C3812682
1544,renal function : ! : n ( % ),C0232804
1544,renal function *,C0232804
1544,renal function ( ml / min ),C0232804;C0439445
1544,renal function ( egfr ) according to mdrd,C0232804;C0680240;C1739039;C3811844;C3812682;C3839656
1544,renal function ( egfr,C0232804;C1739039;C3811844;C3812682
1544,renal function,C0232804
1544,deterioration in renal function ( investigator reported ),C0035173;C0232804;C0868945
1543,tender joint count ( nmbr - nmbr possible joints ),C0240094;C4554549;C4696258
1542,tender joints ( nmbr - joint count ),C0451530
1542,tender joint count of nmbr joints,C0451530
1542,tender joint count ( range nmbr - nmbr joints ),C0451530;C1514721;C2348147;C3542016
1542,tender joint count ( nmbr – nmbr joints ),C0451530
1542,tender joint count ( nmbr joints ),C0451530
1542,tender joint count ( nmbr - nmbr joints ),C0451530
1542,tender joint count ( nmbr - nmbr ),C0451530
1542,tender joint count ( nmbr - nmbr  per tender joint ),C0451530
1542,tender joint count ( nmbr ),C0451530
1542,tender joint count ( n / nmbr ),C0451530
1542,tender joint count,C0451530
1542,tender - joint count ( of nmbr joints ),C0451530
1542,tender - joint count,C0451530
1541,swollen joints ( nmbr - joint count ),C0451521
1541,swollen joint count of nmbr joints,C0451521
1541,swollen joint count ( range nmbr - nmbr joints ),C0451521;C1514721;C2348147;C3542016
1541,swollen joint count ( nmbr — nmbr  per swollen joint ),C0451521
1541,swollen joint count ( nmbr – nmbr joints ),C0451521
1541,swollen joint count ( nmbr joints ),C0451521
1541,swollen joint count ( nmbr - nmbr possible joints ),C0332149;C0451521;C1705910;C2362652
1541,swollen joint count ( nmbr - nmbr joints ),C0451521
1541,swollen joint count ( nmbr - nmbr ),C0451521
1541,swollen joint count ( nmbr ),C0451521
1541,swollen joint count ( n / nmbr ),C0451521
1541,swollen joint count,C0451521
1541,swollen - joint count ( of nmbr joints assessed ) — no .,C0451521
1541,swollen - joint count ( of nmbr joints ),C0451521
1541,swollen - joint count,C0451521
1540,recent treatment ( < nmbr months mmf / ggs ),C0039798;C0083765;C0087111;C0209368;C0332185;C0439231;C1522326;C1533734;C1705169;C3538994;C3848524;C3887704
1540,mycophenolate mofetil - cyclophosphamide,C0010583;C0209368
1540,mycophenolate mofetil,C0209368
1540,mmf ( n = nmbr ),C0083765;C0209368;C3848524
1540,inadequate response ( > nmbr months mmf / ggs ),C0083765;C0205412;C0209368;C0439231;C0439856;C0871261;C1704632;C1706817;C2911692;C3848524
1539,£ l nmbr kg,C1637390
1538,- o . os,C2673162
1537,nmbr - nmbr ft,C1881534;C3890579
1537,> nmbr ft,C1881534;C3890579
1537,< nmbr ft,C1881534;C3890579
1536,mh + crpnorr,C0026514;C2930980
1535,nmbr % clf,C3540486;C4553190
1534,nmbr % cit,C0008864;C0523573;C1427027;C4553421
1533,fg > nmbr,C0016703;C0439214;C2348814
1532,ck > nmbrxuln,C0009212;C0010287;C1872855
1532,ck > nmbr x ulnnmbr,C0009212;C0010287;C1519815;C1872855
1531,th c,C0039725;C0039738;C1420718;C4282123;C4285344
1531,th ( nmbr % ),C0039725;C0039738;C1420718;C4282123;C4285344
1531,nmbrth — nmbrth percentiles,C0039725;C0039738;C1264641;C1420718;C4282123;C4285344
1531,nmbrth : nmbr . nmbr - nmbr pmol / l,C0039725;C0039738;C0439284;C1420718;C4282123;C4285344
1531,nmbrth - nmbrth percentiles,C0039725;C0039738;C1264641;C1420718;C4282123;C4285344
1530,vasp pri - defined hpr ( % patients ),C0034044;C0255567;C1421428;C1826843;C3539761;C3539762
1529,low risk ( ri = nmbr - nmbr ),C0035487;C1826843;C3272281;C3538919
1529,( ri = nmbr ),C0035487;C1826843
1528,heparin plus gpi ( n = nmbr,C0019134;C0332287;C0770546;C1415351
1528,heparin plus a gpi ( n = nmbr ),C0019134;C0770546;C1415351
1528,gpi used during pci,C1415351
1527,tj ( nmbr - nmbr ),C0039247
1527,tj ( nmbr % ),C0039247
1527,sou ti africa,C0001737;C0039247;C0040302;C1553045;C1704756
1527,- nmbr . nmbr ± nmbr . nmbr § ti,C0039247;C0040302;C1553045;C1704756
1526,sex — no . / total no . ( % ),C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
1526,sex — no . ( % ),C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
1526,sex ( p = nmbr ),C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
1526,sex ( no . ),C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
1526,sex ( interaction : p = nmbr . nmbr ),C0009253;C0036864;C0079399;C0804628;C1314687;C1522384;C1704675
1526,sex ( % ),C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
1526,intercourse satisfac -,C0009253
1525,p value for dm vs . no dm,C4086240
1524,tp vs no tp,C0036183;C3541334
1523,type of index event — no . ( % ),C0600653;C0918012;C1552854;C1561488;C1637833;C2986546
1523,type of event — no . ( % ),C1561488
1523,type of event :,C1561488
1523,type of event,C1561488
1522,( fxs ),C0016667
1521,( yes / no ),C1512698
1520,( pg / mg ),C1627892
1519,percent improvement,C0439165;C2986411
1519,haq - di improvement from baseline to week nmbr,C0168634;C1442488;C2986411;C3826998;C4321476
1519,haq - di improvement > nmbr . nmbr,C2986411;C3826998;C4321476
1518,peri - or postmenopausal,C0347985
1518,peri - operative cabg participants :,C0010055;C0347985;C0679646;C1882154
1518,peri - op statins : no ( n = nmbr ),C0347985;C0360714
1518,peri - op beta - blockers : no ( n = nmbr ),C0001645;C0347985
1517,non - drug - eluting stent,C1322815;C1518422
1517,drug eluting stent,C1322815
1517,drug - eluting stent — no . ( % ),C1322815
1517,drug - eluting stent implanted — no . ( % ),C1322815
1517,drug - eluting stent implanted ( at least one ),C1322815
1517,drug - eluting stent implanted,C1322815
1517,drug - eluting stent,C1322815
1516,prior treatment — %,C1514463
1516,prior treatment historynmbr,C0019664;C0019665;C0262512;C0262926;C1514463;C1705255;C2004062
1516,prior treatment,C1514463
1516,prior tnfi treatment,C1514463
1516,prior therapy,C1514463
1516,prior lev treatment,C0023556;C1514463
1516,prior ed therapy,C1514463;C3538926
1515,prior treatment — no . ( % ),C1514463
1515,prior ms treatment with ifn - beta or glatiramer acetate . no . ( % ),C0015980;C1514463;C2349943;C3539704;C3713294
1515,prior ms treatment with ifn - beta or,C0015980;C1514463;C2349943;C3539704;C3713294
1514,nmbrrd tertile ( > nmbr mg / dl [ > nmbr . nmbr mmol / l] ) d,C0439190;C0439269;C0567349;C0694666;C2348885;C3642216;C4553350
1514,nmbrrd > nmbr . nmbr,C0694666;C4553350
1514,> nmbrrd quartile,C0694666;C2828255;C4553350
1513,subgroup w . r . t . re - cover,C0180153;C0232024;C0556581;C1079230;C1515021;C1999244;C2986904;C3888055
1513,re - medy,C0556581;C2986904
1513,re - cover nmbr warfarin,C0180153;C0556581;C1999244;C2986904;C3888055
1513,re - cover nmbr dabigatran,C0180153;C0556581;C1999244;C2986904;C3888055
1513,re - cover ii,C0180153;C0556581;C1999244;C2986904;C3888055
1513,re - cover / re - cover ii,C0180153;C0556581;C1999244;C2986904;C3888055
1512,apremilast nmbr mg bid n = nmbr,C0024671;C0026410;C0439269;C1678805;C1960952;C2346927;C4321396;C4521761
1512,apremilast,C1678805
1511,varespladib ( n = nmbr ),C2713485
1511,varespladib,C2713485
1510,prednisone use,C0032952;C0042153;C0457083;C1947944
1510,prednisone,C0032952
1510,% pred,C0032952;C0044955
1509,smedian prednisone dose,C0032952;C0178602;C0869039;C1114758
1509,prednisone or equivalent dose ( mg / day ),C0032952
1509,prednisone - equivalent dose — mg,C0024671;C0026410;C0032952;C0178602;C0205163;C0439185;C0439269;C0869039;C1114758;C1960952;C2346927;C4321396;C4521761
1509,prednisone - equivalent dose,C0032952;C0178602;C0205163;C0439185;C0869039;C1114758
1509,corticosteroid dose ( prednisone,C0001617;C0032952;C0178602;C0869039;C1114758;C3536709
1509,< median prednisone dose,C0032952;C0178602;C0549183;C0869039;C0876920;C1114758;C2347635;C2348144;C2939193
1508,juvenile myoclonic epilepsy,C0270853
1507,patients with diabetic nephropathy,C0011881;C0030705;C1442864
1507,diabetic kidney disease,C0011881
1506,extensive disease other,C0849867
1505,severe disease,C1836348
1505,nmbr ( severe disease ),C1836348
1504,baseline dyspnea index score,C0449820;C1511069;C4050231
1504,baseline dyspnea index,C1511069
1503,enalapril + aliskiren dm = nmbr non - dm = nmbr,C0011816;C0014025;C1120110;C3250443
1503,dm - ( aliskiren vs . placebo ),C0011816;C1120110;C3250443
1503,dm + ( aliskiren vs . placebo ),C0011816;C1120110;C3250443
1503,aliskiren dm = nmbr non - dm = nmbr,C0011816;C1120110;C3250443
1503,aliskiren ( n = nmbr ),C1120110
1503,aliskiren ( dm - vs . dm + ),C0011816;C1120110;C3250443
1503,aliskiren,C1120110
1502,bivalirudin used during pci,C0168273
1502,bivalirudin used,C0168273
1502,bivalirudin only,C0168273;C0205171;C1720467
1502,bivalirudin alone ( n = nmbr ),C0168273;C0205171;C0439044;C0679994
1502,bivalirudin - heparin plus gpi,C0019134;C0168273;C0770546;C1415351
1502,bivalirudin ( n = nmbr ),C0168273
1502,bivalirudin ( n = nmbr,C0168273
1502,bivalirudin,C0168273
1501,ivabradine group ( n = nmbr ),C0257190;C0441848
1501,ivabradine group,C0257190;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
1501,ivabradine ( n = nmbr ),C0257190
1501,ivabradine,C0257190
1500,colectomy ( partial or total ),C0009274
1499,benzodiazepine or bzra ‡,C0005064;C3536850;C4048284
1498,pulmonary congestion ( cxr ),C0006888;C0039985;C0242073
1498,chest x - ray,C0039985
1497,dietary epa - dha intake ( mg / day ) *,C0142831;C0439422;C1286104;C2348308
1497,dha intake on food frequency questionnaire,C0034394;C0142831;C1286336;C1512806;C2348308;C2986698
1497,dha ( n = nmbr ),C0142831;C2348308
1496,vas ( nmbr - nmbr ),C0042815;C3536884;C3827561
1496,ptga ( nmbr - nmbr cm vas ),C0042815;C3536884;C3827561
1496,psa pain ( vas ),C0042815;C3810537;C3813209
1496,pain vas,C0042815
1496,pain ( vas ),C0042815
1496,baseline skin pain vas,C0042815;C0168634;C0241136;C0444099;C1123023;C1442488;C1963195;C3536884;C3827561;C4520765
1496,( nmbr - nmbr - cm vas ),C0042815;C3536884;C3827561
1495,riva roxa ban n / n { % ) nmbr ( nmbr . nmbr ),C0683610;C4553947
1494,suit quartile nmbr ( b nmbr . nmbr nmol / mmol ) ( n = nmbr ),C1532564;C1533073;C2828255
1494,suit quartile nmbr ( > nmbr . nmbr nmol / mmol ) ( n = nmbr ),C1532564;C1533073;C2828255
1494,suit quartile nmbr ( > nmbr . nmbr - < nmbr . nmbr nmol / mmol ) ( n = nmbr ),C1532564;C1533073;C2828255
1493,bilateral disease ( % ) ' j ' ' j ',C1511113
1492,vascular disease indicator no ( n = nmbr ),C0021212;C0042373;C1235732;C1522602
1492,ischemic heart disease indicator no ( n = nmbrl ),C0010054;C0021212;C0151744;C1235732;C1522602
1491,positive for anti - cyclic citrullinated peptide antibody — no . ( % ) f,C0741132;C1320283
1490,gliclazide ( modified release ) 一 no . ( % ) ^,C0017631
1489,traditional chinese medicine for respiratory disease — no . ( % ),C0025124;C0035204;C0035242;C1515884
1488,tion  os = overall satisfaction  qmax = maximal urinary flow rate .,C0229090;C0230028;C0262950;C0393706;C0429784;C1561953;C4086680
1488,nmbr . nmbr ( nmbr . nmbr - nmbr . os ),C0229090;C0230028;C0262950;C0393706;C1561953
1487,om nmbr mg / aml nmbr mg ( n = nmbr ),C0023465;C0023467;C0028971;C1319635;C1705272
1487,olmesartan medoxomil nmbrmg / hctznmbr . nmbrmg ( n = nmbr ),C0020261;C0386393;C1319635
1487,feno nmbr mg / eze nmbr mg ( n = nmbr ),C1319635
1487,dabigatran nmbr mg nmbr mg % per yr,C0439234;C1319635;C2348066
1486,olmesartan along with diuretic ( n - nmbr ),C0012798;C1098320
1486,olmesartan along with ccb ( n - nmbr ),C0006684;C1098320
1486,olmesartan / ccb - olmesartan / diuretic,C0006684;C1098320
1486,olmesartan ( n = nmbr ),C1098320
1485,question nmbr ( morning stiffness since arising ),C0457086;C1522634
1485,question nmbr ( length of morning stiffness since arising ),C0457086;C1444754;C1522634;C1706316
1484,b - agonists ( short - acting ) a,C0243192;C2987634
1484,b - agonists ( long - acting ) a,C0243192;C2987634
1483,placebo - ezetimibe nmbr / simvastatin nmbr - fenofibrate nmbr - ezetimibe nmbr / simvastatin nmbr / ezetimibe nmbr,C0032042;C0033228;C1532737;C1696465;C1706408
1483,fenofibrate ( n = nmbr ),C0033228
1482,( incl . uncertain ),C0268281;C1418854
1481,indian ( indian subcontinent ),C0454693
1480,tjc ( nmbr joints ),C0022417;C0392905
1480,tjc ( / nmbr joints ),C0022417;C0392905
1480,sjc ( nmbr joints ),C0022417;C0392905
1480,sjc ( / nmbr joints ),C0022417;C0392905
1480,joint damage outcomes ( mitt population ),C0010957;C0022417;C0032659;C0392905;C1257890;C1274040;C1706309;C1883709
1479,study drug loading days ( actual ) : nmbr ( n = nmbr ),C0013175;C0237400;C0439228;C1708715
1479,actual or estimated weight,C0237400
1479,actual ( l ),C0237400
1478,severity of airflow limitation ( gold nmbr - nmbr ),C0018026;C0231999;C0439793;C0443288;C0449295;C0522510;C1304897
1478,severity of airflow limitation ( gold nmbr ),C0018026;C0231999;C0439793;C0443288;C0449295;C0522510;C1304897
1478,severity of airflow limitation,C0231999;C0439793;C0443288;C0449295;C0522510
1478,restriction in normal activities in the past nmbr weeks,C0443288;C4697852
1478,nmbr = some restrictions  no help needed,C0443288
1477,interval pain onset to admission,C0184666;C0809949;C1272706;C1507009;C1552654;C1552713
1477,interval from symptom onset to qualifying ecg obtained in the er — hr,C1272706;C1552654;C1552713;C4086878
1477,interval from randomization to angiography,C0034656;C1272706;C1552654;C1552713
1477,interval from onset of symptoms,C1272706;C1552654;C1552713;C4086878
1477,interval from clopidogrel loading,C0070166;C1272706;C1552654;C1552713;C1708715
1477,interval clopidogrel to pci,C0070166;C1272706;C1552654;C1552713;C4049621
1477,interval between clinical evaluation and initiation oftreatment — no . ( % ),C0205210;C1261322;C1272706;C1552654;C1552713;C2826267;C4084924
1477,interval between clinical evaluation and initiation of treatment — no . ( % ),C0205210;C1261322;C1272706;C1552654;C1552713;C2826267;C4084924
1476,simple partial ( ia ),C0020980;C0205352;C0694634;C0728938;C1550516;C1947960
1476,partial evolving to secondarily generalized ( ic ),C0020750;C0205246;C0332253;C0728938;C1550516;C4554818
1475,greater than or equal to nmbr mm hg,C0439093
1475,greater than or equal to nmbr ml / min / nmbr . nmbrmnmbr,C0439093
1475,greater than or equal to nmbr %,C0439093
1474,normal function or mild impairment,C4296962
1474,normal function ( crcl > nmbr ml / min  n = nmbr [nmbr . nmbr % ] ),C0439445;C1846718;C4296962
1473,normal weight ( bmi < nmbr ),C0005910;C0043100;C0578022;C1305866;C1705104;C2712185;C4229017
1473,normal ( bmi < nmbr ),C4229017
1472,door - to - balloon time — hr,C4296144
1471,tolal choleslerol - lo - hdl choleslerol ralio,C0206579;C1232424;C3715113
1471,nmbr . nmbr ( lo . i ),C0021966;C0206579;C0221138;C1232424
1471,nmbr . nmbr ( lo - nmbr . nmbr ),C0206579;C1232424
1471,lo ( lo - lo ),C0206579;C1232424
1470,sokolow – lyon voltage ( mv ),C0598352;C1454484;C1705503;C4281602
1470,sokolow - lyon voltage,C0598352
1470,cornell voltage duration ( mv × ms ),C0449238;C0598352;C1454484;C1705503;C2349943;C2926735;C3539704;C3713294;C4281602
1469,younger subjects ( aged < nmbr years ),C0332239
1469,younger patients ( agednmbr years ),C0030705;C0332239
1468,older subjects ( aged > nmbr years ',C0580836
1468,older patients ( aged > nmbr years ),C0030705;C0580836
1467,adults ( aged   ≥ nmbr y ),C0001675
1466,adolescents ( aged nmbr - nmbr y ),C0205653
1465,vte / vte - related deathsb,C0439849;C0445223;C0630906
1465,vte / vte - related deathsa,C0439849;C0445223;C0630906
1465,any vte or vte - related death — no . ( % ),C0630906
1465,any vte - related death,C0425043;C0630906
1464,unprovoked vte n ( % ),C0630906
1464,previous vte n ( % ),C0205156;C0630906;C1552607
1463,"met atopy and ige nmbr - nmbr ku / l criteria "" ( n = nmbr )",C0392707;C0428210;C1550543;C3539705;C4317104
1463,met / tzd,C0428210;C1550543;C4317104
1463,met / su / tzd,C0038642;C0428210;C1550543;C1705534;C4317104
1463,met ( n = nmbr ),C0428210;C1550543;C4317104
1463,met % △ ( se ),C0036919;C0428210;C1550543;C4317104
1463,add - on to metnmbr,C0428210;C1550543;C1883712;C4317104
1463,add - on to met + sunmbr,C0038642;C0428210;C1550543;C1705534;C1883712;C4317104
1463,add - on to met + su,C0038642;C0428210;C1550543;C1705534;C1883712;C4317104
1463,add - on to met,C0428210;C1550543;C1883712;C4317104
1462,time to first sare * ( % ),C0040223;C0205435;C1279901;C3541383
1462,time to first oral or systemic corticosteroid ( % ),C0040223;C0205435;C0442027;C1279901;C3541383;C4521986
1462,time to first morbidity / mortality event up to the end of the treatment periodd,C0026538;C0026565;C0026566;C0040223;C0205435;C0220880;C0441471;C1279901;C3541383;C4019010
1462,time to first inhaled corticosteroid ( % ),C0001617;C0004048;C0040223;C0205435;C1279901;C3536709;C3541383
1462,time to first exacerbation,C0040223;C0205435;C1279901;C3541383;C4086268
1462,time from first eval,C0040223;C0205435;C1279901;C1707957;C2698624;C3541383
1462,time - to - first - infusion from hip surgery ( days ),C0040223;C0205435;C0574032;C1279901;C1827465;C3541383
1462,symptoms onset to first balloon inflation,C0021398;C0205435;C0336867;C0441144;C1279901;C1318493;C4086878
1462,received first loading dose,C0205435;C1279901;C1514756;C3714444
1462,randomization to first balloon inflation,C0021398;C0034656;C0205435;C0336867;C0441144;C1279901;C1318493
1462,mean time to first subcutaneous injectiong,C0040223;C0205435;C0443315;C0444504;C1279901;C2347634;C2348143;C3541383
1462,mean time to first oral dose postsurgeryh,C0040223;C0178602;C0205435;C0442027;C0444504;C0869039;C1114758;C1279901;C2347634;C2348143;C3541383;C4521986
1462,first year *,C0205435;C0439234;C0439508;C1279901
1462,first mace,C0205435;C0349381;C0949745;C1279901;C1445339
1462,first loading dose,C0205435;C1279901;C3714444
1462,first hhf,C0205435;C1279901
1462,first diagnosed,C0205435;C1279901
1462,first - recorded event  no . ( and % ) of patients,C0205435;C1279901
1462,first - generation stentt,C0079411;C0205435;C1279901;C3146294
1462,first ( n = nmbr ),C0205435;C1279901
1462,components of the first cid,C0205435;C0449432;C1279901;C1707433
1462,af first diagnosis > nmbr years,C0011900;C0205435;C0344434;C0439234;C1279901;C1704338;C1704656;C4049859
1461,initial type of heparin treatment received,C0019134;C0205265;C0455708;C0770546;C1279901;C1555582;C1705685
1461,initial treatment randomization,C0034656;C0039798;C0087111;C0205265;C1279901;C1522326;C1533734;C1555582;C1705169;C1705685;C3538994;C3887704
1461,initial timi flow,C0205265;C1279901;C1555582;C1705685;C3272266
1461,initial heparin — no . ( % ) §,C0019134;C0205265;C0770546;C1279901;C1555582;C1705685
1461,initial heparin treatment duration on or after randomization,C0019134;C0205265;C0444921;C0770546;C1279901;C1555582;C1705685;C3259042
1461,initial heparin treatment duration,C0019134;C0205265;C0444921;C0770546;C1279901;C1555582;C1705685;C3259042
1461,initial diagnosis — no . ( % ),C0011900;C0205265;C1279901;C1555582;C1704338;C1704656;C1705685
1461,initial aspirin — no . ( % ),C0004057;C0205265;C1279901;C1555582;C1705685
1461,> = nmbr^ initial heparin treatment duration,C0019134;C0205265;C0444921;C0770546;C1279901;C1555582;C1705685;C3259042
1461,> = nmbr day s initial heparin treatment duration,C0019134;C0205265;C0332173;C0439228;C0439505;C0444921;C0770546;C1279901;C1555582;C1705685;C3259042
1460,multivitamins,C0301532;C3714835
1459,metastatic,C0036525;C1522484;C4085632
1458,epistaxis,C0014591;C4554627
1457,dip joint arthritis,C0003864;C0932510;C4552845
1457,arthritis type *,C0003864;C0332307;C1547052;C4552845
1457,arthritis,C0003864;C4552845
1456,lv systolic dysfunction,C0023128;C0731033;C0749225;C1881413
1456,lv ejection fractionb,C0023128;C0302131;C0336969;C0731033;C0812388;C1881413
1456,lv diastolic dysfunction,C0023128;C0520863;C0731033;C1881413
1456,latvia,C0023128
1455,urinary tract infection,C0042029;C0262655;C4554638
1454,utis,C0042029
1454,uti,C0042029;C0077906;C1412376
1453,dermatitis atopic,C0011603
1452,cholecystitis chronic,C0008325;C1963083;C4553186
1451,enthesitis count,C0750480;C1282952;C1705566
1451,enthesitis,C1282952
1450,contusion,C0009938
1449,congestion *,C0700148;C2826600
1448,constipation,C0009806;C1963087;C3641755;C4084722;C4084723;C4084724
1447,constitutional,C1511487
1446,option,C1518601;C1550456
1445,ambition,C0870128
1444,placebo - linagliptin,C0032042;C1696465;C1706408;C2746078
1444,linagliptin ( n z nmbr ),C2746078
1444,linagliptin ( n = nmbr ) ',C2746078
1444,linagliptin ( n = nmbr ),C2746078
1444,linagliptin,C2746078
1444,comparator - linagliptin,C1707454;C2746078;C4553389;C4553390
1443,not hispanie / latino,C0086528;C1518422
1443,latino,C0086528
1443,hispanie / latino,C0086528
1443,hispanic / latino,C0086409;C0086528
1442,immobilization — no . ( % ),C0020944;C4048292
1442,immobilization at randomization,C0020944;C0034656;C4048292
1442,immobilization,C0020944;C4048292
1441,without tamsulosin,C0257343
1441,with tamsulosin,C0257343
1441,tamsulosin nmbr . nmbrmg vs . nmbr . nmbrmg,C0024671;C0026410;C0257343;C0439269;C1960952;C2346927;C4321396;C4521761
1441,tamsulosin nmbr . nmbr mg vs . placebo,C0024671;C0026410;C0257343;C0439269;C1960952;C2346927;C4321396;C4521761
1441,tamsulosin nmbr . nmbr mg ( n = nmbr ),C0024671;C0026410;C0257343;C0439269;C1960952;C2346927;C4321396;C4521761
1441,tamsulosin ( w = nmbr ),C0257343
1441,tamsulosin ( n = nmbr ),C0257343
1441,tamsulosin,C0257343
1440,simvastatin ( nmbr / nmbr mg / d ) ( n = nmbr ),C0074554;C0439422
1440,simvastatin ( nmbr / nmbr mg / d ),C0074554;C0439422
1440,simvastatin ( n = nmbr . nmbr ),C0074554
1440,simvastatin ( n = nmbr ),C0074554
1440,simvastatin ( n = nmbr,C0074554
1440,simvastatin,C0074554
1440,placebo + nmbr mg / d of simvastatin ( n = nmbr ),C0032042;C0074554;C0439422;C1696465;C1706408
1440,placebo + nmbr mg / d of simvastatin,C0032042;C0074554;C0439422;C1696465;C1706408
1440,exetimibe / simvastatin,C0074554
1439,simvastatin nmbr mg plus fenofibrate nmbr mg ( n = nmbr /,C0033228;C0074554;C0332287;C1319635
1439,simvastatin monotherapy ( n = nmbr,C0074554
1438,lowest tg tertile,C0337445;C1708760
1438,lowest activated clotting,C0005778;C1328723;C1708760;C1879547
1438,lowest,C1708760
1437,with lowest hbanmbrcd,C0007928;C0019016;C0034283;C1708760;C1825777;C3538758;C4552032
1437,with lowest bwb,C1708760
1436,lower dose,C0445550;C1708745
1436,lower - dose,C0445550;C1708745
1436,low dose,C0445550;C1708745
1436,low - dose edoxaban vs warfarin,C0445550;C1708745;C2975435
1436,low - dose edoxaban ( n = nmbr ),C0445550;C1708745;C2975435
1436,low - dose edoxaban,C0445550;C1708745;C2975435
1436,low - dose corticosteroid user,C0001617;C0445550;C1548600;C1706077;C1708745;C3536709
1435,tier nmbraes,C1412268;C2699274
1435,tier nmbr aes,C1412268;C2699274
1435,other selected aes,C1412268;C1707391;C2699274
1435,most common aes ‡,C0205214;C0205393;C1412268;C1522138;C2699274;C3245511
1435,most common aes in any group,C0205214;C0205393;C0441833;C0687744;C1257890;C1412268;C1519504;C1522138;C1705428;C1705429;C2699274;C3245511
1435,any aes,C1412268;C2699274
1435,aes related to,C1412268;C2699274
1435,aes leading to dose reduction of study drugb,C1412268;C2699274
1435,aes leading to discontinuation of study drugb,C1412268;C2699274
1435,aes leading to,C1412268;C2699274
1435,aes in ≥ nmbr japanese patients in a study arm,C0030705;C0376247;C1412268;C1556094;C2699274
1435,aes *,C1412268;C2699274
1435,> nmbr aes leading to discontinuation,C1412268;C2699274
1435,> nmbr aes,C1412268;C2699274
1434,high - dosage ics plus laba with baseline blood eosinophils anmbr cells per pl ( n = nmbr ),C0178602;C0205250;C0815320;C1299351;C2700149;C2986497;C3887512;C3889660;C4321237;C4522209;C4551720
1434,high - dosage ics plus laba with baseline blood eosinophils > nmbr cells per pl ( n = nmbr ),C0178602;C0205250;C0815320;C1299351;C2700149;C2986497;C3887512;C3889660;C4321237;C4522209;C4551720
1434,high - dosage ics plus laba with baseline blood eosinophils < nmbr cells per pl ( n = nmbr ),C0178602;C0205250;C0815320;C1299351;C2700149;C2986497;C3887512;C3889660;C4321237;C4522209;C4551720
1434,calima overalldhigh - dosage ics / laba and baseline blood eosinophils > nmbr cells / ml ( n = nmbr ),C0178602;C0815320;C2986497;C4551720
1434,calima japandhigh - dosage ics / laba and baseline blood eosinophils > nmbr cells / ml ( n = nmbr ) y,C0178602;C0815320;C2986497;C4551720
1434,brv dosage,C0155502;C0178602;C2986497
1433,rolofylline dose,C0166128;C0178602;C0869039;C1114758
1433,ptrend across doses,C0178602
1433,patients with supplemental vitamin d dose of nmbr iu / day starting at screeningc,C0030705;C0178602;C0420176;C0439465;C0439659;C0869039;C1114758;C3541352
1433,ocs dose *,C0178602;C0869039;C1114758
1433,need for nmbr ng edoxaban dose at,C0017887;C0027552;C0028074;C0178602;C0686904;C0869039;C1114758;C2975435
1433,methotrexate dose | |,C0025677;C0178602;C0869039;C1114758
1433,methotrexate dose on day nmbr — mg per wl < nmbr,C0025677;C0178602;C0332173;C0439228;C0439422;C0439505;C0869039;C1114758;C4086581
1433,methotrexate dose at baseline,C0025677;C0168634;C0178602;C0869039;C1114758;C1442488
1433,levodopa dose,C0023570;C0178602;C0869039;C1114758
1433,iglar dose at randomization ( u / day ),C0034656;C0178602;C0456683;C0869039;C1114758
1433,ezetimibe / simvastatin - double dose statin - rosuvastatin,C0178602;C0205173;C0360714;C0869039;C0965129;C1114758;C1532737;C1705764;C1705765
1433,etoricoxib dose,C0178602;C0869039;C0972314;C1114758
1433,edoxaban dose adjusted at randomisation,C0178602;C0869039;C1114758;C2975435
1433,doubling statin dose,C0178602;C0205173;C0360714;C0869039;C1114758;C1705764
1433,dose reduction at randomization — no . ( % )  i ,C0034656;C0178602;C0301630;C0392756;C0869039;C1114758;C1293152;C4551656
1433,dose reduction at randomization,C0034656;C0178602;C0301630;C0392756;C0869039;C1114758;C1293152;C4551656
1433,dose reduced at randomization *,C0178602;C0869039;C1114758
1433,dose equivalent,C0178602;C0205163;C0439185;C0869039;C1114758
1433,dose adjusted,C0178602;C0869039;C1114758
1433,dose ( n ),C0178602;C0869039;C1114758
1433,dose ( iu ),C0049272;C0178602;C0439453;C0694756;C0869039;C1114758
1433,dose,C0178602;C0869039;C1114758
1433,canakinumab dose ( per month ),C0178602;C0332177;C0439231;C0869039;C1114758;C2718773
1433,canakinumab dose ( per mo ),C0026544;C0178602;C0332177;C0869039;C1114758;C2718773
1433,canakinumab dose,C0178602;C0869039;C1114758;C2718773
1433,baseline su dose > nmbr / nmbr maximal,C0038642;C0168634;C0178602;C0869039;C1114758;C1442488;C1705534
1433,baseline su dose < nmbr / nmbr maximal,C0038642;C0168634;C0178602;C0869039;C1114758;C1442488;C1705534
1433,basal insulin dose at run - in ( u / day ),C0178602;C0205112;C0366513;C0456683;C0650607;C0869039;C1114758;C3274438
1433,all doses ( n = nmbr ),C0178602
1433,all doses,C0178602
1433,( phase nmbr dose - finding trial ),C0008976;C0037088;C0178602;C0205390;C0243095;C0869039;C1114758;C1710475;C2825141
1432,sacral and / or lumbar,C0036037
1431,subcortical wml load diameter,C0815275;C1301886;C1550025;C1704782;C1708715
1430,bail ‐ out use of glycoprotein iib / iiia inhibitors,C0175673
1429,glycoprotein llb / llla receptor inhibitor,C0017968;C0597357;C1999216
1429,glycoprotein llb / llla inhibitors,C0017968;C0243077
1429,glycoprotein llb / llia inhibitor,C0017968;C1999216
1429,glycoprotein llb / illa inhibitor,C0017968;C1999216
1429,glycoprotein ilb / iiia inhibitor before pci],C0017968;C1999216;C4049621;C4697913
1429,glycoprotein iib / iiiareceptorinhibitor,C0017968
1428,negative for helicobacter pylori — no . / total no . ( % ),C4688581
1428,helicobacter pylori - negative,C4688581
1427,factor v leiden or prothrombin mutation,C0380964;C0584960;C1414509;C3542419
1427,factor v leiden ( % ),C0380964;C0584960;C1414509;C3542419
1426,calculated ldl cholesterol ( week nmbr ),C0023824;C0202117;C0332174;C0439230;C0444686;C1441506
1426,calculated annual decline,C0332181;C0444686;C1441506
1425,acute reaction,C0205178;C0443286
1425,acute and delayed reaction,C0205178
1425,acute ( < nmbr hr ),C0205178
1424,aliskiren / valsartan ( n = nmbr ),C2733073
1423,sacubitril / valsartan ( n = nmbr ),C4033631
1423,sacubitril / valsartan,C4033631
1422,no active cancer,C0006826;C0205177;C0998265;C1306459;C3853793;C3888249
1422,ho active cancer,C0006826;C0019905;C0205177;C0998265;C1306459;C1832110;C3853793;C3888249;C3889614
1422,active   versus   placebo,C0205177;C3853793;C3888249
1422,active vs placebo,C0205177;C3853793;C3888249
1422,active smoking,C0037369;C0205177;C0453996;C1881674;C3853793;C3888249
1422,active smokers,C0205177;C0337664;C3853793;C3888249
1422,active smoker,C0205177;C0337664;C3853793;C3888249
1422,active pso winmbr bsa > nmbr %,C0043193;C0205177;C1520135;C3853793;C3888249
1422,active or previous cancer,C0205177;C3853793;C3888249
1422,active comparatorb,C0205177;C3853793;C3888249
1422,active cancer — no . ( % ),C0006826;C0205177;C0998265;C1306459;C3853793;C3888249
1422,active cancer at randomization,C0006826;C0034656;C0205177;C0998265;C1306459;C3853793;C3888249
1422,active cancer at randomisation,C0006826;C0034656;C0205177;C0998265;C1306459;C3853793;C3888249
1422,active cancer at baseline,C0006826;C0168634;C0205177;C0998265;C1306459;C1442488;C3853793;C3888249
1422,active cancer at any timeb,C0006826;C0205177;C0998265;C1306459;C3853793;C3888249
1422,active cancer,C0006826;C0205177;C0998265;C1306459;C3853793;C3888249
1422,active canakinumab ( n   =   nmbr,C0205177;C2718773;C3853793;C3888249
1422,active a,C0205177;C3853793;C3888249
1422,active ( n = nmbr ),C0205177;C3853793;C3888249
1422,active,C0205177;C3853793;C3888249
1421,ease activity],C0205177;C0439167;C0441655;C1331418;C1561536;C3668946;C4049938;C4049939
1421,activity limitation,C0205177;C0439167;C0441655;C0443288;C0449295;C1561536;C3668946;C4049938;C4049939
1421,activity ( range nmbr - nmbr ),C0205177;C0439167;C0441655;C1514721;C1561536;C2348147;C3542016;C3668946;C4049938;C4049939
1421,activity ( nmbr - nmbr vas ),C0042815;C0205177;C0439167;C0441655;C1561536;C3536884;C3668946;C3827561;C4049938;C4049939
1421,activity,C0205177;C0439167;C0441655;C1561536;C3668946;C4049938;C4049939
1420,aortic - valve replacement,C0003506
1419,post - menopausal without hormone replacement,C0019930
1419,post - menopausal with hormone replacement,C0019930
1418,distal forearm,C0588203
1417,diltiazem or verapamil,C0012373
1416,passive smoker,C0425309
1415,assigned to topiramate,C1516050;C1552601
1415,assigned to placebo,C0032042;C1516050;C1552601;C1696465;C1706408
1414,previous balloon angioplasty,C0002996;C0002997;C0205156;C1552607
1414,coronary angioplasty or stenting,C0002997;C0190211
1414,balloon angioplasty — no . ( % ),C0002996;C0002997
1414,balloon angioplasty plus abciximab,C0002996;C0002997;C0288672;C0332287
1414,balloon angioplasty,C0002996;C0002997
1413,prior angioplasty,C0162577;C0332152;C1548817;C2826257
1413,peripheral angioplasty,C0162577;C0205100;C1548817
1413,angioplasty,C0162577;C1548817
1412,stent plus abciximab,C0038257;C0288672;C0332287
1412,stent / abciximab - stent / placebo,C0032042;C0038257;C0288672;C1696465;C1706408
1412,nmbr abciximab ( n = nmbr ),C0288672
1412,macce ( % ) abciximab placebo,C0032042;C0288672;C1696465;C1706408
1412,abciximab vs . primary,C0288672
1412,abciximab no . / total ( % ),C0288672
1412,abciximab ( n = nmbr ),C0288672
1412,abciximab,C0288672
1411,flecainide,C0016229
1410,bumetanide,C0006376
1409,effect size^,C0814843
1409,effect size !,C0814843
1408,lifestyle behaviours,C0004927;C0023676;C0677505
1408,lifestyle behaviors,C0004927;C0023676;C0677505
1408,lifestyle,C0023676
1407,placebo - ideglira,C0032042;C1696465;C1706408;C4308663
1407,ideglira - ideg - lira,C1555441;C4308663
1407,ideglira - ideg,C4308663
1407,ideglira,C4308663
1406,legend,C2729544
1405,flex aln^,C0729594;C2681220
1404,leinmbr,C0023401;C0428209
1404,lei > nmbr ( n = nmbr ),C0023401;C0428209
1404,lei,C0023401;C0428209
1403,pvd,C0085096;C4521226
1403,peripheral vascular disease,C0085096
1403,peripheral arterial disease — no . ( % ) §,C0085096;C1704436
1403,peripheral arterial disease — no . ( % ),C0085096;C1704436
1403,peripheral arterial disease §,C0085096;C1704436
1403,peripheral arterial disease ( n = nmbr nmbr ),C0085096;C1704436
1403,peripheral arterial disease,C0085096;C1704436
1403,any peripheral arterial disease,C0085096;C1704436
1403,any established peripheral arterial disease,C0085096;C0443211;C1272684;C1704436
1402,symptomatic pad of lower extremities *,C0023216;C0182158;C0231220;C0332568;C3540603;C3669270;C3814046;C4319657
1402,risk factors for pad,C0035648;C0182158;C0332568;C1553898;C3540603;C3669270;C3814046;C4319657
1402,prior pad,C0182158;C0332152;C0332568;C2826257;C3540603;C3669270;C3814046;C4319657
1402,pad symptoms ( % ),C0182158;C0332568;C0683368;C1457887;C3540603;C3669270;C3814046;C4319657
1402,pad lower extremities,C0182158;C0332568;C3540603;C3669270;C3814046;C4319657
1402,pad details,C0182158;C0332568;C1522508;C3540603;C3669270;C3814046;C4319657
1402,pad at baseline,C0168634;C0182158;C0332568;C1442488;C3540603;C3669270;C3814046;C4319657
1402,pad ( n - nmbr,C0182158;C0332568;C3540603;C3669270;C3814046;C4319657
1402,pad,C0182158;C0332568;C3540603;C3669270;C3814046;C4319657
1402,no pad baseline,C0168634;C0182158;C0332568;C1442488;C3540603;C3669270;C3814046;C4319657
1402,no pad ( n - nmbr,C0182158;C0332568;C3540603;C3669270;C3814046;C4319657
1401,budesonide / formoterol fdc,C0340427;C1276807;C1413520;C3539652
1401,budesonide - formoterol nmbr ^g + nmbr . nmbr ^g ( n = nmbr ),C1276807;C1319635
1401,budesonide - formoterol nmbr + nmbr . nmbr ^g ( n = nmbr ),C0439267;C1276807
1401,budesonide - formoterol ( n = nmbr ),C1276807
1401,budesonide - budesonide / formoterol,C1276807
1400,budesonide — no . ( % ),C0054201
1400,budesonide nmbr ^g ( n = nmbr ),C0054201;C0439267
1400,budesonide mmx nmbr mg,C0024671;C0026410;C0054201;C0439269;C1960952;C2346927;C4321396;C4521761
1400,budesonide ( n = nmbr ),C0054201
1400,budesonide,C0054201
1399,non ‐ elderly,C0001792;C1518422;C1999167
1399,non - elderly ( < nmbr years ),C0001792;C0439234;C1518422;C1999167
1399,elderly ( > nmbr years ),C0001792;C0439234;C1999167
1399,elderly,C0001792;C1999167
1398,ssomgdayp . eq .,C0205163;C0439185
1398,eqnmbrda health index status score,C0011318;C0018759;C0205163;C0439185;C0449820;C0600653;C0918012;C1552854;C1637833;C2986546;C3668815;C4050231
1398,eq - nmbrdprofile - mobility,C0080078;C0205163;C0425245;C0439185;C0449580;C4318935
1398,eq - nmbrd mobility,C0080078;C0205163;C0425245;C0439185;C0449580;C4318935
1398,eq - nmbrd - nmbr   l,C0205163;C0439185
1398,eq - nmbrd ( visual analog score ),C0205163;C0234621;C0243071;C0439185;C0449820;C4050231
1398,< nmbr mgday p . eq .,C0205163;C0439185
1397,coronary heart disease risk equivalents,C0439185;C1277690;C4049980
1397,chd risk equivalents,C0439185;C1282512;C4049980
1396,the american college of rheumatology ) .,C0035452;C0557806;C0596070
1396,some college / tech,C0557806;C1826596
1396,some college,C0557806
1396,college degree or higher,C0441889;C0449286;C0542560;C0557806;C2348088
1395,stent length per lesion,C0038257;C0221198;C1444754;C1546698;C1706316
1395,mean total stent length per lesion,C0038257;C0221198;C0439175;C0439810;C0444504;C1444754;C1546698;C1706316;C2347634;C2348143
1395,lesion length ≥ nmbr mm,C0221198;C1444754;C1546698;C1706316;C4330985;C4554674
1395,lesion length > nmbr mm,C0221198;C1444754;C1546698;C1706316;C4330985;C4554674
1395,lesion length $ nmbr mm,C0221198;C1444754;C1546698;C1706316;C4330985;C4554674
1395,lesion length,C0221198;C1444754;C1546698;C1706316
1395,laa length,C1444754;C1706316
1394,swollen,C0038999
1394,question nmbr ( pain / swelling in joints other than neck / back / hips ),C0003862;C0013604;C0038999;C1522634
1394,number of swollen joints ( nmbr assessed ),C0038999;C0449813
1394,number of swollen joints ( nmbr - nmbr ),C0038999;C0449813
1393,kdl cholesterol ( mmol / ),C0008377;C0439190
1393,h dl cholesterol < nmbr mg / dl,C0008377;C0024671;C0026410;C0033727;C0369286;C0439269;C0441932;C0564385;C1960952;C2346927;C3539687;C4321396;C4521761;C4528284
1393,fasting cholesterol — mg / dl,C0008377;C0015663;C0439269
1393,csf cholesterol,C0008377;C3540512;C3889436
1393,cholesterol — mmol / liter,C0008377;C0439190;C0475211
1393,cholesterol — mg / dl,C0008377;C0439269
1393,cholesterol ( ng / ml ),C0008377;C0439275
1393,cholesterol ( mg / dl ),C0008377;C0439269
1393,cholesterol ( % ),C0008377
1393,cholesterol,C0008377
1393,aldl cholesterol,C0008377
1392,> nmbr / tmol / liter — no . ( % ),C0475211
1392,> nmbr . nmbr pmol / liter hscrp level,C0439192;C0441889;C0456079;C0475211;C1547707;C2946261
1392,> nmbr . nmbr pmol / liter,C0439192;C0475211
1392,< nmbr . nmbr pmol / liter,C0439192;C0475211
1392,< nmbr . nmbr mmol / liter triglyceride level,C0428475;C0439190;C0475211
1392,< nmbr . nmbr mmol / liter estimated gfr,C0439190;C0475211
1392,< nmbr . nmbr mmol / liter apob : apoa - l ratio,C0003592;C0003593;C0456603;C0475211;C0523508;C1532563;C1547037;C3252643;C4553344;C4553379
1391,score on modified rankin scale — no . ( % ) §,C0449820;C2984908;C3854213;C4050231
1391,score on modified rankin scale ( ' % / ',C0449820;C2984908;C3854213;C4050231
1391,modified rankin scale — no . ( % ) |,C2984908;C3854213
1391,modified rankin scale score,C0449820;C2984908;C3854213;C4050231
1391,modified rankin scale at screening,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164;C2984908;C3854213
1390,enrolled into osler,C4684790
1390,enrolled in the americas,C0002454;C0596070;C4684790
1390,enrolled in russia or georgia,C0035970;C4684790
1390,enrolled from re - cover study — no . ( % ),C4684790
1390,enrolled from re - cover ii study — no . ( % ),C4684790
1389,psoriasis body surface area > nmbr %,C0005902;C0033860
1389,affected body - surface area > nmbr % — no . { % ),C0005902;C0205148;C0392760;C1314939;C1879646
1388,involved intestinal area,C0021853;C1879646
1388,involved gl areas,C0018229;C1423073;C1427674;C1879646
1387,sle markers,C0005516;C0024141
1387,fgf - nmbr low / > nmbr elevated biomarkers,C0005516;C0016026;C0205250;C0205251;C0919505;C1550472;C3163633;C3890211;C4048187;C4321351;C4522223
1387,fgf - nmbr low / < nmbr elevated biomarkers,C0005516;C0016026;C0205250;C0205251;C0919505;C1550472;C3163633;C3890211;C4048187;C4321351;C4522223
1387,fgf - nmbr high / > nmbr elevated biomarkers,C0005516;C0016026;C0205250;C0919505;C1299351;C2700149;C3163633;C3887512;C3889660;C4321237;C4522209
1387,fgf - nmbr high / < nmbr elevated biomarkers,C0005516;C0016026;C0205250;C0919505;C1299351;C2700149;C3163633;C3887512;C3889660;C4321237;C4522209
1387,elevated biomarkers and st - segment changes,C0005516;C0205250;C3163633
1387,biomarker low,C0005516
1387,biomarker levels,C0005516;C0441889
1387,biomarker high,C0005516
1386,old stroke *,C1536121
1385,aldosterone use,C0002006;C0042153;C0457083;C1947944
1385,aldosterone blockers,C0002006
1385,aldosterone blocker,C0002006
1384,dutasteride ( w = nmbr ),C0754659
1384,dutasteride ( n = nmbr ),C0754659
1384,dutasteride,C0754659
1384,combined ( dutasteride / ta msu losi n ),C0024776;C0039297;C0205195;C0754659;C1412759;C1506978;C1705538;C3272501;C4553364
1383,ras - aldosterone inhibitor^,C0002006;C0002007;C0034678;C0525678;C1514727
1383,aldosterone inhibitor,C0002007
1383,aldosterone antagonists ( e . g . spironolactone ),C0002007;C2757004
1383,aldosterone antagonists,C0002007;C2757004
1383,aldosterone antagonist,C0002007;C2757004;C3536833
1382,salmeterol / fluticasone nmbr / nmbr   μ g b . i . d .,C0086706;C0939232
1382,salmeterol - fluticasone group ( n = nmbr ),C0441848;C0939232
1382,fluticasone - salmeterol ( n = nmbr ),C0939232
1382,fluticasone - fluticasone / salmeterol,C0939232
1381,catheter site — femoral,C0449652
1381,catheter access site,C0085590;C0444454;C0449652;C0589360;C1554204
1380,lathosterol ( jimol / l ),C0064673
1380,csf lathosterol ( | jlg / cll ),C0023434;C0064673;C3540512;C3889436
1379,salmeterol nmbr gg bid,C0017454;C0018370;C0073992
1379,salmeterol ( n[nmbr ),C0073992
1379,salmeterol ( n [nmbr ),C0073992
1379,salmeterol ( n = nmbr ),C0073992
1379,salmeterol,C0073992
1378,without hx of hf,C0018488;C0262926;C1313497;C1538440;C3273279;C3814444
1378,stroke / m l / hf hospitalization,C0018488;C0019993;C0038454;C0456616;C1313497;C1538440;C3273279;C4554100
1378,recurrent hf hospitalization,C0018488;C0019993;C1313497;C1455761;C1538440;C2945760;C3273279
1378,recurrent hf,C0018488;C1313497;C1455761;C1538440;C2945760;C3273279
1378,prior hf n = nmbr,C0018488;C0332152;C1313497;C1538440;C2826257;C3273279
1378,prior hf hospitalization,C0018488;C0019993;C0332152;C1313497;C1538440;C2826257;C3273279
1378,prior hf ( n = nmbr,C0018488;C0332152;C1313497;C1538440;C2826257;C3273279
1378,previous hf hospitalization,C0018488;C0019993;C0205156;C1313497;C1538440;C1552607;C3273279
1378,pharmacological therapy for hf,C0013217;C0018488;C1313497;C1538440;C3273279
1378,participants without hf at baseline,C0018488;C0679646;C1313497;C1538440;C3273279
1378,participants with hf at baseline,C0018488;C0679646;C1313497;C1538440;C3273279
1378,no prior hf n = nmbr,C0018488;C0332152;C1313497;C1538440;C2826257;C3273279
1378,no prior hf hospitalization,C0018488;C0019993;C0332152;C1313497;C1538440;C2826257;C3273279
1378,no prior hf ( n = nmbr,C0018488;C0332152;C1313497;C1538440;C2826257;C3273279
1378,no hx of hf ( n = nmbr ),C0018488;C0262926;C1313497;C1538440;C3273279;C3814444
1378,new hf medication,C0013227;C0018488;C0205314;C1313497;C1538440;C3244316;C3273279;C4284232
1378,hospitalization for hf previous year,C0018488;C0019993;C0205156;C0439234;C0439508;C1313497;C1538440;C1552607;C3273279
1378,hosp . worsening hf,C0018488;C0332271;C1313497;C1457868;C1538440;C1546960;C3273279
1378,hosp . for hf,C0018488;C1313497;C1538440;C3273279
1378,history of hf hospitalization,C0018488;C0551577;C1313497;C1538440;C3273279
1378,hf symptomatic improvement,C0018488;C0231220;C1313497;C1538440;C2986411;C3273279
1378,hf or lvef < nmbr % associated with index event,C0018488;C1313497;C1538440;C3273279
1378,hf hosp .,C0018488;C1313497;C1538440;C3273279
1378,hf duration,C0018488;C0449238;C1313497;C1538440;C2926735;C3273279
1378,hf,C0018488;C1313497;C1538440;C3273279
1378,enrolment through hf,C0018488;C1313497;C1516879;C1538440;C1696073;C3273279;C3888021
1378,duration of hf,C0018488;C0449238;C1313497;C1538440;C2926735;C3273279
1378,congestive hf,C0018488;C0742742;C1313497;C1538440;C3273279
1378,clinical features of hf,C0018488;C0683325;C1313497;C1538440;C3273279
1378,all ~ cause mort / hf hosp .,C0015127;C0018488;C1313497;C1524003;C1538440;C3273279;C3815322
1378,admission for hf in previous year,C0018488;C0184666;C0809949;C1313497;C1538440;C3273279
1377,lung neoplasm malignant,C0024121
1376,inflammation,C0021368
1376,baseline inflammation markers,C0005516;C0021368;C0168634;C1442488
1375,black / african,C0337824
1374,hispanic american,C0019576
1374,hispanic / latin american,C0019576
1373,nocturnal back pain,C1970122
1372,total back pain,C0004604;C0439175;C0439810;C1963071;C4553945
1372,back pain,C0004604;C1963071;C4553945
1371,question nmbr ( neck / back / hip pain ),C0004600;C0004604;C0007859;C0019552;C0019559;C0022122;C0027530;C0205095;C0460009;C1505163;C1522634;C1963071;C1963180;C1995000;C3159206;C3538851;C4284725;C4551516;C4553909;C4553945
1371,neck pain,C0007859;C1963180;C4553909
1370,toast classification of qualifying stroke ( % ),C0038454;C1514624;C1710306;C4521230;C4554100
1370,toast classification of qualifying stroke,C0038454;C1514624;C1710306;C4521230;C4554100
1370,toast classification,C1710306;C4521230
1369,angina class iii or iv — no . ( % ),C0264677
1369,angina class iii or iv prior myocardial infarction,C0264677
1369,angina class iii or iv prior,C0264677
1368,killip class lll - iv,C1261077;C2697847
1367,killip class ii - iv,C0022326;C1710602;C2697845;C2697847;C4082587;C4265176
1367,killip class ii,C2697845
1367,killip class > ii ( % ),C2697845
1366,killip class i — no . ( % ),C2697844
1366,killip class > i,C2697844
1365,nyha class iv,C1882087
1364,nyha classes iii - iv,C0278962
1364,nyha class iii / iv,C0278962
1363,nyha class ii ( n = nmbrlnmbr ),C1882085
1363,nyha class ii ( n = nmbr ),C1882085
1363,nyha class ii,C1882085
1363,nyha class > ii,C1882085
1362,nyha functional class iii ( % ),C0205245;C0542341;C1882086;C2700217
1362,nyha functional class iii,C0205245;C0542341;C1882086;C2700217
1362,nyha class iii or iv ( n = nmbr ),C1882086
1362,nyha class iii or iv,C1882086
1362,nyha class iii,C1882086
1361,nyha_class,C1882083
1361,nyha class — no . ( % ) $,C1882083
1361,nyha class — no . ( % ),C1882083
1361,nyha class within past month — no . / total no . ( % ),C1882083;C4331910
1361,nyha class not reported,C1882083
1361,nyha class nmbr or higher,C1882083
1361,nyha class nmbr - nmbr : no { n = llll ),C1882083
1361,nyha class ( when patient was last in stable condition before admission ),C1882083
1361,nyha class ( when patient was last in stable condition,C1882083
1361,nyha class,C1882083
1361,nyha chf class,C0018802;C1882083
1361,new york heart association congestive heart failure class,C0018802;C1882083
1361,new york heart association class,C1882083
1360,pravastatin vs usual care,C0085542
1360,pravastatin n = nmbr,C0085542
1360,pravastatin ( n = nmbr >,C0085542
1360,pravastatin ( n = nmbr ),C0085542
1360,pravastatin,C0085542
1360,diet plus pravastatin group ( n = nmbr ),C0012155;C0012159;C0085542;C0332287;C0441848;C1519433;C2983588;C3668949
1360,diet diet + pravastatin,C0012155;C0012159;C0085542;C1519433;C2983588;C3668949
1360,diet - i - pravastatin ( n = nmbr ),C0012155;C0012159;C0021966;C0085542;C0221138;C1519433;C2983588;C3668949
1360,diet + pravastatin nmbr / nmbr ( nmbr . nmbr ),C0012155;C0012159;C0085542;C1519433;C2983588;C3668949
1360,diet + pravastatin group,C0012155;C0012159;C0085542;C0441833;C0687744;C1257890;C1519433;C1519504;C1705428;C1705429;C2983588;C3668949
1360,diet + pravastatin ( n = nmbr ),C0012155;C0012159;C0085542;C1519433;C2983588;C3668949
1360,diet + pravastatin,C0012155;C0012159;C0085542;C1519433;C2983588;C3668949
1360,atorvastatin - pravastatin,C0085542;C0286651
1359,time from onset of pain to randomization — hr,C0030193;C0449244;C0518090;C1962977;C2984058;C4085210;C4085211;C4085212;C4553004;C4554132
1359,time from onset of pain to randomization,C0030193;C0449244;C0518090;C1962977;C2984058;C4085210;C4085211;C4085212;C4553004;C4554132
1359,patient assessment of pain ( nmbr - nmbr mm ),C0030193;C0030198;C0030705;C0518090;C0679830;C1962977;C2984058;C4085210;C4085211;C4085212;C4330985;C4553004;C4554132;C4554674
1359,patient assessment of pain ( nmbr - nmbr cm,C0030193;C0030198;C0030705;C0518090;C0679830;C1962977;C2984058;C4085210;C4085211;C4085212;C4553004;C4554132
1359,patient ' s assessment of pain !,C0030193;C0030198;C0030705;C0518090;C0679830;C1962977;C2984058;C4085210;C4085211;C4085212;C4553004;C4554132
1359,patient ' s assessment of pain,C0030193;C0030198;C0030705;C0518090;C0679830;C1962977;C2984058;C4085210;C4085211;C4085212;C4553004;C4554132
1359,pain subscale,C0030193;C0518090;C1962977;C2984058;C4085210;C4085211;C4085212;C4553004;C4554132
1359,pain,C0030193;C0518090;C1962977;C2984058;C4085210;C4085211;C4085212;C4553004;C4554132
1358,non - fatal mi,C1302234;C1518422;C1705232;C3810814
1358,mi ( fatal / nonfatal ),C1302234;C1705232;C3810814
1358,fatal or nonlatal stroke,C1302234;C1705232
1358,fatal or nonlatal myocardial inlarctlon,C1302234;C1705232
1358,fatal or nonfatal stroke,C1302234;C1705232
1358,fatal or nonfatal myocardial infarction,C1302234;C1705232
1358,fatal or non - fatal stroke,C1302234;C1705232
1358,fatal or non - fatal myocardial infarction,C1302234;C1705232
1358,fatal bleeding,C0019080;C1302234;C1705232
1358,fatal bleed,C0019080;C1302234;C1705232
1358,fatal and nonfatal stroke,C1302234;C1705232
1358,fatal and nonfatal ml,C1302234;C1705232
1358,fatal aes,C1302234;C1412268;C1705232;C2699274
1358,fatal / nonfatal stroke,C0038454;C1302234;C1705232;C4554100
1358,fatal / nonfatal ml,C0439526;C1302234;C1705224;C1705232;C3887665
1358,fatal / nonfatal mi ( excluding silent mi ),C1302234;C1705232;C3810814
1358,fatal / nonfatal mi,C1302234;C1705232;C3810814
1358,fatal & nonfatal hospitalized stroke,C0038454;C0701159;C1302234;C1705232;C4554100
1358,fatal & nonfatal ccvd,C1302234;C1705232
1358,fatal,C1302234;C1705232
1357,stable angina — no . ( % ),C0340288
1357,stable angina ( n = nmbr,C0340288
1357,stable angina ( n - nmbr,C0340288
1357,stable angina,C0340288
1357,histor y of stable angina,C0340288
1357,chronic stable angina,C0340288
1356,tolvaptan ( n = nmbr ),C1176308
1356,tolvaptan,C1176308
1355,caribbean,C0043122;C0206155;C1331005
1354,taiwan,C0039260
1353,cuban,C1553379
1352,clean,C1947930
1351,golimumab combined ( n = nmbr ),C0205195;C2353893
1351,combined n = nmbr,C0205195
1351,combined golimumab groups,C0205195;C2353893
1351,combined fatal / nonfatal outcomes,C0205195;C0206277
1351,combined estimated gfr and albuminuria status,C0205195
1351,combined end poir,C0205195;C0444930;C2746065
1351,combined end points,C0205195;C2349179
1351,combined end point,C0205195;C2349179;C2826544
1351,combined efficacy and safety endpoint,C0205195;C1280519;C1707887
1351,combined chd,C0205195;C0280604;C3542407
1351,combined ( n = nmbr ),C0205195
1351,combined,C0205195
1350,other combination,C0205195;C1947911;C3811910
1350,iglarlixi ( fixed - ratio combination ),C0205195;C0443218;C0456603;C1547037;C1947911;C2827483;C3714578;C3811910
1350,combination treatment ifx + aza,C0004482;C0020823;C0039798;C0087111;C0205195;C1522326;C1533734;C1705169;C1947911;C3538994;C3811910;C3887704
1350,combination - facilitated pci ( n = nmbr ),C0205195;C1947911;C3811910
1350,combination - facilitated pci ( % ),C0205195;C1947911;C3811910;C4049621
1350,combination ( n = nmbr ),C0205195;C1947911;C3811910
1350,combination,C0205195;C1947911;C3811910
1349,prior analgesic products,C0002771;C0332152;C2826257
1349,analgesic medication,C0002771
1348,interim analysis ( all patients ),C4684691
1348,interim analysis,C4684691
1347,previous anti - inflammatory / antirheumatic products n ( % ),C0003191;C0205156;C0333348;C0432633;C1514468;C1552607
1347,inflammatory,C0333348
1346,prior antiinflammatory / antirheumatic products,C0003191;C0003209;C0332152;C1514468;C1515999;C2826257
1346,anti - inflammatory drugs,C0003209
1345,renal parameters,C0022646;C0449381
1345,parameters,C0449381
1345,other lipid parameters,C0023779;C0449381
1345,lipid parameters,C0023779;C0449381
1345,glycaemic parameters,C0005802;C0449381
1345,biometric parameters,C0005544;C0449381;C2718322
1345,baseline lipid parameters,C0023779;C0168634;C0449381;C1442488
1344,height in meters .,C0441074;C0489786
1344,> = nmbr meters,C0441074
1344,< nmbr meters,C0441074
1343,spirometry,C0037981
1343,spirometric values at baseline,C0037981;C0042295;C0168634;C0183441;C1442488
1343,baseline spirometry,C0037981;C0168634;C1442488
1342,treatment satisfaction,C3476649
1341,potential injection site reactions,C0151735;C3245505
1341,injection - site reaction,C0151735;C4551923
1340,total cataract extraction,C0007389;C0185115;C0439175;C0439810;C0684295;C3665439
1340,total cataract,C3665439
1339,without baseline vertebral fracture,C0080179;C0168634;C1442488
1339,with baseline vertebral fracture,C0080179;C0168634;C1442488
1339,vertebral fractures at baseline,C0080179;C0168634;C1442488
1339,vertebral fracture and / or t score s - nmbr . nmbr,C0080179
1339,vertebral fracture and / or t score - nmbr . nmbr,C0080179
1339,vertebral fracture,C0080179
1339,spinal fractures,C0080179;C0518450
1339,clinical vertebral fractures,C0080179;C0205210
1339,baseline vertebral fracture,C0080179;C0168634;C1442488
1338,glatiramer acetate,C0289884
1337,levetiracetam,C0377265;C3693636
1336,biventricular pacemaker,C1719274
1335,implanted pacemaker,C0848753
1334,lacunar,C0241970;C1459585
1333,glomerular,C0022663;C0268731
1332,• iii : death from cv causes,C0011065;C0439070;C1306577;C1705160;C3538987;C4048877;C4082313;C4318503;C4552775
1332,• death from cv causes,C0011065;C1306577;C3538987;C4048877;C4082313;C4318503;C4552775
1332,vascular death,C0005847;C0011065;C1306577;C1558950;C1801960;C4082313;C4552775
1332,primary endpoint death / mi / idr / st,C0011065;C0036056;C1306577;C2986535;C3272372;C3810814;C4082313;C4552775
1332,primary end point : death / mi / idr / st,C0011065;C0036056;C1306577;C2986535;C3272372;C3810814;C4082313;C4552775
1332,noncardiovascular death,C0011065;C1306577;C4082313;C4552775
1332,noncardiac death,C0011065;C1306577;C4082313;C4552775
1332,non - cvd deaths,C0007222;C0011065;C1306577;C1518422
1332,no . of deaths,C0011065;C1306577
1332,nmbr days composite of death / new mi / urgent revascularization and definite st,C0011065;C0205199;C0439609;C0581603;C1306577;C1547335;C3272275;C3810814;C4082313;C4552775;C4689466
1332,malignancy death,C0006826;C0011065;C1306459;C1306577;C4082313;C4282132;C4552775
1332,macce ( death,C0011065;C1306577;C4082313;C4552775
1332,hazard ratio for cardiovascular death,C0007226;C0011065;C1306577;C2985465;C3887460;C4082313;C4552775
1332,deaths,C0011065;C1306577
1332,death or stent thrombosis,C0011065;C1306577;C4082313;C4552775
1332,death or nmbrmwd decrease > nmbr m,C0011065;C1306577;C4082313;C4552775
1332,death or myocardial infarction,C0011065;C1306577;C4082313;C4552775
1332,death or mi at nmbr days,C0011065;C1306577;C4082313;C4552775
1332,death or ich,C0011065;C1306577;C4082313;C4552775
1332,death or disabling stroke,C0011065;C1306577;C4082313;C4552775
1332,death or absolute fvc decrease > nmbr %,C0011065;C1306577;C4082313;C4552775
1332,death from,C0011065;C1306577;C4082313;C4552775
1332,death due to renal failure ®,C0011065;C0035078;C0678226;C1306577;C1963154;C4082313;C4552775
1332,death due to renal failure or sustained esrd,C0011065;C0035078;C0678226;C1306577;C1963154;C4082313;C4552775
1332,death / udmi / idr,C0011065;C1306577;C4082313;C4552775
1332,death / st,C0011065;C0036056;C1306577;C3272372;C4082313;C4552775
1332,death / q - wave mi / idr,C0011065;C0861151;C1306577;C4082313;C4552775
1332,death / q - ml / stent thrombosis,C0011065;C0439526;C1306577;C1705224;C3887665;C3897493;C4082313;C4552775
1332,death / q - mi / idr,C0011065;C1306577;C3810814;C4082313;C4552775
1332,death / mi / idr / st / gusto - defined moderate or severe bleeding,C0011065;C0036056;C1306577;C3272372;C3810814;C4082313;C4552775
1332,death / mi / idr / st,C0011065;C0036056;C1306577;C3272372;C3810814;C4082313;C4552775
1332,death *,C0011065;C1306577;C4082313;C4552775
1332,death ( all cause ),C0011065;C1306577;C4082313;C4552775
1332,death ( all - cause ),C0011065;C1306577;C4082313;C4552775
1332,death,C0011065;C1306577;C4082313;C4552775
1332,dead ( n = nmbr ),C0011065
1332,cv death or ml,C0011065;C1306577;C3538987;C4048877;C4082313;C4318503;C4552775
1332,cv death or hhf,C0011065;C1306577;C3538987;C4048877;C4082313;C4318503;C4552775
1332,cv death or hf hospitalization n,C0011065;C1306577;C3538987;C4048877;C4082313;C4318503;C4552775
1332,cv death or hf hosp .,C0011065;C1306577;C3538987;C4048877;C4082313;C4318503;C4552775
1332,cv death or first hhf,C0011065;C1306577;C3538987;C4048877;C4082313;C4318503;C4552775
1332,cv death n,C0011065;C1306577;C3538987;C4048877;C4082313;C4318503;C4552775
1332,cv death / mi / stroke / ucr,C0011065;C0038454;C1306577;C3538987;C3810814;C4048877;C4082313;C4318503;C4552775;C4554100
1332,cv death / mi / stroke,C0011065;C0038454;C1306577;C3538987;C3810814;C4048877;C4082313;C4318503;C4552775;C4554100
1332,cv death / hf hospitalization,C0011065;C0018488;C0019993;C1306577;C1313497;C1538440;C3273279;C3538987;C4048877;C4082313;C4318503;C4552775
1332,cv death + hf hospitalization,C0011065;C0018488;C0019993;C1306577;C1313497;C1538440;C3273279;C3538987;C4048877;C4082313;C4318503;C4552775
1332,cv death,C0011065;C1306577;C3538987;C4048877;C4082313;C4318503;C4552775
1332,composite of death / mi / urg ent revasc,C0011065;C0205199;C0378365;C0919420;C1306577;C1367721;C1547335;C1705448;C3810814;C3889152;C4082313;C4552775
1332,composite of death / mi / stro ke / urgent revasc / definit e acute stent thrombosis,C0011065;C0022558;C0155626;C0205199;C0378365;C0439609;C1306577;C1547335;C3272275;C3897493;C4082313;C4552775
1332,cardiovascular death ®,C0007226;C0011065;C1306577;C3887460;C4082313;C4552775
1332,cardiovascular death or nonfatal myocardial infarction,C0007226;C0011065;C1306577;C3887460;C4082313;C4552775
1332,cardiovascular death or nonfatal mi ( excluding silent mi ),C0007226;C0011065;C1306577;C3887460;C4082313;C4552775
1332,cardiovascular death or hospitalized hf,C0007226;C0011065;C1306577;C3887460;C4082313;C4552775
1332,cardiovascular death or hospitalization for heart failure,C0007226;C0011065;C1306577;C3887460;C4082313;C4552775
1332,cardiovascular death or heart failure hospitalization,C0007226;C0011065;C1306577;C3887460;C4082313;C4552775
1332,cardiovascular death and hospital admission for heart failure,C0007226;C0011065;C1306577;C3887460;C4082313;C4552775
1332,cardiovascular death / hospitalization for heart failure,C0007226;C0011065;C1306577;C3887460;C3898876;C4082313;C4552775
1332,cardiovascular death *,C0007226;C0011065;C1306577;C3887460;C4082313;C4552775
1332,cardiovascular death ( n = nmbr ),C0007226;C0011065;C1306577;C3887460;C4082313;C4552775
1332,cardiovascular death !,C0007226;C0011065;C1306577;C3887460;C4082313;C4552775
1332,cardiovascular death,C0007226;C0011065;C1306577;C3887460;C4082313;C4552775
1332,cad death,C0011065;C1306577;C1504769;C2239547;C3813548;C4082313;C4284121;C4552775
1332,any death,C0011065;C1306577;C4082313;C4552775
1332,all death,C0011065;C1306577;C4082313;C4552775
1332,all - cause death / stroke / see,C0011065;C0015127;C0038454;C1306577;C1524003;C4082313;C4552775;C4554100
1332,a cardiovascular death or hospitalization for heart failure,C0007226;C0011065;C1306577;C3887460;C4082313;C4552775
1331,adcs - adl score *,C0449820;C3641947;C4050231
1331,adcs - adl,C3641947
1330,adas — cog score,C0449820;C3539026;C4050231
1330,adas - cog score *,C0449820;C3539026;C4050231
1330,adas - cog,C3539026
1329,ada nmbr / nmbr n[nmbr,C1060325;C3811629
1329,ada nmbr / nmbr ( n[nmbr ),C1060325;C3811629
1329,ada ifg,C1060325;C1334085;C1708411;C3811629
1329,ada,C1060325;C3811629
1328,cdai §,C0683448;C1413248;C3273706
1328,cdai score §,C0683448;C1413248;C3273706
1328,cdai score < nmbr,C0683448;C1413248;C3273706
1328,cdai score,C0683448;C1413248;C3273706
1328,cdai > nmbr,C0683448;C1413248;C3273706
1328,cdai < nmbrt,C0683448;C1413248;C3273706
1328,cdai < nmbr . nmbr *,C0683448;C1413248;C3273706
1328,cdai ( nmbr - nmbr ),C0683448;C1413248;C3273706
1328,cdai,C0683448;C1413248;C3273706
1327,sdai < nmbr t,C3871128
1327,sdai < nmbr . nmbr *,C3871128
1327,sdai ( nmbr - nmbr ),C3871128
1327,sdai,C3871128
1326,lower dose edoxaban regimen,C0441994;C1548802;C2003888;C2348331;C2975435
1326,higher dose edoxaban regimen,C0205250;C2348331;C2975435
1326,higher - dose edoxaban vs warfarin,C0444956;C2975435
1326,higher - dose edoxaban ( n = nmbr ),C0444956;C2975435
1326,high - dose edoxaban vs warfarin,C0444956;C2975435
1326,high - dose edoxaban ( n = nmbr ),C0444956;C2975435
1326,high - dose edoxaban,C0444956;C2975435
1326,edoxaban lower dose vs warfarin,C2975435
1326,edoxaban higher dose vs warfarin,C0444956;C2975435
1325,ld edoxaban vs warfarin,C0694649;C2975435
1325,hd edoxaban vs warfarin,C2975435
1325,edoxaban warfarin,C0043031;C2975435
1325,edoxaban vs . warfarin,C2975435
1325,edoxaban n = nmbr n / n ( % ),C2975435
1325,edoxaban n = nmbr,C2975435
1325,edoxaban n / n  rate ( % ),C0871208;C1521828;C2975435
1325,edoxaban ( n = nmbr ),C2975435
1325,edoxaban,C2975435
1324,sys : ns dia : < nmbr . nmbr,C0038944;C1112705;C1425041;C1705982;C1706546
1324,ns,C0038944;C1112705;C1705982
1323,npi - nmbr score *,C1412208;C1549728;C3539727
1323,npi,C1412208;C1549728;C3539727
1322,smoking status — no . { % ),C1519386
1322,smoking status — no . ( % ),C1519386
1322,smoking status current,C0521116;C1519386;C1705970
1322,smoking status . no . ( % ),C1519386
1322,smoking status *,C1519386
1322,smoking status ( previous ) ( n ),C0205156;C1519386;C1552607
1322,smoking status ( ongoing ) ( n ),C0549178;C1519386
1322,smoking status ( % ),C1519386
1322,smoking status,C1519386
1321,swollen joints > nmbr,C0152031
1321,joint swelling,C0152031
1320,smoking — current,C0037369;C0453996;C0521116;C1705970;C1881674
1320,smoking pack year ( years ) fl,C0037369;C0439234;C0439508;C0453996;C1277691;C1300812;C1708024;C1881674
1320,smoking pack year ( years ) ^,C0037369;C0439234;C0439508;C0453996;C1277691;C1881674
1320,smoking pack - yearsb,C0037369;C0453996;C1881674;C1968515;C2825051;C2828395
1320,smoking pack - yearsa,C0037369;C0453996;C1881674;C1968515;C2825051;C2828395
1320,smoking pack - years,C0037369;C0453996;C1277691;C1881674
1320,smoking index — pack - yr §,C0037369;C0439234;C0453996;C0600653;C0918012;C1552854;C1637833;C1881674;C1968515;C2825051;C2828395;C2986546
1320,smoking in the past year,C0037369;C0453996;C1881674;C4086728
1320,smoking : ex - smoker,C0037369;C0453996;C1881674
1320,smoking : current smoker,C0037369;C0453996;C1881674
1320,smoking * ( > nmbr pack - years ),C0037369;C0453996;C1277691;C1881674
1320,smoking *,C0037369;C0453996;C1881674
1320,smoking ( ever ),C0037369;C0453996;C1881674
1320,smoking ( current ),C0037369;C0453996;C0521116;C1705970;C1881674
1320,smoking ( a ),C0037369;C0453996;C1881674
1320,smoking ( % ),C0037369;C0453996;C1881674
1320,smoking ' ! ',C0037369;C0453996;C1881674
1320,smoking,C0037369;C0453996;C1881674
1320,past smoking,C0037369;C0453996;C1444637;C1881674;C4284302
1320,no smoking,C0037369;C0453996;C1881674
1320,no current smoking,C0037369;C0453996;C0521116;C1705970;C1881674
1320,current smoking — no . / total no . ( % ),C0037369;C0453996;C0521116;C1705970;C1881674
1320,current smoking — no . ( % ),C0037369;C0453996;C0521116;C1705970;C1881674
1320,current smoking *,C0037369;C0453996;C0521116;C1705970;C1881674
1320,current smoking ( % ),C0037369;C0453996;C0521116;C1705970;C1881674
1320,current smoking,C0037369;C0453996;C0521116;C1705970;C1881674
1319,dmard | |,C0242708
1319,dmard user,C0242708;C1548600;C1706077
1319,dmard or corticosteroid,C0242708
1319,dmard at baseline,C0168634;C0242708;C1442488
1318,dmard − ( n   =   nmbr ),C0242708
1318,dmard - ir / anti - tnf - ir,C0022065;C0022071;C0242708;C1448132;C1448177
1318,dmard + ( n   =   nmbr ),C0242708
1317,patients with prior dmard use,C0030705;C0042153;C0242708;C0332152;C0457083;C1947944;C2826257
1317,other dmards,C0242708
1317,other dmard use,C0042153;C0242708;C0457083;C1947944
1316,mean score on haq - di §,C3533236;C3826998;C4321476
1316,health assessment questionnaire - disability index,C4321476
1316,haq di score ( nmbr - nmbr ),C0449820;C3826998;C4050231;C4321476
1316,haq di,C3826998;C4321476
1316,haq - di total score,C2964552;C3826998;C4321476
1316,haq - di scoreff,C3826998;C4321476
1316,haq - di scored,C3826998;C4321476
1316,haq - di score ( nmbr - nmbr ),C0449820;C3826998;C4050231;C4321476
1316,haq - di score,C0449820;C3826998;C4050231;C4321476
1316,haq - di mcide,C3826998;C4321476
1316,haq - di * *,C3826998;C4321476
1316,haq - di *,C3826998;C4321476
1316,haq - di ( nmbr - nmbr ),C3826998;C4321476
1316,haq - di,C3826998;C4321476
1316,( haq - di,C3826998;C4321476
1316,% with haq - di decrease > nmbr . nmbr,C0392756;C0547047;C3826998;C4321476
1315,sustained decrease of > nmbr % in egfr ®,C0392756;C0443318;C0547047
1315,primary outcome : nmbr % decrease in womac pain score,C0205225;C0392756;C0439612;C0439631;C0547047;C0582148;C1274040
1315,nmbrmwd decrease > nmbr m,C0369637;C0392756;C0441923;C0547047
1315,nmbr % decrease in womac pain score,C0392756;C0547047;C0582148
1315,moderate decrease ( nmbr - < nmbr mlymin per nmbr . nmbr mnmbr ),C0205081;C0369637;C0392756;C0441923;C0547047;C1881878;C4049705;C4049706;C4085643;C4321335
1315,mild decrease ( nmbr - < nmbr ml / min per nmbr . nmbr mnmbr ),C0369637;C0392756;C0439445;C0441923;C0547047;C2945599
1315,hb decrease ≥ nmbr g / dl,C0019046;C0392756;C0439267;C0547047;C3642216;C3843510
1315,a decrease of > nmbr points in the cdai score,C0392756;C0547047;C2924612
1314,reduced ef,C0392756
1314,hf without known reduced ef ( n = nmbr ),C0018488;C0205309;C0392756;C1313497;C1538440;C3273279
1314,hf without known reduced ef,C0018488;C0205309;C0392756;C1313497;C1538440;C3273279
1314,hf ' without known reduced ef,C0018488;C0205309;C0392756;C1313497;C1538440;C3273279
1313,seizure reduction from baseline,C0036572;C0168634;C0301630;C0392756;C1293152;C1442488;C1959629;C4551656;C4553401
1313,rr reduction,C0301630;C0392756;C1293152;C4551656;C4554402
1313,reduction of hbanmbrc from baseline ≥ nmbr . nmbr %,C0019016;C0301630;C0392756;C1293152;C1825777;C3538758;C4551656
1313,reduction in odds %,C0301630;C0392756;C1293152;C4551656
1313,rate reduction ( % ),C0301630;C0392756;C0871208;C1293152;C1521828;C4551656
1313,nmbr ‐ point reduction in selena – sledai score,C0301630;C0392756;C0451528;C1293152;C1552961;C2347617;C3714763;C4551656
1313,mild reduction in egfr,C0301630;C0392756;C1293152;C1739039;C2945599;C3811844;C3812682;C4551656
1313,dose reduction,C0178602;C0301630;C0392756;C0869039;C1114758;C1293152;C4551656
1313,composite of nmbr % reduction in egfr,C0205199;C0301630;C0392756;C1293152;C1547335;C4551656
1313,body weight reduction > nmbr %,C0005910;C0242821;C0301630;C0392756;C0460148;C1262477;C1268086;C1293152;C1305866;C4082212;C4551656
1313,any dose reduction,C0178602;C0301630;C0392756;C0869039;C1114758;C1293152;C4551656
1313,% reduction,C0301630;C0392756;C1293152;C4551656
1312,proportion of predicted normal fevnmbr value   §,C0086715;C0520835;C0681842;C1522609;C1709707;C1882327;C3714541
1312,percentage of predicted pre - bronchodilator fev^,C0439165;C0681842;C1549488;C1561533;C1882327;C2599602;C3714541
1312,percent of predicted value before bronchodilation^,C1882327
1312,fevnmbr   % of predicted normal post - bronchodilator,C0520835;C0681842;C1882327;C2599594
1312,> nmbr % predicted to < nmbr % predicted,C0681842;C1882327
1312,> nmbr % predicted arr ( n = nmbr ),C0681842;C1882327;C2170357;C4084934
1312,> nmbr % predicted,C0681842;C1882327
1312,< nmbr % predicted arr ( n = nmbr,C0681842;C1882327;C2170357;C4084934
1312,< nmbr % predicted,C0681842;C1882327
1312,% predicted value ( sd ),C0681842;C1522609;C1882327;C2699239
1312,% predicted prebronchodilator fevnmbr,C0681842;C1882327;C2599602;C3714541
1312,% predicted pre - bronchodilator fevnmbr,C0681842;C1882327;C2599602;C3714541
1312,% predicted pre - bd,C0005126;C0332152;C0681842;C0740175;C1882327;C2257086;C2344255;C3669034;C4050145
1312,% predicted post - bronchodilator fevnmbr,C0681842;C1882327
1312,% predicted post - bronchodilator fev,C0681842;C1882327
1312,% predicted,C0681842;C1882327
1312,% of predicted normal value *,C0086715;C0681842;C1882327
1312,% of predicted,C0681842;C1882327
1311,apolipoprotein anmbr ( mg / dl ),C0003592;C0439269;C0523508
1311,apolipoprotein anmbr ( g / l ),C0003592;C0439294;C0456615;C0523508
1311,apolipoprotein a,C0003592;C0523508
1311,apoanmbr,C0003592;C0523508;C4553344;C4553379
1311,apoa - nmbr,C0003592;C0523508;C4553344;C4553379
1311,apo b / apo a - l ratio ( mean ),C0003592;C0444504;C0456603;C0523508;C1447574;C1547037;C2347634;C2348143;C4521365;C4553344
1311,apo b / apo a - l,C0003592;C0523508;C1447574;C4521365;C4553344
1311,apo anmbr ( mg / dl ),C0003592;C0439269;C0523508;C4553344;C4553379
1311,apo anmbr ( g / l ),C0003592;C0439294;C0456615;C0523508;C4553344;C4553379
1311,apo anmbr,C0003592;C0523508;C4553344;C4553379
1311,apo a - nmbr,C0003592;C0523508;C4553344;C4553379
1310,apolipoprotein a - i *,C0085201;C1677784
1310,apolipoprotein a - i,C0085201;C1677784
1310,apob : apoa - i,C0003593;C0085201;C1677784;C3252643
1310,apoa - i,C0085201;C1677784
1310,apo a - i ( mg / dl ) *,C0085201;C0439269;C1677784
1310,apo a - i,C0085201;C1677784
1309,apobnmbr,C0003593;C3252643
1309,apob : apoanmbr ratio,C0003592;C0003593;C0456603;C0523508;C1547037;C3252643;C4553344;C4553379
1309,apob : apoanmbr,C0003592;C0003593;C0523508;C3252643;C4553344;C4553379
1309,apob : apoal ratio,C0003593;C0456603;C1547037;C3252643
1309,apob : apoal,C0003593;C3252643
1309,apob : apoa - nmbr ratio,C0003592;C0003593;C0456603;C0523508;C1547037;C3252643;C4553344;C4553379
1309,apob : apoa - l ratio,C0003592;C0003593;C0456603;C0523508;C1547037;C3252643;C4553344;C4553379
1309,apob : apoa - i ratio,C0003593;C0085201;C0456603;C1547037;C1677784;C3252643
1309,apob,C0003593;C3252643
1309,apo b : apo a - i ratio,C0003593;C0085201;C0456603;C1547037;C1677784;C3252643
1309,apo b *,C0003593;C3252643
1309,apo b,C0003593;C3252643
1309,apo - b,C0003593;C3252643
1308,apolipoprotein b^,C0003593
1308,apolipoprotein b nmbr,C0003593
1308,apolipoprotein b ( g / l ),C0003593;C0439294;C0456615
1308,apolipoprotein b,C0003593
1307,lpa,C1096202;C1439335;C3539666;C4049711;C4553379
1307,lp ( a ) §,C0065058;C1439335;C4553379
1307,lp ( a ) ( μ mol / l ),C0065058;C0347982;C1439335;C4553379
1307,lp ( a ) ( week nmbr ),C0065058;C0332174;C0439230;C1439335;C4553379
1307,lp ( a ) ( pmol / l ),C0065058;C0439284;C1439335;C4553379
1307,lp ( a ),C0065058;C1439335;C4553379
1307,lipoprotein ( a ) tx difference vs pbo,C0041403;C0065058;C0125953;C1096202;C1439335;C1705241;C1705242
1307,lipoprotein ( a ) ( nmol / l ),C0065058;C0125953;C0439282;C1096202;C1439335
1307,lipoprotein ( a ) ( mmol / l ),C0065058;C0125953;C1096202;C1439335;C1532563
1307,lipoprotein ( a ) ( mg / dl ),C0065058;C0125953;C0439269;C1096202;C1439335
1307,lipoprotein ( a ),C0065058;C0125953;C1096202;C1439335
1307,baseline lipoprotein ( a ) ( nmol / l ),C0065058;C0125953;C0168634;C0439282;C1096202;C1439335;C1442488
1306,sitagliptin nmbr nmbr . nmbr 士 nmbr . nmbr nmbr - h postprandial plasma glucose ( ppg ) ( mmol / l ),C0202042;C0376674;C0455280;C1418888;C1565750;C2827804
1306,ppg,C1418888
1306,nmbr - h ppg ( mmol / l ) *,C1418888;C2827804
1306,nmbr - h ppg ( mmol / l ),C1418888;C2827804
1305,psa ‐ modified shs of hands and feet,C0018563;C0392747;C1552914;C3810537;C3813209;C3889737
1305,psa ‐ modified mases score ( nmbr – nmbr scale ),C0392747;C3810537;C3813209;C3889737
1305,psa subtypes,C0449560;C3810537;C3813209
1305,psa reported,C3810537;C3813209
1305,psa duration ( years ),C0439234;C0449238;C2926735;C3810537;C3813209
1305,psa duration,C0449238;C2926735;C3810537;C3813209
1305,psa - modified total shs,C3810537;C3813209
1305,psa - modified shs of hands & feetnmbr ( nmbr - nmbr ),C0016504;C0018563;C0347981;C0392747;C1552914;C3810537;C3813209;C3889737
1305,psa - modified shs ( nmbr - nmbr ),C0392747;C3810537;C3813209;C3889737
1305,psa - modified mases score ( nmbr - nmbr ),C0392747;C3810537;C3813209;C3889737
1305,psa ( ng / ml ),C0439275;C3810537;C3813209
1305,psa ( n = nmbr ),C3810537;C3813209
1305,psa,C3810537;C3813209
1305,no psa ( n = nmbr ),C3810537;C3813209
1305,no psa,C3810537;C3813209
1304,pm,C0030266;C4049155
1304,lta ( max response to nmbr pm adp ) defined hpr ( % patients ),C0030266;C0523452;C2611142;C4049155
1303,weeks_measured,C0439230
1303,weeks,C0439230
1303,week   nmbr,C0332174;C0439230
1303,week nmbra,C0332174;C0439230
1303,week nmbr responders,C0332174;C0439230
1303,week nmbr outcomes,C0332174;C0439230;C1274040
1303,week nmbr outcome,C0332174;C0439230;C1274040
1303,week nmbr fpg,C0332174;C0439230
1303,week nmbr czp nmbr mg qnmbrw ( n = nmbr ),C0024671;C0026410;C0054841;C0332174;C0439230;C0439269;C1861828;C1872109;C1960952;C2346927;C4321396;C4521761
1303,week nmbr czp nmbr mg qnmbrw,C0024671;C0026410;C0054841;C0332174;C0439230;C0439269;C1861828;C1872109;C1960952;C2346927;C4321396;C4521761
1303,week nmbr czp dose combined ( n   =   nmbr ),C0054841;C0178602;C0332174;C0439230;C0869039;C1114758;C1861828;C1872109
1303,week nmbr czp dose combined,C0054841;C0178602;C0332174;C0439230;C0869039;C1114758;C1861828;C1872109
1303,week nmbr crp,C0332174;C0439230;C3890735;C4048285
1303,week nmbr / et,C0332174;C0439230
1303,week nmbr - baseline,C0168634;C0332174;C0439230;C1442488
1303,week nmbr * ’ ’,C0332174;C0439230
1303,week nmbr *,C0332174;C0439230
1303,week nmbr ( non - ee responders ),C0332174;C0439230;C1518422
1303,week nmbr ( mmol / l ),C0332174;C0439230;C1532563
1303,week nmbr ( mean,C0332174;C0439230;C0444504;C2347634;C2348143
1303,week nmbr ( geometric mean,C0332174;C0439230;C2986759
1303,week nmbr ( before ee ),C0332174;C0439230
1303,week nmbr % of patients,C0030705;C0332174;C0439230
1303,"week nmbr  % ( n ) "" """,C0332174;C0439230
1303,week nmbr,C0332174;C0439230
1303,week and,C0332174;C0439230
1303,week - nmbr changea,C0332174;C0439230;C4349366
1303,week,C0332174;C0439230
1303,triglycerides ( week nmbr ) a,C0041004;C0332174;C0439230
1303,seizure frequency during nmbr ‐ week baseline,C0149775;C0168634;C0332174;C0439230;C1442488
1303,pt baseline ( week nmbr ),C0032743;C0168634;C0332174;C0439230;C0699718;C1442488
1303,pbo to czp week nmbr dose combined,C0031962;C0054841;C0178602;C0332174;C0439230;C0869039;C1114758;C1861828;C1872109
1303,pasi # nmbr at week nmbr,C0332174;C0439230;C4528685
1303,open - label phase ( baseline = week nmbr ),C0168634;C0205390;C0332174;C0439230;C1442488;C1709323;C1710475
1303,nmbr wk,C0332174;C0439230
1303,nmbr week,C0332174;C0439230
1303,nmbr / week ( n = nmbr ),C0332174;C0439230
1303,nmbr - nmbr / week ( n = nmbr ) nmbr - nmbr / week ( n = nmbr ),C0332174;C0439230
1303,nmbr - nmbr / week ( n = nmbr ),C0332174;C0439230
1303,nmbr - nmbr / week,C0332174;C0439230
1303,night - time awakenings / week,C0332174;C0439230;C0860510
1303,ldl particle size ( week nmbr ),C0332174;C0439230;C3641256
1303,ldl particle numbers ( week nmbr ),C0237753;C0332174;C0439230;C0449788;C2612459
1303,habitual fish intake : < nmbr servings / wk ( n = nmbr ),C0205353;C0332174;C0439230;C0556216;C1519269
1303,fevnmbr at week nmbr,C0332174;C0439230;C3714541
1303,elevated at wk nmbr — no . ( % ) nmbr,C0205250;C0332174;C0439230;C3163633
1303,elevated at wk nmbr — no . ( % ) !,C0205250;C0332174;C0439230;C3163633
1303,dose ratio at week nmbr ( nmbr % cl ),C0178602;C0332174;C0439230;C0456603;C0596019;C0869039;C1114758;C1547037
1303,db baseline ( week nmbr ),C0168634;C0332174;C0439230;C1418892;C1442488
1303,clinical efficacy at week nmbr,C0087113;C0332174;C0439230
1303,cfb at week nmbr,C0009002;C0332174;C0439230;C1824728
1303,cardioversion in previous nmbr wk,C0013778;C0205156;C0332174;C0439230;C1552607
1303,at week nmbr,C0332174;C0439230
1303,at six weeks,C0205452;C0439230
1303,apob ( week nmbr ),C0003593;C0332174;C0439230;C3252643
1303,additional radiographic findings at week nmbr,C0332174;C0439230;C0444708;C1524062;C2607943;C2926606;C3539655
1303,acrnmbr week nmbr responders,C0332174;C0439230;C1412134;C1515941
1303,> nmbr weeks,C0439230
1303,> nmbr servings / wk ( n = nmbr ),C0332174;C0439230;C1519269
1303,> nmbr / week,C0332174;C0439230
1303,< nmbr weeks,C0439230
1303,< nmbr week,C0332174;C0439230
1303,- - - - - - - - - - - - week nmbr - - - - - - - - - - - - - - - - -,C0332174;C0439230
1303,- - - - - - - - - - - - - week nmbr - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -,C0332174;C0439230
1303,- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - week nmbr - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -,C0332174;C0439230
1303,- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - week nmbr - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -,C0332174;C0439230
1303,( week ),C0332174;C0439230
1302,week nmbr hbanmbrc,C0019016;C0332174;C0439230;C1825777;C3538758
1302,hbanmbrc nmbr weeks,C0019016;C0439230;C1825777;C3538758
1302,hbanmbrc at week nmbr,C0019016;C0332174;C0439230;C1825777;C3538758
1302,hbanmbrc at nmbr weeks *,C0019016;C0439230;C1825777;C3538758
1302,at weeks nmbr and nmbr,C0439230
1301,full po pulatio n,C0443225;C0946289
1301,duration of full - dose warfarin therapy before enrollment ( mo ),C0366686;C0443225;C0444917
1300,qol due to urinary symptoms,C0426359;C0518214;C0678226
1300,amputation due to diabetes — no . ( % ),C0598284;C0678226
1299,insulin lispro mix nmbr / lispro mix nmbr - insulin glargine / insulin lispro,C0293359
1299,all dulaglutide nmbr . nmbr mg + insulin lispro / insulin glargine ( n = nmbr ),C0024671;C0026410;C0293359;C0439269;C0907402;C1960952;C2346927;C3179549;C4321396;C4521761
1298,amlodipine / valsartan nmbr to nmbr / nmbr mg ( n = nmbr ),C0024671;C0026410;C0439269;C1960952;C1962523;C2346927;C4321396;C4521761
1298,amlodipine / valsartan nmbr / nmbr vs nmbr / nmbr mg,C1962523
1298,amlodipine / valsartan nmbr / nmbr mg / v = nmbr,C0024671;C0026410;C0439269;C1960952;C1962523;C2346927;C4321396;C4521761
1298,amlodipine / valsartan nmbr / nmbr mg ( n = nmbri ),C0024671;C0026410;C0439269;C1960952;C1962523;C2346927;C4321396;C4521761
1298,amlodipine / valsartan nmbr / nmbr mg ( n = nmbr ),C0024671;C0026410;C0439269;C1960952;C1962523;C2346927;C4321396;C4521761
1298,amlodipine - amlodipine / valsartan,C1962523
1297,other glp - nmbr receptor agonist,C0018301;C1422069;C1425391;C1539338;C2350813;C4543206
1297,hazard ratio glp - nmbr analogue vs placebo [nmbr % cl],C0018301;C0243071;C1422069;C1425391;C1539338;C2350813;C2985465
1297,glp - nmbr receptor agonists,C0018301;C1422069;C1425391;C1539338;C2350813;C4543206
1297,glp - nmbr receptor agonist ( other than study drug ),C0013175;C0018301;C1422069;C1425391;C1539338;C2350813;C4543206
1297,glp - nmbr receptor agonist,C0018301;C1422069;C1425391;C1539338;C2350813;C4543206
1297,glp - nmbr analogue,C0018301;C0243071;C1422069;C1425391;C1539338;C2350813
1296,primary trial end point,C0008976;C2986535
1296,primary renal endpoint or death,C0022646;C2986535
1296,primary renal endpoint,C0022646;C2986535
1296,primary endpointnmbr,C2986535
1296,primary endpoint^,C2986535
1296,primary endpoint ’,C2986535
1296,primary endpoint at nmbr months,C0439231;C2986535
1296,primary endpoint at nmbr days,C0439228;C2986535
1296,primary endpoint :,C2986535
1296,primary endpoint,C2986535
1296,primary end point |,C2986535
1296,primary end point *,C2986535
1296,"primary end point """,C2986535
1296,primary end point,C2986535
1296,primary end - point,C2986535
1296,primary cv endpoint,C2986535;C3538987;C4048877;C4318503
1295,primary end point kaplan - meier rate,C0871208;C1521828;C2986535
1295,nace ( primary endpoint ),C2986535
1295,event rate ( % ) of primary endpoints,C0441471;C0871208;C1521828;C2986535;C4019010
1294,secondary endpoints :,C4528314
1294,key secondary end point : st,C0036056;C3272372;C4528314
1293,time - to - first infusion,C0040223;C0205435;C0574032;C1279901;C1827465;C3541383
1293,no . of infusions,C0574032
1293,last infusion in the horizon - pft,C0024119;C0053122;C0279232;C0574032;C1517741;C1827465
1293,infusion administered — no . / total no . ( % ),C0574032;C1827465
1293,glyceryl trinitrate infusion,C0017887;C0574032;C1827465
1293,core study to first infusion,C0205435;C0444669;C0557651;C0574032;C1167518;C1279901;C1706352;C1827465;C1882467;C2603343;C3274653
1292,ontario and mcmaster universities osteoarthritis index ( womac ) can range from nmbr to nmbr for the pain subscale,C0029040
1291,time to death due to pah or hospitalization due to pah up to the end of the treatment periodd,C1301931
1291,time to all - cause death up to end of the study,C0007465;C0015127;C0040223;C1301931;C1524003;C3541383
1290,table nmbr baseline characteristics of total study sample and stratified by treatment assignment and testosterone levela,C0039224;C0168634;C0370003;C0947343;C1315074;C1442488;C1706074;C2347026;C4684572
1290,table nmbr . selected baseline characteristics of the study patients . *,C0039224;C1706074
1290,table nmbr . characteristics of the patients at baseline . *,C0039224;C0815172;C1706074
1290,table nmbr . characteristics of patients treated with losartan and atenolol *,C0039224;C0815172;C1706074
1289,alanine aminotransferase or aspartate aminotransferase > nmbrx upper limit of normal ( n = nmbr ),C0001899;C0057041;C1415274;C3887708
1289,alanine aminotransferase increased,C0001899;C0057041;C1415274;C3887708
1289,alanine aminotransferase,C0001899;C0057041;C1415274;C3887708
1288,daytime nasal symptoms score change from baseline,C0231918;C0332169
1288,baseline daytime nasal symptoms score,C0168634;C0231918;C0332169;C1442488
1287,duration of prior alendronate use,C0102118;C0332152;C1881378;C2826257;C2826775
1287,duration of previous use of vka,C0205156;C1552607;C1881378;C2826775
1287,duration of alendronate use,C0102118;C1881378;C2826775
1287,duration antiplatelet use as % of study duration ( sd ),C0557651;C1881378;C2603343;C2699239;C2826775
1286,daily dose of study medication prescribed,C0013175;C2348070
1286,daily dose of inhaled glucocorticoid — no . ( % ) §,C0004048;C0017710;C2348070
1285,residual perfusion defect > nmbr % on lung scan,C1457869;C1518040;C1609982
1284,perfusion defectsatinclusion,C0031001;C4281794
1283,stratification factors,C1514984
1283,stratification factor : menopausal status,C1513126;C1514984
1282,who / idf impaired fasting glucose,C1272092
1282,impaired fasting glucose §,C1272092
1282,impaired fasting glucose,C1272092
1282,ada impaired fasting glucose,C1060325;C1272092;C3811629
1281,impaired glucose tolerance or impaired fasting glucose — no . ( % ),C0271650
1281,impaired glucose tolerance or impaired fasting glucose,C0271650
1281,both impaired glucose tolerance and impaired fasting glucose tolerance — no .,C0271650
1280,fluvastatin ( n = nmbr ),C0082608
1280,clow - potency stratum : simvastatin nmbrmg  pravastatin nmbr mg  fluvastatin nmbr mg  atorvastatin nmbr mg  high - potency stratum : simvastatin nmbr mg  atorvastatin,C0074554;C0082608;C0085542;C0205250;C0286651;C1299351;C1319635;C2700149;C2985073;C3245505;C3887512;C3889660;C4321237;C4522209
1279,the test for heterogeneity ( interaction ) indicates whether the treatment effect varied significantly among the sub - groups . the hochberg method was applied to each of the two comparisons of the treatment groups . bmi denotes body - mass index ( the weight in kilograms divided by the square of the height in meters ) .,C0019409;C0022885;C0039593;C0242960;C0392366;C0456984;C1515976;C1704675;C3831328;C4318744
1279,pvalue for heterogeneity,C0019409;C0242960
1279,pfor heterogeneity,C0019409;C0242960;C1151635
1279,p value for heterogeneity （ rosiglitazone versus metformin ）,C0019409;C0242960;C0289313;C1709380
1279,p value for heterogeneity （ rosiglitazone versus glyburide ）,C0019409;C0242960;C0289313;C1709380
1279,p value for heterogeneity,C0019409;C0242960;C1709380
1279,heterogeneity test,C0019409;C0022885;C0039593;C0242960;C0392366;C0456984;C1515976;C3831328;C4318744
1279,heterogeneity or trend p value,C0019409;C0242960
1279,heterogeneity or trend p vaiue,C0019409;C0242960
1279,heterogeneity / trend test,C0019409;C0022885;C0039593;C0242960;C0392366;C0456984;C1515976;C1521798;C3831328;C4318744;C4554533
1278,sensitive responders ( n = nmbr ),C0020517;C0332324;C1522640
1278,sensitive responder ( n = nmbr ),C0020517;C0332324;C1522640
1278,sensitive,C0020517;C0332324;C1522640
1278,hypersensitivity,C0020517;C0520946
1278,allergic disease by historyb,C0020517;C0851444
1277,steroid - sparing remission *,C0038317;C0544452;C0687702
1277,steroid - free remission,C0038317;C0332296;C0544452;C0687702;C1880497;C1996904
1277,remission component of variable,C0439828;C0449432;C0544452;C0687702;C1705248;C4553760
1277,remission,C0544452;C0687702
1277,dasnmbr - esr remission,C0051767;C0057671;C0544452;C0687702;C3811131
1277,asdas inactive disease,C0544452
1276,estrogens,C0014939;C3537250;C3541386;C3714615
1275,no estrogen,C0014939;C2936882;C4542544
1275,estrogen supplementation -,C0014939;C0242297;C2936882;C4542544
1275,estrogen supplementation,C0014939;C0242297;C2936882;C4542544
1275,estrogen ( ' % ? ),C0014939;C2936882;C4542544
1275,estrogen,C0014939;C2936882;C4542544
1274,tophi present,C0221248
1274,presence of tophi,C0150312;C0221248;C0392148;C3854307
1274,history / presence of tophi,C0019664;C0019665;C0150312;C0221248;C0262512;C0262926;C0392148;C1705255;C2004062;C3854307
1273,prior mi diagnosis :,C0332132;C3810814
1273,prior diagnosis - no . ( % ),C0332132
1273,previous diagnosis,C0332132
1273,no previous diagnosis of diabetes mellitus,C0011849;C0332132
1272,type of insulin,C0457592
1272,type of basal insulin,C0205112;C0332307;C0457592;C0650607;C1547052
1272,insulin type,C0457592
1271,temporary discontinuation of study drug,C0013175;C0205374;C0457454;C1444662;C1548539;C3245481;C4552847
1271,premature treatment discontinuation,C0039798;C0087111;C0151526;C0205252;C0457454;C1444662;C1522326;C1533734;C1705169;C3538994;C3887704;C4018905;C4552847
1271,premature discontinuation,C0151526;C0205252;C0457454;C1444662;C4018905;C4552847
1271,drug discontinuation not due to death,C0013227;C0457454;C1254351;C1444662;C4552847
1271,discontinued,C1444662
1271,discontinuation of lama prior to baseline,C0457454;C0999593;C1416775;C1444662;C4552847
1271,discontinuation of ics / laba prior to baseline,C0457454;C0815320;C1444662;C4551720;C4552847
1270,discontinuations teaes,C0457454
1270,discontinuations due to ae,C0457454;C0678226;C3887670
1270,discontinuations,C0457454
1269,american ‐ indian / alaska native,C0002460
1269,american indian or native alaskan,C0002460
1269,american indian or alaskan native,C0002460
1269,american indian or alaskan,C0002460
1269,"american indian or alaska native "" :",C0002460
1269,american indian or alaska native,C0002460
1269,american indian or alaska,C0002460
1269,american indian or,C0002460
1269,american indian / native alaskan,C0002460;C0682125
1269,american indian / alaskan native,C0002460;C0238611
1269,american indian / alaska native,C0002460
1269,american indian /,C0002460
1269,american indian,C0002460
1268,allergic rhinitis — no . ( % ),C1334103;C2607914;C4552864
1268,allergic rhinitis duration,C0449238;C1334103;C2607914;C2926735;C4552864
1268,allergic rhinitis,C1334103;C2607914;C4552864
1267,electrocardiographic findings — no . ( % ),C0438154
1267,electrocardiographic findings at randomization,C0034656;C0438154
1267,ecg findings,C0438154
1266,catecholamines or corticosteroids without hospitalization,C0007412
1265,type of hospitalization,C3177060
1264,required hospitalization,C1708385
1263,community hospital ( % ),C0020003
1263,community hospital,C0020003
1262,total mortality all,C0026565;C0026566;C0439175;C0439810
1262,total mortality,C0026565;C0026566;C0439175;C0439810
1262,shfm annual mortality,C0026565;C0026566;C0332181
1262,overall mortality,C0026565;C0026566;C0282416;C1561607
1262,non cv mortality,C0026565;C0026566;C1518422;C3538987;C4048877;C4318503
1262,non - cv mortality,C0026565;C0026566;C1518422;C3538987;C4048877;C4318503
1262,mortality outcomes,C0026565;C0026566;C1274040
1262,mortality,C0026565;C0026566
1262,cv mortality,C0026565;C0026566;C3538987;C4048877;C4318503
1262,all - causa mortality,C0026565;C0026566;C3903827
1261,ended > nmbr days before trial entry,C0008976;C0439228;C1272693;C1705654;C2746065
1261,end of trial,C0008976;C0444930;C2746065
1261,dual iv - end of trial hbanmbrc,C0008976;C0019016;C0205173;C0444930;C0444972;C1554184;C1825777;C2746065;C3538758
1261,dual ii - end of trial hbanmbrc,C0008976;C0019016;C0205173;C0444930;C0444967;C1554184;C1825777;C2746065;C3538758
1261,dual i extension - end of trial hbanmbrc,C0008976;C0019016;C0021966;C0205173;C0221138;C0231448;C0444930;C1554184;C1825777;C1880641;C2746065;C3538758
1260,trial nmbr,C0008976
1260,trial,C0008976
1260,cure trial,C0008976;C1880198
1260,completed trial,C0008976;C0205197;C3854010
1260,combined trials,C0008976;C0205195
1260,all trials,C0008976
1259,trial completers,C0008976
1259,global trial population,C0008976;C0032659;C0205246;C1257890;C2348867
1258,iv inotropic drug,C1971835
1257,inotropic agent,C0304509
1256,tiotropium + olodaterol nmbr / nmbr pg,C0030827;C0072225;C1266240;C4032878
1256,tiotropium + olodaterol nmbr / nmbr,C4032878
1256,tiotropium + olodaterol nmbr . nmbr / nmbr pg,C0030827;C0072225;C1266240;C4032878
1255,tnl ultrapositive > nmbr . nmbr pg / l,C0439278;C1540071
1254,tni ultrapositive ≥ nmbr . nmbr µ g / l,C0077401;C0439294;C0456615
1254,tni ultrapositive,C0077401
1253,proportions,C1709707
1253,proportion taking pulmonary medications ( % ) b,C1709707
1253,proportion,C1709707
1253,mean proportion ( % ),C0444504;C1709707;C2347634;C2348143
1253,fvc ( l ) proportion taking pulmonary medications ( % ) b,C1709707;C3714541
1253,blood eosinophil proportion ( % ),C0014467;C1709707
1252,tcomparison of proportion of patients with nyha class lll / iv heart failure .,C0030705;C1709707
1252,proportion of responders n / n ( % ),C1709707
1252,proportion of patients with trough fevi > nmbr ml above baseline,C0030705;C1709707
1252,proportion of patients who achieved acrnmbr n / n ( % ),C0030705;C1709707
1252,proportion of patients in corticosteroid - free clinical remission at week nmbr,C0030705;C1709707
1252,proportion of days without heartburn at week nmbr,C0439228;C1709707
1252,proportion of angioedema - free days from week nmbr to week nmbrx,C0002994;C0332296;C0439228;C1709707;C1880497;C1996904
1251,with tiotropium,C0213771
1251,placebo tiotropium n = nmbr non - tiotropium n = nmbr,C0032042;C0213771;C1518422;C1696465;C1706408
1251,non - tiotropium,C0213771;C1518422
1251,laba plus ics ( tiotropium n = nmbr,C0213771;C0332287;C0815320;C4551720
1251,ics ( tiotropium n = nmbr,C0213771;C0815320;C4551720
1251,formoterol tiotropium n = nmbr non - tiotropium n = nmbr,C0060657;C0213771;C1518422
1251,( tiotropium n = nmbr non - tiotropium n = nmbr nmbr,C0213771;C1518422
1251,( tiotropium n = nmbr non - tiotropium n = nmbr ),C0213771;C1518422
1251,( tiotropium n = nmbr,C0213771
1250,indacaterol + tiotropium ( n[nmbr ),C0213771;C1722260
1250,differences between indacaterol + tiotropium versus tiotropium + placebo,C0213771;C1705241;C1705242;C1722260
1249,tiotropium vs . salmeterol,C0213771
1249,tiotropium nmbr   μ g ( n   =   nmbr ),C0213771;C0439267
1249,tiotropium nmbr pg,C0030827;C0072225;C0213771;C1266240
1249,tiotropium nmbr meg ( n = nmbr ),C0024489;C0025175;C0072225;C0213771
1249,tiotropium nmbr m g,C0213771;C0456715
1249,tiotropium nmbr gg qd,C0017454;C0018370;C0213771;C0332173
1249,tiotropium nmbr . nmbr μ g ( n   = nmbr ),C0213771;C0439267
1249,tiotropium nmbr . nmbr   μ g ( n   =   nmbr ),C0213771;C0439267
1249,tiotropium nmbr . nmbr pg,C0030827;C0072225;C0213771;C1266240
1249,tiotropium group ( n = nmbr ),C0213771;C0441848
1249,tiotropium ( nznmbr ),C0027978;C0213771
1249,tiotropium ( n z nmbr ),C0213771
1249,tiotropium ( n = nmbr ),C0213771
1249,tiotropium,C0213771
1248,tiotropium salmeterol no . of patients / total no .,C0073992;C0213771
1248,tiotropium + placebo ( n[nmbr ),C0032042;C0213771;C1696465;C1706408
1248,tiotropium + placeb ( n[nmbr ),C0213771
1248,laba ( tiotropium n = nmbr  placebo n = nmbr ),C0032042;C0213771;C1696465;C1706408
1248,( tiotropium n = nmbr  placebo n =,C0032042;C0213771;C1696465;C1706408
1247,uncontrolled on oad ( s ),C0205318
1247,uncontrolled on basal insulin,C0205318;C0650607
1247,uncontrolled : acq - nmbr > nmbr . nmbr,C0205318;C2919686
1247,uncontrolled,C0205318
1246,contrast volume > nmbr ml,C0009924;C0439526;C0449468;C1690016;C1705102;C1705224;C1979874;C2700258;C3887665
1246,contrast volume > nmbr ( ml ),C0009924;C0439526;C0449468;C1690016;C1705102;C1705224;C1979874;C2700258;C3887665
1246,contrast volume ( ml ),C0009924;C0439526;C0449468;C1690016;C1705102;C1705224;C1979874;C2700258;C3887665
1246,contrast volume,C0009924;C0449468;C1690016;C1705102;C1979874;C2700258
1246,contrast used ( ml ) *,C0009924;C1979874
1245,two or more at baseline,C0205448
1245,two or more antihypertensive medications,C0205448
1245,two of the above,C0205448
1245,ast > nmbrx uln on two consecutive visits,C0205448;C0545082;C1415181;C1512346;C1519815;C1707491;C3891303
1245,alt > nmbrx uln on two consecutive visits,C0205448;C0545082;C1266129;C1512346;C1519815;C1707491;C4553172
1244,two or more,C0205448
1244,two arm,C0205448;C0446516;C3715044;C4553528
1243,worsened,C1457868;C4084902
1243,significant worsening in kccq clinical score ( ≥ nmbr ) at nmbr mo †,C0332271;C0449820;C1457868;C1546960;C2826293;C3476798;C4050231
1243,significant worsening in kccq clinical score ( > nmbr ) at nmbr monthsnmbr,C0332271;C0449820;C1457868;C1546960;C2826293;C3476798;C4050231
1243,significant worsening in kccq clinical,C0237881;C0332271;C0750502;C1457868;C1546944;C1546960;C3476798
1243,no worsening in pga,C0016410;C0332271;C1457868;C1546960;C3541266;C4050369
1242,no . in the nmbr mo before screening,C0026544;C0220908;C0220909;C0332177;C1698960;C1710031;C1710032;C1710477;C2348164
1242,nmbrmo,C0026544;C0332177
1242,nmbr to < nmbr mo,C0026544;C0332177
1242,nmbr mo - nmbr y,C0026544;C0332177
1242,nmbr mo,C0026544;C0332177
1242,nmbr - nmbr mo,C0026544;C0332177
1242,nmbr - < nmbrmo,C0026544;C0332177
1242,fall in last nmbr mo,C0026544;C0085639;C0238715;C0332177;C4553726
1242,at least nmbr / mo,C0026544;C0332177
1242,antiplatelet within nmbr mo before randomization,C0026544;C0332177
1242,> nmbr mo,C0026544;C0332177
1242,< nmbrmo,C0026544;C0332177
1242,< nmbr mo,C0026544;C0332177
1241,serum ua < nmbrmg / dl by month nmbr,C0041580;C0042014;C0229671;C0332177;C0439231;C0439269;C1546774;C1550100
1241,nmbr month l,C0332177;C0439231
1241,monthnmbr,C0332177;C0439231
1241,monthly,C0332177
1241,month nmbr,C0332177;C0439231
1241,fpg month nmbr ( mg / dl ),C0332177;C0439231;C0439269
1241,ccsc at nmbr month before enrollment,C0332177;C0439231;C1516705
1240,tnf antagonist - naive ®,C0231491;C1448177
1240,tnf antagonist - naive subgroup ( n - nmbr ),C0231491;C1079230;C1448177;C1515021
1240,tnf antagonist - naive ' ’,C0231491;C1448177
1240,tnf antagonist - exposed,C0231491;C1448177
1240,tnf antagonist,C0231491;C1448177
1240,prior tnf antagonist treatment - yes,C0231491;C1448177;C1514463;C1549445;C1705108;C1710701
1240,prior tnf antagonist treatment - no,C0231491;C1448177;C1514463
1240,prior tnf antagonist,C0231491;C0332152;C1448177;C2826257
1240,prior therapy with tnf antagonist,C0231491;C0279936;C0332152;C1448177;C1514463;C2826257
1239,anti ‐ tnf ‐ na ï ve,C0042469;C0597484;C1272460;C1448177;C1546968;C1879645;C3714652;C4049872;C4321495;C4552882
1239,anti - tnf ir,C0022065;C0022071;C1448132;C1448177
1239,anti - tnf - naive,C1448177
1239,anti - tnf,C1448177
1238,type of tnf antagonist failure,C0231174;C0231491;C0332307;C0680095;C1448177;C1547052
1238,tnf antagonist - failure population ( n - nmbr ),C0032659;C0231174;C0231491;C0680095;C1257890;C1448177
1238,tnf - naivea,C1448177
1238,tnf - naive patientsa,C1448177
1238,tnf - failurea,C1448177
1238,tnf - failure patientsa,C0231174;C0680095;C1448177
1238,prior tnf antagonist failure - yes,C0231174;C0231491;C0332152;C0680095;C1448177;C1549445;C1705108;C1710701;C2826257
1238,prior tnf antagonist failure - no,C0231174;C0231491;C0332152;C0680095;C1448177;C2826257
1238,prior tnf antagonist failure,C0231174;C0231491;C0332152;C0680095;C1448177;C2826257
1238,prior anti - tnf treatment,C1448177;C1514463
1238,nmbr prior tnf antagonist failures,C0231174;C0231491;C0332152;C0680095;C1448177;C2826257
1238,nmbr prior tnf antagonist failure,C0231174;C0231491;C0332152;C0680095;C1448177;C2826257
1238,any prior anti - tnf treatment failure,C0162643;C0231174;C0235828;C0332152;C0521983;C0680095;C1448177;C1514463;C1547544;C2826257
1237,therapy - fatigue ( facit - f,C0015672;C0039798;C0087111;C1363945;C3272505;C3463815;C4050243;C4554645
1237,question nmbr ( fatigue / tiredness ),C0015672;C1522634;C3463815;C4050243;C4553152;C4554645
1237,fatigue ( range nmbr - nmbr ),C0015672;C1514721;C2348147;C3463815;C3542016;C4050243;C4554645
1237,fatigue,C0015672;C3463815;C4050243;C4554645
1237,facit - fatigue . mean nmbrsd ( range nmbr - nmbr ),C0015672;C0444504;C1514721;C2347634;C2348143;C2348147;C2699239;C3463815;C3476791;C3542016;C4050243;C4554645
1237,energy / fatigue,C0015672;C0424589;C0542479;C1442080;C3463815;C4050243;C4330907;C4554645
1236,africa or near east,C0001737
1236,africa *,C0001737
1236,africa ! near east,C0001737;C1707877
1236,africa,C0001737
1235,african descent,C0027567
1235,african,C0027567
1234,atypical absence,C0595948
1233,surgical technique,C0683469
1232,unrelated to effectiveness,C0445356;C1280519;C1704623;C4553491
1231,primary / key efficacy endpoint,C1280519;C1707887;C1709665;C2349179;C2826544
1231,peripheral limb vascular efficacy,C0015385;C0150936;C0947487;C1280519;C1707887
1231,overall efficacy,C0282416;C1280519;C1561607;C1707887
1231,efficacy parameter,C0549193;C1280519;C1704769;C1707887;C2350001
1231,efficacy measures,C1280519;C1707887
1231,efficacy endpoints *,C1280519;C1707887;C2349179
1231,efficacy endpoint,C1280519;C1707887;C2349179;C2826544
1231,efficacy end points,C1280519;C1707887;C2349179
1231,efficacy and safety : net adverse clinical events *,C1280519;C1707887
1231,efficacy,C1280519;C1707887
1230,prior electrical cardioversion for af ( n = nmbr nmbr ),C0013778;C0332152;C0344434;C0542380;C2826257;C4049859
1230,prior af ablation,C0332152;C0344434;C0547070;C1261381;C2826257;C4049859
1230,af pattern,C0344434;C0449774;C4049859
1230,af or atrial flutter 卞,C0344434;C4049859
1230,af or atrial flutter !,C0344434;C4049859
1230,af alone refers to atrial fi - brillation without coexisting cardiovascular conditions but with left atrial dilatation . ace denotes angiotensin - con - verting enzyme,C0344434;C4049859
1230,af alone,C0344434;C4049859
1230,af,C0344434;C4049859
1229,type of atrial fibrillation — no . / total no . ( % ),C0004238;C0332307;C0344434;C1547052;C1963067
1229,type of atrial fibrillation - n ( % ),C0004238;C0332307;C0344434;C1547052;C1963067
1229,type of atrial fibrillation ( n = nmbr nmbr ),C0004238;C0332307;C0344434;C1547052;C1963067
1229,type of atrial fibrillation ( % ),C0004238;C0332307;C0344434;C1547052;C1963067
1229,type of atrial fibrillation,C0004238;C0332307;C0344434;C1547052;C1963067
1229,symptoms of atrial fibrillation in the nmbr months before randomization — no . ( % ),C0004238;C0344434;C0683368;C1457887;C1963067
1229,symptoms of atrial fibrillation in the nmbr months before randomiza -,C0004238;C0344434;C0683368;C1457887;C1963067
1229,rate of atrial fibrillation,C0004238;C0344434;C0871208;C1521828;C1963067
1229,no atrial fibrillation,C0004238;C0344434;C1963067
1229,first episode of atrial fibrillation ( vs . recurrent episode ) — no . ( % ) f,C0004238;C0205435;C0332189;C0344434;C1279901;C1963067
1229,ecg atrial fibrillation,C0004238;C0344434;C1623258;C1963067
1229,duration of qualifying atrial fibrillation » nmbr days — no . ( % ),C0004238;C0344434;C0439228;C0449238;C1514624;C1963067;C2926735
1229,duration of last qualifying episode of atrial fibrillation > nmbr days,C0004238;C0332189;C0344434;C0439228;C0449238;C1514624;C1963067;C2926735
1229,current atrial fibrillation or flutter on ecg,C0004238;C0344434;C0521116;C1705970;C1963067
1229,atrial fibrillation — no . / total no . ( % ),C0004238;C0344434;C1963067
1229,atrial fibrillation — no . ( % ),C0004238;C0344434;C1963067
1229,atrial fibrillation type,C0004238;C0332307;C0344434;C1547052;C1963067
1229,atrial fibrillation pattern,C0004238;C0344434;C0449774;C1963067
1229,atrial fibrillation or flutter — no . ( % ),C0004238;C0344434;C1963067
1229,atrial fibrillation or flutter ( ecg ) §,C0004238;C0344434;C1963067
1229,atrial fibrillation or flutter,C0004238;C0344434;C1963067
1229,atrial fibrillation onset,C0004238;C0206132;C0332162;C0344434;C1963067
1229,atrial fibrillation alone ) ,C0004238;C0344434;C1963067
1229,atrial fibrillation . no . ( % ),C0004238;C0344434;C1963067
1229,atrial fibrillation ( % ),C0004238;C0344434;C1963067
1229,atrial fibrillation !,C0004238;C0344434;C1963067
1229,atrial fibrillation,C0004238;C0344434;C1963067
1229,> nmbr episodes of atrial fibrillation in previous nmbr mo,C0004238;C0332189;C0344434;C1963067
1228,non - cvd mortality,C0007222;C0026565;C0026566;C1518422
1228,cvd or mi,C0007222
1228,cvd mortality,C0007222;C0026565;C0026566
1227,cvd subjects,C0007222
1227,cvd deaths,C0007222;C0011065;C1306577
1227,cvd death,C0007222;C0011065;C1306577;C4082313;C4552775
1226,no cardiovascular disease ( n = nmbr ),C0007222
1226,medical history of cv disease or heart failure,C0007222;C0262926
1226,cardiovascular disease n ( % ),C0007222
1226,cardiovascular disease history ‡,C0007222;C0007226;C0012634;C0019664;C0019665;C0262512;C0262926;C0683519;C1705255;C1880008;C2004062;C3887460
1226,cardiovascular disease history,C0007222;C0007226;C0012634;C0019664;C0019665;C0262512;C0262926;C0683519;C1705255;C1880008;C2004062;C3887460
1226,cardiovascular disease ( n = nmbr ),C0007222
1226,any cardiovascular disease history,C0007222;C0007226;C0012634;C0019664;C0019665;C0262512;C0262926;C0683519;C1705255;C1880008;C2004062;C3887460
1225,no cvd,C0007222
1225,cvd,C0007222
1225,combined nmbr - year cvd,C0007222;C0205195;C0439234;C0439508
1225,combined cvd,C0007222;C0205195
1225,chronic cvd,C0007222;C0205191
1224,prior cvd,C0007222;C0332152;C2826257
1224,prior cardiovascular disease,C0007222;C0332152;C2826257
1224,no prior cvd,C0007222;C0332152;C2826257
1224,no cardiovascular disordernmbr ',C0007222
1224,cardiovascular disorder,C0007222
1224,cardiovascular disease *,C0007222
1224,cardiovascular disease,C0007222
1224,any cardiovascular disease,C0007222
1223,primary ep ( cvd / mi / ri ),C0007222;C0035487;C0205225;C0439612;C0439631;C1826843;C1880476;C3810814;C4321526
1223,nmbr - nmbr with cv disease ( n = nmbr ),C0007222
1223,cvd without mi or stroke ( n = nmbr ),C0007222;C3810814
1223,cvd / mi / stroke / urgent vascular hospitalization,C0007222;C3810814
1223,cvd / mi / stroke / urgent coronary revascularization,C0007222;C3810814
1223,cvd / mi / stroke / revascularization / urgent vascular hospitalization,C0005847;C0007222;C0019993;C0038454;C0439609;C0581603;C1558950;C1801960;C3272275;C3810814;C4554100
1223,cvd / mi / stroke,C0007222;C0038454;C3810814;C4554100
1223,cv disease,C0007222
1222,cvd without ml^troke,C0007222;C0439526;C1705224;C3887665
1222,cvd without ml / stroke,C0007222;C0038454;C0439526;C1705224;C3887665;C4554100
1222,cvd without miatroke,C0007222
1221,py = nmbr . nmbr ),C0030428;C3538810
1221,py = nmbr ),C0030428;C3538810
1221,py *,C0030428;C3538810
1221,pa,C0030428;C3541314
1221,no pa,C0030428;C3541314
1221,nmbr . nmbr per nmbr py,C0030428;C3538810
1220,vdz / pla n = nmbr,C0456170
1220,pla « = nmbr,C0456170
1220,pla n = nmbr,C0456170
1220,pla,C0456170
1220,atio - pla,C0456170
1219,pv,C0030840;C0032463
1218,pav,C0058890
1217,standard bp lowering,C0037623;C0441994;C1415692;C1442989;C1708288;C2003888;C2828392;C4318478
1217,patientswith bp $ nmbr / nmbr mmhg ( abpm ) at baseline,C0037623;C0168634;C0439475;C1415692;C1442488;C1708288;C4318478
1217,patientswith bp,C0037623;C1415692;C1708288;C4318478
1217,patients with bp $ nmbr / nmbr mmhg ( abpm ) at baseline,C0030705;C0037623;C0439475;C1415692;C1708288;C4318478
1217,other bp drug,C0013227;C0037623;C1254351;C1415692;C1708288;C4318478
1217,key : fc = fasting glucose  bp = * this category did not include ar have nmbr of the indicated charac,C0015663;C0017725;C0037623;C1415692;C1708288;C2983605;C4318478
1217,hypertension ( bp > nmbr / nmbr mmhg or using antihypertensive medication ),C0020538;C0037623;C0439475;C1415692;C1708288;C1963138;C4318478
1217,bp variable,C0037623;C0439828;C1415692;C1708288;C4318478;C4553760
1217,bp in pre - treated patients,C0037623;C1415692;C1708288;C4318478
1217,bp goal attainment,C0037623;C0680230;C1415692;C1708288;C4318478
1217,bp goal at week nmbr,C0018017;C0037623;C0332174;C0439230;C1415692;C1571704;C1708288;C4318478
1217,bp and fasting glucose results,C0037623;C1415692;C1708288;C4318478
1217,bp < nmbr / nmbr,C0037623;C1415692;C1708288;C4318478
1217,bp - lowering treatments,C0037623;C0087111;C0441994;C1415692;C1708288;C2003888;C4318478
1217,bp - lowering treatment ( n = nmbr ),C0037623;C0039798;C0087111;C0441994;C1415692;C1522326;C1533734;C1705169;C1708288;C2003888;C3538994;C3887704;C4318478
1217, abbreviations : bp  blood pressure  dbp  diastolic blood pressure  dm  diabetes mellitus  ldl - c  low - density lipoprotein cholesterol  ncep atp iii  national cholesterol education program – adult treatment panel iii  or  odds ratio  sbp  systolic blood pressure,C0002680;C0006938;C0037623;C1415692;C1708288;C3887950;C4050020;C4318478
1216,chest discomfort,C0235710
1215,lipid disorder,C0154251
1214,liver disorder,C0023895
1214,hepatic disorders,C0023895
1213,卞 at discharge .,C0012621;C0030685;C2926602
1213,thienopyridine at discharge,C0012621;C0030685;C1120149;C2926602
1213,therapy at discharge,C0012621;C0030685;C0039798;C0087111;C1363945;C2926602
1212,sf - nmbrvnmbr domain scores,C0037712;C1880389;C1883221;C3541951
1212,os domain,C0229090;C0230028;C0262950;C0393706;C1561953;C1880389;C1883221;C3541951
1212,iief - ef domain score,C0449820;C1880389;C1883221;C3541951;C3641331;C4050231
1212,ibdq domain scores,C1880389;C1883221;C3541951
1212,ef domain,C1880389;C1883221;C3541951
1211,history of peripheral vascular disease,C1881056
1210,history of cerebrovascular disease — no . { % ),C0585890
1210,history of cerebrovascular disease,C0585890
1209,prior history of cardiovascular disease,C0332152;C0455539;C2826257
1209,history of cardiovascular disease — no . { % ),C0455539
1209,history of cardiovascular disease — no . ( % ) ^ |,C0455539
1209,history of cardiovascular disease — no . ( % ),C0455539
1209,history of cardiovascular disease,C0455539
1208,atherosclerotic vascular disease — no .,C0004153
1208,atherosclerotic vascular disease history †,C0004153;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
1208,atherosclerotic vascular disease history,C0004153;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
1208,atherosclerotic vascular disease,C0004153
1208,atherosclerotic cardiovascular disease *,C0004153
1208,atherosclerotic cardiovascular disease,C0004153
1207,microvascular disease history,C0443258;C0683519
1207,disease history,C0683519
1207,cv disease history,C0007222;C0019664;C0019665;C0262512;C0262926;C0683519;C1705255;C2004062;C3538987;C4048877;C4318503
1206,ccv history / condition at baseline,C0168634;C0683519;C1442488
1206,ccv history / condition,C0683519
1205,patient history of disease n ( % ),C0030705;C0683519;C0730226;C0850708;C0944983
1205,patient history of disease,C0030705;C0683519;C0730226;C0850708;C0944983
1205,history of thyroid disease,C0040132;C0683519;C0730226;C0850708;C0944983;C3540038
1205,history of peripheral artery disease — no . { % ),C0489868;C0683519;C0730226;C0850708;C0944983
1205,history of peripheral artery disease,C0489868;C0683519;C0730226;C0850708;C0944983
1205,history of peripheral arterial disease ( % ),C0003842;C0205100;C0221464;C0683519;C0730226;C0850708;C0944983
1205,history of peripheral arterial disease,C0003842;C0205100;C0221464;C0683519;C0730226;C0850708;C0944983
1205,history of microvascular eye disease 本,C0015392;C0015397;C0019664;C0019665;C0262512;C0262926;C0443258;C0683519;C0700042;C0730226;C0850708;C0944983;C1705255;C2004062
1205,history of microvascular disease — no . ( % ),C0443258;C0683519;C0730226;C0850708;C0944983
1205,history of microvascular disease ( % ),C0443258;C0683519;C0730226;C0850708;C0944983
1205,history of microvascular disease,C0443258;C0683519;C0730226;C0850708;C0944983
1205,history of major microvascular disease — no . ( % ),C0205082;C0205164;C0443258;C0683519;C0730226;C0850708;C0944983;C4318856;C4521762
1205,history of major macrovascular disease — no . ( % ),C0205082;C0205164;C0683519;C0730226;C0850708;C0944983;C4318856;C4521762
1205,history of macrovascular disease at baseline,C0683519;C0730226;C0850708;C0944983
1205,history of macrovascular disease ( % ),C0683519;C0730226;C0850708;C0944983
1205,history of macrovascular disease,C0683519;C0730226;C0850708;C0944983
1205,history of ischemic heart disease — no . ( % ),C0018787;C0475224;C0683519;C0730226;C0850708;C0944983
1205,history of fistullzing disease,C0683519;C0730226;C0850708;C0944983
1205,history of fistulizing disease,C0683519;C0730226;C0850708;C0944983
1205,history of fistulising disease,C0683519;C0730226;C0850708;C0944983
1205,history of disease refractory to treatment with tnf antagonist — no . ( % ),C0683519;C0730226;C0850708;C0944983
1205,history of cv disease,C0683519;C0730226;C0850708;C0944983;C3538987;C4048877;C4318503
1205,history of coronary heart disease at,C0018787;C0683519;C0730226;C0850708;C0944983
1205,history of coronary heart disease,C0018787;C0683519;C0730226;C0850708;C0944983
1205,history of coronary arteiy disease,C0018787;C0683519;C0730226;C0850708;C0944983
1205,history of carotid disease - n ( % ),C0683519;C0730226;C0741968;C0850708;C0944983
1205,history of atherosclerotic vascular disease — no . ( % ) §,C0005847;C0333482;C0683519;C0730226;C0850708;C0944983;C1558950;C1801960
1205,baseline history of vascular disease ( % ),C0005847;C0168634;C0683519;C0730226;C0850708;C0944983;C1442488;C1558950;C1801960
1204,totalhdl cholesterol ratio,C0008377;C0456603;C1547037
1204,total cholesterohhdl cholesterol ratio,C0201950;C0456603;C0543421;C1547037
1204,ratio of women to men — %,C0043210;C0456603;C1547037
1204,ratio of urinary albumin ( mg ) to creatinine ( g ) median,C0024671;C0026410;C0439269;C0456603;C1547037;C1960952;C2346927;C2362049;C4321396;C4521761
1204,ratio of urinary albumin ( mg ) to creatinine ( g ),C0024671;C0026410;C0439269;C0456603;C1547037;C1960952;C2346927;C2362049;C4321396;C4521761
1204,ratio of ldl to hdl cholesterol,C0456603;C1547037
1204,ratio of ldl to hdl,C0456603;C1547037
1204,ratio of hrs ( nmbr % cl ),C0456603;C0596019;C1547037;C1568891
1204,ratio,C0456603;C1547037
1204,rate ratio { nmbr % cl ),C0456603;C0596019;C0871208;C1521828;C1547037
1204,rate ratio vs placebo ( nmbr % ci ),C0456603;C0871208;C1521828;C1547037
1204,rate ratio ( nmbr % cl ),C0456603;C0596019;C0871208;C1521828;C1547037
1204,rate ratio ( nmbr % ci ),C0008107;C0456603;C0871208;C1521828;C1547037;C3259781
1204,rate ratio ( lebrikizumab vs placebo,C0456603;C0871208;C1521828;C1547037;C2981360
1204,rate ratio,C0456603;C0871208;C1521828;C1547037
1204,pepsinogen i / ii ratio,C0030915;C0456603;C0523817;C1547037
1204,ldl cholesterohhdl cholesterol ratio,C0023824;C0202117;C0456603;C1547037
1204,hzard ratio,C0456603;C1547037
1204,epa / aa ratio,C0282379;C0456603;C1235746;C1547037;C1882141;C4554792
1204,e / a ratio,C0456603;C1547037
1204,creatinine — mg / dl urinary albumin - to - creatinine ratio §,C0010294;C0439269;C0456603;C1547037;C1561535;C2362049
1204,cardiothoracic ratio > nmbr . nmbr,C0456603;C1547037;C4055270
1204,cardiothoracic ratio,C0456603;C1547037;C4055270
1203,ukraine,C0041580
1203,ua ( n = nmbr ),C0041580;C0042014
1203,ua,C0041580;C0042014
1202,ta ( n = nmbr ),C0039297;C1506978;C1705538;C3272501;C4553364
1202,ta,C0039297;C1506978;C1705538;C3272501;C4553364
1201,use of concomitant lipid - modifying therapy,C0023779;C0392747;C1524063;C1707479
1201,prior lipid - modifying therapy,C0023779;C0392747;C1514463
1201,nonbiologic disease - modifying drug other than methotrexate : :,C0025677;C0392747;C4036059
1201,concomitant lipid - modifying therapy — no . { % ),C0023779;C0392747;C1707479
1200,total psa ‐ modified shs,C0392747;C2986589;C3889737
1200,modified total sharp score * *,C0392747;C1444775;C1539835;C2964552;C3889737;C3890003
1200,modified total sharp score,C0392747;C1444775;C1539835;C2964552;C3889737;C3890003
1200,modified se - adl scale,C0001288;C0036919;C0175659;C0349674;C0392747;C1420005;C1947916;C3889737
1200,modified has - bled score,C0392747;C3889737
1200,modified has - bled > nmbr,C0392747;C3889737
1200,modified has - bled < nmbr,C0392747;C3889737
1200,modified has - bled $ nmbr,C0392747;C3889737
1200,modified has - bled,C0392747;C3889737
1200,modified hachinski ischemia scale,C0022116;C0175659;C0349674;C0392747;C1947916;C3889737;C4321499
1200,modified acc or aha lesion class bnmbr or c,C0175754;C0282160;C0392747;C3541413;C3889737
1199,volume change,C0392747;C0443172;C0449468;C1690016;C1705102;C1705241;C2700258;C4319952
1199,third primary ( change in updrs score / wk,C0205225;C0205437;C0392747;C0439612;C0439631;C0443172;C1705241;C3639721;C4319952
1199,tadalafil nmbr mg mean change ( sd ),C0024671;C0026410;C0392747;C0439269;C0443172;C0444504;C1176316;C1705241;C1960952;C2346927;C2347634;C2348143;C2699239;C4319952;C4321396;C4521761
1199,systolic blood pressure ( change from baseline ),C0392747;C0443172;C1705241;C4274438;C4319952
1199,supplementary table nmbr . change from baseline in urine albumin - to - creatinine ratio by hbanmbrc at baseline in patients with normoalbuminuria microalbuminuria and macroalbuminuria .,C0039224;C0168634;C0392747;C0443172;C1442488;C1705241;C1706074;C4319952
1199,subgroup analysis : change from baseline in hbanmbrc at week nmbr per baseline hbanmbrc category,C0168634;C0392747;C0443172;C1442488;C1705241;C2986480;C4319952
1199,st change > nmbr mm,C0036056;C0392747;C0443172;C1705241;C3272372;C4319952;C4330985;C4554674
1199,secondary ( change in total updrs score from baseline to final visit in phase nmbr ),C0027627;C0175668;C0205436;C0392747;C0439175;C0439810;C0443172;C1705241;C3639721;C4319952
1199,second primary ( estimated change in total updrs score from baseline to wk nmbr ),C0205225;C0205436;C0392747;C0439175;C0439612;C0439631;C0439810;C0443172;C0457385;C0565930;C0750572;C1561503;C1705190;C1705241;C3639721;C4319952
1199,retinal severity change,C0035298;C0392747;C0439793;C0443172;C0522510;C1705241;C4319952
1199,placebo mean change ( sd ),C0032042;C0392747;C0443172;C0444504;C1696465;C1705241;C1706408;C2347634;C2348143;C2699239;C4319952
1199,percent change,C0392747;C0439165;C0443172;C1705241;C4319952
1199,pbo - adjusted ls mean change ( se ),C0023668;C0031962;C0036919;C0392747;C0443172;C0444504;C0456081;C1705241;C2347634;C2348143;C4319952
1199,pbo - adjusted ls mean change,C0023668;C0031962;C0392747;C0443172;C0444504;C0456081;C1705241;C2347634;C2348143;C4319952
1199,patients with change from baseline in total psa ‐ modified shs ≤ nmbr,C0030705;C0392747;C0443172;C1705241;C4319952
1199,patients with change from baseline in psa - modified total shs score # nmbr,C0030705;C0392747;C0443172;C1705241;C4319952
1199,nominal change,C0392747;C0443172;C1705241;C4319952
1199,no change,C0392747;C0443172;C1705241;C4319952
1199,nmbr year mean change from baseline,C0168634;C0392747;C0439234;C0439508;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C4319952
1199,median change in atheroma volume,C0264956;C0392747;C0443172;C0449468;C0549183;C0876920;C1690016;C1705102;C1705241;C2347635;C2348144;C2700258;C2939193;C4319952
1199,median change,C0392747;C0443172;C0549183;C0876920;C1705241;C2347635;C2348144;C2939193;C4319952
1199,mean change in sgrq,C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C4319952
1199,mean change in sbp from baseline,C0085805;C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C4319952
1199,mean change in fevnmbr,C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C3714541;C4319952
1199,mean change in dbp from baseline,C0392747;C0443172;C0444504;C0536221;C1705241;C2347634;C2348143;C3813197;C4281799;C4319952
1199,mean change in acq score,C0392747;C0443172;C1705241;C2919686;C3533236;C4319952
1199,mean change from baseline in the number of,C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C4319952
1199,mean change from baseline in fevnmbr % predicted,C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C4319952
1199,mean change from baseline in acq overall score ( sd ) *,C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C4319952
1199,mean change from baseline bp at week nmbr,C0168634;C0392747;C0443172;C0444504;C0488053;C1268766;C1442488;C1705241;C2347634;C2348143;C4319952
1199,mean change from baseline,C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C4319952
1199,mean change at week nmbr,C0332174;C0392747;C0439230;C0443172;C0444504;C1705241;C2347634;C2348143;C4319952
1199,mean change,C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C4319952
1199,mean % change in fn bmd,C0392747;C0443172;C0444504;C1570610;C1705241;C2347634;C2348143;C4319952
1199,lyear mean change from baseline,C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C4319952
1199,ls mean change ± sea,C0023668;C0036493;C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C4319952
1199,ls mean change from baselinenmbr,C0023668;C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C4319952
1199,ls mean change from baseline ( se ),C0023668;C0036919;C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C4319952
1199,ls mean change from baseline,C0023668;C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C4319952
1199,ls mean change ( se ),C0023668;C0036919;C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C4319952
1199,ls mean change,C0023668;C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C4319952
1199,ls mean ( s . e . ) primary endpoint : % change from baseline to week nmbr,C0023668;C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C2986535;C4319952
1199,ls mean % change from baseline _ se,C0023668;C0036919;C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C4319952
1199,hbanmbrc ( change from baseline ),C0019016;C0168634;C0392747;C0443172;C1442488;C1705241;C1825777;C3538758;C4319952
1199,fvc change,C0392747;C0443172;C1705241;C3714541;C4319952
1199,fpg change ( mg / dl ) *,C0392747;C0439269;C0443172;C1705241;C4319952
1199,first primary ( change in updrs score / wk,C0205225;C0205435;C0392747;C0439612;C0439631;C0443172;C1279901;C1705241;C3639721;C4319952
1199,fasting plasma glucose ( change from baseline ),C0168634;C0392747;C0443172;C0583513;C1442488;C1705241;C4319952
1199,dynamic measure of β - cell function ( ϕ s ) ( change from baseline ) – assessed for mmtt subset only,C0007613;C0079809;C0242485;C0392747;C0443172;C0729333;C1705241;C4319952
1199,changes in shs,C0392747;C0443172
1199,changes ( a ) in metabolic syndrome parameters hdl cholesterol,C0392747;C0443172;C1705241;C4319952
1199,changenmbr,C0392747;C0443172;C1705241;C4319952
1199,change to   week nmbr,C0332174;C0392747;C0439230;C0443172;C1705241;C4319952
1199,change to week nmbr * ’ ’,C0332174;C0392747;C0439230;C0443172;C1705241;C4319952
1199,change to week nmbr *,C0332174;C0392747;C0439230;C0443172;C1705241;C4319952
1199,change to week nmbr,C0332174;C0392747;C0439230;C0443172;C1705241;C4319952
1199,change in tg,C0337445;C0392747;C0443172;C1705241;C4319952
1199,change in tc,C0039411;C0040642;C0041405;C0041698;C0392747;C0443172;C1705241;C1824670;C3272447;C4319952;C4522122
1199,change in sesbp,C0392747;C0443172;C1705241;C4319952
1199,change in sedbp,C0392747;C0443172;C1705241;C4319952
1199,change in sbp ( nmbr months ),C0085805;C0392747;C0439231;C0443172;C1705241;C4319952
1199,change in sbp,C0085805;C0392747;C0443172;C1705241;C4319952
1199,change in retinal pathology,C0030664;C0035298;C0205469;C0392747;C0443172;C0677042;C1705241;C4319952
1199,change in psa ‐ modified shs,C0392747;C0443172;C1705241;C3810537;C3813209;C3889737;C4319952
1199,change in pav,C0058890;C0392747;C0443172;C1705241;C4319952
1199,change in nt - probnp at nmbr months ( log - transformed ),C0392747;C0443172;C0669479;C0754710;C1705241;C4319952
1199,change in nt - probnp at nmbr,C0392747;C0443172;C0669479;C0754710;C1705241;C4319952
1199,change in mtss ( mean ),C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C4319952
1199,change in lp ( a ),C0065058;C0392747;C0443172;C1439335;C1705241;C4319952;C4553379
1199,change in ldl ‐ c,C0392747;C0443172;C1705241;C4319952
1199,change in hdl ‐ c,C0392747;C0443172;C1705241;C3715113;C4319952
1199,change in hbanmbrc nmbr to month nmbr ( % ),C0019016;C0392747;C0443172;C1705241;C1825777;C3538758;C4319952
1199,change in hbalc after nmbr weeks etd ( nmbr % cl ),C0392747;C0443172;C1705241;C4319952
1199,change in haq - di ( mean ) t,C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C3826998;C4319952;C4321476
1199,change in fpg nmbr to month nmbr ( mg / dl ),C0392747;C0443172;C1705241;C4319952
1199,change in fevnmbr at week nmbr,C0392747;C0443172;C1705241;C3714541;C4319952
1199,change in femoral neck bmd from fit baseline to flex baseline,C0015815;C0392747;C0443172;C1705241;C4319952
1199,change in erosion score ( mean ),C0333307;C0392747;C0443172;C1705241;C1880549;C1959609;C3533236;C3887524;C4319952
1199,change in dasnmbr > nmbr . nmbr,C0051767;C0057671;C0392747;C0443172;C1705241;C4319952
1199,change in dasnmbr - esr ( mean ) i physical function outcomes week nmbr,C0021966;C0051767;C0057671;C0221138;C0332174;C0392747;C0439230;C0443172;C0444504;C0516981;C1274040;C1705241;C2347634;C2348143;C3811131;C4049916;C4319952
1199,change from pre - to,C0332152;C0392747;C0443172;C0740175;C1705241;C2257086;C3669034;C4319952
1199,change from baseline to week nmbr in weekly iss,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
1199,change from baseline to week nmbr in uasnmbr,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
1199,change from baseline to week nmbr in dlqi scorez,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
1199,change from baseline to week nmbr,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
1199,change from baseline to final apbm,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
1199,change from baseline to eos,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
1199,change from baseline in sgrq,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
1199,change from baseline in pre - bd,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
1199,change from baseline in post - bd,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
1199,change from baseline in morning pef during weeks nmbr - nmbr,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
1199,change from baseline in mean nmbr - h sbp,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
1199,change from baseline in mean nmbr - h dbp,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
1199,change from baseline in hbanmbrc ( % ),C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
1199,change from baseline in fevj ( mb ),C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
1199,change from baseline in dasnmbr - esr,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
1199,change from baseline in aqlq { s ) score,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
1199,change from baseline in acq - nmbr score,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
1199,change from baseline in acq - nmbr,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
1199,change from baseline in % predicted fevnmbr,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
1199,change from baseline at week nmbr,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
1199,change from baseline ( % ),C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
1199,change from,C0392747;C0443172;C1705241;C4319952
1199,change at week nmbr,C0332174;C0392747;C0439230;C0443172;C1705241;C4319952
1199,change,C0392747;C0443172;C1705241;C4319952
1199,body weight ( change from baseline ),C0005911;C0168634;C0392747;C0443172;C1303013;C1442488;C1705241;C4319952
1199,before a change to the enrollment form was implemented in august nmbr . bnp,C0348078;C0376315;C0392747;C0443172;C1516879;C1522492;C1696073;C1705241;C3888021;C4255237;C4319952
1199,at c change ( % ) *,C0392747;C0443172;C1705241;C4319952
1199,adjusted mean ± se change from baseline,C0036919;C0168634;C0392747;C0443172;C0444504;C0456081;C1442488;C1705241;C2347634;C2348143;C4319952
1199,adjusted mean change from baseline,C0168634;C0392747;C0443172;C0444504;C0456081;C1442488;C1705241;C2347634;C2348143;C4319952
1199,adjusted mean _ se change from baseline,C0036919;C0168634;C0392747;C0443172;C0444504;C0456081;C1442488;C1705241;C2347634;C2348143;C4319952
1199,adjusted change from baseline,C0168634;C0392747;C0443172;C0456081;C1442488;C1705241;C4319952
1199,( mean change,C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C4319952
1199,( mean % change,C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C4319952
1199,% change median baseline crp > nmbrmg / l,C0392747;C0443172;C1705241;C4319952
1199,% change from baseline to week nmbr,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
1199,% change from baseline ls means ( se ),C0023668;C0036919;C0168634;C0392747;C0443172;C1442488;C1704970;C1705241;C4319952
1199,% change ( median  qnmbr  qnmbr ),C0392747;C0443172;C1705241;C4319952
1199,% change ( meantse ),C0392747;C0443172;C1705241;C4319952
1199,% change ( meanlse ),C0392747;C0443172;C1705241;C4319952
1199,% change ( mean ± se ),C0036919;C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C4319952
1199,% change,C0392747;C0443172;C1705241;C4319952
1198,voiding subscore,C0042034;C4067975
1197,irritative subscore,C0441723;C1706307;C2700617
1196,storage subscore,C0337174;C1698986;C1753314
1196,ipss storage subscore,C0337174;C1019118;C1698986;C1753314;C1998280;C2827405;C3811063
1195,week nmbr mayo endoscopy subscorea,C0014245;C0332174;C0439230;C0454788;C1077578
1195,patients with evaluable endoscopy,C0014245;C2986511
1195,endoscopy subscore,C0014245
1194,stool frequency subscore,C0015733;C0183622;C0376249;C0439603;C0871396;C1561548;C1705502;C3898838;C4321352
1194,baseline focal seizure frequency / nmbr days,C0149775;C0168634;C0205234;C0376249;C0439228;C0439603;C0751495;C0871396;C1442488;C1561548;C1705502;C3898838;C4321352
1194,> nmbr % focal seizure frequency responders,C0149775;C0205234;C0376249;C0439603;C0751495;C0871396;C1561548;C1705502;C3898838;C4321352
1193,study protocol,C1507394;C2348563;C2599718
1193,original dabigatran protocol,C0205313;C0442711;C1507394;C1522729;C2347409;C2348066;C2348563;C2599718;C3715209;C4282383
1193,atv nmbr mg study protocol,C0024671;C0026410;C0210243;C0439269;C0674679;C1145759;C1334862;C1507394;C1960952;C2346927;C2348563;C2599718;C4321396;C4521761
1193,amended dabigatran protocol,C0442711;C1507394;C1522729;C1691222;C2348066;C2348563;C2599718;C3715209;C4282383
1192,use of rescue albuterol,C0001927;C1524063
1192,salbutamol,C0001927
1191,work and school,C0043227
1190,schwab & england score,C0014282
1189,womac pain score,C0582148
1189,haq pain score,C0102923;C0451208;C0582148
1188,previous labd alone,C0205156;C0396059;C1552607
1188,labd alone,C0396059
1187,syndrome,C0039082
1187,specific syndromes,C0039082;C0205369;C1552740;C1558916
1187,nonmetabolic syndrome ( n = nmbr ),C0039082
1187,cardiometabolic syndrome,C0039082
1186,metabolic syndromenmbr baseline lipids,C0023779;C0168634;C0524620;C1442488
1186,metabolic syndrome — no . ( % ) nmbr,C0524620
1186,metabolic syndrome — no . ( % ) ^,C0524620
1186,metabolic syndrome — no . ( % ) !,C0524620
1186,metabolic syndrome w / o tnmbrdm,C0011816;C0524620;C3250443
1186,metabolic syndrome visit nmbr low - density lipoprotein cholesterol strata,C0524620
1186,metabolic syndrome characteristics,C0524620;C1521970
1186,metabolic syndrome * n = nmbr,C0524620
1186,metabolic syndrome ( n = nmbr ),C0524620
1186,metabolic syndrome ( > nmbr of nmbr characteristics ),C0524620;C1521970
1186,metabolic syndrome ( % ) b,C0524620
1186,metabolic syndrome ( % ),C0524620
1185,without metabolic syndrome,C0524620
1185,with metabolic syndrome,C0524620
1185,the metabolic syndrome^,C0524620
1185,prevalence of each metabolic syndrome criterion,C0033105;C0220900;C0243161;C0524620
1185,participants without metabolic syndrome,C0524620;C0679646
1185,participants with metabolic syndrome,C0524620;C0679646
1185,no metabolic syndrome,C0524620
1185,metabolic syndromenmbr *,C0524620
1185,metabolic syndrome *,C0524620
1185,metabolic syndrome,C0524620
1184,total subjects,C0439175;C0439810;C0681850;C1550501;C1706203;C2349001;C2697811
1184,subjects with prevalent vertebral fracture,C0033105;C0080179;C0220900;C0681850;C1550501;C1706203;C2349001;C2697811
1184,subjects with imputed value for end ‐ of ‐ treatment body weight,C0681850;C1522609;C1550501;C1706203;C2349001;C2697811;C2699638
1184,subjects who did receive labd prior to the study,C0681850;C1550501;C1706203;C2349001;C2697811
1184,subjects who did not receive labd prior to the study,C0681850;C1550501;C1706203;C2349001;C2697811
1184,subjects stratified by baseline pra,C0681850;C1550501;C1706203;C2349001;C2697811
1184,subjects randomized,C0681850;C1550501;C1706203;C2349001;C2697811
1184,subjects n,C0681850;C1550501;C1706203;C2349001;C2697811
1184,subjects ( n ),C0681850;C1550501;C1706203;C2349001;C2697811
1184,subjects $ nmbr years of age,C0681850;C1550501;C1706203;C2349001;C2697811
1184,subjects,C0681850;C1550501;C1706203;C2349001;C2697811
1184,subject group,C0441833;C0681850;C0687744;C1257890;C1519504;C1550501;C1705428;C1705429;C1706203;C2349001;C2697811
1184,subject disposition,C0681850;C0743223;C1550501;C1705555;C1706203;C2349001;C2697811
1184,subject completion status,C0205197;C0449438;C0681850;C0805732;C1550501;C1554962;C1706203;C2348577;C2349001;C2697811;C3891295
1184,number of subjects in analysis,C0237753;C0449788;C0681850;C1550501;C1706203;C2349001;C2697811
1184,number of subjects,C0237753;C0449788;C0681850;C1550501;C1706203;C2349001;C2697811
1184,non - diabetic subjects,C0241863;C0681850;C1518422;C1550501;C1706203;C2349001;C2697811
1184,no . of subjects,C0681850;C1550501;C1706203;C2349001;C2697811
1184,diabetic subjects,C0241863;C0681850;C1550501;C1706203;C2349001;C2697811
1184,( nmbr subjects ),C0681850;C1550501;C1706203;C2349001;C2697811
1183,without beta blocker,C0001645
1183,with beta blocker,C0001645
1183,use of beta - blockers,C0001645;C1524063
1183,use of beta - blocker,C0001645;C1524063
1183,no beta - blocker,C0001645
1183,beta - blocker — no . / total no . ( % ),C0001645
1183,beta - blocker ( except sotalol ),C0001645;C0037707
1183,beta - adrenergic blocker,C0001645;C2757061;C3536830
1182,no betablocker use,C0001645;C0042153;C0457083;C1947944
1182,no beta - blocker use,C0001645;C0042153;C0457083;C1947944
1182,betablocker use,C0001645;C0042153;C0457083;C1947944
1182,betablocker,C0001645
1182,beta blockers,C0001645
1182,beta blocker users,C0001645;C1706077
1182,beta blocker use ( % ),C0001645;C0042153;C0457083;C1947944
1182,beta blocker use,C0001645;C0042153;C0457083;C1947944
1182,beta blocker,C0001645
1182,beta - blockers ( all ),C0001645
1182,beta - blockers,C0001645
1182,beta - blocker — no . ( % ),C0001645
1182,beta - blocker use,C0001645;C0042153;C0457083;C1947944
1182,beta - blocker n ( % ),C0001645
1182,beta - blocker !,C0001645
1182,beta - blocker,C0001645
1181,alpha nmbr blockers,C0001641
1181,alpha blockers,C0001641
1181,alpha - blockers,C0001641
1181,alpha - blocker / other vasodilator,C0001641
1181,alpha - blocker,C0001641
1180,intestinal area involved — no . ( % ),C0017446;C0021853;C0205146
1180,intestinal area involved,C0017446;C0021853;C0205146
1180,gastrointestinal area involved — no . / total no . ( % ),C0017446;C0205146;C0521362
1180,gastrointestinal area involved,C0017446;C0205146;C0521362
1180,colonic area involved,C0009368;C0017446;C0205146
1180,arterial area ( mmnmbr ),C0003842;C0017446;C0205146;C0221464;C4330985;C4554674
1180,area of retinal thickening within the grid,C0017446;C0205146;C1302690
1180,area of retinal hemorrhage within the grid,C0017446;C0035317;C0205146
1180,area of fluorescein leakage within the grid,C0017446;C0205146;C4476700
1180,area,C0017446;C0205146
1180,abbreviations : da  disc area  e - etdrs  electronic early treatment diabetic retinopathy study  iop  intraocular pressure  oct  optical coherence tomography .,C0000723;C0011318;C0011884;C0013850;C0017446;C0021888;C0180459;C0205146;C0920367;C1547561;C1556138;C1705370;C2348299;C3161471;C3668815;C4281784
1179,question nmbr ( discomfort from any areas tender to touch / pressure ),C0152054;C0205146;C0234234;C0439815;C0702221;C1522634;C2364135;C4319729
1179,areas,C0205146;C4319729
1178,vessel size,C0005847;C0456389
1178,treated vessel - native coronary,C0005847;C0018787;C0302891;C1522326
1178,treated vessel ( s ),C0005847;C1522326
1178,treated vessel !,C0005847;C1522326
1178,treated vessel,C0005847;C1522326
1178,single vessel coronary artery diseasea,C0005847;C0265903
1178,no . of vessels with > nmbr % stenosis,C0005847
1178,no . of vessels,C0005847
1178,no . of treated vessels,C0005847;C1522326
1178,nmbr vessels or left main,C0005847
1178,multi vessel ( or left main ),C0005847;C0439064;C3266262
1177,vessel treated,C0005847
1177,restenotic vessel,C0005847;C0333186
1177,one vessel,C0005847;C0205447
1177,number of vessels treated,C0005847;C0237753;C0449788
1177,number of treated vessels ( per patient ),C0005847;C0237753;C0449788;C1522326
1177,number of treated vessels,C0005847;C0237753;C0449788;C1522326
1177,number of diseased vessels,C0005847;C0237753;C0449788
1177,no . of vessels treated,C0005847
1177,nmbr vessels,C0005847
1177,nmbr vessel,C0005847
1177,> nmbr vessels treated,C0005847
1177,> nmbr lesions per vessel,C0005847;C0221198
1177,> nmbr diseased vessels,C0005847
1176,vascular territory # nmbr,C0005847;C1301808;C1558950;C1801960;C2983136
1176,vascular risk score — no . { % ) ^,C0005847;C0035647;C1558950;C1801960;C4552904
1176,vascular risk score |,C0005847;C0035647;C0449820;C1558950;C1801960;C4050231;C4552904
1176,vascular risk score *,C0005847;C0035647;C0449820;C1558950;C1801960;C4050231;C4552904
1176,vascular disordersb,C0005847;C1558950;C1801960
1176,vascular accidents,C0000924;C0005847;C1558950;C1801960
1176,vascular access site †,C0005847;C0205145;C0589360;C0750138;C1515974;C1558950;C1801960;C2825164
1176,vascular,C0005847;C1558950;C1801960
1176,urgent vascular hospitalization,C0005847;C0019993;C0439609;C1558950;C1801960;C3272275
1176,no culprit vessel identified,C0005847
1176,culprit vessel,C0005847
1176,any vascular diasease,C0005847;C1558950;C1801960
1176,any vascular *   efficacy,C0005847;C1280519;C1558950;C1707887;C1801960
1175,indacaterol nmbr ug versus placebo,C0041573;C0439211;C1722260
1175,indacaterol nmbr ug versus indacaterol nmbr ug,C0041573;C0439211;C1722260
1175,indacaterol nmbr ug ( n = nmbr ),C0041573;C0439211;C1722260
1175,indacaterol nmbr mg[n z nmbr],C0024671;C0026410;C0439269;C1722260;C1960952;C2346927;C4321396;C4521761
1175,indacaterol nmbr mg,C0024671;C0026410;C0439269;C1722260;C1960952;C2346927;C4321396;C4521761
1175,indacaterol n = nmbr,C1722260
1175,indacaterol group ( n = nmbr ),C0441848;C1722260
1175,indacaterol / glycopyrronium nmbr / nmbr   μ g o . d .,C0439417;C1722260;C3814772
1175,indacaterol - glycopyrronium group ( n = nmbr ),C0441848;C1722260;C3814772
1174,undetermined,C0205258;C3536725;C4082977
1174,indeterminate or unknown,C0205258
1174,indeterminate nfs - nmbr . nmbr < nfs < nmbr . nmbr ! n = nmbr ),C0205258;C1513839
1174,indeterminate ! !,C0205258
1173,interquartile range — yr,C0439234;C1711350
1173,interquartile range — ml / min,C0439445;C1711350
1173,interquartile range height — cm,C0489786;C1711350
1173,interquartile range,C1711350
1173,* interquartile range,C1711350
1173,( interquartile range ) ( mm ),C1711350;C4330985;C4554674
1172,interruption ( n = nmbr ),C0332453;C1512900
1172,interruption,C0332453;C1512900
1171,intermediate / long - acting + fast - acting,C0015663;C0079613;C0205103;C0205166;C0456962;C1550465;C1704930;C1706317;C1869853;C2827755;C2985769;C3889971;C3890007;C4048375
1171,intermediate - acting,C0205103;C1550465;C2827755;C3889971
1171,intermediate ( nmbr - nmbr ),C0205103;C1550465;C2827755;C3889971
1171,intermediate ( nmbr ) ( n = nmbr  nmbr  nmbr % ),C0205103;C1550465;C2827755;C3889971
1171,intermediate ( nmbr ),C0205103;C1550465;C2827755;C3889971
1171,intermediate,C0205103;C1550465;C2827755;C3889971
1171,inter p - value,C0205103;C1548610
1171,inter . p - value,C0205103;C1548610
1171,inter .,C0205103;C1548610
1170,intracerebral,C0442111
1169,intraperitoneal,C0442120
1168,intracranial,C0524466
1168,extracranial,C0580586
1167,intracranial hemorrhage †,C0151699;C4554169
1167,intracranial hemorrhage,C0151699;C4554169
1167,intracranial bleeding,C0151699
1167,intracranial bleed,C0151699
1166,intertrochanteric,C0745355
1165,trochanter,C0162370
1164,nitrates ( oral or topical ),C0028125;C0699857;C3848573
1164,nitrates ( % ),C0028125;C0699857;C3848573
1164,nitrates,C0028125;C0699857;C3848573
1164,nitrate — no . ( % ),C0028125;C0699857;C3848573
1164,nitrate use,C0028125;C0042153;C0457083;C0699857;C1947944;C3848573
1164,nitrate ( oral or topical ),C0028125;C0699857;C3848573
1164,nitrate ( oral or intravenous ),C0028125;C0699857;C3848573
1164,nitrate,C0028125;C0699857;C3848573
1163,renal subgroup,C0022646;C1079230;C1515021
1163,renal impairmentt,C0022646
1163,renal impairmentf,C0022646
1163,renal functionc,C0022646
1163,renal functionb,C0022646
1163,renal functiona,C0022646
1163,renal events,C0022646;C0441471;C3541888
1163,renal,C0022646
1162,secondary kidney composite outcome,C0022646;C0027627;C0175668;C0205199;C0205436;C0227665;C1274040;C1547335
1162,exploratory kidney and microvascular outcomes,C0022646;C0227665
1161,denosumab ( n = nmbr ) n ( % ),C1690432
1161,denosumab ( n = nmbr ),C1690432
1161,denosumab,C1690432
1160,centrilobular emphysema,C0221227
1159,centrally acting sympathomimetics,C3653511
1158,central america and south america,C0007674
1157,general health vas,C0042815;C0424575;C3536884;C3827561;C4018875
1157,general health ( self - reported ),C0424575;C4018875
1157,general health,C0424575;C4018875
1156,neuraxial anaesthesia,C0002903;C0002912;C0002930;C3714787;C4049933
1156,neuraxial alonee,C3714787
1156,central nervous system,C3540014;C3714787
1155,personal relationships,C1552027
1154,cerebral hemorrhage,C2937358
1153,cerebral embolism,C0007780
1152,cerebral thrombosis,C0079102;C0151945;C0795687
1151,penetrating no . of resections,C0205321
1151,penetrating disease,C0012634;C0205321
1151,penetrating,C0205321
1150,neoplasia,C0027651;C1882062
1150,detected during tumor evaluation,C0027651;C0220825;C0442726;C1261322;C1511790;C1578706;C3273930
1149,tenecteplase and pci ( n = nmbr ),C0872913
1149,tenecteplase,C0872913
1148,metabolism and nutrition,C0025519;C0025520
1147,metabolic syndromeb,C0311400;C1524026;C2707259
1146,mental status ( baseline spmsq scores ),C0168634;C0278060;C1442488
1146,mental status,C0278060
1145,betanmbr selective,C0330390;C0439096;C2004068
1145,beta receptor antagonist,C0330390;C0439096;C2004068;C4543207
1145,beta bloekers,C0330390;C0439096;C2004068
1144,beta - carotene ( n = nmbr,C0053396;C0696105
1144,beta - carotene,C0053396;C0696105
1143,central or south america,C0205099;C1879652
1143,central and south america and mexico,C0205099;C1879652
1143,central and south america,C0205099;C1879652
1143,central and eastern europe,C0205099;C1879652
1143,central / south america and mexico,C0007674;C0037713;C0205099;C1710133;C1879652
1143,central / south america,C0007674;C0037713;C0205099;C1710133;C1879652
1143,central / south,C0205099;C1710133;C1879652
1143,central / eastern europe and russia hr ( nmbr % cl ),C0015177;C0205099;C0682369;C1707877;C1879652
1143,central / eastern europe / russia,C0015177;C0035970;C0205099;C0682369;C1707877;C1879652
1143,central / eastern,C0205099;C1707877;C1879652
1142,centre,C0205099;C3810851
1142,center location,C0205099
1142,center level ttr,C0032923;C0205099;C0441889;C0456079;C1421224;C1547707;C2946261;C3810851
1142,center,C0205099;C3810851
1141,net ep nmbr,C1456447;C1880476;C3853572;C3887809;C3890893;C4321526
1141,net clinical benefit : cv death,C0011065;C1306577;C1456447;C3538987;C3853572;C3887809;C3890893;C4048877;C4082313;C4318503;C4552775;C4684590
1141,net clinical benefit *,C1456447;C3853572;C3887809;C3890893;C4684590
1141,net adverse clinical events at day nmbr,C0205210;C0332173;C0439228;C0439505;C0877248;C1456447;C1705413;C3853572;C3887809;C3890893
1140,stent placement,C0522776
1140,stent implanted — no . ( % ),C0522776
1140,stent implanted,C0522776
1140,number of implanted stents,C0237753;C0449788;C0522776
1139,retinopathy — no . ( % ),C0035309;C1962966
1139,retinopathy — %,C0035309;C1962966
1139,retinopathy ( stage nmbr / nmbr / nmbr / nmbr ),C0035309;C0205390;C1300072;C1306673;C1962966
1139,retinopathy,C0035309;C1962966
1138,neuropathy — no . ( % ),C0442874
1138,neuropathy,C0442874
1137,metastatic disease,C0027627;C2939419;C2939420
1136,secondary p,C0027627;C0175668;C0205436
1136,secondary outcomes,C0027627;C0175668;C0205436;C1274040
1136,secondary outcome,C0027627;C0175668;C0205436;C1274040
1136,secondary nonresponse,C0027627;C0175668;C0205436
1136,secondary ip,C0027627;C0175668;C0205436;C1308226;C4049997
1136,secondary iii *,C0027627;C0175668;C0205436;C0439070;C1705160
1136,secondary end points nmbr,C0027627;C0175668;C0205436;C2349179
1136,secondary end points iii,C0027627;C0175668;C0205436;C0439070;C1705160;C2349179
1136,secondary end points ii,C0027627;C0175668;C0205436;C1710602;C2349179;C4082587
1136,secondary end points,C0027627;C0175668;C0205436;C2349179
1136,secondary dvt . ' fe,C0027627;C0149871;C0175668;C0205436;C2926618;C3848561;C3899446
1136,secondary *,C0027627;C0175668;C0205436
1136,secondary ' outcomes,C0027627;C0175668;C0205436;C1274040
1136,secondary # nmbr,C0027627;C0175668;C0205436
1136,key secondary end points,C0027627;C0175668;C0205436;C2349179
1135,yes previous revascularization,C0205156;C0581603;C1549445;C1552607;C1705108;C1710701
1135,severe episodes in previous year — no . / patient,C0205082;C0205156;C0332189;C0439234;C0439508;C1552607;C4050465;C4050466
1135,previous warfarin use,C0042153;C0043031;C0205156;C0457083;C1552607;C1947944
1135,previous vte — no . ( % ),C0205156;C0630906;C1552607
1135,previous vte,C0205156;C0630906;C1552607
1135,previous vka use ( stratified randomization ),C0042153;C0205156;C0457083;C1552607;C1947944;C4687737
1135,previous vka use,C0042153;C0205156;C0457083;C1552607;C1947944
1135,previous venous thromboembolism — no . ( % ),C0205156;C1552607;C1861172
1135,previous use of systemic steroids for ciu / csu,C0205156;C0205373;C0281991;C1552607
1135,previous use of systemic steroids,C0205156;C0205373;C0281991;C1552607
1135,previous use of other biologic agents in addition to tne,C0005515;C0205156;C1524063;C1552607
1135,previous use of nonbiologic systemic therapy,C0205156;C1515119;C1524063;C1552607
1135,previous use of niacin or niaspan §,C0027996;C0205156;C1142562;C1524063;C1552607
1135,previous use of digoxin,C0012265;C0205156;C1524063;C1552607
1135,previous use of biologic systemic therapy,C0005515;C0005527;C0205156;C0205373;C0205460;C1515119;C1524063;C1552607
1135,previous use of antiarrhythmic drugs,C0003195;C0205156;C1524063;C1552607
1135,previous use of amiodarone,C0002598;C0205156;C1524063;C1552607
1135,previous transient ischemic attack,C0007787;C0205156;C0917805;C1552607
1135,previous transient ischaemic attack / ischaemic stroke previous warfarin use,C0007787;C0038454;C0042153;C0043031;C0205156;C0457083;C0917805;C1552607;C1947944;C4554100
1135,previous tnf antagonist exposure,C0205156;C0231491;C0274281;C0332157;C1448177;C1552607
1135,previous tnf - antagonist use,C0042153;C0205156;C0231491;C0457083;C1448177;C1552607;C1947944
1135,previous tia or stroke,C0007787;C0205156;C0917805;C1054154;C1552607
1135,previous tia,C0007787;C0205156;C0917805;C1054154;C1552607
1135,previous therapy,C0039798;C0087111;C0205156;C1363945;C1552607
1135,previous therapies,C0087111;C0205156;C1552607
1135,previous systemic treatment,C0205156;C0678812;C1552607
1135,previous stroke 一 no . ( % ),C0205156;C1552607
1135,previous stroke — no . ( % ) concomitant treatment — no . ( % ),C0205156;C1552607
1135,previous stroke — no . ( % ),C0205156;C1552607
1135,previous stroke yes ( n,C0205156;C1552607;C3841753
1135,previous stroke ortransient ischaemic attack ( % ),C0038454;C0205156;C0745413;C1552607;C4554100
1135,previous stroke ortia nmbr - nmbr,C0038454;C0205156;C1552607;C4554100
1135,previous stroke ortia,C0038454;C0205156;C1552607;C4554100
1135,previous stroke or transient ischemic attack — no . / total,C0038454;C0205156;C1552607;C4554100
1135,previous stroke or transient ischemic attack,C0038454;C0205156;C1552607;C4554100
1135,previous stroke or tl a nmbr - nmbr,C0038454;C0205156;C1552607;C4554100
1135,previous stroke or tl a,C0038454;C0205156;C1552607;C4554100
1135,previous stroke or tia ( n = nmbr ),C0038454;C0205156;C1552607;C4554100
1135,previous stroke or tia ( % ),C0038454;C0205156;C1552607;C4554100
1135,previous stroke or tia,C0038454;C0205156;C1552607;C4554100
1135,previous stroke / tia,C0007787;C0038454;C0205156;C0917805;C1054154;C1552607;C4554100
1135,previous stroke *,C0038454;C0205156;C1552607;C4554100
1135,previous stroke,C0038454;C0205156;C1552607;C4554100
1135,previous statin use,C0042153;C0205156;C0360714;C0457083;C1552607;C1947944
1135,previous segments resection ( s ) *,C0205156;C1552607;C2987624
1135,previous segmental resection — no . ( % ),C0205156;C1552607;C2987624
1135,previous revascularization,C0205156;C0581603;C1552607
1135,previous respiratory disease other than copd — no . ( % ),C0024117;C0035204;C0035242;C0205156;C1412502;C1552607;C3714496
1135,previous receipt of therapy against tnf - a — no . ( % ),C0039798;C0087111;C0205156;C1363945;C1552607
1135,previous ptca,C0205156;C1552607;C2936173
1135,previous percutaneous coronary intervention,C0205156;C1532338;C1552607
1135,previous pdenmbr - i therapy,C0021966;C0039798;C0087111;C0205156;C0221138;C1363945;C1552607
1135,previous pci or cabg,C0205156;C1552607;C4049621
1135,previous pci / cabg,C0010055;C0205156;C1552607;C4049621
1135,previous pci ( % total ),C0205156;C0439175;C0439810;C1552607;C4049621
1135,previous pci,C0205156;C1552607;C4049621
1135,previous or current use of im or cs : no,C0205156;C1552607
1135,previous or current use of im and cs : no,C0205156;C1552607
1135,previous or current im use : no,C0205156;C1552607
1135,previous or current cs use : no,C0205156;C1552607
1135,previous oad ( % ),C0205156;C1552607
1135,previous nmbrari use,C0205156;C1412533;C1552607;C4521376
1135,previous nmbr - ari use ( % ),C0205156;C1412533;C1552607;C4521376
1135,previous myocardiaunfarction,C0205156;C1552607
1135,previous myocardial infarction ( % ),C0027051;C0205156;C0428953;C1552607;C2926063;C3810814;C4552959
1135,previous myocardial infarction,C0027051;C0205156;C0428953;C1552607;C2926063;C3810814;C4552959
1135,previous ml,C0205156;C0439526;C1552607;C1705224;C3887665
1135,previous mi — no . ( % ),C0205156;C1552607;C3810814
1135,previous mi and tnmbrdm,C0205156;C1552607;C3810814
1135,previous mi ( % ),C0205156;C1552607;C3810814
1135,previous mi,C0205156;C1552607;C3810814
1135,previous metformin use,C0025598;C0042153;C0205156;C0457083;C1552607;C1947944
1135,previous medication for respiratory disease — no . ( % ),C0012634;C0013227;C0035204;C0035242;C0205156;C0418986;C1552607;C3244316;C4284232
1135,previous limb or foot amputation,C0015385;C0205156;C1552607
1135,previous lev only,C0023556;C0205156;C0205171;C1552607;C1720467
1135,previous labd only,C0205156;C0205171;C0396059;C1552607;C1720467
1135,previous ischemic stroke ortia,C0205156;C0948008;C1552607
1135,previous ischemic stroke / tia ( n = nmbr  nmbr . nmbr % ),C0007787;C0205156;C0917805;C0948008;C1054154;C1552607
1135,previous ischemic stroke,C0205156;C0948008;C1552607
1135,previous infliximab therapy — no . of patients ( % ) * *,C0205156;C1552607;C4076075
1135,previous infliximab therapy | |,C0205156;C1552607;C4076075
1135,previous infarction ( % of group ),C0021308;C0205156;C0441833;C0687744;C1257890;C1519504;C1552607;C1705428;C1705429
1135,previous infarction,C0021308;C0205156;C1552607
1135,previous ics only,C0205156;C0205171;C0815320;C1552607;C1720467;C4551720
1135,previous ics alone,C0205156;C0815320;C1552607;C4551720
1135,previous ics / labd,C0205156;C0396059;C0815320;C1552607;C4551720
1135,previous hypersensitivity reaction — no . ( % ),C0020517;C0205156;C1552607
1135,previous htn,C0020538;C0205156;C1552607
1135,previous hf,C0018488;C0205156;C1313497;C1538440;C1552607;C3273279
1135,previous heart failure — no . ( % ),C0018801;C0018802;C0205156;C1552607;C4554158
1135,previous heart failure,C0018801;C0018802;C0205156;C1552607;C4554158
1135,previous exposure to a vitamin k antagonist — no . ( % ) current or former never,C0042839;C0087161;C0205156;C0231491;C0332157;C0597277;C1552607;C1708601;C2825076;C3714656
1135,previous episode of heart failure,C0018801;C0018802;C0205156;C0332189;C1552607;C4554158
1135,previous dmards use,C0205156;C0242708;C1552607
1135,previous dmards,C0205156;C0242708;C1552607
1135,previous disease — no . ( % ) f,C0012634;C0205156;C1552607
1135,previous disease and drug use,C0012634;C0205156;C1552607
1135,previous disease :,C0012634;C0205156;C1552607
1135,previous digoxin use ( % ),C0012265;C0042153;C0205156;C0457083;C1552607;C1947944
1135,previous digoxin use,C0012265;C0042153;C0205156;C0457083;C1552607;C1947944
1135,previous diabetes mellitus,C0011849;C0205156;C1552607
1135,previous diabetes,C0011847;C0011849;C0205156;C1552607
1135,previous cvd^,C0007222;C0205156;C1552607
1135,previous coronary revascularization — no . ( % ),C0205156;C0877341;C1552607
1135,previous coronary revascularization,C0205156;C0877341;C1552607
1135,previous coronary revascularisation,C0205156;C0877341;C1552607
1135,previous congestive heart failure — no . ( % ),C0018802;C0205156;C1552607
1135,previous congestive heart failure ( % ),C0018802;C0205156;C1552607
1135,previous congestive heart failure,C0018802;C0205156;C1552607
1135,previous clinical stroke or transient ischemic attack ( % ),C0038454;C0205156;C0205210;C1552607;C4554100
1135,previous clinical stroke or tia,C0038454;C0205156;C0205210;C1552607;C4554100
1135,previous chf — no . ( % ),C0018802;C0205156;C1552607
1135,previous chf,C0018802;C0205156;C1552607
1135,previous cardiovascular disease !,C0007222;C0205156;C1552607
1135,previous cancerc,C0205156;C1552607
1135,previous cancer — no . ( % ),C0006826;C0205156;C0998265;C1306459;C1552607
1135,previous cancer,C0006826;C0205156;C0998265;C1306459;C1552607
1135,previous cabg surgery,C0010055;C0038894;C0038895;C0205156;C0543467;C1274039;C1552607
1135,previous cabg ( % total ),C0010055;C0205156;C0439175;C0439810;C1552607
1135,previous cabg,C0010055;C0205156;C1552607
1135,previous bowel resection performed — no . of patients ( % ),C0205156;C0741614;C1552607
1135,previous bdmard received,C0205156;C1552607
1135,previous antiparkinson medication,C0003405;C0205156;C1552607
1135,previous antihypertensive treatment — no . ( % ),C0003364;C0039798;C0087111;C0205156;C1522326;C1533734;C1552607;C1705169;C3538994;C3887704
1135,previous antiarrhythmic treatment — no . ( % ),C0003195;C0039798;C0087111;C0205156;C1522326;C1533734;C1552607;C1705169;C3537142;C3538994;C3887704
1135,previous anti - tnf therapy,C0205156;C0281481;C1552607
1135,previous angioplasty,C0162577;C0205156;C1548817;C1552607
1135,previous angina pectoris,C0002962;C0205156;C1552607
1135,previous angina,C0002962;C0205156;C1552607
1135,previous analgesic products n ( % ),C0002771;C0205156;C1552607
1135,previous ami,C0205156;C1552607;C4319936
1135,previous af,C0205156;C0344434;C1552607;C4049859
1135,previous acute hypersensitivity reaction to infliximab — no . of patients ( % ),C0205156;C0413234;C0666743;C1552607
1135,previous a - blocker use,C0205156;C1552607
1135,previous a - blocker,C0205156;C1552607
1135,previous,C0205156;C1552607
1135,phototherapy previous systemic treatment,C0031765;C0205156;C0678812;C1552607
1135,participated in a previous febuxostat studyb,C0205156;C0249529;C1552607
1135,no previous stroke ortia,C0038454;C0205156;C1552607;C4554100
1135,no previous stroke or tia ( n = nmbr ),C0038454;C0205156;C1552607;C4554100
1135,no previous stroke / tia,C0007787;C0038454;C0205156;C0917805;C1054154;C1552607;C4554100
1135,no previous myocardial infarction nmbr / nmbr,C0027051;C0205156;C0428953;C1552607;C2926063;C3810814;C4552959
1135,no previous myocardial infarction,C0027051;C0205156;C0428953;C1552607;C2926063;C3810814;C4552959
1135,no previous ischemic stroke / tia ( n = nmbr nmbr  nmbr . nmbr % ),C0007787;C0205156;C0917805;C0948008;C1054154;C1552607
1135,no previous dmard therapy,C0039798;C0087111;C0205156;C0242708;C1363945;C1552607
1135,no previous copd medication,C0013227;C0024117;C0205156;C1412502;C1552607;C3244316;C3714496;C4284232
1135,no . previous dmard,C0205156;C0242708;C1552607
1135,no . previous alpha - blocker use,C0001641;C0042153;C0205156;C0457083;C1552607;C1947944
1135,no . of previous venous thromboembolic events,C0205156;C1552607;C1861172;C1997614;C3160733
1135,no . of previous csdmards,C0205156;C1552607
1135,no . of previous ciu / csu medications,C0013227;C0205156;C0578870;C0802604;C1552607;C2598133;C4284232
1135,no . of previous biologic dmards — no . ( % ),C0205156;C1552607;C4055380
1135,necessitating hospitalization in previous year — no . ( % ),C0019993;C0205156;C0439234;C0439508;C1552607
1135,in previous year,C0205156;C0439234;C0439508;C1552607
1135,hospitalization in previous year with management of heart failure as major component — no . ( % ),C0019993;C0205156;C0439234;C0439508;C1552607
1135,hospitalization in previous year with management of heart failure,C0019993;C0205156;C0439234;C0439508;C1552607
1135,exacerbations in the previous year,C0205156;C0439234;C0439508;C1552607;C4086268
1135,exacerbations in previous year requiring hospitalization and / or ed visit,C0019993;C0205156;C0439234;C0439508;C1552607;C4086268
1135,exacerbations in previous year requiring hospitalization,C0019993;C0205156;C0439234;C0439508;C1552607;C4086268
1135,exacerbations in previous year,C0205156;C0439234;C0439508;C1552607;C4086268
1135,exacerbation rate in the previous year ( range ),C0205156;C0439234;C0439508;C0871208;C1514721;C1521828;C1552607;C2348147;C3542016;C4086268
1135,exacerbation in previous year,C0205156;C0439234;C0439508;C1552607;C4086268
1135,elevated natriuretic peptides in previous nmbr days — no . ( % ) : ! :,C0205156;C0205250;C0439228;C1144709;C1552607;C3163633
1135,elevated natriuretic peptides in previous nmbr days — no . ( % ) $,C0205156;C0205250;C0439228;C1144709;C1552607;C3163633
1135,copd exacerbations during the previous year,C0205156;C0439234;C0439508;C0740304;C1552607
1135,copd exacerbation history in the previous year,C0019664;C0019665;C0205156;C0262512;C0262926;C0439234;C0439508;C0740304;C1552607;C1705255;C2004062
1135,completed previous febuxostat study,C0205156;C0249529;C1552607;C2348557
1135,> nmbr previous venous thromboembolisms ( % ),C0205156;C1552607;C1997614
1135,> nmbr in previous,C0205156;C1552607
1134,smoker ( current / former ),C0205156;C0337664;C0521116;C0750523;C1705970
1134,former smoking,C0037369;C0205156;C0453996;C0750523;C1881674
1134,former or never diabetes,C0205156;C0750523
1134,former or never,C0205156;C0750523
1134,former or current smokers ( % ),C0205156;C0750523
1134,former n z nmbr,C0205156;C0750523
1134,former / current smoker ( n = nmbr nmbr ),C0205156;C0337671;C0521116;C0750523;C1705970;C3173209;C3241966
1134,former ( n   = nmbr,C0205156;C0750523
1134,former,C0205156;C0750523
1133,types of fibrinolytic agent,C0016018;C0332307
1133,thrombolytic treatment before randomization,C0016018;C0034656;C0039798;C0087111;C0520997;C1522326;C1533734;C1705169;C3538994;C3887704
1133,thrombolytic agents,C0016018
1133,fibrinolytic agents before or after entry,C0016018
1133,fibrinolytic agent — no . ( % ) : t,C0016018
1133,fibrinolytic agent given,C0016018
1133,fibrinolytic agent before randomisation,C0016018;C0034656
1132,thrombolytic therapy,C0040044
1132,fibrinolytics,C0040044
1132,fibrinolytic therapy — no . ( % ),C0040044
1132,fibrinolytic,C0040044
1131,ticagrelor pre ‐ hosp ( n = nmbr ),C0332152;C0740175;C1999375;C2257086;C3669034
1131,ticagrelor nmbr mg vs . placebo hr ( nmbr % ci ),C0024671;C0026410;C0439269;C1960952;C1999375;C2346927;C4321396;C4521761
1131,ticagrelor nmbr mg no diabetes n = nmbr,C0024671;C0026410;C0439269;C1960952;C1999375;C2346927;C4321396;C4521761
1131,ticagrelor nmbr mg nmbr yr km %,C0024671;C0026410;C0439234;C0439269;C1960952;C1999375;C2346927;C3887676;C4321396;C4521761
1131,ticagrelor nmbr mg nmbr year km ( % ),C0024671;C0026410;C0439234;C0439269;C0439508;C1960952;C1999375;C2346927;C3887676;C4321396;C4521761
1131,ticagrelor nmbr mg km %,C0024671;C0026410;C0439269;C1960952;C1999375;C2346927;C3887676;C4321396;C4521761
1131,ticagrelor nmbr mg diabetes n = nmbr,C0011847;C0011849;C0024671;C0026410;C0439269;C1960952;C1999375;C2346927;C4321396;C4521761
1131,ticagrelor nmbr mg,C0024671;C0026410;C0439269;C1960952;C1999375;C2346927;C4321396;C4521761
1131,ticagrelor in ‐ hosp ( n = nmbr ),C1999375
1131,ticagrelor,C1999375
1130,prehospital ticagrelor ( n = nmbr ),C1999375
1130,pre hospital ticagrelor,C0019994;C0332152;C0740175;C1510665;C1999375;C2257086;C3669034
1130,pre - hospital ticagrelor ( n = nmbr ),C0019994;C0332152;C0740175;C1510665;C1999375;C2257086;C3669034
1130,in hospital ticagrelor,C0019994;C1510665;C1999375
1130,in - hospital ticagrelor ( n = nmbr ),C0019994;C1510665;C1999375
1129,hemoglobin level,C0019029;C1314664
1129,hemoglobin concentration — g / liter,C0019029;C0086045;C0439267;C0475211;C1314664;C1318517;C1319312;C1446561;C3827302
1128,hemoglobin ( g rnmbr ),C0205090;C0684010;C1319312;C2603358
1128,hemoglobin ( g nmbr ! ),C1319312
1127,hemoglobin anmbrc ( % ),C0019020;C3889898
1127,hemoglobin anmbrc,C0019020;C3889898
1127,hemoglobin a^c,C0019020;C3889898
1127,hemoglobin - anmbrc ( % ) ' • ■ * *,C0019020;C3889898
1126,prior biologic use,C0005515;C0042153;C0205460;C0332152;C0457083;C1947944;C2826257
1126,prior biologic exposure,C0005515;C0205460;C0274281;C0332152;C0332157;C2826257
1126,biological,C0005532;C0205460
1126,biologic naive,C0005515;C0205460
1126,biologic,C0005515;C0205460
1125,other biologic agent,C0005515
1125,biologics user,C0005515;C0005522;C1548600;C1706077;C4553887
1125,biologic agents,C0005515
1124,israel,C0022271
1124,il - nmbr,C0020898;C0021764;C0022271
1123,ileum or colon,C0020885
1123,ileum and colon,C0020885
1123,ileum,C0020885
1122,iop,C0578862
1121,idm,C0270221
1120,immunologic,C0152036;C0205470
1120,imm only,C0205171;C0205470;C1720467
1120,imm,C0205470
1119,stroke of undetermined cause,C0015127;C0038454;C1524003
1119,range ed etiology ( n ),C0015127;C1314792;C1514721;C1524003;C2348147;C3538926;C3542016
1119,pah origin / cause,C0015127;C1418251;C1524003
1119,pah etiology :,C0015127;C0030123;C1314792;C1524003;C3203102;C4284467
1119,pah etiology,C0015127;C0030123;C1314792;C1524003;C3203102;C4284467
1119,other determined etiology,C0015127;C0521095;C1314792;C1524003
1119,other cause,C0015127;C1524003
1119,non - ischaemic cause,C0015127;C0475224;C1518422;C1524003
1119,non - ischaemic aetiology,C0015127;C0475224;C1314792;C1518422;C1524003
1119,ischemic hf etiology,C0015127;C0018488;C0475224;C1313497;C1314792;C1524003;C1538440;C3273279
1119,ischemic etiology ( % ),C0015127;C0475224;C1314792;C1524003
1119,ischemic etiology,C0015127;C0475224;C1314792;C1524003
1119,ischemic cause,C0015127;C0475224;C1524003
1119,ischemic aetiology,C0015127;C0475224;C1314792;C1524003
1119,ischaemic etiology n ( % ),C0015127;C0475224;C1314792;C1524003
1119,ischaemic cause,C0015127;C0475224;C1524003
1119,ischaemic aetiology,C0015127;C0475224;C1314792;C1524003
1119,hf cause,C0015127;C0018488;C1313497;C1524003;C1538440;C3273279
1119,etiology ( % ),C0015127;C1314792;C1524003
1119,etiology,C0015127;C1314792;C1524003
1119,ed etiology,C0015127;C1314792;C1524003;C3538926
1119,any cause,C0015127;C1524003
1119,all cause mortality or hosp . for worsening hf hs - crp < nmbr . nmbr mg / l,C0015127;C0026565;C0026566;C0444868;C1524003;C3539085
1119,all cause mortality,C0015127;C0026565;C0026566;C0444868;C1524003;C3539085
1119,all - cause mortality or hf hospitalization^,C0015127;C0026565;C0026566;C0444868;C1524003;C3539085
1119,all - cause mortality or hf hospitalization,C0015127;C0026565;C0026566;C0444868;C1524003;C3539085
1119,all - cause mortality at nmbr year,C0015127;C0026565;C0026566;C0439234;C0439508;C0444868;C1524003;C3539085
1119,all - cause mortality ( no . of events ),C0015127;C0026565;C0026566;C0444868;C1524003;C3539085
1119,all - cause mortality ( n = nmbr ),C0015127;C0026565;C0026566;C0444868;C1524003;C3539085
1119,all - cause mortality,C0015127;C0026565;C0026566;C0444868;C1524003;C3539085
1119,all - cause mortalitv,C0015127;C1524003
1119,all - cause hospitalization,C0015127;C0019993;C1524003
1119,all - cause death n,C0011065;C0015127;C1306577;C1524003;C4082313;C4552775
1119,all - cause death,C0011065;C0015127;C1306577;C1524003;C4082313;C4552775
1119,all - cause,C0015127;C1524003
1119,aetiology of pah,C0015127;C0030123;C1314792;C1524003;C3203102;C4284467
1119,aetiology,C0015127;C1314792;C1524003
1119,acute stroke of other determined cause,C0015127;C0521095;C0751956;C1524003
1118,type nmbr diabetes 一 no . ( % ),C1320657
1118,type nmbr diabetes — no . { % ) §,C1320657
1118,type nmbr diabetes — no . ( % ) §,C1320657
1118,type nmbr diabetes — no . ( % ),C1320657
1118,type nmbr diabetes pbo ( n = nmbr ) vs evomab ( n = nmbr ),C0031962;C1320657
1118,type nmbr diabetes mellitusa,C1320657
1118,type nmbr diabetes mellitus ’,C1320657
1118,type nmbr diabetes mellitus ' nmbr ',C1320657
1118,type nmbr diabetes mellitus,C1320657
1118,type nmbr diabetes meiiitus,C1320657
1118,type nmbr diabetes duration,C0449238;C1320657;C2926735
1118,type nmbr diabetes . n ( % ),C1320657
1118,type nmbr diabetes *,C1320657
1118,type nmbr diabetes ( n = nmbr,C1320657
1118,type nmbr diabetes,C1320657
1118,no type nmbr diabetes ( n = nmbr,C1320657
1118,known duration of type nmbr diabetes ( years ),C0205309;C0439234;C0449238;C1320657;C2926735
1118,known duration of type nmbr diabetes,C0205309;C0449238;C1320657;C2926735
1118,duration of type nmbr diabetes mellitus ( years ),C0439234;C0449238;C1320657;C2926735
1118,duration of type nmbr diabetes mellitus,C0449238;C1320657;C2926735
1118,duration of type nmbr diabetes categories,C1320657;C1547660
1118,duration of type nmbr diabetes ( years ),C0439234;C0449238;C1320657;C2926735
1118,duration of type nmbr diabetes,C0449238;C1320657;C2926735
1118,diabetes mellitus ( type nmbr or nmbr ),C1320657
1118,diabetes mellitus ( type nmbr ),C1320657
1117,diet only,C0012155;C0012159;C0205171;C1519433;C1720467;C2983588;C3668949
1117,diet nmbr / nmbr ( nmbr . nmbr ),C0012155;C0012159;C1519433;C2983588;C3668949
1117,diet group ( n = nmbr ),C0012155;C0012159;C0441848;C1519433;C2983588;C3668949
1117,diet and exercise,C0012155;C0012159;C1519433;C2983588;C3668949
1117,diet alone,C0012155;C0012159;C1519433;C2983588;C3668949
1117,diet ( n 二 nmbr ),C0012155;C0012159;C1519433;C2983588;C3668949
1117,diet ( n = nmbr ),C0012155;C0012159;C1519433;C2983588;C3668949
1117,diet,C0012155;C0012159;C1519433;C2983588;C3668949
1116,with des,C0011702;C4551552
1116,type of des,C0011702;C0332307;C1547052;C4551552
1116,older des ( n = nmbr ),C0011702;C0580836;C4551552
1116,no des,C0011702;C4551552
1116,new des ( n = nmbr ),C0011702;C0205314;C4551552
1116,des type,C0011702;C0332307;C1547052;C4551552
1116,des implantation for restenosis,C0011702;C0021107;C0029976;C0333186;C4551552
1116,des,C0011702;C4551552
1116,> nmbr des type,C0011702;C0332307;C1547052;C4551552
1115,without diabetes,C0011847;C0011849
1115,with diabetes,C0011847;C0011849
1115,undiagnosed diabetes mellitus,C0011849;C1408353
1115,undiagnosed diabetes ( n = nmbr ),C0011847;C0011849;C1408353
1115,short ( < nmbr years ) duration of diabetes,C0011847;C0011849;C0439234;C0439593
1115,postbaseline new - onset diabetes - n ( % ),C0011847;C0011849;C0746890
1115,people without diabetes n = nmbr,C0011847;C0011849;C0027361
1115,people with diabetes n = nmbr,C0011847;C0011849;C0027361
1115,other ( % ) diabetes ( interaction : p = nmbr . nmbr ),C0011847;C0011849;C1704675
1115,no diabetes mellitus,C0011849
1115,no diabetes ( p = . onmbr ),C0011847;C0011849
1115,no diabetes ( p = . nmbr ),C0011847;C0011849
1115,no diabetes ( n = nmbr,C0011847;C0011849
1115,no diabetes ( n - nmbr,C0011847;C0011849
1115,no diabetes,C0011847;C0011849
1115,new diabetes — no . ( % ),C0011847;C0011849;C0205314
1115,new diabetes,C0011847;C0011849;C0205314
1115,new - onset diabetes §,C0011847;C0011849;C0746890
1115,new - onset diabetes,C0011847;C0011849;C0746890
1115,n o diabetes,C0011847;C0011849;C0369718;C0441922
1115,long ( inmbr years ) duration of diabetes,C0011847;C0011849;C0021966;C0221138;C0439234;C0439591
1115,long ( > nmbr years ) duration of diabetes,C0011847;C0011849;C0439234;C0439591
1115,individuals without diabetes,C0011847;C0011849;C0027361;C0237401
1115,individuals with tnmbrdm ( scale diabetes ),C0011816;C0011847;C0011849;C0027361;C0175659;C0237401;C0349674;C1947916;C3250443
1115,individuals with diabetes,C0011847;C0011849;C0027361;C0237401
1115,hx of diabetes,C0011847;C0011849;C0262926;C3814444
1115,"high risk of diabetes """,C0011847;C0011849;C0332167
1115,high risk of diabetes,C0011847;C0011849;C0332167
1115,high risk for diabetes *,C0011847;C0011849;C0205250;C0332167;C1171304;C1299351;C2700149;C3272283;C3887512;C3889660;C4050568;C4319571;C4321237;C4522209
1115,duration of diabetes microvascular disease — no . ( % ),C0011847;C0011849;C0443258;C0872146
1115,diagnosed diabetes ( n = nmbr ),C0011847;C0011849;C0011900
1115,diabetesnmbr ( % ),C0011847;C0011849
1115,diabetesnmbr,C0011847;C0011849
1115,diabetes^,C0011847;C0011849
1115,diabetes — no . ( % ),C0011847;C0011849
1115,diabetes | | yes,C0011847;C0011849;C1549445;C1705108;C1710701
1115,diabetes | |,C0011847;C0011849
1115,diabetes with target organ disease *,C0011847;C0011849;C0012634;C0178784;C1521840;C2986546
1115,diabetes t,C0011847;C0011849
1115,diabetes present nmbr ( nmbr . nmbr ),C0011847;C0011849;C0150312;C0449450
1115,diabetes n ( % ),C0011847;C0011849
1115,diabetes mellitust,C0011847;C0011849
1115,diabetes mellitus :,C0011849
1115,diabetes mellitus !,C0011849
1115,diabetes mellitus,C0011849
1115,diabetes melitus,C0011847;C0011849
1115,diabetes medication,C0011847;C0011849;C0013227;C3244316;C4284232
1115,diabetes etiology,C0011847;C0011849;C0015127;C1314792;C1524003
1115,diabetes durationa < median,C0011847;C0011849;C0549183;C0876920;C2347635;C2348144;C2939193
1115,diabetes classificationa,C0011847;C0011849
1115,diabetes bl,C0005918;C0006413;C0011847;C0011849;C1552663;C2827109
1115,diabetes and untreated hypertension,C0011847;C0011849
1115,diabetes and currently on an oral hypoglycaemic agent orinsulin,C0011847;C0011849
1115,diabetes absent nmbr ( nmbr . nmbr ),C0011847;C0011849
1115,diabetes *,C0011847;C0011849
1115,diabetes ( p = . oonmbr ),C0011847;C0011849
1115,diabetes ( p = . onmbr ),C0011847;C0011849
1115,diabetes ( p = . nmbr ),C0011847;C0011849
1115,diabetes ( n [ % ] ) *,C0011847;C0011849
1115,diabetes ( n = nmbr ),C0011847;C0011849
1115,diabetes ( n - nmbr,C0011847;C0011849
1115,diabetes ( % ),C0011847;C0011849
1115,diabetes,C0011847;C0011849
1115,all without diabetes ( n = nmbr ),C0011847;C0011849
1115,all with diabetes ( n = nmbr ),C0011847;C0011849
1114,diabetes mellitus 一 no . ( % ),C0011849
1114,diabetes mellitus — no . / total no . ( % ),C0011849
1114,diabetes mellitus — no . ( % ),C0011849
1114,diabetes mellitus yes ( n,C0011849;C1549445;C1705108;C1710701
1114,diabetes mellitus n = nmbr,C0011849
1114,diabetes mellitus [n ( % ) ],C0011849
1114,diabetes mellitus ( % ),C0011849
1113,past treatment for paod,C2945691
1112,planned treatment duration,C4528394
1111,prior treatment status,C0332152;C0449438;C0749659;C1514463;C2826257
1111,prestudy treatment status,C0749659
1110,time to treatment initiation ( min ),C0589507;C0702093;C1158830;C1524029;C1704686;C3494202;C3813700
1110,time to treatment initiation ( min ,C0589507;C0702093;C1158830;C1524029;C1704686;C3494202;C3813700
1110,time to treatment ( min ) t,C0702093;C1524029;C3494202;C3813700
1110,time to treatment,C3494202
1109,pretreatment triglycerides,C0041004;C1550147;C2709094;C3539075;C3539076
1109,pretreatment hdl - c,C1550147;C2709094;C3539075;C3539076;C3715113
1109,pretreatment / concomitant treatment,C0039798;C0087111;C0521115;C1522326;C1533734;C1550147;C1705169;C2709094;C3538994;C3539075;C3539076;C3887704
1109,pre - treatment[n ( % ) ]c,C1550147;C2709094;C3539075;C3539076
1109,no pretreatment,C1550147;C2709094;C3539075;C3539076
1109,nmbr prolonged antithrombotic pretreatment ( n = nmbr ),C0439590;C1550147;C2709094;C3539075;C3539076
1109,high - dose statin pretreatment ( n = nmbr ),C0360714;C0444956;C1550147;C2709094;C3539075;C3539076
1109,duration of clopidogrel pretreatment 一 hr median,C0070166;C0449238;C0549183;C0876920;C1550147;C2347635;C2348144;C2709094;C2926735;C2939193;C3539075;C3539076
1109,duration of clopidogrel pretreatment — hr median,C0070166;C0449238;C0549183;C0876920;C1550147;C2347635;C2348144;C2709094;C2926735;C2939193;C3539075;C3539076
1109,clopidogrel pretreatment duration,C0070166;C0449238;C1550147;C2709094;C2926735;C3539075;C3539076
1108,infrequent exacerbator,C0521114
1107,most frequent serious teaes,C0205393;C0205404;C0332183
1107,most frequent aesa,C0205393;C0332183
1107,frequent or continuous,C0332183
1107,frequent exacerbator,C0332183
1106,snmbr exacerbations,C0565930;C2603362;C4086268
1106,nmbr exacerbations,C4086268
1106,nmbr exacerbation,C4086268
1106,exacerbations requiring oral steroids / antibiotics ( past year ) ( % ),C4086268
1106,exacerbations requiring hospitalisation ( past year ) ( % ),C4086268
1106,exacerbations in the year before study,C0439234;C0439508;C4086268
1106,exacerbations in the prev . year : nmbr,C0439234;C0439508;C1552852;C4086268
1106,exacerbations in the past nmbr months n,C4086268;C4331910
1106,exacerbations in previous nmbr mo ( n ),C0026544;C0205156;C0332177;C1552607;C4086268
1106,exacerbations in past nmbr mo — no . ( % ),C0026544;C0332177;C1444637;C4086268;C4284302
1106,exacerbations,C4086268
1106,exacerbation within previous nmbr mo,C0026544;C0205156;C0332177;C1552607;C4086268
1106,exacerbation within nmbr mo,C0026544;C0332177;C4086268
1106,exacerbation rate per year,C0439234;C0439508;C0871208;C1521828;C4086268
1106,exacerbation historyh,C4086268
1106,> nmbr exacerbations,C4086268
1106,$ nmbr exacerbations,C4086268
1105,patients with > nmbr exacerbation requiring er visit or admission to hospital in the nmbr months before screening,C1512346;C3810541;C3811131;C4086268
1105,patients with > nmbr exacerbation requiring admission to hospital in the nmbr months before screening,C0030673;C4086268
1104,patients with > nmbr exacerbations resulting in hospital admission,C0030705;C4086268
1104,patients with > nmbr exacerbations resulting in emergency department visit,C0030705;C4086268
1104,patients with > nmbr exacerbations resulting in ed visit,C0030705;C4086268
1104,patients with > nmbr exacerbation in previous nmbr months,C0030705;C4086268
1104,no . of exacerbations in past year,C4086268
1104,mod / sev exacerbation rates,C0011860;C0439793;C0458216;C0871208;C1521828;C2983285;C4086268
1104,mod / sev exacerbation rate,C0011860;C0439793;C0458216;C0871208;C1521828;C2983285;C4086268
1104,mean annualized exacerbation rate,C0444504;C0871208;C1521828;C2347634;C2348143;C4086268
1104,hospitalized for an exacerbation,C0701159;C4086268
1104,hospitalized exacerbation rates,C0701159;C0871208;C1521828;C4086268
1104,annual exacerbation rate,C0332181;C0871208;C1521828;C4086268
1104,adjusted exacerbation rate { per patient peryear ),C0030705;C0456081;C0871208;C1521828;C4086268
1104,adjusted exacerbation rate ( per patient peryear ),C0030705;C0456081;C0871208;C1521828;C4086268
1103,college graduate or more,C0682187
1102,ohs graduate,C0268353;C1861455
1101,hs graduate / ged,C0588053;C1547183;C1880947
1100,nmbr - h postprandial c - peptide ( ng / ml ),C0006558;C0376674;C2827809
1100,c peptide,C0006558
1100,c - peptide,C0006558
1099,asthma exacerbations,C0349790
1099,annual asthma exacerbation rates,C0332181;C0349790;C0871208;C1521828
1098,copd exacerbation : yes,C0740304;C1549445;C1705108;C1710701
1098,copd exacerbation : no,C0740304
1097,erythrocyte sedimentation rate — mm / hr | |,C1176468;C1619634;C4330985;C4554674
1097,erythrocyte sedimentation rate ( mm / h ),C0456680;C1176468;C1619634
1097,erythrocyte sedimentation rate,C1176468;C1619634
1096,locally advanced,C1517927
1095,advanced,C0205179
1094,six - minute walk distance,C0012751;C3900196
1094,nmbrmw distance,C0012751;C0024548;C0026385;C0556966
1093,• nmbr : death from any cause,C0007465
1093,• death from any cause,C0007465
1093,death from cardiovascular causes,C0007226;C0007465;C3887460
1093,death from any cause,C0007465
1093,cause of death unknown,C0007465;C4050444
1093,by cause of death,C0007465;C4050444
1092,inclusion findings ( % ),C0007637;C1512693;C2607943;C2926606;C3539655
1092,inclusion diagnosis,C0007637;C0011900;C1512693;C1704338;C1704656
1092,inclusion criteria — no . ( % ),C1512693
1092,inclusion criteria,C1512693
1092,accp bleeding risk at inclusion,C0007637;C1512693;C3251812
1091,statin + er niacin ( n = nmbr ),C0027996;C0360714;C1142562;C3810541;C3811131
1091,niacin + statin,C0027996;C0360714;C1142562
1091,niacin ( n = nmbr ),C0027996;C1142562
1091,niacin,C0027996;C1142562
1090,diclofenac nmbr mg ( n nmbr nmbr ),C0012091;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
1090,diclofenac nmbr mg ( n = nmbr ) n ( % ),C0012091;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
1090,diclofenac nmbr mg,C0012091;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
1090,diclofenac ( n = nmbr nmbr ),C0012091
1090,diclofenac ( n = nmbr ),C0012091
1090,diclofenac ( n = nmbr,C0012091
1090,diclofenac,C0012091
1089,no digoxin scd,C0012265
1089,no digoxin n = nmbr nmbr ( nmbr % ),C0012265
1089,digoxin scd,C0012265
1089,digoxin or digitalis preparations,C0012265
1089,digoxin or digitalis preparation,C0012265
1089,digoxin or digitalis glycoside,C0012265
1089,digoxin n = nmbr ( nmbr % ),C0012265
1089,digoxin n ( % ),C0012265
1089,digoxin / digitalis glycoside,C0012253;C0012265
1089,digoxin,C0012265
1088,meglitinides ( glinides ),C0065880;C1579432;C3537178
1088,meglitinide,C0065880
1087,nateglinide n / n,C0903898
1087,nateglinide and repaglinide,C0903898
1087,nateglinide ( n = nmbr ),C0903898
1086,paclitaxel - eluting stent use,C0038257;C0042153;C0144576;C0457083;C1947944
1086,paclitaxel - eluting,C0144576
1086,paclitaxel,C0144576
1085,pioglitazone group ( n = nmbr ),C0071097;C0441848
1085,pioglitazone dose,C0071097;C0178602;C0869039;C1114758
1085,pioglitazone ( n = nmbr ),C0071097
1085,pioglitazone ( n = nmbr,C0071097
1085,pioglitazone,C0071097
1084,rosiglitazone versus metformin,C0289313
1084,rosiglitazone versus glyburide,C0289313
1084,rosiglitazone nmbr mg daily,C0024671;C0026410;C0289313;C0332173;C0439269;C1960952;C2346927;C4321396;C4521761
1084,rosiglitazone nmbr mg daik,C0024671;C0026410;C0289313;C0439269;C1960952;C2346927;C4321396;C4521761
1084,rosiglitazone ( n = nmbr ),C0289313
1084,rosiglitazone,C0289313
1083,risk marker and model,C1519104
1082,risk group,C0242444
1081,shock risk indext,C0035647;C0036974;C4552904
1081,risk stratum,C0035647;C4552904
1081,risk score category ( points ),C0035647;C0449820;C0683312;C3889287;C4050231;C4552904
1081,risk category ( points ),C0035647;C0683312;C3889287;C4552904
1081,risk categories,C0035647;C0683312;C4552904
1081,risk at,C0035647;C4552904
1081,risk *,C0035647;C4552904
1081,risk,C0035647;C4552904
1081,no increased risk for falls,C0000921;C0035647;C0085639;C1849142;C4552904;C4699158
1081,ncep risk category at study entry,C0035647;C1705654;C2983287;C2983669;C4552904
1081,increased risk for falls,C0000921;C0035647;C0085639;C1849142;C4552904;C4699158
1080,drinker ( nmbr to nmbr drinks / week ),C0332174;C0439230;C0452428;C0556338
1080,drinker ( nmbr - nmbr drinks / week ),C0556338
1080,drinker ( % ) a,C0556338
1080,drinker ( % ),C0556338
1080,drinker,C0556338
1079,very high risk,C0035647;C0332167;C0442804;C0442824;C2984081;C3272283;C4050568;C4319571;C4321397;C4552904
1079,moderately high risk without atherosclerotic vascular disease *,C0004153;C0205081;C0332167;C1881878;C3272283;C4050568;C4085643;C4319571;C4321491
1079,moderately high risk,C0205081;C0332167;C1881878;C3272283;C4050568;C4085643;C4319571;C4321491
1079,higher risk ( n = nmbr ),C0332167;C3272283;C4050568;C4319571
1079,high risk without atherosclerotic vascular disease +,C0004153;C0332167;C3272283;C4050568;C4319571
1079,high risk with atherosclerotic vascular disease *,C0004153;C0332167;C3272283;C4050568;C4319571
1079,high risk and more symptoms ( group d ),C0332167;C3272283;C4050568;C4319571
1079,high risk and fewer symptoms ( group c ),C0332167;C3272283;C4050568;C4319571
1079,high risk *,C0332167;C3272283;C4050568;C4319571
1079,high risk ( ri ≥ nmbr ),C0035487;C0332167;C1826843;C3272283;C4050568;C4319571
1079,high risk ( nmbr - nmbr ),C0332167;C3272283;C4050568;C4319571
1079,high risk ( n nmbr nmbr ),C0332167;C3272283;C4050568;C4319571
1079,high risk ( ? ics ),C0332167;C0815320;C3272283;C4050568;C4319571;C4551720
1079,high risk ( > nmbr ),C0332167;C3272283;C4050568;C4319571
1079,high risk ( - ics ),C0332167;C0815320;C3272283;C4050568;C4319571;C4551720
1079,high risk,C0332167;C3272283;C4050568;C4319571
1079,high fracture risk stratum,C0016658;C0332167;C3272283;C4050568;C4319571
1079,high cv risk,C0332167;C3272283;C3538987;C4048877;C4050568;C4318503;C4319571
1079,high - risk cvd,C0007222;C0332167;C3272283;C4050568;C4319571
1079,high - risk criterion,C0243161;C0332167;C3272283;C4050568;C4319571
1079,high - risk clinical features,C0332167;C0683325;C3272283;C4050568;C4319571
1079,high - risk,C0332167;C3272283;C4050568;C4319571
1079,high ( > nmbr risk factor ),C0035648;C0205250;C0332167;C1299351;C1521761;C2700149;C2827422;C3272283;C3887512;C3889660;C4050568;C4319571;C4321237;C4522209
1079,> nmbr ( high risk ),C0332167;C3272283;C4050568;C4319571
1078,arterial access site,C3272298
1077,radial access site,C0442038;C0589360;C0920847
1077,access site,C0589360
1076,nt estimated,C0332126;C1449832;C3889152;C4050156;C4283901;C4284038
1075,no estimate,C0750572
1075,estimate,C0750572
1075,effect estimate,C0750572;C1280500;C1518681;C2348382
1074,left anterior descending,C0205386;C0441998;C1547177
1074,l eft anterior descending,C0205094;C0205386;C0439394;C0451214;C1547177;C1706495;C3642217
1074,descent,C0205386;C0680043
1073,leisure,C0086542
1072,left shoulder,C0524469
1071,leflunomide,C0063041
1070,unprotected left main stented,C0038257;C0205091;C0205225;C0443246;C1542147;C1552822
1070,left side,C0205091
1070,left main treated,C0205091;C0205225;C0443246;C1522326;C1542147;C1552822
1070,left main disease,C0012634;C0205091;C0205225;C0443246;C1542147;C1552822
1070,left main artery,C0003842;C0205091;C0205225;C0226004;C0443246;C1542147;C1552822
1070,left main,C0205091;C0205225;C0443246;C1542147;C1552822
1070,left - sided colitisz,C0205091;C0443246
1070,left,C0205091;C0443246;C1552822
1069,total bleeds,C0232100
1069,total bleeding,C0232100
1068,rectal bleeding subscore {,C0018932;C0267596
1068,rectal bleeding subscore,C0018932;C0267596
1067,number of arterial beds involved,C0003842;C0004916;C0221464;C0237753;C0449788
1067,> nmbr beds,C0004916
1067,< nmbr beds,C0004916
1066,crusade bleeding score,C0019080;C0449820;C4050231
1066,bleeding outcomes,C0019080;C1274040
1066,bleeding,C0019080
1066,any gusto bleeding,C0019080
1065,gusto severe bleed,C0019080;C0205082;C4050465;C4050466
1065,any overt bleed,C0019080
1064,without stent,C0038257
1064,with stent^l,C0038257
1064,with stent,C0038257
1064,with any stent,C0038257
1064,prior stent,C0038257;C0332152;C2826257
1064,other stent,C0038257
1064,no . of stents,C0038257
1064,minimum stent diameter,C0038257;C4054490
1063,type of drug - eluting stent,C0038257;C0332307;C0457591;C1322815;C1547052
1063,stent type implanted,C0038257;C0332307;C1547052
1063,stent type,C0038257;C0332307;C1547052
1063,stent,C0038257
1062,stenting plus medical therapy ( n = nmbr ),C0038257;C0418981;C2348535
1062,stent plus medical therapy,C0038257;C0418981
1062,stent group ( n = nmbr ),C0038257;C0441848
1062,stent ( n = nmbr ),C0038257
1062,previous stenting ( % previous pci ),C0038257;C0205156;C1552607;C2348535;C4049621
1062,multivessel stenting,C0038257;C2348535
1062,des ( % previous stenting ),C0011702;C0038257;C0205156;C1552607;C2348535;C4551552
1061,time to rx,C0040223;C1425688;C1521941;C2709207;C3541383
1061,time to randomization from symptom onset,C0034656;C0040223;C3541383
1061,time to randomization ( h ),C0033727;C0034656;C0040223;C0369286;C0441932;C0564385;C3541383;C4528284
1061,time to randomization,C0034656;C0040223;C3541383
1061,time to randomisation from symptom onset ( h ),C0034656;C0040223;C3541383
1061,time to randomisation [hours] ( interaction : p = nmbr . nmbr ),C0034656;C0040223;C0439227;C1704675;C3541383
1061,time to first cv hospitalization or death from any cause,C0019993;C0040223;C0205435;C1279901;C3538987;C3541383;C4048877;C4318503
1061,time to balloon / needle,C0027551;C0040223;C0336867;C0441144;C1882041;C3541383
1061,time to angiography — hr,C0002978;C0040223;C3541383
1061,time since start of fit,C0040223;C3541383
1061,time since start insulin ( years ),C0040223;C3541383
1061,time since rheumatoid arthritis diagnosis,C0040223;C3541383
1061,time since randomization,C0040223;C3541383
1061,time since qualifying event,C0040223;C3541383
1061,time since psoriasis diagnosis,C0040223;C3541383
1061,time since psa onset,C0040223;C3541383
1061,time since psa diagnosis ( years ),C0040223;C3541383
1061,time since prior alendronate use,C0040223;C3541383
1061,time since primary diagnosis,C0040223;C3541383
1061,time since pd diagnosis,C0040223;C3541383
1061,time since pah diagnosisc ( years ),C0040223;C3541383
1061,time since onset ( h ),C0040223;C3541383
1061,time since most recent myocardial,C0040223;C3541383
1061,time since ipf diagnosisa,C0040223;C3541383
1061,time since first psoriasis diagnosis ( y ),C0040223;C3541383
1061,time since first luts ( years ),C0040223;C3541383
1061,time since first copd diagnosis ( years ),C0040223;C3541383
1061,time since first af diagnosis,C0040223;C3541383
1061,time since epilepsy diagnosis ( years ),C0040223;C3541383
1061,time since end of fit,C0040223;C3541383
1061,time since diagnosis — mo,C0040223;C3541383
1061,time since diagnosis of type nmbr diabetes mellitus,C0040223;C3541383
1061,time since diagnosis of type nmbr diabetes - no . ( % ),C0040223;C3541383
1061,time since diagnosis of type nmbr diabetes,C0040223;C3541383
1061,time since diagnosis of tnmbrdm,C0040223;C3541383
1061,time since diagnosis of sle,C0040223;C3541383
1061,time since diagnosis of psa ( years ),C0040223;C3541383
1061,time since diagnosis of pah — yrf,C0040223;C3541383
1061,time since diagnosis of pah years #,C0040223;C3541383
1061,time since diagnosis of osteoarthritis — yr,C0040223;C3541383
1061,time since diagnosis of ln,C0040223;C3541383
1061,time since diagnosis of heart failure,C0040223;C3541383
1061,time since diagnosis of diabetesa,C0040223;C3541383
1061,time since diagnosis of diabetes — no . ( % ),C0040223;C3541383
1061,time since diagnosis of diabetes ( years ) ( median,C0040223;C3541383
1061,time since diagnosis of diabetes,C0040223;C3541383
1061,time since diagnosis of copd,C0040223;C3541383
1061,time since diagnosis of ciu / csuf ( y ),C0040223;C3541383
1061,time since diagnosis of ciu / csu ( years ) nmbr,C0040223;C3541383
1061,time since diagnosis,C0040223;C3541383
1061,time since copd diagnosis ( yrs ),C0040223;C3541383
1061,time since cessation of full - dose warfarin therapy,C0040223;C3541383
1061,time since cabg,C0040223;C3541383
1061,time since bph diagnosis ( years ),C0040223;C3541383
1061,time since asthma diagnosis years,C0040223;C3541383
1061,time since asthma diagnosis [years],C0040223;C3541383
1061,time since asthma diagnosis ( years ),C0040223;C3541383
1061,time since asthma,C0040223;C3541383
1061,time since as diagnosis ( years ),C0040223;C3541383
1061,time since as diagnosis,C0040223;C3541383
1061,time sample drawn ( h ),C0040223;C3541383
1061,time of randomization ( interaction : p = nmbr . nmbr ),C0034656;C0040223;C1704675;C3541383
1061,time of randomization,C0034656;C0040223;C3541383
1061,time in trial,C0040223;C3541383
1061,time from randomization to pci — hr,C0034656;C0040223;C3541383
1061,time from randomization to pci ( st - elevation mi ),C0034656;C0040223;C3541383
1061,time from randomization to pci ( non - st - elevation mi ),C0034656;C0040223;C3541383
1061,time from randomization to coronary angiography — hr,C0034656;C0040223;C3541383
1061,time from randomization to cabg — hr,C0034656;C0040223;C3541383
1061,time from randomisation to nmbrst balloon inflation ( h ),C0034656;C0040223;C3541383
1061,time from ra diagnosis,C0011900;C0040223;C1704338;C1704656;C3538806;C3541383;C4048756
1061,time from qualifying mi,C0040223;C1514624;C3541383;C3810814
1061,time from qualifying event to randomization,C0040223;C0441471;C1514624;C3541383;C4019010
1061,time from psoriatic arthritis diagnosis [a],C0003872;C0011900;C0040223;C1704338;C1704656;C3541383
1061,time from presentation to randomization — hr,C0040223;C0449450;C3541383
1061,time from parkinson ’ s disease diagnosis in months,C0011900;C0030567;C0040223;C1704338;C1704656;C3541383
1061,time from most recent qualifying,C0040223;C0332185;C1514624;C3541383
1061,time from longest event to randomisation,C0040223;C0441471;C1522425;C3541383;C4019010
1061,time from ld to pci  min  median ( qnmbr – qnmbr ),C0040223;C0694649;C3541383
1061,time from index acs event to randomisation ( days ),C0040223;C0441471;C0600653;C0742343;C0918012;C1552854;C1637833;C2986546;C3541383;C4019010;C4318612
1061,time from hospitalization to randomization — hr,C0019993;C0040223;C3541383
1061,time from event to randomization — days,C0040223;C0441471;C3541383;C4019010
1061,time from acute coronary syndrome to randomization ( days ),C0040223;C0948089;C3541383
1061,time from,C0040223;C3541383
1061,time ( sec ) *,C0040223;C0565930;C3541383
1061,time,C0040223;C3541383
1061,on oac at time of randomisation,C0034656;C0040223;C3541383
1061,medications at time of randomization — no . ( % ),C0013227;C0034656;C0040223;C0802604;C2598133;C3541383;C4284232
1061,medications at the time of randomization — no . ( % ),C0013227;C0034656;C0040223;C0802604;C2598133;C3541383;C4284232
1061,medication at time of randomization — no . ( % ),C0013227;C0034656;C0040223;C3244316;C3541383;C4284232
1061,median time from index acute coronary syndrome to randomization ( iqr ) — mo,C0040223;C0549183;C0600653;C0876920;C0918012;C0948089;C1552854;C1637833;C2347635;C2348144;C2939193;C2986546;C3541383
1061,mean time since diagnosis ( years ),C0040223;C0444504;C2347634;C2348143;C3541383
1061,mean time since diagnosis,C0040223;C0444504;C2347634;C2348143;C3541383
1061,mean time since asthma,C0040223;C0444504;C2347634;C2348143;C3541383
1061,mean time since as diagnosis,C0040223;C0444504;C2347634;C2348143;C3541383
1061,daily “ off ” time,C0040223;C0332173;C3541383
1061,at any time,C0040223;C3541383
1060,postoperative use of p - blocker,C0032790;C1524063
1060,diabetes with use of oral diabetes drugs,C0011847;C0011849;C0020616;C0029167;C0175795;C0304289;C0442027;C1524063;C4521986
1060,diabetes with no use of diabetes drugs,C0020616;C1524063
1059,concomitant use of nsaids to week nmbr,C0003211;C0521115;C1524063
1059,concomitant use of conventional synthetic dmard up to nmbr mo — no . { % ) methotrexate,C0242708;C0439858;C0521115;C1524063;C1883254
1059,concomitant use of bosentan,C0252643;C0521115;C1524063
1058,using hrt or raloxifene at baseline ( % ),C1524063
1058,using alendronate at baseline ( % ),C1524063
1058,use of ticagrelor,C1524063;C1999375
1058,use of systemic glucocorticoid at random -,C0017710;C0205373;C1524063
1058,use of statins,C0360714;C1524063
1058,use of statin at any follow - up visit ( % ),C0360714;C1524063
1058,use of oral glucocorticoids,C0017710;C0442027;C1524063;C3540777;C3540778;C4521986
1058,use of loop diuretics,C0354100;C1524063
1058,use of inhaled glucocorticoids at screening — no . ( % ),C0004048;C0017710;C1524063;C3540777;C3540778
1058,use of inhaled glucocorticoids at baseline,C0004048;C0017710;C1524063;C3540777;C3540778
1058,use of ics at baseline,C0815320;C1524063;C4551720
1058,use of high - dose inhaled glucocorticoid — no . { % ),C0444956;C1524063
1058,use of clopidogrel,C0070166;C1524063
1057,use of pci or thrombolysis within one day of randomization,C1524063;C4049621
1057,use of methotrexate at randomization —,C0025677;C1524063
1057,use of low - dose aspirin ( < nmbr mg daily ),C0024671;C0026410;C0332173;C0439269;C1524063;C1960952;C2346927;C2608320;C4321396;C4521761
1057,use of low - dose aspirin ( < nmbr,C1524063;C2608320
1057,use of aspirin at time of qualifying event ( % ),C0004057;C1524063
1056,serum creatinine — pmol / liter,C0201976;C0439192;C0475211;C0600061
1056,serum creatinine — mg / dl §,C0201976;C0439269;C0600061
1056,serum creatinine — mg / dl | |,C0201976;C0439269;C0600061
1056,serum creatinine — mg / dl,C0201976;C0439269;C0600061
1056,serum creatinine level,C0600061
1056,serum creatinine > nmbr pmol / l . n ( % ) |,C0201976;C0439284;C0600061
1056,serum creatinine > nmbr mmol / l,C0201976;C0600061;C1532563
1056,serum creatinine > nmbr / xmol / l,C0201976;C0600061
1056,serum creatinine . mg / dl,C0201976;C0439269;C0600061
1056,serum creatinine ( pmol / l ),C0201976;C0439284;C0600061
1056,serum creatinine ( mmol / l ),C0201976;C0600061;C1532563
1056,serum creatinine ( mg / dl ),C0201976;C0439269;C0600061
1056,serum creatinine ( gmol / ),C0201976;C0600061
1056,serum creatinine,C0201976;C0600061
1056,preoperative serum creatinine > nmbr pmol / l,C0201976;C0439284;C0445204;C0600061
1056,mean serum creatinine,C0201976;C0444504;C0600061;C2347634;C2348143
1056,increase in serum creatinine,C0201976;C0442805;C0600061
1056,first serum creatinine,C0201976;C0205435;C0600061;C1279901
1056,doubling of serum creatinine,C0201976;C0205173;C0600061;C1705764
1056,doubling of baseline serum creatinine or esrd rr ( ci ) “,C0168634;C0201976;C0205173;C0600061;C1442488;C1705764
1056,composite of doubling of serum creatinine,C0201976;C0205173;C0205199;C0600061;C1547335;C1705764
1056,composite endpoint of doubling of serum creatinine,C0201976;C0205173;C0205199;C0600061;C1547335;C1705764;C2349179;C2826544
1056,changes in serum creatinine,C0201976;C0392747;C0443172;C0600061
1056,acute increase in serum creatinine,C0010294;C0201976;C0205178;C0442805;C0600061;C1546542;C1561535
1055,lce — l - dopa / carbidopa / entacapone  lc — l - dopa / carbidopa  pd — parkinson disease  updrs — rating scale  adl — activities of daily living  pdq - nmbr — parkinson disease questionnaire .,C0001288;C0030567;C0165921;C0353697;C0441655;C0681889;C1420005;C1423759;C3273355;C3639721
1055,l - dopa / carbidopa - l - dopa / carbidopa / entacapone,C0165921;C0353697
1055,entacapone,C0165921
1054,statin use at study entry,C0360714;C0869040;C1705654
1054,spacer use during the study,C0221874;C0869040
1053,menopausal status and use of ht,C1513126
1053,menopausal status and use of hrt ( % ) y,C1513126
1053,menopausal status and hormone therapy use premenopausal,C1513126
1053,menopausal status and hormone therapy use,C1513126
1052,primary management strategy,C0001554;C0205225;C0376636;C0439612;C0439631;C0679199;C1273870;C3273539
1052,medical management only — no . { % ),C0001554;C0199168;C0205171;C0205476;C0376636;C1273870;C1720467;C3273539
1052,medical management only,C0001554;C0199168;C0205171;C0205476;C0376636;C1273870;C1720467;C3273539
1052,management of event — no . ( % ),C0001554;C0376636;C0441471;C1273870;C3273539;C4019010
1052,management distribution medical treatment,C0001554;C0030677;C0199168;C0205476;C0376636;C0520511;C0679624;C1273870;C1704711;C3273539
1052,management distribution,C0001554;C0376636;C0520511;C1273870;C1704711;C3273539
1052,managed medically — no . / total no . ( % ),C1273870
1052,acs management,C0001554;C0376636;C0742343;C1273870;C3273539;C4318612
1051,oral medications,C0304289
1051,oral anti - dm drug status,C0011816;C0029167;C0175795;C0304289;C0449438;C3250443
1051,concomitant oral anti - dm drugs,C0011816;C0029167;C0175795;C0304289;C0521115;C3250443
1050,oral anticoagulants,C0354604
1050,oral anticoagulant — no . / total no . ( % ),C0354604
1050,oral anticoagulant n ( % ),C0354604
1050,oral anticoagulant drugs,C0354604
1050,oral anticoagulant agent,C0354604
1050,oral anticoagulant,C0354604
1049,medications at coronary angiography,C0013227;C0085532;C0802604;C1548829;C2598133;C4284232
1049,coronary angiography — no . ( % ),C0085532;C1548829
1049,coronary angiography during the index hospitalization,C0002978;C0019993;C0085532;C0428776;C0600653;C0918012;C1548829;C1552854;C1637833;C2986546
1049,coronary angiography during the index hospital stay,C0002978;C0085532;C0428776;C0600653;C0918012;C1548829;C1552854;C1637833;C2986546;C3489408
1049,coronary angiography and intervention,C0085532;C1548829
1049,coronary angiography,C0085532;C1548829
1048,periprocedural anticoagulant,C0003280;C0848112;C3536711
1048,other anticoagulant,C0003280;C0848112;C3536711
1048,intravenous anticoagulant prior to pre - pci angiography,C0002978;C0003280;C0332152;C0348016;C0740175;C0848112;C2257086;C3536711;C3669034;C4049621
1048,intravenous anticoagulant during hospitalization,C0003280;C0019993;C0348016;C0848112;C3536711
1048,intravenous anticoagulant during hospitalisation *,C0003280;C0019993;C0348016;C0848112;C3536711
1048,any anticoagulant,C0003280;C0848112;C3536711
1048,anticoagulants,C0003280
1048,anticoagulant,C0003280;C0848112;C3536711
1047,anticoagulant — no . ( % ),C0003280;C0848112;C3536711
1047,anticoagulant group ( n = nmbr ),C0003280;C0441848;C0848112;C3536711
1047,anti - coagulants - no . ( % ),C0848112
1047,anti - coagulants,C0848112
1046,percentages,C0439165;C1549488;C1561533
1046,percentage with disease duration < nmbr years,C0439165;C0439234;C0872146;C1549488;C1561533
1046,percentage unless otherwise noted . cabg indicates coronary artery bypass graft  lvh  left ventricular hypertrophy  nsaids  nonsteroidal antiinflammatory drugs  pvd  peripheral vascular disease  tia  transient ischemic attack . ‘ history of hypercholesterolemia or reporting use of lipid - lowering medications at baseline . thistory of or currently have elevated serum creatinine level < nmbr mg / dl . tbased on participant history or review of chart .,C0439165;C1549488;C1561533
1046,percentage points,C0439165;C1549488;C1561533
1046,percentage of p,C0439165;C1549488;C1561533
1046,percentage of fevj reversibility,C0439165;C0449261;C1549488;C1561533
1046,percentage of females,C0086287;C0439165;C1549488;C1561533
1046,percentage of days without heartburn,C0439165;C0439228;C1549488;C1561533
1046,percentage of bsa involved,C0439165;C1549488;C1561533
1046,percentage,C0439165;C1549488;C1561533
1046,mean percentage of nights without heartburn,C0240526;C0439165;C0444504;C1549488;C1561533;C2347634;C2348143
1046,between - treatment comparison of percentage change from baseline in total hip bmd,C0439165;C1299575;C1549488;C1561533;C1707455
1045,percentage of time in therapeutic inr range,C0040223;C0439165;C1549488;C1561533;C3541383
1045,percent work time missed due to asthma,C0040223;C0043227;C0439165;C3541383
1045,percent overall work impairment due to asthma,C0439165
1045,percent of the time that inr was in the therapeutic range,C0040223;C0439165;C3541383
1044,new - onset atrial fibrillation,C0741281
1043,left atrial dimension,C3275097
1042,primary indication,C1549995
1041,laboratory examination,C0260877
1040,modmy al randcnxzaton,C0202311
1039,normal renal function,C0232805
1038,formal education,C0681344
1037,total occlusion,C0001168;C0011382;C0028778;C0439175;C0439810;C0441597;C1110554;C1947917
1037,small - artery occlusion ( lacune ),C0001168;C0011382;C0028778;C0226001;C0241970;C0264995;C0441597;C0700321;C1110554;C1947917
1037,small - artery occlusion,C0001168;C0011382;C0028778;C0226001;C0264995;C0441597;C0700321;C1110554;C1947917
1036,transient st elevation,C0040704;C0205374;C0520886
1036,transient,C0040704;C0205374
1036,prior transient ischaemic,C0040704;C0205374;C0332152;C0475224;C2826257
1036,associated with transient or reversible risk factor,C0040704;C0205374;C0332281
1035,temporary risk factor,C0035648;C0205374;C1548539;C3245481
1035,temporary factors,C0205374;C1521761;C1548539;C2827422;C3245481
1034,urinary protein - to - creatinine ratio | |,C1096054
1033,urine albumin - to - ereatinine ratio,C0001924;C0042038;C0456603;C0587185;C1273442;C1547037;C2362049
1033,urinary albumimcreatinine ratio,C1273442
1032,urine albumin / creatinine ratio ( mg / g ),C0455271;C1300563;C1318330
1032,urine albumin / creatinine ratio,C0455271;C1318330
1032,urine albumin / creatinine ( mg / mmol ),C0455271;C0567349;C1318330;C2348885
1032,urine albumin - to - creatinine ratio - no . ( % ) § §,C0455271;C1318330
1032,urine albumin - to - creatinine ratio,C0455271;C1318330
1032,urinary albumin : creatinine ratioa ( mg / g ),C0455271;C1300563;C1318330
1032,urinary albumin : creatinine ratio^,C0455271;C1318330
1032,urinary albumin : creatinine ratio *,C0455271;C1318330
1032,urinary albumin : creatinine ratio ( pg / mg ),C0455271;C1318330;C1627892
1032,urinary albumin : creatinine ratio ( mg / g ),C0455271;C1300563;C1318330
1032,urinary albumin / creatinine ratio,C0455271;C1318330
1032,urinary albumin - to - creatinine ratio^,C0455271;C1318330
1032,urinary albumin - to - creatinine ratio — no . ( % ) §,C0455271;C1318330
1032,urinary albumin - to - creatinine ratio §,C0455271;C1318330
1031,albumin creatinine ratio,C0486293;C1318293
1031,albumin / creatinine ratio - mg / mmol,C0486293;C0567349;C1318293;C2348885
1031,albumin / creatinine ratio,C0486293;C1318293
1031,albumin - to - creatinine ratio ( acr ),C0486293;C1318293;C1412134;C1515941
1031,"albumin - to - creatinine ratio ' i "" /",C0021966;C0221138;C0486293;C1318293
1031,albumin - to - creatinine ratio,C0486293;C1318293
1030,clinical dementia rating sum of boxes,C0179400;C0451074;C1515051;C1638312
1030,clinical dementia rating score,C4304227
1029,clinical presentation of vte at initial diagnosis — no . ( % ),C0630906;C2708283
1029,clinical presentation,C2708283
1028,creatinine clearance by c - g ( ml / min ),C0151280;C0439267
1028,creatinine clearance at admission ( ml / min ),C0151280;C0184666;C0809949
1028,creatinine clearance > nmbr to < nmbr ml / min — no . ( % ) f,C0151280
1027,creatine clearance category nmbr to < nmbr ml / min nmbr / nmbr,C0373595;C0439445;C0683312;C3889287
1027,creatine clearance category,C0373595;C0683312;C3889287
1027,creatine clearance,C0373595
1026,renal function : creatinine clearance,C0232804;C0812399
1026,creatinine clearance ， : : nmbr ml / min,C0439445;C0812399
1026,creatinine clearance — no . ( % ),C0812399
1026,creatinine clearance — ml / min,C0439445;C0812399
1026,creatinine clearance category [ml / min],C0439445;C0683312;C0812399;C3889287
1026,creatinine clearance < nmbr ml / min — no . ( % ) weight < nmbr kg — no . ( % ),C0439445;C0812399
1026,creatinine clearance < nmbr ml / min ( % ),C0439445;C0812399
1026,creatinine clearance < nmbr ml / min,C0439445;C0812399
1026,creatinine clearance ( ml / min ),C0439445;C0812399
1026,creatinine clearance,C0812399
1026,baseline creatinine clearance,C0168634;C0812399;C1442488
1025,serum nmbr ( oh ) d concentrations,C0220853;C0683149
1024,previous number of ciu / csu medications,C0205156;C0578870;C1552607;C1718138
1024,number of medications,C1718138
1023,method of insulin administration,C0025663;C0199782;C0449851;C0871511
1023,insulin administration,C0199782
1022,no hemoconcentration hemoconcentration,C0549409;C0854379
1021,posterior circulation,C0005775;C0205095;C1516559
1020,no regular consumption,C0009830;C0205272;C1947907
1019,parenteral anticoagulation,C0003281;C0030547;C2917212;C2919015;C3537050;C4522267
1019,intended duration of anticoagulation,C0003281;C0449238;C1283828;C1551357;C2917212;C2919015;C2926735;C3537050
1019,duration of initial anticoagulation,C0003281;C0205265;C0449238;C1279901;C1555582;C1705685;C2917212;C2919015;C2926735;C3537050
1018,limb amputation,C0002689
1017,social interaction,C0037420
1016,lung infection,C0876973;C4552950
1015,lacunar infarction,C0333559
1014,omega nmbr allocation,C1706778;C1719844
1014,insulin glargine allocation,C0907402;C1706778
1014,glargine allocation,C0907402;C1706778
1013,erectile dysfunction,C0242350;C1961100
1012,severe dysfunction,C3274777
1011,measures of lung function,C0035245;C0079809;C1879489
1011,lung function,C0035245
1010,additional investigations,C2359834
1009,laboratory investigations,C0022877;C1261322;C3244292;C4283904
1009,investigations,C1261322
1008,serious infections,C0205404;C3714514
1008,infections and infestations,C3714514
1008,infections,C3714514
1007,t wave inversion,C0520888
1007,t - wave inversion only,C0205171;C0520888;C1720467
1007,t - wave inversion,C0520888
1007,symmetric t wave inversions,C0332516;C0520888;C2699744
1007,symmetric t - wave inversions,C0332516;C0520888;C2699744
1006,type of intervention,C3274412
1005,age distribution,C0001782
1004,no reperfusion,C0035124;C0684253
1004,acute reperfusion,C0035124;C0205178;C0684253
1003,type bnmbr / c lesions,C4264484
1002,patients with remission,C1277626
1001,time to admission,C3854258;C3854259
1000,presentation to tertiary care hospital — %,C0337954;C0449450
1000,presentation *,C0449450
1000,dx at presentation,C0449450;C3538936
1000,acs presentation,C0449450;C0742343;C4318612
999,spirometry after bronchodilation §,C0037981;C1371299;C3537072
999,before bronchodilation — liters §,C0475211;C1371299;C3537072
999,before bronchodilation,C1371299;C3537072
999,after bronchodilation,C1371299;C3537072
998,boost intensify premix i ( global patient population ),C1511253;C1874596
998,boost intensify all ( pan - asian patient population ),C1511253;C1874596
997,digit symbol substitution,C0582802;C0679214;C1555721;C1698987;C1706204;C3241971
997,b digit symbol substitution,C0582802;C0679214;C1555721;C1698987;C1706204;C3241971
996,previous hospitalization for heart failure,C0205156;C1552607;C3898876
996,hospitalization for heart failure within previous nmbr mo — no . ( % ),C3898876
996,hospitalization for heart failure within nmbr mo,C3898876
996,hospitalization for heart failure or cv death,C3898876
996,hospitalization for heart failure or cv,C3898876
996,hospitalization for heart failure n ( % ),C3898876
996,hospitalization for heart failure,C3898876
996,hospitalisation for heart failure,C3898876
996,heart failure hospitalizations,C3898876
996,heart failure hospitalisation or cv death,C3898876
995,score on asthma control questionnaire * *,C4706265
994,health assessment questionnaire score,C2960025
993,st george ' s respiratory questionnaire total score !,C0439175;C0439810;C3472502
993,score on st . george ' s respiratory questionnaire^^,C3472502
992,logistic regression,C0206031
992,bmultivariate logistic regression with variables forced in the modela,C0206031;C0439828
992,aunivariate logistic regression .,C0206031
991,— nmbr . nmbr < fn t - score < — nmbr . nmbr,C0449820;C1570610;C4050231
991,— nmbr . nmbr < fn t - score,C0449820;C1570610;C4050231
991,womac stiffness score,C0427008;C0449820;C4050231
991,womac score,C0449820;C4050231
991,ukpds nmbr - year risk score > nmbr %,C0035647;C0439234;C0439508;C0449820;C4050231;C4552904
991,ukpds nmbr - year risk score < nmbr %,C0035647;C0439234;C0439508;C0449820;C4050231;C4552904
991,tlmi risk score,C0035647;C0449820;C4050231;C4552904
991,timi risk score — no . / total no . ( % ) f,C0035647;C0449820;C4050231;C4552904
991,timi risk score — no . / total no . ( % ) : c,C0035647;C0449820;C4050231;C4552904
991,timi risk score — no . ( % ) : t,C0035647;C0449820;C4050231;C4552904
991,timi risk score — %,C0035647;C0449820;C4050231;C4552904
991,timi risk score nmbr - nmbr,C0035647;C0449820;C4050231;C4552904
991,timi risk score category — no . ( % ),C0035647;C0449820;C0683312;C3889287;C4050231;C4552904
991,timi risk score > nmbr,C0035647;C0449820;C4050231;C4552904
991,timi risk score *,C0035647;C0449820;C4050231;C4552904
991,timi risk score ( interaction : p = nmbr . nmbr ),C0035647;C0449820;C1704675;C4050231;C4552904
991,timi risk score !,C0035647;C0449820;C4050231;C4552904
991,timi risk score,C0035647;C0449820;C4050231;C4552904
991,tim nmbr nsk score,C0449820;C1313407;C3541335;C3711667;C3827754;C3890185;C4050231;C4319633
991,symbol digit score,C0449820;C0582802;C0679214;C1698987;C3241971;C4050231
991,stroke risk score,C0449820;C1277291;C4050231
991,shs ( nmbr - nmbr  per nmbr score ),C0449820;C4050231
991,sf - nmbr score,C0037712;C0449820;C4050231
991,sf - nmbr ( health transition score ),C0037712;C0376627;C0449820;C4050231
991,score 一 no . ( % ),C0449820;C4050231
991,score on the minnesota living with heart failure scaled,C0026183;C0449820;C0595998;C4050231;C4520849;C4551704
991,score of > nmbr . nmbr — %,C0449820;C4050231
991,score of $ nmbr,C0449820;C4050231
991,score of # nmbr,C0449820;C4050231
991,score nmbr . nmbr,C0449820;C4050231
991,score nmbr - nmbr,C0449820;C4050231
991,score improvement,C0449820;C2986411;C4050231
991,score at week nmbr,C0332174;C0439230;C0449820;C4050231
991,score > nmbr . nmbr,C0449820;C4050231
991,score > nmbr %,C0449820;C4050231
991,score ( > nmbr ) at nmbr monthsb unadjusted or,C0449820;C4050231
991,score,C0449820;C4050231
991,rope score * *,C0449820;C1563164;C4050231
991,rope score,C0449820;C1563164;C4050231
991,rentrop score,C0449820;C4050231
991,ppbc score,C0449820;C4050231
991,pasi scorenmbr,C0449820;C4050231;C4528685
991,pasi score > nmbr *,C0449820;C4050231;C4528685
991,pasi score ( nmbr - nmbr ) t,C0449820;C4050231;C4528685
991,pasi score ( nmbr - nmbr ) d,C0449820;C4050231;C4528685
991,pasi score ( nmbr - nmbr ),C0449820;C4050231;C4528685
991,pasi score ! * *,C0449820;C4050231;C4528685
991,pasi score,C0449820;C4050231;C4528685
991,partial mayo score $ | |,C0449820;C0454788;C0728938;C1077578;C1550516;C4050231
991,partial mayo score,C0449820;C0454788;C0728938;C1077578;C1550516;C4050231
991,oab - q score,C0449820;C3641332;C4050231
991,nmbrms score †,C0449820;C2349943;C3539704;C3713294;C4050231
991,modified rankin score,C0392747;C0449820;C3889737;C4050231
991,mhis score,C0449820;C4050231
991,mayo score ( nmbr - nmbr ),C0449820;C0454788;C1077578;C4050231
991,mayo score,C0449820;C0454788;C1077578;C4050231
991,ls t - score < — nmbr . nmbr,C0023668;C0449820;C4050231
991,jsn score ( nmbr - nmbr ),C0449820;C4050231
991,jsn score,C0449820;C4050231
991,joint space narrowing score,C0449820;C1859695;C4050231
991,hit - nmbr score,C0272285;C0332159;C0449820;C1708373;C4050231
991,fsn score,C0449820;C4050231
991,framingham risk score *,C0035647;C0449820;C3166866;C4050231;C4552904
991,framingham risk score ( % ),C0035647;C0449820;C3166866;C4050231;C4552904
991,framingham risk score,C0035647;C0449820;C3166866;C4050231;C4552904
991,fn t - score < — nmbr . nmbr,C0449820;C1570610;C4050231
991,fn t - score < = - nmbr . nmbr ( % ),C0449820;C1570610;C4050231
991,flex fn f - score < - nmbr . nmbr,C0016327;C0449820;C1570610;C4050231
991,femoral neck t - score,C0015815;C0449820;C4050231
991,femoral neck bmd t - score,C0015815;C0449820;C4050231
991,erosion score ( nmbr – nmbr scale ),C0175659;C0333307;C0349674;C0449820;C1880549;C1947916;C1959609;C3887524;C4050231
991,erosion score ( nmbr - nmbr ),C0333307;C0449820;C1880549;C1959609;C3887524;C4050231
991,erosion score,C0333307;C0449820;C1880549;C1959609;C3887524;C4050231
991,enthesitis score *,C0449820;C1282952;C4050231
991,enthesitis score ( mases,C0449820;C1282952;C4050231
991,cumulative nsaid score,C0003211;C0449820;C1511559;C3536840;C4050231
991,crusade score,C0449820;C4050231
991,crohn ' s disease activity index score],C0449820;C0451071;C4050231
991,ci - aki risk score,C0008107;C0022660;C0035647;C0330978;C0449820;C3259781;C4050231;C4552904
991,charlson comobility score,C0449820;C4050231
991,chanmbrsnmbr score,C0449820;C1420648;C4050231
991,chanmbrdsnmbrvasc score ( % ),C0449820;C1420648;C3714751;C4050231
991,chanmbrdsnmbrvasc score,C0449820;C1420648;C3714751;C4050231
991,chanmbrdsnmbr - vasc score ( median,C0449820;C0549183;C0876920;C1420648;C2347635;C2348144;C2939193;C3714751;C4050231
991,chanmbrdsnmbr - vasc score,C0449820;C1420648;C3714751;C4050231
991,cadillac score,C0449820;C4050231
991,accp score,C0449820;C4050231
991,- nmbr < flex fn f - score,C0016327;C0449820;C1570610;C4050231
991,- nmbr . nmbr < ls t - score < — nmbr . nmbr,C0023668;C0449820;C4050231
991,- nmbr . nmbr < ls t - score,C0023668;C0449820;C4050231
991,- nmbr . nmbr < flex fn f - score < - nmbr,C0016327;C0449820;C1570610;C4050231
991,% improvement in enthesitis score at week nmbr,C0449820;C1282952;C2986411;C4050231
991,% improvement in dactylitis score at week nmbr,C0239161;C0449820;C2986411;C4050231
990,use oforal glucose - lowering agent — no . ( % ),C0042153;C0457083;C1947944
990,use ( % ),C0042153;C0457083;C1947944
990,use,C0042153;C0457083;C1947944
990,systemic glucocorticoid use at randomization,C0017710;C0034656;C0042153;C0205373;C0457083;C1947944
990,systemic glucocorticoid use at randomisation,C0017710;C0034656;C0042153;C0205373;C0457083;C1947944
990,saba use,C0042153;C0457083;C1947944
990,rotablator use,C0042153;C0457083;C1260867;C1947944
990,recurrent vte ( statin use vs non - use ),C0042153;C0360714;C0457083;C0630906;C1455761;C1947944;C2945760
990,preoperative use p - blocker,C0042153;C0445204;C0457083;C1947944
990,preoperative p - blocker use yes,C0042153;C0445204;C0457083;C1549445;C1705108;C1710701;C1947944
990,postoperative glucocorticoid use,C0017710;C0032790;C0042153;C0457083;C1947944
990,other llt use,C0042153;C0457083;C1947944;C2347090
990,oam use [n ( % ) ],C0042153;C0457083;C1947944
990,oad use,C0042153;C0457083;C1947944
990,no use,C0042153;C0457083;C1947944
990,no metformin use,C0025598;C0042153;C0457083;C1947944
990,no concomitant cortcosteroid use,C0042153;C0457083;C0521115;C1947944
990,multivitamin use yes,C0042153;C0301532;C0457083;C1549445;C1705108;C1710701;C1947944
990,multivitamin use ( current ),C0042153;C0301532;C0457083;C0521116;C1705970;C1947944
990,multivitamin use,C0042153;C0301532;C0457083;C1947944
990,metformin use,C0025598;C0042153;C0457083;C1947944
990,mesalamine use,C0042153;C0127615;C0457083;C1947944
990,major bleeding ( statin use vs non - use ),C0019080;C0042153;C0205082;C0205164;C0360714;C0457083;C1947944;C4318856;C4521762
990,low - dose aspirin use strata * n ( % ),C0042153;C0457083;C1947944;C2608320
990,low - dose aspirin use at baseline yes,C0042153;C0168634;C0457083;C1442488;C1549445;C1705108;C1710701;C1947944;C2608320
990,low - dose aspirin use at baseline,C0042153;C0168634;C0457083;C1442488;C1947944;C2608320
990,low - dose aspirin use . strata *,C0042153;C0457083;C1947944;C2608320
990,low - dose aspirin use,C0042153;C0457083;C1947944;C2608320
990,lama use,C0042153;C0457083;C0999593;C1416775;C1947944
990,laba use,C0042153;C0457083;C1947944
990,inhaled glucocorticoid use at screening,C0004048;C0017710;C0042153;C0220908;C0220909;C0457083;C1698960;C1710031;C1710032;C1710477;C1947944;C2348164
990,hrt use,C0042153;C0282402;C0457083;C1947944
990,dopamine agonist use,C0042153;C0178601;C0457083;C1947944;C3536925
990,cox - nmbr selective inhibitor use,C0036576;C0042153;C0085387;C0457083;C1707391;C1947944
990,concomitant statin use,C0042153;C0360714;C0457083;C0521115;C1947944
990,concomitant mao - b inhibitor use,C0042153;C0457083;C0521115;C0595265;C1947944;C2917433
990,concomitant conventional dmard use,C0042153;C0242708;C0439858;C0457083;C0521115;C1947944
990,concomitant aspirin use,C0004057;C0042153;C0457083;C0521115;C1947944
990,concomitant antibiotic use,C0003232;C0042153;C0457083;C0521115;C1947944
990,cholinesterase inhibitor use at baseline,C0008425;C0042153;C0168634;C0457083;C1442488;C1947944;C3536756;C4521309
990,cholinesterase inhibitor use,C0008425;C0042153;C0457083;C1947944;C3536756;C4521309
990,cgm use,C0042153;C0457083;C1947944
990,care use,C0042153;C0457083;C1947933;C1947944
990,before bronchodilator use,C0006280;C0042153;C0457083;C1947944
990,background laba use - yes,C0042153;C0457083;C1549445;C1705108;C1706907;C1710701;C1947944
990,background laba use,C0042153;C0457083;C1706907;C1947944
990,any use,C0042153;C0457083;C1947944
990,antithrombotic use,C0042153;C0457083;C1947944
990,antiplatelet use,C0042153;C0457083;C1947944
990,anorexigen use,C0042153;C0457083;C1947944
990,albuterol use ( sd ),C0001927;C0042153;C0457083;C1947944;C2699239
990,albuterol use,C0001927;C0042153;C0457083;C1947944
990,after bronchodilator use,C0006280;C0042153;C0457083;C1947944
989,maintenance dose,C3714445
988,heparin use,C0239945
987,either ocs use,C3844638
986,tobacco abuse,C0040336
986,current tobacco abuse,C0040336;C0521116;C1705970
985,nmbrhr prandial glucose ' * ’,C0017725;C1998602;C4553624
985,nmbr - hour postload glucose,C0017725;C0439227;C0564385
985,glucose,C0017725
984,prior tnf inhibitor exposure,C0274281;C0332152;C0332157;C1448177;C1999216;C2826257
984,prior exposure to topiramate,C0076829;C0274281;C0332152;C0332157;C2826257
984,prior exposure to levetiracetam,C0274281;C0332152;C0332157;C0377265;C2826257;C3693636
984,prior exposure to lamotrigine,C0064636;C0274281;C0332152;C0332157;C0524166;C2826257
984,prior exposure to carbamazepine,C0006949;C0006950;C0274281;C0332152;C0332157;C0682993;C2826257
984,prior anti - tnf exposure,C0274281;C0332152;C0332157;C1448177;C2826257
984,pollen exposure,C0032385;C0274281;C0332157;C0795585;C1320238
984,no prior tnf inhibitor exposure,C0274281;C0332152;C0332157;C1448177;C1999216;C2826257
984,exposure,C0274281;C0332157
984,exposed,C0332157
983,exposure to study drug — days,C0013175;C0332157;C0439228
983,exposed ( n = nmbr ),C0332157
982,coronary artery stenosis > nmbr %,C0242231
982,> nmbr % stenosis of coronary,C0242231
982,> nmbr % coronary stenosis,C0242231
981,in - stent restenosis of des,C0011702;C3272317;C4551552
981,in - stent restenosis,C3272317
980,vessels with stenosis > nmbr %,C0679403
980,non - stenotic vessels,C0679403;C1518422
980,> nmbr vessels with > nmbr % stenosis,C0679403
979,venous graft,C0042449;C0181074;C0332835;C0348013;C1961139
979,venous,C0042449;C0348013
979,vein bypass stented,C0042449;C0741847
979,history of recurrent venous thromboembolism,C0042449;C0348013;C0455533;C1455761;C2945760
979,family history of venous thromboembolism ( % ),C0015576;C0042449;C0241889;C0348013;C0455533;C1704727;C1997614
978,nilvadipine,C0132512
977,oxcarbazepine,C0069751
976,hydralazine,C0020223
975,methylxanthines,C0066447
974,xanthinesnmbr,C0043318;C3541955
974,xanthines,C0043318;C3541955
974,xanthine,C0043314;C0043318
973,dizziness,C0012833;C0042571;C1963093;C4084788;C4085547;C4085548;C4085549;C4553830
972,philippines,C0031529
971,thiazides,C0541746
971,thiazide users,C0541746;C1706077
971,thiazide,C0541746
970,thienopyridine use,C0042153;C0457083;C1120149;C1947944
970,thienopyridine type,C0332307;C1120149;C1547052
970,thienopyridine n = nmbr,C1120149
970,thienopyridine at baseline,C0168634;C1120149;C1442488
970,thienopyridine alone,C1120149
970,thienopyridine ( n = nmbr ),C1120149
970,thienopyridine,C1120149
970,planned thienopyridine at enrollment,C1120149;C1709561
970,planned thienopyridine at baseline,C0168634;C1120149;C1301732;C1442488
970,no thienopyridine,C1120149
970,- thienopyridine,C1120149
970,+ thienopyridine,C1120149
969,thiazolidinediones *,C1257987;C3541957
969,thiazolidinediones,C1257987;C3541957
969,thiazolidinedione 一 no . ( % ),C0289779;C1257987;C3537039
969,thiazolidinedione yes,C0289779;C1257987;C1549445;C1705108;C1710701;C3537039
969,thiazolidinedione use at baseline,C0042153;C0168634;C0289779;C0457083;C1257987;C1442488;C1947944;C3537039
969,thiazolidinedione no,C0289779;C1257987;C3537039
969,thiazolidinedione based,C0289779;C1257987;C3537039
969,thiazolidinedione ( includes pioglitazone ),C0289779;C1257987;C3537039
969,thiazolidinedione,C0289779;C1257987;C3537039
969,any thiazolidinedione,C0289779;C1257987;C3537039
968,time in therapeutic range before inclusion,C0040223;C0087111;C0302350;C0460097;C1554109;C3541383
968,time in therapeutic range,C0040223;C0087111;C0302350;C0460097;C1554109;C3541383
968,median time in therapeutic range for warfarin recipients,C0040223;C0087111;C0302350;C0460097;C0549183;C0876920;C1554109;C2347635;C2348144;C2939193;C3541383
968,in therapeutic range for warfarin subjects,C0043031;C0460097
968,center - level ihr percent time in therapeutic range for warfarin subjects,C0040223;C0087111;C0205099;C0302350;C0439165;C0441889;C0456079;C0460097;C1547707;C1554109;C2946261;C3541383;C3810851
967,use of parenteral antithrombotic agents — no . ( % ),C0030547;C1524063;C1704311;C4522267
967,use of parenteral antithrombotic,C0030547;C1524063;C4522267
967,parenteral anticoagulalion before randomization,C0030547;C0034656;C4522267
966,previousdistaldeep - veinthrombosisorsuperficial - vein thrombosis,C0042487
965,action tested is between the continuous variable and treatment .,C0441472;C3266814
964,- [the null hypothesis is that there are no differences among subgroups  for age and time since randomization  the inter -,C4684719
963,diffusion capacity of the lung for carbon monoxide,C0231971
962,method used to diagnose the incident pulmonary embolism,C0025663;C0449851;C0871511
962,method of assessing ejection fraction,C0025663;C0302131;C0336969;C0449851;C0812388;C0871511;C1264633;C1516048
961,hemodynamic parameters at baseline in the patients enrolled in the hemodynamic substudy,C0019010;C0168634;C0449381;C1442488;C4281788
961,haemodynamics and lv function,C0019010;C4281788
960,radiographic progression based on change from baseline > sdc,C0242656;C0444708;C0449258
960,first disease - progression outcome to occur §,C0205435;C0242656;C0449258;C0679250;C1274040;C1279901;C1335499;C1947900;C3542417;C4552808
960,disease - progression composite outcome !,C0205199;C0242656;C0449258;C0679250;C1274040;C1335499;C1547335;C1947900;C3542417;C4552808
960,% patients with no progression,C0030705;C0242656;C0449258
959,antidiabetes drug usage [ % ( n ) ],C0242510
958,beta - blockers through hospital discharge or day nmbr — %,C0001645;C0586003
958,ace inhibitors through hospital discharge or day nmbr — %,C0003015;C0586003
957,patients with eot data,C2707520
957,* patient characterization data are reproduced from morrow et al . ( nmbr ) .,C1880022;C2707520
956,estimated response rate and odds ratio,C0237629;C0750572
956,estimated proportions ( % ) and odds ratios,C0750572;C1709707
956,estimated means and treatment differences ( % ),C0750572;C1704970
956,estimated means and difference,C0750572;C1704970
956,estimated glomerular filtration,C0232809;C0750572
956,estimated creatinine clearance — ml / min §,C0439445;C0750572;C0812399
956,estimated creatinine clearance — ml / min  i ,C0021966;C0023806;C0221138;C0439445;C0702093;C0750572;C0812399;C1524029;C3813700
956,estimated creatinine clearance < nmbr rmb ' mint,C0452249;C0522467;C0750572;C0812399;C1337213;C1576800;C3890003
956,estimated creatinine clearance < nmbr ml / mint,C0439526;C0452249;C0522467;C0750572;C0812399;C1337213;C1576800;C1705224;C3887665;C3890003
956,estimated creatinine clearance < nmbr ml / min *,C0439445;C0750572;C0812399
956,estimated creatinine clearance ( ml / min ),C0439445;C0750572;C0812399
956,"estimated creatinine clearance "" ! """,C0750572;C0812399
956,estimated * creatinine clearance < nmbr mlvmin,C0750572;C0812399
955,rate estimate ( nmbr % ci ),C0008107;C0750572;C0871208;C1521828;C3259781
955,estimate ( nmbr % cl ),C0596019;C0750572
955,estimate ( nmbr % ci ),C0008107;C0750572;C3259781
954,patient ' s history of :,C0679831;C1369882
954,in patients with a history of chronic angina who have presented with an acute,C0002962;C0205191;C0679831
953,patients with specific disease characteristics,C0030705;C0205369;C0599878;C1552740
953,patients with specific disease characteris -,C0205369;C0683521;C1552740
952,randomised patients with basdai assessment at baseline and week nmbr,C0679830;C1998004
952,patient assessment of disease activity,C0679830;C1292728
952,patient assessment of arthritis pain,C0679830;C4317006
952,patient ' s assessment of pain ( nmbr - nmbr vas ),C0042815;C0679830
951,patient global assessment of disease,C0012634;C4054229
951,patient ' s global assessment of disease,C0012634;C4054229
951,patient ' s global assessment of,C4054229
951,patient ' s global assessment ( vas ),C0042815;C3536884;C3827561;C4054229
951,patient ' s global assessment !,C4054229
951,patient ' s global assessment,C4054229
950,intended durat - sm of antccagubficn,C0036154;C1283828;C1551357;C4553627
949,intention to treat,C0162425;C1283828
949,intention - to - treat without st - segment - elevation myocardial infarction,C0162425;C1283828
949,intention - to - treat with st - segment - elevation myocardial infarction,C0162425;C1283828
949,intention - to - treat,C0162425;C1283828
949,intent to use gp iib / iiia,C0162425;C1283828;C1550453
949,intent to use glycoprotein iib / iiia inhibitor,C0162425;C1283828;C1550453
949,intent to use dti,C0162425;C1283828;C1550453
949,intent to use direct thrombin,C0162425;C1283828;C1550453
949,intent of early invasive strategy,C0162425;C0205281;C0679199;C1279919;C1283828;C1334278;C1550453
949,intent of conservative strategy,C0162425;C0679199;C1283828;C1550453
949,intent - to - treatb,C0162425;C1283828;C1550453
948,patent foramen ovale,C0016522;C0344724
947,patient ' s preference not to take vka,C0376409
947,patient ' s preference not to take,C0376409
946,percent change from baseline to week nmbr in auc ( mean,C3272907
946,percent change from baseline at week nmbr,C3272907
945,tests for categoric,C0589061
944,patient status after wake - up,C0449437;C1170730
943,thienopyridine drug at start of open - label period,C0439531;C1120149;C1709323;C1948053;C2348346
943,placebo ‐ controlled period,C0439531;C1706408;C1948053
942,white ethnicity,C0007457;C0015031;C0043157;C0220938;C0243103
942,othery ethnicity,C0015031;C0243103
942,ethnicitynmbr ',C0015031;C0243103
942,ethnicity t,C0015031;C0243103
942,ethnicity - no . ( % ),C0015031;C0243103
942,ethnicity ( % ),C0015031;C0243103
942,ethnicity,C0015031;C0243103
942,ethnic origin white,C0007457;C0015031;C0043157;C0220938
942,ethnic origin *,C0015031
942,ethnic origin,C0015031
941,ethnic minority group — no . ( % ),C0015031;C0026192;C0680174;C1879937
941,ethnic group — no . ( % ) ',C0015031;C1879937
941,ethnic group ( % ),C0015031;C1879937
941,ethnic group,C0015031;C1879937
941,ethnic background,C0015031
940,troponin or ckmb value,C0041199
940,troponin nmbr at baseline *,C0041199;C0168634;C1442488
940,troponin nmbr at baseline,C0041199;C0168634;C1442488
940,troponin level,C0041199;C0441889;C0456079;C1547707;C2946261
940,troponin ( - ),C0041199
940,troponin ( + ),C0041199
940,troponin,C0041199
939,troponin t ( pg / ml ),C0077404;C0439297;C1420827
939,troponin t,C0077404;C1420827
939,elevated troponin t ( > nmbr . nmbr / xg / l ),C0017209;C0077404;C0205250;C1292284;C1420827;C1421532;C3163633
938,no atopy ( n = nmbr ),C0392707;C3539705
938,atopy by phadiatop test,C0022885;C0039593;C0392366;C0392707;C0456984;C1441070;C1515976;C3539705;C3831328;C4318744
938,atopy ( specific ige ) c,C0205369;C0392707;C1552740;C3539705
938,atopy ( n = nmbr,C0392707;C3539705
938,atopic ( based on phadiatop test ),C0392707
938,atopic,C0392707
937,loop or thiazide diuretic^,C0445022
937,loop or thiazide diuretic : ! :,C0445022
937,loop or thiazide diuretic #,C0445022
937,loop or thiazide diuretic,C0445022
937,loop diureties,C0445022
937,loop at enrollment,C0445022;C1516879;C1696073;C3888021
937,loop,C0445022
936,loop diuretics,C0354100
936,loop diuretic use,C0042153;C0354100;C0457083;C1947944;C3536704
936,loop diuretic,C0354100;C3536704
935,lymphadenopathy,C0497156;C4282165
934,myopathy,C0026848
933,lymphocytes,C0024264;C4018897
932,monocytes,C0026473
931,values were reported for nmbr patients in the spironolactone group and nmbr,C0042295
931,values were calculated using t tests for continuous variables and chi - square,C0042295
931,values are presented as mean sd unless stated otherwise . data shown are for the randomized population . * body mass index values were missing from nmbr patients in the aliskiren group and nmbr patients in the hydrochlorothiazide group . † obesity was defined as body mass index nmbr kg / mnmbr . ‡ metabolic syndrome was defined according to the third report of the national cholesterol education program expert panel on detection  evaluation  and treatment of high blood cholesterol in adults ( adult treatment panel iii ) criterianmbr as any nmbr of the following : waist circumference nmbr cm for men or nmbr cm for women  triglycerides nmbr mg / dl  high - density lipoprotein cholesterol nmbr mg / dl for men or nmbr mg / dl for women  mssbp nmbr mm hg or msdbp nmbr mm hg  fasting glucose nmbr mg / dl . § by medical history . aliskiren  n nmbr  hydrochlorothiazide  n nmbr .,C0042295
931,nt - probnp values were reported in nmbr of nmbr patients enrolled in this stratum,C0042295;C0669479;C0754710
931,laboratory values in patients with history of diabetes,C0022877;C0030705;C0042295;C3244292;C4283904
931,laboratory values at randomization ( median and iqr ),C0022877;C0034656;C0042295;C0549183;C0876920;C2347635;C2348144;C2939193;C3244292;C4283904
931,laboratory values at admission ( median and iqr ),C0022877;C0042295;C0184666;C0549183;C0809949;C0876920;C2347635;C2348144;C2939193;C3244292;C4283904
931,* plus – minus values are means ± sd . percentages may not total nmbr because of rounding . the body - mass index is the weight in kilograms divided by the square of the height in meters . to convert the values for creatinine to micromoles per liter,C0042295;C0332288
931,* plus - minus values are means 士 sd . race or ethnic group was self - determined . the body - mass index is the weight in kilograms divided by,C0042295;C0332288
931,* plus - minus values are means ± sd . there were no significant differences ( at,C0042295;C0332288
931,( nmbr . nmbr % )  values were not collected for nmbr patients ( nmbr . nmbr % ) who were enrolled,C0042295
931, † nitrates includes all preparations except as - needed nitroglycerin . ‡ any antianginal drug includes any nitrate ( as defined above )  calcium - channel blocker  or beta - blocker . § the body - mass index is the weight in kilograms divided by the square of the height in meters . ¶ to convert values for cholesterol to millimoles per liter  multiply by nmbr . nmbr . to convert values for triglycerides to millimoles per liter  multiply by nmbr . nmbr .,C0042295;C0332288
930,values are mean ± sd  median [quartile range]  or % . ace indicates angiotensin - converting enzyme  arb  angiotensin receptor blocker  bnp  b - type natriuretic peptide  bp  blood pressure  bun  blood urea nitrogen  lvef  left ventricular ejection fraction  and nt - probnp  n - terminal pro - b - type natriuretic peptide .,C0042295
930,values are expressed as percentages unless otherwise indicated . bmi  body mass index  cabg  coronary artery bypass ischemic attack  nsaids  nonsteroidal anti - inflammatory drugs  sbp  systolic bp  dbp  diastolic bp . * history of or currently taking antidiabetic or lipid - lowering medications .,C0042295
930,abbreviations : bmi  body mass index  cabg  coronary artery bypass graft  nsaids  nonsteroidal anti - inflammatory drugs  pci  percutaneous coronary interventions . * values expressed as number ( percentage ) unless otherwise indicated . percentages may not equal nmbr due to rounding . fhistory of or currently taking antidiabetic or lipid - lowering medications . ^history of or currently have elevated serum creatinine level but less than nmbr mg / dl_ ( < nmbr pmol / l ) . § patients with a history of skin  prostate  and other cancers with long survival expectancy were not excluded . | | lnsulin and / or oral hypoglycemics . ildata for women only ( n = nmbr for calcium antagonist strategy and n = nmbr for non - calcium antagonist strategy ) .,C0000723;C0003211;C0010055;C0042295;C1305855;C1532338;C3536840
930, blood pressure nmbr / nmbr mm hg  on antihypertensive medication  or diagnosis of hypertension based on medical history . n number of randomly assigned patients  ncep atp national cholesterol education program adult treatment panel .,C0042295
929,abbreviations : ace  angiotensin - converting enzyme  bmi  body mass index ( calculated as weight in kilograms divided by height in meters squared )  dm  diabetes mellitus  hbanmbrc  hemoglobin anmbrc  hmg - coa  nmbr - hydroxy - nmbr - methylglutaryl coenzyme a . asome subjects took more than nmbr oral anti - dm drug in addition to metformin  and thus the total number of concomitant oral anti - dm drugs in the columns exceed the “ n ” values in the colesevelam hydrochloride and placebo group headings . bsulfonylureas include chlorpropamide  glibenclamide  glimepiride  glipizide  and tolazamide . cthiazolidinediones include pioglitazone  pioglitazone hydrochloride  rosiglitazone  and rosiglitazone maleate . d - glucosidase inhibitors include acarbose or miglitol .,C0000723;C0022709;C1305855
928,angiotensin - converting enzyme or angiotensin receptor blocker,C0022709;C1452534
928,ace = angiotensin - converting enzyme . arb = angiotensin receptor blockers .,C0022709;C0597357;C3888198
927,† includes patients originally randomized to placebo who were switched to secukinumab per the study designs .   ‡ aes that occurred in at least nmbr . nmbr % of the patients in the any secukinumab group during the nmbr ‐ week placebo ‐ controlled period and events with an eair of at least nmbr . nmbr cases per nmbr patient ‐ years in the any secukinumab group during the entire treatment period . events listed according to preferred term in the medical dictionary for regulatory activities ( meddra version nmbr . nmbr )  sorted in descending order of eair in the any secukinumab group for the entire treatment period . the entire treatment period for safety data was from baseline to week nmbr visit of the last patient enrolled in these studies . ae  adverse event  as  ankylosing spondylitis  eair  exposure adjusted incidence rates    n  number of randomized patients  sae  serious adverse event  urti  upper respiratory tract infection .,C0332257;C1552866;C2700399
926,included in this study ( n = nmbr ),C0332257;C0557651;C2603343
926,( including hypertension ),C0332257
925,investigator - reported hypoglycaemia *,C0035173
925,investigator - reported hypoglycaemia,C0035173
925,investigator - reported aes,C0035173;C0684224;C0700287;C1412268;C2699274;C4319718
925,investigator - determined myocardial infarction,C0035173
925,investigator - defined drug - related aes,C0035173
925,* determined by investigator to be possibly  probably or definitely related to study drug tmyopathy defined as cpk > nmbr x uln with associated muscle symptoms with no other plausible etiology ^consecutive defined as two or more measurements at least one week apart or one measurement < nmbr days after the last dose of study drug ( presumed consecutive ) § two patients had incomplete data to assess chd status simva = simvastatin  eze = ezetimibe  ae = adverse event  alt = alanine aminotransferase  ast = aspartate aminotransferase  cpk = creatine phosphokinase  uln = upper limit of normal,C0035173;C0521095
924,reported high cholesterol ' !,C0020443;C0684224;C0700287;C1522133;C4319718
924,hypercholesterolemia 一 no . ( % ),C0020443;C1522133
924,hypercholesterolemia — no . ( % ) *,C0020443;C1522133
924,hypercholesterolemia — no . ( % ),C0020443;C1522133
924,hypercholesterolemia *,C0020443;C1522133
924,hypercholesterolemia ( > nmbr mg / dl ),C0020443;C0439269;C1522133
924,hypercholesterolemia ( % ),C0020443;C1522133
924,hypercholesterolemia,C0020443;C1522133
924,hypercholesterolaemia ( % ),C0020443;C1522133
924,hypercholesterolaemia,C0020443;C1522133
924,elevated cholesterol,C0020443
924,duration of hypercholesterolemia ( yr ),C0020443;C0439234;C0449238;C1522133;C2926735
924,duration of hypercholesterolemia  mean ± sd ( years ),C0020443;C0439234;C0444504;C0449238;C1522133;C2347634;C2348143;C2699239;C2926735
924,duration of hypercholesterolaemia  mean ± sd ( year ),C0020443;C0439234;C0439508;C0444504;C0449238;C1522133;C2347634;C2348143;C2699239;C2926735
924,* hypercholesterolemia was defined as a low - density lipoprotein cholesterol level at enrollment of more than nmbr mg per deciliter ( nmbr . nmbr mmol per liter ) after an overnight fast . † nonsustained ventricular tachycardia was defined as nmbr or more consecutive ventricular beats at a heart rate of more than nmbr beats per minute . ‡ to convert weight to kilograms  divide by nmbr . nmbr . § to convert values for creatinine to micromoles per liter  multiply by nmbr . nmbr . ¶ data for follow - up medication were available for nmbr patients ( amiodarone  nmbr  placebo  nmbr  and icd  nmbr ) . ace de - notes angiotensin - converting enzyme  and arb angiotensin ii – receptor blocker . ¿ p < nmbr . nmbr for the comparison among the groups,C0020443;C1522133
923,serum ldl cholesterol,C0428474
922,serum total cholesterol ( mmol / l ),C0587184;C1287371;C1532563
922,serum total cholesterol,C0587184;C1287371
922,serum cholesterol,C0587184
922,mean serum cholesterol,C0444504;C0587184;C2347634;C2348143
921,non ‐ hdl cholesterol,C0729627;C1535899
921,non - hdl cholesterol j,C0729627;C1535899
921,non - hdl cholesterol ( week nmbr ),C0332174;C0439230;C0729627;C1535899
921,non - hdl cholesterol ( mmol / l ),C0729627;C1532563;C1535899
921,non - hdl cholesterol ( mg / dl ),C0439269;C0729627;C1535899
921,non - hdl cholesterol,C0729627;C1535899
920,non - hdl cholesterol / apob ( ratio ),C0003593;C0456603;C0729627;C1518422;C1535899;C1547037;C2938854;C3252643
920,ldl / hdl cholesterol ratio,C2938854
919,total cholesterol level,C0878805;C1445957
918,total cholesterol - to - hdl cholesterol ratio,C0428619
917,total cholesterol^,C0201950;C0543421
917,total cholesterol *,C0201950;C0543421
917,total cholesterol ( week nmbr ),C0201950;C0332174;C0439230;C0543421
917,total cholesterol ( sd ),C0201950;C0543421;C2699239
917,total cholesterol ( mmol / l ) :,C0201950;C0543421;C1532563
917,total cholesterol ( mmol / l ),C0201950;C0543421;C1532563
917,total cholesterol ( mmo nmbr / nmbr ),C0201950;C0543421
917,total cholesterol,C0201950;C0543421
917,tertile of total cholesterol at baseline,C0201950;C0543421
917,lipid concentrations total cholesterol ( mmol / l ),C0023779;C0086045;C0201950;C0543421;C1532563
916,hdl - c   high - density lipoprotein cholesterol    ldl - c   low - density lipoprotein cholesterol    sestandard error    tg   triglycerides .,C0023822;C0337445;C0743559;C0858892;C1608199
915,terol  hdl - c  high - density lipoprotein cholesterol ,C0023822
915,high density lipoprotein cholesterol - mg / dl * *,C0023822;C0439269
915,high density lipoprotein cholesterol,C0023822
915,high - density lipoprotein cholesterol — mg / dl,C0023822;C0439269
915,high - density lipoprotein cholesterol metabolic syndrome,C0023822;C0524620
915,high - density lipoprotein cholesterol mean ( mg / dl ± sd ),C0023822;C0439269;C0444504;C2347634;C2348143;C2699239
915,high - density lipoprotein cholesterol,C0023822
915,baseline high - density lipoprotein cholesterol ( mg / dl ),C0023822;C0168634;C0439269;C1442488
914,hdl cholesterol^ :,C0023822;C0392885
914,hdl cholesterol — mg / dl,C0023822;C0392885;C0439269
914,hdl cholesterol §,C0023822;C0392885
914,hdl cholesterol mean,C0023822;C0392885;C0444504;C2347634;C2348143
914,hdl cholesterol > nmbr - nmbr mmol / l,C0023822;C0392885;C1532563
914,hdl cholesterol < nmbr mg / dl *,C0023822;C0392885;C0439269
914,hdl cholesterol < nmbr - nmbr mmol / l,C0023822;C0392885;C1532563
914,hdl cholesterol < nmbr ( men ) or < nmbr mg / dl ( women ),C0023822;C0025266;C0392885
914,hdl cholesterol *,C0023822;C0392885
914,hdl cholesterol ( week nmbr ) a,C0023822;C0332174;C0392885;C0439230
914,hdl cholesterol ( sd ),C0023822;C0392885;C2699239
914,hdl cholesterol ( mmol / l ) :,C0023822;C0392885;C1532563
914,hdl cholesterol ( mmol / l ),C0023822;C0392885;C1532563
914,hdl cholesterol ( mg / dl ),C0023822;C0392885;C0439269
914,hdl cholesterol,C0023822;C0392885
914,hdl - cholesterol ( mmol / l ),C0023822;C0392885;C1532563
914,hdl - cholesterol ( mg / dl ),C0023822;C0392885;C0439269
914,hdl - cholesterol,C0023822;C0392885
914,- hdl cholesterol,C0023822;C0392885
913,risk reduction ( %  nmbr % ci ),C0008107;C1137094;C3259781
913,risk reduction,C1137094
913,% risk reduction ( nmbr % ci ),C0008107;C1137094;C3259781
913, ¿ ldl cholesterol levels are shown according to the median value ( nmbr mg per deciliter [nmbr . nmbr mmol per liter] ) and according to the values that divide the subjects into three equal groups ( < nmbr  nmbr to nmbr  and > nmbr mg per deciliter [ < nmbr . nmbr  nmbr . nmbr to nmbr . nmbr  and > nmbr . nmbr mmol per liter] ) .,C0008107;C0009667;C0439165;C1137094;C3259781
912,nmbr mg / dl ldl cholesterol | |,C0023824;C0202117;C0439269
912,ldl cholesterol^ :,C0023824;C0202117
912,ldl cholesterol — mg / dl | |,C0023824;C0202117;C0439269
912,ldl cholesterol — mg / dl,C0023824;C0202117;C0439269
912,ldl cholesterol mean ( mg / dl ± sd ),C0023824;C0202117;C0439269;C0444504;C2347634;C2348143;C2699239
912,ldl cholesterol mean,C0023824;C0202117;C0444504;C2347634;C2348143
912,ldl cholesterol at baseline ( mmol / l ) * ldl cholesterol at screening,C0023824;C0168634;C0202117;C1442488;C1532563
912,ldl cholesterol > nmbr - nmbr mmol / l,C0023824;C0202117;C1532563
912,ldl cholesterol < nmbr - nmbr mmol / l,C0023824;C0202117;C1532563
912,ldl cholesterol ( sd ),C0023824;C0202117;C2699239
912,ldl cholesterol ( mmol / l ) :,C0023824;C0202117;C1532563
912,ldl cholesterol ( mmol / l ),C0023824;C0202117;C1532563
912,ldl cholesterol ( mg / dl ),C0023824;C0202117;C0439269
912,ldl cholesterol,C0023824;C0202117
912,ldl - cholesterol ( mmol / l ),C0023824;C0202117;C1532563
912,ldl - cholesterol ( mmol / ),C0023824;C0202117;C0439190
912,ldl - cholesterol ( mg / dl ),C0023824;C0202117;C0439269
912,ldl - cholesterol (,C0023824;C0202117
912,ldl - cholesterol,C0023824;C0202117
912,baseline ldl cholesterol ( derived ),C0023824;C0168634;C0202117;C1442488
912,baseline ldl cholesterol,C0023824;C0168634;C0202117;C1442488
912,- ldl cholesterol,C0023824;C0202117
912,* the nmbr substrata with baseline ( bl ) ldl cholesterol nmbr to nmbr mg / dl and nmbr to nmbr mg / dl were combined to make nmbr group with bl ldl cholesterol nmbr to nmbr mg / dl because of small numbers of patients included in the substrata with nmbr to nmbr mg / dl . † bl hdl cholesterol cutoffs were nmbr or nmbr mg / dl for men and nmbr or nmbr mg / dl for women . bars indicate se . bmi body mass index  e ezetimibe nmbr mg  hdl - c hdl cholesterol  ldl - c ldl cholesterol  tg triglycerides,C0005918;C0006413;C0023824;C0168634;C0202117;C1442488;C1552663;C2827109
911,low density lipoprotein cholesterol - mg / dltt,C0023824;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
911,low density lipoprotein cholesterol,C0023824
911,low - density lipoprotein cholesterol — mg / dlf,C0023824;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
911,low - density lipoprotein cholesterol,C0023824
910,use of ace inhibitor,C0003015;C1524063;C4541021
910,no ace inhibitor / arb,C0003015;C3888198;C4541021
910,neither ace inhibitor nor arb,C0003015;C4541021
910,current use of an ace inhibitor,C0003015;C0521116;C1524063;C1705970;C4541021
910,both ace inhibitor and arb,C0003015;C4541021
910,ace inhibitors or arbs,C0003015
910,ace inhibitors or arb,C0003015
910,ace inhibitors or angiotensin receptor blockers,C0003015
910,ace inhibitors or angiotensin ii blockers,C0003015
910,ace inhibitors or angiotensin ii,C0003015
910,ace inhibitors or angiotensin - receptor blockers^,C0003015
910,ace inhibitors or angiotensin - receptor blockers,C0003015
910,ace inhibitors and arb,C0003015
910,ace inhibitors / sartans,C0003015;C1563745
910,ace inhibitors / arbs,C0003015;C3888198
910,ace inhibitors / arb,C0003015
910,ace inhibitors,C0003015
910,ace inhibitor — no . ( % ),C0003015;C4541021
910,ace inhibitor yes,C0003015;C1549445;C1705108;C1710701;C4541021
910,ace inhibitor use ( % ),C0003015;C0042153;C0457083;C1947944;C4541021
910,ace inhibitor treatment,C0003015;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C4541021
910,ace inhibitor or arb use,C0003015;C4541021
910,ace inhibitor or arb at last follow - up,C0003015;C4541021
910,ace inhibitor or arb at enrollment,C0003015;C4541021
910,ace inhibitor or arb,C0003015;C4541021
910,ace inhibitor or angiotensin receptor blocker,C0003015;C4541021
910,ace inhibitor or angiotensin ii receptor blocker,C0003015;C4541021
910,ace inhibitor or angiotensin ii receptor,C0003015;C4541021
910,ace inhibitor or angiotensin - receptor blocker — no . / total no . ( % ),C0003015;C4541021
910,ace inhibitor monotherapy,C0003015;C4541021
910,ace inhibitor at last follow - up,C0003015;C0589120;C1522577;C1704685;C3274571;C4541021
910,ace inhibitor at enrollment,C0003015;C1516879;C1696073;C3888021;C4541021
910,ace inhibitor and / or arb,C0003015;C4541021
910,ace inhibitor / arb,C0003015;C3888198;C4541021
910,ace inhibitor,C0003015;C4541021
910,ace - inhibitors / arbs,C0003015;C3888198
910,ace - inhibitors,C0003015
910,ace - inhibitor use,C0003015;C0042153;C0457083;C1947944;C4541021
910,ace - inhibitor or arb ( % ),C0003015;C4541021
909,dipeptidyl peptidase nmbr inhibitors,C0003015
909,dipeptidyl peptidase nmbr inhibitor,C0003015;C2757044;C3536837
909,dipeptidyl peptidase - nmbr inhibitor,C0003015;C2757044;C3536837
909,angiotensin - converting enzyme inhibitors^,C0003015;C2757044
909,angiotensin - converting enzyme inhibitors / angiotensin receptor blockers,C0003015;C0597357;C2757044
909,angiotensin - converting enzyme inhibitors,C0003015;C2757044
909,angiotensin - converting enzyme inhibitor or angiotensin receptor blocker use ( mitt population ),C0003015;C2757044;C3536837;C4541021
909,angiotensin - converting enzyme inhibitor or angiotensin receptor blocker,C0003015;C2757044;C3536837;C4541021
909,angiotensin - converting enzyme inhibitor / angiotensin receptor blocker,C0003015;C0597357;C2757044;C3536837;C4541021
909,angiotensin - converting enzyme inhibitor,C0003015;C2757044;C3536837;C4541021
909,angiotensin - converting - enzyme inhibitor or angiotensin - receptor blocker §,C0003015;C2757044;C3536837;C4541021
909,angiotensin - converting - enzyme inhibitor or angiotensin -,C0003015;C2757044;C3536837;C4541021
909,angiotensin - converting - enzyme inhibitor,C0003015;C2757044;C3536837;C4541021
909,abbreviations : acei  angiotensin - converting enzyme inhibitor  arb  angiotensin receptor blocker  bpm  beats per minute  ccb  calcium channel blocker  msdbp  mean sitting diastolic blood pressure  mssbp  mean sitting systolic blood pressure . values are no . ( % ) unless otherwise indicated . amean ± sd . bmore severe  > nmbr and < nmbr mm hg / > nmbr and < nmbr mm hg  less severe  > nmbr and < nmbr mm hg / > nmbr and < nmbr mm hg . blood pressure at baseline is with monotherapy ( ie  before switch to amlodipine / valsar - tan therapy ) .,C0000723;C0003015;C0597357;C2757044;C3536837;C3888198;C4541021
908,two lesions,C0205448;C0221198
908,treated lesions ‡,C0221198;C1522326
908,stents per lesion,C0038257;C0221198;C1546698
908,stented lesions,C0038257;C0221198
908,no . of treated lesions,C0221198;C1522326
908,modified acc / aha lesion class bnmbr or cj,C0221198;C0392747;C0456387;C1518526;C1546698;C1705943;C3889737;C4072694
908,modified acc / aha lesion class bnmbr / c,C0050451;C0101856;C0221198;C0392747;C0456387;C0772110;C1518526;C1546698;C1705943;C3889737
908,modified acc - aha lesion class bnmbr or c,C0221198;C0392747;C0456387;C1518526;C1546698;C1705943;C3889737;C4072694
908,mean stent diameter per lesion,C0038257;C0221198;C0552409;C1546698
908,lesions treated per patient,C0221198
908,lesions bnmbr / c,C0221198;C1546698
908,lesions,C0221198
908,lesion ( s ),C0221198;C1546698
908,intervention in complex lesions,C0221198;C1292781
908,direct stenting per lesion ‡,C0038257;C0221198;C0439851;C1546698;C1947931;C2348535
908,age > nmbr gd lesion > nmbr n = nmbr,C0001779;C0221198;C1546698
908,age > nmbr gd lesion = nmbr n = nmbr,C0001779;C0221198;C1546698
908,age < nmbr gd lesion > nmbr n = nmbr,C0001779;C0221198;C1546698
908,age < nmbr gd lesion = nmbr n = nmbr,C0001779;C0221198;C1546698
908,age / gd lesion,C0001779;C0221198;C1546698
908,acc / aha lesion class bnmbr or c,C0221198;C0456387;C1518526;C1546698;C1705943;C4072694
907,with higher classes indicating greater limitations on physical activity owing to,C0205250;C0456387;C1518526;C1705943;C4019422
907,renal biopsy class,C0194073;C0456387;C1518526;C1705943
907,non - hdl - c in nmbr classes,C0456387;C1518422;C1518526;C1705943;C3715113;C4019422
907,modified braunwald class,C0392747;C0456387;C1518526;C1705943;C3889737
907,kilip class,C0456387;C1518526;C1705943
907,egfr in nmbr classes,C0456387;C1518526;C1705943;C1739039;C3811844;C3812682;C4019422
907,class nmbr or no symptoms,C0456387;C1518526;C1705943
907,class nmbr antiarrhythmic agents,C0003195;C0301380;C0456387;C1518526;C1705943
907,class nmbr,C0456387;C1518526;C1705943
907,class ll - iv,C0456387;C1518526;C1705943
907,class l / ll heart failure,C0456387;C1518526;C1705943
907,class ic,C0020750;C0456387;C1518526;C1705943;C4554818
907,class ib,C0456387;C1518526;C1705943;C2744579;C3890035;C4283819
907,class ia,C0020980;C0456387;C0694634;C1518526;C1705943;C1947960
907,class > nmbr,C0456387;C1518526;C1705943
907,calculated ldl - c in nmbr classes,C0444686;C0456387;C1441506;C1518526;C1705943;C4019422
907,baseline trl - c in nmbr classes,C0168634;C0456387;C1442488;C1518526;C1705943;C4019422
907,baseline triglycerides in nmbr classes,C0041004;C0168634;C0456387;C1442488;C1518526;C1705943;C4019422
907,baseline numberf of adm classes,C0168634;C0215825;C0456387;C1442488;C1518526;C1705943;C4019422;C4521767
907,baseline lp ( a ) in nmbr classes,C0065058;C0168634;C0456387;C1439335;C1442488;C1518526;C1705943;C4019422;C4553379
907,baseline hdl - c in nmbr classes,C0168634;C0456387;C1442488;C1518526;C1705943;C3715113;C4019422
907,baseline hbanmbrc in nmbr classes,C0019016;C0168634;C0456387;C1442488;C1518526;C1705943;C1825777;C3538758;C4019422
907,baseline albumin / creatinine ratio in nmbr classes,C0168634;C0456387;C0486293;C1318293;C1442488;C1518526;C1705943;C4019422
907,age in nmbr classes,C0001779;C0456387;C1518526;C1705943;C4019422
906,enox,C3147679
905,ment,C0084844;C1538994
904,nnt,C1417750
903,network,C0150775;C1513822;C1705739;C1882071
902,necrosis,C0027540;C1334928
901,neutrophils,C0027950
900,severity ofhypertension [n ( % ) ]b,C0439793;C0522510
900,severity of hypertensionb,C0439793;C0522510
900,severity of heartburnb,C0439793;C0522510
900,severity of copda,C0439793;C0522510
900,severity of copd — no . ( % ) f,C0024117;C0439793;C0522510;C1412502;C3714496
900,severity of copd *,C0024117;C0439793;C0522510;C1412502;C3714496
900,severity of copd,C0024117;C0439793;C0522510;C1412502;C3714496
900,severity of airflow obstruction,C0028778;C0231999;C0439793;C0522510;C1882136
900,severity n ( % ),C0439793;C0522510
900,severity,C0439793;C0522510
900,nocturnal heartburn severity,C0018834;C0240526;C0439793;C0522510
900,nice classification of copd severity of obstruction,C0008902;C0008903;C0024117;C0028778;C0439793;C0522510;C0678229;C1412502;C1882136;C3714496;C4087029
900,morning stiffness severity,C0439793;C0457086;C0522510
900,luts severity,C0439793;C0522510;C0574785
900,heartburn severity during the run - in periodt,C0018834;C0439793;C0522510;C3274438
900,ed severity * *,C0439793;C0522510;C3538926
900,ed severity,C0439793;C0522510;C3538926
900,bph - luts severity,C0005001;C0439793;C0522510;C0574785;C1704272
900,any severity,C0439793;C0522510
899,lowzmedium intensity,C0522510
899,baseline statin intensity,C0168634;C0360714;C0522510;C1442488
899,baseline luts severity * :,C0168634;C0439793;C0522510;C0574785;C1442488
899,baseline luts severity,C0168634;C0439793;C0522510;C0574785;C1442488
899,baseline heart failure severity nyha class i,C0018801;C0018802;C0168634;C0439793;C0522510;C1442488;C1882084;C4554158
899,baseline heart failure severity amongthose with priorheartfailure,C0018801;C0018802;C0168634;C0439793;C0522510;C1442488;C4554158
899,baseline ed severity * * :,C0168634;C0439793;C0522510;C1442488;C3538926
898,with ckd intensive ( n = nmbr ),C0162425;C0522510;C1283828;C1550453;C1561643
898,no - ckd intensive ( n = nmbr ),C0162425;C0522510;C1283828;C1550453;C1561643
898,intensive therapy ( n = nmbr ),C0039798;C0087111;C0162425;C0522510;C1283828;C1363945;C1550453
898,intensive glycemia lowering,C0005802;C0162425;C0441994;C0522510;C1283828;C1550453;C2003888
898,intensive bp lowering,C0037623;C0162425;C0441994;C0522510;C1283828;C1415692;C1550453;C1708288;C2003888;C4318478
898,intensive ( n = nmbr ),C0162425;C0522510;C1283828;C1550453
898,intensitynmbr,C0522510
898,intense,C0522510
897,cardiac catheterization,C0018795
897,cardiac catheterisation or pci for index event,C0018795
896,cardiac rhythm disorders,C0264886
896,cardiac rhythm disorder at baseline yes,C0168634;C0264886;C1442488;C1549445;C1705108;C1710701
896,cardiac rhythm disorder at baseline no,C0168634;C0264886;C1442488
895,cardiac biomarker status !,C0005516;C0018787;C0449438;C0449442;C1271630;C1522601;C1999091;C2735302
895,cardiac biomarker,C1271630
895,cardiac - biomarker status 一 no . / total no . ( % ) $,C0005516;C0018787;C0449438;C0449442;C1271630;C1522601;C1999091;C2735302
895,cardiac - biomarker status — no . / total no . ( % ) $,C0005516;C0018787;C0449438;C0449442;C1271630;C1522601;C1999091;C2735302
894,cardiogenic shock during first nmbr hr after randomization,C0036980;C0205435;C1279901
894,cardiogenic shock,C0036980
893,carotid artery — no . ( % ),C0007272;C0162859
893,carotid artery intervention *,C0007272;C0162859;C0184661;C0397581;C0741968;C0886296;C1273869
893,carotid artery diseaset,C0007272;C0162859
892,• ii : death from coronary heart disease,C0010054;C0010068;C0011065;C1306577;C1710602;C1956346;C4082313;C4082587;C4552775
892,• death from coronary heart disease,C0010054;C0010068;C0011065;C1306577;C1956346;C4082313;C4552775
892,stable coronary artery disease,C0010054;C0010068;C0205360;C1547311;C1956346
892,previous coronary heart disease,C0010054;C0010068;C0205156;C1552607;C1956346
892,previous coronary artery disease,C0010054;C0010068;C0205156;C1552607;C1956346
892,only coronary artery disease,C0010054;C0010068;C0205171;C1720467;C1956346
892,multivessel coronary artery disease — no . / total no . ( % ),C0010054;C0010068;C1956346
892,multivessel coronary artery disease,C0010054;C0010068;C1956346
892,documented coronary artery disease,C0010054;C0010068;C1301725;C1609436;C1956346
892,coronary heart disease — no . ( % ),C0010054;C0010068;C1956346
892,coronary heart disease death,C0010054;C0010068;C0011065;C1306577;C1956346;C4082313;C4552775
892,coronary heart disease ( % ),C0010054;C0010068;C1956346
892,coronary heart disease,C0010054;C0010068;C1956346
892,coronary disease,C0010068;C1956346
892,coronary artery disease^,C0010054;C0010068;C1956346
892,coronary artery disease — no . / total no . ( % ),C0010054;C0010068;C1956346
892,coronary artery disease — no . ( % ) : c,C0010054;C0010068;C1956346
892,coronary artery disease — no . ( % ) : ! :,C0010054;C0010068;C1956346
892,coronary artery disease — no . ( % ),C0010054;C0010068;C1956346
892,coronary artery disease — %,C0010054;C0010068;C1956346
892,coronary artery disease §,C0010054;C0010068;C1956346
892,coronary artery disease history,C0010054;C0010068;C0019664;C0019665;C0262512;C0262926;C1705255;C1956346;C2004062
892,coronary artery disease *,C0010054;C0010068;C1956346
892,coronary artery disease ( n = nmbr nmbr ),C0010054;C0010068;C1956346
892,coronary artery disease ( % ),C0010054;C0010068;C1956346
892,coronary artery disease,C0010054;C0010068;C1956346
892,any established coronary artery disease,C0010054;C0010068;C0443211;C1272684;C1956346
892,any coronary artery disease,C0010054;C0010068;C1956346
892,* atherosclerotic coronary heart disease,C0010054;C0010068;C0018787;C0333482;C1956346
891,infarction nmbr - nmbr days,C0021308;C0439228
891,infarction before age nmbr ( a ),C0001779;C0021308
891,infarction > nmbr days previously,C0021308;C0439228
891,infarct ion w ithin previous nmbr day s,C0021308;C0022023;C0205156;C0332173;C0439228;C0439505;C1552607;C1700702
891,infarct - related vessel ( % ),C0021308
890,q waves in the infarct territory at baseline *,C0021308;C0429089;C1301808;C1305738;C2983136
890,q wave in the infarct territory at baseline *,C0021308;C0429089;C1301808;C1305738;C2983136
890,infarct territory ( % ),C0021308;C1301808;C2983136
889,vertebrobasilar infarct,C0021308;C0545733
889,symptomatic infarct swelling,C0013604;C0021308;C0038999;C0231220
889,prior infarction,C0021308;C0332152;C2826257
889,nonfatal myocardiail infarction,C0021308
889,nonfatai myocardiai infarction,C0021308
889,no infarct visible,C0021308
889,myocardiai infarction,C0021308
889,infarction,C0021308
889,infarct size,C0021308;C0456389
889,carotid infarct,C0021308;C0741968
889,cardioembolic infarction,C0021308
889,atherothrombotic infarction,C0021308
889,any infarct,C0021308
888,year of publication of primary results,C0034036;C0034037;C0205225;C0439234;C0439508;C0439612;C0439631;C1274040;C1546471;C1704324;C2825142
888,second co - primary outcome,C0205225;C0205436;C0439612;C0439631;C0457385;C0565930;C1274040;C1561503;C1705190;C3245499
888,primary target vessel ( % ),C0205225;C0439612;C0439631;C0449618
888,primary study joint,C0022417;C0205225;C0392905;C0439612;C0439631;C0557651;C1706309;C2603343
888,primary safety outcome -,C0036043;C0205225;C0439612;C0439631;C1274040;C1705187
888,primary pcit,C0205225;C0439612;C0439631
888,primary pci no .,C0205225;C0439612;C0439631;C4049621
888,primary pci n = nmbr,C0205225;C0439612;C0439631;C4049621
888,primary pci ( n = nmbr ),C0205225;C0439612;C0439631;C4049621
888,primary pci,C0205225;C0439612;C0439631;C4049621
888,primary outcomes,C0205225;C0439612;C0439631;C1274040
888,primary outcome plus revascularization or nonfatal hf,C0205225;C0332287;C0439612;C0439631;C0581603;C1274040
888,primary outcome ( nmbr - point mace ),C0205225;C0349381;C0439612;C0439631;C0949745;C1274040;C1445339;C1552961;C2347617;C3714763
888,primary outcome ! ( n = nmbr ),C0205225;C0439612;C0439631;C1274040
888,primary outcome !,C0205225;C0439612;C0439631;C1274040
888,primary outcome,C0205225;C0439612;C0439631;C1274040
888,primary nonresponse,C0205225;C0439612;C0439631
888,primary efficacy outcome,C0205225;C0439612;C0439631;C1274040;C1280519;C1707887
888,primary cause of chf,C0015127;C0018802;C0205225;C0439612;C0439631;C1524003
888,primary angioplasty ( n = nmbr ),C0162577;C0205225;C0439612;C0439631;C1548817
888,primary and secondary prevention subgroups  adjusted for age  gender  hypertension  diabetes mellitus  and smoking . hr indicates hazard ratio  nmbr % cl  nmbr % confidence interval  tia  transient ischemic attack .,C0205225;C0439612;C0439631
888,primary + gusto severe bleeding,C0019080;C0205082;C0205225;C0439612;C0439631;C4050465;C4050466
888,primary + gusto moderate or severe bleeding,C0205225;C0439612;C0439631
888,primary *,C0205225;C0439612;C0439631
888,primary,C0205225;C0439612;C0439631
888,medical history duration of heart failure ( years ) primary cause of heart failure,C0015127;C0199168;C0205225;C0205476;C0439234;C0439612;C0439631;C0449238;C0455531;C1524003;C2926735
888,first co - primary outcome,C0205225;C0205435;C0439612;C0439631;C1274040;C1279901;C3245499
888,fibrinolysis primary pci ( n = nmbr ) ( n = nmbr ) no . of patients / total no . ( % ),C0016017;C0205225;C0439612;C0439631;C1305868;C4049621
888,chd ( primary outcome ),C0205225;C0280604;C0439612;C0439631;C1274040;C3542407
887,prior pci or cabg surgery,C0332152;C2826257;C4049621
887,prior pci or cabg,C0332152;C2826257;C4049621
887,prior pci,C0332152;C2826257;C4049621
887,prerandomization pci,C4049621
887,pre - randomization pci,C0034656;C0332152;C0740175;C2257086;C3669034;C4049621
887,pci delay due to low risk,C4049621
887,no prior pci,C0332152;C2826257;C4049621
887,no pci,C4049621
886,secondary pci,C0027627;C0175668;C0205436;C4049621
886,received pci,C1514756;C4049621
886,before pci,C4049621
886,and after pci,C4049621
886,after pci,C4049621
885,treated with pci — no . / total no . ( % ),C0332293;C4049621
885,single vessel pci,C0005847;C0037179;C0087136;C0205171;C4049621
885,pci — no . { % ),C4049621
885,pci — no . ( % ),C4049621
885,pci alone ( n = nmbr ),C0205171;C0439044;C0679994;C4049621
885,no pci or cabg — no . ( % ),C4049621
885,nmbr vessel pci,C0005847;C4049621
885,multivessel pci,C4049621
885,facilitated pci ( n = nmbr ),C4049621
884,reteplase / abciximab - facilitated pci ( n = nmbr ),C0256103;C0288672;C4049621
884,ret / abx - facil . pci,C0389252;C4049621
884,combo - facilitated pci,C4049621
884,abx - facil . pci,C4049621
884,abciximab - facilitated pci ( n = nmbr ),C0288672;C4049621
884,abciximab - facilitated pci,C0288672;C4049621
883,pci orcabg,C4049621
883,pci > nmbr month ago,C0332177;C0439231;C4049621
883,pci :,C4049621
883,pci ( % ),C4049621
883,pci,C4049621
882,pci postindex event,C0441471;C4019010;C4049621
882,pci or cabg surgery for index event,C4049621
882,pci for index event,C0441471;C0600653;C0918012;C1552854;C1637833;C2986546;C4019010;C4049621
882,morphine use for index event / pci,C0242000;C0441471;C0600653;C0918012;C1552854;C1637833;C2986546;C4019010;C4049621
881,tertile nmbr index pci performed,C0600653;C0918012;C1552854;C1637833;C2986546;C4049621
881,pci performed,C4049621
881,index pci performed,C0600653;C0918012;C1552854;C1637833;C2986546;C4049621
880,bb after randomisation,C0004739;C0034656;C0332297
880,bb,C0004739;C0332297
880,- < — ■ bb — - ►,C0004739;C0332297
879,bmnmbr,C0006416
879,bm i < nmbr,C0006416;C0021966;C0221138
878,bl h / y : unilateral,C0005918;C0006413;C0033727;C0369286;C0441932;C0564385;C1552663;C2827109;C4528284
878,bl h / y : bilateral,C0005918;C0006413;C0033727;C0369286;C0441932;C0564385;C1552663;C2827109;C4528284
878,bl bmnmbr < nmbr kg / m^,C0005918;C0006413;C0006416;C1532718;C1552663;C2827109
878,bl bml > nmbr kg / m^,C0005918;C0006413;C1532718;C1552663;C2827109
878,bl bml > nmbr ke / m^,C0005918;C0006413;C0022558;C0369637;C0441923;C1552663;C2827109
878,bl bml < nmbr kg / m^,C0005918;C0006413;C1532718;C1552663;C2827109
878,bl bmioo kg / m^,C0005918;C0006413;C1532718;C1552663;C2827109
878,bl,C0005918;C0006413;C1552663;C2827109
878,\bl - sc n / n,C0005918;C0006413;C0282380;C1552663;C2827109
877,bundle branch block,C0006384;C1879286
876,left bundle - branch block,C0023211;C0344420;C2828132
875,in emergency department before ambulance transfer,C0002422;C0040671;C0562508;C1705822;C3846685;C4319192
875,in ambulance,C0002422;C3846685
875,ambulance ( % ),C0002422;C3846685
875,ambulance,C0002422;C3846685
874,cnmbrenmbr fab bolus and infusion ( n = nmbr ),C1186706;C1511237;C1705509;C3812160
874,cnmbrenmbr fab bolus ( n = nmbr ),C1186706;C1511237;C1705509;C3812160
874,cnmbrenmbr fab bolus,C1186706;C1511237;C1705509;C3812160
874,bolus of heparin given,C0019134;C0770546;C1186706;C1511237;C1705509;C3812160
874,bolus and infusion,C1186706;C1511237;C1705509;C3812160
874,bolus and corrections,C1186706;C1511237;C1705509;C3812160
874,bolus alone,C1186706;C1511237;C1705509;C3812160
874,bolus administered — no . ( % ),C1186706;C1511237;C1705509;C3812160
874,bolus,C1186706;C1511237;C1705509;C3812160
873,sprint acr > nmbr - nmbr,C1412134;C1515941
873,sprint acr < nmbr - nmbr,C1412134;C1515941
873,male acr definition,C0086582;C1412134;C1515941;C1550452;C1704788;C1706180;C1706428;C1706429;C3539107;C3888054
873,female acr definition,C0043210;C0086287;C1412134;C1515941;C1550452;C1704788;C1705497;C1705498;C3539107;C3888054
873,evaluable for acrnmbr at week nmbr,C1412134;C1515941;C1516986
873,b . acr nmbr,C1412134;C1515941
873,acrnmbr,C1412134;C1515941
873,acr deciles,C1412134;C1515941
873,acr,C1412134;C1515941
873,accord acr > nmbr - nmbr,C0680240;C1412134;C1515941
873,accord acr < nmbr - nmbr,C0680240;C1412134;C1515941
873,a . acr nmbr,C1412134;C1515941
872,ace or arb,C1452534;C4284014
872,ace - lorarb,C1452534;C4284014
872,ace - l / arbs,C1452534;C3888198;C4284014
872,ace - i / arb,C0021966;C0221138;C1452534;C3888198;C4284014
872,ace,C1452534;C4284014
871,arbs,C3888198
871,arb monotherapy,C3888198
871,arb / ace,C1452534;C3888198;C4284014
871,arb ( n,C3888198
871,arb,C3888198
871,aceis / arbs,C3888198
871,acei / arb therapy,C0039798;C0087111;C1363945;C3888198
871,acei / arb and bb after randomisation,C3888198
871,acei / arb,C3888198
871,ace inhibitor / arb therapy,C1444755;C3888198
871,ace / arb users,C1452534;C1706077;C3888198;C4284014
871,ace / arb use,C1452534;C3888198;C4284014
871,ace / arb medication ( % ),C0013227;C1452534;C3244316;C3888198;C4284014;C4284232
871,ace / arb,C1452534;C3888198;C4284014
870,without acei / arb,C3888198
870,with acei / arb,C3888198
870,use of ace inhibitors / arbs,C0003015;C1524063;C3888198
870,previously on acei + arb,C3888198
870,peri - op ace - inhibitors / arbs : no ( n = nmbr ),C0003015;C0347985;C3888198
870,baseiine acei / arb,C3888198
870,arbs or ace inhibitors,C3888198
870,arb or ace inhibitor,C3888198
869,ccbs,C0006684
869,ccb,C0006684
869,caleium ehannel bloekers ( ccb ),C0006684
869,calcium channel blockers,C0006684;C2757014
869,calcium channel blocker ( % ),C0006684;C3536851;C4521885
869,calcium channel blocker,C0006684;C3536851;C4521885
869,calcium channel antagonists,C0006684;C2757014
869,calcium antagonists,C0006684
869,calcium antagonist,C0006684
869,calcium - channel blockers ( % ),C0006684;C2757014
869,calcium - channel blockers,C0006684;C2757014
869,calcium - channel blocker *,C0006684;C3536851;C4521885
869,calcium - channel blocker ( ratelowering ),C0006684;C3536851;C4521885
869,calcium - channel blocker,C0006684;C3536851;C4521885
869,calcium - channel antagonists,C0006684;C2757014
869,baseiine ccb,C0006684
869,arb - arb / ccb,C0006684;C3888198
869,arb + ccb ( n = nmbr ),C0006684;C3888198
869,= calcium channel blocker  bmi = body,C0006684;C0242821;C0460148;C0578022;C1268086;C3536851;C4082212;C4521885
868,non - calcium antagonist strategy ( ncas ) ( events / n ),C0006684;C0441471;C0679199;C1413309;C1518422;C3541888;C3813543
868,non - calcium antagonist strategy ( n = nmbr nmbr ),C0006684;C0679199;C1518422
868,calcium antagonist — no . ( % ),C0006684
868,calcium antagonist strategy ( n = nmbr nmbr ),C0006684;C0679199
868,calcium antagonist strategy ( cas ) ( events / n ),C0006684;C0441471;C0679199;C3541888
867,brain volume,C1113695
866,prostate volume ( ml ),C0439526;C1441416;C1705224;C3887665
866,prostate volume ( cmnmbr ),C1441416
865,voided volume,C0042034;C0449468;C1552835;C1690016;C1705102;C2700258
865,total macular volume,C0332574;C0449468
865,tnmbr lesion volume,C0221198;C0449468;C1546698;C1690016;C1705102;C2603360;C2700258
865,pvr volume,C0242852;C0449468;C0456261;C1419141;C1690016;C1705102;C2700258
865,normalized volume measures,C0449468;C1690016;C1705102;C1882115;C2700258
864,type of tnf failure,C0231174;C0332307;C0680095;C1448177;C1547052
864,prior immunnosupressive failure but no anti - tnf failure,C0231174;C0332152;C0680095;C2826257
864,prior corticosteroid failure only,C0001617;C0205171;C0231174;C0332152;C0680095;C1720467;C2826257;C3536709
864,prior biologic therapeutic failures,C0005515;C0087111;C0205460;C0231174;C0302350;C0332152;C0680095;C2826257
864,prior anti - tnf failure,C0231174;C0332152;C0680095;C1448177;C2826257
864,heat failure,C0018837;C0231174;C0680095
864,failure,C0231174;C0680095
864,biologic therapeutic failure,C0005515;C0087111;C0205460;C0231174;C0302350;C0680095
864,> nmbr failure,C0231174;C0680095
863,freedom from gtc seizures,C1299590
862,outcome measure,C0086749
861,patient - reported outcome measures,C4277735
860,duration of procedure,C2346509
859,elective procedure,C0747973
858,dental procedure,C0011331
857,pre - procedure,C3272300
857,post - procedure,C3272301
856,other diagnostic procedure *,C0430022;C1546908
855,cardiac procedure :,C1279986
854,baseline systolic blood pressure ( mm hg ),C0439475;C4274438
854,baseline systolic blood pressure,C4274438
853,baseline diastolic blood pressure ( mm hg ),C0439475;C4274392
853,baseline diastolic blood pressure,C4274392
852,mean systolic blood pressure ( sd ),C0039155;C0428886;C0444504;C0488053;C0488055;C0871470;C1306620;C2347634;C2348143;C2699239
852,mean systolic blood pressure,C0039155;C0428886;C0444504;C0488053;C0488055;C0871470;C1306620;C2347634;C2348143
852,mean diastolic blood pressure ( sd ),C0012000;C0428883;C0428886;C0444504;C0488053;C1305849;C2347634;C2348143;C2699239
852,mean diastolic blood pressure,C0012000;C0428883;C0428886;C0444504;C0488053;C1305849;C2347634;C2348143
852,mean blood pressure,C0428886;C0488053
852,mean arterial pressure,C0428886
852,mean ( s . d . ) systolic blood pressure,C0039155;C0428886;C0444504;C0488053;C0488055;C0871470;C1306620;C2347634;C2348143
852,mean ( s . d . ) diastolic blood pressure,C0012000;C0428883;C0428886;C0444504;C0488053;C1305849;C2347634;C2348143
851,pulsed blood pressure,C0232108
850,visit nmbr blood pressures :,C0545082;C1272641;C1512346;C2826704
850,arterial blood pressure,C1272641
849,pulse pressure,C0949236
849,mean pulse pressure,C0232117;C0391850;C0444504;C0445074;C0949236;C1947910;C2347634;C2348143
848,forearm fracture,C1305215
847,femur fracture,C0015802
846,patella fracture,C0159849
845,tibia fracture,C0040185
845,fibula fracture,C0149699
844,foot fracture,C0272774
843,wrist fracture,C0435630;C4553927
842,hand fracture,C0435632
841,ankle fracture,C0159877;C4552974
840,upper limb fracture,C0178316
839,humerus fracture,C0020162
838,radius fracture,C0034628
837,clavicle fracture,C0159658
836,thoracic cage fractures,C0222762
835,pelvic fractures,C0149531
835,hip fracture only,C0019557;C0149531;C0205171;C1720467;C4552776
835,hip fracture + > nmbr,C0019557;C0149531;C4552776
835,hip fracture,C0019557;C0149531;C4552776
834,fragile,C0302113
834,e major non - vertebral fragility fractures ( fas ),C0205082;C0205164;C0302113;C0549207;C1518422;C4318856;C4521762
834,d non - vertebral fragility fractures ( fas ),C0073187;C0302113;C0332173;C0549207;C1518422;C4484261
833,fractures,C0016658
833,fracture,C0016658
833,bone fracture due to fall,C0016658;C0085639;C0238715;C0678226;C4553726
833,bone fracture,C0016658
832,prior nonvertebral fracture at age > nmbr years,C0016658;C0332152;C1510829;C2826257
832,prior nonvertebral fracture,C0016658;C0332152;C2826257
832,nonvertebral fractures,C0016658
832,nonvertebral fracture,C0016658
831,fractures ( site not specified ),C0016658
831,fracture history ( predefined ),C0016658;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
830,stsd > nmbr mm on admission ( n = nmbr,C0184666;C0809949;C4330985;C4554674
830,statin during admission,C0184666;C0360714;C0809949
830,risk level at admission,C0184666;C0809949;C2923839
830,p blocker before admission,C0184666;C0369773;C0809949;C2603361
830,no stsd > nmbr mm on admission ( n = nmbr,C0184666;C0809949;C4330985;C4554674
830,no statin during admission,C0184666;C0360714;C0809949
830,nmbr blocker before admission,C0184666;C0809949
830,medical therapy before admission,C0184666;C0418981;C0809949
830,before admission ),C0184666;C0809949
830,aspirin before admission,C0004057;C0184666;C0809949
830,admission k,C0184666;C0597277;C0809949;C1708601
830,admission grace score,C0184666;C0809949
830,admission crcl,C0184666;C0809949;C1846718
829,tnfi - ir,C0022065;C0022071;C1448132
829,tnf - ir,C0022065;C0022071;C1448132;C1448177
829,homa_ir,C0022065;C0022071;C1448132
829,homa . ir,C0022065;C0022071;C1448132
829,homa - ir score,C0022065;C0022071;C0449820;C1448132;C4050231
829,homa - ir ( % ) b,C0022065;C0022071;C1448132
829,homa - ir,C0022065;C0022071;C1448132
829,dmard - ir,C0022065;C0022071;C0242708;C1448132
829,dmard - biologic ir,C0005515;C0022065;C0022071;C0205460;C0242708;C1448132
829,bdmard - ir,C0022065;C0022071;C1448132
828,gpiib - iiia inhibitors,C0016011;C0243077
828,gp iib / iiia inhibitors,C0016011;C0243077
828,gp iib / iiia inhibitor used,C0016011;C1999216
828,gp iib / iiia inhibitor before pci — no . ( % ),C0016011;C1999216;C4049621
828,glycoprotein iib / iiia inhibitort,C0016011
828,glycoprotein iib / iiia inhibitors,C0016011;C0243077
828,glycoprotein iib / iiia inhibitor,C0016011;C1999216
828,bivalirudin plus glycoprotein iib / iiia inhibitors ( n = nmbr ),C0016011;C0168273;C0243077
828,any glycoprotein iib / iiia inhibitor use,C0016011;C0042153;C0457083;C1947944;C1999216
827,use of proton inhibitors,C0033727;C0243077;C1524063
827,tnf inhibitors,C0243077;C1448177
827,raas inhibitors,C0243077
827,non - tnf inhibitors,C0243077;C1448177;C1518422
827,no ilb / iiia inhibitors,C0243077;C4697913
827,no . of previous tne inhibitors,C0205156;C0243077;C1552607;C3896585
827,inhibitors — no . { % ) se - nmbr physical functioning score^^,C0243077
827,ilb / iiia inhibitors,C0243077;C4697913
827,gp llb / llla inhibitors,C0243077;C1705010;C3811116
826,monoamine oxidase b inhibitors,C2917290;C3653412
825,α - glucosidase inhibitor,C1512211
825,a - glucosidase inhibitors ' nmbr,C1512211
825,a - glucosidase inhibitors,C1512211
825,a - glucosidase inhibitor,C1512211
824,hmg - coa reductase inhibitors,C0360714;C2756999;C3539119
823,alpha reductase inhibitors,C0439095;C0597153;C1655741;C2003941;C2350010
822,renin inhibitors,C2917241;C3653375
822,renin - angiotensin inhibitors,C0003018;C2917241;C3653375;C4521302
821,sglt - nmbr inhibitors^,C3665045
820,p - gp inhibitor,C3898062
819,factor xa inhibitor,C2825027;C4553708
818,converting enzyme inhibitor,C0014432;C0919438;C4521603
818,angiotension converting enzyme - inhibitor,C0014432;C0919438;C4521603
817,cholesterol absorption inhibitor ( ezetimibe ),C0000854;C0003277;C1142985;C1999216;C2347023;C2347080;C2698776;C2825050;C2945742
816,pnmbrynmbr inhibitor maintenance,C0024501;C0369773;C1999216;C2603361
816,pnmbrynmbr inhibitor loading dos,C0369773;C1428722;C1708715;C1999216;C2603361
816,pnmbrynmbr inhibitor,C0369773;C1999216;C2603361
816,inhibitor,C1999216
815,tnf inhibitor,C1448177;C1999216
815,reason for discontinuation of previous tnfa inhibitor,C0205156;C0392360;C0457454;C1444662;C1448177;C1552607;C1710304;C1999216;C4552847
815,other sglt - nmbr inhibitor,C1999216
814,renin – angiotensin system inhibitor,C0035096;C1999216;C2984247
814,renin - angiotensin system inhibitor use,C0035096;C0042153;C0457083;C1947944;C1999216;C2984247
813,raas inhibitor use,C0042153;C0457083;C1947944;C1999216
813,raas inhibitor,C1999216
813,potent phosphorylated glycoprotein inhibitor use,C0017968;C0042153;C0457083;C1947944;C1999216;C3245505
813,gpifo ' llia inhibitor use before angography,C0042153;C0457083;C1947944;C1999216
813,gpifeellla inhibitor use before angography,C0042153;C0457083;C1947944;C1999216
813,glycoprotein iib / iiia inhibitor use before angiography,C0002978;C0016011;C0042153;C0457083;C1947944;C1999216
812,nmbr nil,C0442734
811,nmbr ix,C0015491
810,oil,C0028908;C0032085;C1517288;C3541397
810,- oil,C0028908;C0032085;C1517288;C3541397
809,iuss score,C0439453
809,iu,C0049272;C0439453;C0694756
808,randomized group by subgroup interaction,C0034656;C0441833;C0687744;C1079230;C1257890;C1515021;C1519504;C1704675;C1705428;C1705429;C3815594
808,randomization to end of study,C0034656
808,randomization to angiography,C0002978;C0034656
808,randomization to,C0034656
808,randomization stratum,C0034656
808,randomization groups nmbr and nmbr,C0034656;C0441833;C0687744;C1257890;C1519504;C1552839;C1705428;C1705429
808,randomization group,C0034656;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
808,randomization - to - angiography distribution time,C0002978;C0034656;C0681683
808,randomization - to - angiography,C0002978;C0034656
808,randomization - to -,C0034656
808,randomization ),C0034656
807,randomized treatments,C0034656;C0087111;C3815594
807,randomized treatment,C0034656;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3815594;C3887704
807,randomized to receiveaspirin,C0034656;C3815594
807,randomized to receive vitamin e,C0034656;C3815594
807,randomized to receive beta carotene,C0034656;C3815594
807,randomized to receive aspirin yes,C0034656;C3815594
807,randomized to canakinumab nmbr mg,C0034656;C3815594
807,randomized to aspirin use,C0004057;C0034656;C0042153;C0457083;C1947944;C3815594
807,randomized to active yitamin e,C0034656;C0205177;C3815594;C3853793;C3888249
807,randomized < nmbr hr after presentation — %,C0034656;C0449450;C3815594
807,randomized,C0034656;C3815594
807,no . randomized,C0034656;C3815594
807,all randomized women,C0034656;C0043210;C3815594
806,year from randomization,C0034656;C0439234;C0439508
806,vka at randomization,C0034656
806,treatments at randomisation,C0034656;C0087111
806,treatmentofpulmonary embolismpriorto randomization,C0034656
806,treatment randomization,C0034656;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
806,treatment before randomization,C0034656;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
806,treatment at randomization,C0034656;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
806,treatment at randomisation,C0034656;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
806,treatment after randomization,C0034656;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
806,to randomization,C0034656
806,thienopyridine at randomization,C0034656;C1120149
806,sulfasalazine use at randomization,C0034656;C0036078;C0042153;C0457083;C1947944
806,renal function at randomization,C0034656;C0232804
806,randomization,C0034656
806,randomisation scheme,C0034656;C1519193
806,randomisation,C0034656
806,patient characteristics at randomization,C0034656;C0815172
806,other llt at randomization,C0034656;C2347090
806,no vka at randomization,C0034656
806,nihss at randomization,C0034656;C1697238
806,mtx use at randomization,C0025677;C0034656;C0042153;C0457083;C1417487;C1947944
806,medications at timing of randomization,C0034656;C2359859
806,malignancy at randomization,C0006826;C0034656;C1306459;C4282132
806,length of stay ( randomization to discharge,C0023303;C0034656
806,killip class iv at randomization,C0034656;C2697847
806,heparin pre - randomization,C0019134;C0034656;C0332152;C0740175;C0770546;C2257086;C3669034
806,heparin at randomization,C0019134;C0034656;C0770546
806,edoxaban at randomization,C0034656;C2975435
806,diabetes at randomization,C0011847;C0011849;C0034656
806,creatinine clearance at randomization ( ixrs ),C0034656;C0812399
806,creatinine clearance at randomization,C0034656;C0812399
806,corticosteroid use at randomization,C0034656;C0239126
806,biochemical parameters at randomization,C0034656;C0205474;C0449381
806,beta - blocker use at randomization,C0001645;C0034656;C0042153;C0457083;C1947944
806,at randomization,C0034656
806,aspirin use at randomization,C0004057;C0034656;C0042153;C0457083;C1947944
806,aspirin dose at randomization,C0034656;C4696290
806,asastoppedat randomization,C0034656
806,antiplatelet at randomization,C0034656
806,age at randomization ( years ),C0034656;C1510829
806,age at randomization,C0001779;C0034656
806,age at randomisation,C0001779;C0034656
806,age at lipid randomization ( y ),C0001779;C0034656;C0065033
805,other outcomes,C1274040
805,ischemic outcomes,C0475224;C1274040
805,baseline outcomes,C0168634;C1274040;C1442488
805,adverse outcome,C1274040
804,result,C1274040;C1546471;C2825142
804,ancova result,C0814908;C1274040;C1546471;C2825142
803,“ relative risk of outcome in acei group iw control group . bbaseline variables for models included : logarithm of age,C0242492;C1274040
803,outcomes during accord,C0680240;C1274040
803,outcome according to stage of cancer — no . / total no . ( % ),C0027646;C0680240;C1274040
803,outcome according to primary cancer site — no . / total no . ( % ),C0680240;C0872338;C1274040
803,outcome according to no . of risk factors for vte,C0035648;C0680240;C1274040;C1553898
802,outcomes,C1274040
802,outcome type,C0332307;C1274040;C1547052
802,outcome severity,C0439793;C0522510;C1274040
802,outcome and metabolizer phenotype,C1274040
802,outcome - variant,C0205419;C1274040
802,outcome ( n,C1274040
802,outcome,C1274040
801,gastroduodenum,C0391900
801,gastroduodenal,C0450199
800,score distribution : < nmbr,C0449820;C0520511;C1704711;C4050231
800,score distribution :,C0449820;C0520511;C1704711;C4050231
800,hbanmbrc distribution at baseline,C0019016;C0168634;C0520511;C1442488;C1704711;C1825777;C3538758
800,hbanmbrc distribution,C0019016;C0520511;C1704711;C1825777;C3538758
800,distribution — no . { % ),C0520511;C1704711
800,distribution — no . ( % ),C0520511;C1704711
800,distribution time,C0040223;C0520511;C1704711;C3541383
800,anmbrc distribution ( % ),C0520511;C1704711
799,patients with established cv disease aged > nmbr years .,C0007222;C0030705;C0443211;C1272684;C1510829
799,established renal disease *,C0022658;C0443211;C1272684
799,established cvd / chronic kidney disease ( age > nmbr ) ^ * ’,C0001779;C0007222;C0443211;C1272684;C1561643;C4553188
799,established cvd ( age > nmbr ),C0001779;C0007222;C0443211;C1272684
799,established cardiovascular disease,C0007222;C0443211;C1272684
799,established atherosclerotic disease — no . { % ),C0012634;C0333482;C0443211;C1272684
799,established atherosclerotic disease,C0012634;C0333482;C0443211;C1272684
799,established atherosclerotic cv disease §,C0007222;C0333482;C0443211;C1272684
799,established atherosclerotic cardiovascular disease — no . { % ),C0004153;C0443211;C1272684
799,established atherosclerotic cardiovascular disease,C0004153;C0443211;C1272684
799,established atherosclerotic,C0333482;C0443211;C1272684
799,established ascvd or > nmbr cv risk factors,C0443211;C1272684;C3665365
799,established ascvd,C0443211;C1272684;C3665365
799,established ( n = nmbr ),C0443211;C1272684
799,established,C0443211;C1272684
798,smoking history : ex - smoker,C0337664;C1519384
798,smokers : qvanmbr - nmbrfc,C0337664;C2983605
798,smokers,C0337664
798,smoker or ex - smoker,C0337664
798,smoker ( % ) a,C0337664
798,smoker ( % ),C0337664
798,smoker,C0337664
798,past smoker,C0337664;C1444637;C4284302
798,noncurrent smoker,C0337664
798,ever - smoker,C0337664;C3887636
797,timi flow grade nmbr of mi culprit vessel pre ‐ pci,C0005847;C0441800;C0919553;C3244287;C3272266;C3810814
797,timi flow grade nmbr of mi culprit vessel post ‐ pci,C0005847;C0441800;C0856742;C0919553;C3244287;C3272266;C4049621
797,rankin grade,C0441800;C0919553;C3244287
797,nerd grade,C0441800;C0919553;C3244287
797,mmrc grade,C0441800;C0919553;C3244287;C3826977
797,mean mmrc grade,C0441800;C0444504;C0919553;C2347634;C2348143;C3244287;C3826977
797,initial timi flow grade nmbr,C0205265;C0441800;C0919553;C1279901;C1555582;C1705685;C3244287;C3272266
797,grade of hypertension,C0020538;C0441800;C0919553;C1963138;C3244287
797,grade nmbr ( severe copd ),C0441800;C0919553;C3244287
797,grade nmbr ( moderate copd ),C0441800;C0919553;C3244287
797,grade nmbr,C0441800;C0919553;C3244287
797,grade > nmbr,C0441800;C0919553;C3244287
797,gold grade nmbr,C0018026;C0441800;C0919553;C1304897;C3244287
797,final timi flow grade post - ppci,C0205088;C0441800;C0687676;C0919553;C1546485;C1704687;C3244287;C3272266;C3469826;C3853528
797,final timi flow grade < nmbr,C0205088;C0441800;C0919553;C1546485;C3244287;C3272266;C3853528
797,dyspnoea - mmrc grade,C0013404;C0441800;C0919553;C1963100;C3244287;C3826977
797,dyspnea – mmrc grade,C0013404;C0441800;C0919553;C1963100;C3244287;C3826977
796,location of ml,C0439526;C0450429;C1515974;C1705224;C3887665;C4284930;C4284931
796,location of infarction — no . ( % ) §,C0021308;C0450429;C1515974;C4284930;C4284931
796,location of infarction,C0021308;C0450429;C1515974;C4284930;C4284931
796,location of disease,C0012634;C0450429;C1515974;C4284930;C4284931
796,location of crohn ' s disease,C0010346;C0450429;C1515974;C4284930;C4284931
796,location,C0450429;C1515974;C4284930;C4284931
796,lesion location,C0221198;C0450429;C1515974;C1546698;C4284930;C4284931
796,infarct related artery location,C0003842;C0021308;C0226004;C0439849;C0445223;C0450429;C1515974;C4284930;C4284931
796,infarct location — no . / total no . ( % ),C0021308;C0450429;C1515974;C4284930;C4284931
796,infarct location anterior,C0021308;C0450429;C1515974;C4284930;C4284931
796,infarct location ( interactsn $ : p = nmbr . nmbr ),C0021308;C0450429;C1515974;C4284930;C4284931
796,infarct location,C0021308;C0450429;C1515974;C4284930;C4284931
796,disease location / type : terminal ileum,C0227327;C0450429;C0457464;C1515974;C4284930;C4284931
796,disease location ( % ) *,C0012634;C0450429;C1515974;C4284930;C4284931
796,disease location,C0012634;C0450429;C1515974;C4284930;C4284931
796,anterior infarct location,C0340293;C0450429;C1515974;C2349195;C4284930;C4284931
795,years of follow - up,C0439234;C0589120;C1522577;C1704685;C3274571
795,warfarin at last follow - up,C0043031;C0589120;C1522577;C1704685;C3274571
795,thiazide at last follow - up,C0541746;C0589120;C1522577;C1704685;C3274571
795,statin at last follow - up,C0360714;C0589120;C1522577;C1704685;C3274571
795,sbp during the follow - up period ( mmhg ),C0085805;C0439475;C0439531;C0589120;C1522577;C1704685;C1948053;C3274571
795,nmbr - month follow - up median ( iq range ),C0332177;C0439231;C0549183;C0589120;C0876920;C1514721;C1522577;C1704685;C2347635;C2348144;C2348147;C2939193;C3274571;C3542016
795,mean glycated hemoglobin reduction during characteristic follow - up ( nmbr % ci ) percent,C0017853;C0439165;C0444504;C0520870;C0589120;C1521970;C1522577;C1704685;C2347634;C2348143;C3274571
795,loop at last follow - up,C0445022;C0589120;C1522577;C1704685;C3274571
795,fracture during follow - up,C0016658;C0589120;C1522577;C1704685;C3274571
795,follow - up in - trial at nmbr yr,C0008976;C0439234;C0589120;C1522577;C1704685;C3274571
795,follow - up,C0589120;C1522577;C1704685;C3274571
795,end of follow - up,C0444930;C0589120;C1522577;C1704685;C2746065;C3274571
795,digoxin at last follow - up,C0012265;C0589120;C1522577;C1704685;C3274571
795,dbp during the follow - up period ( mmhg ),C0439475;C0439531;C0536221;C0589120;C1522577;C1704685;C1948053;C3274571;C3813197;C4281799
795,beta - blocker at last follow - up |,C0001645;C0589120;C1522577;C1704685;C3274571
795,at end of follow - up — no . / total no . ( % ),C0444930;C0589120;C1522577;C1704685;C2746065;C3274571
795,at end of follow - up — no . ( % ),C0444930;C0589120;C1522577;C1704685;C2746065;C3274571
795,at end of follow - up,C0444930;C0589120;C1522577;C1704685;C2746065;C3274571
795,aspirin at last follow - up,C0004057;C0589120;C1522577;C1704685;C3274571
795,arb at last follow - up,C0589120;C1522577;C1704685;C3274571;C3888198
794,standard control ( n = nmbr ) no . of patients ( percent ),C0243148;C1442989;C1550141;C1882979;C2587213;C2828392;C3274648;C4553389
794,standard control,C0243148;C1442989;C1550141;C1882979;C2587213;C2828392;C3274648;C4553389
794,rhythm - control group ( n = nmbr ),C0243148;C0441848;C0871269;C1523018;C1550141;C1882979;C2587213;C3274648;C3828331;C4553389
794,intensive control ( n = nmbr ) no . of patients ( percent ),C0162425;C0243148;C0522510;C1283828;C1550141;C1550453;C1882979;C2587213;C3274648;C4553389
794,intensive control,C0162425;C0243148;C0522510;C1283828;C1550141;C1550453;C1882979;C2587213;C3274648;C4553389
794,good control ( < nmbr ),C0205170;C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
794,glycaemic control ( hbanmbrc ),C0005802;C0019016;C0243148;C1550141;C1825777;C1882979;C2587213;C3274648;C3538758;C4553389
794,fair control ( nmbr - nmbr . nmbr ),C0243148;C1550141;C1882979;C2587213;C2911689;C3274648;C4553389
794,controls ( n = nmbr ),C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
794,control of sitting bp at week nmbr,C0037623;C0243148;C0277814;C1415692;C1550141;C1708288;C1882979;C2584297;C2587213;C3274648;C4050224;C4318478;C4553389
794,control nmbr months ( n - nmbr ),C0243148;C0439231;C1550141;C1882979;C2587213;C3274648;C4553389
794,control n = nmbr,C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
794,control group ( n = nmbr ),C0243148;C0441848;C1550141;C1882979;C2587213;C3274648;C4553389
794,control baseline ( n - nmbr ),C0168634;C0243148;C1442488;C1550141;C1882979;C2587213;C3274648;C4553389
794,control = warfarin,C0043031;C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
794,control ( nznmbr ),C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
794,control ( n z nmbr ),C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
794,control ( n = nmbr ),C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
794,control ( n - nmbr ),C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
794,control,C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
794,bp control,C0037623;C0243148;C1415692;C1550141;C1708288;C1882979;C2587213;C3274648;C4318478;C4553389
794,asthma control,C0004096;C0243148;C1550141;C1882979;C2587213;C2984299;C3274648;C4553389
794,asthma - control status at randomization — no . ( % ),C0004096;C0034656;C0243148;C0449438;C1550141;C1882979;C2587213;C2984299;C3274648;C4553389
794,active - control study,C0243148;C0557651;C1550141;C1706449;C1882979;C2347179;C2587213;C2603343;C3274648;C4553389
794,( % ) control ( nmbr ),C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
794,% asthma control days {,C0004096;C0243148;C0439228;C1550141;C1882979;C2587213;C2984299;C3274648;C4553389
793,controllednmbr — no . ( % ),C2587213;C2911690
793,controlled : acq - nmbr < nmbr . nmbr,C2587213;C2911690;C2919686
793,controlled,C2587213;C2911690
792,nmbr low ( n = nmbr ),C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
792,low ’,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
792,low { < nmbr % ),C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
792,low tt < nmbr . nmbr ( n = nmbr ),C0205251;C1452561;C1550472;C3890211;C4048187;C4321351;C4522223;C4554543
792,low trs : nmbr - nmbr ( n = nmbr,C0205251;C0266427;C0968917;C1150746;C1550472;C3890211;C4048187;C4321351;C4522223
792,low subgroup,C0205251;C1079230;C1515021;C1550472;C3890211;C4048187;C4321351;C4522223
792,low potencyc,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
792,low periostin subgroup (,C0205251;C0219433;C1079230;C1424662;C1515021;C1550472;C3812270;C3890211;C4048187;C4321351;C4522223
792,low perceived social support only,C0030971;C0037438;C0205171;C0205251;C0748877;C1540833;C1550472;C1720467;C3669642;C3890211;C4048187;C4321351;C4522223
792,low or moderate,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
792,low nfs nfs < - nmbr . nmbr ( n = nmbr ),C0205251;C1513839;C1550472;C3890211;C4048187;C4321351;C4522223
792,low feno subgroup (,C0205251;C1079230;C1515021;C1550472;C3890211;C4048187;C4321351;C4522223
792,low eosinophil subgroup (,C0014467;C0205251;C1079230;C1515021;C1550472;C3890211;C4048187;C4321351;C4522223
792,low cnmbr / cnmbr and anti - dsdna,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
792,low cnmbr ( < nmbr mg / dl ),C0205251;C0439269;C1550472;C3890211;C4048187;C4321351;C4522223
792,low cnmbr ( < nmbr . nmbr g / l ),C0205251;C0439294;C0456615;C1550472;C3890211;C4048187;C4321351;C4522223
792,low - molecular - weight only,C0026385;C0041667;C0205171;C0205251;C1521991;C1550472;C1720467;C3890211;C4048187;C4321351;C4522223
792,low - molecular - weight,C0026385;C0041667;C0205251;C1521991;C1550472;C3890211;C4048187;C4321351;C4522223
792,low - ceiling diuretic,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
792,low ( no risk factor ),C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
792,low ( nmbr - nmbr ) ( n = nmbr  nmbr  nmbr % ),C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
792,low ( nmbr - nmbr ),C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
792,low ( n = nmbr ),C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
792,low ( > nmbr . nmbr and < nmbr ),C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
792,low ( < nmbr % ) baseline hbanmbrc,C0019016;C0168634;C0205251;C1442488;C1550472;C1825777;C3538758;C3890211;C4048187;C4321351;C4522223
792,low ( < nmbr % ) baseline hbalc,C0168634;C0205251;C1442488;C1550472;C3890211;C4048187;C4321351;C4522223
792,low ( < nmbr % ),C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
792,low,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
791,mean duration of disease,C0444504;C0872146;C2347634;C2348143
791,mean disease duration,C0444504;C0872146;C2347634;C2348143
791,mean ( sd ) disease duration,C0444504;C0872146;C2347634;C2348143;C2699239
791,duration of disease — yr^ mean,C0439234;C0444504;C0872146;C2347634;C2348143
791,duration of disease — yr : t,C0439234;C0872146
791,duration of disease — yr,C0439234;C0872146
791,duration of disease — mo,C0026544;C0332177;C0872146
791,duration of disease since,C0872146
791,duration of disease before baseline,C0872146
791,duration of disease ( yr ),C0439234;C0872146
791,duration of disease ( years ),C0439234;C0872146
791,duration of disease ( y ),C0872146
791,duration of disease,C0872146
791,disease duration : < baseline mean,C0168634;C0444504;C0872146;C1442488;C2347634;C2348143
791,disease duration,C0872146
790,uc disease duration ( y ),C0872146
790,median disease duration — yr,C0439234;C0549183;C0872146;C0876920;C2347635;C2348144;C2939193
790,disease duration nmbr to bnmbr years ( n = nmbr ),C0439234;C0872146
790,disease duration b nmbr years ( n = nmbr ),C0439234;C0872146
790,disease duration [year],C0439234;C0439508;C0872146
790,disease duration > nmbr years ( n = nmbr ),C0439234;C0872146
790,disease duration > nmbr years,C0439234;C0872146
790,disease duration ( yr ),C0439234;C0872146
790,disease duration ( years ),C0439234;C0872146
790,disease duration ( y ),C0872146
789,use of rescue medication,C0240320
789,use of other medications — no . ( % ),C0240320
789,rescue medication use,C0240320
789,prior medication use,C0240320;C0332152;C2826257
789,no use ofdiabetes drugs — no . ( % ),C0240320
789,medication use at entry ( % ),C0240320;C1705654
789,medication use ( % ) aspirin,C0004057;C0240320
789,medication use ( % ),C0240320
789,medication use,C0240320
789,diabetes - related medication use,C0011847;C0011849;C0240320;C0439849;C0445223
789,concomitant medication use,C0240320;C0521115
788,mmse score *,C0449820;C0451306;C4050231
788,mmse score,C0449820;C0451306;C4050231
788,mmse nmbr - nmbr,C0451306
788,mmse > nmbr,C0451306
788,mmse = mini - mental state examination  adas — cog = alzhei -,C0451306;C3539026
788,mmse < nmbr,C0451306
788,mmse ( points ),C0451306
788,mini - mental state examination,C0451306
788,a mini - mental state examination,C0451306
787,without dyspnoea,C0013404;C1963100
787,with dyspnoea,C0013404;C1963100
787,no dyspnoea ( n = nmbr ),C0013404;C1963100
787,mmrc dyspnea scale score : t : t,C0013404;C1963100;C3826977;C4049715
787,dyspnoea ( n = nmbr ),C0013404;C1963100
787,dyspnea t,C0013404;C1963100
787,dyspnea,C0013404;C1963100
787,clopidogrel dyspnoea vs no dyspnoea *,C0013404;C0070166;C1963100
787,cdr - sob,C0013404;C4521843
787,borg dyspnea score who functional class,C0013404;C0449820;C1963100;C4050231
786,valvular heart disease — no . ( % ),C0018824;C1963123
786,valvular heart disease,C0018824;C1963123
786,cardiac valvular disease,C0018824
785,valvular disease ( % ),C3258293
785,valvular disease,C3258293
784,structural heart disease — no . ( % ) f,C1290384
784,structural heart disease §,C1290384
784,structural heart disease,C1290384
783,no cardiac disease,C0018799
783,no apparent heart disease,C0018799;C0750489
783,isehemie heart disease,C0018799
783,cardiac disorders ( soc ),C0018799
783,cardiac disorder,C0018799
783,cardiac disease,C0018799
782,vessel disease,C0042373
782,vascular disease,C0042373
782,previous vascular disease,C0042373;C0205156;C1552607
782,other vascular disease — no . ( % ),C0042373
782,other vascular disease ( cvd or pad ),C0007222;C0042373
782,other vascular disease,C0042373
782,double - vessel disease,C0042373;C0205173;C1705764;C1705765
782,any vascular disease,C0042373
781,polyvascular disease * status,C3176928
781,physician ' s global assessment of disease status score,C0449820;C3176928;C4050231;C4050369
781,patient ' s global assessment of disease status score,C0449820;C3176928;C4050231;C4054229
781,global assessment of disease status score,C0281858;C0449820;C3176928;C4050231
780,sitagliptin nmbr nmbr . nmbr 士 nmbr . nmbr fasting plasma glucose ( fpg ) ( mmol / l ),C0015663;C0202042;C0455280;C1532563;C1565750
780,nmbr - hr plasma glucose — mg / dl,C0202042;C0439269;C0455280
780,nmbr - h plasma glucose during ogtt ( mmol / l ),C0029161;C0202042;C0455280;C2827804
780,fasting plasma glucose — mg / dl,C0015663;C0202042;C0439269;C0455280
780,fasting plasma glucose nmbr medan,C0015663;C0202042;C0455280
780,fasting plasma glucose categories,C0015663;C0202042;C0455280;C0683312
780,fasting plasma glucose *,C0015663;C0202042;C0455280
780,fasting plasma glucose ( mmol / l ) nmbr,C0015663;C0202042;C0455280;C1532563
780,fasting plasma glucose ( mmol / l ),C0015663;C0202042;C0455280;C1532563
780,fasting plasma glucose ( mg / dl ) nmbr,C0015663;C0202042;C0439269;C0455280
780,fasting plasma glucose ( mg / dl ),C0015663;C0202042;C0439269;C0455280
780,fasting plasma glucose,C0015663;C0202042;C0455280
780,fascng plasma glucose a medan,C0202042;C0455280
780,chd  coronary heart disease  eze / simva  ezetimibe / simvastatin combination tablet  fpg  fasting plasma glucose  pvd  peripheral vascular disease ,C0010068;C0015663;C0039225;C0074554;C0085096;C0202042;C0455280;C1532737;C1705223;C4319774
780,casual plasma glucose ( mg / dl ),C0202042;C0439269;C0455280
780,baseline fasting plasma glucose,C0015663;C0168634;C0202042;C0455280;C1442488
779,medical historv,C0199168;C0205476
779,medical characteristics,C0199168;C0205476;C1521970
779,medical and lifestyle history,C0199168;C0205476
779,first medical contact — no . ( % ) §,C0199168;C0205435;C0205476;C1279901
779,first medical contact in ambulance,C0002422;C0199168;C0205435;C0205476;C0332158;C0337611;C1279901;C1705415;C3812666;C3846685
779,first medical contact,C0199168;C0205435;C0205476;C0332158;C0337611;C1279901;C1705415;C3812666
778,§ classes on the canadian cardiovascular society ( ccs ) scale range from i to iv,C0007226;C0037455;C0175659;C0238884;C0349674;C1514721;C1879987;C1947916;C2348147;C3542016;C3887460
778,ccs class §,C1879987
777,diagnostic catheterization,C0596429
776,dual i extension,C0021966;C0205173;C0221138;C0231448;C1554184;C1880641
776,dual antiplatelet,C0205173;C1554184
775,previously untreated isolated systolic hypertension,C0332155;C0745133
775,isolated systolic hypertension^,C0745133
775,isolated systolic hypertension ⁎,C0745133
775,isolated systolic hypertension,C0745133
774,disease stage,C0699749
773,decreased appetite,C0232462
772,endoscopic disease severity,C0014245;C0442418;C0521117
772,disease severity,C0521117
772,copd disease severity,C0024117;C0521117;C1412502;C3714496
771,chf score ( u ),C0018802;C0439148;C0449820;C4050231
771,chf on losartan ( % ),C0018802;C0126174
771,chf ( % ),C0018802
771,chf,C0018802
770,chronic heart failure class ii - iii,C0018802;C0264716;C0439070;C0441886;C0441887;C1705160;C1710602;C2698968;C2698969;C4082587
770,chronic heart failure,C0018802;C0264716
769,prior congestive heart failure yes,C0018802;C0332152;C1549445;C1705108;C1710701;C2826257
769,prior congestive heart failure,C0018802;C0332152;C2826257
769,history congestive heart failure,C0018802;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
769,histor y of congestive heart failure — no . ( % ),C0018802
769,congestive heart failure †,C0018802
769,congestive heart failure — %,C0018802
769,congestive heart failure §,C0018802
769,congestive heart failure at randomisation,C0018802;C0034656
769,congestive heart failure ( definite ),C0018802
769,congestive heart failure ( chf ) ( in past nmbr weeks ),C0018802;C2987125
769,congestive heart failure ( < nmbr wk ),C0018802;C0332174;C0439230
769,congestive heart failure,C0018802
768,worsening heart failure,C0018801;C0018802;C0332271;C1457868;C1546960;C4554158
768,recurrent heart failure,C0018801;C0018802;C1455761;C2945760;C4554158
768,prior heart failure — no . { % ),C0018801;C0018802;C0332152;C2826257;C4554158
768,prior heart failure yes,C0018801;C0018802;C0332152;C1549445;C1705108;C1710701;C2826257;C4554158
768,prior heart failure ( n = nmbr,C0018801;C0018802;C0332152;C2826257;C4554158
768,prior heart failure,C0018801;C0018802;C0332152;C2826257;C4554158
768,primary cause of heart failure,C0015127;C0018801;C0018802;C0205225;C0439612;C0439631;C1524003;C4554158
768,previous hospital admission for heart failure,C0018801;C0018802;C0184666;C0205156;C1552607;C4554158
768,participants without heart failure,C0018801;C0018802;C0679646;C4554158
768,participants with heart failure,C0018801;C0018802;C0679646;C4554158
768,p value heart failure vs no heart failure,C0018801;C0018802;C1709380;C4554158
768,no prior heart failure ( n = nmbr,C0018801;C0018802;C0332152;C2826257;C4554158
768,no prior heart failure,C0018801;C0018802;C0332152;C2826257;C4554158
768,no heart failure,C0018801;C0018802;C4554158
768,main etiology of heart failure,C0015127;C0018801;C0018802;C0205225;C1314792;C1524003;C1542147;C4554158
768,ischemic heart failure etiology,C0015127;C0018801;C0018802;C0475224;C1314792;C1524003;C4554158
768,hospitalized heart failure,C0018801;C0018802;C0701159;C4554158
768,hospitalized for heart failure during that time period,C0018801;C0018802;C0701159;C4554158
768,hospitalized / fatal heart failure,C0018801;C0018802;C0701159;C1302234;C1705232;C4554158
768,hospital admission for heart failure,C0018801;C0018802;C0184666;C4554158
768,histor y of heart failure,C0018801;C0018802;C4554158
768,heart failure ‡,C0018801;C0018802;C4554158
768,heart failure — no . / total no . ( % ),C0018801;C0018802;C4554158
768,heart failure — no . ( % ),C0018801;C0018802;C4554158
768,heart failure or lvef < nmbr % associated with index acs event,C0018801;C0018802;C4554158
768,heart failure nyha ii - iii,C0018801;C0018802;C0439070;C1275491;C1705160;C1710602;C4082587;C4554158
768,heart failure nmbr yr before admission,C0018801;C0018802;C0184666;C0439234;C0809949;C4554158
768,heart failure nmbr month before admission,C0018801;C0018802;C0184666;C0332177;C0439231;C0809949;C4554158
768,heart failure nmbr mo before admission,C0018801;C0018802;C0026544;C0184666;C0332177;C0809949;C4554158
768,heart failure criteria met,C0018801;C0018802;C0243161;C4554158
768,heart failure cause,C0015127;C0018801;C0018802;C1524003;C4554158
768,heart failure at entry,C0018801;C0018802;C1705654;C4554158
768,heart failure *,C0018801;C0018802;C4554158
768,heart failure ( treated / hospitalized / fatal ),C0018801;C0018802;C4554158
768,heart failure ( nyha ii ‐ iii ),C0018801;C0018802;C0439070;C1275491;C1705160;C1710602;C4082587;C4554158
768,heart failure ( hf ),C0018488;C0018801;C0018802;C1313497;C1538440;C3273279;C4554158
768,heart failure ( class l - lll ),C0018801;C0018802;C0456387;C1261077;C1518526;C1705943;C4554158
768,heart failure ( class i — iii ),C0018801;C0018802;C0021966;C0221138;C0439070;C0441885;C0441887;C1319793;C1705160;C2698967;C2698969;C4554158
768,heart failure,C0018801;C0018802;C4554158
768,fatal & nonfatal hospitalized heart failure,C0018801;C0018802;C0701159;C1302234;C1705232;C4554158
768,congestive heart failure — no . ( % ) | |,C0018802
768,congestive heart failure — no . ( % ) |,C0018802
768,congestive heart failure — no . ( % ),C0018802
768,combined cardiac failure,C0018801;C0018802;C0205195
768,cause of heart failure — no . ( % ),C0015127;C0018801;C0018802;C1524003;C4554158
768,cause of heart failure,C0015127;C0018801;C0018802;C1524003;C4554158
768,cardiac failure —,C0018801;C0018802
768,cardiac failure §,C0018801;C0018802
768,cardiac failure *,C0018801;C0018802
768,cardiac failure,C0018801;C0018802
767,valsartan / hctz ( n = nmbr ),C0020261;C0216784
767,valsartan / hctz,C0020261;C0216784
767,val / hctz ( n = nmbr ),C0020261;C0042285;C0523975
767,v alsartan / hctz,C0020261
767,v / hctz ( n = nmbr ),C0020261
767,v / hctz,C0020261
767,hctz * ( n = nmbr ),C0020261
767,hctz *,C0020261
767,hctz,C0020261
766,hctz = hydrochlorothiazide . * based on wilcoxon nmbr - sample rank - sum tests for age and body mass index,C0020261
766,hctz = hydrochlorothiazide . * based on a ' / _nmbr test,C0020261
766,hctz - hydrochlorothiazide . * data were missing for some patients .,C0020261;C1511726;C3245479;C3714741
765,telmisartan / amlodipine - telmisartan / amlodipine / hydrochlorothiazide,C0020261;C0051696;C0939233;C2733369
765,olmesartan nmbr - olmesartan nmbr / hydrochlorothiazide nmbr . nmbr,C0020261;C1098320
765,hydrochlorothiazide,C0020261
764,• any stroke,C0038454;C4554100
764,with prior mi / stroke ( n = nmbr ),C0038454;C0332152;C2826257;C3810814;C4554100
764,time from qualifying stroke to randomization,C0038454;C0040223;C1514624;C3541383;C4554100
764,time from onset of qualifying stroke to randomization,C0038454;C0449244;C1514624;C4554100
764,stroke — no . / total no . ( % ),C0038454;C4554100
764,stroke — no . ( % ),C0038454;C4554100
764,stroke thought due to atherothrombotic disease,C0038454;C4554100
764,stroke subtype,C0038454;C0449560;C4554100
764,stroke ortiab,C0038454;C4554100
764,stroke ortia,C0038454;C4554100
764,stroke or transient ischemic attack,C0038454;C4554100
764,stroke or tia — no . ( % ),C0038454;C4554100
764,stroke or tia,C0038454;C4554100
764,stroke or systemic embolism,C0038454;C4554100
764,stroke or systemic,C0038454;C4554100
764,stroke or see,C0038454;C4554100
764,stroke or se ( s / se ),C0038454;C4554100
764,stroke or pvd,C0038454;C4554100
764,stroke or cerebrovascular disease,C0038454;C4554100
764,stroke or,C0038454;C4554100
764,stroke of atherosclerotic origin,C0038454;C0079946;C0333482;C0439659;C1550512;C4554100
764,stroke of any etiology,C0015127;C0038454;C1314792;C1524003;C4554100
764,stroke non - fatal,C0038454;C4554100
764,stroke n = nmbr,C0038454;C4554100
764,stroke n ( % ),C0038454;C4554100
764,stroke deaths,C0011065;C0038454;C1306577;C4554100
764,stroke at entry ( vs transient ischemic attack ),C0038454;C1705654;C4554100
764,stroke at entry,C0038454;C1705654;C4554100
764,stroke any,C0038454;C4554100
764,stroke and tia,C0038454;C4554100
764,stroke / transient ischemic attack,C0038454;C4554100
764,stroke / see,C0038454;C4554100
764,stroke / se,C0036919;C0038454;C4554100
764,stroke / non -,C0038454;C4554100
764,stroke / m nmbr,C0038454;C0369637;C0441923;C4554100
764,stroke / embolism,C0013922;C0038454;C1704212;C4554100
764,stroke ( vs tia ),C0038454;C4554100
764,stroke ( fatal / nonfatal ),C0038454;C4554100
764,stroke,C0038454;C4554100
764,sensorimotor stroke,C0038454;C4554100
764,qualifying stroke,C0038454;C1514624;C4554100
764,pure sensory stroke,C0038454;C0445254;C2247561;C4554100
764,prior stroke or tza,C0038454;C0332152;C2826257;C4554100
764,prior stroke or transient ischemic attack,C0038454;C0332152;C2826257;C4554100
764,prior stroke or tia,C0038454;C0332152;C2826257;C4554100
764,prior stroke / tia,C0007787;C0038454;C0332152;C0917805;C1054154;C2826257;C4554100
764,prior stroke / mi,C0038454;C0332152;C2826257;C3810814;C4554100
764,prior stroke ( n = nmbr ),C0038454;C0332152;C2826257;C4554100
764,prior stroke ( % ),C0038454;C0332152;C2826257;C4554100
764,prior stroke,C0038454;C0332152;C2826257;C4554100
764,prior ml / stroke,C0038454;C0332152;C0439526;C1705224;C2826257;C3887665;C4554100
764,prior mi / stroke,C0038454;C0332152;C2826257;C3810814;C4554100
764,nonfatal stroke ®,C0038454;C4554100
764,nonfatal stroke ( n = nmbr ),C0038454;C4554100
764,nonfatal stroke,C0038454;C4554100
764,non - fatal stroke,C0038454;C1302234;C1518422;C1705232;C4554100
764,no stroke n = nmbr nmbr,C0038454;C4554100
764,no stroke ( n = nmbr ),C0038454;C4554100
764,no prior stroke / tia,C0007787;C0038454;C0332152;C0917805;C1054154;C2826257;C4554100
764,no prior stroke ( n = nmbr ),C0038454;C0332152;C2826257;C4554100
764,no prior stroke,C0038454;C0332152;C2826257;C4554100
764,no . of strokes / no . of patients in category ( and % ),C0038454
764,no . of strokes ( % ),C0038454
764,new stroke *,C0038454;C0205314;C4554100
764,history of stroke or transient ischemic attack,C0019664;C0019665;C0038454;C0262512;C0262926;C1705255;C2004062;C4554100
764,history of stroke or tia — no . ( % ),C0019664;C0019665;C0038454;C0262512;C0262926;C1705255;C2004062;C4554100
764,history of stroke or tia - n ( % ),C0019664;C0019665;C0038454;C0262512;C0262926;C1705255;C2004062;C4554100
764,hemispheric stroke n = nmbr,C0038454;C0205139;C4554100
764,fatal stroke,C0038454;C1302234;C1705232;C4554100
764,early ichaem ic stroke,C0020750;C0038454;C1279919;C4554100;C4554818
764,disabling stroke,C0038454;C4554100
764,cvd / stroke / see,C0007222;C0038454;C4554100
764,atherothrombotic stroke,C0038454;C4554100
764,any stroke ( n = nmbr ),C0038454;C4554100
764,any stroke,C0038454;C4554100
764,all stroke,C0038454;C4554100
764,a stroke,C0038454;C4554100
763,stroke / tia,C0007787;C0038454;C0917805;C1054154;C4554100
763,no stroke / tia,C0007787;C0038454;C0917805;C1054154;C4554100
763,hx stroke / tia,C0007787;C0038454;C0262926;C0917805;C1054154;C3814444;C4554100
763,cerebrovascular accident / tia,C0007787;C0038454;C0917805;C1054154
763,cerebrovascular accident,C0038454
762,concomitant cardiovascular therapy — no . ( % ),C0007226;C0521115;C0587038;C1707479;C3887460
762,concomitant cardiovascular therapy ( taken > nmbr days ),C0007226;C0521115;C0587038;C1707479;C3887460
762,concomitant cardiovascular therapy,C0007226;C0521115;C0587038;C1707479;C3887460
762,concomitant cardiovascular therapies — no . ( % ),C0007226;C0521115;C0587038;C1707479;C3887460
762,cardiovascular therapies — no . { % ),C0587038
761,previous cardiovascular events,C0205156;C1320716;C1552607
761,previous cardiovascular event — no . ( % ),C0205156;C1320716;C1552607
761,previous cardiovascular event at randomization,C0034656;C0205156;C1320716;C1552607
761,previous cardiovascular event ( % ),C0205156;C1320716;C1552607
761,cardiovascular events,C1320716
760,patients with microvascular complications,C0009566;C0030705;C0443258;C1171258
760,microvascular outcome,C0443258;C1274040
760,microvascular eye diseased,C0015392;C0443258;C0700042
760,microvascular complicationsb,C0443258
760,microvascular complications,C0009566;C0443258;C1171258
759,endovascular — no . ( % ),C0524425
759,endovascular,C0524425
758,without cerebrovascular disease,C0007820
758,with cerebrovascular disease,C0007820
758,prior cerebrovascular disease,C0007820;C0332152;C2826257
758,only cerebrovascular disease,C0007820;C0205171;C1720467
758,ischemic cerebrovascular disease,C0007820;C0475224
758,chd + cerebrovascular disease men nmbr / nmbr ( nmbr . nmbr ),C0007820;C0025266;C0280604;C3542407
758,cerebrovascular disorders,C0007820
758,cerebrovascular disease n ( % ),C0007820
758,cerebrovascular disease,C0007820
758,cerebral vascular disease,C0007820
757,previous cerebrovascular event,C0205156;C0441471;C1552607;C1880018;C4019010
757,pervious cerebrovascular event,C0205326;C0441471;C1880018;C4019010
757,cerebrovascular or peripheral arterial disease,C1880018
757,cerebrovascular,C1880018
756,secondary cardiovascular endpoint,C0007226;C3887460;C4528314
756,primary cardiovascular endpoint,C0007226;C2986535;C3887460
756,previous history of cardiovascular events,C0007226;C2004062;C3887460
756,non - cardiovascular mortality,C0007226;C0026565;C0026566;C1518422;C3887460
756,no . of predictors of cardiovascular risk,C0007226;C0035647;C2698872;C3887460;C4552904
756,high cardiovascular risk,C0007226;C0332167;C3272283;C3887460;C4050568;C4319571
756,extended cardiovascular endpoint,C0007226;C0231448;C0231449;C0439792;C2349179;C2826544;C3887460
756,exploratory cardiovascular and death outcomes,C0007226;C3887460
756,core cardiovascular endpoint,C0007226;C0444669;C1167518;C1706352;C1882467;C2349179;C2826544;C3274653;C3887460
756,cardiovascular status,C0007226;C0449438;C3887460
756,cardiovascular risk,C0007226;C0035647;C3887460;C4552904
756,cardiovascular mortality or mi,C0007226;C0026565;C0026566;C3887460
756,cardiovascular mortality,C0007226;C0026565;C0026566;C3887460
756,cardiovascular metabolic syndrome risk lactors,C0007226;C0035647;C0524620;C3887460;C4552904
756,cardiovascular inclusion criteriat,C0007226;C0007637;C1512693;C3887460
756,cardiovascular hospitalization,C0007226;C0019993;C3887460
756,cardiovascular hospitalisation §,C0007226;C0019993;C3887460
756,cardiovascular and respiratory,C0007226;C3887460
756,cardiovascular and oral hypoglycemic drugs - no . ( % ),C0007226;C3887460
756,cardiovascular,C0007226;C3887460
756,baseline cardiovascular assessment,C0007226;C0168634;C0846600;C1442488;C3887460;C4684571
756,any cardiovascular diseased,C0007226;C3887460
756,all cardiovascular,C0007226;C3887460
755,with revascularisation,C0581603
755,urgent peripheral revascularization,C0205100;C0439609;C0581603;C3272275
755,target - vessel revascularization,C0449618;C0581603
755,revascularization in nmbr days,C0439228;C0581603
755,revascularization,C0581603
755,revascularisation but no antiplatelets,C0581603
755,revascularisation,C0581603
755,prior revascularization ( n = nmbr,C0332152;C0581603;C2826257
755,prior revascularization ( % ),C0332152;C0581603;C2826257
755,prior revascularization,C0332152;C0581603;C2826257
755,peripheral revascularization ( n = nmbr ),C0205100;C0581603
755,peripheral revascularization,C0205100;C0581603
755,peripheral revascularisation,C0205100;C0581603
755,peripheral arterial revascularization,C0003842;C0205100;C0221464;C0581603
755,pci revascularization,C0581603;C4049621
755,no revascularisation,C0581603
755,no prior revascularization ( n = nmbr,C0332152;C0581603;C2826257
755,no peripheral revascularization ( n = nmbr,C0205100;C0581603
755,carotid revascularization,C0581603;C0741968
755,arterial revascularization,C0003842;C0221464;C0581603
755,any revascularization,C0581603
755,any peripheral revascularization,C0205100;C0581603
754,• urgent coronaiy revascularization > nmbr days,C0439228;C0439609;C0581603;C3272275
754,urgent revascularization because of unstable angina,C0002965;C0439609;C0581603;C3272275
754,urgent revascularizati on,C0439609;C3272275
754,urgent revascularisation due to unstable angina,C0002965;C0439609;C0581603;C0678226;C3272275
754,nmbr days urgent revascularization,C0439228;C0439609;C0581603;C3272275
753,lelt ventricular hypertrophy *,C0340279
752,left ventricular systolic dysfunction,C1277187;C1963159;C4553199
751,left ventricular ejection,C2733342
751,left ventricular dysfunction,C0242698
750,left ventricular systolic or diastolic dysfunction,C0039155;C0225897
750,left ventricular ef,C0225897
749,right ventricular dysfunction — no . / total no . ( % ) §,C0242707;C1556315
749,right ventricular dysfunction,C0242707;C1556315
748,cypnmbranmbr inhibitors,C0243077;C1418793;C2634343
748,cypnmbranmbr,C1418793;C2634343
747,ipah / hpah,C0152171;C0340543;C0637939;C1150929
747,ipah,C0152171
746,sleep,C0037313
745,pleased,C3829994;C4264468
744,alert,C0239110;C2004580;C3665546;C3669039;C4084853;C4553014
743,ale < nmbr,C0678386;C2632076
743,ale,C0678386;C2632076
742,feet,C0016504;C0347981
742,beyond popliteal pedal,C0016504;C0442037;C0687080
741,large / very large,C0442824;C0549177;C2984081
740,bare metal,C0025552
740,bare - metal,C0025552
739,rarely,C0522498
738,rarely / never,C4035880
737,safety variable,C0036043;C0439828;C1705187;C4553760
737,safety,C0036043;C1705187
736,with baseline crp level of > nmbr mg / liter,C0024671;C0026410;C0168634;C0439269;C0441889;C0456079;C0475211;C1442488;C1547707;C1960952;C2346927;C2946261;C3890735;C4048285;C4321396;C4521761
736,use at baseline,C0042153;C0168634;C0457083;C1442488;C1947944
736,triglycerides at baseline,C0041004;C0168634;C1442488
736,treatment at baseline,C0039798;C0087111;C0168634;C1442488;C1522326;C1533734;C1705169;C3538994;C3887704
736,treated at baseline,C0168634;C1442488;C1522326
736,systolic bp at baseline :,C0168634;C0871470;C1442488
736,sulfonylurea use at baseline,C0038766;C0042153;C0168634;C0457083;C1442488;C1947944;C3536898
736,subpopulation analyses according to baseline hbanmbrc,C0002778;C0019016;C0168634;C0441837;C0680240;C0936012;C1442488;C1524024;C1825777;C3538758
736,steroid use at baseline ( mg / day ),C0168634;C0281991;C0439422;C1442488
736,statin use at baseline :,C0042153;C0168634;C0360714;C0457083;C1442488;C1947944
736,statin use at baseline,C0042153;C0168634;C0360714;C0457083;C1442488;C1947944
736,ss at baseline,C0168634;C1442488;C2699257;C3891295;C4551874
736,smokers ( at baseline ),C0168634;C0337664;C1442488
736,smoker at baseline,C0168634;C0337664;C1442488
736,sbp at baseline,C0085805;C0168634;C1442488
736,s - asa compounds at baseline,C0004057;C0010139;C0043474;C0168634;C1442488;C3853627
736,remission by : baseline steroid doses,C0038317;C0168634;C0178602;C0544452;C0687702;C1442488
736,remission by : baseline duration of steroid,C0038317;C0168634;C0814126;C1442488
736,ratio to baseline in total ige at week nmbr,C0168634;C0456603;C1442488;C1547037
736,ratio to baseline in eosinophil count at week nmbr,C0168634;C0456603;C1442488;C1547037
736,randomisation visit ( baseline ),C0034656;C0168634;C0545082;C1442488;C1512346;C2826704
736,pre - bronchodilator fefnmbr . nmbr ( ml / s ) baseline blood eosinophil count,C0005767;C0005768;C0014467;C0168634;C0200638;C0229664;C0439390;C0750480;C0750879;C1442488;C1705566;C2599602
736,percent atheroma volume at baseline,C0168634;C0264956;C1442488;C1690016;C3887614
736,pef at baseline,C0030771;C0168634;C1442488;C1518922;C1542834
736,parameters at baseline,C0168634;C0449381;C1442488
736,parameter at baseline,C0168634;C0549193;C1442488;C1704769;C2350001
736,oral corticosteroid use at baseline,C0001617;C0168634;C0239126;C0442027;C1442488;C1527415;C3536709;C4521986
736,one at baseline,C0168634;C0205447;C1442488
736,on statins at baseline,C0168634;C0360714;C1442488
736,on aspirin at baseline,C0004057;C0168634;C1442488
736,on antihypertensive medication at baseline,C0003364;C0168634;C1442488
736,ocs at baseline,C0168634;C1442488
736,nvf at flex baseline - nmbr < flex fn t - score,C0168634;C0449820;C1442488;C1570610;C4050231
736,normoalbuminuria at baseline ( nmbr % of patients treated ),C0030705;C0168634;C1442488
736,normal baseline crp,C0168634;C0205307;C0231683;C0439166;C1442488;C2347086;C3890735;C4048285;C4553972
736,none at baseline,C0168634;C1442488
736,no mtx use at baseline,C0025677;C0042153;C0168634;C0457083;C1417487;C1442488;C1947944
736,no mtx at baseline,C0025677;C0168634;C1417487;C1442488
736,no mra at baseline,C0168634;C0243032;C1442488;C1609165;C3891069
736,no chd at baseline,C0168634;C0280604;C1442488;C3542407
736,no aspirin at baseline,C0004057;C0168634;C1442488
736,no asa use at baseline,C0004057;C0042153;C0168634;C0457083;C1442488;C1947944;C3853627
736,nmbr med at baseline,C0168634;C1442488;C4321267
736,nihss at baseline,C0168634;C1442488;C1697238
736,mtx use at baseline,C0025677;C0042153;C0168634;C0457083;C1417487;C1442488;C1947944
736,mtx at baseline,C0025677;C0168634;C1417487;C1442488
736,mtss at baseline observed case,C0168634;C1442488
736,mra at baseline,C0168634;C0243032;C1442488;C1609165;C3891069
736,motor updrs subscore ( baseline ),C0168634;C1442488;C1513492;C1705994;C3639721
736,mmrc at baseline,C0168634;C1442488;C3826977
736,mildlydecreased baseline gfr ( nmbr - nmbr ml / min / nmbr . nmbrmnmbr ),C0017654;C0168634;C0369637;C0439445;C0441923;C1424601;C1442488
736,microalbuminuria at baseline ( nmbr % of patients treated ),C0030705;C0168634;C0730345;C1442488
736,mental activities updrs subscore ( baseline ),C0168634;C0229992;C0441655;C1442488;C3639721
736,memantine use at baseline,C0025242;C0042153;C0168634;C0457083;C1442488;C1947944
736,medication use at baseline — no . ( % ),C0168634;C0240320;C1442488
736,medication use at baseline - n ( % ),C0168634;C0240320;C1442488
736,medication use at baseline,C0168634;C0240320;C1442488
736,mean baseline nasal congestion score,C0027424;C0168634;C1442488;C3533236;C4554631
736,mean baseline ldl - c ( mmol / l ),C0168634;C0444504;C1442488;C1532563;C2347634;C2348143
736,mean ( ± sd ) baseline score,C0168634;C1442488;C2699239;C3533236
736,macroalbuminuria at baseline ( nmbr % of patients treated ),C0030705;C0168634;C1442488
736,ldl - c at baseline :,C0168634;C1442488
736,killip at baseline,C0168634;C1442488
736,intensified baseline ( n - nmbr ),C0168634;C1442488
736,insulin at baseline,C0021641;C0168634;C1442488;C1533581;C1579433;C3714501
736,in remission at maintenance study baseline,C0024501;C0168634;C0544452;C0557651;C0687702;C1442488;C2603343
736,improvement from baseline ≥   nmbr,C0168634;C1442488;C2986411
736,hypertension severity at baseline,C0168634;C1442488;C4013784
736,hscrp at baseline,C0168634;C1442488
736,hscrp ( post - baseline / baseline ratio ),C0168634;C0456603;C0687676;C1442488;C1547037;C1704687;C3469826
736,heart rate at baseline ( bpm,C0018810;C0168634;C1442488
736,heart rate at baseline,C0018810;C0168634;C1442488
736,heart - rate group at baseline,C0018810;C0168634;C0441833;C0687744;C1257890;C1442488;C1519504;C1705428;C1705429
736,hdl - c at baseline .,C0168634;C1442488;C3715113
736,gm  geometric mean  gmr  geometric mean ratio over baseline  uacr  urinary albumimcreatinine ratio . % reduction : nmbr x ( nmbr — ratio of gmr for losartan versus gmr for placebo ) . amean of change  with change calculated as difference between time indicated and baseline as measured for each participant  difference of changes between treatment groups . cp - values compare differences from no change .,C0017480;C0042027;C0168634;C0301630;C0392756;C0456603;C1293152;C1442488;C1522544;C1524119;C1547037;C1704695;C2986759;C3854019;C4551656
736,for baseline hemoglobin nmbr g nmbr ’,C0168634;C1319312;C1442488
736,for baseline hemoglobin < nmbr g nmbr ',C0168634;C1319312;C1442488
736,flex baseline bmd t score,C0168634;C0449820;C1442488;C4050231
736,flex baseline bmd t - score at lumbar spine ( meanisd ),C0024091;C0168634;C0449820;C1442488;C3887615;C4050231
736,flex baseline bmd t - score at femoral neck ( meanisd ),C0015815;C0168634;C0449820;C1442488;C4050231
736,flex baseline bmd,C0168634;C1442488
736,fevnmbr   at baseline ( randomization ) ∗,C0034656;C0168634;C1442488;C3714541
736,fevnmbr at baseline,C0168634;C1442488;C3714541
736,fevnmbr / fvc at baseline ( randomization ) ( % ) ∗,C0034656;C0168634;C1442488;C3714541
736,femoral neck f - score at flex baseline,C0015815;C0016327;C0168634;C0449820;C1442488;C4050231
736,fbg baseline,C0168634;C1442488
736,estimated gfr ( ml / min / nmbr . nmbr mnmbr ) lipid baseline lipid profile,C0017654;C0023779;C0168634;C0369637;C0439445;C0441923;C0750572;C1424601;C1442488;C1979963;C2003903
736,estimated cv risk at baseline,C0168634;C1442488;C1519101;C3538987;C4048877;C4318503
736,enthesitis score at baseline,C0168634;C0449820;C1282952;C1442488;C4050231
736,egfr at baseline,C0168634;C1442488;C1739039;C3811844;C3812682
736,ecg findings at baseline — no . ( % ),C0168634;C0438154;C1442488
736,dlqi improvement from baseline to week nmbr,C0168634;C1442488;C2986411;C3899393
736,diuretic use at baseline,C0012798;C0042153;C0168634;C0457083;C1442488;C1947944
736,diabetic retinopathy at baseline,C0011884;C0168634;C1442488
736,diabetes duration at baseline,C0011847;C0011849;C0168634;C0449238;C1442488;C2926735
736,diabetes at baseline,C0011847;C0011849;C0168634;C1442488
736,dbp nmbr . nmbr ( nmbr . nmbr ) baseline lipid profile,C0023779;C0168634;C0536221;C1442488;C1979963;C2003903;C3813197;C4281799
736,dactylitis score at baseline,C0168634;C0239161;C0449820;C1442488;C4050231
736,czp baseline,C0054841;C0168634;C1442488;C1861828;C1872109
736,csdmard use at baseline^,C0042153;C0168634;C0457083;C1442488;C1947944
736,creatinine > nmbr x baseline,C0010294;C0168634;C1442488;C1561535
736,creatinine > nmbr . nmbrx baseline and above uln,C0010294;C0168634;C1442488;C1561535
736,corticosteroid use at baseline - yes,C0168634;C0239126;C1442488;C1549445;C1705108;C1710701
736,corticosteroid use at baseline - no,C0168634;C0239126;C1442488
736,corticosteroid use at baseline,C0168634;C0239126;C1442488
736,conventional synthetic dmard use at baseline,C0042153;C0168634;C0242708;C0439858;C0457083;C1442488;C1883254;C1947944
736,concentrations at baseline,C0086045;C0168634;C1442488
736,comparison with baseline ( mean,C0168634;C0444504;C1442488;C1707455;C2347634;C2348143
736,comparison with baseline,C0168634;C1442488;C1707455
736,common study baseline,C0168634;C0205214;C0557651;C1442488;C1522138;C2603343;C3245511
736,coiticosieroids at baseline,C0168634;C1442488
736,ckd at baseline,C0168634;C1442488;C1561643
736,chd at baseline,C0168634;C0280604;C1442488;C3542407
736,changes from baseline in mssbp and msdbp are shown as least - squares mean sem . * p nmbr . nmbr vs nmbr y .,C0168634;C0392747;C0443172;C1442488
736,changes at baseline,C0168634;C0392747;C0443172;C1442488
736,change from baseline to week nmbr in weekly size of largest hive score,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
736,change from baseline to week nmbr in weekly no . of hives score,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
736,change from baseline stage nmbr ckd,C0168634;C0597205;C0679846;C1442488;C1561643
736,change from baseline in rescue medication use ( puffs per day ),C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
736,change from baseline in,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
736,change from baseline *,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
736,change from baseline,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
736,bsl  baseline  cl  confidence interval  esrd  end - stage renal disease  hb  hemoglobin  k ( rate )  # of events per nmbr patient - years of follow - up  rrr  relative risk reduction  yr  year . ^treatment effect of losartan versus placebo . interaction test between treatment group and hemoglobin group ( < nmbr or > nmbrg i - nmbr ) . cmultivariate cox model with baseline log urinary albumimcreatinine ratio  serum albumin  serum creatinine  and hemoglobin as covariates . dmultivariate cox model with baseline log urinary albumimcreatinine ratio  serum albumin  serum creatinine  and hemoglobin and change in hemoglobin at year nmbr as covariates .,C0009667;C0019046;C0022661;C0168634;C0441471;C0596019;C0871208;C1442488;C1521828;C3541888
736,bsl  baseline  cl  confidence interval  esrd  end - stage renal disease  hb  hemoglobin  hr  hazard ratio  k ( rate )  # of events per nmbr patient - years of follow - up  yr  year . multivariate cox model with hemoglobin category and baseline urinary albumimcreatinine ratio  serum albumin  serum creatinine  and hemoglobin as covariates .,C0009667;C0019046;C0022661;C0026538;C0035078;C0168634;C0205088;C0441471;C0699829;C1442488;C2316810;C2985465;C3541888
736,bmi at baseline ( kg / mnmbr ),C0168634;C0578022;C1442488;C1532718
736,biomarkers at baseline,C0005516;C0168634;C1442488
736,biguanide use at baseline,C0005382;C0042153;C0168634;C0457083;C1442488;C1947944;C3537187;C4317165
736,beta - blocker use at baseline,C0001645;C0042153;C0168634;C0457083;C1442488;C1947944
736,baseline £ std,C0168634;C1442488
736,baseline who functional class,C0168634;C1442488
736,baseline who function class,C0168634;C1442488
736,baseline vfx,C0168634;C1442488
736,baseline variable,C0168634;C0439828;C1442488;C4553760
736,baseline value,C0168634;C1442488;C1522609
736,baseline use of hormone therapy ( % ),C0168634;C0279025;C1442488;C1524063
736,baseline use of adm,C0168634;C0215825;C1442488;C1524063;C4521767
736,baseline uric acid,C0041980;C0168634;C1442488
736,baseline upgr,C0168634;C1442488
736,baseline uasnmbr,C0168634;C1442488
736,baseline uacr > nmbr mg / g,C0168634;C1300563;C1442488
736,baseline uacr < nmbr mg / g,C0168634;C1300563;C1442488
736,baseline triglycerides > nmbr mg / dl and,C0041004;C0168634;C0439269;C1442488
736,baseline triglycerides < nmbr mg / dl,C0041004;C0168634;C0439269;C1442488
736,baseline triglycerides,C0041004;C0168634;C1442488
736,baseline trig > nmbr millycerides g / dl,C0168634;C0202236;C0439267;C1442488;C1519533
736,baseline treatments,C0087111;C0168634;C1442488
736,baseline total cholesterol,C0168634;C0201950;C0543421;C1442488
736,baseline tophusa,C0168634;C1442488
736,baseline tjc,C0168634;C1442488
736,baseline therapy,C0039798;C0087111;C0168634;C1363945;C1442488
736,baseline tg,C0168634;C0337445;C1442488
736,baseline tc,C0039411;C0040642;C0041405;C0041698;C0168634;C1442488;C1824670;C3272447;C4522122
736,baseline tbp,C0168634;C1442488
736,baseline tava,C0168634;C1442488
736,baseline t - score at femoral neck,C0015815;C0168634;C0449820;C1442488;C4050231
736,baseline systolic bp,C0168634;C0871470;C1442488
736,baseline sua,C0168634;C1442488
736,baseline ste in worst lead,C0168634;C1420459;C1442488;C1522166;C3811127
736,baseline statin use,C0042153;C0168634;C0360714;C0457083;C1442488;C1947944
736,baseline spga,C0168634;C1442488
736,baseline smoking status,C0168634;C1442488;C1519386
736,baseline sjc,C0168634;C1442488
736,baseline sitting sbp,C0085805;C0168634;C0277814;C1442488;C2584297;C4050224
736,baseline sitting dbp,C0168634;C0277814;C0536221;C1442488;C2584297;C3813197;C4050224;C4281799
736,baseline sitosterol / lathosterol,C0037215;C0064673;C0168634;C0220914;C1442488
736,baseline sitosterol / cholesterol,C0008377;C0037215;C0168634;C0220914;C1442488
736,baseline sitosterol,C0037215;C0168634;C0220914;C1442488
736,baseline sildenafil dose mg,C0024671;C0026410;C0168634;C0178602;C0439269;C0529793;C0869039;C1114758;C1442488;C1960952;C2346927;C4321396;C4521761
736,baseline shs ( nmbr - nmbr ),C0168634;C1442488
736,baseline sgrq total score,C0168634;C1442488;C2964552
736,baseline sgrq score,C0168634;C1442488
736,baseline sesbp,C0168634;C1442488
736,baseline serum urate ( mg / dl ) a,C0168634;C0439269;C0455272;C1442488
736,baseline serum mg > = nmbr . nmbr mmol / l,C0024671;C0026410;C0168634;C0229671;C0439190;C0439268;C0439269;C1442488;C1532563;C1546774;C1550100;C1960952;C2346927;C4321396;C4521761
736,baseline serum mg < nmbr . nmbr mmol / l,C0024671;C0026410;C0168634;C0229671;C0439190;C0439268;C0439269;C1442488;C1532563;C1546774;C1550100;C1960952;C2346927;C4321396;C4521761
736,baseline serum k +,C0168634;C0302353;C1442488
736,baseline sedbp,C0168634;C1442488
736,baseline scales,C0168634;C1442488
736,baseline sbp { p = o - nmbr ),C0085805;C0168634;C1442488
736,baseline sbp ( mm hg ),C0085805;C0168634;C0439475;C1442488
736,baseline sbp ( mm ),C0085805;C0168634;C1442488;C4330985;C4554674
736,baseline sbp,C0085805;C0168634;C1442488
736,baseline rst - segment elevation,C0168634;C0439775;C0441635;C0702240;C1425219;C1442488
736,baseline rst - segment,C0168634;C0441635;C1425219;C1442488
736,baseline renal function ( eclcr ),C0168634;C0232804;C1442488
736,baseline ptga,C0168634;C1442488
736,baseline pssi score,C0168634;C1442488
736,baseline prednisone or oral prednisone equivalent daily dose,C0032952;C0168634;C1442488
736,baseline prediabetes,C0168634;C0362046;C1442488
736,baseline ppasi score,C0168634;C1442488
736,baseline post - bronchodilator fevnmbr   ( sd ),C0168634;C1442488;C2599594;C2699239;C3714541
736,baseline post - bronchodilator % predicted fev,C0168634;C1442488
736,baseline pos frequency per nmbr days,C0168634;C0585290;C1262869;C1442488;C3496112;C3496399
736,baseline pfd,C0016065;C0168634;C1442488;C1839454;C2827389;C3889643
736,baseline peripheral artery disease,C0168634;C1442488;C1704436;C4025272
736,baseline pcsi < nmbra,C0168634;C1442488
736,baseline pava,C0135567;C0168634;C1442488
736,baseline pasi score,C0168634;C0449820;C1442488;C4050231;C4528685
736,baseline pasi,C0168634;C1442488;C4528685
736,baseline parameter,C0168634;C0549193;C1442488;C1704769;C2350001
736,baseline ocs use : yes,C0168634;C1442488
736,baseline normoglycemia,C0168634;C0580545;C1442488
736,baseline normoglycaemia ( fpg < nmbr . nmbr mmol / l ) - n,C0168634;C0580545;C1442488;C1532563
736,baseline non - hdl - ca,C0168634;C1442488;C1518422;C3715113;C3887642
736,baseline nmbr - mlnute walk distance :,C0168634;C0429886;C1442488
736,baseline nmbr - min walk distance m,C0168634;C0369637;C0429886;C0441923;C0702093;C1442488;C1524029;C3813700
736,baseline nihss score ( % ) #,C0168634;C1442488;C1697238
736,baseline nihss score,C0168634;C1442488;C1697238
736,baseline nihss,C0168634;C1442488;C1697238
736,baseline nih stroke scale — no . ( % ) ^,C0168634;C1442488;C1697238;C3484372
736,baseline nbp,C0168634;C1442488
736,baseline mwd,C0168634;C1442488
736,baseline mssbp / msdbp,C0168634;C1442488
736,baseline mssbp ( mmhg ),C0168634;C0439475;C1442488
736,baseline msdbp ( mmhg ),C0168634;C0439475;C1442488
736,baseline monthly pos seizure rate,C0036572;C0168634;C0332177;C0871208;C1262869;C1442488;C1521828;C1959629;C3496112;C3496399;C4553401
736,baseline microalbumin : < nmbr,C0168634;C0201838;C1442488;C2362049
736,baseline metformin,C0025598;C0168634;C1442488
736,baseline medications,C0013227;C0168634;C0802604;C1442488;C2598133;C4284232
736,baseline medication,C0013227;C0168634;C1442488;C3244316;C4284232
736,baseline medical therapy,C0168634;C0418981;C1442488
736,baseline measurements,C0168634;C0242485;C1442488
736,baseline mdrd egfr > nmbr ml / min / nmbr . nmbr mnmbr,C0168634;C0369637;C0439445;C0441923;C1442488;C1739039;C3811844;C3812682;C3839656
736,baseline mdrd egfr < nmbr ml / min / nmbr . nmbr mnmbr,C0168634;C0369637;C0439445;C0441923;C1442488;C1739039;C3811844;C3812682;C3839656
736,baseline mayo score,C0168634;C0449820;C0454788;C1077578;C1442488;C4050231
736,baseline lvef,C0168634;C0428772;C0488728;C1442488
736,baseline lp ( a ),C0065058;C0168634;C1439335;C1442488;C4553379
736,baseline low - density lipoprotein cholesterol ( mg / dl ),C0023824;C0168634;C0439269;C1442488
736,baseline los angeles grade of eo,C0024015;C0168634;C1442488
736,baseline lipids,C0023779;C0168634;C1442488
736,baseline lipid therapy,C0023779;C0039798;C0087111;C0168634;C1363945;C1442488
736,baseline lipid profile,C0023779;C0168634;C1442488;C1979963;C2003903
736,baseline lipid and lipoprotein values,C0023779;C0168634;C1442488
736,baseline lipid and apolipoprotein levels,C0023779;C0168634;C1442488
736,baseline lipid / lipoprotem values,C0023779;C0042295;C0168634;C1442488
736,baseline lipid / lipoprotein values,C0042295;C0168634;C0443602;C1442488
736,baseline ldl ‐ c,C0168634;C1442488
736,baseline ldl - c strata,C0168634;C1442488
736,baseline ldl - c nmbr . nmbr to < nmbr . nmbr mmol / lc,C0168634;C0439190;C1442488
736,baseline ldl - c > nmbr mg / dl,C0168634;C0439269;C1442488
736,baseline ldl - c > nmbr . nmbr to < nmbr . nmbr mmol / lc,C0168634;C0439190;C1442488
736,baseline ldl - c :,C0168634;C1442488
736,baseline ldl - c,C0168634;C1442488
736,baseline ldl ( mg % ),C0024671;C0026410;C0168634;C0439269;C1442488;C1960952;C2346927;C4321396;C4521761
736,baseline insulin dose ( u = kg ) [lsm ( se ) ],C0036919;C0168634;C0366513;C1300561;C1442488
736,baseline ifg ( fpg nmbr . nmbr - nmbr . nmbr mmol / l ) - n,C0168634;C1334085;C1442488;C1532563;C1708411
736,baseline if have nmbr yr follow - up *,C0168634;C1442488
736,baseline ics use : yes,C0168634;C0815320;C1442488;C4551720
736,baseline ics use : no,C0168634;C0815320;C1442488;C4551720
736,baseline ics use,C0168634;C0815320;C1442488;C4551720
736,baseline ics dose,C0168634;C0178602;C0815320;C0869039;C1114758;C1442488;C4551720
736,baseline ics,C0168634;C0815320;C1442488;C4551720
736,baseline ibdq total score,C0168634;C1442488;C2964552
736,baseline hstni,C0168634;C1442488
736,baseline hs - crp tertiles ( mg / i],C0021966;C0024671;C0026410;C0168634;C0221138;C0439269;C1442488;C1960952;C2346927;C3890735;C4048285;C4321396;C4521761
736,baseline high - sensitivity crp,C0168634;C1441604;C1442488;C3890735;C4048285
736,baseline hemoglobin aj^ values,C0004486;C0019046;C0042295;C0168634;C0230613;C1442488
736,baseline hemoglobin,C0019046;C0168634;C1442488
736,baseline heart rate ( beats / min ),C0018810;C0168634;C1442488
736,baseline heart rate,C0018810;C0168634;C1442488
736,baseline hdl ‐ c,C0168634;C1442488;C3715113
736,baseline hdl - c,C0168634;C1442488;C3715113
736,baseline hbi,C0168634;C1442488
736,baseline hbanmbrc^,C0019016;C0168634;C1442488;C1825777;C3538758
736,baseline hbanmbrc ≥ nmbr mmol / mol ( ≥ nmbr . nmbr % ),C0019016;C0168634;C1442488;C1825777;C3538758;C3829066
736,baseline hbanmbrc ≥ nmbr . nmbr % ( nmbr mmol / mol ),C0019016;C0168634;C1442488;C1825777;C3538758;C3829066
736,baseline hbanmbrc ≤ median nmbr . nmbr % ( nmbr mmol / mol ),C0019016;C0168634;C0549183;C0876920;C1442488;C1825777;C2347635;C2348144;C2939193;C3538758;C3829066
736,baseline hbanmbrc > nmbr . nmbr %,C0019016;C0168634;C1442488;C1825777;C3538758
736,baseline hbanmbrc > median nmbr . nmbr % ( nmbr mmol / mol ),C0019016;C0168634;C0549183;C0876920;C1442488;C1825777;C2347635;C2348144;C2939193;C3538758;C3829066
736,baseline hbanmbrc < nmbr . nmbr % ( nmbr mmol / mol ),C0019016;C0168634;C1442488;C1825777;C3538758;C3829066
736,baseline hbanmbrc < nmbr . nmbr %,C0019016;C0168634;C1442488;C1825777;C3538758
736,baseline hbanmbrc ( % ),C0019016;C0168634;C1442488;C1825777;C3538758
736,baseline hbanmbrc,C0019016;C0168634;C1442488;C1825777;C3538758
736,baseline hbalc^,C0168634;C1442488
736,baseline hbalc ’,C0168634;C1442488
736,baseline hbalc > nmbr mmol / mol ( > nmbr . nmbr % ),C0168634;C1442488;C3829066
736,baseline hbalc > nmbr . nmbr % ( nmbr mmol / mol ) nmbr,C0168634;C1442488;C3829066
736,baseline hbalc > nmbr % to < nmbr %,C0168634;C1442488
736,baseline hbalc > nmbr %,C0168634;C1442488
736,baseline hbalc < nmbr . nmbr % ( nmbr mmol / mol ) nmbr,C0168634;C1442488;C3829066
736,baseline hbalc < nmbr %,C0168634;C1442488
736,baseline hbalc,C0168634;C1442488
736,baseline hba^c,C0019016;C0168634;C1442488;C1825777;C3538758
736,baseline hb nmbrg i nmbr n = nmbr,C0062408;C0086706;C0168634;C1442488
736,baseline hb < nmbr g nmbr nmbr n = nmbr,C0062408;C0168634;C0439267;C1442488
736,baseline glycated hemoglobin ( % ),C0017853;C0168634;C1442488
736,baseline glycated,C0168634;C1442488
736,baseline gfr < nmbr ml / min per nmbr . nmbr mnmbr,C0017654;C0168634;C0369637;C0439445;C0441923;C1424601;C1442488
736,baseline gfr < nmbr ml / min / nmbr . nmbrmnmbr,C0017654;C0168634;C0369637;C0439445;C0441923;C1424601;C1442488
736,baseline fvc,C0168634;C1442488;C3714541
736,baseline fpg,C0168634;C1442488
736,baseline fevnmbr % predicted,C0168634;C1442488;C3714541
736,baseline fevnmbr #,C0168634;C1442488;C3714541
736,baseline fevnmbr,C0168634;C1442488;C3714541
736,baseline fev,C0168634;C1442488;C3714541
736,baseline fecal caicrctectin,C0015733;C0168634;C1442488
736,baseline ezetimibe usec,C0168634;C0439224;C1142985;C1442488
736,baseline estimated gfr,C0168634;C1442488
736,baseline egfr > nmbr ml / min / nmbr . nmbr mnmbr,C0168634;C0369637;C0439445;C0441923;C1442488;C1739039;C3811844;C3812682
736,baseline egfr < nmbr ml / min / nmbr . nmbr mnmbrc,C0168634;C0369637;C0439445;C0441923;C1442488;C1739039;C3811844;C3812682
736,baseline egfr < nmbr ml / min / nmbr . nmbr mnmbr,C0168634;C0369637;C0439445;C0441923;C1442488;C1739039;C3811844;C3812682
736,baseline ecrq nmbr nmbr to < nmbr ml / min,C0168634;C0439445;C1442488
736,baseline ecro < nmbr mumin,C0168634;C1442488
736,baseline ecrcl nmbr nmbr ml / min,C0168634;C0439445;C1442488
736,baseline ecrcl k nmbr to < nmbr ml / min,C0168634;C0439445;C0597277;C1442488;C1708601
736,baseline ecrcl,C0168634;C1442488
736,baseline dmard use,C0042153;C0168634;C0242708;C0457083;C1442488;C1947944
736,baseline dlqi,C0168634;C1442488;C3899393
736,baseline dlco . mmol kpa - ’ -,C0168634;C0263428;C0439190;C0439474;C1442488;C1516251
736,baseline dipeptidyl peptidase nmbr,C0022709;C0168634;C1442488
736,baseline diabetes mellitus therapy,C0168634;C0948092;C1442488
736,baseline diabetes,C0011847;C0011849;C0168634;C1442488
736,baseline dbp,C0168634;C0536221;C1442488;C3813197;C4281799
736,baseline data,C0168634;C1442488;C1511726;C3245479;C3714741
736,baseline dasnmbr,C0051767;C0057671;C0168634;C1442488
736,baseline dad ( n   = nmbr + nmbr ),C0168634;C1442488;C3641946
736,baseline cv treatment,C0039798;C0087111;C0168634;C1442488;C1522326;C1533734;C1705169;C3538987;C3538994;C3887704;C4048877;C4318503
736,baseline cv medications,C0013227;C0168634;C0802604;C1442488;C2598133;C3538987;C4048877;C4284232;C4318503
736,baseline crp levels ≥ nmbr mg / l,C0168634;C0439268;C0441889;C1442488;C3890735;C4048285
736,baseline crp levels < nmbr mg / l,C0168634;C0439268;C0441889;C1442488;C3890735;C4048285
736,baseline crp category ( mg / l ),C0168634;C0439268;C0683312;C1442488;C3889287;C3890735;C4048285
736,baseline crp < nmbrmg / l,C0168634;C0439268;C1442488;C3890735;C4048285
736,baseline crp ( mg / dl ),C0168634;C0439269;C1442488;C3890735;C4048285
736,baseline crp,C0168634;C1442488;C3890735;C4048285
736,baseline crohn ' s disease medications,C0010346;C0013227;C0168634;C0802604;C1442488;C2598133;C4284232
736,baseline creatinine,C0010294;C0168634;C1442488;C1561535
736,baseline crcl,C0168634;C1442488;C1846718
736,baseline corticosteroid use ( mg ),C0024671;C0026410;C0168634;C0239126;C0439269;C1442488;C1960952;C2346927;C4321396;C4521761
736,baseline concomitant cardiovascular medications,C0007220;C0168634;C0521115;C1442488
736,baseline ckd egfr > nmbr ml / min / nmbr . nmbr mnmbr,C0168634;C0369637;C0439445;C0441923;C1442488;C1561643;C1739039;C3811844;C3812682
736,baseline ckd egfr < nmbr ml / min / nmbr . nmbr mnmbr,C0168634;C0369637;C0439445;C0441923;C1442488;C1561643;C1739039;C3811844;C3812682
736,baseline characteristic,C0168634;C1442488
736,baseline cdr - sb ( n   = nmbr + nmbr ),C0038111;C0168634;C1442488;C3811240;C4521843
736,baseline cdai score,C0168634;C0683448;C1413248;C1442488;C3273706
736,baseline cdai,C0168634;C0683448;C1413248;C1442488;C3273706
736,baseline cardiovascular medications,C0007220;C0168634;C1442488
736,baseline cardiovascular medication,C0007220;C0168634;C1442488
736,baseline cardiovascular disease,C0007222;C0168634;C1442488
736,baseline cardiac biomarkers elevated,C0168634;C1442488;C2735101;C2735102
736,baseline cardiac biomarkers,C0168634;C1442488;C2735101;C2735102
736,baseline bsa,C0168634;C1442488
736,baseline bp,C0037623;C0168634;C1415692;C1442488;C1708288;C4318478
736,baseline body mass index,C0005893;C0168634;C0578022;C1305855;C1442488
736,baseline bmi,C0168634;C0578022;C1442488
736,baseline bmd t score at femoral neck,C0015815;C0168634;C0449820;C1442488;C4050231
736,baseline bii,C0168634;C1413059;C1442488
736,baseline basfi,C0168634;C1442488
736,baseline basdai,C0168634;C1442488;C1998004
736,baseline aspirin use strata,C0004057;C0042153;C0168634;C0457083;C1442488;C1947944
736,baseline aspirin use,C0004057;C0042153;C0168634;C0457083;C1442488;C1947944
736,baseline aspirin dose < nmbr mg,C0024671;C0026410;C0168634;C0439269;C1442488;C1960952;C2346927;C4321396;C4521761;C4696290
736,baseline asdas - crp,C0168634;C1442488;C3890735;C4048285
736,baseline anti - hypertensive usea,C0003364;C0168634;C1442488
736,baseline anmbrc ( % ) [lsm ( se ) ],C0036919;C0168634;C1442488
736,baseline anmbrc ( % ),C0168634;C1442488
736,baseline alc category,C0168634;C0683312;C1424945;C1442488;C3811058;C3889287
736,baseline alc < nmbr . nmbr %,C0168634;C1424945;C1442488;C3811058
736,baseline albuminuria,C0001925;C0168634;C1442488
736,baseline albumin : < nmbr,C0001924;C0168634;C1442488
736,baseline age,C0001779;C0168634;C1442488
736,baseline adas - cog nmbr,C0168634;C1442488;C3539026
736,baseline abi,C0168634;C1328319;C1442488;C3888326
736,baseline ^ste,C0168634;C1420459;C1442488;C3811127
736,baseline / concomitant therapies,C0168634;C1442488;C1707479
736,baseline - adjusted hr,C0168634;C1442488
736,baseline - - mdrd,C0168634;C1442488;C3839656
736,baseline ( sd ),C0168634;C1442488;C2699239
736,baseline ( n ),C0168634;C1442488
736,baseline ( mmol / l ),C0168634;C1442488;C1532563
736,baseline % predicted fevnmbr,C0168634;C1442488
736,baseline % bsa involvement,C0168634;C1314939;C1442488
736,baseline,C0168634;C1442488
736,b - blockers at baseline,C0168634;C1442488
736,available baseline blood specimen n,C0168634;C0178913;C0470187;C1442488
736,atrial fibrillation on baseline ecg,C0168634;C0344434;C1442488
736,at ldl - c ( bq ) goal * at baseline - no . ( % ),C0018017;C0168634;C0560038;C1442488;C1571704;C3541236
736,at baseline — no . ( % ),C0168634;C1442488
736,at baseline,C0168634;C1442488
736,asthma control test score at baseline,C0168634;C1442488;C2733224
736,aspirin use at baseline,C0004057;C0042153;C0168634;C0457083;C1442488;C1947944
736,aspirin at baseline,C0004057;C0168634;C1442488
736,asa use at baseline,C0004057;C0042153;C0168634;C0457083;C1442488;C1947944;C3853627
736,antiepileptic drug type at baseline,C0003299;C0168634;C0332307;C0457591;C1442488;C1547052;C3537002
736,anmbrc at baseline ≥ nmbr . nmbr %,C0168634;C1442488
736,anmbrc at baseline < nmbr . nmbr %,C0168634;C1442488
736,angina class at baseline,C0002962;C0168634;C0456387;C1442488;C1518526;C1705943
736,alc < nmbr . nmbr % at baseline,C0168634;C1424945;C1442488;C3811058
736,albuminuria ( acr > nmbr m . g / g ) at baseline to normoalbuminuria,C0001925;C0168634;C0369637;C0441923;C1319635;C1412134;C1442488;C1515941
736,age at baseline years,C0168634;C1442488;C1510829
736,age at baseline in years,C0001779;C0168634;C1442488
736,age at baseline ( years ),C0168634;C1442488;C1510829
736,af on baseline ecg,C0168634;C0344434;C1442488;C1623258;C4049859
736,adjusted for all baseline variablesnmbr,C0168634;C0439828;C0456081;C1442488
736,adjusted for all baseline variables and interaction between acei and baseline upb,C0168634;C0439828;C0456081;C1442488
736,adjusted for all baseline variables,C0168634;C0439828;C0456081;C1442488
736,activities of daily living updrs subscore ( baseline ),C0001288;C0168634;C1442488;C3639721;C4050548
736,a from baseline,C0168634;C1442488
736,> nmbr mg / dl baseline high - sensitivity crp,C0168634;C0439269;C1441604;C1442488;C3890735;C4048285
736,> nmbr med at baseline cardiac disorder *,C0018799;C0168634;C1442488;C4321267
736,> nmbr % blood eosinophils at baseline,C0014467;C0168634;C1442488
736,< nmbr % blood eosinophils at baseline,C0014467;C0168634;C1442488
736,( baseline ),C0168634;C1442488
736,% change from baseline,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
736, abbreviations : bmi  body mass index  bp  blood pressure  chd  coronary heart disease  crucial  cluster randomized usual care vs caduet investigation assessing long - term - risk  dbp  diastolic blood pressure  dm  diabetes mellitus  hdl - c  high - density lipoprotein cholesterol  ldl - c  low - density lipoprotein cholesterol  sd  standard deviation  sbp  systolic blood pressure  tc  total cholesterol  tg  triglyceride .,C0030705;C0168634;C0332293;C1442488
735,hypertension requiring treatment,C0578998
734,dates of recruitment,C0011008;C2348077;C2949735
733,type of treatment,C0455708
733,type of reference treatment strategy,C0455708;C0679199;C1514811;C1706462
732,albumin measurements^^,C0201838
731,laboratory measurements,C0681902
730,took prior antihyperglycemic agent ( any ),C1515187
730,taking statins,C0360714;C1515187
730,taking antihypertensive treatment at,C1515187
730,taking antihypertensive medication at baseline,C1515187
729,methotrexate treatment !,C0746573
728,insulin treatment,C0745343
727,on - treatment,C4684449
726,active treatment,C1704532
725,medical treatment,C0679624
724,conventional treatment ( n = nmbr ),C2945704
724,conventional treatment,C2945704
723,teaes ( > nmbr % in any treatment group ) *,C0374505
723,teaes ( > nmbr % in any treatment group ),C0374505
723,asian itt population by treatment group,C0032659;C0039798;C0078988;C0087111;C0374505;C1257890;C1522326;C1533734;C1705169;C3538994;C3887704
722,physical component summary,C0031809;C0205485;C0449432;C1509143;C1552616;C1705248;C1706244
722,mental component summary,C0229992;C0449432;C1552616;C1705248;C1706244
722,component . for all instruments,C0449432;C1705248;C4551823
721,components,C0449432
721,chadsnmbrcomponents,C0007928;C0449432;C1413373
720,mental component score ( mcs ),C0229992;C0449432;C0449820;C1705248;C4050231
720,mental component,C0229992;C0449432;C1705248
720,mental,C0229992
719,symptom duration,C0449238;C1457887;C2926735;C3854129
719,symptom bother,C1457887;C3854129
719,symptom - free days in the past nmbr weeks ( % ),C0332296;C0439228;C0677547;C1444637;C1457887;C1880497;C1996904;C2987125;C3854129;C4284302
719,ra symptom duration — year,C0439234;C0439508;C0449238;C1457887;C2926735;C3538806;C3854129;C4048756
719,ra symptom duration < nmbr months — number ( % ),C0237753;C0439231;C0449238;C0449788;C1457887;C2926735;C3538806;C3854129;C4048756
719,placebo ( symptom days a week ),C0032042;C0439228;C1457887;C1696465;C1706408;C3854129
719,number of symptom days per week,C0237753;C0439228;C0449788;C1457887;C3854129
719,nmbr to nmbr symptom days per week,C0677547;C1457887;C3854129
719,hf symptom worsened,C0018488;C1313497;C1457887;C1538440;C3273279;C3854129
719,hf symptom unchanged,C0018488;C1313497;C1457887;C1538440;C3273279;C3854129
719,budesonide { symptom days a week ),C0054201;C0439228;C1457887;C3854129
719,budesonide ( symptom days a week ),C0054201;C0439228;C1457887;C3854129
719,baseline symptom days perweek,C0168634;C0439228;C1442488;C1457887;C3854129
719,> nmbr symptom days per week,C0677547;C1457887;C3854129
719,> lto £ nmbr symptom days per week,C0677547;C1457887;C3854129
718,time from symptoms to treatment,C0040223;C0683368;C1457887;C3541383
718,time from symptoms to randomization,C0040223;C0683368;C1457887;C3541383
718,time from symptoms onset to nmbrst balloon inflation ( h ),C0449244;C0683368;C1457887
718,time from symptom onset to start of fibrinolytic therapy — hr,C0040223;C0449244;C1457887;C3541383;C3854129;C4086878
718,time from symptom onset to randomization,C0040223;C0449244;C1457887;C3541383;C3854129;C4086878
718,time from symptom onset to enrollment,C0040223;C0449244;C1457887;C3541383;C3854129;C4086878
718,time from symptom onset to balloon inflation,C0040223;C0449244;C1457887;C3541383;C3854129;C4086878
717,who fc iii symptoms at baseline,C0168634;C0439070;C0683368;C1442488;C1457887;C1705160;C2983605
717,who fc ii symptoms at baselinenmbr,C0168634;C0683368;C1442488;C1457887;C1710602;C2983605;C4082587
717,who fc ii symptoms at baselinef,C0683368;C1457887;C1710602;C2983605;C4082587
717,who fc ii symptoms at baseline,C0168634;C0683368;C1442488;C1457887;C1710602;C2983605;C4082587
717,systemic symptoms,C0205373;C0683368;C1457887
717,symptoms and feelings,C0683368;C1457887
717,symptoms,C0683368;C1457887
717,nocturnal symptoms in past week,C0240526;C0683368;C1457887;C2987125
717,no symptoms,C0683368;C1457887
717,nmbr = no symptoms,C0683368;C1457887
717,nmbr = minor symptoms  no limitations,C0026193;C0205165;C0683368;C1457887
717,hf symptoms and signs,C0018488;C0683368;C1313497;C1457887;C1538440;C3273279
717,daytime symptoms more than twice per week,C0332169;C0683368;C1457887;C1720725;C1948050
717,days with asthma symptoms / week,C0004096;C0677547;C0683368;C1457887;C2984299
717,asthma symptoms in the past nmbr weeks,C0004096;C0683368;C1457887;C2984299;C2987125
716,n - terminal pro - brain natriuretic peptide,C3272900
715,atrial flutter / fibrillation,C0155709
715,atrial fibrillation / flutter,C0155709
715,atrial fibrillation / atrial flutter,C0155709
714,atrial flutter,C0004239;C0344423;C1963068
713,fibrillation / flutter ),C0016385;C0232197;C2242390
713,arial flutter or fibrillation,C0016385;C2242390
712,apoe   ε nmbr carrier,C0003595;C0007294;C0523511;C0560175;C1325398;C1412481;C1706209;C3273162
712,apoe enmbr carriers,C0003595;C0007294;C0523511;C1412481
712,ala carriers,C0007294;C0523459;C3888236
711,carrier ( n = nmbr ),C0007294;C0560175;C1325398;C1706209;C3273162
711,apolipoprotein e carrier,C0003595;C0007294;C0560175;C1325398;C1706209;C3273162
710,cancer surgery,C0920424
709,minor surgery,C0038904
709,major surgery,C0679637
708,urgent surgery,C2188405
708,emergent / urgent surgery,C0750573;C2188405
707,prior cardiac surgery,C0018787;C0018821;C0332152;C0455610;C0524727;C1522601;C2826257
707,other cardiac surgery,C0018821;C0524727
707,cardiac surgery type,C0018821;C0332307;C0524727;C1547052
706,prior surgery for cd,C0007928;C0034283;C0455610;C4552032
706,prior surgery : no,C0455610
706,prior oabg surgery,C0455610
706,prior cabg surgery,C0010055;C0455610
706,history of cabg surgery,C0010055;C0455610
705,value for nteraction,C1522609
705,ap - value from an ancova with corresponding baseline lipid value as the covariate and with a effect for treatment group .,C0002680;C0814908;C1522609;C3887950
704,value *,C1522609
704,value,C1522609
704,l ’ - value ’,C0439394;C1522609;C1706495;C3642217
704,d - value,C1522609
704,/ ’ - valuenmbr ’,C1522609
704,"/ ’ - value """,C1522609
703,subpopulation analyses according to bmi,C0578022;C0680240;C1514228
703,main accord endpoint,C0205225;C0680240;C1542147;C2349179;C2826544
703,accord primary,C0680240
702,class i or no symptoms,C0441885;C1319793;C2698967
702,class i or iii aad use in nmbr months before enrollment,C0441885;C1319793;C2698967
702,class i,C0441885;C1319793;C2698967
701,class iv only,C0205171;C0441888;C1720467;C2698970
701,class iv glomerulonephritis,C0017658;C0441888;C2698970
701,class iv,C0441888;C2698970
700,class ii ( b - blockers ),C0441886;C2698968
700,class ii,C0441886;C2698968
700,class > ii,C0441886;C2698968
699,normal coronary angiography,C0853522
698,previous coronary angioplasty,C2114427
697,right coronary artery,C1261316
696,right coronary,C0225808
695,index inclusion acute coronary syndrome,C0007637;C0600653;C0918012;C0948089;C1512693;C1552854;C1637833;C2986546
695,acute coronary syndrome nmbr,C0948089
695,acute coronary syndrome,C0948089
694,seizure worry,C0036572;C0233481;C1959629;C4553401
694,seizure types reported during baselinee,C0036572;C0332307;C1959629;C4553401
694,seizure types reported during baseline,C0036572;C0332307;C1959629;C4553401
693,time from end of fit,C0036572;C1522314;C2349186;C4048158;C4553125
693,convulsion,C0036572;C4048158
692,charlson comorbidity index,C4546361
691,catheterization performed for qualifying event,C0007430
691,catheterization laboratory in center,C0007430;C0022877;C0205099;C3244292;C4283904;C4534362
691,catheterization laboratory in,C0007430;C0022877;C3244292;C4283904
690,h pylori serology *,C0036745;C0079488;C0220911;C0455278
689,helicobacter pylori infection ( + ) ( n ),C0850666
689,h . pylori infection,C0850666
688,ticlopidine after completion of study drug,C0013175;C0013227;C0040207;C0205197;C1254351;C1554962;C2348557
688,open - label clopidogrel after completion of study drug,C0013227;C0070166;C0205197;C1254351;C1554962;C1709323
688,age of completion of highest education,C0001779;C0013621;C0013622;C0013658;C0039401;C0205197;C1522410;C1554962
688,age at completion of highest level of,C0001779;C0205197;C1554962;C4321237
687,complete ulcer healing at week nmbr,C0205197;C0332174;C0333293;C0439230;C0725685;C3853530;C4283785
687,complete healinga,C0205197;C0725685;C3853530;C4283785
687,complete clinical response at week nmbr,C0205197;C3853530;C4283785
686,cangrelor n / n ( % ),C1121991
686,cangrelor dyspnoea vs no dyspnoea *,C0013404;C1121991;C1963100
686,cangrelor clopidogrel no . of events / total no . ( % ),C0070166;C1121991
686,cangrelor ( n = nmbr ) n / n ( % ),C1121991
686,cangrelor ( n = nmbr ),C1121991
686,cangrelor,C1121991
685,ongoing atopic or allergic condition — no . { % ),C0392707;C0549178
685,nmbr / nmbr ( nmbr . nmbr ) ( continued ),C0549178
685,nmbr ( nmbr . nmbr ) ( continued ),C0549178
685,continuous variables,C0439828;C0549178
685,continuous,C0549178
685,continued use of gpa,C0549178;C1524063;C3495801;C4553145
685,continued treatment study,C0549178;C3161471
685,continued thienopyridine n = nmbr subjects,C0549178;C1120149
685,continued thienopyridine n ( % ),C0549178;C1120149
685,continued thienopyridine ( n nmbr nmbr ),C0549178;C1120149
685,continued thienopyridine ( n = nmbr ),C0549178;C1120149
685,continued thienopyridine %,C0549178;C1120149
685,continue thienopyridine n = nmbr,C0549178
684,scale — cognitive portion  ldl — low -,C0175659;C0349674;C0449719;C1516691;C1947916
684,cognitive subscale on alzheimer ' s disease assessment scale,C0450989;C1516691
684,cognitive,C1516691
683,hormone therapy use,C0042153;C0279025;C0457083;C1947944
683,hormone therapy,C0279025
683,hormonal therapy — no . ( % ),C0279025
682,combined therapy vsta msu iosin,C0024776;C0033972;C1412759
682,combined therapy vsdutasteride,C0033972
682,combined therapy ( / v = nmbr ),C0033972
681,standard therapy ( n = nmbr ),C2936643
681,standard therapy,C2936643
680,others,C1955473;C3539125
680,all others eteed for nmbr mg edoxaban dose at,C1955473;C2975435;C3539125;C4086581
680,all others,C1955473;C3539125
679,elective surgery,C0206058
679,elective peripheral revascularization,C0205100;C0206058;C0439608;C0581603
678,selected key secondary efficacy endpoints,C1280519;C1707391;C1707887;C4528314
678,select lipids and lipoproteins,C1707391
677,patients without clinically evident vascular disease,C0030705;C0042373;C3887511
677,patients with clinically evident vascular disease,C0030705;C0042373;C3887511
677,evidence or thombus,C3887511
677,clinically evident vascular disease,C0042373;C3887511
676,hiatus hernia,C3489393
676,esophageal hiatal hernia *,C3489393
675,saphenous vein graft,C0729538
675,saphenous - vein graft,C0729538
674,diabetes therapy at baseline ( alone or in combination ),C0168634;C1442488;C3274787;C3539002
674,diabetes therapy,C3274787;C3539002
673,without lipid - lowering agents,C0086440
673,with lipid - lowering agents,C0086440
673,revascularisation + antiplatelets + lipid - lowering agents + p blockers,C0086440;C0581603
673,prior lipid - lowering agent use,C0042153;C0086440;C0332152;C0457083;C1947944;C2826257
673,other lipid lowering drugs,C0086440
673,lipid lowering drugs,C0086440
673,lipid lowering agents,C0086440
673,lipid lowering agent n ( % ),C0086440
673,lipid - lowering drugs,C0086440
673,lipid - lowering drug * *,C0086440
673,lipid - lowering drug,C0086440
673,lipid - lowering agents ( % ),C0086440
673,lipid - lowering agents,C0086440
673,lipid - lowering agent §,C0086440
673,lipid - lowering agent,C0086440
673,any lipid - lowering agent use,C0042153;C0086440;C0457083;C1947944
673,any lipid - lowering agent,C0086440
672,use of concomitant lipid - lowering therapy - no . ( % ),C0521115;C0585943;C1524063
672,lipid ‐ lowering therapies,C0585943
672,lipid lowering therapy,C0585943
672,lipid - lowering therapy — no . ( % ),C0585943
672,lipid - lowering therapy - no . ( % ),C0585943
672,lipid - lowering therapy,C0585943
672,concomitant lipid - lowering therapy ( any ),C0521115;C0585943
672,concomitant lipid - lowering therapy,C0521115;C0585943
672,background lipid - lowering therapy,C0585943;C1706907
671,two - dimensional echocardiography,C0013524
670,computed tomographic angiography,C1536105
669,radionuclide ventriculography,C0017200;C0034610
668,duplex ultrasonography,C3825392
667,pharmacotherapy,C0013216;C0013217
667,other drug therapy,C0013216;C0013217
667,drug therapy at admission 一 no . ( % ) aspirin,C0013216;C0013217;C0184666;C0809949
667,drug therapy at admission — no . ( % ) aspirin,C0013216;C0013217;C0184666;C0809949
667,drug therapy,C0013216;C0013217
666,no htn,C0020538
666,htn hx,C0020538;C0262926;C3814444
666,htn,C0020538
666,high blood pressure,C0020538;C2926615
666,elevated blood pressure,C0020538;C0497247
665,resistant htn n = nmbr,C0020538;C0332325;C1514892;C1550464;C2827757
665,resistant htn : spiro n = nmbr,C0020538;C0332325;C1514892;C1550464;C2827757
665,resistant htn : placebo n = nmbr,C0020538;C0032042;C0332325;C1514892;C1550464;C1696465;C1706408;C2827757
665,no resistant htn n = nmbr,C0020538;C0332325;C1514892;C1550464;C2827757
664,without hypertension at baseline to hypertension,C0020538;C0168634;C1442488;C1963138
664,treated hypertension :,C0020538;C1522326;C1963138
664,treated for hypertension,C0020538;C1522326;C1963138
664,systemic hypertension,C0020538
664,systemic arterial hypertension,C0020538
664,reported hypertension *,C0020538;C0684224;C0700287;C1963138;C4319718
664,prior hypertension,C0020538;C0332152;C1963138;C2826257
664,previous hypertension,C0020538;C0205156;C1552607;C1963138
664,no hypertension ( n = nmbr ),C0020538;C1963138
664,no hypertension,C0020538;C1963138
664,isoiated systoiic hypertension *,C0020538;C1963138
664,hypertensionnmbr ( % ),C0020538;C1963138
664,hypertension^,C0020538;C1963138
664,hypertension 本,C0020538;C1963138
664,hypertension 一 no . ( % ),C0020538;C1963138
664,hypertension — no . / total no . ( % ),C0020538;C1963138
664,hypertension — no . ( % ) |,C0020538;C1963138
664,hypertension — no . ( % ) hypercholesterolemia — no . ( % ),C0020538;C1963138
664,hypertension — no . ( % ),C0020538;C1963138
664,hypertension § yes,C0020538;C1549445;C1705108;C1710701;C1963138
664,hypertension §,C0020538;C1963138
664,hypertension severity,C0020538;C0439793;C0522510;C1963138
664,hypertension serum lipid values,C0020538;C0042295;C0428462;C1963138
664,hypertension requiring medical treatment,C0020538;C1963138
664,hypertension n ( % ),C0020538;C1963138
664,hypertension at baseline,C0020538;C0168634;C1442488;C1963138
664,hypertension and left ventricular hypertrophy,C0020538;C1963138
664,hypertension absent,C0020538;C1963138
664,hypertension : no ( n = nmbr ),C0020538;C1963138
664,hypertension / yes,C0020538;C1549445;C1705108;C1710701;C1963138
664,hypertension *,C0020538;C1963138
664,hypertension ( n 二 nmbr ),C0020538;C1963138
664,hypertension ( > nmbr / nmbr mm hg or taking,C0020538;C0439475;C1963138
664,hypertension ( % ) : t,C0020538;C1963138
664,hypertension ( % ),C0020538;C1963138
664,hypertension !,C0020538;C1963138
664,hypertension,C0020538;C1963138
664,hyper - tension,C0020538;C1963138
664,duration of hypertension ( years ),C0020538;C0439234;C0449238;C1963138;C2926735
664,duration of hypertension ( months ),C0020538;C0439231;C0449238;C1963138;C2926735
664,duration of hypertension,C0020538;C0449238;C1963138;C2926735
664,arterial hypertension — no . ( % ),C0020538
664,arterial hypertension *,C0020538
664,arterial hypertension,C0020538
664,> nmbr . nmbr kg / mnmbr hypertension :,C0020538;C1532718;C1963138
663,st segment depression,C0520887
663,st depression > nmbr mm,C0520887;C4330985;C4554674
663,st - segment depression > nmbr mm — no . ( % ),C0520887;C4330985;C4554674
663,st - segment depression > nmbr mm,C0520887;C4330985;C4554674
663,st - segment depression > nmbr . nmbr mv on admission,C0520887;C1454484;C1705503;C4281602
663,st - segment depression > nmbr . nmbr mv,C0520887;C1454484;C1705503;C4281602
663,st - segment depression < nmbr . nmbr mv,C0520887;C1454484;C1705503;C4281602
663,st - segment depression,C0520887
662,st depression or elevation,C0520887
662,st depression ( without st elevation ),C0011570;C0011581;C0344315;C0439775;C0460137;C0520886;C0520887;C0702240;C4049644;C4084909;C4085311;C4553827
662,st - segment depression or t - wave inversion on ecg,C0520887
662,st - depression and t - wave inversion,C0520887
662,no st depression or elevation,C0520887
661,ntprobnp ( pg / ml ),C0439297;C0669479;C0754710
661,nt - probnpnmbr pmol - l - nmbr,C0439284;C0669479;C0754710
661,nt - probnp ， pmol / h,C0033727;C0369286;C0439192;C0441932;C0564385;C0669479;C0754710;C4528284
661,nt - probnp — pg / ml * *,C0439297;C0669479;C0754710
661,nt - probnp — pg / ml,C0439297;C0669479;C0754710
661,nt - probnp ( pg / ml ) h,C0030827;C0033727;C0072225;C0369286;C0439297;C0439391;C0439526;C0441932;C0564385;C0669479;C0754710;C1266240;C1705224;C2827929;C3887665;C4528284
661,nt - probnp ( pg / ml ) ( qnmbr - qnmbr ),C0439297;C0669479;C0754710
661,nt - probnp ( pg / ml ),C0439297;C0669479;C0754710
661,nt - probnp,C0669479;C0754710
661,nt - pro bnp,C0669479;C0754710
661,nt - pro - bnp — pmol / literf,C0439192;C0669479;C0754710
661,nt - pro - bnp — pmol / liter - j -,C0439192;C0475211;C0669479;C0754710
661,nt - pro - bnp,C0669479;C0754710
661,n - terminal pro - bnp — pg / ml §,C0439297;C0669479
660,on step - nmbr drug,C0013227;C1254351;C1261552;C1704379;C1705117;C2825408;C3814463
660,. nmbr step or incident vitrectomy or photocoagulation,C1261552;C1704379;C1705117;C2825408;C3814463
659,severe / moderate,C1299393
659,moderate - to - severe copd exacerbation,C0740304;C1299393
659,gusto severe / moderate,C1299393
658,any new anti - hyperglycemic rx,C0205314;C1425688;C1521941;C2709207
657,new vertebral fracture at nmbr months,C0080179;C0205314;C0439231
657,new or worsening vertebral fracture at nmbr months,C0205314
657,a new vertebral fractures ( mfas ),C0080179;C0205314;C1549796;C1549980
656,no new jsn among patients with ≥ nmbr uninvolved joint at baseline ¶,C0030705;C0205314
656,no new erosions among patients with ≥ nmbr uninvolved joint at baseline ¶,C0030705;C0205314;C0333307;C1959609
656,no new a or and no more than nmbr new bilag b domain score,C0205314
655,new use of gpa,C0205314;C1524063;C3495801;C4553145
655,new or worsentna neohrodathv,C0205314
655,new or worsenina neohrodathv,C0205314
655,new or suspected thrombus,C0205314
654,steroids § §,C0038317
654,steroids,C0038317
654,other steroids,C0038317
654,on steroid at baseline,C0038317;C0168634;C1442488
654,baseline steroids,C0038317;C0168634;C1442488
653,steroids ( other ),C0038317
653,steroids ( n = nmbr vs nmbr ),C0038317
653,steroids ( inhaled ) a,C0038317
653,steroid - free cr - nmbr,C0038317;C0201975;C0332296;C1880497;C1996904;C3539604;C3711669;C4084730;C4553336;C4553337
653,no steroids ( n = nmbr vs nmbr ),C0038317
652,steroid use at baseline,C0168634;C0281991;C1442488
652,steroid use,C0281991
652,no steroid use at baseline ( ref ),C0168634;C0281991;C1425988;C1442488
651,stage nmbrb : nmbr - nmbr ml / min / nmbr . nmbr mnmbr,C0369637;C0439445;C0441781;C0441923
651,stage nmbrb : > = nmbr and < nmbr,C0441781
651,stage nmbrb,C0441781
650,participation in phase a,C0205390;C0679823;C1710475
650,double - dummy phase * *,C0205390;C1710475;C4684647
649,stage of pda,C0013274;C0205390;C0226047;C1300072;C1306673;C4282128
649,stage nmbra ckd cohort ( secondary analysis ),C0205390;C1300072;C1306673
649,stage nmbra ckd cohort ( post hoc analysis excluding metformin users ),C0205390;C1300072;C1306673
649,stage nmbra : nmbr - nmbr ml / min / nmbr . nmbr mnmbr,C0205390;C1300072;C1306673
649,stage nmbra : egfr > = nmbr and < nmbr ml / min per nmbr . nmbr mnmbr,C0205390;C1300072;C1306673
649,stage nmbra : > = nmbr and < nmbr,C0205390;C1300072;C1306673
649,stage nmbra,C0205390;C1300072;C1306673
649,stage nmbr ckd egfr nmbr to nmbr ml / min ( n = nmbr ),C0205390;C1300072;C1306673
649,stage nmbr ckd egfr > nmbr ml / ( n = nmbr ),C0205390;C1300072;C1306673
649,stage nmbr : > = nmbr,C0205390;C1300072;C1306673
649,stage nmbr : < nmbr,C0205390;C1300072;C1306673
649,stage nmbr ( four - variable modification of diet in kidney disease ),C0205390;C1300072;C1306673
649,stage nmbr ( cockcroft - gault ),C0205390;C1300072;C1306673
649,stage nmbr,C0205390;C1300072;C1306673
649,stage iv,C0205390;C1300072;C1306673
649,stage > nmbr chronic kidney disease ( % ),C0205390;C1300072;C1306673
649,hoehn and yahr stage ( range,C0205390;C1300072;C1306673;C1514721;C2348147;C3542016
649,hoehn and yahr stage ( baseline ),C0168634;C0205390;C1300072;C1306673;C1442488
649,hoehn and yahr stage,C0205390;C1300072;C1306673
649,hoehn & yahr stage ( “ on ” ),C0205390;C1300072;C1306673
649,hoehn & yahr stage ( “ off ” ),C0205390;C1300072;C1306673
649,hoehn & yahr stage,C0205390;C1300072;C1306673
648,sbp,C0085805
648,range of sbp,C0085805;C1514721;C2348147;C3542016
648,ambulatory sbp,C0085805;C0439841
647,sbp > nmbrmnn hg,C0025424;C0085805;C0428257;C2347108;C2347109;C2348272
647,sbp > nmbrmmhg n = nmbr,C0085805;C0439475
647,sbp < nmbrmmhg n = nmbr,C0085805;C0439475
647,sbp ( mmhg ) < nmbr,C0085805;C0439475
647,sbp ( mmhg ) *,C0085805;C0439475
647,sbp ( mmhg ),C0085805;C0439475
647,sbp ( mmghg ),C0085805
647,sbp ( mm hg ),C0085805;C0439475
647,nmbr < sbp < nmbrmmhg n = nmbr,C0085805;C0439475
647,nmbr < sbp < nmbr mmhg n = nmbr,C0085805;C0439475
646,sbp indicates systolic blood pressure  dbp  diastolic blood pressure  aa  arachidonic acid  epa  eicosapentaenoic acid . values for age  bmi  total cholesterol  ldl cholesterol  hdl cholesterol  sbp  dbp  aa  epa  and epa / aa ratio represent the mean values represent the median ( interquartile range ) . p values are for the differences between the no epa and epa groups .,C0085805
646,sbp  systolic blood pressure  sd  standard deviation  dbp  diastolic blood pressure  b . p . m .  beats per minute  mi  myocardial infarction  tia  transient ischaemic attack .,C0085805;C0369637;C0428883;C0441923;C0488055;C0871420;C0871470;C1306620;C2699239
646,bmi = body mass index  bnp = brain natriuretic peptide  dbp = diastolic blood pressure  gfr = glomerular filtration rate  hr = heart rate  iqr = interquartile range  kccq = kansas city cardiomyopathy questionnaire  n = number  nt = n - terminal  nyha = new york heart association  sbp = systolic blood pressure,C0017654;C0018810;C0054015;C0085805;C0205088;C0332126;C0428883;C0459867;C0488055;C0871470;C1095989;C1275491;C1305855;C1306620;C1417808;C1424601;C1449832;C1561549;C1705314;C1705315;C1711350;C2982014;C3476086;C3476798;C3889152;C4050156;C4283901;C4284038
646,bmi : body mass index  dbp : diastolic blood pressure  gm : geometric mean  sbp : systolic blood pressure . the analysis was based on observed data without imputation on missing values . asubgroup of patients in whom nmbr h urine was collected ( see materials and methods section ) .,C0017480;C0085805;C0428883;C0488055;C0871470;C1305855;C1306620;C2986759;C3854019
645,mostly satisfied,C0205393;C0750554
645,mostly dissatisfied,C0205393;C0750554
645,most frequent non - infectious teaesb,C0205393;C0239998;C1518422
645,most frequent infections,C0205393;C0239998
644,cluster seizures,C0036572;C1555715;C1704332
644,cluster nmbr : reversible,C1555715;C1704332
644,cluster nmbr : not reversible,C1555715;C1704332
644,cluster nmbr : diuretic ( n = nmbr ),C1555715;C1704332
643,history of osteoporotic fracture,C4075937
642,history of alcohol use,C0551571;C0552479
641,history of diabetes mellitus ( n = nmbr ),C0455488
641,history of diabetes mellitus,C0455488
640,history of a transient ischaemic attack,C0455536
639,history of hyperlipidemia ( % ),C4695788
638,history of falls in year before randomization,C1561668;C2919132
638,history of falls,C1561668;C2919132
637,no history of migraine,C0455512
636,history of pvd,C4534349
635,no history of cancer,C0455471
635,history of cancer,C0455471
634,no history of heart failure at baseline,C0455531
634,infarction ( yr ) history of congestive heart failure ( % ),C0021308;C0439234;C0455531;C0742742
634,history of heart failure — no . { % ),C0455531
634,history of heart failure — no . ( % ),C0455531
634,history of heart failure at baseline,C0455531
634,history of heart failure,C0455531
634,history of congestive heart failure,C0455531;C0742742
634,any history of congestive heart failure,C0455531;C0742742
633,tertiary amines,C3653356
632,tertiary endpoints :,C0205372;C2349179
632,tertiary end points,C0205372;C2349179
632,tertiary,C0205372
631,western friroce,C1705493
631,western eu,C0015179;C1705493;C3665627
631,western,C1705493
630,central europe,C0682369
629,eastern and central europe,C1707877
629,east europe,C0015176;C1707877
628,eastern european,C0239309
627,eastern europe and africa,C0015177
627,eastern europe ( n   = nmbr,C0015177
627,eastern europe ( n = nmbr ),C0015177
627,eastern europe ( % ),C0015177
627,eastern europe,C0015177
626,western europe plus other,C0043129
626,western europe hr ( nmbr % cl ),C0043129;C0596019
626,western europe and other,C0043129
626,western europe and lebanon,C0043129
626,western europe and israel,C0043129
626,western europe and australia,C0043129
626,western europe / australia / israel,C0004340;C0015176;C0022271;C0043128;C0043129
626,western europe / australia,C0004340;C0015176;C0043128;C0043129
626,western europe ( n   = nmbr,C0043129
626,western europe ( n = nmbr ),C0043129
626,western europe ( including south africa ),C0043129
626,western europe ( % ),C0043129
626,western europe,C0043129
625,forearm,C0016536
624,korean,C1556095
624,korea,C0022771
623,north ameriea,C1709269
623,north,C1709269
622,southern europe,C0037724
621,shared epitope,C0003316;C0237876;C1522138
620,short term^,C0443303
620,short term ( n = nmbr ) +,C0443303
619,mouth ulceration,C0149745
618,south american,C0425359
618,north american,C0425358;C2700615
617,south asian,C1519427
617,south asia,C0037723;C1519427
616,south america ( n = nmbr ),C0037713
616,south america ( % ),C0037713
616,south america,C0037713
616,south africa / south america,C0001737;C0002454;C0037712;C0037713
615,southern hemisphere,C0205139;C1710133
615,south or central american,C1710133
615,south or central america,C1710133
615,south ! central america,C0007674;C0037713;C0205099;C1710133;C1879652
615,south,C1710133
614,testing order,C0039593;C0392366;C1705175;C1705176;C1705177;C1705178;C1882348;C3889825;C4284072
613,leukotriene modifier,C0023545;C0205349;C1514623;C1516451;C3542952
612,treatment with open - label perindopril,C0136123;C3640652
612,perindopril,C0136123
611,direction of hr,C0449738
610,section nmbrc,C0152060;C0700320;C1522472;C1552923;C1705191;C3714523
610,section nmbrb,C0152060;C0700320;C1522472;C1552923;C1705191;C3714523
610,section nmbra,C0152060;C0700320;C1522472;C1552923;C1705191;C3714523
609,prevention ),C0199176;C1706420;C2700409
609,gissi prevention nmbr / nmbr - nmbr / nmbr,C0199176;C1706420;C2700409
608,resection performed — no . { % ),C0015252;C0728940
608,resection performed,C0015252;C0728940
607,fevi reversibility — %,C3830088
606,reversibility to salbutamol,C1271924
605,renin inhibitor ( e . g . aliskerin ),C1960108;C3537174;C4521920
605,renin inhibitor,C1960108;C3537174;C4521920
604,reversible to bronchodilator,C0006280;C0205343
604,reversible to albuterolc,C0205343
604,reversible ( % ),C0205343
604,reversible,C0205343
604,non - reversible ( % ),C0205343;C1518422
603,peripheral artery disease 一 no . ( % ),C1704436;C4025272
603,peripheral artery disease — no . ( % ),C1704436;C4025272
603,peripheral artery disease details,C1704436;C4025272
603,peripheral artery disease - -,C1704436;C4025272
603,peripheral artery disease *,C1704436;C4025272
603,peripheral artery disease,C1704436;C4025272
603,peripheral arterial stenosis,C4025272
603,peripheral - artery stenosis,C4025272
603,peripheral - artery disease — no . ( % ),C1704436;C4025272
603,peripheral - artery disease ( % ),C1704436;C4025272
603,peripheral - artery disease,C1704436;C4025272
603,only peripheral artery disease,C0205171;C1704436;C1720467;C4025272
602,peripheral artery occlusive disease ( stage nmbr / nmbr / nmbr / nmbr / nmbr ),C0205390;C1300072;C1306673;C1306889
602,peripheral artery occlusive disease,C1306889
601,peripheral artery revascularization without amputation,C0002688;C0332840;C0489868;C0581603;C1546539
601,peripheral artery diseasef,C0489868
601,peripheral artery diseaseb,C0489868
601,peripheral artery,C0489868
600,preoperative heart rate ( beats per minute ),C0018810;C0445204
600,nmbr - lead ecg heart rate,C0018810;C0179504
600,heart rates ( beats / minutes ),C0018810
600,heart rate 一 beats / min,C0018810
600,heart rate — bpm,C0018810
600,heart rate — beats / min,C0018810
600,heart rate > nmbr bpm,C0018810
600,heart rate < nmbr bpm,C0018810
600,heart rate ( sd ),C0018810;C2699239
600,heart rate ( min − nmbr ),C0018810;C0702093;C1524029;C3813700
600,heart rate ( bpmnmbr ) *,C0018810
600,heart rate ( bpm ) *,C0018810
600,heart rate ( bpm ),C0018810
600,heart rate ( beats per minute ),C0018810
600,heart rate ( beats per min ),C0018810
600,heart rate ( beats / min ),C0018810
600,heart rate,C0018810
600,< nmbr mm hg heart rate,C0018810;C0439475
599,preamendment,C1548596
598,before amendment ( % ),C0680532;C2346732
598,before amendment,C0680532;C2346732
598,after amendment ( % ),C0680532;C2346732
598,after amendment,C0680532;C2346732
597,treatment arm ( zoledronate ) ( % ),C0392938;C1522541
597,treatment arm,C1522541
597,by treatment arm,C1522541
596,duration alendronate use,C0042153;C0102118;C0449238;C0457083;C1947944;C2926735
596,current alendronate use,C0042153;C0102118;C0457083;C0521116;C1705970;C1947944
596,alendronate ( n = nmbr ),C0102118
596,alendronate,C0102118
595,european union,C0015179
595,eu,C0015179;C3665627
595,eastern eu,C0015179;C1707877;C3665627
594,edge ii,C0205154;C1710602;C2697523;C4082587
594,edge,C0205154;C2697523
593,mean lumbar spine t score,C0024091;C3533236;C3887615
593,lumbar spine bmd t - score,C0024091;C0449820;C3887615;C4050231
593,lumbar spine bmd t -,C0024091;C3887615
593,lumbar spine,C0024091;C3887615
592,t - score categories lumbar spineb,C0024090;C0683312;C3854607
592,lumbar,C0024090
591,plasma lipoproteins,C0023820;C0032105;C1550098;C4521445
591,plasma dha,C0032105;C0142831;C1550098;C2348308;C4521445
591,plasma creatine,C0010286;C0032105;C1550098;C4521445
590,sulfasalazine treatment,C0036078;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
590,sulfasalazine,C0036078
589,sulphonamides,C0038760
588,lacosamide,C0893761
587,on drug treatment ( % ),C0150270;C3469597
587,days of study - drug administration ( % ) * * nmbr day,C0150270;C2826182;C3469597
587,concomitant drug treatment,C0150270;C0521115;C3469597
586,treatment with any bp lowering drugs,C0037623;C0441994;C1415692;C1708288;C2003888;C3469597;C4318478
586,treatment with antiplatelet drugs,C3469597
585,atorvastatin nmbrmg,C0024671;C0026410;C0286651;C0439269;C1960952;C2346927;C4321396;C4521761
585,atorvastatin nmbr mg + ezetimibe nmbr mg ( n = nmbr ),C0286651;C1142985;C1319635
585,atorvastatin nmbr mg,C0024671;C0026410;C0286651;C0439269;C1960952;C2346927;C4321396;C4521761
585,atorvastatin monotherapy ( n = nmbr * ),C0286651
585,atorvastatin,C0286651
584,dose of atorvastatin,C0178602;C0286651;C0869039;C1114758
584,concomitant atorvastatin dose,C0178602;C0286651;C0521115;C0869039;C1114758
584,atorvastatin { n = nmbr,C0286651
584,atorvastatin dose,C0178602;C0286651;C0869039;C1114758
584,atorvastatin ( n = nmbr,C0286651
583,rosuvastatin   n   =   nmbr,C0965129
583,rosuvastatin n = nmbr,C0965129
583,rosuvastatin +,C0965129
583,rosuvastatin ( n = nmbr . nmbr ),C0965129
583,rosuvastatin ( n = nmbr ),C0965129
583,rosuvastatin ( n = nmbr,C0965129
583,rosuvastatin,C0965129
583,i rosuvastatin ( n = nmbr ),C0021966;C0221138;C0965129
583,dose of rosuvastatin,C0178602;C0869039;C0965129;C1114758
582,mdi / hfa,C0015458;C0993596;C1839839;C4049613
582,mdi,C0993596;C1839839;C4049613
582,gp mdi,C0993596;C1705010;C1839839;C3811116;C4049613
582,gff mdi,C0993596;C1839839;C4049613
582,ff mdi,C0993596;C1839839;C4049613;C4554348
581,ni,C0028075;C2348274;C3869926;C3869927
581,> nmbr ml / niin / lnmbrni -,C0028075;C1635169;C2348274;C3869926;C3869927
581,< nmbr ml / min / nmbr . nmbrni -,C0028075;C0439445;C2348274;C3869926;C3869927
580,who functional class ii / iii,C0205245;C0439070;C0441886;C0441887;C0542341;C1705160;C1710602;C2698968;C2698969;C2700217;C4082587
580,updrs total ( ii + iii ),C0439070;C0439175;C0439810;C1705160;C1710602;C3639721;C4082587
580,updrs iii ( motor ),C0439070;C1513492;C1705160;C1705994;C3639721
580,nyha iii or iv § ( n = nmbr nmbr ),C0439070;C1275491;C1705160
580,nyha iii or iv,C0439070;C1275491;C1705160
580,nyha iii,C0439070;C1275491;C1705160
580,ncep atp iii risk factors,C0035648;C0439070;C1553898;C1705160;C2744579;C4552600
580,ncep atp - iii metabolic syndrome features,C0439070;C0524620;C1705160;C2744579;C4552600
580,iii or iv,C0439070;C1705160
580,iii and iv ejection fraction,C0439070;C1705160
580,iii and iv,C0439070;C1705160
580,iii : fevnmbr > nmbr % - < nmbr % predicted,C0439070;C1705160;C3714541
580,iii / iv,C0022326;C0439070;C1705160;C4265176
580,iii - iv,C0022326;C0439070;C1705160;C4265176
580,iii ( nmbr ),C0439070;C1705160
580,iii ( n z nmbr ),C0439070;C1705160
580,iii & iv,C0022326;C0439070;C1705160;C4265176
580,iii,C0439070;C1705160
580,ii / iii,C0439070;C1705160;C1710602;C4082587
580,ii - iii,C0439070;C1705160;C1710602;C4082587
580,gold iii - iv,C0018026;C0022326;C0439070;C1304897;C1705160;C4265176
580,class iii / iii - v,C0439070;C0457166;C1705160;C1880098
579,no mi ( n - nmbr,C3810814
579,mi > nmbr months *,C0439231;C3810814
579,mi < nmbr months *,C0439231;C3810814
579,mi *,C3810814
579,mi,C3810814
579,index mi ( n - nmbr,C0600653;C0918012;C1552854;C1637833;C2986546;C3810814
579,any mi ( n - nmbr,C3810814
578,mi or cad,C3810814
578,hx mi or stroke,C0262926;C3810814;C3814444
577,• any mi,C3810814
577,nocad / mi,C3810814
577,no mi,C3810814
577,no cad / mi,C1504769;C2239547;C3810814;C3813548;C4284121
577,large mi,C0549177;C3810814
577,any mi,C3810814
577,: mi,C3810814
576,nonfatal mi + fatal chdt,C1302234;C1705232;C3810814
576,nonfatal mi ( n = nmbr ),C3810814
576,chd ( nonfatal mi + fatal chd ),C0280604;C1302234;C1705232;C3542407;C3810814
575,type of mi ( % ),C0332307;C1547052;C3810814
575,type of mi,C0332307;C1547052;C3810814
575,qualifying mi type,C0332307;C1514624;C1547052;C3810814
575,mi — no . ( % ),C3810814
575,mi type unknown ( % ),C0332307;C1547052;C3810814
574,type of myocardial infarction — no . ( % ),C0027051;C0332307;C0428953;C1547052;C2926063;C3810814;C4552959
574,suspected myocardial infarction,C0027051;C0332147;C0428953;C0750491;C2926063;C3810814;C4552959
574,previous myocardial infarction — no . ( % ),C0027051;C0205156;C0428953;C1552607;C2926063;C3810814;C4552959
574,nonfatal myocardial infarction ®,C0027051;C0428953;C2926063;C3810814;C4552959
574,nonfatal myocardial infarction,C0027051;C0428953;C2926063;C3810814;C4552959
574,non - fatal myocardial infarction,C0027051;C0428953;C1302234;C1518422;C1705232;C2926063;C3810814;C4552959
574,no myocardial infarction at presentation ( n = nmbr ),C0027051;C0428953;C0449450;C2926063;C3810814;C4552959
574,myocardial infarction — no . ( % ),C0027051;C0428953;C2926063;C3810814;C4552959
574,myocardial infarction §,C0027051;C0428953;C2926063;C3810814;C4552959
574,myocardial infarction within the previous nmbr yr,C0027051;C0205156;C0428953;C0439234;C1552607;C2926063;C3810814;C4552959
574,myocardial infarction or angina,C0027051;C0428953;C2926063;C3810814;C4552959
574,myocardial infarction n ( % ),C0027051;C0428953;C2926063;C3810814;C4552959
574,myocardial infarction before index acs — no . ( % ),C0027051;C0428953;C0600653;C0742343;C0918012;C1552854;C1637833;C2926063;C2986546;C3810814;C4318612;C4552959
574,myocardial infarction at presentation ( n = nmbr ),C0027051;C0428953;C0449450;C2926063;C3810814;C4552959
574,myocardial infarction :,C0027051;C0428953;C2926063;C3810814;C4552959
574,myocardial infarction / cabg / pci < nmbr years,C0010055;C0027051;C0428953;C0439234;C2926063;C3810814;C4049621;C4552959
574,myocardial infarction / cabg / pci,C0010055;C0027051;C0428953;C2926063;C3810814;C4049621;C4552959
574,myocardial infarction ( % ),C0027051;C0428953;C2926063;C3810814;C4552959
574,myocardial infarction,C0027051;C0428953;C2926063;C3810814;C4552959
574,histor y of myocardial infarction,C0027051;C0428953;C2926063;C3810814;C4552959
574,fatal myocardial infarction,C0027051;C0428953;C1302234;C1705232;C2926063;C3810814;C4552959
574,cardiovasculardeath / myocardial infarction / stroke,C0027051;C0038454;C0428953;C2926063;C3810814;C4552959;C4554100
574,cardiovascular death / myocardial infarction / stroke,C0011065;C0027051;C0428953;C1306577;C2926063;C3810814;C4082313;C4552775;C4552959
574,b . myocardial infarction,C0027051;C0428953;C2926063;C3810814;C4552959
574,abbreviations : chd  coronary heart disease  cl  confidence interval  ml  myocardial infarction  rr  relative risk . ^defined as a composite end point comprising the first of any of these events : nonfatal ml  nonfatal stroke  or cardiovascular death . tp value for interaction < . nmbr for major cardiovascular event . no other interactions are significant . ^calculated as weight in kilograms divided by the square of height in meters . § hypertension was defined as a self - reported systolic blood pressure > nmbr mm hg  a diastolic blood pressure > nmbr mm hg  or physician - diagnosed hypertension . | | hyperlipidemia was defined as a self - reported total cholesterol > nmbr mg / dl_ ( nmbr . nmbr mmol / l ) or physician - diagnosed high cholesterol . ^diabetes defined by self - report . # calculated using the framingham risk score among nmbr nmbr women who provided a blood sample at baseline .,C0000723;C0009667;C0010068;C0027051;C0242492;C0428953;C0439526;C0596019;C1705224;C2926063;C3810814;C3887665;C4552959;C4554402
574,abbreviations : ace  angiotensin - converting enzyme  iqr  interquartile range  ml  myocardial infarction . si conversion : to convert creatinine clearance to ml / s  multiply by nmbr . nmbr . * data are expressed as no . / total ( % ) unless otherwise specified . festimated using cockroft - gault equation . tthe timi risk score was used to categorize patients at low ( nmbr - nmbr )  intermediate ( nmbr - nmbr )  and high ( nmbr - nmbr ) risk . nmbr,C0000723;C0022709;C0027051;C0428953;C0439526;C0439836;C1705224;C1711350;C2926063;C3810814;C3887665;C4552959
573,number of visits,C1549755
572,number of individuals,C1549735
571,numbers of events ( % ) :,C4330837
571,number of events ( annualised rate [ % ] ),C4330837
571,number of events,C4330837
570,number of treated lesions ( per patient ),C0449791;C1522326
570,number of treated lesions,C0449791;C1522326
570,number of lesions,C0449791
569,number of treated patients,C1522326;C2360800
569,number of patients with fractures,C2360800
569,number of patients with exacerbations in the previous nmbr months,C2360800
569,number of patients with events,C2360800
569,number of patients with dose available,C2360800
569,number of patients with available data,C2360800
569,number of patients with,C2360800
569,number of patients randomized,C2360800
569,number of patients > nmbr years ( % ),C0439234;C2360800
569,number of patients ( % ) or mean 士 sd,C2360800
569,number of patients ( % ) or mean ± sd,C2360800
569,number of patients,C2360800
569,number of ( % ) patients > nmbr years,C0439234;C2360800
569,number ( % ) of patients with event,C2360800
569,number ( % ) of patients,C2360800
568,western european includinq australia,C0004340;C0043128;C0239307;C0239312;C1535514
568,non - european trial,C0008976;C0239307;C1518422;C1535514
568,non - european,C0239307;C1518422;C1535514
568,european trial,C0008976;C0239307;C1535514
568,european subcategories,C0239307;C1515010;C1535514
568,european or arab,C0239307;C1535514
568,european,C0239307;C1535514
567,unknown — no . { % ),C0439673;C3541433;C4050014
567,unknown type,C0332307;C0439673;C1547052;C3541433;C4050014
567,unknown or missing,C0439673;C3541433;C4050014
567,unknown / missing,C0439673;C3541433;C4050014
567,unknown ( none of the above ),C0439673;C3541433;C4050014
567,unknown ( % ),C0439673;C3541433;C4050014
567,unknown,C0439673;C3541433;C4050014
567,non - detectable / unknown,C0439673;C1518422;C3541433;C3830527;C4050014
567,no / unknown,C0439673;C3541433;C4050014
566,≥ nmbr to < nmbr ml / min / nmbr . nmbr mnmbr,C0369637;C0439445;C0441923
566,severe ( < nmbr ml · min − nmbr · nmbr . nmbr m − nmbr ),C0205082;C0369637;C0439445;C0441923;C4050465;C4050466
566,nmbrmwt ( m ),C0369637;C0441923
566,nmbr to onmbr ml / min / nmbr . nmbr mnmbr,C0369637;C0439445;C0441923;C0483204
566,nmbr to o nmbr ml / min / nmbr . nmbr mnmbr,C0369637;C0439445;C0441923;C0483204
566,nmbr to < nmbr ml per nmbr - nmbr mnmbr,C0369637;C0439526;C0441923;C1705224;C3887665
566,nmbr to < nmbr ml min ’ nmbr nmbr . nmbr m ' nmbr,C0369637;C0439445;C0441923
566,nmbr to < nmbr ml / min / nmbr . nmbrmnmbr,C0369637;C0439445;C0441923
566,nmbr to < nmbr ml / min / nmbr . nmbr mnmbr,C0369637;C0439445;C0441923
566,nmbr to < nmbr ml / min / nmbr . nmbr m^,C0369637;C0439445;C0441923
566,nmbr to < nmbr m um in,C0369637;C0441923
566,nmbr exacerbation in prev nmbr m ( n = nmbr ),C0369637;C0441923;C1552852;C4086268
566,nmbr . nmbr - nmbr . nmbr ml / min / nmbr . nmbr mnmbr,C0369637;C0439445;C0441923
566,min per nmbr . nmbr mnmbr,C0369637;C0441923;C0702093;C1524029;C3813700
566,mild ( nmbr – nmbr ml · min − nmbr · nmbr . nmbr m − nmbr ),C0369637;C0439445;C0441923;C2945599
566,mean — ml / min / nmbr . nmbr mnmbr of body - surface area,C0017446;C0205146;C0369637;C0439445;C0441923;C0444504;C0489451;C2347634;C2348143
566,mean — ml / min / nmbr . nmbr mnmbr level — no . ( % ),C0369637;C0439445;C0441889;C0441923;C0444504;C0456079;C1547707;C2347634;C2348143;C2946261
566,mab,C0003250;C0369637
566,m being,C0369637;C0441923
566,m,C0369637;C0441923
566,less than nmbr ml / min / nmbr . nmbrmnmbr,C0369637;C0439092;C0439445;C0441923
566,hr ( b . p . m . ),C0369637;C0441923
566,heart rate ( b . p . m . ),C0018810;C0369637;C0441923
566,azl - m nmbr mg nmbr - cld nmbr mg ( n = lnmbr ),C0369637;C0441923;C2827881
566,azl - m nmbr mg + cld nmbr mg,C0369637;C0441923;C1319635
566,azl - m / cld ( n = nmbr ),C0369637;C0441923
566,azl - m + hctz ( n = nmbr ),C0020261;C0369637;C0441923
566,azl - m + cldb,C0369637;C0441923
566,azl - m,C0369637;C0441923
566,> nmbr to < nmbrml / min / nmbr . nmbrmnmbr,C0369637;C0439445;C0441923
566,> nmbr to < nmbriiil / iiim / nmbr . nmbr mnmbr,C0369637;C0441923
566,> nmbr to < nmbr ml / min / nmbr . nmbr m^,C0369637;C0439445;C0441923
566,> nmbr ml min - nmbr nmbr . nmbr m ' nmbr,C0369637;C0439445;C0441923
566,> nmbr ml / min / nmbr . nmbr mnmbr — no . ( % ),C0369637;C0439445;C0441923
566,> nmbr exacerbation in prev nmbr m ( n = nmbr ),C0369637;C0441923;C1552852;C4086268
566,> nmbr . nmbr ml / min / nmbr . nmbr mnmbr,C0369637;C0439445;C0441923
566,"< nmbr ml min ’ nmbr nmbr . nmbr m "" nmbr",C0369637;C0439445;C0441923
566,< nmbr ml / min / nmbr . nmbr mnmbr — no . ( % ),C0369637;C0439445;C0441923
566,< nmbr ml / min / nmbr . nmbr mnmbr nt - pro - bnp,C0369637;C0439445;C0441923;C0669479;C0754710
566,< nmbr ml / min / nmbr . nmbr m^ — no . { % ),C0369637;C0439445;C0441923
566,< nmbr . nmbr ml / min / nmbr . nmbr mnmbr,C0369637;C0439445;C0441923
565,ipah / fpah / drug and toxin,C0013227;C0152171;C1254351;C1419079
565,epilepsy drug,C0013227;C0014544;C1254351
565,due to drug - relateda ae,C0013227;C1254351;C3887670
565,drug ‐ relateda,C0013227;C1254351
565,drug naive,C0013227;C1254351
565,drug eluting,C0013227;C1254351
565,drug and insulint,C0013227;C1254351
565,drug - relateda,C0013227;C1254351
565,drug - related teaesnmbr,C0013227;C0439849;C0445223;C1254351
565,drug - related teaes *,C0013227;C0439849;C0445223;C1254351
565,drug - related teaes,C0013227;C0439849;C0445223;C1254351
565,drug - related saes,C0013227;C0439849;C0445223;C1254351;C1519255;C1622657;C4553214
565,drug - related ae *,C0013227;C0439849;C0445223;C1254351;C3887670
565,drug - eluting,C0013227;C1254351
565,because of drug ‐ relateda   ae,C0013227;C1254351;C3887670
565,any drug - related ae,C0013227;C0439849;C0445223;C1254351;C3887670
565,antithrombotic drug use at time of event,C0013227;C0040223;C0441471;C1254351;C1524063;C3541383;C4019010
565,> nmbr drug - related aes *,C0013227;C0439849;C0445223;C1254351;C1412268;C2699274
565,> nmbr drug - related,C0013227;C0439849;C0445223;C1254351
564,other drugs — no . ( % ),C0013227;C3687832
564,other drugs,C0013227;C3687832
564,number of antidiabetes drugs at screening,C0013227;C0237753;C0449788;C3687832
564,no . of previous anti - tnf drugs — no . ( % ),C0013227;C0205156;C1448177;C1552607;C3687832
564,no . of drugs,C0013227;C3687832
564,lowering drugs,C0013227;C0441994;C2003888;C3687832
564,immunomodulatory drugs,C0013227;C3687832
564,drugs used in diabetes,C0013227;C3687832
564,drugs and toxins,C0013227;C3687832
564,annanginal drugs ( nmbr / l / s » nmbr ) ^,C0013227;C3687832
563,use of medications for pah — no . ( % ),C0013227;C0802604;C1524063;C2598133;C4284232
563,use of medication from randomization through nmbr hr — no . / total no . ( % ),C0013227;C1524063;C3244316;C4284232
563,use of medication for pah,C0013227;C1524063;C3244316;C4284232
563,use of medication at baseline — no . ( % ),C0013227;C1524063;C3244316;C4284232
563,use of cardiac medication *,C0013227;C0018787;C1522601;C1524063;C3244316;C4284232
563,use of blood pressure lowering medication *,C0013227;C0020649;C1524063;C3244316;C4284232
563,systemic sle medications,C0013227;C0024141;C0205373;C0802604;C2598133;C4284232
563,study medication — no . ( % ),C0013227;C0557651;C2603343;C3244316;C4284232
563,selected medications — no . ( % ),C0013227;C0802604;C1707391;C2598133;C4284232
563,selected baseline medications,C0013227;C0168634;C0802604;C1442488;C1707391;C2598133;C4284232
563,pulmonary medications ( % ),C0013227;C0024109;C0802604;C2598133;C2707265;C2709248;C4284232;C4522268
563,prior medications,C0013227;C0332152;C0802604;C2598133;C2826257;C4284232
563,previous medications,C0013227;C0205156;C0802604;C1552607;C2598133;C4284232
563,periprocedural medications — no . / total no . ( % ),C0013227;C0802604;C2598133;C4284232
563,periprocedural medications — no . / total no .,C0013227;C0802604;C2598133;C4284232
563,periprocedural medications,C0013227;C0802604;C2598133;C4284232
563,other medications,C0013227;C0802604;C2598133;C4284232
563,other medication usage,C0013227;C0457083;C3244316;C4284232
563,op concomitant medications ( % ),C0013227;C0521115;C0802604;C2598133;C4284232
563,on maximum tolerated medications ( % ) median ( nmbrth to nmbrth quartile ) sua ( mg / dl ),C0013227;C0039725;C0039738;C0439269;C0549183;C0802604;C0806909;C0876920;C1420718;C1552615;C2347635;C2348144;C2598133;C2826546;C2828255;C2939193;C4282123;C4284232;C4285344
563,on bp medication,C0013227;C0037623;C1415692;C1708288;C3244316;C4284232;C4318478
563,medications — no . { % ) * *,C0013227;C0802604;C2598133;C4284232
563,medications — no . ( % ),C0013227;C0802604;C2598133;C4284232
563,medications through day nmbr,C0013227;C0332173;C0439228;C0439505;C0802604;C2598133;C4284232
563,medications taken at time of randomization statins,C0013227;C0802604;C2598133;C4284232
563,medications on admission,C0013227;C0802604;C2598133;C4284232
563,medications in use at baseline — no . / total no . ( % ),C0013227;C0802604;C2598133;C4284232
563,medications in use at baseline — no . ( % ),C0013227;C0802604;C2598133;C4284232
563,medications in use at baseline,C0013227;C0802604;C2598133;C4284232
563,medications in the hospital after randomization — no . ( % ),C0013227;C0019994;C0802604;C1510665;C2598133;C4284232
563,medications for crohn ' s disease taken at baseline — no . ( % ),C0010346;C0013227;C0802604;C2598133;C4284232
563,medications during hospitalization or at discharge,C0013227;C0019993;C0802604;C2598133;C4284232
563,medications before admission,C0013227;C0184666;C0802604;C0809949;C2598133;C4284232
563,medications at randomization,C0013227;C0034656;C0802604;C2598133;C4284232
563,medications at baselinet,C0013227;C0802604;C2598133;C4284232
563,medications at baseline,C0013227;C0168634;C0802604;C1442488;C2598133;C4284232
563,medications antihypertensive drugs,C0003364;C0013227;C0802604;C2598133;C4284232
563,medications . no . ( % ),C0013227;C0802604;C2598133;C4284232
563,medications *,C0013227;C0802604;C2598133;C4284232
563,medications ( % ),C0013227;C0802604;C2598133;C4284232
563,medications,C0013227;C0802604;C2598133;C4284232
563,medication — no . ( % ),C0013227;C3244316;C4284232
563,medication within nmbr days before enrolment,C0013227;C0439228;C3244316;C4284232
563,medication useb,C0013227;C3244316;C4284232
563,medication use — no . { % ),C0013227;C3244316;C4284232
563,medication use — no . ( % ) ^ |,C0013227;C3244316;C4284232
563,medication use — no . ( % ),C0013227;C3244316;C4284232
563,medication taken alone or in combination,C0013227;C3244316;C4284232
563,medication prior to admission,C0013227;C0184666;C0332152;C0809949;C3244316;C4284232
563,medication nmbr ( nmbr . nmbr ),C0013227;C3244316;C4284232
563,medication in use at the baseline,C0013227;C3244316;C4284232
563,medication continued into double - blind treatment period,C0013227;C3244316;C4284232
563,medication at time of randomization,C0013227;C0034656;C0040223;C3244316;C3541383;C4284232
563,medication at randomization,C0013227;C0034656;C3244316;C4284232
563,medication at entry ( % ),C0013227;C1705654;C3244316;C4284232
563,medication,C0013227;C3244316;C4284232
563,lipids medications,C0013227;C0023779;C0802604;C2598133;C4284232
563,lipid medication,C0013227;C0023779;C3244316;C4284232
563,in - hospital medication,C0013227;C0019994;C1510665;C3244316;C4284232
563,dm medication,C0011816;C0013227;C3244316;C3250443;C4284232
563,discharge medication,C0012621;C0013227;C0030685;C2926602;C3244316;C4284232
563,cv medication,C0013227;C3244316;C3538987;C4048877;C4284232;C4318503
563,concurrent medications,C0013227;C0205420;C0802604;C2598133;C4284232
563,concurrent medication,C0013227;C0205420;C3244316;C4284232
563,concomitant pd medications at baseline,C0013227;C0168634;C0521115;C0802604;C1442488;C2598133;C4284232;C4553228;C4553229
563,concomitant medications — no . ( % ),C0013227;C0521115;C0802604;C2598133;C4284232
563,concomitant medications in > nmbr % of subjects,C0013227;C0521115;C0681850;C0802604;C1550501;C1706203;C2349001;C2598133;C2697811;C4284232
563,concomitant medications for ulcerative colitis — no . ( % ),C0009324;C0013227;C0521115;C0802604;C2598133;C4284232
563,concomitant medications at baseline,C0013227;C0168634;C0521115;C0802604;C1442488;C2598133;C4284232
563,concomitant medications ( yes ),C0013227;C0521115;C0802604;C1549445;C1705108;C1710701;C2598133;C4284232
563,concomitant medications ( % ),C0013227;C0521115;C0802604;C2598133;C4284232
563,concomitant medications,C0013227;C0521115;C0802604;C2598133;C4284232
563,concomitant medication — no . { % ) | ace inhibitor,C0013227;C0521115;C3244316;C4284232
563,concomitant medication — no . ( % ),C0013227;C0521115;C3244316;C4284232
563,concomitant medication | |,C0013227;C0521115;C3244316;C4284232
563,concomitant medication ( > nmbr % ),C0013227;C0521115;C3244316;C4284232
563,concomitant medication ( % ),C0013227;C0521115;C3244316;C4284232
563,concomitant medication,C0013227;C0521115;C3244316;C4284232
563,concomitant asthma medications,C0004096;C0013227;C0521115;C0802604;C2598133;C2984299;C4284232
563,cardiac medications during indexhospitalization and / or discharge,C0013227;C0018787;C0802604;C1522601;C2598133;C4284232
563,cardiac medications during index hospitalization — no . ( % ),C0013227;C0019993;C0428776;C0802604;C2598133;C4284232
563,cardiac medications during index hospitalization,C0013227;C0019993;C0428776;C0802604;C2598133;C4284232
563,cardiac medications during index hospital stay and / or discharge,C0013227;C0428776;C0802604;C2598133;C3489408;C4284232
563,cancer medications,C0006826;C0013227;C0802604;C0998265;C1306459;C2598133;C4284232
563,blood - pressure medications at randomization — no . / total no . ( % ),C0005823;C0013227;C0033095;C0034656;C0460139;C0802604;C0849164;C1271104;C1272641;C1306345;C2598133;C4284008;C4284232
563,baseline medications ( % ),C0013227;C0168634;C0802604;C1442488;C2598133;C4284232
563,baseline antihyperglycemic medications,C0013227;C0020616;C0168634;C0802604;C1442488;C2598133;C4284232
563,baseline anti - hyperglycemic medications,C0013227;C0168634;C0802604;C1442488;C2598133;C4284232
563,any ulcerative colitis medication,C0009324;C0013227;C3244316;C4284232
563,any medication,C0013227;C3244316;C4284232
563,any copd medication,C0013227;C0024117;C1412502;C3244316;C3714496;C4284232
563,any blood pressure medications ( % ),C0005823;C0013227;C0033095;C0460139;C0802604;C0849164;C1271104;C1272641;C1306345;C2598133;C4284008;C4284232
563,antithrombotic medications,C0013227;C0802604;C2598133;C4284232
563,antihyperglycemic medications,C0013227;C0020616;C0802604;C2598133;C4284232
563,antihyperglycemic medication usage,C0013227;C0020616;C0457083;C3244316;C4284232
563,antihyperglycaemic medication at baseline,C0013227;C0020616;C0168634;C1442488;C3244316;C4284232
563,antianginal medications,C0013227;C0802604;C1874267;C2598133;C3537168;C4284232
563,anti - arthritic medications,C0013227;C0802604;C2598133;C4284232
563,acute medication intake ( days / month ),C0013227;C0205178;C0556971;C1512806;C3244316;C4284232
563,> nmbr concomitant medication,C0013227;C0521115;C3244316;C4284232
562,total population n,C3258257
562,total population ( n = nmbr ),C3258257
562,total population,C3258257
562,total ho population ( n = nmbr ),C0019905;C1832110;C3258257;C3889614
562,total carmelina population,C3258257
561,total study population ( n = nmbr ),C0439175;C0439810;C0557651;C2348561;C2603343;C3258257
561,total study population ( n = nmbr,C0439175;C0439810;C0557651;C2348561;C2603343;C3258257
561,total study population,C0439175;C0439810;C0557651;C2348561;C2603343;C3258257
561,total study itt population ( n = nmbr ),C0439175;C0439810;C0557651;C2348561;C2603343;C3258257
561,study population,C2348561
560,recent use of allopurinol ( within nmbr days of,C0002144;C0332185;C1524063
560,allopurinol,C0002144
559,sgrq total score * ( units ),C0439148;C1519795;C2964552;C3853603
559,sgrq total score ( units ) : ! :,C0439148;C1519795;C2964552;C3853603
559,sgrq total score ( units ),C0439148;C1519795;C2964552;C3853603
559,or per unit for continuous variables,C0439148;C0439453;C1509845;C1519795;C1704753;C1880519;C3853603
559,mtss units,C0439148;C1519795;C3853603
559,ipss ( unit ),C0439148;C0439453;C1019118;C1509845;C1519795;C1704753;C1880519;C1998280;C2827405;C3811063;C3853603
559,cnmbr - unit sgrq total score increase,C0439148;C0439453;C0442805;C1509845;C1519795;C1704753;C1880519;C2964552;C3853603
559,% anti - ccp + ( > nmbr units ),C0439148;C1519795;C3853603;C4318437
558,intrathoracic or intraperitoneal surgery,C0595836
557,infarct on brain imaging^,C0751955
557,infarct on brain imaging 丰,C0751955
556,duration of treatment in the healing study,C0444921
556,duration of oral antidiabetic treatment,C0442027;C0444921;C0935929;C4521986
555,treatment duration mean ( sd ),C0444504;C0444921;C2347634;C2348143;C2699239;C3259042
555,treatment duration,C0444921;C3259042
554,mitral regurgitation,C0026266
554,mitral insufficiency,C0026266
553,lipid trial participants - n ( % ),C0023779;C1997894;C2242969
553,lipid trial participants #,C0023779;C1997894;C2242969
553,lipid trial participants,C0023779;C1997894;C2242969
553,lioid trial participants,C1997894;C2242969
552,health practices,C0018684
551,health habits,C0679786
550,male patients *,C0150904
550,male patients,C0150904
549,female patients^,C0150905
549,female patients,C0150905
548,postbaseline binding antibodies,C0003241;C1145667;C1167622
547,angiotensin ii antagonists,C0003009;C0243076;C1366631;C3714928
546,vitamin k antagonists,C3653316
545,pooled simvastatin factorial studies,C0074554;C1709595;C2349200;C2826344;C4522255
545,atorvastatin factorial study,C0286651;C2826344
544,notable abnormalities,C0000768;C0000769;C4288581
544,concordant stress test abnormalities,C0000768;C0000769;C0015260;C3494508;C4553529
543,structural,C0678594
542,bowel stricturing,C0267465
541,transfusions,C0005841;C0199960;C1879316
541,transfusion ≥ nmbr units rbcs or whole blood,C0005841;C0014792;C0199960;C0439148;C1519795;C1879316;C3853603
541,transfusion,C0005841;C0199960;C1879316
541,blood transfusion,C0005841;C0281867
541,any blood transfusion,C0005841;C0281867
541,any blood product transfusion,C0005841;C0199960;C0281867;C0456388;C1514468;C1547007;C1704444;C1879316
540,rv and pulmonary vascular,C0035190;C3889272
539,environmental stimuli,C0450025
538,third heart sound,C0232237;C0232278
537,repaired congenital shunts,C0009678;C0205340;C0232180;C0542331;C1442858;C1744681
537,repaired congenital shunt,C0009678;C0205340;C0232180;C0542331;C1442858;C1744681
537,pfo with mild - to - moderate shunt and atrial septal aneurysm,C0232180;C0542331;C1299392;C1442858
537,pfo with large shunt without atrial septal aneurysm,C0232180;C0542331;C0549177;C1442858
537,pfo with large shunt and atrial septal aneurysm,C0232180;C0542331;C0549177;C1442858
537,large shunt,C0232180;C0542331;C0549177;C1442858
537,congenital shunts,C0009678;C0232180;C0542331;C1442858;C1744681
536,syndesmophyte present,C0221690
535,reteplase,C0256103
534,streptokinase,C0038418
533,use of supplemental oxygen,C4067893;C4554557
532,supplementary oxygen,C0030054
532,supplemental oxygen,C4534306
531,subgoup_name,C0027365;C1547383;C4522128
530,subgroup analyses,C2986480
530,prespecified subgroup analyses,C2986480
530,additional subgroup analyses,C1524062;C2986480
529,≥ nmbr sae,C1519255;C1622657;C4553214
529,serious adverse events,C1519255
529,saes,C1519255;C1622657;C4553214
529,due to sae,C1519255;C1622657;C4553214
529,due to drug - relateda sae,C0013227;C1254351;C1519255;C1622657;C4553214
529,because of sae,C1519255;C1622657;C4553214
529,because of drug ‐ relateda   sae,C0013227;C1254351;C1519255;C1622657;C4553214
529,any sae,C1519255;C1622657;C4553214
528,smoking past,C0037369;C0453996;C1444637;C1881674;C4284302
528,smoking in past yr,C0037369;C0439234;C0453996;C1444637;C1881674;C4284302
528,past or nonsmoker ( n = nmbr ),C1444637;C4284302
528,past or nonsmoker,C1444637;C4284302
528,past or never,C1444637;C4284302
528,past or current angina pectoris,C1444637;C4284302
528,past or current,C1444637;C4284302
528,past,C1444637;C4284302
528,intra - abdominal abscess ( past ),C0243001;C1444637;C4284302
528,current / past smoker,C1444637;C3173209;C3241966;C4284302
527,target nail napsi score ( nmbr – nmbr scale ),C0027342;C1432728;C1521840;C2986546;C3538766
527,ras % target dose,C0034678;C0178602;C0525678;C0869039;C1114758;C1521840;C2986546
527,beta - blocker % target dose,C0001645;C0178602;C0869039;C1114758;C1521840;C2986546
527,( % of target ) ∗,C1521840;C2986546
526,treatment period index dvt : event,C0039798;C0087111;C0149871;C0439531;C0441471;C0600653;C0918012;C1522326;C1533734;C1552854;C1637833;C1705169;C1948053;C2926618;C2986546;C3538994;C3887704;C3899446;C4019010
526,treatment of the index ml,C0039798;C0087111;C0439526;C0600653;C0918012;C1522326;C1533734;C1552854;C1637833;C1705169;C1705224;C2986546;C3538994;C3887665;C3887704
526,suit index,C0600653;C0918012;C1552854;C1637833;C2986546
526,risk factor profile index event,C0035648;C0441471;C0600653;C0918012;C1552854;C1637833;C1979963;C2003903;C2986546;C4019010
526,revascularization during index hospitalization,C0019993;C0581603;C0600653;C0918012;C1552854;C1637833;C2986546
526,procedures for index event,C0025664;C0184661;C0441471;C0600653;C0918012;C1552854;C1637833;C2700391;C2986546;C3538935;C4019010
526,prior to index event,C0441471;C0600653;C0918012;C1552854;C1637833;C2986546;C4019010
526,prior ml ( before index acs ),C0332152;C0439526;C0600653;C0742343;C0918012;C1552854;C1637833;C1705224;C2826257;C2986546;C3887665;C4318612
526,prior cabg ( before index acs ),C0010055;C0332152;C0600653;C0742343;C0918012;C1552854;C1637833;C2826257;C2986546;C4318612
526,previous pci ( before index acs ),C0205156;C0600653;C0742343;C0918012;C1552607;C1552854;C1637833;C2986546;C4049621;C4318612
526,previous ml ( before index acs ),C0205156;C0439526;C0600653;C0742343;C0918012;C1552607;C1552854;C1637833;C1705224;C2986546;C3887665;C4318612
526,previous cabg ( before index acs ) *,C0010055;C0205156;C0600653;C0742343;C0918012;C1552607;C1552854;C1637833;C2986546;C4318612
526,presentation of index event,C0441471;C0449450;C0600653;C0918012;C1552854;C1637833;C2986546;C4019010
526,positive cu index test,C0022885;C0039593;C0392366;C0439178;C0456984;C0600653;C0918012;C1177210;C1446409;C1514241;C1515976;C1552854;C1637833;C2347872;C2825490;C2986546;C3812269;C3831328;C4318744
526,pci for index mi ( % ),C0600653;C0918012;C1552854;C1637833;C2986546;C3810814;C4049621
526,pci during index hospitalization,C0019993;C0600653;C0918012;C1552854;C1637833;C2986546;C4049621
526,other antithrombotic medication for index event — no . ( % ),C0013227;C0441471;C0600653;C0918012;C1552854;C1637833;C2986546;C3244316;C4019010;C4284232
526,nternational index of,C0600653;C0918012;C1552854;C1637833;C2986546
526,no revascularization for index acs event,C0441471;C0581603;C0600653;C0742343;C0918012;C1552854;C1637833;C2986546;C4019010;C4318612
526,medical therapy during index hospitalization — %,C0019993;C0418981;C0600653;C0918012;C1552854;C1637833;C2986546
526,medical history before index acute coronary syndrome — no . { % ),C0262926;C0600653;C0918012;C0948089;C1552854;C1637833;C1704706;C2986546
526,mean slicc damage index score ± sd,C0010957;C0600653;C0918012;C1552854;C1637833;C1883709;C2699239;C2986546;C3533236
526,mean preoperative abpi of the index,C0444504;C0445204;C0600653;C0918012;C1552854;C1637833;C2347634;C2348143;C2986546
526,mass index ,C0577559;C0577573;C0600653;C0918012;C1096155;C1306372;C1552854;C1637833;C2986546;C3152252;C3539882;C4283905
526,lv mass index ( g / mnmbr - nmbr ),C0455825;C0456715;C0600653;C0918012;C1552854;C1637833;C2986546
526,locafon of index dvt,C0149871;C0600653;C0918012;C1552854;C1637833;C2926618;C2986546;C3899446
526,leeds dactylitis index - basic,C0239161;C0600653;C0918012;C1552854;C1637833;C2986546
526,labs at the index acs event,C0441471;C0587081;C0600653;C0742343;C0918012;C1552854;C1637833;C2986546;C4019010;C4318612
526,kheeatne index dvt,C0149871;C0600653;C0918012;C1552854;C1637833;C2926618;C2986546;C3899446
526,interval after index event,C0441471;C0600653;C0918012;C1272706;C1552654;C1552713;C1552854;C1637833;C2986546;C4019010
526,insulinogenic index ( dinsulino_nmbro min / dglucoseo - nmbro min ),C0600653;C0702093;C0918012;C1524029;C1552854;C1637833;C2986546;C3813700
526,indication for index procedure,C0600653;C0918012;C1552854;C1637833;C2315323;C2986546
526,indication for index pci,C0392360;C0600653;C0918012;C1552854;C1637833;C2986546;C3146298;C4049621
526,index pe : event during,C0070939;C0441471;C0600653;C0918012;C1552854;C1637833;C1880476;C2986546;C4019010;C4284304
526,index events : pe ± dvt n ( % ),C0070939;C0149871;C0441471;C0600653;C0918012;C1552854;C1637833;C1880476;C2926618;C2986546;C3541888;C3899446;C4284304
526,index events : dvt n ( % ),C0149871;C0441471;C0600653;C0918012;C1552854;C1637833;C2926618;C2986546;C3541888;C3899446
526,index events,C0441471;C0600653;C0918012;C1552854;C1637833;C2986546;C3541888
526,index event — no . ( % ),C0441471;C0600653;C0918012;C1552854;C1637833;C2986546;C4019010
526,index event to randomization,C0034656;C0441471;C0600653;C0918012;C1552854;C1637833;C2986546;C4019010
526,index event subtype,C0441471;C0449560;C0600653;C0918012;C1552854;C1637833;C2986546;C4019010
526,index event not confirmed,C0441471;C0600653;C0918012;C1552854;C1637833;C2986546;C4019010
526,index event information,C0441471;C0600653;C0918012;C1533716;C1552854;C1637833;C2986546;C4019010
526,index event asymptomatic or unconfirmed,C0441471;C0600653;C0918012;C1552854;C1637833;C2986546;C4019010
526,index event,C0441471;C0600653;C0918012;C1552854;C1637833;C2986546;C4019010
526,index acute coronary syndrome — no . { % ),C0600653;C0918012;C0948089;C1552854;C1637833;C2986546
526,index acs — no . ( % ),C0600653;C0742343;C0918012;C1552854;C1637833;C2986546;C4318612
526,index acs event,C0441471;C0600653;C0742343;C0918012;C1552854;C1637833;C2986546;C4019010;C4318612
526,index acs ( % ),C0600653;C0742343;C0918012;C1552854;C1637833;C2986546;C4318612
526,homa - ir index,C0022065;C0022071;C0600653;C0918012;C1448132;C1552854;C1637833;C2986546
526,health state index score,C0449820;C0600653;C0683314;C0918012;C1552854;C1637833;C2986546;C4050231
526,for treatment of index event,C0039798;C0087111;C0441471;C0600653;C0918012;C1522326;C1533734;C1552854;C1637833;C1705169;C2986546;C3538994;C3887704;C4019010
526,extent of index pe ' ( n,C0070939;C0439792;C0600653;C0918012;C1552854;C1637833;C1880476;C2986546;C4284304
526,extent of index event,C0439792;C0441471;C0600653;C0918012;C1552854;C1637833;C2986546;C4019010
526,extent of index dvt ' ( n,C0149871;C0439792;C0600653;C0918012;C1552854;C1637833;C2926618;C2986546;C3899446
526,disposition index,C0600653;C0743223;C0918012;C1552854;C1637833;C1705555;C2986546
526,des type at index procedure,C0011702;C0455713;C0600653;C0918012;C1552854;C1637833;C2986546;C4551552
526,cu index test,C0022885;C0039593;C0392366;C0456984;C0600653;C0918012;C1177210;C1515976;C1552854;C1637833;C2347872;C2986546;C3831328;C4318744
526,cornell index,C0600653;C0918012;C1552854;C1637833;C2986546
526,composite physiologic index §,C0205199;C0205463;C0600653;C0918012;C1547335;C1552854;C1637833;C2986546
526,clinical indication at the index procedure,C0205210;C0600653;C0918012;C1552854;C1637833;C2315323;C2347896;C2986546
526,classification of index venous thromboembolism — no . ( % ),C0008902;C0008903;C0600653;C0678229;C0918012;C1552854;C1637833;C1997614;C2986546
526,charlson index ( % ),C0600653;C0918012;C1552854;C1637833;C2986546
526,characteristics of the index ml,C0439526;C0600653;C0918012;C1521970;C1552854;C1637833;C1705224;C2986546;C3887665
526,cabg during index hospitalization,C0010055;C0019993;C0600653;C0918012;C1552854;C1637833;C2986546
526,body weight index ( kg / mnmbr ),C0005910;C0600653;C0918012;C1305866;C1532718;C1552854;C1637833;C2986546
526,before index acs event,C0441471;C0600653;C0742343;C0918012;C1552854;C1637833;C2986546;C4019010;C4318612
526,at index event : no . ( % ),C0441471;C0600653;C0918012;C1552854;C1637833;C2986546;C4019010
526,at index event,C0441471;C0600653;C0918012;C1552854;C1637833;C2986546;C4019010
526,at index acs event,C0441471;C0600653;C0742343;C0918012;C1552854;C1637833;C2986546;C4019010;C4318612
526,angiography during index hospitalization,C0002978;C0019993;C0600653;C0918012;C1552854;C1637833;C2986546
525,number stent > nmbr,C0038257;C0237753;C0449788
525,"number ste "" t > nmbr",C0237753;C0449788;C1420459;C3811127
525,number resulting in hospital admission,C0237753;C0449788
525,number resulting in emergency department visit,C0237753;C0449788
525,number resulting in ed visit,C0237753;C0449788
525,number randomized,C0237753;C0449788
525,number of “ off ” periods,C0237753;C0449788
525,number of vessels disease,C0042373;C0237753;C0449788
525,number of stents implanted,C0038257;C0237753;C0449788
525,number of stents ( per patient ),C0038257;C0237753;C0449788
525,number of stents,C0038257;C0237753;C0449788
525,number of stent = nmbr,C0038257;C0237753;C0449788
525,number of stent = l or nmbr or nmbr,C0038257;C0237753;C0449788
525,number of previous tnfa inhibitors,C0205156;C0237753;C0243077;C0449788;C1448177;C1552607;C1710304
525,number of previous reported aeds,C0180309;C0205156;C0237753;C0449788;C0684224;C0700287;C1552607;C4319718
525,number of previous dmards,C0205156;C0237753;C0242708;C0449788;C1552607
525,number of previous anti - tnf treatments for psoriatic arthritis,C0087111;C0205156;C0237753;C0449788;C1448177;C1552607
525,number of previous anti - tnf treatments for psa,C0087111;C0205156;C0237753;C0449788;C1448177;C1552607
525,number of people ( n ),C0027361;C0237753;C0449788
525,number of participants with an event,C0237753;C0449788;C0679646
525,number of exacerbations nmbr months before randomisation,C0237753;C0439231;C0449788;C4086268
525,number of exacerbations in the past nmbr months,C0237753;C0449788;C4086268
525,number of exacerbations in the nmbr months before screening,C0237753;C0449788;C4086268
525,number of exacerbations in the last nmbr months,C0237753;C0449788;C4086268
525,number of exacerbations in previous year,C0237753;C0449788;C4086268
525,number of exacerbations in previous nmbr   months,C0237753;C0449788;C4086268
525,number of exacerbations in previous nmbr months,C0237753;C0449788;C4086268
525,number of exacerbations in last nmbr months,C0237753;C0449788;C4086268
525,number of exacerbations,C0237753;C0449788;C4086268
525,number of exacerbation in the previous nmbr months,C0237753;C0449788;C4086268
525,number of er visits in last year prior to baseline,C0237753;C0449788;C3810541;C3811131
525,number of e,C0237753;C0449788
525,number of copd exacerbations within nmbr months,C0237753;C0449788;C0740304
525,number of copd exacerbations in the previous year,C0237753;C0449788;C0740304
525,number of concomitant csdmards,C0237753;C0449788;C0521115
525,number of concomitant aedsc,C0237753;C0449788;C0521115
525,number of concomitant aeds,C0180309;C0237753;C0449788;C0521115
525,number of co - aeds,C0180309;C0237753;C0449788;C3245499
525,number of clinically significant asthma exacerbations in last year prior to baseline,C0237753;C0237881;C0349790;C0449788;C0750502;C1546944
525,number of antihypertensive agent reported,C0003364;C0237753;C0449788
525,number and % of participants with events,C0237753;C0449788
525,number ( % ) reporting migraine on nmbr - month questionnaire,C0034394;C0149931;C0237753;C0332177;C0439231;C0449788;C0700287
525,number ( % ),C0237753;C0449788
525,number,C0237753;C0449788
525,non - epa number of <,C0237753;C0449788;C1518422
525,missing — number / n ( % ),C0237753;C0449788;C1551393;C1705492;C3272743
525,mean number of clinically significant asthma exacerbations †,C0237753;C0237881;C0349790;C0444504;C0449788;C0750502;C1546944;C2347634;C2348143
525,mean ( sd ) number of exacerbations *,C0237753;C0444504;C0449788;C2347634;C2348143;C2699239;C4086268
525,event number,C0237753;C0441471;C0449788;C4019010
525,^numbers do not always sum to group totals due to missing information for some variables . fbody mass index was calculated as weight in kilograms divided by the square of height in meters . ^hypertension was defined as a self - reported systolic blood pressure > nmbr mm hg,C0237753;C0449788
525,> qnmbr ( nmbr . nmbr ) — number / n ( % ),C0237753;C0449788
525,> qnmbr ( nmbr . nmbr ) - qnmbr ( nmbr . nmbr ) — number / n ( % ),C0237753;C0449788
525,> qnmbr ( nmbr . nmbr ) - qnmbr ( nmbr ) — number / n ( % ),C0237753;C0449788
525,> qnmbr ( nmbr ) — number / n ( % ),C0237753;C0449788
525,> qnmbr ( nmbr ) - qnmbr ( nmbr . nmbr ) — number / n ( % ),C0237753;C0449788
525,> nmbr months — number / n ( % ),C0237753;C0439231;C0449788
525,> median ( nmbr . nmbr years ) — number / n ( % ),C0237753;C0439234;C0449788;C0549183;C0876920;C2347635;C2348144;C2939193
525,> median ( nmbr . nmbr ) — number / n ( % ),C0237753;C0449788;C0549183;C0876920;C2347635;C2348144;C2939193
525,> median ( nmbr ) — number / n ( % ),C0237753;C0449788;C0549183;C0876920;C2347635;C2348144;C2939193
525,< qnmbr ( nmbr . nmbr ) — number / n ( % ),C0237753;C0449788
525,< qnmbr ( nmbr ) — number / n ( % ),C0237753;C0449788
525,< nmbr months — number / n ( % ),C0237753;C0439231;C0449788
525,< median ( nmbr . nmbr years ) — number / n ( % ),C0237753;C0439234;C0449788;C0549183;C0876920;C2347635;C2348144;C2939193
525,< median ( nmbr . nmbr ) — number / n ( % ),C0237753;C0449788;C0549183;C0876920;C2347635;C2348144;C2939193
525,< median ( nmbr ) — number / n ( % ),C0237753;C0449788;C0549183;C0876920;C2347635;C2348144;C2939193
524,tnfi - na ï ve,C0042469;C0597484;C1272460;C1546968;C1879645;C3714652;C4049872;C4321495;C4552882
524,tnf - na ï ve,C0042469;C0597484;C1272460;C1448177;C1546968;C1879645;C3714652;C4049872;C4321495;C4552882
524,rando . in na * *,C0597484;C1272460;C1546968;C1879645;C4049872;C4552882
524,not rando . in na *,C0597484;C1272460;C1518422;C1546968;C1879645;C4049872;C4552882
524,na ï ve,C0042469;C0597484;C1272460;C1546968;C1879645;C3714652;C4049872;C4321495;C4552882
524,na,C0597484;C1272460;C1546968;C1879645;C4049872;C4552882
524,n / a,C1272460
524,n . a .,C1272460
524,mn - na ï ve population,C0026327;C0026405;C0032659;C0042469;C0597484;C1257890;C1272460;C1546968;C1879645;C3714652;C4049872;C4285072;C4321495;C4552882
524,ci = confidence interval  na = not applicable or not analyzed .,C0008107;C0009667;C0597484;C1272460;C1546968;C1879645;C3259781;C4049872;C4552882
524,all mn - na ï ve patients,C0026327;C0026405;C0030705;C0042469;C0597484;C1272460;C1546968;C1879645;C3714652;C4049872;C4285072;C4321495;C4552882
523,anmbrc [n ( % ) ],C1272460
523,anmbr + enmbr ( n = nmbr ),C1272460
523,a / v ( n = nmbr ) v ( n = nmbr ),C0560268;C1272460;C3887614
523,a / v ( n = nmbr ),C1272460
522,very good or excellent,C3641222
521,recent cardiovascular eventf,C0007226;C0332185;C3887460
521,recent,C0332185
520,regadenoson ( n = nmbr ),C1698215
520,regadenoson,C1698215
519,radial access — no . / total no . ( % ),C0442038;C0920847
519,radial access,C0442038;C0444454;C0920847;C1554204
519,radial,C0442038;C0920847
518,treatment throughout study,C1521826;C3161471
518,previous treatment in the healing study,C0043240;C0205156;C0205249;C1521826;C1552607;C3161471
517,study treatment,C1521826
517,induction study treatment,C0205263;C0557651;C0857127;C1521826;C2603343;C4049995
516,two agents,C0205448;C0450442;C1254351;C1521826
516,study treatment — no . / total no . ( % ),C1521826
516,ras agents,C0034678;C0450442;C0525678;C1254351;C1521826
516,p - blocking agents,C0233660;C0332206;C0369773;C0450442;C1254351;C1521826;C2603361
516,other blood glucose - lowering agents,C0005802;C0441994;C0450442;C1254351;C1521826;C2003888
516,oral diabetic agent,C0241863;C0442027;C0450442;C1254351;C1521826;C4521986
516,oral agents use,C0442027;C0450442;C1254351;C1521826;C4521986
516,oral agents,C0442027;C0450442;C1254351;C1521826;C4521986
516,oral agent and / or insulin therapy,C0442027;C0450442;C1254351;C1521826;C4521986
516,oral agent,C0442027;C0450442;C1254351;C1521826;C4521986
516,number of agents,C0237753;C0449788;C0450442;C1254351;C1521826
516,no . of agents,C0450442;C1254351;C1521826
516,diuretic agents ( excluding antialdosterone ),C0012798;C0450442;C1254351;C1521826
516,diuretic agents,C0012798;C0450442;C1254351;C1521826
516,diuretic agent,C0012798;C0450442;C1254351;C1521826
516,conventional agents *,C0439858;C0450442;C1254351;C1521826
516,anyantianginal agent,C0450442;C1254351;C1521826
516,any bp - lowering agents^,C0037623;C0441994;C0450442;C1254351;C1415692;C1521826;C1708288;C2003888;C4318478
516,antialdosterone agents,C0450442;C1254351;C1521826
516,anti - tnf agent ( s ),C0221141;C0313162;C0450442;C1254351;C1448177;C1521826
516,> nmbr oral agents,C0442027;C0450442;C1254351;C1521826;C4521986
515,anti - anaemics,C0857322
514,anaesthesia / analgesia,C0002905
513,regional anaesthesia,C0002911
513,general anaesthesia,C0002915;C2930406
512,new zealand,C0027978;C0324547
512,austral ia / new zealand,C0020980;C0027978;C0324547;C0694634;C1947960
511,australia / new zealand,C4289954
511,asia / australia / new zealand,C0003980;C4289954
510,pancreas,C0030274
509,ggt increased,C1415053
508,no . fingernails,C0222001
507,time intervals,C0872291
506,multivessel ( two vessel,C4012475;C4037954
505,large vessel,C0225990
504,small vessel,C0225988
503,stented vessels,C0183521
503,stented vessel,C0183521
502,type of vessel involved,C1282017
501,two - vessel disease,C0581375
501,triple - vessel disease,C0856738
501,three - vessel disease,C3272265
501,one - vessel disease,C3275121
500,target vessel diameter,C0449618;C1301886
500,target vessel,C0449618
500,number of target vessels,C0237753;C0449618;C0449788
500,no . of target vessels,C0449618
499,influenza,C0021400;C0021403
498,infected,C0439663
497,insufficient,C0205412;C0231180;C0439856
497,inadequate,C0205412;C0439856
496,inhaled^,C0004048
496,inhaled §,C0004048
496,inhaled jnmbr - agonist §,C0004048;C2987634
495,infliximab nmbr mg / kg,C0439272;C0666743
495,infliximab monotherapy,C0666743
495,infliximab combination therapy,C0009429;C0205195;C0556895;C0666743;C1947911;C3811910;C4076075
495,infliximab - naive ( n = nmbr ),C0666743
495,infliximab - experienced ( n = nmbr ),C0666743
495,infliximab ( n = nmbr ),C0666743
495,infliximab ( combined nmbr mg / kg and nmbr mg / kg ),C0205195;C0439272;C0666743
495,infliximab,C0666743
495,inflix,C0666743
495,combined infliximab,C0205195;C0666743
494,hospitalized angina,C0002962;C0701159
494,hospitaiization for angina,C0002962
494,current angina ( % ),C0002962;C0521116;C1705970
494,current angina,C0002962;C0521116;C1705970
494,angina .,C0002962
494,angina,C0002962
493,angina with documented ischemia,C0002962;C0022116;C1301725;C1609436;C4321499
493,angina status — no . ( % ),C0002962;C0449438
493,angina pectoris — no . ( % ),C0002962
493,angina or positive stress test,C0002962
493,angina or acute mi,C0002962
493,angina ( past nmbr weeks ),C0002962;C2987125
492,prior angina pectoris — no . / total no . ( % ),C0002962;C0332152;C2826257
492,prior angina pectoris,C0002962;C0332152;C2826257
492,prior angina ( n = nmbr,C0002962;C0332152;C2826257
492,prior angina,C0002962;C0332152;C2826257
492,no prior angina ( n = nmbr,C0002962;C0332152;C2826257
492,angina pectorisf,C0002962
492,angina pectoris 本,C0002962
492,angina pectoris *,C0002962
492,angina pectoris,C0002962
491,ss years,C0439234;C2699257;C3891295;C4551874
491,ss > nmbr ( n = nmbrvs nmbr ),C2699257;C3891295;C4551874
491,ss < nmbr ( n = nmbrvsnmbr ),C2699257;C3891295;C4551874
490,less than nmbr y ears,C0013443;C0439092;C0521421
490,< nmbr y ears,C0013443;C0521421
489,nmbr [nmbr - nmbrjs,C1552154
489,jsnmbr - agonists,C0243192;C1552154;C2987634
488,smoking history ( pack - years ) ∗,C1277691;C1519384
488,smoking history ( pack - years ),C1277691;C1519384
488,smoking consumption pack - years,C0425291;C1277691
488,pack years,C1277691
488,pack - years smoked,C1277691
488,pack - years ( iqr ),C1277691
488,pack - years,C1277691
488,number of pack years,C0237753;C0449788;C1277691
488,number of pack - years,C0237753;C0449788;C1277691
488,nicotine pack - years,C0028040;C1277691
488,estimated number of pack - years,C0237753;C0449788;C0750572;C1277691
487,q wave,C0429089;C1305738
487,non - q wave,C0429089;C1305738;C1518422
487,non - q - wave ml,C0429089;C0439526;C1305738;C1518422;C1705224;C3887665
486,pathological q waves,C0429090
486,pathologic q waves — no . ( % ),C0429090
486,pathologic q waves,C0429090
485,time from acs to randomization ( median,C0040223;C0742343;C3541383;C4318612
485,time from acs to randomization,C0040223;C0742343;C3541383;C4318612
485,time between index acs and randomization — days,C0040223;C0600653;C0742343;C0918012;C1552854;C1637833;C2986546;C3541383;C4318612
485,time between index acs and randomization ( days ),C0040223;C0600653;C0742343;C0918012;C1552854;C1637833;C2986546;C3541383;C4318612
485,sa acs,C0036243;C0038702;C0742343;C1539696;C1825840;C3539736;C4318612;C4521691
485,pcr after acs,C0032520;C0742343;C3853643;C4050242;C4318612
485,nste acs,C0742343;C4318612
485,nste - acs,C0742343;C4318612
485,no acs,C0742343;C4318612
485,days from acs to randomization,C0439228;C0742343;C4318612
485,days between acs and rand,C0439228;C0742343;C4318612
485,acs ( n = nmbr,C0742343;C4318612
485,acs ( n - nmbr,C0742343;C4318612
485,acs,C0742343;C4318612
484,not hispanic or latino ( n — nmbr ),C1518424
484,not hispanic or latino ( n = nmbr ),C1518424
484,not hispanic or latino,C1518424
484,not hispanic / latino ( n = nmbr,C0086528;C1518424
484,not hispanic / latino,C0086528;C1518424
484,not hispanic,C1518424
484,non - hispanic white,C0007457;C0043157;C0220938;C1518424
484,non - hispanic or latino,C1518424
484,non - hispanic and latino,C1518424
484,non - hispanic / latino,C0086528;C1518424
484,non - hispanic,C1518424
483,white non - hispanic - n ( % ),C0007457;C0043157;C0220938;C1518422;C1518424;C1533020;C1533021
483,white non - hispanic,C0007457;C0043157;C0220938;C1518422;C1518424;C1533020;C1533021
483,white hispanic - n ( % ),C1533020;C1533021
483,white hispanic,C1533020;C1533021
482,unstable angina — no . ( % ),C0002965
482,unstable angina §,C0002965
482,unstable angina age,C0001779;C0002965
482,unstable angina > nmbr mo ago,C0002965;C0026544;C0332177
482,unstable angina *,C0002965
482,unstable angina ( n = nmbr,C0002965
482,rest angina past nmbr h,C0002965;C0033727;C0152172;C0369286;C0441932;C0564385;C1444637;C4284302;C4528284
482,rest angina but not past nmbr h,C0002965;C0152172
482,rest angina,C0002965;C0152172
482,no rest angina,C0002965;C0152172
481,• unstable angina,C0002965
481,worsening angina,C0002965
481,unstable angina,C0002965
481,histor y of unstable angina,C0002965
481,due worsening angina,C0002965;C0678226;C3146286
481,* * * unstable angina,C0002965
480,usa and canada,C0041703
480,usa / canada,C0006823;C0041703
480,usa ( n = nmbr ),C0041703
480,usa ( n = nmbr,C0041703
480,usa,C0041703
480,united states or canada,C0041703
480,united states and canada,C0041703
480,united states ( n   = nmbr,C0041703
480,united states,C0041703
480,non usa,C0041703;C1518422
480,non - united states,C0041703;C1518422
479,method of identification ofstenosis ( % ),C1301921
478,initiation of dialysis,C0011945;C0011946;C0589507;C1059964;C1158830;C1704686;C4551529
477,medication effects,C1319171
476,medication adherence,C2364172
475,medications at discharge or day nmbr,C0806915
475,medications at discharge,C0806915
475,cardiac medications at discharge,C0018787;C0806915;C1522601
474,st - segment deviation timi risk score,C0012727;C0035647;C0036056;C0205419;C0429029;C0429066;C0441635;C0449820;C1114722;C1116089;C1705236;C3272372;C4050231;C4552904
474,st - segment deviation > nmbr mm — no . / total no . ( % ),C0012727;C0036056;C0205419;C0429029;C0429066;C0441635;C1114722;C1116089;C1705236;C3272372;C4330985;C4554674
474,of variation ),C0205419
474,deviation  tg  triglyceride .,C0012727;C0041004;C0205419;C1705236
474,deviation,C0012727;C0205419;C1705236
473,teaes in anmbr % of individuals,C0027361;C0237401
473,proportion ( % ) of individuals • control alirocumab,C0027361;C0237401;C1709707
473,proportion ( % ) of individuals a alirocumab • placebo,C0027361;C0237401;C1709707
473,other individual and exploratory end points,C0027361;C0237401
473,no . ( % ) of individuals *,C0027361;C0237401
473,individuals with type nmbr diabetes,C0027361;C0237401;C1320657
473,individuals with prediabetes,C0027361;C0237401;C0362046
473,individuals with pre - diabetes,C0027361;C0237401;C0362046
473,individual intended study duration — no . ( % ),C0027361;C0237401;C0489652;C1283828;C1551357
473,individual endpoints,C0027361;C0237401;C2349179
472,uc duration,C0449238;C2926735
472,tnmbrd duration,C0449238;C2603360;C2926735
472,ra duration ( years ),C0439234;C0449238;C2926735;C3538806;C4048756
472,ra duration ( months ) *,C0439231;C0449238;C2926735;C3538806;C4048756
472,pci duration,C0449238;C2926735;C4049621
472,morning stiffness duration,C0449238;C0457086;C2926735
472,median duration oftype nmbr diabetes ( iqr ) — yr,C0011847;C0011849;C0439234;C0449238;C0549183;C0876920;C2347635;C2348144;C2926735;C2939193
472,median duration of diabetes ( yr ),C0011847;C0011849;C0439234;C0449238;C0549183;C0876920;C2347635;C2348144;C2926735;C2939193
472,median ( qnmbr : qnmbr ) duration of diabetes,C0011847;C0011849;C0449238;C0549183;C0876920;C2347635;C2348144;C2926735;C2939193
472,mean ± s . d . duration of diabetes,C0011847;C0011849;C0444504;C0449238;C2347634;C2348143;C2926735
472,mean duration of pd,C0444504;C0449238;C2347634;C2348143;C2926735;C4553228;C4553229
472,known duration of tnmbrdm,C0011816;C0205309;C0449238;C2926735;C3250443
472,known duration of diabetes,C0011847;C0011849;C0205309;C0449238;C2926735
472,known duration,C0205309;C0449238;C2926735
472,extended - duration enoxaparin ( n = nmbr ),C0206460;C0231448;C0231449;C0439792;C0449238;C2926735
472,extended - duration enoxaparin,C0206460;C0231448;C0231449;C0439792;C0449238;C2926735
472,ed duration > nmbr yr,C0439234;C0449238;C2926735;C3538926
472,ed duration,C0449238;C2926735;C3538926
472,duration — yr,C0439234;C0449238;C2926735
472,duration since diagnosis ( years ),C0449238;C2926735
472,duration ofdiabetes — yr,C0439234;C0449238;C2926735
472,duration of tnmbrdm > nmbr years,C0011816;C0439234;C0449238;C2926735;C3250443
472,duration of tnmbrdm < nmbr years,C0011816;C0439234;C0449238;C2926735;C3250443
472,duration of tnmbrdm ( years ),C0011816;C0439234;C0449238;C2926735;C3250443
472,duration of tnmbrdm ( % ),C0011816;C0449238;C2926735;C3250443
472,duration of tnmbrdm,C0011816;C0449238;C2926735;C3250443
472,duration of tnmbrd ( years ),C0439234;C0449238;C2926735
472,duration of tnmbrd,C0449238;C2926735
472,duration of study - drug infusion,C0392877;C0449238;C0557651;C2603343;C2926735
472,duration of rat,C0034693;C0034721;C0449238;C2926735
472,duration of ra ( years ),C0439234;C0449238;C2926735;C3538806;C4048756
472,duration of ra ( time from symptom onset ),C0040223;C0449238;C2926735;C3538806;C3541383;C4048756
472,duration of ra,C0449238;C2926735;C3538806;C4048756
472,duration of psoriasis ( years ),C0033860;C0439234;C0449238;C2926735
472,duration of pd,C0449238;C2926735;C4553228;C4553229
472,duration of pci — min,C0449238;C0702093;C1524029;C2926735;C3813700;C4049621
472,duration of pci ( min ),C0449238;C0702093;C1524029;C2926735;C3813700;C4049621
472,duration of pci,C0449238;C2926735;C4049621
472,duration of paod ( years ),C0439234;C0449238;C2926735
472,duration of macular edema,C0024440;C0271051;C0449238;C2926735
472,duration of infusion — hr,C0449238;C0574032;C1827465;C2926735
472,duration of infusion during medical management — hr,C0449238;C0574032;C1827465;C2926735
472,duration of infusion before pci — hr,C0449238;C0574032;C1827465;C2926735
472,duration of infusion before cabg — hr,C0449238;C0574032;C1827465;C2926735
472,duration of infusion after pci — hr,C0449238;C0574032;C1827465;C2926735
472,duration of heart failure ( years ),C0018801;C0018802;C0439234;C0449238;C2926735;C4554158
472,duration of epilepsy,C0014544;C0449238;C2926735
472,duration of dm - years,C0011816;C0439234;C0449238;C2926735;C3250443
472,duration of diabetes — yr^,C0011847;C0011849;C0439234;C0449238;C2926735
472,duration of diabetes — yr,C0011847;C0011849;C0439234;C0449238;C2926735
472,duration of diabetes mellitus,C0011849;C0449238;C2926735
472,duration of diabetes in years,C0011847;C0011849;C0449238;C2926735
472,duration of diabetes by tertiles,C0011847;C0011849;C0449238;C2926735
472,duration of diabetes > nmbr years,C0011847;C0011849;C0439234;C0449238;C2926735
472,duration of diabetes < nmbr yrs,C0011847;C0011849;C0449238;C2926735
472,duration of diabetes < nmbr years,C0011847;C0011849;C0439234;C0449238;C2926735
472,duration of diabetes ( years ) t,C0011847;C0011849;C0439234;C0449238;C2926735
472,duration of diabetes ( years ),C0011847;C0011849;C0439234;C0449238;C2926735
472,duration of diabetes ( y ),C0011847;C0011849;C0449238;C2926735
472,duration of diabetes ( months ),C0011847;C0011849;C0439231;C0449238;C2926735
472,duration of diabetes,C0011847;C0011849;C0449238;C2926735
472,duration of current flare,C0449238;C0521116;C1517205;C1705970;C2926735;C3540542
472,duration of copd — yr,C0024117;C0439234;C0449238;C1412502;C2926735;C3714496
472,duration of copd — days^,C0024117;C0439228;C0449238;C1412502;C2926735;C3714496
472,duration of copd ( yr ) f,C0016327;C0024117;C0439234;C0449238;C1412502;C2926735;C3714496
472,duration of copd ( yr ),C0024117;C0439234;C0449238;C1412502;C2926735;C3714496
472,duration of copd ( years ),C0024117;C0439234;C0449238;C1412502;C2926735;C3714496
472,duration of copd,C0024117;C0449238;C1412502;C2926735;C3714496
472,duration of chf ( months ),C0018802;C0439231;C0449238;C2926735
472,duration of assigned regimen before surgery post - randomisation characteristic * *,C0040808;C0449238;C1516050;C1552601;C2926735;C2945654
472,duration of assigned regimen before surgery post - randomisation characteristic *,C0040808;C0449238;C1516050;C1552601;C2926735;C2945654
472,duration of assigned regimen before surgery,C0040808;C0449238;C1516050;C1552601;C2926735;C2945654
472,duration of as,C0449238;C2926735
472,duration of,C0449238;C2926735
472,duration dm in dm ( years ),C0011816;C0439234;C0449238;C2926735;C3250443
472,duration diabetes ( years ),C0011847;C0011849;C0439234;C0449238;C2926735
472,duration > nmbr years,C0439234;C0449238;C2926735
472,duration > nmbr to < nmbr years,C0439234;C0449238;C2926735
472,duration < nmbr year,C0439234;C0439508;C0449238;C2926735
472,duration,C0449238;C2926735
472,disease characteristics duration of psoriatic arthritis — yr,C0003872;C0439234;C0449238;C0599878;C0872146;C1521970;C2926735
472,diabetes mellitus duration ( sd ),C0011849;C0449238;C2699239;C2926735
472,diabetes mellitus duration,C0011849;C0449238;C2926735
472,diabetes duration subgroups,C0011847;C0011849;C0449238;C1079230;C2926735
472,diabetes duration mean ± sd,C0011847;C0011849;C0444504;C0449238;C2347634;C2348143;C2699239;C2926735
472,diabetes duration ( years ) *,C0011847;C0011849;C0439234;C0449238;C2926735
472,diabetes duration ( years ),C0011847;C0011849;C0439234;C0449238;C2926735
472,diabetes duration ( y ),C0011847;C0011849;C0449238;C2926735
472,diabetes duration ( known ),C0011847;C0011849;C0449238;C2926735
472,diabetes duration,C0011847;C0011849;C0449238;C2926735
472,cd duration,C0007928;C0034283;C0449238;C2926735;C4552032
472,as duration,C0449238;C2926735
472,af duration,C0344434;C0449238;C2926735;C4049859
471,patients with $ nmbr dactylitis digit at week nmbr enthesitis,C0030705;C3863761
471,dactylitis in > nmbr digit,C3863761
470,platelet aggregation inhibitors excluding heparin,C0032177
470,platelet aggregation inhibitors,C0032177
469,± standard deviation . triglyceride,C0041004;C0871420
469,sd = standard deviation  bmi = body mass index  ed = erectile,C0871420;C1305855;C2699239;C3538926
469,rosuva  rosuvastatin  sd  standard deviation  tnmbrdm  type nmbr diabetes mellitus .,C0011816;C0011849;C0332307;C0871420;C0965129;C1320657;C1547052;C2699239;C3250443
468,vitamin k antagonist naive,C1096489;C2267235
468,vitamin k antagonist experiencedk ( n = nmbr nmbr ),C1096489;C2267235
468,vitamin k antagonist experienced,C1096489;C2267235
468,vitamin k antagonist ( e . g . warfarin / coumarol ),C1096489;C2267235
468,vitamin k antagonist,C1096489;C2267235
468,previous use of vitamin k antagonist for > nmbr days — no . ( % ),C0205156;C1096489;C1524063;C1552607;C2267235
468,long - term vitamin k antagonist,C0443252;C1096489;C2267235
467,antibodies to infliximab,C3533054
466,antibiotics * *,C0003232;C0003237;C3540704;C3540705;C3540706;C3540707;C3540708;C3540709;C3540710
465,anti - ccp antibody positive,C0741132;C4318437
465,anti - ccp antibody - positive,C0741132;C4318437
465,anti - ccp antibody ( u /,C0003241;C0003242;C0021027;C0439148;C1167408;C1525410;C1704514;C3665580;C4318437
465,anti - ccp antibodies *,C0003241;C1525410;C1624602;C1704514;C4318437
464,no antianginal drug,C0013227;C1254351;C1874267;C3537168
464,nmbr antianginal drugs,C0013227;C1874267;C3537168;C3687832
464,nmbr antianginal drug,C0013227;C1254351;C1874267;C3537168
464,new anti - anginal therapy,C1874267;C3242274;C3537168
464,intensification of antianginal therapy,C1511484;C1874267;C3537168
464,any antianginal drug !,C0013227;C1254351;C1874267;C3537168
463,dactylitis severity score ) score > nmbr — no . { % ),C0239161;C0457451
463,dactylitis score ( nmbr – nmbr scale ),C0175659;C0239161;C0349674;C0449820;C1947916;C4050231
463,dactylitis score ( nmbr - nmbr ),C0239161;C0449820;C4050231
463,dactylitis score,C0239161;C0449820;C4050231
463,dactylitis,C0239161
462,acuity minor,C0750509
462,acuity major or,C0750509
462,acuity major,C0750509
462,acuity - defined bleeding,C0750509
462,acuity - bleeding major / minor,C0750509
461,unfractionated only,C0205171;C1720467
461,ufh only,C0205171;C1720467
461,ttr ( warfarin arm only ),C0032923;C0043031;C0205171;C0446516;C1421224;C1720467;C3715044;C4553528
461,st - depression only,C0205171;C0520887;C1720467
461,pioglitazone only,C0071097;C0205171;C1720467
461,past only,C0205171;C1444637;C1720467;C4284302
461,oad only,C0205171;C1720467
461,nmbr ( only nmbr distal ),C0205108;C0205171;C1720467;C4522154
461,lieum only,C0205171;C1720467
461,legs only,C0205171;C1140621;C1720467
461,lama ( only monotherapy ),C0205171;C0999593;C1416775;C1720467
461,laba ( only monotherapy ),C0205171;C1720467
461,jbs - nmbr secondary prevention onlynmbr,C0175692;C0205171;C0679699;C0795841;C1416527;C1720467
461,jbs - nmbr primary prevention onlynmbr,C0033144;C0175692;C0205171;C0795841;C1416527;C1720467
461,image only,C0205171;C1704254;C1704922;C1720467;C3542466
461,ileum only,C0020885;C0205171;C1720467
461,ics only,C0205171;C0815320;C1720467;C4551720
461,handihaler only,C0205171;C1720467
461,females only,C0086287;C0205171;C1720467
461,cortical only,C0001613;C0007776;C0022655;C0205171;C1720467
461,class v only,C0205171;C0457166;C1720467;C1880098
461,antimalarials only,C0003374;C0205171;C1720467
461,( women only ),C0043210;C0205171;C1720467
460,lived alone,C0205171;C0439044;C0679994;C1548795;C1634625;C2982691
460,heparin alone ( n = nmbr ),C0019134;C0205171;C0439044;C0679994;C0770546
460,fluticasone alone ( n = nmbr ),C0082607;C0205171;C0439044;C0679994
460,basal alone,C0205112;C0205171;C0439044;C0679994
460,aspirin alone ( n = nmbr ) nmbr . nmbr ± nmbr . nmbr,C0004057;C0205171;C0439044;C0679994
460,aspirin alone ( n = nmbr ) nmbr . nmbr,C0004057;C0205171;C0439044;C0679994
460,aspirin alone ( n = nmbr ),C0004057;C0205171;C0439044;C0679994
460,aspirin alone ( n / n ),C0004057;C0205171;C0439044;C0679994
460,alone,C0205171;C0439044;C0679994
459,single vessel disease,C0037179;C0042373;C0087136;C0205171
459,single - vessel disease,C0037179;C0042373;C0087136;C0205171
459,single,C0037179;C0087136;C0205171
458,other medical history — no . / total no . ( % ),C0262926;C1704706
458,other medical history — no . ( % ),C0262926;C1704706
458,other medical history,C0262926;C1704706
458,medical history — no . / total no . ( % ),C0262926;C1704706
458,medical history — no . ( % ),C0262926;C1704706
458,medical history — %,C0262926;C1704706
458,medical history of diabetic retinopathy §,C0011884;C0262926
458,medical history at randomization — no . ( % ),C0034656;C0262926;C1704706
458,medical history and risk factors — no . ( % ),C0262926;C1704706
458,medical history and risk factors ( % ),C0262926;C1704706
458,medical history and risk factors,C0262926;C1704706
458,medical history : cancer,C0006826;C0262926;C0998265;C1306459;C1704706
458,medical history . no . ( % ),C0262926;C1704706
458,medical history ( % ),C0262926;C1704706
458,medical history,C0262926;C1704706
457,vascular history,C0005847;C0019664;C0019665;C0262512;C0262926;C1558950;C1705255;C1801960;C2004062
457,uc history,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
457,type nmbr diabetes history,C0019664;C0019665;C0262512;C0262926;C1320657;C1705255;C2004062
457,selective vascular history,C0005847;C0019664;C0019665;C0036576;C0262512;C0262926;C1558950;C1705255;C1707391;C1801960;C2004062
457,seizure history,C0019664;C0019665;C0036572;C0262512;C0262926;C1705255;C1959629;C2004062;C4553401
457,revascularization history,C0019664;C0019665;C0262512;C0262926;C0581603;C1705255;C2004062
457,prior history of ml or ischemic stroke,C0019664;C0019665;C0262512;C0262926;C0332152;C0439526;C1705224;C1705255;C2004062;C2826257;C3887665
457,prior history of mi or ischaemic stroke,C0019664;C0019665;C0262512;C0262926;C0332152;C1705255;C2004062;C2826257;C3810814
457,prior history of bleeding on oac,C0019080;C0019664;C0019665;C0262512;C0262926;C0332152;C1705255;C2004062;C2826257
457,presenting history or diagnosis — no . ( % ),C0019664;C0019665;C0262512;C0262926;C0449450;C1705255;C2004062
457,pci history,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C4049621
457,participants without a history of cabg,C0010055;C0019664;C0019665;C0262512;C0262926;C0679646;C1705255;C2004062
457,participants with a history of cabg,C0010055;C0019664;C0019665;C0262512;C0262926;C0679646;C1705255;C2004062
457,parental history of ml before age nmbr y yes,C0019664;C0019665;C0030551;C0262512;C0262926;C0439526;C1705224;C1705255;C2004062;C3887665
457,parental history of mii,C0019664;C0019665;C0030551;C0262512;C0262926;C1705255;C2004062
457,parental history of mi before age nmbr y,C0019664;C0019665;C0030551;C0262512;C0262926;C1705255;C2004062;C3810814
457,oad history,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
457,no history of tnf antagonist treatment — no . ( % ),C0019664;C0019665;C0039798;C0087111;C0231491;C0262512;C0262926;C1448177;C1522326;C1533734;C1705169;C1705255;C2004062;C3538994;C3887704
457,no history of tia / stroke,C0007787;C0019664;C0019665;C0262512;C0262926;C0917805;C1054154;C1705255;C2004062
457,no history of mi ( n = nmbr,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C3810814
457,no history of hf,C0018488;C0019664;C0019665;C0262512;C0262926;C1313497;C1538440;C1705255;C2004062;C3273279
457,no history of extra - intestinal manifestations of ibd ( ref ),C0019664;C0019665;C0021853;C0262512;C0262926;C1280464;C1425988;C1705255;C1883702;C2004062
457,no history of diabetes ( n = nmbr ),C0011847;C0011849;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
457,no history of chf,C0018802;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
457,no history of bowel resections,C0019664;C0019665;C0262512;C0262926;C0741614;C1705255;C2004062
457,no history of af,C0019664;C0019665;C0262512;C0262926;C0344434;C1705255;C2004062;C4049859
457,no fracture history,C0016658;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
457,hypertension history,C0019664;C0019665;C0020538;C0262512;C0262926;C1705255;C1963138;C2004062
457,history pci,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C4049621
457,history ot chd,C0019664;C0019665;C0262512;C0262926;C0280604;C1318464;C1418208;C1705255;C1705587;C2004062;C3542407
457,history ol mi or stroke,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C3810814
457,history ol coronary revascularization *,C0019664;C0019665;C0262512;C0262926;C0877341;C1705255;C2004062
457,history ol chd at baselines,C0019664;C0019665;C0168634;C0262512;C0262926;C0280604;C1705255;C2004062;C3542407
457,history of vte * *,C0019664;C0019665;C0262512;C0262926;C0630906;C1705255;C2004062
457,history of vte,C0019664;C0019665;C0262512;C0262926;C0630906;C1705255;C2004062
457,history of venous,C0019664;C0019665;C0042449;C0262512;C0262926;C0348013;C1705255;C2004062
457,history of upper gl events ( perforations,C0018229;C0019664;C0019665;C0262512;C0262926;C0441471;C0549099;C1282910;C1423073;C1427674;C1705255;C2004062;C3541888
457,history of upper gi events ( perforations,C0019664;C0019665;C0203057;C0262512;C0262926;C0441471;C0549099;C1705255;C2004062;C3541888
457,history of upper,C0019664;C0019665;C0262512;C0262926;C1282910;C1705255;C2004062
457,history of tnf antagonist treatment failure — no . ( % ) * *,C0019664;C0019665;C0162643;C0231491;C0235828;C0262512;C0262926;C0521983;C1448177;C1547544;C1705255;C2004062
457,history of tia or stroke,C0007787;C0019664;C0019665;C0262512;C0262926;C0917805;C1054154;C1705255;C2004062
457,history of tia / stroke,C0007787;C0019664;C0019665;C0262512;C0262926;C0917805;C1054154;C1705255;C2004062
457,history of tia,C0007787;C0019664;C0019665;C0262512;C0262926;C0917805;C1054154;C1705255;C2004062
457,history of symptomatic,C0019664;C0019665;C0231220;C0262512;C0262926;C1705255;C2004062
457,history of strokenmbr,C0019664;C0019665;C0038454;C0262512;C0262926;C1705255;C2004062;C4554100
457,history of strokea,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
457,history of stroke †,C0019664;C0019665;C0038454;C0262512;C0262926;C1705255;C2004062;C4554100
457,history of stroke or tia,C0019664;C0019665;C0038454;C0262512;C0262926;C1705255;C2004062;C4554100
457,history of stroke at baseline,C0019664;C0019665;C0038454;C0262512;C0262926;C1705255;C2004062;C4554100
457,history of stroke / see / tia,C0019664;C0019665;C0038454;C0262512;C0262926;C1705255;C2004062;C4554100
457,history of stroke * *,C0019664;C0019665;C0038454;C0262512;C0262926;C1705255;C2004062;C4554100
457,history of stroke *,C0019664;C0019665;C0038454;C0262512;C0262926;C1705255;C2004062;C4554100
457,history of stroke ( % ),C0019664;C0019665;C0038454;C0262512;C0262926;C1705255;C2004062;C4554100
457,history of stroke,C0019664;C0019665;C0038454;C0262512;C0262926;C1705255;C2004062;C4554100
457,history of statin use,C0019664;C0019665;C0262512;C0262926;C0360714;C1524063;C1705255;C2004062
457,history of second prior mi,C0019664;C0019665;C0205436;C0262512;C0262926;C0332152;C0457385;C0565930;C1561503;C1705190;C1705255;C2004062;C2826257;C3810814
457,history of pci — no . / total no . ( % ) : t,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C4049621
457,history of pci with stenting,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C4049621
457,history of pci or cabg before index event,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C4049621
457,history of pci / ptca,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C2936173;C4049621
457,history of pci,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C4049621
457,history of parental myocardial,C0019664;C0019665;C0027061;C0030551;C0262512;C0262926;C1522564;C1705255;C2004062
457,history of pad,C0019664;C0019665;C0182158;C0262512;C0262926;C0332568;C1705255;C2004062;C3540603;C3669270;C3814046;C4319657
457,history of oxygen use - yes,C0019664;C0019665;C0030054;C0262512;C0262926;C1524063;C1549445;C1705108;C1705255;C1710701;C2004062
457,history of or current cardiac disorders,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
457,history of omalizumab treatment :,C0019664;C0019665;C0039798;C0087111;C0262512;C0262926;C0966225;C1522326;C1533734;C1705169;C1705255;C2004062;C3538994;C3887704
457,history of omalizumab treatment,C0019664;C0019665;C0039798;C0087111;C0262512;C0262926;C0966225;C1522326;C1533734;C1705169;C1705255;C2004062;C3538994;C3887704
457,history of non - hemor - rhagic stroke,C0019664;C0019665;C0038454;C0262512;C0262926;C1518422;C1705255;C2004062;C4554100
457,history of nicotine use,C0019664;C0019665;C0028040;C0262512;C0262926;C1524063;C1705255;C2004062
457,history of more than nmbr prior mi ( % ),C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
457,history of ml or stroke,C0019664;C0019665;C0262512;C0262926;C0439526;C1705224;C1705255;C2004062;C3887665
457,history of ml or ischemic stroke,C0019664;C0019665;C0262512;C0262926;C0439526;C1705224;C1705255;C2004062;C3887665
457,history of ml before index event,C0019664;C0019665;C0262512;C0262926;C0439526;C1705224;C1705255;C2004062;C3887665
457,history of ml at baseline,C0019664;C0019665;C0262512;C0262926;C0439526;C1705224;C1705255;C2004062;C3887665
457,history of ml,C0019664;C0019665;C0262512;C0262926;C0439526;C1705224;C1705255;C2004062;C3887665
457,history of mi or stroke history of coronary,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C3810814
457,history of mi or stroke d,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C3810814
457,history of mi or stroke,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C3810814
457,history of mi ( n = nmbr,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C3810814
457,history of mi,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C3810814
457,history of macroalbuminuriat,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
457,history of lvh on electrocardiogram,C0019664;C0019665;C0149721;C0262512;C0262926;C1705255;C2004062
457,history of lvh on echocardiogram,C0019664;C0019665;C0149721;C0262512;C0262926;C1705255;C2004062
457,history of ischemic stroke,C0019664;C0019665;C0262512;C0262926;C0948008;C1705255;C2004062
457,history of htn,C0019664;C0019665;C0020538;C0262512;C0262926;C1705255;C2004062
457,history of high cholesterol ( a ) nmbr,C0019664;C0019665;C0020443;C0262512;C0262926;C1522133;C1705255;C2004062
457,history of hf or lvef bnmbr % with index event,C0018488;C0019664;C0019665;C0262512;C0262926;C1313497;C1538440;C1705255;C2004062;C3273279
457,history of hf,C0018488;C0019664;C0019665;C0262512;C0262926;C1313497;C1538440;C1705255;C2004062;C3273279
457,history of h pylori eradication *,C0019664;C0019665;C0079488;C0262512;C0262926;C1705255;C2004062
457,history of gi bleeding or ulcer — no . / total no . ( % ),C0017181;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
457,history of extra - intestinal manifestations of ibd,C0019664;C0019665;C0021853;C0262512;C0262926;C1280464;C1705255;C1883702;C2004062
457,history of elms,C0019664;C0019665;C0262512;C0262926;C0330531;C1705255;C2004062;C2980688
457,history of dyspepsia,C0013395;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C4552968
457,history of dyslipidemia,C0019664;C0019665;C0242339;C0262512;C0262926;C1705255;C2004062
457,history of dyslipidaemia,C0019664;C0019665;C0242339;C0262512;C0262926;C1705255;C2004062
457,history of diabetes { p = nmbr * nmbr ),C0011847;C0011849;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
457,history of diabetes requiring drugs,C0011847;C0011849;C0019664;C0019665;C0020616;C0262512;C0262926;C1553893;C1705255;C2004062
457,history of diabetes nyha class,C0011847;C0011849;C0019664;C0019665;C0262512;C0262926;C1705255;C1882083;C2004062
457,history of diabetes :,C0011847;C0011849;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
457,history of diabetes - n ( % ),C0011847;C0011849;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
457,history of diabetes ( n = nmbr ),C0011847;C0011849;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
457,history of diabetes ( a ),C0011847;C0011849;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
457,history of diabetes ( % ),C0011847;C0011849;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
457,history of diabetes,C0011847;C0011849;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
457,history of cvd and of cv risk factors - no . ( % ),C0007222;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
457,history of cvd,C0007222;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
457,history of coronary revascularization d,C0019664;C0019665;C0262512;C0262926;C0877341;C1705255;C2004062
457,history of coronary revascularization,C0019664;C0019665;C0262512;C0262926;C0877341;C1705255;C2004062
457,history of coronary,C0018787;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
457,history of copd,C0019664;C0019665;C0024117;C0262512;C0262926;C1412502;C1705255;C2004062;C3714496
457,history of chronic hf,C0018488;C0019664;C0019665;C0205191;C0262512;C0262926;C1313497;C1538440;C1705255;C2004062;C3273279
457,history of chf before index event,C0018802;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
457,history of chf - n ( % ),C0018802;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
457,history of chf,C0018802;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
457,history of chd at baseline §,C0019664;C0019665;C0262512;C0262926;C0280604;C1705255;C2004062;C3542407
457,history of chd at baseline d,C0019664;C0019665;C0262512;C0262926;C0280604;C1705255;C2004062;C3542407
457,history of chd at baseline,C0019664;C0019665;C0262512;C0262926;C0280604;C1705255;C2004062;C3542407
457,history of chd,C0019664;C0019665;C0262512;C0262926;C0280604;C1705255;C2004062;C3542407
457,history of cardiovascular events,C0019664;C0019665;C0262512;C0262926;C0441471;C1320716;C1705255;C1880008;C2004062;C3541888
457,history of cad / mi,C0019664;C0019665;C0262512;C0262926;C1504769;C1705255;C2004062;C2239547;C3810814;C3813548;C4284121
457,history of cad,C0019664;C0019665;C0262512;C0262926;C1504769;C1705255;C2004062;C2239547;C3813548;C4284121
457,history of cabg,C0010055;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
457,history of bowel resections,C0019664;C0019665;C0262512;C0262926;C0741614;C1705255;C2004062
457,history of bowel resection ( ref ),C0019664;C0019665;C0262512;C0262926;C0741614;C1425988;C1705255;C2004062
457,history of bone disease ( predefined ),C0005940;C0019664;C0019665;C0262512;C0262926;C0262950;C0683519;C0730226;C0850708;C0944983;C1705255;C2004062
457,history of atrial arrhythmia,C0019664;C0019665;C0085611;C0262512;C0262926;C1705255;C2004062
457,history of amputation,C0002688;C0019664;C0019665;C0262512;C0262926;C0332840;C1546539;C1705255;C2004062
457,history of af,C0019664;C0019665;C0262512;C0262926;C0344434;C1705255;C2004062;C4049859
457,history of > nmbr previous vte ( excluding index event ),C0019664;C0019665;C0205156;C0262512;C0262926;C0332196;C0441471;C0600653;C0630906;C0918012;C1552607;C1552854;C1637833;C1705255;C2004062;C2828389;C2986546;C4019010
457,history of ( % ),C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
457,history mi or stroke,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C3810814
457,history coronary revascularization,C0019664;C0019665;C0262512;C0262926;C0877341;C1705255;C2004062
457,history coronary,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
457,history chd,C0019664;C0019665;C0262512;C0262926;C0280604;C1705255;C2004062;C3542407
457,history ( pack - years ),C0019664;C0019665;C0262512;C0262926;C1277691;C1705255;C2004062
457,history,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
457,heart failure history,C0018801;C0018802;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C4554158
457,gout history,C0018099;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
457,fracture history,C0016658;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
457,ed history,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C3538926
457,diabetic history ( years ) x,C0019664;C0019665;C0241863;C0262512;C0262926;C0439234;C1705255;C2004062
457,diabetes history,C0011847;C0011849;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
457,copd history yrs,C0019664;C0019665;C0024117;C0262512;C0262926;C1412502;C1705255;C2004062;C3714496
457,copd exacerbation history,C0019664;C0019665;C0262512;C0262926;C0740304;C1705255;C2004062
457,clinical history — no . ( % ),C0019664;C0019665;C0205210;C0262512;C0262926;C1705255;C2004062
457,clinical history,C0019664;C0019665;C0205210;C0262512;C0262926;C1705255;C2004062
457,chf history,C0018802;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
457,chd history,C0019664;C0019665;C0262512;C0262926;C0280604;C1705255;C2004062;C3542407
457,cardiac history,C0018787;C0019664;C0019665;C0262512;C0262926;C1522601;C1705255;C2004062
457,cad history and risk factors,C0019664;C0019665;C0262512;C0262926;C1504769;C1705255;C2004062;C2239547;C3813548;C4284121
457,cabg history,C0010055;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
457,baseline copd exacerbation history,C0019664;C0019665;C0168634;C0262512;C0262926;C0740304;C1442488;C1705255;C2004062
457,any cvd history ( % ),C0007222;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
457,any cv history / risk factors,C0019664;C0019665;C0035648;C0262512;C0262926;C1553898;C1705255;C2004062;C3538987;C4048877;C4318503
457,anti - hypertensive treatment history,C0003364;C0019664;C0019665;C0039798;C0087111;C0262512;C0262926;C1522326;C1533734;C1705169;C1705255;C2004062;C3538994;C3887704
457,all participants history of cabg,C0010055;C0019664;C0019665;C0262512;C0262926;C0679646;C1705255;C2004062
456,any acuity bleeding,C0333276
455,specific risk of bleeding^,C0205369;C1552740;C3251812
455,risk of bleeding,C3251812
454,receptor blockers,C0597357
454,receptor blocker,C0597357
454,gpiib / iiia receptor inhibitor,C0016011;C0597357;C1999216
453,one or more requiring hospitalization in nmbr mo before screening — no . ( % ) nmbr,C0205447
453,one or more medications,C0205447
453,one or more exacerbations,C0205447
453,one or more copd exacerbations ( n / n [ % ] ),C0205447
453,one or more blood pressure medications,C0205447
453,one - third radius,C0034627;C0205437;C0205447;C1306504
453,distal one - third of radius,C0034627;C0205437;C0205447;C0450168;C0588207;C1306504
453,at least one drug - eluting stent,C0205447;C1322815
452,one tnfi and,C0205447
452,one tnfi *,C0205447
452,one of the above,C0205447
452,one lesion,C0205447;C0221198;C1546698
451,non - q - wave myocardial infarction,C0542269;C3537181
450,family history of myocardial infarction prior to age nmbr,C0455406
449,parental history of myocardial infarction before nmbr yr of age ( % ),C0030551;C1275835
449,parental history of myocardial infarction before age nmbr y yes,C0030551;C1275835
449,parental history of myocardial infarction before age nmbr y,C0030551;C1275835
449,history of myocardial infarction ( % ),C1275835
449,history of myocardial infarction,C1275835
449,history myocardial infarction,C0155668;C1275835
448,prior myocardial infarction 一 no . ( % ),C0155668
448,prior myocardial infarction — no . { % ),C0155668
448,prior myocardial infarction — no . / total no . ( % ),C0155668
448,prior myocardial infarction — no . ( % ),C0155668
448,prior myocardial infarction yes,C0155668;C1549445;C1705108;C1710701
448,prior myocardial infarction ( % ),C0155668
448,prior myocardial infarction,C0155668
448,> nmbr prior myocardial infarction — no . ( % ),C0155668
447,anterior myocardial infarction — no . / total no . ( % ),C0340293
447,anterior myocardial infarction — no . ( % ),C0340293
446,mean ( sd ) calcium intake in mg daily,C0024671;C0026410;C0332173;C0439269;C0444504;C0489458;C1960952;C2346927;C2347634;C2348143;C2699239;C4321396;C4521761
446,dietary calcium intake,C0489458
445,renal dysfunction,C1565489;C3279454
445,non - endstage renal dysfunction *,C0205088;C1518422;C1565489;C3279454
445,non - end - stage renal dysfunction,C0205088;C1518422;C1565489;C3279454
445,no renal dysfunction,C1565489;C3279454
445,impaired renal function †,C1565489
445,impaired renal function §,C1565489
445,history of impaired renal function,C0019664;C0019665;C0262512;C0262926;C1565489;C1705255;C2004062
444,renal impairment *,C1565489
444,renal impairment,C1565489
444,mild to moderate renal impairment *,C1299392;C1565489
444,level of renal impairment ',C0441889;C0456079;C1547707;C1565489;C2946261
444,level of renal impairment,C0441889;C0456079;C1547707;C1565489;C2946261
443,pro - active intervention,C0033382;C0184661;C0205177;C0523852;C0886296;C1273869;C2987124;C3853793;C3888249
443,patient - reported outcomes,C2987124
442,minimal important change threshold ( improvement ) a,C0449864;C2986411;C3845594;C3898777;C4084912
442,medically important infectionsa,C3898777;C4084912
441,micral test result,C0456984;C0587081
441,labs at randomization,C0034656;C0587081
441,laboratory findings,C0587081
440,endothelin - receptor antagonists,C1134681;C2266875
439,leukotriene receptor antagonists,C0595726;C2757015;C3542962
439,leukotriene - receptor antagonist,C0595726;C3537183;C4521995
438,mineralcorticoid receptor antagonist,C4543207
438,alpha receptor antagonist,C0439095;C2003941;C2350010;C4543207
437,mineralocorticoid receptor antagonists,C1373021;C1579268
437,mineralocorticoid receptor antagonist n ( % ),C1579268
437,mineralocorticoid receptor antagonist,C1579268
437,aldosterone receptor antagonists,C1579268
436,glucagon - like peptide - nmbr receptor agonist,C0014361;C4543206
436,glucagon - like peptide - nmbr agonist,C0014361;C2987634
435,antidepressant,C0003289
434,linear regression,C0023733;C2346679
433,inversion,C0021943;C0021945;C1705687;C2349984
432,patients with radiographic erosion,C0030705;C0333307;C0444708;C1880549;C1959609;C3887524
432,erosion,C0333307;C1880549;C1959609;C3887524
432,baseline erosion,C0168634;C0333307;C1442488;C1880549;C1959609;C3887524
432,> nmbr erosion,C0333307;C1880549;C1959609;C3887524
431,time point,C2348792
430,clinical endpoint,C2347784
429,uncertain,C0087130;C4085655
428,shoulder pain,C0037011
427,three or more lesions,C0205449
427,three or more drugs,C0205449
427,three or more agents,C0205449
427,three of seven risk factors,C0035648;C0205449;C0205453;C1553898
426,irregular or ulcerated ica plaquef,C0205271
426,irregular or ulcerated ica p ) laque : [ :,C0205271
425,= cerebrospinal fluid .,C0007806;C0007807
424,chd plus cerebral infarction,C0007785;C0280604;C3542407
424,chd + cerebral infarction,C0007785;C0280604;C3542407
424,cerebral ischemia,C0007785;C0917798
424,cerebral infarction,C0007785
423,puerto rican,C0034043
422,puerperium,C0034042;C0086839;C1879329
421,upper limbs,C1140618
421,upper limb fractures,C1140618
421,upper limb,C1140618
420,inferior mi *,C0340305;C3542426
419,anterior mi,C3536746
418,inferior or posterior,C0542339;C0678975
418,inferior / posterior,C0205095;C0542339;C0678975
418,inferior ( n,C0542339;C0678975
418,inferior ( % ),C0542339;C0678975
418,inferior,C0542339;C0678975
417,absolute time spent “ on ” without troublesome dyskinesia,C0439546
417,absolute time spent “ on ” with troublesome dyskinesia,C0439546
417,absolute time spent “ on ”,C0439546
416,blood urea nitrogen ( mg / dl ),C0005845;C0439269;C0600137
416,blood urea nitrogen,C0005845;C0600137
415,absolute risk difference ( nmbr % cl ),C0035647;C0596019;C1519101;C1549031;C1705241;C1705242;C4552904
415,absolute risk difference ( ci ),C0008107;C0035647;C1519101;C1549031;C1705241;C1705242;C3259781;C4552904
415,absolute difference estimate vs placebo ( nmbr % ci ),C0750572;C1549031
415,absolute change,C1549031
414,absolute risk reductions,C3179139
414,absolute risk reduction ( nmbr % cl ) *,C0596019;C3179139
414,absolute risk reduction ( nmbr % ci ),C0008107;C3179139;C3259781
413,absolute reversibility in fevnmbr,C0205344;C0449261;C3714541
413,absolute fvc decrease > nmbr %,C0205344;C0392756;C0547047;C3714541
413,absolute decrease > nmbr %,C0205344;C0392756;C0547047
413,absolute decline in fvc > nmbr % predicted or death,C0205344;C3714541
413,absolute decline in fvc > nmbr % predicted,C0205344;C3714541
413,absolute ( l ),C0205344
413,absolute,C0205344
412,geometric mean uacr,C2986759
412,geometric mean of baseline,C0168634;C1442488;C2986759
412,geometric mean,C2986759
412,baseline geometric mean ( nmbr ® / l ),C0168634;C1442488;C2986759
412,baseline ( geometric mean,C0168634;C1442488;C2986759
411,bare metal stent,C2825200
411,bare - metal stent — no . ( % ),C2825200
411,bare - metal stent,C2825200
411,all bare metal stents,C2825200
410,age of onset nmbr years ( n = nmbr ),C0206132;C0439234;C3175530
410,age of onset < nmbr years ( n = nmbr ),C0206132;C0439234;C3175530
410,age of onset,C0206132;C3175530
410,age of asthma onset,C0004096;C0206132;C2984299;C3175530
410,age at onset,C0206132;C3870509
410,age at disease onset,C0012634;C0206132;C3870509
409,onset of chest pain,C0024902;C0206132;C0332162
409,onset nmbr [nmbr],C0206132;C0332162
408,predicted normal ) t,C0205307;C0231683;C0439166;C0681842;C1882327;C2347086;C4553972
408,predicted normal ( % ),C0205307;C0231683;C0439166;C0681842;C1882327;C2347086;C4553972
408,percent of predicted normal value,C0205307;C0231683;C0439166;C1882327;C2347086;C4553972
408,normal troponin,C0041199;C0205307;C0231683;C0439166;C2347086;C4553972
408,normal study termination,C0205307;C0231683;C0439166;C0557651;C1549081;C1692758;C2347086;C2603343;C4553972
408,normal responders ( n = nmbr ),C0205307;C0231683;C0439166;C2347086;C4553972
408,normal responder ( n = nmbr ),C0205307;C0231683;C0439166;C2347086;C4553972
408,normal responder,C0205307;C0231683;C0439166;C2347086;C4553972
408,normal or mild ( iief - ef nmbr - nmbr ),C0205307;C0231683;C0439166;C2347086;C4553972
408,normal or increased gfr ( > nmbr ml / mln per nmbr . nmbr m^ ),C0205307;C0231683;C0439166;C2347086;C4553972
408,normal or increased egfr,C0205307;C0231683;C0439166;C2347086;C4553972
408,normal or increased baseline gfr ( > nmbr ml / min / nmbr . nmbr mnmbr ),C0205307;C0231683;C0439166;C2347086;C4553972
408,normal or high egfr ( > nmbr ml / min per nmbr . nmbr mnmbr ) at baseline to low egfr ( < nmbr ml / min per nmbr . nmbr mnmbr ),C0205307;C0231683;C0439166;C2347086;C4553972
408,normal hscrp,C0205307;C0231683;C0439166;C2347086;C4553972
408,normal hbanmbrc,C0019016;C0205307;C0231683;C0439166;C1825777;C2347086;C3538758;C4553972
408,normal fasting glucose level ( n = nmbr ),C0015663;C0202045;C0205307;C0231683;C0439166;C0522082;C2347086;C4553972
408,normal egfr ( nmbr < egfr < nmbr ml / min per nmbr . nmbr mnmbr ) at baseline to high egfr ( > nmbr ml / min per nmbr . nmbr mnmbr ),C0205307;C0231683;C0369637;C0439166;C0439445;C0441923;C1739039;C2347086;C3811844;C3812682;C4553972
408,normal crp and,C0205307;C0231683;C0439166;C2347086;C3890735;C4048285;C4553972
408,normal bnp,C0054015;C0205307;C0231683;C0439166;C1095989;C1417808;C2347086;C2982014;C4553972
408,normal acr ( < nmbr mg / mg ) at baseline to albuminuria ( acr > nmbr mg / g ),C0168634;C0205307;C0231683;C0439166;C1319635;C1412134;C1442488;C1515941;C2347086;C4553972
408,normal > nmbr - nmbr,C0205307;C0231683;C0439166;C2347086;C4553972
408,normal / mild ckd,C0205307;C0231683;C0439166;C1561643;C2347086;C2945599;C4553972
408,normal ( ≥ nmbr ml · min − nmbr · nmbr . nmbr m − nmbr ),C0205307;C0231683;C0369637;C0439166;C0439445;C0441923;C2347086;C4553972
408,normal ( ≤   uln ) n   =   nmbr,C0205307;C0231683;C0439166;C1519815;C2347086;C4553972
408,normal ( £ nmbr ml / minute ),C0205307;C0231683;C0439166;C0439232;C0439526;C0700321;C0702093;C1282918;C1705224;C2347086;C2347166;C3887665;C4553972
408,normal ( egfr ≥ nmbr ),C0205307;C0231683;C0439166;C1739039;C2347086;C3811844;C3812682;C4553972
408,normal ( egfr > nmbr ),C0205307;C0231683;C0439166;C1739039;C2347086;C3811844;C3812682;C4553972
408,normal ( > nmbr mlvmin per nmbr . nmbr mnmbr ),C0205307;C0231683;C0369637;C0439166;C0441923;C2347086;C4553972
408,normal ( > nmbr ml / min ),C0205307;C0231683;C0439166;C0439445;C2347086;C4553972
408,normal ( > nmbr ),C0205307;C0231683;C0439166;C2347086;C4553972
408,normal ( < nmbr . nmbr u / ml ),C0205307;C0231683;C0439166;C0439340;C1880521;C2347086;C2945590;C4553972
408,normal,C0205307;C0231683;C0439166;C2347086;C4553972
408,medium normal ( n = nmbr ),C0009458;C0205307;C0231683;C0439166;C0439536;C1705217;C2347086;C3244283;C4085196;C4522282;C4522283;C4553972
408,lowest normal ( n = nmbr ),C0205307;C0231683;C0439166;C1708760;C2347086;C4553972
408,low normal ( n = nmbr ),C0205251;C0205307;C0231683;C0439166;C1550472;C2347086;C3890211;C4048187;C4321351;C4522223;C4553972
408,high normal ( n = nmbr ),C0205250;C0205307;C0231683;C0439166;C1299351;C2347086;C2700149;C3887512;C3889660;C4321237;C4522209;C4553972
408,crp ( normal < nmbr . nmbr mg / dl ),C0205307;C0231683;C0439166;C0439269;C2347086;C3890735;C4048285;C4553972
407,ulcers / gangrene,C0017086;C0041582
407,ulcer,C0041582;C3887532
406,prasugrel or ticagrelor,C1620287
406,prasugrel,C1620287
405,usual care ( n = nmbrla ),C0023031;C0023749;C0230347;C1947933;C2346906;C3538928;C4553351
405,usual care ( n = nmbra ),C1947933;C3538928
405,usual care ( n = nmbr ),C1947933;C3538928
405,usual care,C1947933;C3538928
405,care,C1947933
404,renal impairment ( crcl < nmbr ml / min ),C0439445;C1565489;C1846718
404,nmbr - nmbr crcl,C1846718
404,crcl at randomization - ml / min,C0034656;C0439445;C1846718
404,crcl at randomization,C0034656;C1846718
404,crcl ( ml / min ) at randomization,C0034656;C0439445;C1846718
404,> nmbr crcl,C1846718
404,< nmbr crcl,C1846718
403,crcl nmbr - nmbr,C1846718
403,crcl at baseline < nmbr ml / min,C0168634;C0439445;C1442488;C1846718
403,crcl at baseline,C0168634;C1442488;C1846718
403,crcl < nmbr,C1846718
403,crcl,C1846718
402,within nmbr h after first procedure,C0033727;C0184661;C0205435;C0369286;C0441932;C0564385;C1279901;C2700391;C3274430;C3539779;C4528284
402,unsuccessful procedure,C0184661;C1272705;C2700391;C3274430;C3539779
402,procedures in the hospital — no . ( % ),C0019994;C0025664;C0184661;C1510665;C2700391;C3538935
402,procedures after discharge — no . ( % ),C0012621;C0025664;C0030685;C0184661;C2700391;C2926602;C3538935
402,procedure * *,C0184661;C2700391;C3274430;C3539779
402,procedure,C0184661;C2700391;C3274430;C3539779
402,peak procedural act — sec,C0025664;C0184661;C0444505;C2700391;C3274430;C3538935;C3539779
402,pci procedure,C0184661;C2700391;C3274430;C3539779;C4049621
402,non pci procedure,C0184661;C1518422;C2700391;C3274430;C3539779;C4049621
402,interventional or surgical procedures,C0184661;C3274035
402,first procedure,C0184661;C0205435;C1279901;C2700391;C3274430;C3539779
402,cystoscopic procedure,C0184661;C0560573;C2700391;C3274430;C3539779
402,baseline procedure,C0168634;C0184661;C1442488;C2700391;C3274430;C3539779
401,with dm ( n proactive intervention ( n = nmbra ),C0011816;C0184661;C0886296;C1273869;C3250443
401,vascular intervention,C0005847;C0184661;C0886296;C1273869;C1558950;C1801960
401,proactive intervention ( n = nmbra ),C0184661;C0886296;C1273869
401,prior coronary intervention or coronary artery bypass grafting,C0018787;C0184661;C0332152;C0886296;C1273869;C2826257
401,prior carotid intervention,C0184661;C0332152;C0741968;C0886296;C1273869;C2826257
401,previous intervention ( % ),C0184661;C0205156;C0886296;C1273869;C1552607
401,previous coronary intervention,C0018787;C0184661;C0205156;C0886296;C1273869;C1552607
401,percutaneous intervention,C0184661;C0522523;C0886296;C1273869
401,multivessel intervention,C0184661;C0886296;C1273869
401,intervention group ( n = nmbr ),C0184661;C0441848;C0886296;C1273869
401,intervention .,C0184661;C0886296;C1273869
401,intervention ( n = nmbr ),C0184661;C0886296;C1273869
401,intervention,C0184661;C0886296;C1273869
401,experimental intervention group ( n = nmbr ),C0184661;C0441848;C0886296;C1273869;C1517586
401,coronary intervention,C0018787;C0184661;C0886296;C1273869
400,present smokerc,C0150312;C0449450
400,present smoker,C0150312;C0337664;C0449450
400,present ( £ nmbr mg / dl ),C0150312;C0439269;C0449450
400,present ( > nmbr mg / dl ),C0150312;C0439269;C0449450
400,present,C0150312;C0449450
400,presence of mets ( % ) a,C0150312;C0392148;C0812270;C1705694;C2939420;C3854307
400,presence of mets,C0150312;C0392148;C0812270;C1705694;C2939420;C3854307
400,presence of honeycombing,C0150312;C0332468;C0349384;C0392148;C3854307
400,presence of erosions,C0150312;C0333307;C0392148;C1959609;C3854307
400,presence of enthesitis,C0150312;C0392148;C1282952;C3854307
400,presence of dactylitis,C0150312;C0239161;C0392148;C3854307
400,presence of angioedema at baseline,C0002994;C0150312;C0392148;C3854307
399,no in - trial stroke n = nmbr,C0008976;C0038454;C0150312;C0332285;C1707101;C4554100
399,in - trial nonfatal or fatal stroke n = nmbr,C0008976;C0150312;C0332285;C1707101
399,in - trial nmbr - year rates per nmbr ( se ) total events / number at risk,C0008976;C0036919;C0150312;C0332285;C0439175;C0439234;C0439508;C0439810;C0441471;C0871208;C1264674;C1521828;C1707101;C3541888;C4288115
399,in - trial and post - trial nmbr - year rates per nmbr ( se ) total events / number at risk,C0008976;C0150312;C0332285;C1707101
399,in - clinic uasnmbr,C0002424;C0150312;C0332285;C0442592;C1707101
399,in - clinic uask,C0002424;C0150312;C0332285;C0442592;C1707101
398,europe nmbr ¶,C0015176
398,europe nmbr +,C0015176
398,europe nmbr ( n = nmbr ),C0015176
398,europe nmbr ( n = nmbr,C0015176
398,europe nmbr,C0015176
398,europe n z nmbr,C0015176
398,europe ii,C0015176;C1710602;C4082587
398,europe i,C0015176;C0021966;C0221138
398,europe and russia,C0015176
398,europe and canada,C0015176
398,europe and australia,C0015176
398,europe / lsrael,C0015176
398,europe ( zone nmbr ),C0015176;C1710706
398,europe ( plus south africa ),C0015176;C0037712;C0332287
398,europe ( non - eu ),C0015176;C0015179;C1518422;C3665627
398,europe ( including south africa ),C0015176
398,europe ( eu ),C0015176;C0015179;C3665627
398,* other - europe ( n = nmbr ),C0015176
397,west europe,C0015176;C1705493
397,w europe,C0015176
397,w est europe,C0015176;C3811127;C3890902
397,w . europe,C0015176
397,non europe,C0015176;C1518422
397,europenmbr,C0015176
397,europe,C0015176
397,e europe,C0015176
397,e . europe,C0015176
396,early use intended,C1279919
396,early routine,C0205547;C1279919
396,early load,C1279919
396,early eptifibatide,C0253563;C1279919
396,early clopidogrel intended,C0070166;C1279919
396,early - start group ( n = nmbr ),C1279919
396,early - eptifibatide group ( n = nmbr ),C0253563;C0441848;C1279919
396,early ( n = nmbr ),C1279919
396,early,C1279919
395,time of qualifying ecg to balloon inflation ( hrs ),C0040223;C1514624;C1623258;C3541383
395,time from qualifying ecg to balloon inflation,C0040223;C1514624;C1623258;C3541383
395,si . gni . fi . canr ecg changes,C1623258;C4050619
395,ecg left ventricular,C1623258
395,ecg changes ( % ) t,C1623258
395,ecg at time of qualifying symptoms,C0040223;C0683368;C1457887;C1514624;C1623258;C3541383
395,ecg and imaging data,C1623258
395,ecg abnormality ( resting ),C1623258;C1704258
395,due to ecg changes,C1623258
394,lvh by electrocardiogram,C0013798;C0149721;C1547122;C1623258
394,lvh ( from electrocardiogram ),C0013798;C0149721;C1547122;C1623258
394,electrocardiography,C0013798;C1623258
394,electrocardiograph results,C0013798;C0180600;C1623258
394,electrocardiogram,C0013798;C1547122;C1623258
394,ecg,C1623258
393,years ( sd ),C0439234;C2699239
393,snmbr years ( n = nmbr ),C0439234;C2986823
393,nmbr years ( n = nmbr ),C0439234
393,nmbr to < nmbr yr — no . { % ),C0439234
393,nmbr to < nmbr yr — no . ( % ),C0439234
393,nmbr = nmbr yr — no . ( % ),C0439234
393,nmbr - nmbr yr — no . ( % ),C0439234
393,average age ( year ),C0001779;C0439234;C0439508;C1510992;C2825518
393,age — yr race — no . ( % ) f,C0001779;C0439234
393,age at menopause ( yr ),C0439234;C1625754;C1629609
393,age > nmbr yr — no . ( % ),C0001779;C0439234
393,age > nmbr yr and st - segment changes,C0001779;C0439234
393,age > nmbr yr and elevated biomarkers,C0001779;C0439234
393,> nmbr yr — no . { % ),C0439234
393,> nmbr yr — no . ( % ),C0439234
393,> nmbr yr ( n = nmbr ),C0439234
393,> nmbr years ( n = nmbr ),C0439234
393,> = nmbr years ( n = nmbr ),C0439234
393,< nmbr yr — no . { % ),C0439234
393,< nmbr yr — no . ( % ),C0439234
393,< nmbr yr ( n = nmbr ),C0439234
393,< nmbr years ( n = nmbr ),C0439234
393,$ nmbr years ( n = nmbr ),C0439234
392,赛 nmbr years,C0439234
392,〉 nmbr years,C0439234
392,■ nmbr years,C0439234
392,≥ nmbr years,C0439234
392,≥ nmbr to < nmbr years,C0439234
392,≥ nmbr . nmbr years,C0439234
392,≤ nmbr years,C0439234
392,» nmbr years,C0439234
392,£ nmbr years,C0439234
392,£ nmbr to < nmbr years,C0439234
392,years ),C0439234
392,xnmbr years,C0439234
392,women > nmbr years,C0043210;C0439234
392,women < nmbr years,C0043210;C0439234
392,snmbr years,C0439234;C0565930;C2603362
392,pt . years = nmbr,C0032743;C0439234;C0699718
392,nmbryr,C0439234
392,nmbr — nmbr years,C0439234
392,nmbr — < nmbr years,C0439234
392,nmbr yr,C0439234
392,nmbr years,C0439234
392,nmbr to nmbr years,C0439234
392,nmbr to < nmbr years,C0439234
392,nmbr nmbr years,C0439234
392,nmbr enmbr years,C0439234
392,nmbr - nmbr years,C0439234
392,nmbr - < nmbr years,C0439234
392,at nmbr years,C0439234
392,a nmbr years,C0439234
392,> nmbr   years,C0439234
392,> nmbr years to < nmbr years,C0439234
392,> nmbr years simva,C0439234
392,> nmbr years or < nmbr crcl,C0439234
392,> nmbr years old,C0439234
392,> nmbr years n z nmbr,C0439234
392,> nmbr years bmi,C0439234;C0578022
392,> nmbr years ( % ),C0439234
392,> nmbr years,C0439234
392,> nmbr to nmbr   years,C0439234
392,> nmbr to nmbr years,C0439234
392,> nmbr to < nmbr years,C0439234
392,> nmbr to < = nmbr years,C0439234
392,> nmbr - nmbr years,C0439234
392,> nmbr - < nmbr years,C0439234
392,> lnmbr years,C0439234;C0439394;C1706495;C3642217
392,> = nmbr years and < nmbr years,C0439234
392,> = nmbr years,C0439234
392,< nmbr years simva,C0439234
392,< nmbr years n z nmbr,C0439234
392,< nmbr years eze / simva,C0439234
392,< nmbr years ( % ),C0439234
392,< nmbr years,C0439234
392,< nmbr . nmbr years,C0439234
392,< lnmbr years,C0439234;C0439394;C1706495;C3642217
392,( years ),C0439234
392,$ nmbr years,C0439234
391,≥ nmbr . nmbr to < nmbr . nmbr years,C0439234
391,≤ nmbr   year,C0439234;C0439508
391,years,C0439234
391,year nmbr,C0439234;C0439508
391,year - nmbr,C0439234;C0439508
391,year,C0439234;C0439508
391,standard care slope lsm ± se ( mm / year ),C0036919;C0439234;C0439508;C0807955;C1442989;C1947933;C2828392;C4330985;C4554674
391,recurrent infections ( > nmbr per year ),C0239998;C0439234;C0439508
391,rate ( % per year ),C0439234;C0439508;C0871208;C1521828
391,rate ( % / year ),C0439234;C0439508;C0871208;C1521828
391,placebo slope lsm ± se ( mm / year ),C0032042;C0036919;C0439234;C0439508;C0807955;C1696465;C1706408;C4330985;C4554674
391,older than nmbr years,C0439234;C0580836
391,nmbr years or older,C0439234
391,nmbr years or more,C0439234
391,nmbr year or more,C0439234;C0439508
391,nmbr - yr %,C0439234
391,nmbr - year risk of chd,C0439234;C0439508;C1282512
391,nmbr - year risk for chd,C0439234;C0439508;C1282512
391,nmbr - year predicted risk ( % ) of,C0439234;C0439508
391,nmbr - year mortality,C0026565;C0026566;C0439234;C0439508
391,nmbr - year km %,C0439234;C0439508;C3887676
391,nmbr - year framingham chd risk ( % ) nmbr mean / sd ),C0439234;C0439508;C0444504;C1282512;C2347634;C2348143;C2699239;C3166866
391,nmbr - year framingham chd risk,C0439234;C0439508;C1282512;C3166866
391,nmbr - nmbr yr ( % ),C0439234
391,mean nmbr - year cvd risk *,C0007222;C0035647;C0439234;C0439508;C0444504;C2347634;C2348143;C4552904
391,mean ( se ) nmbr - year rates per nmbr population,C0036919;C0439234;C0439508;C0871208;C1521828;C2347634
391,insulin glargine slope lsm ± se ( mm / year ),C0036919;C0439234;C0439508;C0807955;C0907402;C4330985;C4554674
391,framingham nmbr - year cv risk score,C0035647;C0439234;C0439508;C0449820;C3166866;C3538987;C4048877;C4050231;C4318503;C4552904
391,difference ( n - nmbr fa - placebo ) lsm ± se ( mm / year ),C0032042;C0036919;C0439234;C0439508;C1696465;C1705241;C1705242;C1706408;C4330985;C4554674
391,difference ( glargine - standard care ) lsm ± se ( mm / year ),C0036919;C0439234;C0439508;C0907402;C1442989;C1705241;C1705242;C1947933;C2828392;C4330985;C4554674
391,baseline to year nmbr,C0168634;C0439234;C0439508;C1442488
391,> year nmbr,C0439234;C0439508
391,> nmbryears,C0439234
391,> nmbr yr — %,C0439234
391,> nmbr yr ( % ),C0439234
391,> nmbr year,C0439234;C0439508
391,> = nmbr yr,C0439234
391,> = medan ( nmbr year - old ),C0439234;C0439508;C0580836
391,< nmbryear,C0439234;C0439508
391,< nmbr year,C0439234;C0439508
391,< median ( nmbr year - old ),C0439234;C0439508;C0549183;C0580836;C0876920;C2347635;C2348144;C2939193
391,< = nmbr yr,C0439234
391,< = nmbr year,C0439234;C0439508
391,% / year,C0439234;C0439508
391,# nmbr year,C0439234;C0439508
390,years since menopause,C0439234
390,mean years since menopause,C0439234;C0444504;C2347634;C2348143
390,> nmbr yr since menopause,C0439234
390,> nmbr years to < nmbr years ( n = nmbr ),C0439234
390,> nmbr years simva ( „ = nmbr },C0439234
390,> nmbr years simva ( n = nmbr ),C0439234
390,> nmbr years nmbr / nmbr ( nmbr . nmbr ),C0439234
390,> nmbr years eze / simva baseline ldl - c,C0168634;C0439234;C1442488
390,> nmbr years eze / simva ( „ = nmbr },C0439234
390,> nmbr years eze / simva ( n = nmbr ),C0439234
390,> nmbr years baseline ldl - c,C0168634;C0439234;C1442488
390,< nmbr yr since menopause,C0439234
390,< nmbr years simva ( n = nmbr },C0439234
390,< nmbr years simva ( n = nmbr ),C0439234
390,< nmbr years eze / simva ( n = nmbr },C0439234
390,< nmbr years eze / simva ( n = nmbr ),C0439234
389,years since diagnosis of type nmbr diabetes,C0439234
389,nmbr - yr risk of coronary heart disease ( % ) ^ |,C0439234;C1277690
389,interval of > nmbr yr since diagnosis of type nmbr diabetes — no . ( % ),C0439234;C1272706;C1552654;C1552713
388,placebo group ( n = nmbr nmbr ) ( nmbr nmbr person years ),C0027361;C0032042;C0439234;C0441848;C1696465;C1706408;C2347489
388,person - years,C0027361;C0439234;C2347489
388,no . of cardiovascular events ( cardiovascular events / nmbr person - years ),C0027361;C0439234;C1320716;C2347489
388,no . / nmbr person - yr,C0027361;C0439234;C2347489
388,event rate ( per nmbr person years ),C0027361;C0439234;C0441471;C0871208;C1521828;C2347489;C4019010
388,event rate ( per nmbr person - years ),C0027361;C0439234;C0441471;C0871208;C1521828;C2347489;C4019010
388,event / patients in group ( incidence / nmbr person - year ),C0021149;C0027361;C0030705;C0220856;C0439234;C0439508;C0441471;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C2347489;C4019010
388,cardiovascular mortality ( per nmbr person - years ),C0007226;C0026565;C0026566;C0027361;C0439234;C2347489;C3887460
388,aspirin group ( n = nmbr nmbr ) ( nmbr nmbr person years ),C0004057;C0027361;C0439234;C0441848;C2347489
388,all - cause mortality ( per nmbr person - years ),C0015127;C0026565;C0026566;C0027361;C0439234;C0444868;C1524003;C2347489;C3539085
387,» nmbr yr,C0439234
387,£ nmbr yr,C0439234
387,no . of pack - yr,C0439234;C1968515;C2825051;C2828395
387,nmbrmoto < nmbr yr,C0439234
387,nmbr to nmbr yr,C0439234
387,nmbr to < nmbr yr,C0439234
387,nmbr mo to nmbr yr,C0026544;C0332177;C0439234
387,nmbr - nmbr yr,C0439234
387,ed > nmbr yr,C0439234;C3538926
387,> nmbr yr,C0439234
387,> nmbr to < nmbr yr,C0439234
387,> nmbr - nmbr yr,C0439234
387,< nmbr yr,C0439234
387,% / yr,C0439234
386,ard ( nmbr % cl ) per nmbr patient - years,C0030705;C0439234;C0596019;C1817569;C1826411
386,> nmbr years vs .   ≤   nmbr years,C0439234
386,> nmbr to   ≤   nmbr years vs .   ≤   nmbr years,C0439234
385,years with gouty arthritis,C0003868;C0439234
385,years with gout,C0018099;C0439234
385,years since symptom onset,C0439234
385,years since pd diagnosis,C0439234
385,years since pah diagnosis,C0439234
385,years since myocardial infarction,C0439234
385,years since mi ( median,C0439234
385,years since last gout flare,C0439234
385,years since diagnosis,C0439234
385,years modified hoehn and yahr stage,C0439234
385,pbo / simva - nmbryr km rale ( % ),C0031962;C0034642;C0439234;C3887676
385,nmbr yr km % ( n ),C0439234;C3887676
385,nmbr - yr km mortality rate,C0026565;C0205848;C0439234;C3887676
385,eze / simva - nmbryr km rale ( % ),C0034642;C0439234;C3887676
385,> nmbr yr from the united states,C0041703;C0439234
384,marital status,C0024819;C1716536;C3172566
383,biomarker status,C0449442
382,diabetes status,C1317301
382,diabetes mellitus status,C1317301
381,sirolimus eluting stent,C0038257;C0072980
381,sirolimus - eluting stent use,C0038257;C0042153;C0072980;C0457083;C1947944
381,sirolimus - eluting,C0072980
381,sirolimus,C0072980
380,small / medium,C0009458;C0439536;C0700321;C1705217;C3244283;C4085196;C4522282;C4522283
380,medium - or low - intensity statin,C0009458;C0439536;C1705217;C3244283;C4085196;C4522282;C4522283
380,medium,C0009458;C0439536;C1705217;C3244283;C4085196;C4522282;C4522283
379,nmbr - nmbr ( mild ),C2945599
379,mildly impaired,C0750532;C2945599
379,mild teaes,C2945599
379,mild or moderate copd,C2945599
379,mild ed,C2945599;C3538926
379,mild ( nnmbr = nmbr ) nmbr,C2945599
379,mild ( nmbr - nmbr ),C2945599
379,mild ( n = nmbr ),C2945599
379,mild ( ipss < nmbr ),C1019118;C1998280;C2827405;C2945599;C3811063
379,mild ( iief - ef nmbr - nmbr ),C2945599;C3641331
379,mild ( gold nmbr ),C0018026;C1304897;C2945599
379,mild ( fev,C2945599;C3714541
379,mild ( > nmbr to < nmbr ),C2945599
379,mild ( < nmbr ),C2945599
379,mild,C2945599
379,< mild,C2945599
378,mild or no dysfunction ( crcl > nmbr ml / min  n = nmbr nmbr  [nmbr . nmbr % ] ),C2945599
378,mild decrease in gfr ( nmbr - nmbr ml / mln per nmbr . nmbr m^ ),C0017654;C0392756;C0439526;C0547047;C1417190;C1424601;C1705224;C2945599;C3815103;C3887665
377,oxidative stress,C0242606
376,relative wall thickness,C0080103;C0205345;C0677535;C1280412;C1547039
376,relative decrease > nmbr %,C0080103;C0205345;C0392756;C0547047;C1547039
375,devices for heart failure at screening visit,C0018787;C0018801;C0018802;C0025078;C0025080;C0220819;C0231174;C0680095;C0699733;C2024216;C4554158
375,devices,C0025080;C0220819;C0699733
374,any dynamic st - segment shift,C0333051;C0429029;C0729333;C2347509
373,van der heijde mtss,C0557775;C1511780
372,d - dimer levelsatinclusion,C0060323
372,d - dimer level,C0060323;C0441889;C0456079;C1547707;C2946261
371,meddra smq,C1140263
370,middle east,C0026068
369,middle third,C0442050
368,mild to moderate,C1299392
368,mild / moderate ( ipss < nmbr ),C1019118;C1299392;C1998280;C2827405;C3811063
368,mild - to - moderate ( ipss < nmbr ),C1019118;C1299392;C1998280;C2827405;C3811063
368,mild - < moderate,C1299392
367,rivastigmine ( n = nmbr ),C0649350
367,rivastigmine,C0649350
366,grip strength > = median,C0429271;C0549183;C0876920;C2347635;C2348144;C2598165;C2939193
366,grip strength < meidan,C0429271;C2598165
365,clinical disease activity index score ( nmbr - nmbr ),C0449820;C3869583;C4050231
365,clinical disease activity index,C3869583
364,simplified disease activity index score ( nmbr - nmbr ),C0449820;C3869582;C4050231
364,simplified disease activity index score,C0449820;C3869582;C4050231
364,simplified disease activity index,C3869582
363,ptga of disease activity ( nmbr ‒ nmbr mm ),C1292728;C4330985;C4554674
363,high disease activity : > nmbr . nmbr,C0012634;C0205250;C1292728;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209;C4699623
363,disease activity],C1292728
363,disease activity ( n ( % ) ),C1292728
363,disease activity,C1292728
362,intermediate risk ( ri = nmbr ),C0035487;C1826843;C3640764
362,intermediate risk,C3640764
361,notatincreased fall risk ( n - nmbr,C1268740
361,at increased fall risk ( n - nmbr ),C0085639;C0205217;C0238715;C0442805;C1268740;C4553726;C4699158
360,sleeping problems in the past nmbr weeks ( % ),C0700201;C2987125
360,night - time awakenings in past nmbr weeks prior to baseline,C0860510;C2987125
360,night - time awakenings in past nmbr weeks ( sd ) *,C0860510;C2699239;C2987125
359,percent impairment while working due to asthma,C0221099;C0439165;C0684336
359,percent activity impairment due to asthma,C0004096;C0221099;C0439167;C0678226;C0684336;C2984299
359,mild impairment ( £ nmbr to,C0221099;C0684336;C2945599
359,mild impairment ( nmbr tonmbrml / min ),C0221099;C0439445;C0684336;C2945599
359,mild impairment ( nmbr to < nmbr ),C0221099;C0684336;C2945599
359,mild impairment,C0221099;C0684336;C2945599
358,impaired fasting glucosex,C0221099
358,impaired fasting glucose level ( n = nmbr ),C0202045;C0221099;C0441889;C0456079;C1272092;C1547707;C2946261
358,impaired fasting giucose levei ( n = nmbr ),C0221099
357,benazepril / hydrochlorothiazide - benazepril / amlodipine,C0051696;C0717481
357,amlodipine vs chlorthalidone overweight,C0051696
357,amlodipine vs chlorthalidone obese,C0051696
357,amlodipine vs chlorthalidone normal,C0051696
357,amlodipine and valsartan,C0051696
357,amlodipine / vaisartan ( n = nmbr ),C0051696
357,amlodipine / lisinopril nmbr,C0051696;C0065374
357,amlodipine / lisinopril / chlorthalidone comparison,C0008294;C0051696;C0065374;C1707455
356,amlodipine nmbrtonmbrmg ( n = nmbr ),C0024671;C0026410;C0051696;C0439269;C1960952;C2346927;C4321396;C4521761
356,amlodipine nmbrmg / v = nmbr,C0024671;C0026410;C0051696;C0439269;C1960952;C2346927;C4321396;C4521761
356,amlodipine ( n = nmbr ),C0051696
356,amlodipine,C0051696
356,! amlodipine,C0051696
355,time from pah diagnosis months,C0011900;C0030123;C0556969;C1704338;C1704656;C3203102;C4284467
355,qualifying diagnosis,C0011900;C1514624;C1704338;C1704656
355,presenting diagnosis,C0011900;C0449450;C1704338;C1704656
355,predominant cardiac diagnosis — no . ( % ),C0011900;C0018787;C1522601;C1542147;C1704338;C1704656
355,index diagnosis,C0011900;C0600653;C0918012;C1552854;C1637833;C1704338;C1704656;C2986546
355,diagnosis — yr,C0011900;C0439234;C1704338;C1704656
355,diagnosis of hefh,C0011900;C1704338;C1704656
355,diagnosis of diabetes,C0011847;C0011849;C0011900;C1704338;C1704656
355,diagnosis of allergic rhinitis,C0011900;C1334103;C1704338;C1704656;C2607914;C4552864
355,diagnosis at presentation — no . ( % ),C0011900;C0449450;C1704338;C1704656
355,diagnosis at presentation,C0011900;C0449450;C1704338;C1704656
355,diagnosis ( years ),C0011900;C0439234;C1704338;C1704656
355,diagnosis ( y ),C0011900;C1704338;C1704656
355,diagnosed,C0011900
354,patients with moderate - to - severe pain ( womac pain score,C0030705;C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
354,no moderate ckd,C0205081;C1561643;C1881878;C4049705;C4049706;C4085643;C4321335
354,no . of moderate or severe exacerbations in previous,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
354,nmbr - nmbr ( moderate ),C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
354,nmbr ( moderate disease ),C0012634;C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
354,moderately impaired,C0205081;C1881878;C4085643;C4321491
354,moderate ’,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
354,moderate trs : nmbr - nmbr ( n = nmbr,C0205081;C0266427;C0968917;C1150746;C1881878;C4049705;C4049706;C4085643;C4321335
354,moderate thrombocytopenia ( < nmbrxnmbr / l ),C0040034;C0205081;C0392386;C1881878;C4049705;C4049706;C4085643;C4321335
354,moderate teaes,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
354,moderate severity,C0205081;C0439793;C0522510;C1881878;C4049705;C4049706;C4085643;C4321335
354,moderate severe ( n = nmbr ) ( n = nmbr ),C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
354,moderate risk ( nmbr - nmbr ),C0035647;C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C4552904
354,moderate risk ( > nmbr - nmbr ),C0035647;C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C4552904
354,moderate risk,C0035647;C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C4552904
354,moderate renal impairment,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
354,moderate or severe renal disease,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
354,moderate or severe impairment,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
354,moderate or severe exacerbations in the previous year ( range ),C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
354,moderate or severe decrease in gfr { < nmbr ml / mln per nmbr . nmbr m^ ),C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
354,moderate or severe decrease in gfr ( < nmbr ml / min / nmbr . nmbr mnmbr ),C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
354,moderate or severe copd exacerbations,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
354,moderate or less airflow limitation,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
354,moderate n z nmbr,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
354,moderate impairment ( nmbr tonmbrml / min ),C0205081;C0221099;C0439445;C0684336;C1881878;C4049705;C4049706;C4085643;C4321335
354,moderate impairment ( nmbr to < nmbr ),C0205081;C0221099;C0684336;C1881878;C4049705;C4049706;C4085643;C4321335
354,moderate impairment,C0205081;C0221099;C0684336;C1881878;C4049705;C4049706;C4085643;C4321335
354,moderate disease activity : > nmbr . nmbr to < nmbr . nmbr,C0012634;C0205081;C1292728;C1513375;C1881878;C3833417;C4049705;C4049706;C4085643;C4321335
354,moderate disease,C0012634;C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
354,moderate copdb [n z nmbr],C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
354,moderate copd,C0024117;C0205081;C1412502;C1881878;C3714496;C4049705;C4049706;C4085643;C4321335
354,moderate ckd at randomization,C0034656;C0205081;C1561643;C1881878;C4049705;C4049706;C4085643;C4321335
354,moderate ckd,C0205081;C1561643;C1881878;C4049705;C4049706;C4085643;C4321335
354,moderate chronic kidney disease,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
354,moderate / severe reduction in egfr,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
354,moderate / severe exacerbations  patient subgroups  n ( % ),C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
354,moderate / severe exacerbations  itt population  n ( % ),C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
354,moderate / severe exacerbation,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
354,moderate / low,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
354,moderate - to -,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
354,moderate - < severe,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
354,moderate ( snmbr % . < nmbr % ),C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
354,moderate ( nnmbr = nmbr ),C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
354,moderate ( nmbr – nmbr ml · min − nmbr · nmbr . nmbr m − nmbr ),C0205081;C0369637;C0439445;C0441923;C1881878;C4049705;C4049706;C4085643;C4321335
354,moderate ( nmbr risk factor ),C0035648;C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
354,moderate ( nmbr < ipss < nmbr ),C0205081;C1019118;C1881878;C1998280;C2827405;C3811063;C4049705;C4049706;C4085643;C4321335
354,moderate ( nmbr - nmbr ),C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
354,moderate ( nmbr % < fev,C0205081;C1881878;C3714541;C4049705;C4049706;C4085643;C4321335
354,moderate ( nmbr % . < nmbr % ),C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
354,moderate ( n = nmbr ),C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
354,moderate ( iief - ef nmbr - nmbr ),C0205081;C1881878;C3641331;C4049705;C4049706;C4085643;C4321335
354,moderate ( gold nmbr ),C0018026;C0205081;C1304897;C1881878;C4049705;C4049706;C4085643;C4321335
354,moderate ( > nmbr to < nmbr ),C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
354,moderate ( > nmbr and < nmbr ),C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
354,moderate ( > nmbr % . < nmbr % ),C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
354,moderate,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
354,gusto moderate bleeding / ich,C0019080;C0019191;C0205081;C1881878;C3272597;C3281105;C4049705;C4049706;C4085643;C4321335
354,> nmbr - nmbr ( moderate risk ),C0035647;C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C4552904
354,> nmbr ( moderate or high bleeding risk ),C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
353,obesity t,C0028754;C1963185
353,obesity *,C0028754;C1963185
353,obesity ( % ) §,C0028754;C1963185
353,obesity,C0028754;C1963185
353,obese,C0028754
353,> nmbr kg / m^ ( obesity ),C0028754;C1532718;C1963185
352,severely impaired,C0205082
352,severe to end - stage impairment ( nmbr ml / min ),C0205082;C0205088;C0221099;C0439445;C0684336;C4050465;C4050466
352,severe teaes,C0205082;C4050465;C4050466
352,severe renal impairment,C0205082;C1565489;C4050465;C4050466
352,severe or worse airflow limitation,C0205082;C4050465;C4050466
352,severe or very severe smoking status,C0205082;C4050465;C4050466
352,severe or very severe copd,C0205082;C4050465;C4050466
352,severe or very severe,C0205082;C4050465;C4050466
352,severe or moderate,C0205082;C4050465;C4050466
352,severe oab subgroup,C0205082;C1079230;C1515021;C4050465;C4050466
352,severe n z nmbr,C0205082;C4050465;C4050466
352,severe impairment ( egfr < nmbr ),C0205082;C0221099;C0684336;C1739039;C3811844;C3812682;C4050465;C4050466
352,severe impairment ( < nmbr ),C0205082;C0221099;C0684336;C4050465;C4050466
352,severe hyperkalemiac,C0205082;C4050465;C4050466
352,severe hyperkalemia ‘ s,C0020461;C0205082;C4050465;C4050466;C4552983
352,severe hyperkalemia ' s,C0020461;C0205082;C4050465;C4050466;C4552983
352,severe exacerbations  itt population  n ( % ),C0032659;C0205082;C1257890;C4050465;C4050466;C4086268
352,severe exacerbations,C0205082;C4050465;C4050466;C4086268
352,severe ed,C0205082;C3538926;C4050465;C4050466
352,severe copdc [n z nmbr],C0205082;C4050465;C4050466
352,severe copd,C0024117;C0205082;C1412502;C3714496;C4050465;C4050466
352,severe aes,C0205082;C1412268;C2699274;C4050465;C4050466
352,severe / very severea,C0205082;C0442824;C2984081;C4050465;C4050466
352,severe / lite threatening,C0205082;C4050465;C4050466
352,severe / life ttireatening,C0205082;C0376558;C4050465;C4050466
352,severe / life threatening,C0205082;C1546953;C2826244;C3537125;C4050465;C4050466
352,severe - very severe,C0205082;C0442824;C2984081;C4050465;C4050466
352,severe ( nnmbr = nmbr ),C0205082;C4050465;C4050466
352,severe ( itt ) ( n = nmbr ),C0205082;C4050465;C4050466
352,severe ( iief - ef nmbr - nmbr ),C0205082;C3641331;C4050465;C4050466
352,severe ( iief - ef < nmbr ),C0205082;C3641331;C4050465;C4050466
352,severe ( gold nmbr ),C0018026;C0205082;C1304897;C4050465;C4050466
352,severe ( fev,C0205082;C3714541;C4050465;C4050466
352,severe ( > nmbr ),C0205082;C4050465;C4050466
352,severe,C0205082;C4050465;C4050466
352,risk of moderate / severe exacerbations,C0205082;C0332166;C4050465;C4050466;C4086268
352,primary safety end point : severe / life - threatening,C0036043;C0205082;C1546953;C1705187;C2826244;C2986535;C3537125;C4050465;C4050466
352,nmbr - nmbr ( severe ),C0205082;C4050465;C4050466
352,more severe^,C0205082;C0205172;C4050465;C4050466
352,more severe,C0205082;C0205172;C4050465;C4050466
352,mild ed severe ed,C0205082;C2945599;C3538926;C4050465;C4050466
352,less severenmbr,C0205082;C0439092;C0547044;C4050465;C4050466
352,less severe,C0205082;C0439092;C0547044;C4050465;C4050466
352,first severe asthma exacerbation,C0205082;C0205435;C0349790;C0581126;C1279901;C4050465;C4050466;C4086268
352,at least nmbr severe flare,C0205082;C1517205;C3540542;C4050465;C4050466
351,timi major bleeding,C0019080;C0205082;C0205164;C4318856;C4521762
351,previous major bleeding,C0019080;C0205082;C0205156;C0205164;C1552607;C4318856;C4521762
351,major st depression or t - wave inversion,C0036056;C0041696;C0205082;C0205164;C0520887;C1269683;C3272372;C4318856;C4521762
351,major st depression or t - wave,C0036056;C0041696;C0205082;C0205164;C0520887;C1269683;C3272372;C4318856;C4521762
351,major st depression or,C0036056;C0041696;C0205082;C0205164;C0520887;C1269683;C3272372;C4318856;C4521762
351,major secondary end pointf,C0027627;C0175668;C0205082;C0205164;C0205436;C0444930;C2746065;C4318856;C4521762
351,major or clinically relevant non - major bleeding,C0205082;C0205164;C4318856;C4521762
351,major or clinically relevant non - major bleed,C0205082;C0205164;C4318856;C4521762
351,major macrovascular events,C0205082;C0205164;C0441471;C3541888;C4318856;C4521762
351,major gl bleeding,C0018229;C0019080;C0205082;C0205164;C1423073;C1427674;C4318856;C4521762
351,major cvd /,C0007222;C0205082;C0205164;C4318856;C4521762
351,major cv event,C0205082;C0205164;C0441471;C3538987;C4019010;C4048877;C4318503;C4318856;C4521762
351,major coronary event,C0205082;C0205164;C0741923;C4318856;C4521762
351,major coronary disease event ( fatal / non - fatal mi ),C0010068;C0012634;C0205082;C0205164;C0441471;C0741923;C1302234;C1518422;C1705232;C1956346;C3810814;C4019010;C4318856;C4521762
351,major coronary,C0018787;C0205082;C0205164;C4318856;C4521762
351,major clinical response,C0205082;C0205164;C4055223;C4318856;C4521762
351,major cerebrovascular,C0205082;C0205164;C1880018;C4318856;C4521762
351,major cardiovascular events,C0205082;C0205164;C1320716;C4318856;C4521762
351,major cardiovascular event *,C0205082;C0205164;C1320716;C4318856;C4521762
351,major cardiovascular event,C0205082;C0205164;C1320716;C4318856;C4521762
351,major cardiovascular,C0007226;C0205082;C0205164;C3887460;C4318856;C4521762
351,major bleeding nmbr to nmbr,C0019080;C0205082;C0205164;C4318856;C4521762
351,major bleeding events *,C0019080;C0205082;C0205164;C0441471;C3541888;C4318856;C4521762
351,major bleeding ( mb ),C0019080;C0024853;C0205082;C0205164;C4318856;C4521762
351,major bleeding,C0019080;C0205082;C0205164;C4318856;C4521762
351,major bleed,C0019080;C0205082;C0205164;C4318856;C4521762
351,major and crnm bleeds,C0205082;C0205164;C4318856;C4521762
351,major amputationsb,C0205082;C0205164;C4318856;C4521762
351,major amputations at week nmbr,C0002688;C0205082;C0205164;C0332174;C0439230;C4318856;C4521762
351,major adverse cardiovascular events,C0007226;C0205082;C0205164;C0877248;C1705413;C3887460;C4318856;C4521762
351,major / crnm bleed,C0205082;C0205164;C4318856;C4521762
351,major,C0205082;C0205164;C4318856;C4521762
351,intracranial disease of major artery 寸,C0205082;C0205164;C0524466;C0852949;C4318856;C4521762
351,intracranial disease of major artery disease t,C0012634;C0205082;C0205164;C0752138;C4318856;C4521762
351,history of major microvascular disease,C0205082;C0205164;C0443258;C0683519;C0730226;C0850708;C0944983;C4318856;C4521762
351,history of major macrovascular disease,C0205082;C0205164;C0683519;C0730226;C0850708;C0944983;C4318856;C4521762
351,history of major cardiovascular disease,C0205082;C0205164;C0455539;C4318856;C4521762
351,history of major bleeding,C0019080;C0019664;C0019665;C0205082;C0205164;C0262512;C0262926;C1705255;C2004062;C4318856;C4521762
351,gi major bleeding,C0017181;C0205082;C0205164;C4318856;C4521762
351,combined major macrovascular events .,C0205082;C0205164;C0205195;C0441471;C3541888;C4318856;C4521762
351,combined major macrovascular events,C0205082;C0205164;C0205195;C0441471;C3541888;C4318856;C4521762
351,b major cardiovascular events,C0205082;C0205164;C1320716;C4318856;C4521762
351,as major component — no . ( % ),C0205082;C0205164;C0449432;C1705248;C4318856;C4521762
351,all major cardiovascular events,C0205082;C0205164;C1320716;C4318856;C4521762
351,> nmbr % stenosis of major artery,C0038449;C0205082;C0205164;C4318856;C4521762
351,- major bleed,C0019080;C0205082;C0205164;C4318856;C4521762
350,slnmbr mm hg,C0439475
350,nmbrto < nmbrmmhg,C0439475
350,nmbro - inmbr mm hg,C0021966;C0221138;C0439475;C0483204
350,nmbr to nmbr mm hg,C0439475
350,nmbr to < nmbrmmhg,C0439475
350,nmbr to < nmbr mm hg,C0439475
350,nmbr mm hg,C0439475
350,nmbr . nmbr to < nmbr . nmbr mmhg,C0439475
350,nmbr . nmbr to < nmbr . nmbr mm hg,C0439475
350,less than nmbr mm hg,C0439092;C0439475
350,dbp mm hg,C0439475;C0536221;C3813197;C4281799
350,^nmbr mm hg,C0439475
350,> nmbr to < nmbr mm hg,C0439475
350,> nmbr mm hg,C0439475
350,> nmbr . nmbr mm hg,C0439475
350,> nmbr - < nmbr mmhg,C0439475
350,> = nmbr mmhg,C0439475
350,> = nmbr - < nmbr mmhg,C0439475
350,< nmbr mm hg,C0439475
350,< nmbr . nmbr mm hg,C0439475
349,s nmbr mmhg,C0439475;C0565930;C2603362
349,nmbrlnmbrmmhg,C0439394;C0439475;C1706495;C3642217
349,nmbr mmhg,C0439475
349,mm hg,C0439475
349,> nmbrmmhg,C0439475
349,> nmbr mmhg,C0439475
349,< nmbrmmhg,C0439475
349,< nmbr mmhg,C0439475
348,syst . bp ( mmhg ),C0037623;C0439475;C1415692;C1708288;C4318478
348,sbp ≥ nmbr mmhg,C0085805;C0439475
348,sbp > nmbrmmhg,C0085805;C0439475
348,sbp > nmbrmm hg,C0085805;C0439475
348,sbp > nmbr mmhg or dbp > nmbr mmhg,C0085805;C0439475
348,sbp > nmbr mmhg and / or dbp > nmbr mmhg,C0085805;C0439475
348,sbp > nmbr mmhg,C0085805;C0439475
348,sbp > nmbr mm hg and / or dbp > nmbr mm hg nmbr / nmbr,C0085805;C0439475
348,sbp < nmbrmmhg,C0085805;C0439475
348,sbp < nmbrmm hg,C0085805;C0439475
348,sbp < nmbr mmhg and dbp < nmbr mmhg,C0085805;C0439475
348,sbp < nmbr mmhg,C0085805;C0439475
348,sbp < nmbr mm hg and dbp < nmbr mm hg nmbr / nmbr,C0085805;C0439475
348,pulse pressure ( mmhg ),C0439475;C0949236
348,pulse pressure ( mm hg ),C0439475;C0949236
348,nmbr to < nmbr mm hg — no . { % ),C0439475
348,mssbp > nmbrmmhg,C0439475
348,mssbp > nmbr mmhg,C0439475
348,mssbp < nmbrmmhg,C0439475
348,mssbp < nmbr mmhg,C0439475
348,mssbp ( mm hg ),C0439475
348,msdbp ( mm hg ),C0439475
348,mean bp ( mmhg ),C0037623;C0439475;C0444504;C1415692;C1708288;C2347634;C2348143;C4318478
348,map ( mmhg ),C0024779;C0439475;C1706473;C4050322
348,bp component ( mm hg ),C0037623;C0439475;C0449432;C1415692;C1705248;C1708288;C4318478
348,apasp ( per mmhg ),C0439475
348,> nmbr mm hg — no . ( % ),C0439475
348,< nmbr mm hg — no . ( % ),C0439475
347,systolic pressure — mm hg,C0439475;C0871470
347,systolic bp ( mmhg ) *,C0439475;C0871470
347,systolic bp ( mmhg ),C0439475;C0871470
347,systolic bp ( mm hg ),C0439475;C0871470
347,sitting diastolic blood pressure ( mm hg ),C0439475;C1319894
347,sitting blood pressure — mmhg,C0439475;C0580946
347,diastolic bp ( mmhg ) *,C0428883;C0439475
347,diastolic bp ( mmhg ),C0428883;C0439475
347,diastolic bp ( mm hg ),C0428883;C0439475
347,at home systolic pressure > nmbr mm hg,C0439475;C0871470;C4534363
347,at home systolic pressure < nmbr mm hg,C0439475;C0871470;C4534363
347,at home diastolic pressure > nmbr mm hg,C0428883;C0439475;C4534363
347,at home diastolic pressure < nmbr mm hg,C0428883;C0439475;C4534363
347,at clinic systolic pressure > nmbr mm hg,C0002424;C0439475;C0442592;C0871470
347,at clinic systolic pressure < nmbr mm hg,C0002424;C0439475;C0442592;C0871470
347,at clinic diastolic pressure > nmbr mm hg,C0002424;C0428883;C0439475;C0442592
347,at clinic diastolic pressure < nmbr mm hg,C0002424;C0428883;C0439475;C0442592
346,nmbr - nmbr / nmbr - nmbr mm hg,C0439475
346,mean — mm hg,C0439475;C0444504;C2347634;C2348143
346,blood pressure : systolic / diastolic ( mm hg ) ( mean,C0439475;C0444504;C2347634;C2348143;C2704328
346,> nmbr / > nmbr mm hg,C0439475
346,< nmbr / nmbr mmhg,C0439475
346,< nmbr / nmbr mm hg +,C0439475
346,< nmbr / nmbr mm hg,C0439475
346,< nmbr / < nmbr mm hg,C0439475
345,warfarin at enrollment,C0043031;C1516879;C1696073;C3888021
345,us site of enrollment,C1516879;C1696073;C2945843;C3888021
345,thienopyridine at enrollment,C1120149;C1516879;C1696073;C3888021
345,thiazide at enrollment,C0541746;C1516879;C1696073;C3888021
345,symptom onset to enrollment,C1516879;C1696073;C3888021;C4086878
345,statin at enrollment,C0360714;C1516879;C1696073;C3888021
345,reason for enrollment in active a — no . ( % ),C0392360;C1516879;C1696073;C3888021
345,reason for enrollment in active a,C0392360;C1516879;C1696073;C3888021
345,primary enrollment diagnoses,C0332137;C0801658;C1516879;C1696073;C3888021
345,pre - enrollment antihyperglycemic therapy,C0020616;C1516879;C1696073;C1882440;C3888021
345,other medications at enrollment,C0013227;C0802604;C1516879;C1696073;C2598133;C3888021;C4284232
345,medications at enrolment,C0013227;C0802604;C1516879;C1696073;C2598133;C3888021;C4284232
345,medications at enrollment,C0013227;C0802604;C1516879;C1696073;C2598133;C3888021;C4284232
345,medication use before enrollment,C0240320;C1516879;C1696073;C3888021
345,medication at enrollment — no . ( % ),C0013227;C1516879;C1696073;C3244316;C3888021;C4284232
345,medication after enrolment,C0013227;C1516879;C1696073;C3244316;C3888021;C4284232
345,laba use at enrolment,C0042153;C0457083;C1516879;C1696073;C1947944;C3888021
345,enrollment to randomization,C0034656;C1516879;C1696073;C3888021
345,enrollment by region,C0017446;C0205147;C1516879;C1696073;C3888021
345,digoxin at enrollment,C0012265;C1516879;C1696073;C3888021
345,beta - blocker at enrollment,C0001645;C1516879;C1696073;C3888021
345,aspirin at enrollment,C0004057;C1516879;C1696073;C3888021
345,arb at enrollment,C1516879;C1696073;C3888021;C3888198
345,antithrombotic use before enrollment,C0042153;C0457083;C1516879;C1696073;C1947944;C3888021
345,age at enrolment,C0001779;C1516879;C1696073;C3888021
345,age at enrollment ( years ),C1510829;C1516879;C1696073;C3888021
344,study end concentration,C0086045;C0444930;C0557651;C1446561;C2603343;C2746065;C3827302
344,serum creatinine concentration and randomization to losartan,C0010294;C0086045;C0201976;C0600061;C0683149;C1446561;C1561535;C3827302
344,patients with baseline crp concentration £ nmbr mg / l,C0030705;C0086045;C0168634;C0439268;C1442488;C1446561;C3827302;C3890735;C4048285
344,patients with baseline crp concentration < nmbr mg / l,C0030705;C0086045;C0168634;C0439268;C1442488;C1446561;C3827302;C3890735;C4048285
344,non - hdlc concentration,C0086045;C1446561;C1518422;C1704429;C3827302
344,mean baseline ibdq score ( sd ) § crp concentration,C0086045;C0168634;C1442488;C1446561;C2699239;C3533236;C3827302;C3890735;C4048285
344,ldl - c concentration,C0086045;C1446561;C3827302
344,hdlc - concentration,C0086045;C1446561;C1704429;C3827302
344,geometric mean crp concentration ( mg / l ),C0086045;C0439268;C1446561;C2986759;C3827302;C3890735;C4048285
344,geometric cnmbr concentration,C0086045;C0449829;C1446561;C3827302
344,crp concentration > nmbr mg / l,C0086045;C0439268;C1446561;C3827302;C3890735;C4048285
344,crp concentration > nmbr . nmbr mg / dl ( nmbr mg / l ),C0086045;C1446561;C2827881;C3642216;C3827302;C3890735;C4048285
344,blood leucocyte concentration ( nmbr cells per l ),C0023516;C0086045;C0347983;C0427728;C0699870;C1313904;C1446561;C3827302
344,blood eosinophil concentration,C0014467;C0086045;C0427728;C0699870;C1313904;C1446561;C3827302
344,baseline hbanmbrc concentration,C0019016;C0086045;C0168634;C1442488;C1446561;C1825777;C3538758;C3827302
344,baseline concentration,C0086045;C0168634;C1442488;C1446561;C3827302
344,baseline bnp concentration ( pg / ml ),C0054015;C0086045;C0168634;C0439297;C1095989;C1417808;C1442488;C1446561;C2982014;C3827302
343,venous insufficiency,C0042485
342,acute respiratory insufficiency,C0865850
341,sufficient,C0205410
340,jnmbr coefficient,C1707429
340,coefficient,C1707429
339,organ system involvement,C0460002;C1314939
339,nail involvement,C0027342;C1314939;C1432728;C3538766
339,involved gastrointestinal,C0521362;C1314939
339,dip involvement,C1314939;C3539618
338,non - smokers receiving lipid lowering drugs,C0337672;C4554605
338,non - smokers receiving lipid - lowering drugs,C0337672;C4554605
338,non - smokers ( at baseline ),C0168634;C0337672;C1442488;C4554605
337,non - enzyme inducing,C0014442;C1518422;C4521602
337,enzyme inducing,C0014442;C4521602
336,pancreatic cancer,C0235974;C0346647;C2984259
335,non - colorectal cancer,C0009402;C0346629;C1518422;C1527249;C2984278;C3542412
335,colorectal cancer,C0009402;C0346629;C1527249;C2984278;C3542412
334,poor compliance / noncompliance,C0032646;C0376405;C0457432
334,noncompliant,C0457432
334,non - compliance,C0376405;C0457432
333,wafarin event incidence / n,C0021149;C0220856;C0441471;C4019010
333,nmbr - year cumulative incidence,C0021149;C0220856;C0439234;C0439508;C1511559
333,incidence^,C0021149;C0220856
333,incidence of each outcome,C0021149;C0220856;C1274040
333,incidence *,C0021149;C0220856
333,incidence,C0021149;C0220856
333,factors dabigatran event incidence / n,C0021149;C0220856;C0441471;C1521761;C2348066;C2827422;C4019010
333,event incidence / n,C0021149;C0220856;C0441471;C4019010
333,cumulative incidence nmbryears,C0021149;C0220856;C0439234;C1511559
333,cumulative incidence nmbr years,C0021149;C0220856;C0439234;C1511559
333,cumulative incidence lyear,C0021149;C0220856;C1511559
333,^ ≥ nmbr % incidence in any treatment group in the overall safety population .,C0021149;C0220856;C0374505
332,qmaxi rn l / s,C2827110;C3540639;C4281819
331,qmax ( ml / s ),C0439390
331,> nmbr ml / s,C0439390
331,< nmbr ml / s,C0439390
330,sex m / f,C0009253;C0036864;C0079399;C0804628;C1306057;C1314687;C1522384
330,m / f,C1306057
329,azl - ma,C0024443;C3887485
329,> = nmbr kg / manmbr,C0022718;C0024443;C0439209;C3887485;C4054209
329,< nmbr kg / manmbr,C0022718;C0024443;C0439209;C3887485;C4054209
328,mmp - nmbr ( ng / ml ) *,C0439275;C0623362;C0919336
328,mmp - nmbr ( ng / ml ),C0439275;C0623362;C0919336
328,mmp - nmbr,C0623362;C0919336
327,no mvd ( n - nmbr,C1417507;C3272839
327,mvd ( n - nmbr,C1417507;C3272839
326,om nmbrmg / aml nmbr mg,C0023465;C0023467;C0028971;C1319635;C1705272
326,om nmbr mg / hctz nmbr mg ( n = nmbr ),C0020261;C0028971;C1319635;C1705272
326,om nmbr mg / hctz nmbr mg,C0020261;C0028971;C1319635;C1705272
326,om nmbr mg / aml nmbr mg,C0023465;C0023467;C0028971;C1319635;C1705272
326,om nmbr / aml nmbr / hctz nmbr mg,C0020261;C0023465;C0023467;C0024671;C0026410;C0028971;C0439269;C1705272;C1960952;C2346927;C4321396;C4521761
326,om nmbr / aml nmbr / hctz nmbr . nmbr mg *,C0020261;C0023465;C0023467;C0024671;C0026410;C0028971;C0439269;C1705272;C1960952;C2346927;C4321396;C4521761
326,om nmbr / aml nmbr / hctz nmbr . nmbr mg,C0020261;C0023465;C0023467;C0024671;C0026410;C0028971;C0439269;C1705272;C1960952;C2346927;C4321396;C4521761
326,om nmbr / aml nmbr /,C0023465;C0023467;C0028971;C1705272
326,om nmbr /,C0028971;C1705272
326,new om,C0028971;C0205314;C1705272
325,stent diameter < nmbr mm,C0038257;C1301886;C4330985;C4554674
325,stent diameter $ nmbr mm,C0038257;C1301886;C4330985;C4554674
325,sokolow - lyon ( mm ) *,C4330985;C4554674
325,r wave in avl ( mm ),C0429091;C0449216;C4330985;C4554674
325,ptgada ( mm ),C4330985;C4554674
325,physician global assessment ( nmbr - nmbr mm vas ),C0042815;C3536884;C3827561;C4050369;C4330985;C4554674
325,physician ' s global assessment of disease activity ( nmbr - nmbr mm vas ),C0042815;C3536884;C3827561;C4050369;C4330985;C4554674
325,phgada ( mm ),C4330985;C4554674
325,patient global assessment of pain ( vas nmbr - nmbr mm ),C0042815;C4054229;C4330985;C4554674
325,patient global assessment ( nmbr - nmbr mm vas ),C0042815;C3536884;C3827561;C4054229;C4330985;C4554674
325,patient ' s global assessment of disease activity ( nmbr - nmbr mm vas ),C0042815;C3536884;C3827561;C4054228;C4330985;C4554674
325,pain ( nmbr mm vas ),C0042815;C4330985;C4554674
325,pain ( nmbr - nmbr mm vas ),C0042815;C4330985;C4554674
325,nmbr . nmbr - nmbr . nmbr mm,C4330985;C4554674
325,nmbr - nmbr mm,C4330985;C4554674
325,nmbr - nmbr . nmbr mm,C4330985;C4554674
325,mean of jsw ( mm ),C0444504;C2347634;C2348143;C4330985;C4554674
325,lvdd ( mm ),C4330985;C4554674
325,long ( > nmbrmm ) stenting yes ( n = nmbr ),C0038257;C0205166;C1549445;C1705108;C1706317;C1710701;C2348535;C4330985;C4554674
325,> nmbr to < nmbr cells / mm^,C0007584;C0007634;C4330985;C4554674
325,> nmbr to < nmbr cells / mm ’,C0007584;C0007634;C4330985;C4554674
325,> nmbr mm ( n = nmbr ),C4330985;C4554674
325,> nmbr mm,C4330985;C4554674
325,> nmbr cells / mm^,C0007584;C0007634;C4330985;C4554674
325,> nmbr . nmbrmm,C4330985;C4554674
325,> nmbr . nmbr mm,C4330985;C4554674
325,< nmbr mm,C4330985;C4554674
325,< nmbr cells / mm^,C0007584;C0007634;C4330985;C4554674
325,< = nmbr . nmbrmm,C4330985;C4554674
324,albiglutide events / patients ( %,C0030705;C0441471;C2607479;C3541888
324,albiglutide ( n = nmbr ),C2607479
323,alprostadil n / n %,C0002335
323,alprostadil n / n,C0002335
323,alprostadil ( n = nmbr ),C0002335
322,adherence to study regimen — no . ( % ) ff,C1510802
322,adherence to study regimen — no . ( % ),C1510802
322,adherence > nmbr %,C1510802
321,plaque score ( nmbr - nmbr ),C0429153
320,aggressive ( nmbr ),C0001807;C0580822
320,aggressive ( n = nmbr ),C0001807;C0580822
319,s wave in vnmbr ( mm ),C0456681;C4301968
318,mean wall thickness ( cm ),C0677535;C4054557
317,exercise category ( % ),C3669314
316,metabolizer phenotype ( % ) §,C0031437;C1285572
315,dose adjustment n ( % ),C2826232
314,distal anastomosis ( % ),C0448964
313,kl nmbr ( % ),C1366480;C1416656;C1704887
312,hi ) ah ( % ),C0018619;C0239849;C1412082;C1412316;C1431594;C1836672;C4552857
311,fraction ( % ),C1264633;C1554103
310,strain ( % ),C0080194;C0456178;C1518614;C2987481
309,attack ( % ),C0277793;C1261512;C1304680
308,ib ( nmbr . nmbr ),C2744579;C3890035;C4283819
308,complex partial ( ib ),C0439855;C0728938;C1550516;C1704241;C2744579;C3890035;C4283819
307,ixekizumab every nmbr weeks ( n = nmbr ),C3489764
306,mitral valve disease ( n = nmbr nmbr ),C0026265;C4553832
306,aortic valve disease ( n = nmbr nmbr ),C1260873;C4553103
305,standard treatment ( n - nmbr ),C4684780
304,very elderly patients ( n - nmbr ),C0442824;C0870602;C2984081
304,elderly patients ( n — nmbr ),C0870602
303,hope patients with coronary - artery disease ( n = nmbr ),C0010054;C0010068;C0030705;C0392347;C1956346
303,hope ( n = nmbr ),C0392347
302,warfarin group ( n = nmbr ),C0043031;C0441848
302,rate - control group ( n = nmbr ),C0441848;C0489879
302,no epa group n = nmbr,C0441848
302,no - diuretics group ( n = nmbr ),C0012798;C0441848
302,nc group ( n = nmbr ),C0027964;C0028407;C0067895;C0265987;C0441848
302,lower - target group ( n = nmbr ),C0441848;C0441994;C1521840;C1548802;C2003888;C2986546
302,higher - target group ( n = nmbr ),C0205250;C0441848;C1521840;C2986546
302,group c ( n = nmbr ),C0441848
302,group b ( n = nmbr ),C0441848
302,group a ( n = nmbr ),C0441848
302,fatty acid group ( n = nmbr ),C0015684;C0441848
302,etoricoxib group ( n = nmbr nmbr ),C0441848;C0972314
302,epa group n = nmbr,C0441848
302,diuretics group ( n = nmbr ),C0012798;C0441848
302,diclofenac group ( n = nmbr nmbr ),C0012091;C0441848
302,device group ( n = nmbr ),C0025080;C0441848;C0699733
302,colesevelam hydrochloride group ( n = nmbr ),C0441848;C0541154
302,c group ( n = nmbr ),C0441848
302,benazepril - hydrochlorothiazide group ( n = nmbr ),C0441848;C0717481
302,benazepril - amlodipine group ( n = nmbr ),C0051696;C0053091;C0441848
302,aspirin group ( n = nmbr ),C0004057;C0441848
302,antiplatelet - only group ( n = nmbr ),C0205171;C0441848;C1720467
302,antiplatelet - onl group ( n = nmbr ),C0441848
301,mar ( itt ) ( n = nmbr ),C3829202;C4255469
300,nmbr early intervention ( n = nmbr ),C0242687;C1964029
299,tirofiban ( n = nmbr ),C0247025
299,heparin ± tirofiban ( n = nmbr ),C0019134;C0247025;C0770546
299,heparin plus tirofiban ( n = nmbr ),C0019134;C0247025;C0332287;C0770546
299,heparin + tirofiban ( n = nmbr ),C0019134;C0247025;C0770546
298,teriparatide n / n ( % ),C0070093
298,teriparatide ( n   =   nmbr ),C0070093
297,ularitide n / n ( % ),C0077910
297,ularitide ( n = nmbr ),C0077910
296,rotigotine n = nmbr,C1700683;C4318637
296,rotigotine ( n = nmbr ),C1700683;C4318637
295,roflumilast ( n = nmbr,C0965618
294,montelukast ( n = nmbr ),C0298130
293,post - fibrinolysis angioplasty ( n = nmbr ),C0016017;C0162577;C0687676;C1305868;C1548817;C1704687;C3469826
293,fibrinolysis ( n = nmbr ),C0016017;C1305868
292,normotensive ( n = nmbr ),C2712122
291,no colchicine ( n = nmbr ),C0009262
291,colchicine ( n = nmbr ),C0009262
290,readmission ( n = nmbr ),C1548168;C4489276
290,no readmission ( n = nmbr ),C1548168;C4489276
289,bempedoic acid ( n = nmbr ),C3659310
288,semuloparin ( n = nmbr ),C2700104
287,dalteparin ( n = nmbr ),C0206461
286,solifenacin ( n = nmbr ),C1099677
286,sildenafil ( n = nmbr ),C0529793
285,metoprolol group ( n = nmbr ),C0025859;C0441848
285,metoprolol ( n = nmbr nmbr ),C0025859
284,monitoring group ( n = nmbr ),C0150369;C0441848;C1283169
284,monitoring ( n = nmbr ),C0150369;C1283169
283,> nmbr days to nmbr year ( n = nmbr ),C0556972
282,non - carrier ( n = nmbr ),C2986416
281,entocort ec ( n = nmbr ),C1170256
280,umec nmbr . nmbr mcg ( n = nmbr ),C0439211;C3463985
280,tio inmbr mcg ( n = nmbr ),C0021966;C0221138;C0439211;C3463985
279,rnmbr + ezio ( n = nmbr ),C0687673
279,rnmbr ( n = nmbr ),C0687673
278,£ nmbr yo ( n = nmbr ),C1413296
278,< nmbr yo ( n = nmbr ),C1413296
277,ifx + aza ( n = nmbr ),C0004482;C0020823
277,ifx ( n = nmbr ),C0020823
276,oxypurinol ( n = nmbr ),C0030086
275,nebivolol ( n = nmbr ),C0068475
274,blisibimod ( n = nmbr ),C3713826
273,levosimendan ( n   = nmbr ),C0246904
272,inconsistent fao ( n [ nmbr ),C0016457;C0442809
271,colesevelam ( n = nmbr ),C0541155
270,cholecystectomy ( n = nmbr ),C0008320
269,eplerenone ( n   = nmbr ),C0961485
268,canrenone ( n z nmbr ),C0006882
267,nintedanib ( n   =   nmbr ),C2930789
267,nintedanib ( n = nmbr ),C2930789
266,risedronate n / n ( % ),C0246719
266,risedronate ( n   =   nmbr ),C0246719
266,risedronate ( n = nmbr ),C0246719
265,tdi e ' ( septal ) ( cm / sec ),C0205976;C0439392;C0442004;C2674784;C3714807
265,septal anomaly — no . ( % ),C0332447;C0442004;C1704258
264,"pre - bronchodilator fevi / fvc "" %",C0802741;C2599602;C3815113
264,fevi / fvc ( % ),C0802741;C3815113
263,electrophysiological study — no . ( % ) weight — ibj,C0850293
262,coronary risk factors — no . ( % ),C2024776
261,lone atrial fibrillation — no . ( % ) §,C0340489
260,geographic distribution - no . ( % ),C0681686
259,abdominal aortic — no . ( % ),C0003484
258,acarbose 一 no . ( % ),C0050393
257,tics — no . ( % ),C0040188;C0278076;C2169806;C3889970
256,nmbr - nmbr vr — no . ( % ),C3476815
256,< nmbr vr — no . ( % ),C3476815
255,iwqol - lite total score ( arbitrary units ) #,C0439183;C2964552
255,iwqol - lite physical score ( arbitrary units ),C0439183;C4483112
254,> nmbr ^mol / liter — no . ( % ),C0347982
254,( nmbr - sitosterol ( p . mol / l ),C0037215;C0220914;C0347982
253,nfs > nmbr . nmbr ( high ),C1555018
253,nfs < - nmbr . nmbr ( low ),C1555018
253,low nafld fibrosis score ( nfs < - nmbr . nmbr ),C0205251;C0400966;C1550472;C1555018;C1954436;C1954437;C3890211;C4048187;C4321351;C4522223
253,high nafld fibrosis score ( nfs > nmbr . nmbr ),C0205250;C0400966;C1299351;C1555018;C1954436;C1954437;C2700149;C3887512;C3889660;C4321237;C4522209
252,umec nmbr . nmbr | ig ( n = nmbr ),C0021027;C0305052;C0360506
252,tio nmbr | ig ( n = nmbr ),C0021027;C0305052;C0360506
252,sfc nmbr / nmbr | ig bid n = nmbr,C0021027;C0305052;C0360506;C4521536
252,qvanmbr nmbr / nmbr | ig od n = nmbr,C0021027;C0229089;C0305052;C0360506;C0439164;C1512019;C3273373;C3665488
252,olodaterol nmbr | ig tiotropium n = nmbr non - tiotropium n = nmbr,C0021027;C0305052;C0360506;C1518422;C4032878
252,olodaterol nmbr nmbr | ig tiotropium n = nmbr non - tiotropium n = nmbr,C0021027;C0305052;C0360506;C1518422;C4032878
252,ig ( n = nmbr ),C0021027;C0305052;C0360506
252,ff nmbr | ig ( n = nmbr ),C0021027;C0305052;C0360506;C4554348
252,ff / vi nmbr / nmbr | ig ( n = nmbr ),C0021027;C0205999;C0305052;C0360506;C4554348
251,三 nmbr to < nmbr,C0040363;C0041260;C1883351
251,≥ nmbr to < nmbr %,C0040363;C0041260;C1883351
251,nmbr to less than nmbr,C0040363;C0041260;C1883351
251,nmbr to < nmbr bpm ( n = nmbr ),C0040363;C0041260;C1883351
251,nmbr to < nmbr . nmbr %,C0040363;C0041260;C1883351
251,nmbr to < nmbr ( % ),C0040363;C0041260;C1883351
251,nmbr to < nmbr,C0040363;C0041260;C1883351
251,nmbr nmbr . nmbr ( nmbr . nmbr ) [nmbr ( nmbr . nmbr ) ] nmbr . nmbr ( - nmbr . nmbr to nmbr . nmbr ) [nmbr . nmbr ( - nmbr . nmbr to nmbr . nmbr ) ],C0040363;C0041260;C1883351
251,nmbr nmbr . nmbr ( nmbr . nmbr ) [nmbr ( nmbr . nmbr ) ] - nmbr . nmbr ( - nmbr . nmbr to nmbr . nmbr ) [ - nmbr . nmbr ( - nmbr . nmbr to nmbr . nmbr ) ],C0040363;C0041260;C1883351
251,nmbr nmbr . nmbr ( nmbr . nmbr ) [nmbr ( nmbr . nmbr ) ] - nmbr . nmbr ( - nmbr . nmbr to - nmbr . nmbr ) [ - nmbr . nmbr ( - nmbr . nmbr to - nmbr . nmbr ) ] - nmbr . nmbr ( nmbr . nmbr ) [ - nmbr . nmbr ( nmbr . nmbr ) ],C0040363;C0041260;C1883351
251,nmbr nmbr . nmbr ( nmbr . nmbr ) [nmbr ( nmbr . nmbr ) ] - nmbr . nmbr ( - nmbr . nmbr to - nmbr . nmbr ) [ - nmbr . nmbr ( - nmbr . nmbr to - nmbr . nmbr ) ],C0040363;C0041260;C1883351
251,nmbr . nmbr to nmbr . nmbr ( % ),C0040363;C0041260;C1883351
251,nmbr . nmbr to nmbr . nmbr %,C0040363;C0041260;C1883351
251,nmbr . nmbr to nmbr . nmbr,C0040363;C0041260;C1883351
251,> nmbrto < nmbr uln,C0040363;C0041260;C1519815;C1883351
251,> nmbr to s nmbr yrs,C0040363;C0041260;C1883351
251,> nmbr to nmbr,C0040363;C0041260;C1883351
251,> nmbr to < nmbr egfr,C0040363;C0041260;C1739039;C1883351;C3811844;C3812682
251,> nmbr to < nmbr,C0040363;C0041260;C1883351
251,> nmbr . nmbrto < nmbr . nmbr %,C0040363;C0041260;C1883351
251,> nmbr . nmbr to < nmbr . nmbr,C0040363;C0041260;C1883351
251,> nmbr % to < nmbr %,C0040363;C0041260;C1883351
251,> - nmbr . nmbr to < - nmbr . nmbr,C0040363;C0041260;C1883351
251,$ nmbr to,C0040363;C0041260;C1883351
250,— b - h —,C0033727;C0369286;C0441932;C0564385;C4528284
250,within nmbr h after,C0033727;C0369286;C0441932;C0564385;C4528284
250,within nmbr h,C0033727;C0369286;C0441932;C0564385;C4528284
250,use of hnmbr bloekers,C0033727;C0369286;C0441932;C0564385;C1524063;C4528284
250,urgency episodes / nmbrh,C0033727;C0332189;C0369286;C0439609;C0441932;C0564385;C4528284
250,sbp ( mean over nmbr h ),C0033727;C0085805;C0369286;C0441932;C0444504;C0564385;C2347634;C2348143;C4528284
250,ptca < nmbr h,C0033727;C0369286;C0441932;C0564385;C2936173;C4528284
250,pre - h,C0033727;C0332152;C0369286;C0441932;C0564385;C0740175;C2257086;C3669034;C4528284
250,nocturia episodes / nmbrh,C0028734;C0033727;C0332189;C0369286;C0441932;C0564385;C4528284
250,nmbr — e - h,C0033727;C0369286;C0441932;C0564385;C4528284
250,nmbr to < nmbr h,C0033727;C0369286;C0441932;C0564385;C4528284
250,nmbr - nmbrh,C0033727;C0369286;C0441932;C0564385;C4528284
250,nmbr - h pmg ( mg / dl ),C0033727;C0369286;C0439269;C0441932;C0564385;C4528284
250,nmbr - h pmg,C0033727;C0369286;C0441932;C0564385;C4528284
250,micturitions / nmbrh,C0033727;C0042034;C0369286;C0441932;C0564385;C4528284
250,mean nmbr - h sbp *,C0033727;C0085805;C0369286;C0441932;C0444504;C0564385;C2347634;C2348143;C4528284
250,mean nmbr - h dbp +,C0033727;C0369286;C0441932;C0444504;C0536221;C0564385;C2347634;C2348143;C3813197;C4281799;C4528284
250,incontinence episodes / nmbrh,C0021167;C0033727;C0332189;C0369286;C0441932;C0564385;C4528284
250,in - h,C0033727;C0369286;C0441932;C0564385;C4528284
250,i - h,C0021966;C0033727;C0221138;C0369286;C0441932;C0564385;C4528284
250,hnmbr receptor antagonist,C0033727;C0369286;C0441932;C0564385;C4528284;C4543207
250,hnmbr blocker ( n,C0033727;C0369286;C0441932;C0564385;C4528284
250,hnmbr - receptor antagonist,C0033727;C0369286;C0441932;C0564385;C4528284;C4543207
250,h,C0033727;C0369286;C0441932;C0564385;C4528284
250,first dose admin . nmbr - nmbrh / nmbr - nmbrh post onset of symptoms,C0033727;C0205435;C0369286;C0439568;C0441932;C0564385;C1279901;C4084955;C4086878;C4528284
250,dbp ( mean over nmbr h ),C0033727;C0369286;C0441932;C0444504;C0536221;C0564385;C2347634;C2348143;C3813197;C4281799;C4528284
250,baseline nmbr - h ppg,C0033727;C0168634;C0369286;C0441932;C0564385;C1418888;C1442488;C4528284
250,b + h ( n = nmbr ),C0033727;C0369286;C0441932;C0564385;C4528284
250,after nmbr h,C0033727;C0369286;C0441932;C0564385;C4528284
250,> nmbrh,C0033727;C0369286;C0441932;C0564385;C4528284
250,> nmbr to < nmbr h,C0033727;C0369286;C0441932;C0564385;C4528284
250,> nmbr h,C0033727;C0369286;C0441932;C0564385;C4528284
250,> = nmbrh,C0033727;C0369286;C0441932;C0564385;C4528284
250,< nmbrh,C0033727;C0369286;C0441932;C0564385;C4528284
250,< nmbr h,C0033727;C0369286;C0441932;C0564385;C4528284
249,symptom onset to hospital arrival,C0019994;C1510665;C1555577;C1706079;C4086878
249,symptom onset to arrival in catheterization laboratory,C1555577;C1706079;C4086878
249,randomization to arrival in catheterization laboratory,C0034656;C1555577;C1706079
248,spondylitis with peripheral arthritis,C0038012;C0238694
248,asymmetric peripheral arthritis,C0238694;C0332514
247,previous pdenmbr inhibitors,C0031638;C0205156;C1552607
247,pdenmbr inhibitors,C0031638
247,pdenmbr inhibitor monotherapy,C0031638
246,time from hospital admission to pci,C0019994;C0040223;C1510665;C1959907;C3541383
246,time from hospital admission to enrollment,C0019994;C0040223;C1510665;C1959907;C3541383
246,pre - hospital,C0019994;C0332152;C0740175;C1510665;C2257086;C3669034
246,pci - hospital,C0019994;C1510665;C4049621
246,non - pci hospital / ambulance,C0002422;C0019994;C1510665;C1518422;C3846685;C4049621
246,in - hospital,C0019994;C1510665
246,hospital factor # nmbr,C0019994;C1510665;C1521761;C2827422
246,duration from hospital admission to pci,C0019994;C0449238;C1510665;C1959907;C2926735
245,visits nmbrenmbr,C0545082;C1512346;C2826704
245,visit nmbr sbp,C0085805;C0545082;C1512346;C2826704
245,visit nmbr ldl cholesterol strata,C0023824;C0202117;C0545082;C1512346;C2826704
245,visit nmbr dbp,C0536221;C0545082;C1512346;C2826704;C3813197;C4281799
245,visit,C0545082;C1512346;C2826704
245,sbp at visit nmbr,C0085805;C0545082;C1512346;C2826704
245,no . with visit,C0545082;C1512346;C2826704
245,ed visit related to exacerbation,C0545082;C1512346;C2826704;C3538926
245,dbp at visit nmbr,C0536221;C0545082;C1512346;C2826704;C3813197;C4281799
244,hospitalized without airway compromise,C0701159;C4055482
244,airway compromise,C4055482
243,high - school graduate or ged,C0870649;C1549971
243,high - school graduate,C0870649;C1549971
242,tpm - naive,C0076829
242,tpm - exposed,C0076829
242,topiramate,C0076829
241,total sample = nmbr ( % ),C0370003;C0439175;C0439810;C2347026
241,sample sizea,C0370003;C2347026
241,atwo ‐ sample t ‐ test .,C0370003;C0871472;C2347026
241, geometric mean with nmbr % confidence interval in parenthesis .,C0000723;C0023128;C0162864;C0205098;C0205448;C0225897;C0334121;C0370003;C0731033;C0871472;C1256463;C1280412;C1704614;C1707455;C1739039;C1881413;C2347026;C3811844;C3812682;C4318736
240,troponin positive ( n = nmbr ),C0041199;C0439178;C1446409;C1514241;C2825490;C3812269
240,ruled out non - fatal pe with or,C1446409
240,rf positive ( > nmbr iu / ml ),C0035448;C0201660;C0439178;C0439458;C0748398;C1446409;C1514241;C1547111;C2825490;C3812269
240,rf positive,C0035448;C0201660;C0439178;C0748398;C1446409;C1514241;C1547111;C2825490;C3812269
240,rf - positive,C0035448;C0201660;C0439178;C0748398;C1446409;C1514241;C1547111;C2825490;C3812269
240,positive vs . negative,C0439178;C1446409;C1514241;C2825490;C3812269
240,positive troponin or ck - mb,C0041199;C0439178;C1446409;C1514241;C2825490;C3812269
240,positive troponin i or t,C0077401;C0439178;C1446409;C1514241;C2825490;C3812269
240,positive hla - bnmbr status,C0019737;C0439178;C0449438;C0550853;C1415561;C1446409;C1514241;C2825490;C3812269
240,positive for rheumatoid factor — no . ( % ) : t,C0035448;C0201660;C0439178;C1446409;C1514241;C2825490;C3812269
240,positive for rheumatoid factor,C0035448;C0201660;C0439178;C1446409;C1514241;C2825490;C3812269
240,positive for hla - bnmbr,C0019737;C0439178;C0550853;C1415561;C1446409;C1514241;C2825490;C3812269
240,positive ctnl ( n = nmbr ),C0439178;C1446409;C1514241;C2825490;C3812269
240,positive atopic status,C0392707;C0439178;C0449438;C1446409;C1514241;C2825490;C3812269
240,positive,C0439178;C1446409;C1514241;C2825490;C3812269
240,low complement / anti - dsdna positive ( n = nmbr ),C0012854;C0311474;C0432633;C0439178;C1446409;C1514241;C2825490;C3812269;C3897137
240,hla ‐ bnmbr positive,C0019737;C0439178;C0550853;C1415561;C1446409;C1514241;C2825490;C3812269
240,hla - bnmbr positive at baseline,C0019737;C0168634;C0439178;C0550853;C1415561;C1442488;C1446409;C1514241;C2825490;C3812269
240,hla - bnmbr positive,C0019737;C0439178;C0550853;C1415561;C1446409;C1514241;C2825490;C3812269
240,gad positive — no . ( % ) ^,C0270549;C0439178;C1414925;C1446409;C1514241;C2825490;C3812269
240,anticyclic citrullinated peptide positive^,C0439178;C1320283;C1446409;C1514241;C2825490;C3812269
240,anti - gad positive ( n = nmbr ),C0270549;C0432633;C0439178;C1414925;C1446409;C1514241;C2825490;C3812269
240,anti - gad positive,C0270549;C0439178;C1414925;C1446409;C1514241;C2825490;C3812269
240,anti - dsdna positive,C0439178;C0741099;C1446409;C1514241;C2825490;C3812269
240,anti - ccp positive ( > nmbr u / ml ),C0439178;C0439340;C1446409;C1514241;C1880521;C2825490;C2945590;C3812269;C4318437
240,anti - ccp positive,C0439178;C1446409;C1514241;C2825490;C3812269;C4318437
240,acpa positive ( > nmbr iu / ml ),C0439178;C0439458;C1446409;C1514241;C1525410;C1706063;C2825490;C3812269
240,acpa positive,C0439178;C1446409;C1514241;C1525410;C1706063;C2825490;C3812269
240,* * positive stress test,C0015260;C0439178;C1446409;C1514241;C2825490;C3494508;C3812269
239,russia and georgia,C0035970
239,russia / ukraine / belarus,C0006539;C0035970;C0041580
239,russia / georgia ( n = nmbr ),C0017452;C0017454;C0035970
239,russia / georgia,C0017452;C0017454;C0035970
238,russia,C0035970
238,rsnmbr ( cc ) & rsnmbr,C0008318;C0035970;C3538933;C3714753;C3813325
238,rsnmbr ( ac ) & rsnmbr,C0001246;C0003354;C0035970;C1412573;C2000891;C3539770;C3714753;C3813325
238,rsnmbr ( aa ) & rsnmbr,C0035970;C0282379;C1235746;C1882141;C3714753;C3813325;C4554792
238,rsnmbr & rsnmbr,C0035970;C3714753;C3813325
238,rsnmbr,C0035970;C3714753;C3813325
238,rs - totala,C0035970;C3714753;C3813325
238,rs - chest symptomsd,C0035970;C0817096;C1527391;C3714753;C3813325
238,rs - breathlessnessb,C0035970;C3714753;C3813325
238,e - rs total scoreb,C0035970;C0439175;C0439810;C3714753;C3813325
237,rnmbr,C0205090;C0684010;C2603358
237,right ventriculardysfunction atinclusion,C0205090;C0444532
237,right,C0205090;C0444532
237,r | r ' ' ' ( nmbr % ci ),C0008107;C0205090;C0684010;C2603358;C3259781
237,r ight coronary,C0205090;C0684010;C2603358
237,r ight coronar y artery,C0003842;C0205090;C0226004;C0684010;C2603358
237,r,C0205090;C0684010;C2603358
237,> < nmbr . nmbr  < nmbr . nmbr  r < mmse = mini - mental ,C0205090;C0451306;C0684010;C2603358
236,self - rated health status,C0018759;C0036588;C0871208;C1551994
235,unadjusted nmbr - y risk per nmbr population = se ( adjusted rate ),C0036919;C0242444;C0456081;C0871208;C1439367;C1521828;C2987720
235,rosuvastatin of patients ( rate ),C0030705;C0871208;C0965129;C1521828
235,rosuvastatin n ( rate ) nmbr,C0871208;C0965129;C1521828
235,rosuvastatin n ( rate ) *,C0871208;C0965129;C1521828
235,rosuvastatin n ( rate ),C0871208;C0965129;C1521828
235,rates,C0871208;C1521828
235,rate ‡,C0871208;C1521828
235,rate †,C0871208;C1521828
235,rate of sares,C0871208;C1521828
235,rate of non - progression ( defined as cfb in mtss £ nmbr . nmbr ),C0871208;C1521828;C3839460
235,rate of non - progression ( defined as cfb in mtss £ nmbr ),C0871208;C1521828;C3839460
235,rate in all participants,C0679646;C0871208;C1521828
235,rate difference ( lebrikizumab - placebo ),C0032042;C0871208;C1521828;C1696465;C1705241;C1705242;C1706408;C2981360
235,rate difference ( events / year ),C0439234;C0439508;C0441471;C0871208;C1521828;C1705241;C1705242;C3541888
235,rate / nmbr pyo,C0033809;C0871208;C1521828
235,rate * ( n ),C0871208;C1521828
235,rate *,C0871208;C1521828
235,rate,C0871208;C1521828
235,proportion of > = nmbr % responder rates,C0871208;C1521828;C1709707
235,nmbr yr . km rate,C0439234;C0871208;C1521828;C3887676
235,nmbr - yr rate / nmbr participants,C0439234;C0679646;C0871208;C1521828
235,nmbr - y rate per nmbr persons ( se ),C0027361;C0036919;C0871208;C1521828
235,nmbr - y kaplan - meier rate ( nmbr % ci ),C0008107;C0871208;C1521828;C3259781
235,nmbr - wk kaplan - meier rate,C0332174;C0439230;C0871208;C1521828
235,km rates { % ) p / s,C0234833;C0722388;C0871208;C1521828;C3887676
235,km rates { % ) e / s,C0871208;C1521828;C3887676
235,km rate ( % ),C0871208;C1521828;C3887676
235,km event rate ( % ),C0441471;C0871208;C1521828;C3887676;C4019010
235,kaplan - meier rates,C0871208;C1521828
235,k ( rate ),C0597277;C0871208;C1521828;C1708601
235,health - care use rate ( peryear ),C0814514;C0871208;C1521828
235,filtration rate nmbr - nmbr,C0016107;C0871208;C1521828
235,crude rate,C0871208;C1521828
235,adjusted rate of fevnmbr   decline ( se ),C0036919;C0456081;C0871208;C1521828;C3714541
235,> nmbr % responder rate,C0871208;C1521828
235,* rate is number of events per nmbr patient - years of follow - up . fthe p value for number of patients from log - rank,C0871208;C1521828
234,total cholesterolnmbr > nmbr mg / dl,C0201950;C0439269;C0543421
234,total cholesterolnmbr < nmbr mg / dl,C0201950;C0439269;C0543421
234,total cholesterol — mg / dl,C0201950;C0439269;C0543421
234,total cholesterol > nmbr mg / dl,C0201950;C0439269;C0543421
234,total cholesterol - mg / dl * *,C0201950;C0439269;C0543421
234,total cholesterol ( mg / dl ),C0201950;C0439269;C0543421
234,"total cholesterol  mg / dl "" ^",C0201950;C0439269;C0543421
234,toial cholcsierol ( mg / dl ),C0439269
234,lipid levels — mg / dlj total cholesterol,C0024671;C0026410;C0201950;C0428460;C0439269;C0543421;C1960952;C2346927;C4321396;C4521761
234,lipid levels — mg / dl,C0428460;C0439269
233,plasma lipids ( mg / dl ) nmbr total cholesterol mean,C0023779;C0439269;C0444504;C0858034;C2347634;C2348143
233,plasma cholesterol — mg / dl,C0439269;C0858034
232,beam   <   nmbr   mg / dl at week nmbr,C0332174;C0338248;C0439230;C0439269;C2347880;C4521565
232,beam values ( mg / dl ),C0042295;C0338248;C0439269;C2347880;C4521565
231,patients with low ( < nmbr mg / dl ) cnmbr,C0030705;C0205251;C0439269;C1550472;C3890211;C4048187;C4321351;C4522223
231,non - hdl - c ( mg / dl ) * *,C0439269;C1518422;C3715113
231,non - hdl - c ( mg / dl ),C0439269;C1518422;C3715113
231,non - hdl ( mg / dl ) < nmbr,C0439269;C1518422;C3715113
231,metsyn with ldl > nmbr . nmbr mg / dl,C0439269
231,ldl - c nmbr - nmbr mg / dl,C0439269
231,ldl - c > nmbr mg / dl,C0439269
231,ldl - c < nmbrmg / dl,C0439269
231,ldl - c < nmbr mg / dl,C0439269
231,ldl - c ( mg / dl ) < nmbr,C0439269
231,ldl - c ( mg / dl ) * *,C0439269
231,ldl - c ( mg / dl ),C0439269
231,impaired fasting glucose ( > nmbr mg / dl ) ( % ),C0439269;C1272092
231,hdl < nmbr mg / dl,C0439269;C3715113
231,hdl - c < nmbrmg / dl . n ( % ),C0439269;C3715113
231,hdl - c < nmbr mg / dl_,C0439269;C3715113
231,hdl - c < nmbr mg / dl,C0439269;C3715113
231,hdl - c ( mg / dl ) *,C0439269;C3715113
231,hdl - c ( mg / dl ),C0439269;C3715113
231,hdl ( mg / dl ),C0439269;C3715113
230,women : < nmbr mg / dl ( < nmbr . nmbr mmol / l ),C0043210;C0439269;C1532563
230,triglycerides > nmbr mg / dl ( > nmbr . nmbr mmol / l ),C0041004;C0439269;C1532563
230,triglycerides $ nmbr mg / dl ( nmbr . nmbr mmol / l ),C0041004;C0439269;C1532563
230,nmbrst tertile ( < = nmbr mg / dl [ < = nmbr . nmbr mmol / l] ) b,C0036056;C0439269;C1532563;C3272372
230,nmbrnd tertile ( > nmbr to < = nmbr mg / dl [ > nmbr . nmbr to < = nmbr . nmbr mmol / l] ) c,C0439269
230,mg / dl fpg ( mmol / l ),C0439269;C1532563
230,men : < nmbr mg / dl ( < nmbr . nmbr mmol / l ),C0025266;C0439269;C1532563
230,ldl - c < nmbr mg / dl ( nmbr . nmbr mmol / l ),C0439269;C1532563
230,hdl - c > nmbr mg / dl ( nmbr . nmbr mmol / l ),C0439269;C1532563;C3715113
230,fc > nmbr mg / dl ( > _ nmbr . nmbr mmol / l ) or history of diabetes,C0439269;C1532563;C2983605
230,> nmbr mg / dl ( > nmbr . nmbr mmol / l ) + +,C0439269;C1532563
230,< nmbr mg / dl ( < nmbr . nmbr mmol / l ),C0439269;C1532563
230,( $ nmbr mg / dl [nmbr . nmbr mmol / l] ),C0439269;C1532563
229,≥ nmbr to < nmbr mg / dl,C0439269
229,≥ nmbr mg / dl,C0439269
229,£ nmbr mg / dl,C0439269
229,tgs ( mg / dl ),C0439269;C1156212;C1537574
229,tg mg / dl,C0337445;C0439269
229,tg > nmbr mg / dl,C0337445;C0439269
229,tg ( mg / dl ),C0337445;C0439269
229,tc ( mg / dl ),C0039411;C0040642;C0041405;C0041698;C0439269;C1824670;C3272447;C4522122
229,rf ( mg / dl ),C0035448;C0201660;C0439269;C0748398;C1547111
229,nmbr to < nmbr mg / dl,C0439269
229,nmbr nmbr mg / dl,C0439269
229,nmbr mg / dl,C0439269
229,nmbr - nmbr mg / dl *,C0439269
229,nmbr - nmbr mg / dl,C0439269
229,mg / dl,C0439269
229,fsg ( mg / dl ),C0439269
229,fpg ( mg / dl ) x,C0439269
229,fpg ( mg / dl ),C0439269
229,fbs > = nmbr mg / dl,C0439269;C3812213
229,fbs < nmbr mg / dl,C0439269;C3812213
229,fbg ( mg / dl ),C0439269
229,bun ( mg / dl ),C0439269
229,apolipoprotein b ( mg / dl ),C0003593;C0439269
229,apob ( mg / dl ),C0003593;C0439269;C3252643
229,apoal ( mg / dl ) *,C0439269
229,apo b ( mg / dl ) * *,C0003593;C0439269;C3252643
229,apo b ( mg / dl ),C0003593;C0439269;C3252643
229,> nmbr to < nmbr mg dl,C0439269
229,> nmbr to < nmbr mg / dl,C0439269
229,> nmbr mg dl,C0439269
229,> nmbr mg / dl — %,C0439269
229,> nmbr mg / dl simva nmbr = nmbr],C0439269
229,> nmbr mg / dl simva ( „ = nmbr ),C0439269
229,> nmbr mg / dl simva,C0439269
229,> nmbr mg / dl eze / simva nmbr = nmbr },C0439269
229,> nmbr mg / dl eze / simva ( „ = nmbr ),C0439269
229,> nmbr mg / dl eze / simva,C0439269
229,> nmbr mg / dl,C0439269
229,> nmbr & < nmbr mg / dl,C0439269
229,> = nmbrmg / dl,C0439269
229,< nmbr mg / dl simva ( n = nmbr],C0439269
229,< nmbr mg / dl simva ( n = nmbr ),C0439269
229,< nmbr mg / dl simva,C0439269
229,< nmbr mg / dl eze / simva ( n = nmbr },C0439269
229,< nmbr mg / dl eze / simva ( n = nmbr ),C0439269
229,< nmbr mg / dl eze / simva,C0439269
229,< nmbr mg / dl *,C0439269
229,< nmbr mg / dl,C0439269
229,( mg / dl ± sd ),C0439269;C2699239
229,( mg / dl ),C0439269
228,crp > nmbr mg / nmbr,C0024671;C0026410;C0439269;C1960952;C2346927;C3890735;C4048285;C4321396;C4521761
228,crp > nmbr . nmbr mg / dl,C0439269;C3890735;C4048285
228,crp ( mg / dl ) < nmbr . nmbr,C0439269;C3890735;C4048285
228,crp ( mg / dl ) * *,C0439269;C3890735;C4048285
228,crp ( mg / dl ),C0439269;C3890735;C4048285
228,> nmbr . nmbr mg / dl,C0439269
228,< nmbr . nmbr mg / dl,C0439269
227,uric acid tertile nmbr ( nmbr . nmbr to < nmbr . nmbr mg / dl ),C0041980;C0439269
227,uric acid tertile nmbr ( > nmbr . nmbr mg / dl ),C0041980;C0439269
227,uric acid tertile nmbr ( < nmbr . nmbr mg / dl ),C0041980;C0439269
227,uric acid fertile nmbr ( > nmbr . nmbr mg / dl ),C0015895;C0041980;C0439269
227,uric acid ( mg / dl ),C0041980;C0439269
227,triglycerides — mg / dl^,C0041004;C0439269
227,triglycerides — mg / dl | |,C0041004;C0439269
227,triglycerides — mg / dl,C0041004;C0439269
227,triglycerides > nmbr mg / dl,C0041004;C0439269
227,triglycerides - mg / dl * *,C0041004;C0439269
227,triglycerides * ( mg / dl ),C0041004;C0439269
227,triglycerides ( mg / dl ) * *,C0041004;C0439269
227,triglycerides ( mg / dl ),C0041004;C0439269
227,triglyceride ( mg / dl ) nmbr,C0041004;C0439269
227,triglyceride ( mg / dl ),C0041004;C0439269
227,plasma triglyceride — mg / dl,C0032105;C0041004;C0439269;C1550098;C4521445
227,nmbr . nmbr mg / dl triglycerides^,C0041004;C0439269
227,median triglyceride ( mg / dl ),C0041004;C0439269;C0549183;C0876920;C2347635;C2348144;C2939193
227,hdl cholesterol — mg / dl triglycerides — mg / dl,C0023822;C0024671;C0026410;C0041004;C0392885;C0439269;C1960952;C2346927;C3539687;C4321396;C4521761
227,glucose — mg / dl,C0017725;C0439269
227,glucose ( mg / dl ),C0017725;C0439269
227,fasting glucose — mg / dl,C0015663;C0017725;C0439269
227,fasting glucose > nmbr mg / dl *,C0015663;C0017725;C0439269
227,fasting glucose > nmbr mg / dl,C0015663;C0017725;C0439269
227,fasting glucose ( mg / dl ),C0015663;C0017725;C0439269
226,week nmbr — mg / liter^,C0024671;C0026410;C0332174;C0439230;C0439269;C0475211;C1960952;C2346927;C4321396;C4521761
226,week nmbr — mg / liter,C0024671;C0026410;C0332174;C0439230;C0439269;C0475211;C1960952;C2346927;C4321396;C4521761
226,week nmbr ertugliflozin nmbr   mg vs . placebo,C0024671;C0026410;C0332174;C0439230;C0439269;C1960952;C2346927;C4079805;C4321396;C4521761
226,week nmbr ertugliflozin nmbr mg vs placebo,C0024671;C0026410;C0332174;C0439230;C0439269;C1960952;C2346927;C4079805;C4321396;C4521761
226,week nmbr ertugliflozin nmbr mg vs . placebo,C0024671;C0026410;C0332174;C0439230;C0439269;C1960952;C2346927;C4079805;C4321396;C4521761
226,vonoprazan nmbr mg n = nmbr,C0024671;C0026410;C0439269;C1960952;C2346927;C4080009;C4321396;C4521761
226,vildagliptin nmbr mg daily + glimepiride,C0024671;C0026410;C0061323;C0332173;C0439269;C1570906;C1960952;C2346927;C4321396;C4521761
226,viidagliptin nmbr mg daily + glimepiride,C0024671;C0026410;C0061323;C0332173;C0439269;C1960952;C2346927;C4321396;C4521761
226,vi nmbr mg ( n = nmbr ),C0024671;C0026410;C0205999;C0439269;C1960952;C2346927;C4321396;C4521761
226,uric acid ( mg / dl ) creatinine clearance ( ml / min per nmbr . nmbr mnmbr ),C0024671;C0026410;C0041980;C0151280;C0369637;C0439269;C0441923;C1960952;C2346927;C3642208;C4321396;C4521761
226,upa nmbrmg qd,C0024671;C0026410;C0042071;C0332173;C0439269;C1706177;C1960952;C2346927;C4321396;C4521761
226,upa nmbr mg qd,C0024671;C0026410;C0042071;C0332173;C0439269;C1706177;C1960952;C2346927;C4321396;C4521761
226,u » c » ( mg / g ),C0024671;C0026410;C0439148;C0439267;C0439269;C1300563;C1532633;C1638407;C1960952;C2346927;C2608091;C4321396;C4521761
226,toricoxib nmbr mg n = nmbr ) ( % ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
226,tofacitinib nmbr mg two times a day,C0024671;C0026410;C0439269;C1960952;C2346927;C2930696;C4321396;C4521761
226,tofacitinib nmbr mg twice daily n = nmbr,C0024671;C0026410;C0439269;C0585361;C1960952;C2346927;C2930696;C4321396;C4521761
226,tofacitinib nmbr mg bid [n = nmbr |,C0024671;C0026410;C0439269;C1960952;C2346927;C2930696;C4321396;C4521761
226,tofacitinib nmbr mg bid ( n   = nmbr ),C0024671;C0026410;C0439269;C1960952;C2346927;C2930696;C4321396;C4521761
226,tofacitinib nmbr mg bid ( n = nmbr ),C0024671;C0026410;C0439269;C1960952;C2346927;C2930696;C4321396;C4521761
226,tiotropium nmbrmg ( n = nmbr,C0024671;C0026410;C0213771;C0439269;C1960952;C2346927;C4321396;C4521761
226,tiotropium nmbrmg,C0024671;C0026410;C0213771;C0439269;C1960952;C2346927;C4321396;C4521761
226,tiotropium nmbr mg respimat ® ( n z nmbr ),C0024671;C0026410;C0213771;C0439269;C1960952;C2346927;C4321396;C4521761
226,tiotropium nmbr mg respimat ® ( n = nmbr ),C0024671;C0026410;C0213771;C0439269;C1960952;C2346927;C4321396;C4521761
226,tiotropium nmbr mg ( n = nmbr ),C0024671;C0026410;C0213771;C0439269;C1960952;C2346927;C4321396;C4521761
226,tiotropium nmbr mg,C0024671;C0026410;C0213771;C0439269;C1960952;C2346927;C4321396;C4521761
226,tiotropium nmbr . nmbr mg,C0024671;C0026410;C0213771;C0439269;C1960952;C2346927;C4321396;C4521761
226,tiotropium / olodaterol nmbr / nmbr mg ( n = nmbr ),C0024671;C0026410;C0439269;C1960952;C2346927;C4032878;C4321396;C4521761
226,tiotropium / olodaterol nmbr / nmbr mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4032878;C4321396;C4521761
226,tiotropium / olodaterol nmbr . nmbr / nmbr mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4032878;C4321396;C4521761
226,tiotropium + olodaterol nmbr / nmbr mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4032878;C4321396;C4521761
226,tiotropium + olodaterol nmbr . nmbr / nmbr mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4032878;C4321396;C4521761
226,tcz - sc nmbr mg every other week ( n = nmbr ),C0024671;C0026410;C0282380;C0439269;C1960952;C2346927;C4321396;C4521761
226,t nmbr . nmbr mg,C0024671;C0026410;C0439269;C1960952;C2346927;C2603360;C4321396;C4521761
226,sotagliflozin nmbr mg ( n = nmbr ),C0024671;C0026410;C0439269;C1960952;C2346927;C3896939;C4321396;C4521761
226,sita nmbr mg ( n = nmbr ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
226,sirukumab nmbr mg qnmbrw,C0024671;C0026410;C0439269;C1960952;C2346927;C3254570;C4321396;C4521761
226,simvastatin nmbr mg ( n = nmbr ) *,C0024671;C0026410;C0074554;C0439269;C1960952;C2346927;C4321396;C4521761
226,simvastatin nmbr mg ( n = nmbr ),C0024671;C0026410;C0074554;C0439269;C1960952;C2346927;C4321396;C4521761
226,simvastatin nmbr mg ( n = nmbr,C0024671;C0026410;C0074554;C0439269;C1960952;C2346927;C4321396;C4521761
226,simvastatin nmbr mg,C0024671;C0026410;C0074554;C0439269;C1960952;C2346927;C4321396;C4521761
226,silodosin nmbr mg ( n = nmbr ),C0024671;C0026410;C0439269;C1870115;C1960952;C2346927;C4321396;C4521761
226,sfc nmbr / nmbr mg twice daily ( n = nmbr ),C0024671;C0026410;C0439269;C0585361;C1960952;C2346927;C4321396;C4521536;C4521761
226,sfc nmbr / nmbr mg twice daily ( n = nmbr,C0024671;C0026410;C0439269;C0585361;C1960952;C2346927;C4321396;C4521536;C4521761
226,semaglutide nmbr . nmbr mg,C0024671;C0026410;C0439269;C1960952;C2346927;C3885068;C4321396;C4521761
226,secukinumab nmbr   mg no load ( n   =   nmbr ),C0024671;C0026410;C0439269;C1960952;C2346927;C3179547;C4321396;C4521761
226,secukinumab nmbr   mg ( n   =   nmbr ),C0024671;C0026410;C0439269;C1960952;C2346927;C3179547;C4321396;C4521761
226,secukinumab nmbr mg ( n nmbr nmbr ),C0024671;C0026410;C0439269;C1960952;C2346927;C3179547;C4321396;C4521761
226,secukinumab nmbr mg ( n = nmbr ),C0024671;C0026410;C0439269;C1960952;C2346927;C3179547;C4321396;C4521761
226,secukinumab intravenous nmbr mg ( n = nmbr ),C0024671;C0026410;C0348016;C0439269;C1960952;C2346927;C3179547;C4321396;C4521761
226,sc belimumab nmbr mg ( n = nmbr ),C0024671;C0026410;C0282380;C0439269;C1723401;C1960952;C2346927;C4321396;C4521761
226,saxa nmbr mg nmbr metformin ( n nmbr nmbr ),C0024671;C0025598;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
226,saxa nmbr mg ( n nmbr nmbr ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
226,saxa nmbr . nmbr mg ( n = nmbr ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
226,saxa nmbr . nmbr mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
226,sal nmbr mg,C0024671;C0026410;C0036140;C0037494;C0206136;C0439269;C1960952;C2346927;C4321396;C4521761
226,rosuvastatin nmbr mg,C0024671;C0026410;C0439269;C0965129;C1960952;C2346927;C4321396;C4521761
226,rosuvastatin nmbr - nmbr mg ( n = nmbr ),C0024671;C0026410;C0439269;C0965129;C1960952;C2346927;C4321396;C4521761
226,rosuva nmbr mg n = nmbr,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
226,rosuva nmbr mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
226,rituximab ( nmbrxnmbr mg ) + mtx ( n = nmbr ),C0024671;C0025677;C0026410;C0393022;C0439269;C1417487;C1960952;C2346927;C4321396;C4521761
226,rituximab ( nmbrxnmbr mg ) + mtx,C0024671;C0025677;C0026410;C0393022;C0439269;C1417487;C1960952;C2346927;C4321396;C4521761
226,rf ( mg / dl  per unit ),C0024671;C0026410;C0035448;C0201660;C0439148;C0439269;C0439453;C0748398;C1509845;C1519795;C1532632;C1547111;C1638407;C1704753;C1880519;C1960952;C2346927;C3642216;C3853603;C4321396;C4521761
226,r nmbr mg + fa ( « = nmbr ),C0024671;C0026410;C0205090;C0439269;C0684010;C1960952;C2346927;C2603358;C4321396;C4521761
226,r nmbr mg + fa,C0024671;C0026410;C0205090;C0439269;C0684010;C1960952;C2346927;C2603358;C4321396;C4521761
226,r nmbr mg ( « = nmbr ),C0024671;C0026410;C0205090;C0439269;C0684010;C1960952;C2346927;C2603358;C4321396;C4521761
226,r nmbr mg ( n = nmbr ),C0024671;C0026410;C0439269;C0687673;C1960952;C2346927;C4321396;C4521761
226,r nmbr mg,C0024671;C0026410;C0205090;C0439269;C0684010;C1960952;C2346927;C2603358;C4321396;C4521761
226,pravastatin nmbr mg,C0024671;C0026410;C0085542;C0439269;C1960952;C2346927;C4321396;C4521761
226,placebofigolimumab nmbr mg / nmbr mgt,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
226,placebo → golimumab nmbr mg / nmbr mga,C0024671;C0026410;C0032042;C0065879;C0439269;C1696465;C1706408;C1960952;C2346927;C2353893;C4321396;C4521761
226,placebo tolvaptan ( nmbr mg ) ( n nmbr nmbr ) ( n nmbr nmbr ),C0024671;C0026410;C0032042;C0439269;C1176308;C1696465;C1706408;C1960952;C2346927;C4321396;C4521761
226,pitavastatin nmbr mg,C0024671;C0026410;C0439269;C1101838;C1960952;C2346927;C4321396;C4521761
226,pen - label empagliflozin nmbr mg ( baseline hbanmbrc > nmbr % ),C0019016;C0024671;C0026410;C0168634;C0181496;C0439269;C1424886;C1442488;C1825777;C1960952;C2346927;C2827499;C3273588;C3490348;C3538758;C4319659;C4321396;C4521761;C4522130;C4551445
226,pbo czp nmbr mg qnmbrw week nmbr ( n = nmbr ),C0024671;C0026410;C0031962;C0054841;C0332174;C0439230;C0439269;C1861828;C1872109;C1960952;C2346927;C4321396;C4521761
226,p - value d nmbr mg vs . warfarin,C0024671;C0026410;C0439269;C1709380;C1960952;C2346927;C4321396;C4521761
226,omalizumab nmbr mg ( n [ nmbr ),C0024671;C0026410;C0439269;C0966225;C1960952;C2346927;C4321396;C4521761
226,olodaterol nmbr mg ( n = nmbr ),C0024671;C0026410;C0439269;C1960952;C2346927;C2934193;C4321396;C4521761
226,olmesartan medoxomil nmbr mg ( n = nmbr ),C0024671;C0026410;C0386393;C0439269;C1960952;C2346927;C4321396;C4521761
226,no . of nmbr - mg tablets of acetaminophen,C0024671;C0026410;C0439269;C1243102;C1960952;C2346927;C4321396;C4521761
226,nmbrmg vs placebo,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
226,nmbrmg / nmbr mgc,C0024671;C0026410;C0439269;C1960952;C2346927;C3888239;C4321396;C4521761
226,nmbrmg ( n = nmbr ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
226,nmbrmg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
226,nmbr   mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
226,nmbr mg twice daily n = nmbr,C0024671;C0026410;C0439269;C0585361;C1960952;C2346927;C4321396;C4521761
226,nmbr mg sirukumab every nmbr weeks ( n = nmbr ),C0024671;C0026410;C0439269;C1960952;C2346927;C3254570;C4321396;C4521761
226,nmbr mg qw nmbr . nmbr pt yrs,C0024671;C0026410;C0032743;C0043011;C0439269;C0699718;C1960952;C2346927;C4321396;C4521761
226,nmbr mg qnmbrw,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
226,nmbr mg qd ( n = nmbr ),C0024671;C0026410;C0332173;C0439269;C1960952;C2346927;C4321396;C4521761
226,nmbr mg ld,C0024671;C0026410;C0439269;C0694649;C1960952;C2346927;C4321396;C4521761
226,nmbr mg ew n = nmbr,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
226,nmbr mg eow n = nmbr,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
226,nmbr mg clopidogrel load,C0024671;C0026410;C0070166;C0439269;C1550025;C1704782;C1708715;C1960952;C2346927;C4321396;C4521761
226,nmbr mg biw nmbr . nmbr pt yrs,C0024671;C0026410;C0032743;C0439269;C0699718;C1960952;C2346927;C4321396;C4521761
226,nmbr mg bid,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
226,nmbr mg a,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
226,nmbr mg / nmbr mgb,C0024671;C0026410;C0373680;C0439269;C1960952;C2346927;C4321396;C4521761
226,nmbr mg / kgf ( n = nmbr ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
226,nmbr mg ( nmbr,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
226,nmbr mg ( n nmbr nmbr ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
226,nmbr mg ( n = nmbr ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
226,nmbr mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
226,nmbr / nmbr mg ( n = nmbr ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
226,nmbr / nmbr mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
226,nmbr . nmbrmg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
226,nmbr . nmbr mg bid,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
226,nmbr . nmbr mg ( n = nmbr ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
226,nmbr . nmbr mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
226,mtx ≥ nmbr mg / week,C0024671;C0025677;C0026410;C0332174;C0439230;C0439269;C1417487;C1960952;C2346927;C4321396;C4521761
226,mtx ≤ nmbr mg / week,C0024671;C0025677;C0026410;C0332174;C0439230;C0439269;C1417487;C1960952;C2346927;C4321396;C4521761
226,mtx £ nmbr mg / week,C0024671;C0025677;C0026410;C0332174;C0439230;C0439269;C1417487;C1960952;C2346927;C4321396;C4521761
226,mtx sio mg / week,C0024671;C0025677;C0026410;C0332174;C0439230;C0439269;C1039355;C1417487;C1960952;C2346927;C4321396;C4521761
226,mtx exposure ( mg / week ),C0024671;C0025677;C0026410;C0274281;C0332157;C0332174;C0439230;C0439269;C1417487;C1960952;C2346927;C4321396;C4521761
226,mtx dose > nmbr mg / week,C0024671;C0026410;C0332174;C0366550;C0439230;C0439269;C1960952;C2346927;C4321396;C4521761
226,mtx > nmbr – nmbr mg / week,C0024671;C0025677;C0026410;C0332174;C0439230;C0439269;C1417487;C1960952;C2346927;C4321396;C4521761
226,mtx > nmbr mg / week,C0024671;C0025677;C0026410;C0332174;C0439230;C0439269;C1417487;C1960952;C2346927;C4321396;C4521761
226,mtx < nmbr mg / week,C0024671;C0025677;C0026410;C0332174;C0439230;C0439269;C1417487;C1960952;C2346927;C4321396;C4521761
226,mepolizumab nmbr mg ( n = nmbr ),C0024671;C0026410;C0439269;C0969324;C1960952;C2346927;C4321396;C4521761
226,lv mass index ( mg / mnmbr ),C0024671;C0026410;C0369637;C0439269;C0441923;C0455825;C0600653;C0918012;C1552854;C1637833;C1960952;C2346927;C2986546;C4321396;C4521761
226,lovastatin nmbr mg,C0024027;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
226,llraglutide nmbr - nmbr mg mean ( n ),C0024671;C0026410;C0439269;C0444504;C1960952;C2346927;C2347634;C2348143;C4321396;C4521761
226,liraglutide nmbr . nmbr mg n = nmbr,C0024671;C0026410;C0439269;C1456408;C1960952;C2346927;C4321396;C4521761
226,liraglutide nmbr . nmbr mg mean ( n ),C0024671;C0026410;C0439269;C0444504;C1456408;C1960952;C2346927;C2347634;C2348143;C4321396;C4521761
226,liraglutide nmbr . nmbr mg ls means ( n ),C0023668;C0024671;C0026410;C0439269;C1456408;C1704970;C1960952;C2346927;C4321396;C4521761
226,liraglutide nmbr . nmbr mg ( n = nmbr ),C0024671;C0026410;C0439269;C1456408;C1960952;C2346927;C4321396;C4521761
226,liraglutide nmbr . nmbr mg,C0024671;C0026410;C0439269;C1456408;C1960952;C2346927;C4321396;C4521761
226,liraglutide nmbr - nmbr mg mean ( n ),C0024671;C0026410;C0439269;C0444504;C1456408;C1960952;C2346927;C2347634;C2348143;C4321396;C4521761
226,liraglutide nmbr - nmbr mg ( n = nmbr ),C0024671;C0026410;C0439269;C1456408;C1960952;C2346927;C4321396;C4521761
226,liraglutide ( nmbr . nmbr mg ) ± oad,C0024671;C0026410;C0439269;C1456408;C1960952;C2346927;C4321396;C4521761
226,iv - nmbr mg,C0022326;C0024671;C0026410;C0439269;C1960952;C2346927;C4265176;C4321396;C4521761
226,intended clopidogrel dose nmbr mg,C0024671;C0026410;C0070166;C0178602;C0439269;C0869039;C1114758;C1283828;C1551357;C1960952;C2346927;C4321396;C4521761
226,ind / gly nmbr / nmbr mg once daily ( n = nmbr ),C0017890;C0024671;C0026410;C0332173;C0439269;C0523677;C1960952;C2346927;C4049864;C4321396;C4521761
226,ind / gly nmbr / nmbr mg once daily ( n = nmbr,C0017890;C0024671;C0026410;C0332173;C0439269;C0523677;C1960952;C2346927;C4049864;C4321396;C4521761
226,i moderate  nmbr mg of pravastatin ( n = nmbr ),C0021966;C0024671;C0026410;C0085542;C0205081;C0221138;C0439269;C1881878;C1960952;C2346927;C4049705;C4049706;C4085643;C4321335;C4321396;C4521761
226,i intensive  nmbr mg of atorvastatin ( n = nmbr ),C0021966;C0024671;C0026410;C0162425;C0221138;C0286651;C0439269;C0522510;C1283828;C1550453;C1960952;C2346927;C4321396;C4521761
226,hscrp — mg / liter,C0024671;C0026410;C0439269;C0475211;C1960952;C2346927;C4321396;C4521761
226,high - sensitivity crp — mg / liter | |,C0024671;C0026410;C0439269;C0475211;C1441604;C1960952;C2346927;C3890735;C4048285;C4321396;C4521761
226,golimumab nmbr mg / nmbr mgt,C0024671;C0026410;C0439269;C1960952;C2346927;C2353893;C4321396;C4521761
226,golimumab nmbr mg ( n = nmbr ) †,C0024671;C0026410;C0439269;C1960952;C2346927;C2353893;C4321396;C4521761
226,golimumab nmbr mg ( n = nmbr ),C0024671;C0026410;C0439269;C1960952;C2346927;C2353893;C4321396;C4521761
226,golimumab nmbr / nmbr mg,C0024671;C0026410;C0439269;C1960952;C2346927;C2353893;C4321396;C4521761
226,glycopyrronium nmbr mg ( n = nmbr ),C0024671;C0026410;C0439269;C1960952;C2346927;C3814772;C4321396;C4521761
226,gly nmbr . nmbr mg b . i . d . n = nmbr,C0024671;C0026410;C0152277;C0439269;C1415124;C1960952;C2346927;C4321396;C4521761
226,geometric mean ofcrp — mg / liter ( range ),C0024671;C0026410;C0439269;C0475211;C1514721;C1960952;C2346927;C2348147;C2986759;C3542016;C4321396;C4521761
226,fp nmbr mg,C0016704;C0024671;C0026410;C0439269;C1419068;C1419906;C1960952;C2346927;C3541238;C3541412;C4321396;C4521761
226,fluvastatin nmbr mg,C0024671;C0026410;C0082608;C0439269;C1960952;C2346927;C4321396;C4521761
226,feno nmbr mg ( n = nmbr ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
226,famotidine nmbr mg ( n = nmbr ),C0015620;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
226,fa nmbr mg ( « = nmbr ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
226,fa nmbr mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
226,ezetimibe nmbr mg + statin ( n = nmbr,C0024671;C0026410;C0360714;C0439269;C1142985;C1960952;C2346927;C4321396;C4521761
226,ezetimibe nmbr mg ( n — nmbr ),C0024671;C0026410;C0439269;C1142985;C1960952;C2346927;C4321396;C4521761
226,ezetimibe nmbr mg ( n = nmbr * ),C0024671;C0026410;C0439269;C1142985;C1960952;C2346927;C4321396;C4521761
226,ezetimibe nmbr mg ( n = nmbr ),C0024671;C0026410;C0439269;C1142985;C1960952;C2346927;C4321396;C4521761
226,eze nmbr mg ( n = nmbr ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
226,eze nmbr mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
226,eze = ezetimibe nmbr mg  pooled sinva = simvastatin pooled across doses  pooled eze / sinva = ezetimibe / simvastatin tablet pooled across doses  bni = body mass index  ldl - c = low - density lipoprotein cholesterol  t g = triglycerides  t c = total cholesterol  hdl - c = high - density lipoprotein cholesterol  apo — apolipoprotein  c rp — c - neactive protein  rlp - c = remnant - like particle - cholesterol .,C0024671;C0026410;C0439269;C1142985;C1960952;C2346927;C4321396;C4521761
226,eze / simva nmbr / nmbr mg n = nmbr,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
226,eze / simva nmbr / nmbr mg ( n = nmbr ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
226,evolocumab nmbr mg every nmbrweeks ( n = nmbr ),C0024671;C0026410;C0439269;C1960952;C2346927;C3529352;C4321396;C4521761
226,etoricoxib nmbr mg n = nmbr n ( % ),C0024671;C0026410;C0439269;C0972314;C1960952;C2346927;C4321396;C4521761
226,etn nmbr mg + mtx n = nmbr,C0014758;C0024671;C0025677;C0026410;C0439269;C0717758;C1417487;C1960952;C2346927;C4321396;C4521761
226,esrd saxa nmbr . nmbr mg ( n = nmbr ),C0022661;C0024671;C0026410;C0035078;C0439269;C1960952;C2316810;C2346927;C4321396;C4521761
226,ertuglrflozin nmbr mg vs placebo / glimepiride,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
226,ertugliflozin nmbr   mg ( n   =   nmbr ),C0024671;C0026410;C0439269;C1960952;C2346927;C4079805;C4321396;C4521761
226,ertugliflozin nmbr mg vs placebo / glirneplride,C0024671;C0026410;C0439269;C1960952;C2346927;C4079805;C4321396;C4521761
226,ertugliflozin nmbr mg vs placebo / glinepiride,C0024671;C0026410;C0439269;C1960952;C2346927;C4079805;C4321396;C4521761
226,ertugliflozin nmbr mg vs placebo / glimepiride,C0024671;C0026410;C0439269;C1960952;C2346927;C4079805;C4321396;C4521761
226,ertugliflozin nmbr mg vs placebo / giimepiride,C0024671;C0026410;C0439269;C1960952;C2346927;C4079805;C4321396;C4521761
226,ertugliflozin nmbr mg ( n   =   nmbr ),C0024671;C0026410;C0439269;C1960952;C2346927;C4079805;C4321396;C4521761
226,ertugliflozin nmbr mg ( n nmbr nmbr ),C0024671;C0026410;C0439269;C1960952;C2346927;C4079805;C4321396;C4521761
226,ertugliflozin nmbr mg ( n = nmbr ),C0024671;C0026410;C0439269;C1960952;C2346927;C4079805;C4321396;C4521761
226,ertuglifldzin nmbr mg vs placebo / glinepiride,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
226,erlugliflozin nmbr mg vs placebo / glimepiride,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
226,empagliflozin nmbr mg ( n = nmbr ),C0024671;C0026410;C0439269;C1960952;C2346927;C3490348;C4321396;C4521761
226,empagliflozin nmbr mg,C0024671;C0026410;C0439269;C1960952;C2346927;C3490348;C4321396;C4521761
226,empaglifiozin nmbr mg ( w = nmbr ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
226,empaglifiozin nmbr . nmbr mg ( w = nmbr ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
226,empagiiflozin nmbr mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
226,eduglinozin nmbr mg vs placebo / glimepiride,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
226,dulaglutide nmbr · nmbr mg ( n = nmbr ),C0024671;C0026410;C0439269;C1960952;C2346927;C3179549;C4321396;C4521761
226,dulaglutide nmbr . nmbr mg *,C0024671;C0026410;C0439269;C1960952;C2346927;C3179549;C4321396;C4521761
226,dulaglutide nmbr . nmbr mg ( n = nmbr ),C0024671;C0026410;C0439269;C1960952;C2346927;C3179549;C4321396;C4521761
226,dulaglutide nmbr . nmbr mg,C0024671;C0026410;C0439269;C1960952;C2346927;C3179549;C4321396;C4521761
226,dose ( mg / week ),C0024671;C0026410;C0178602;C0332174;C0439230;C0439269;C0869039;C1114758;C1960952;C2346927;C4321396;C4521761
226,de nmbr mg bid ( n - nmbr,C0011198;C0017480;C0024671;C0026410;C0439269;C1960952;C2346927;C3541240;C4321396;C4521761
226,dapagliflozin nmbrmg,C0024671;C0026410;C0439269;C1960952;C2346927;C2353951;C4321396;C4521761
226,dapagliflozin nmbr mg group ( n = nmbr ),C0024671;C0026410;C0439269;C0441848;C1960952;C2346927;C2353951;C4321396;C4521761
226,dapagliflozin nmbr mg + insulin ( n   = nmbr ),C0021641;C0024671;C0026410;C0439269;C1533581;C1579433;C1960952;C2346927;C2353951;C3714501;C4321396;C4521761
226,dapagliflozin nmbr mg + insulin ( n = nmbr ),C0021641;C0024671;C0026410;C0439269;C1533581;C1579433;C1960952;C2346927;C2353951;C3714501;C4321396;C4521761
226,dapagliflozin nmbr mg ( n = nmbr ),C0024671;C0026410;C0439269;C1960952;C2346927;C2353951;C4321396;C4521761
226,dapagliflozin nmbr mg,C0024671;C0026410;C0439269;C1960952;C2346927;C2353951;C4321396;C4521761
226,daily dose nmbr mg n = nmbr,C0024671;C0026410;C0439269;C1960952;C2346927;C2348070;C4321396;C4521761
226,daily dose nmbr - nmbr mg n = nmbr,C0024671;C0026410;C0439269;C1960952;C2346927;C2348070;C4321396;C4521761
226,daily dose > nmbr mg n = nmbr,C0024671;C0026410;C0439269;C1960952;C2346927;C2348070;C4321396;C4521761
226,dabigatran nmbr mg versus warfarin,C0024671;C0026410;C0439269;C1960952;C2346927;C2348066;C4321396;C4521761
226,dabigatran nmbr mg versu swarfarin,C0024671;C0026410;C0439269;C1960952;C2346927;C2348066;C4321396;C4521761
226,dabigatran nmbr mg bid vs warfarin,C0024671;C0026410;C0439269;C1960952;C2346927;C2348066;C4321396;C4521761
226,czp nmbr mg qnmbrw,C0024671;C0026410;C0054841;C0439269;C1861828;C1872109;C1960952;C2346927;C4321396;C4521761
226,czp nmbr mg every nmbr weeks ( n = nmbr ),C0024671;C0026410;C0054841;C0439269;C1861828;C1872109;C1960952;C2346927;C4321396;C4521761
226,czp nmbr mg ( nnmbr ),C0024671;C0026410;C0054841;C0439269;C1861828;C1872109;C1960952;C2346927;C4321396;C4521761
226,czp nmbr mg ( n nmbr nmbr ),C0024671;C0026410;C0054841;C0439269;C1861828;C1872109;C1960952;C2346927;C4321396;C4521761
226,czp nmbr mg ( n nmbr ),C0024671;C0026410;C0054841;C0439269;C1861828;C1872109;C1960952;C2346927;C4321396;C4521761
226,czp nmbr mg ( n = nmbr ),C0024671;C0026410;C0054841;C0439269;C1861828;C1872109;C1960952;C2346927;C4321396;C4521761
226,czp nmbr mg ( n = lll ),C0024671;C0026410;C0054841;C0439269;C1261077;C1861828;C1872109;C1960952;C2346927;C4321396;C4521761
226,czp nmbr mg,C0024671;C0026410;C0054841;C0439269;C1861828;C1872109;C1960952;C2346927;C4321396;C4521761
226,crp — mg / liter^,C0024671;C0026410;C0439269;C0475211;C1960952;C2346927;C3890735;C4048285;C4321396;C4521761
226,crp ( mg / dl  per unit ),C0024671;C0026410;C0439148;C0439269;C0439453;C1509845;C1519795;C1532632;C1638407;C1704753;C1880519;C1960952;C2346927;C3642216;C3853603;C3890735;C4048285;C4321396;C4521761
226,clopidogrel loading dose nmbr mg,C0024671;C0026410;C0070166;C0439269;C1960952;C2346927;C3714444;C4321396;C4521761
226,cld nmbr mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
226,carisbamate nmbr mg ( n = nmbr ),C0024671;C0026410;C0439269;C1871983;C1960952;C2346927;C4321396;C4521761
226,canagliflozin nmbr mg vs sitagliptin nmbr mg,C0024671;C0026410;C0439269;C1960952;C2346927;C2974540;C4321396;C4521761
226,cana nmbrmg ( n = nmbr ),C0024671;C0026410;C0439269;C1418845;C1960952;C2346927;C4321396;C4521761
226,cana nmbr mg ( n nmbr nmbr ),C0024671;C0026410;C0439269;C1418845;C1960952;C2346927;C4321396;C4521761
226,cana nmbr mg ( n = nmbr ) *,C0024671;C0026410;C0439269;C1418845;C1960952;C2346927;C4321396;C4521761
226,cana nmbr mg ( n = nmbr ),C0024671;C0026410;C0439269;C1418845;C1960952;C2346927;C4321396;C4521761
226,cana nmbr mg ( n - nmbr ),C0024671;C0026410;C0439269;C1418845;C1960952;C2346927;C4321396;C4521761
226,cana nmbr mg,C0024671;C0026410;C0439269;C1418845;C1960952;C2346927;C4321396;C4521761
226,body mass index ( mg / mnmbr ),C0005893;C0024671;C0026410;C0369637;C0439269;C0441923;C0578022;C1305855;C1960952;C2346927;C4321396;C4521761
226,belimumab nmbr mg sc ( n nmbr ),C0024671;C0026410;C0282380;C0439269;C1723401;C1960952;C2346927;C4321396;C4521761
226,baricitinib nmbr mg qd ( n = nmbr ),C0024671;C0026410;C0332173;C0439269;C1960952;C2346927;C4044947;C4321396;C4521761
226,baricitinib nmbr mg ( n = nmbr ),C0024671;C0026410;C0439269;C1960952;C2346927;C4044947;C4321396;C4521761
226,azl - m nmbr mg ( n = nmbr ),C0024671;C0026410;C0369637;C0439269;C0441923;C1960952;C2346927;C4321396;C4521761
226,average weekly mtx dose ( mg / week ) t,C0024671;C0026410;C0332174;C0366550;C0439230;C0439269;C1510992;C1960952;C2346927;C2825518;C4321396;C4521761
226,average weekly mtx dose ( mg / week ),C0024671;C0026410;C0332174;C0366550;C0439230;C0439269;C1510992;C1960952;C2346927;C2825518;C4321396;C4521761
226,average dose ( mg / week ),C0024671;C0026410;C0178602;C0332174;C0439230;C0439269;C0869039;C1114758;C1510992;C1960952;C2346927;C2825518;C4321396;C4521761
226,atvnmbr mg ( n = nmbr ),C0024671;C0026410;C0210243;C0439269;C0674679;C1145759;C1334862;C1960952;C2346927;C4321396;C4521761
226,atv nmbr mg,C0024671;C0026410;C0210243;C0439269;C0674679;C1145759;C1334862;C1960952;C2346927;C4321396;C4521761
226,atorvastatin nmbr mg and simvastatin nmbr - nmbr mg ( zi = nmbr ),C0024671;C0026410;C0286651;C0439269;C1960952;C2346927;C4321396;C4521761
226,atorvastatin nmbr mg ( zi = nmbr ),C0024671;C0026410;C0043476;C0286651;C0439269;C1960952;C2346927;C4321396;C4521761
226,atorvastatin nmbr mg ( n = nmbr ),C0024671;C0026410;C0286651;C0439269;C1960952;C2346927;C4321396;C4521761
226,atorvastatin nmbr mg ( n = nmbr,C0024671;C0026410;C0286651;C0439269;C1960952;C2346927;C4321396;C4521761
226,ato nmbr mg and sim nmbr^nmbr mg ( n = nmbr ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
226,ato nmbr mg and sim nmbr - nmbr mg ( n = nmbr ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
226,ato nmbr mg ( n = nmbr ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
226,aspirin nmbr mg ( n = nmbr ),C0004057;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
226,asa > nmbr mg,C0004057;C0024671;C0026410;C0439269;C1960952;C2346927;C3853627;C4321396;C4521761
226,asa < nmbr mg,C0004057;C0024671;C0026410;C0439269;C1960952;C2346927;C3853627;C4321396;C4521761
226,aplxaban nmbr . nmbr mg bid,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
226,apixaban nmbr mg bid,C0024671;C0026410;C0439269;C1831808;C1960952;C2346927;C4321396;C4521761
226,apixaban nmbr . nmbr mg bid,C0024671;C0026410;C0439269;C1831808;C1960952;C2346927;C4321396;C4521761
226,amlodipine / wlsartan inmbr / nmbr mg,C0021966;C0024671;C0026410;C0051696;C0221138;C0439269;C1960952;C2346927;C4321396;C4521761
226,amlodipine / valsartan nmbr / nmbr mg,C0024671;C0026410;C0439269;C1960952;C1962523;C2346927;C4321396;C4521761
226,ami nmbr mg n = nmbr,C0024671;C0026410;C0439269;C1960952;C2346927;C4319936;C4321396;C4521761
226,ami nmbr mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4319936;C4321396;C4521761
226,alogliptin nmbr mg + pioglitazone ( n = nmbr ),C0024671;C0026410;C0439269;C1960952;C2346927;C3535925;C4321396;C4521761
226,alogliptin nmbr . nmbr mg + pioglitazone ( n = nmbr ),C0024671;C0026410;C0439269;C1960952;C2346927;C3535925;C4321396;C4521761
226,allopurinol nmbr mg ( n = nmbr ) +,C0002144;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
226,allopurinol nmbr / nmbr mg n = nmbr,C0002144;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
226,allopurinol nmbr / nmbr mg daily n = nmbr,C0002144;C0024671;C0026410;C0332173;C0439269;C1960952;C2346927;C4321396;C4521761
226,> nmbr to < nmbr - nmbr mg / week,C0024671;C0026410;C0332174;C0439230;C0439269;C1960952;C2346927;C4321396;C4521761
226,> nmbr mg / liter,C0024671;C0026410;C0439269;C0475211;C1960952;C2346927;C4321396;C4521761
226,> nmbr mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
226,> nmbr . nmbr mg / liter antiplatelet agents,C0024671;C0026410;C0085826;C0439269;C0475211;C1960952;C2346927;C4321396;C4521761
226,> nmbr . nmbr mg / liter,C0024671;C0026410;C0439269;C0475211;C1960952;C2346927;C4321396;C4521761
226,> nmbr - nmbr mg / week,C0024671;C0026410;C0332174;C0439230;C0439269;C1960952;C2346927;C4321396;C4521761
226,< nmbr mg / liter,C0024671;C0026410;C0439269;C0475211;C1960952;C2346927;C4321396;C4521761
226,< nmbr mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
226,< nmbr . nmbr mg / liter,C0024671;C0026410;C0439269;C0475211;C1960952;C2346927;C4321396;C4521761
225,volumetric bmd by qct,C0412669;C0445383
224,morphometric vertebral,C0200760;C0549207
223,north america plus australia and new zealand,C0004340;C0028405;C0332287
223,north america n z nmbr,C0028405
223,north america hr ( nmbr % cl ),C0028405;C0596019
223,north america / oceania,C0028405;C0282279;C4085681
223,north america *,C0028405
223,north america ( plus australia and new zealand ),C0004340;C0028405;C0332287
223,north america ( plus america and new zealand ),C0028405;C0332287
223,north america ( n = nmbr ),C0028405
223,north america ( % ),C0028405
223,north america,C0028405
222,native latin,C0302891
222,native coronary - artery lesions,C0205042;C0221198;C0302891
221,native american or alaskan native,C0282204;C1515945
221,native american or alaska native,C0282204;C1515945
221,native american / alaskan,C0238611;C0282204;C0596070;C0682125;C1515945
221,native american,C0282204;C1515945
220,latin america or south africa,C0023122
220,latin america hr ( nmbr % cl ),C0023122;C0596019
220,latin america ( n = nmbr ),C0023122
220,latin america,C0023122
219,latin american subgroup,C1079230;C1515021;C1553378
219,latin american,C1553378
218,with long - acting jnmbr - agonists,C0079613;C0205166;C0243192;C1704930;C1706317;C1869853;C2987634;C3890007;C4048375
218,short - acting bnmbr - agonists,C0079613;C0243192;C1282927;C1704930;C1806781;C1869853;C2350002;C2987634;C3890007;C4048375
218,short - acting anticholinergics,C0079613;C0242896;C1282927;C1704930;C1806781;C1869853;C2350002;C3537307;C3540711;C3890007;C4048375
218,short - acting,C0079613;C1282927;C1704930;C1806781;C1869853;C2350002;C3890007;C4048375
218,long acting nitratef,C0079613;C0205166;C1704930;C1706317;C1869853;C3890007;C4048375
218,long - acting^,C0079613;C0205166;C1704930;C1706317;C1869853;C3890007;C4048375
218,long - acting or short - acting nitrates,C0079613;C0205166;C1704930;C1706317;C1869853;C3890007;C4048375
218,long - acting nitrates,C0028125;C0079613;C0205166;C1704930;C1706317;C1869853;C3890007;C4048375
218,long - acting nitrate agents,C0028125;C0079613;C0205166;C0450442;C0699857;C1254351;C1521826;C1704930;C1706317;C1869853;C3848573;C3890007;C4048375
218,long - acting nitrate,C0028125;C0079613;C0205166;C0699857;C1704930;C1706317;C1869853;C3848573;C3890007;C4048375
218,long - acting bnmbr - agonists,C0079613;C0205166;C0243192;C1704930;C1706317;C1869853;C2987634;C3890007;C4048375
218,long - acting,C0079613;C0205166;C1704930;C1706317;C1869853;C3890007;C4048375
218,baseline short - acting anticholinergics,C0079613;C0168634;C0242896;C1282927;C1442488;C1704930;C1806781;C1869853;C2350002;C3537307;C3540711;C3890007;C4048375
218,act total score ≥   nmbr,C0079613;C1704930;C1869853;C3890007;C4048375
218,act total score   ≥   nmbr and / or improvement from baseline   ≥   nmbr,C0079613;C1704930;C1869853;C3890007;C4048375
218,act . nmbr,C0079613;C1704930;C1869853;C3890007;C4048375
218,act - nmbr,C0079613;C1704930;C1869853;C3890007;C4048375
217,risk factors — no . ( % ),C0035648;C1553898
217,risk factors specified as inclusion criteria — no . ( % ) f,C0035648;C1553898
217,risk factors only,C0035648;C0205171;C1553898;C1720467
217,risk factors for stroke,C0035648;C0038454;C1553898;C4554100
217,risk factors for recurrent vte — no . ( % ) f,C0035648;C0630906;C1455761;C1553898;C2945760
217,risk factors for atherosclerosis,C0003850;C0004153;C0035648;C1553898
217,risk factors bmi ( kg / mnmbr ),C0035648;C0578022;C1532718;C1553898
217,risk factors and medical history,C0035648;C1553898
217,risk factors and immobility level,C0035648;C1553898
217,risk factors and diabetes status ( % ),C0035648;C1553898
217,risk factors ( % of group ),C0035648;C0441833;C0687744;C1257890;C1519504;C1553898;C1705428;C1705429
217,risk factors ( % ),C0035648;C1553898
217,risk factors,C0035648;C1553898
217,risk factor ( predefined ) for falling at screening,C0035648
217,risk factor,C0035648
217,psychosocial risk factors,C0033963;C0035647;C0035648;C0542298;C1458132;C1553898;C4552904
217,other risk factors,C0035648;C1553898
217,other major risk factors,C0035648;C0205082;C0205164;C1553898;C4318856;C4521762
217,non - transient risk factors for recurrent vte,C0035648;C0040704;C0205374;C0439597;C0630906;C1553898
217,no ascvd + additional cv risk factors,C0035648;C1524062;C1553898;C3538987;C3665365;C4048877;C4318503
217,no . of risk factors for venous thromboembolism,C0035648;C1553898
217,no . of risk factors ( % ) | |,C0035648;C1553898
217,multiple risk factors,C0035648;C0439064;C1553898
217,multiple ( > nmbr ) chd risk factors that confer a nmbr - year risk of chd > nmbr %,C0035648;C0280604;C0439064;C1553898;C3542407
217,diagnoses / risk factors,C0011900;C0035648;C1553898
217,cvd risk factors ( age > nmbr ) ^ “ ^,C0001779;C0001783;C0007222;C0035647;C0035648;C1553898;C4552904
217,cvd risk factors ( age > nmbr ),C0001779;C0001783;C0007222;C0035647;C0035648;C1553898;C4552904
217,cv risk factors and history,C0035648;C1553898;C3538987;C4048877;C4318503
217,chadsnmbr risk factors,C0007928;C0035648;C1413373;C1553898
217,baseline risk factors,C0035648;C0168634;C1442488;C1553898
217,ascvdor > nmbr cv risk factors,C0035648;C1553898;C3538987;C4048877;C4318503
217,> nmbr cv risk factors^ or established atherosclerotic cv disease,C0035648;C1553898;C3538987;C4048877;C4318503
217,> nmbr cv risk factors 咐 or established atherosclerotic cv disease,C0035648;C1553898;C3538987;C4048877;C4318503
217,> nmbr additional cv risk factorsnmbr,C0035648;C1524062;C1553898;C3538987;C4048877;C4318503
216,south africa,C0037712
216,short form nmbr ( sf - nmbr ),C0037712;C2964478
216,sfnmbr - pcs,C0037712;C1864389;C1882368
216,sf ‐ nmbr pcs,C0037712;C1864389;C1882368
216,sf ‐ nmbr health survey,C0018762;C0037712
216,sf - nmbrvnmbr pcs,C0037712;C1864389;C1882368
216,sf - nmbrvnmbr mcs,C0037712
216,sf - nmbr summary scores,C0037712;C1552616;C1706244
216,sf - nmbr pcs score,C0037712;C1864389;C1882368
216,sf - nmbr pcs,C0037712;C1864389;C1882368
216,sf - nmbr mcs score,C0037712
216,sf - nmbr mcs,C0037712
216,australia / new zealand / south africa,C0037712;C4289954
215,study nmbr - item short - form general health survey ( sf - nmbr ) can range from nmbr to nmbr for the physical component and from nmbr to nmbr for the mental,C0037712;C0348078;C0376315;C0557651;C1282927;C1522492;C1551338;C1806781;C2350002;C2603343;C3481509;C4255237;C4554251
215,other forms of atherosclerosis^,C0003850;C0004153;C0348078;C0376315
215,other forms of atherosclerosis ’,C0003850;C0004153;C0348078;C0376315
215,other forms of,C0348078;C0376315
215,form / bud,C0348078;C0376315;C1522492;C2700462;C2945744;C4255237
214,received nmbr prior anti - tnf therapy,C0281481;C0332152;C1514756;C2826257
214,received > nmbr prior anti - tnf therapies,C0281481;C0332152;C1514756;C2826257
214,prior years taking warfarin,C0332152;C0439234;C2826257
214,prior vka use for > nmbr d,C0042153;C0332152;C0457083;C1947944;C2826257
214,prior use of systemic,C0205373;C0332152;C1524063;C2826257
214,prior use of synthetic dmards,C0242708;C0332152;C1524063;C1883254;C2826257
214,prior use of conventional dmards only ( biologic - nai ' ve ),C0042469;C0205171;C0332152;C0439858;C1524063;C1720467;C2826257;C3537218;C3714652;C4055380;C4321495
214,prior use of biologics,C0005515;C0005522;C0332152;C1524063;C2826257;C4553887
214,prior use of biologic agents,C0005515;C0332152;C1524063;C2826257
214,prior use of $ nmbr systemic therapies,C0205373;C0332152;C1514463;C1515119;C1524063;C2826257
214,prior upper gi clinical event,C0203057;C0205210;C0332152;C0441471;C2826257;C4019010
214,prior ugi event,C0332152;C0441471;C0560042;C2826257;C4019010
214,prior tnfi,C0332152;C2826257
214,prior thienopyridine ( - ),C0332152;C1120149;C2826257
214,prior thienopyridine ( + ),C0332152;C1120149;C2826257
214,prior sulfasalazine use *,C0036078;C0042153;C0332152;C0457083;C1947944;C2826257
214,prior stroke — no . ( % ),C0332152;C2826257
214,prior stroke ( before index event ),C0332152;C0441471;C0456712;C2826257;C4019010
214,prior statin use ( n = nmbr ),C0042153;C0332152;C0360714;C0457083;C1947944;C2826257
214,prior statin ( n = nmbr,C0332152;C0360714;C2826257
214,prior peripheralarterialdisease,C0332152;C2826257
214,prior peripheral arterial disease,C0085096;C0332152;C1704436;C2826257
214,prior or new diabetes,C0332152;C2826257
214,prior oma use ( n = nmbr ),C0042153;C0332152;C0457083;C1947944;C2826257
214,prior oma use,C0042153;C0332152;C0457083;C1947944;C2826257
214,prior om,C0028971;C0332152;C1705272;C2826257
214,prior oad :,C0332152;C2826257
214,prior oac,C0332152;C2826257
214,prior non - haemorrhagic stroke,C0332152;C0553692;C1518422;C2826257
214,prior non - cns se,C0036919;C0332152;C1518422;C2826257;C3714787
214,prior myocardial intarction,C0027061;C0332152;C1522564;C2826257
214,prior migraine *,C0149931;C0332152;C2826257
214,prior migraine,C0149931;C0332152;C2826257
214,prior mi within nmbr y,C0332152;C2826257;C3810814
214,prior mi n = nmbr,C0332152;C2826257;C3810814
214,prior mi ( n = nmbr,C0332152;C2826257;C3810814
214,prior mi ( n - nmbr,C0332152;C2826257;C3810814
214,prior mi,C0332152;C2826257;C3810814
214,prior mesalazine use *,C0042153;C0127615;C0332152;C0457083;C1947944;C2826257
214,prior lower gi clinical event,C0205210;C0332152;C0441471;C0441994;C1548802;C1708130;C2003888;C2826257;C3539617;C4019010;C4050121
214,prior llt,C0332152;C2347090;C2826257
214,prior lgi event,C0332152;C0441471;C2826257;C4019010
214,prior known stenosis > nmbr %,C0205309;C0332152;C0678234;C1261287;C2632116;C2826257
214,prior insulin use ( years ),C0240016;C0332152;C0439234;C2826257
214,prior implantable cardiodefibrillator,C0021102;C0332152;C2826257
214,prior htn ( n = nmbr,C0020538;C0332152;C2826257
214,prior hospitalizations,C0019993;C0332152;C2826257
214,prior hospitalization for hf,C0018488;C0019993;C0332152;C1313497;C1538440;C2826257;C3273279
214,prior hf hospitalization ( n = nmbr ),C0018488;C0019993;C0332152;C1313497;C1538440;C2826257;C3273279
214,prior gestational diabetes,C0085207;C0332152;C2826257
214,prior failure of anti - tnf therapy — no . ( % ),C0231174;C0281481;C0332152;C0680095;C2826257
214,prior dm,C0011816;C0332152;C2826257;C3250443
214,prior diabetes,C0011847;C0011849;C0332152;C2826257
214,prior cv event,C0332152;C0441471;C2826257;C3538987;C4019010;C4048877;C4318503
214,prior coronary artery bypass surgery,C0010055;C0332152;C2826257
214,prior coronary artery bypass grafting,C0010055;C0332152;C2826257
214,prior coronary artery bypass graft surgery,C0010055;C0332152;C2826257
214,prior coronary artery bypass graft,C0010055;C0332152;C1260596;C2826257
214,prior conventional synthetic dmards,C0242708;C0332152;C0439858;C1883254;C2826257
214,prior chf,C0018802;C0332152;C2826257
214,prior cardiovascular history,C0332152;C1880008;C2826257
214,prior cardiovascular event — no . ( % ) - j -,C0332152;C1320716;C2826257
214,prior cardiovascular event — no . ( % ),C0332152;C1320716;C2826257
214,"prior cardiovascular event "" ' """,C0332152;C1320716;C2826257
214,prior cardiovascular event,C0332152;C1320716;C2826257
214,prior cad,C0332152;C1504769;C2239547;C2826257;C3813548;C4284121
214,prior cabg,C0010055;C0332152;C2826257
214,prior brachytherapy,C0006098;C0332152;C2826257
214,prior bp use,C0037623;C0042153;C0332152;C0457083;C1415692;C1708288;C1947944;C2826257;C4318478
214,prior bisphosphonate usage,C0012544;C0332152;C0457083;C2267018;C2826257
214,prior bb plus acbi plus arb use,C0004739;C0042153;C0332152;C0332287;C0332297;C0457083;C1947944;C2826257;C3888198
214,prior asa use,C0004057;C0042153;C0332152;C0457083;C1947944;C2826257;C3853627
214,prior anti - tnf therapy — no . ( % ),C0281481;C0332152;C2826257
214,prior anti - tnf therapy,C0281481;C0332152;C2826257
214,prior angiography showing stenosis ≥ nmbr %,C0002978;C0332152;C2826257
214,prior angiography showing stenosis > nmbr %,C0002978;C0332152;C2826257
214,prior aeds,C0180309;C0332152;C2826257
214,prior admb,C0332152;C2826257
214,prior acbi or arb use,C0332152;C2826257
214,prior a - blocker use,C0332152;C2826257
214,prior,C0332152;C2826257
214,number of prior csdmards,C0237753;C0332152;C0449788;C2826257
214,number of prior aeds,C0180309;C0237753;C0332152;C0449788;C2826257
214,no prior ugi event,C0332152;C0441471;C0560042;C2826257;C4019010
214,no prior statin ( n = nmbr,C0332152;C0360714;C2826257
214,no prior oma use ( n = nmbr ),C0042153;C0332152;C0457083;C1947944;C2826257
214,no prior oma use,C0042153;C0332152;C0457083;C1947944;C2826257
214,no prior mi n = nmbr,C0332152;C2826257;C3810814
214,no prior mi ( n = nmbr,C0332152;C2826257;C3810814
214,no prior mi,C0332152;C2826257;C3810814
214,no prior llt,C0332152;C2347090;C2826257
214,no prior lgi event,C0332152;C0441471;C2826257;C4019010
214,no prior htn ( n = nmbr,C0020538;C0332152;C2826257
214,no prior hf hospitalization ( n   = nmbr,C0018488;C0019993;C0332152;C1313497;C1538440;C2826257;C3273279
214,no prior hf hospitalization ( n = nmbr,C0018488;C0019993;C0332152;C1313497;C1538440;C2826257;C3273279
214,no prior dm,C0011816;C0332152;C2826257;C3250443
214,no prior cv event,C0332152;C0441471;C2826257;C3538987;C4019010;C4048877;C4318503
214,no prior cabg,C0010055;C0332152;C2826257
214,no prior admc,C0332152;C2826257
214,no . of prior tnfi,C0332152;C2826257
214,no . of prior bdmards,C0332152;C2826257
214,no . of prior aedsd,C0332152;C2826257
214,no . of prior aeds,C0180309;C0332152;C2826257
214,duration of prior statin therapy^,C0332152;C0360714;C0444917;C2826257
214,dissatisfied with / stopped $ nmbr prior systemic therapy because of side effects,C0205373;C0332152;C0870433;C1272691;C1514463;C1515119;C2826257;C4085546
214,dissatisfied with / stopped $ nmbr prior systemic therapies because of side effects,C0205373;C0332152;C0870433;C1272691;C1514463;C1515119;C2826257;C4085546
214,# of prior tnfi among non - tnfi naive,C0332152;C1518422;C2826257
214,# of prior non - tnfi bdmards *,C0332152;C1518422;C2826257
214,# of prior bdmards,C0332152;C2826257
213,leading to study withdrawal,C0332152;C1522538
213,leading to study drug discontinuation,C0332152;C1522538
213,leading to discontinuation,C0332152;C0457454;C1444662;C1522538;C4552847
213,leading to death,C0011065;C0332152;C1306577;C1522538;C4082313;C4552775
212,st ‐ str ≥ nmbr % pre ‐ ci,C0008107;C0036056;C0332152;C0740175;C2257086;C3259781;C3272372;C3669034
212,pre svc,C0231957;C0332152;C0740175;C2257086;C3669034
212,pre fvc,C0332152;C0740175;C2257086;C3669034;C3714541
212,pre fevnmbr,C0332152;C0740175;C2257086;C3669034;C3714541
212,pre - treatedforhypertension [n ( % ) ],C0332152;C0740175;C2257086;C3669034
212,pre - mixed insulin,C0205430;C0332152;C0740175;C2257086;C3160715;C3669034
212,pre - bd fvc snmbr % of predicted,C0005126;C0332152;C0681842;C0740175;C1882327;C2257086;C2344255;C3669034;C3714541;C4050145
212,pre - bd fvc < nmbr % of predicted,C0005126;C0332152;C0681842;C0740175;C1882327;C2257086;C2344255;C3669034;C3714541;C4050145
212,duration of pre - randomization anticoagulant therapy,C0034656;C0332152;C0740175;C2257086;C2711563;C3669034
211,regular alcohol consumption per week,C0001948;C0205272;C0332174;C0439230
211,no alcohol consumption,C0001948
211,drinking,C0001948;C0684271
211,alcohol intake never / rarely,C0001948;C0522498;C2003901
211,alcohol intake ( a ),C0001948
211,alcohol intake ( + ) ( % ),C0001948
211,alcohol intake,C0001948
211,alcohol consumption at baseline,C0001948;C0168634;C1442488
211,alcohol consumption > once weekly,C0001948
211,alcohol consumption *,C0001948
211,alcohol consumption ( yes ) ( n ),C0001948;C1549445;C1705108;C1710701
211,alcohol consumption ( % ),C0001948
211,alcohol consumption !,C0001948
211,alcohol consumption,C0001948
210,current weekly alcohol use ( % ),C0001948;C0332174;C0521116;C1705970
210,current alcohol use,C0001948;C0521116;C1705970
210,current alcohol drinking,C0001948;C0521116;C0556297;C1705970
210,alcohol use ( % ),C0001948
210,alcohol use ( %,C0001948
210,alcohol use,C0001948
209,yes vs . no,C1549445;C1705108;C1710701
209,yes *,C1549445;C1705108;C1710701
209,yes ( stopped for trial ),C1549445;C1705108;C1710701
209,yes ( n = nmbr ),C1549445;C1705108;C1710701
209,yes ( n,C1549445;C1705108;C1710701
209,yes ( any ),C1549445;C1705108;C1710701
209,yes ( % ),C1549445;C1705108;C1710701
209,yes ',C1549445;C1705108;C1710701
209,yes  unknown,C1549445;C1705108;C1710701
209,yes  proliferative,C1549445;C1705108;C1710701
209,yes  non - proliferative,C1549445;C1705108;C1710701
209,yes,C1549445;C1705108;C1710701
209,use of cgm ( yes ),C1524063;C1549445;C1705108;C1710701
209,prior hypertensiona yes,C0332152;C1549445;C1705108;C1710701;C2826257
209,prior hypertension yes,C0020538;C0332152;C1549445;C1705108;C1710701;C1963138;C2826257
209,prior coronary artery disease yes,C0010054;C0010068;C0332152;C1549445;C1705108;C1710701;C1956346;C2826257
209,previous exposure to systemic psoriasis therapyb ( yes ),C0033860;C0205156;C0205373;C0332157;C1549445;C1552607;C1705108;C1710701
209,previous exposure to non - biologic systemic psoriasis therapyb ( yes ),C0005515;C0033860;C0205156;C0205373;C0205460;C0332157;C1518422;C1549445;C1552607;C1705108;C1710701
209,previous exposure to biologic systemic psoriasis therapyb ( yes ),C0005515;C0033860;C0205156;C0205373;C0205460;C0332157;C1549445;C1552607;C1705108;C1710701
209,nasal polyps at baseline : yes,C0027430;C0168634;C1442488;C1549445;C1705108;C1710701
209,naive : yes,C1549445;C1705108;C1710701
209,hiatal hernia ( yes ) ( n ),C1549445;C1705108;C1710701;C3489393
209,diabetic yes,C0241863;C1549445;C1705108;C1710701
209,diabetesh yes,C1549445;C1705108;C1710701
209,baseline sulfonylurea yes,C0038766;C0168634;C1442488;C1549445;C1705108;C1710701;C3536898
209,baseline calcium yes,C0006675;C0006726;C0168634;C1442488;C1549445;C1705108;C1710701;C2936886;C3540037;C3714611
209,atopic at baseline : yes,C0168634;C0392707;C1442488;C1549445;C1705108;C1710701
209,[no / yes] ( % ),C1549445;C1705108;C1710701
208,australia and new zealand,C0004340
208,australia / nz,C0004340;C0027978
208,australia,C0004340
207,untreated at baseline,C0168634;C0332155;C1442488
207,untreated,C0332155
206,nausea and / or vomiting adverse events,C0027497;C1963179;C2984057;C3829611;C4084796;C4085222;C4085661;C4085862;C4255480;C4552888;C4552889;C4553767
206,nausea,C0027497;C1963179;C2984057;C3829611;C4084796;C4085222;C4085661;C4085862;C4255480;C4552888;C4552889;C4553767
205,unclassified,C0205426;C1546437;C2347854;C4085229
204,unspecified,C0205370;C1549663;C2983689;C4048188
203,unstable but no rest angina,C0443343;C1883468
203,unstable anginat,C0443343;C1883468
203,unstable anginad,C0443343;C1883468
203,unstable,C0443343;C1883468
202,subarachnoid hemorrhage,C0038525
201,subdural / epidural,C0038541;C0228134;C0812144
200,lumbar epidural,C0581283
199,sinus tracts / perforation,C0544791;C0549099;C0854572;C1185740;C1881710
199,number of draining fistulae per patient,C0237753;C0449788;C0544791
199,no draining fistulas *,C0544791
199,draining fistulae,C0544791
198,site of disease — no . ( % ),C0012634;C2945843
198,multivessel disease 一 no . ( % ),C0012634
198,multivessel disease — no . ( % ),C0012634
198,disorders ( soc ),C0012634
198,disease and quality - of - life scores,C0012634
198,baseline disease and quality - of - life scores,C0012634;C0168634;C1442488
197,uc disease durslion,C0012634
197,disease site — no . of patients ( % ) |,C0012634;C0205145;C1515974;C2825164
197,disease site — no . ( % ) ^,C0012634;C0205145;C1515974;C2825164
197,disease site,C0012634;C0205145;C1515974;C2825164
197,disease hare . no . ( % ) i,C0012634
196,priorbone disease,C0012634
196,prior disease - modifying drugs resulting in inadequate response — mean no . / patient,C0012634;C0013227;C0332152;C0392747;C2826257;C3687832
196,prior disease,C0012634;C0332152;C2826257
196,disease,C0012634
196,any disease,C0012634
195,polyvascular disease and type nmbr diabetes ( n = nmbr ),C0012634
195,polyvascular disease and no type nmbr diabetes ( n = nmbr ),C0012634
195,polyvascular disease * and type nmbr diabetes status,C0012634
195,polyvascular disease * ( n = nmbr ),C0012634
195,polyvascular disease ( n = nmbr ),C0012634
195,no polyvascular disease * ( n = nmbr nmbr ),C0012634
195,no polyvascular disease ( n = nmbr nmbr ),C0012634
195,no multivessel disease,C0012634
195,multivessel disease,C0012634
195,mer ’ s disease assessment,C0012634;C0673013;C1261322;C1516048;C3810521;C4281714
195,established maerovaseular disease and albuminuria,C0012634;C0443211;C1272684
195,established disease,C0012634;C0443211;C1272684
195,disease extent,C0012634;C0439792
194,underlying disease,C0012634;C4067746
194,priorvascular disease,C0012634
194,peripherai arteriai disease,C0012634
194,microvascular disease *,C0012634;C0443258
194,microvascular disease,C0012634;C0443258
194,macrovascular disease,C0012634
194,exlertl ot disease,C0012634;C1318464;C1418208;C1705587
194,erosive reflux disease,C0012634;C0232483;C0439679;C1882919;C4317146
194,coronarv arterv disease,C0012634
194,cerebrovascuiar disease,C0012634
193,prespecified medical conditions,C0012634;C0199168;C0205476;C0348080;C1705253;C3864998
193,presenting condition,C0012634;C0348080;C0449450;C1705253;C3864998
193,medical conditions,C0012634;C0199168;C0205476;C0348080;C1705253;C3864998
193,history of other medical conditions,C0012634;C0262926;C0348080;C1705253;C3864998
193,currentother ( notpredefined ) medical conditions,C0012634;C0199168;C0205476;C0348080;C1705253;C3864998
193,condition nmbr ( nmbr . nmbr ),C0012634;C0348080;C1705253;C3864998
193,any condition,C0012634;C0348080;C1705253;C3864998
192,ezetimibe / simvastatin nmbr / nmbr mg ( n = nmbr ),C0024671;C0026410;C0439269;C1532737;C1960952;C2346927;C4321396;C4521761
192,ezetimibe / simvastatin group,C0441833;C0687744;C1257890;C1519504;C1532737;C1705428;C1705429
192,ezetimibe / simvastatin,C1532737
192,ezetimibe + simvastatin ( n = nmbr * ),C1532737
192,ezetimibe + simvastatin ( n = nmbr,C1532737
191,receiving concomitant nsaids and / or cox - nmbr inhibitors,C1514756
191,receiving concomitant corticosteroids,C1514756
191,receiving antihypertensive treatment -,C1514756
191,receiving antihypertensive treatment,C1514756
191,receiving antihypertensive,C1514756
191,received drug - eluting stent,C1322815;C1514756
191,received antihypertensive within last nmbr days,C0003364;C0439228;C1514756
191,received an oral aha within nmbr weeks prior to screening,C1514756
190,increase creatinine,C0010294;C0442805;C1561535
190,estimated creatinine clearancet,C0010294;C0750572;C1561535
190,doubling of creatinine †,C0010294;C0205173;C1561535;C1705764
190,doubling of creatinine,C0010294;C0205173;C1561535;C1705764
190,creatinine ≥ nmbr . nmbr mg / dl,C0010294;C0439269;C1561535
190,creatinine — mg / dl,C0010294;C0439269;C1561535
190,creatinine ratio nmbr - nmbr,C0010294;C0456603;C1547037;C1561535
190,creatinine ratio,C0010294;C0456603;C1547037;C1561535
190,creatinine nmbr . nmbr mg / dl medications,C0010294;C0013227;C0439269;C0802604;C1561535;C2598133;C4284232
190,creatinine clearanceb,C0010294;C1561535
190,creatinine ciearance,C0010294;C1561535
190,creatinine ( µ mol / l ),C0010294;C0347982;C1561535
190,creatinine ( p,C0010294;C1561535
190,creatinine ( mg / dl ),C0010294;C0439269;C1561535
190,creatinine ( ^mol / l ) ( median,C0010294;C0347982;C0549183;C0876920;C1561535;C2347635;C2348144;C2939193
190,creatinine,C0010294;C1561535
189,received nmbr prior biologic therapy,C0278947;C1514756
189,received nmbr prior biologic therapies,C0278947;C1514756
189,prior biologic therapy ( including anti - tnfs ),C0278947
188,proteinurianmbr ( g / day ),C0033687;C0439417;C1962972;C4554346
188,proteinuria ( > nmbr g / nmbr h ),C0033687;C0560020;C1962972;C4554346
188,protein in urine,C0033687
187,rosuvastatin + fenofibric acid,C0060179;C0965129
187,rosuvastain + fenofibric acid   n   =   nmbr,C0060179
187,rosuvastain + fenofibric acid nmbr = nmbr,C0060179
187,fenofibric acid   n   =   nmbr,C0060179
187,fenofibric acid nmbr = nmbr,C0060179
187,fenofibric acid - nmbr - low - dose statin,C0060179;C0360714;C0445550;C1708745
187,fenofibric acid - i - low - dose statin,C0021966;C0060179;C0221138;C0360714;C0445550;C1708745
187,fenofibric acid + low - dose statin,C0060179;C0360714;C0445550;C1708745
187,fenofibric acid,C0060179
187,drosuvastatin + fenofibric acid vs . fenofibric acid monotherapy .,C0060179
187,crosuvastatin + fenofibric acid vs . rosuvastatin monotherapy .,C0060179
186,sensitivity analyses,C0002778;C0020517;C0036667;C0312418;C0427965;C0936012;C1511883;C1522640;C1524024;C2346484;C2349185
186,responder analyses ( achieving alc < nmbr . nmbr % ),C0002778;C0936012;C1524024
186,primary analysis,C0002778;C0205225;C0439612;C0439631;C0936012;C1524024
186,prespecified analysis,C0002778;C0936012;C1524024
186,post hoc analysis,C0002778;C0687676;C0936012;C1524024;C1704687;C3469826
186,pooled analysis of sustain nmbr — nmbr trials,C0002778;C0936012;C1524024;C1709595;C2349200;C4522255
186,patients ( full analysis sety ),C0002778;C0030705;C0443225;C0936012;C1524024
186,overall analysis,C0002778;C0282416;C0936012;C1524024;C1561607
186,nmbr days until end of study ( landmark analysis ),C0002778;C0444930;C0936012;C1524024;C2746065;C2826182
186,integrated analysis set ( n = nmbr ),C0002778;C0936012;C1158478;C1524024;C1705422
186,included in analysis,C0002778;C0332257;C0936012;C1524024
186,full analysis set,C0002778;C0036849;C0443225;C0936012;C1442518;C1524024;C1705195
186,final analysis ( all patients ),C0002778;C0205088;C0936012;C1524024;C1546485;C3853528
186,crude analysis,C0002778;C0936012;C1524024
186,analysis compared with the pretreatment condition ( baseline )  n  ldl = low - density lipoprotein  csf = cerebrospinal fluid .,C0002778;C0936012;C1524024
186,analysis,C0002778;C0936012;C1524024
185,history of hypercholesterolemia,C1533076
184,heterozygous familial hypercholesterolemia †,C0342882
184,heterozygous familial hypercholesterolemia,C0342882
183,c - reactive proteinc,C0205332
182,high - sensitivityc - reactive protein,C0033684;C0205250;C0205332;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
182,batellna c - reective protein,C0033684
181,histamine - nmbr - receptor antagonist,C0019590;C4521896
181,anti - histamines,C0019590
180,life - threatening bleeding,C0019080;C1546953;C2826244;C3537125
180,life - threatening bleed,C0019080;C1546953;C2826244;C3537125
180,life - threatening,C1546953;C2826244;C3537125
179,cryptogenic localization - related,C0332240;C0475264;C1744691
179,cryptogenic,C0332240
178,idiopathic / familial,C0015576;C0241888;C0332240
178,idiopathic,C0332240
177,neurocognitive disorders,C0029227;C4041080
176,acute rheumatic disorders,C0001314
175,gastrointestinal disorders,C0017178
175,gastrointestinal ( gi ) disorders,C0017178;C1708130;C3539617;C4050121
174,pr / virgin islands,C0042752;C0279759;C0279766;C1418864;C3538934;C3538935;C3889640;C4048189;C4082178;C4082184;C4085573;C4552913;C4552914
173,pacific islander,C0242191
173,other pacific islander,C0242191
172,unified parkinson disease,C0030567;C1521736;C1548174;C1706076
171,history of carotid artery disease,C0007273;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
171,carotid artery disease,C0007273
170,major diabetic eye disease,C0205082;C0205164;C0342245;C4318856;C4521762
170,diabetic eye disease,C0342245
169,chronic cardiovascular disease,C1290380
168,chronic kidney diseased,C2364010
167,chronic pulmonary disease,C0746102
166,chronic inflammatory disease,C1290886
165,congenital heart disease,C0152021
164,rheumatic heart disease,C0035439
163,connective tissue disease,C0009782
163,connective - tissue disease,C0009782
163,associated with connective tissue disease,C0009782;C0332281
162,type of reflux disease,C0232483;C0457464;C1882919;C4317146
161,gastrooesophageal reflux disease,C0017168;C4553201
161,gastroesophageal reflux disease,C0017168;C4553201
160,inflammatory disease,C1290884
159,inflammatory bowel disease,C0021390
159,active inflammatory bowel disease,C0021390;C0205177;C3853793;C3888249
158,family history of premature coronary heart disease,C0151526;C0205252;C0260520;C1313980;C2317524;C4018905
158,family history of coronary artery disease,C2317524
157,family history of premature heart disease,C0018787;C0151526;C0205252;C0850707;C4018905
157,family history of coronary disease,C0018787;C0850707
156,not reported in ecrf,C1518422
156,not reported / unknown,C1518422
156,not receiving,C1518422
156,not present at screening,C1518422
156,not on an aha,C0050451;C0772110;C1518422
156,non - rheumatic valvular heart disease,C0264757;C1518422
156,non - inhaled steroid use,C0586793;C1518422
156,non - east asianf,C1518422;C1707877
156,non - east asian §,C0078988;C1518422;C1707877
156,non - / ex - tobacco user,C1518422;C3853727
155,timi non - cabg major,C0010055;C1518422
155,safety : non - cabg - related bleeding,C0010055;C0036043;C1518422;C1705187
155,non - cabg related bleeding at nmbr h,C0010055;C1518422
155,non - cabg or combined,C0010055;C1518422
154,no . of non - tnfi,C1518422
154,all non - mn,C0026327;C0026405;C1518422;C4285072
153,not treated,C1518422
153,not tested,C1518422
153,not reported,C1518422
153,not provided,C1518422
153,not perfused,C1518422
153,not localized,C1518422
153,not estimable,C1518422
153,not collected^,C1518422
153,non - us,C1518422
153,non - u . s .,C1518422
153,non - trial p blocker,C0008976;C1518422
153,non - trial antiplatelet,C0008976;C1518422
153,non - rollover,C0517067;C0543436;C1518422
153,non - metsyn,C1518422
153,non - mets,C0812270;C1518422;C1705694;C2939420
153,non - lad,C1518422
153,non - ischemic,C0475224;C1518422
153,non - ischaemic,C0475224;C1518422
153,non - ics +,C0815320;C1518422;C4551720
153,non - hispanicwhite,C1518422
153,non - hishnic,C1518422
153,non - hdlc,C1518422;C1704429
153,non - hdl - c / hdl - c,C1518422;C3715113
153,non - hdl - c *,C1518422;C3715113
153,non - hdl - c ( mmol / l ),C1518422;C1532563;C3715113
153,non - hdl - c ( mmol / l,C1518422;C1532563;C3715113
153,non - hdl - c,C1518422;C3715113
153,non - hdl,C1518422;C3715113
153,non - dm,C0011816;C1518422;C3250443
153,non - diabetics ( n = nmbr ),C0241863;C1518422
153,non - diabetics,C0241863;C1518422
153,non - diabetic ( n = nmbr ),C0241863;C1518422
153,non - diabetic,C0241863;C1518422
153,non - diabetes,C0011847;C0011849;C1518422
153,non - cortical,C0001613;C0007776;C0022655;C1518422
153,non - c,C1518422
152,overall population ( n = nmbr nmbr ) : non - cana ( n = nmbr )  cana nmbr mg ( n = nmbr )  cana nmbr mg ( n = nmbr ),C0032659;C0282416;C1257890;C1319635;C1418845;C1518422;C1561607
152,non - us ( n = nmbr ),C1518422
152,non - epa ( n = nmbr ),C1518422
152,non - cana ( n = nmbr ),C1418845;C1518422
151,other ischaemic heart disease ( non - infarction ),C0010054;C0021308;C0151744;C1518422
151,not hospitalized for heart failure in the year prior to study enrollment,C1518422
150,women taking estrogen,C0043210
150,women ethnic origin,C0015031;C0043210
150,women ( n = nmbr vs nmbr ),C0043210
150,women ( n = nmbr ) events,C0043210;C0441471;C3541888
150,women ( n = nmbr ),C0043210
150,women,C0043210
150,woman,C0043210;C4281745
150,sex ( women,C0009253;C0036864;C0043210;C0079399;C0804628;C1314687;C1522384
150,no . women,C0043210
150,nmbr - nmbr ( women ),C0043210
150,gmi ( women ),C0043210
149,women — no . ( % ),C0043210
149,"women t """,C0043210
149,women men,C0025266;C0043210
149,women / men [ % ],C0025266;C0043210
149,women / men,C0025266;C0043210
149,women - no . ( % ),C0043210
149,women ( n ( % ) ),C0043210
149,women ( % ),C0043210
149,men : women ( % ),C0025266;C0043210
149,men / women,C0025266;C0043210
149,hdl < nmbr / nmbr mg / dl ( nmbr . nmbr / nmbr . nmbr mmol / l ) for men / women,C0025266;C0043210;C3642216;C3715113;C3898312
149,all women,C0043210
149,( _ > nmbr . nmbr mmol / l ) hdl - c women : < nmbr mg / dl ( < nmbr . nmbr mmol / l ) men : < nmbr mg / dl,C0025266;C0043210;C3539687;C3715113;C3898312
148,no methotrexate,C0025677
148,methotrexate user,C0025677;C1548600;C1706077
148,methotrexate use at randomization,C0025677;C0034656;C0042153;C0457083;C1947944
148,methotrexate use at randomisation,C0025677;C0034656;C0042153;C0457083;C1947944
148,methotrexate use at baseline,C0025677;C0042153;C0168634;C0457083;C1442488;C1947944
148,methotrexate use,C0025677;C0042153;C0457083;C1947944
148,methotrexate plus other csdmardfl,C0025677
148,methotrexate alone^,C0025677
148,methotrexate,C0025677
148,csdmard otherthan methotrexate,C0025677
148,concomitant methotrexate use,C0025677;C0042153;C0457083;C0521115;C1947944
148,concomitant methotrexate,C0025677;C0521115
148,concomitant csdmards other than methotrexate,C0025677;C0521115
148,. nmbr kg mtx use,C0022718;C0025677;C0042153;C0439209;C0457083;C1417487;C1947944;C4054209
147,tcz + mtx ( n ),C0025677;C1417487
147,ssz + mtx ( n = nmbr ),C0025677;C1417487
147,placebo + mtx ( n = nmbr ),C0025677;C0032042;C1417487;C1696465;C1706408
147,non - mtx csdmards,C0025677;C1417487;C1518422
147,non - mtx,C0025677;C1417487;C1518422
147,nmbr tcz + mtx mtx,C0025677;C1417487
147,nmbr tcz + mtx,C0025677;C1417487
147,nmbr non - mtx,C0025677;C1417487;C1518422
147,nmbr mg + mtx,C0024671;C0025677;C0026410;C0439269;C1417487;C1960952;C2346927;C4321396;C4521761
147,mtx plus infliximab,C0025677;C0332287;C0666743;C1417487
147,mtx only,C0025677;C0205171;C1417487;C1720467
147,mtx naive or free,C0025677;C1417487
147,mtx n = nmbr,C0025677;C1417487
147,mtx ir,C0022065;C0022071;C0025677;C1417487;C1448132
147,mtx > nmbr and £ nmbr mg / week,C0025677;C1417487
147,mtx > nmbr and si nmbr mg / week,C0025677;C1417487
147,mtx - ir,C0022065;C0022071;C0025677;C1417487;C1448132
147,mtx + othetcsdmards,C0025677;C1417487
147,mtx + other csomards,C0025677;C1417487
147,mtx + other csdmards,C0025677;C1417487
147,mtx + non - mtx,C0025677;C1417487;C1518422
147,mtx ( n = nmbr ),C0025677;C1417487
147,mtx ( n ),C0025677;C1417487
147,mtx,C0025677;C1417487
147,lef + mtx ( n = nmbr ),C0025677;C1417487
147,hcq + mtx ( n = nmbr ),C0020336;C0025677;C1417487
147,etn + mtx ( n = nmbr ),C0014758;C0025677;C0717758;C1417487
147,csdmards + mtx ( n = nmbr ),C0025677;C1417487
147,concomitant use of mtx to week nmbr,C0025677;C0521115;C1417487;C1524063
147,concomitant mtx —,C0025677;C0521115;C1417487
147,concomitant mtx use,C0025677;C0042153;C0457083;C0521115;C1417487;C1947944
146,txnmbr,C0041403
146,tx,C0041403
146,triglycerides tx difference vs pbo,C0041004;C0041403;C1705241;C1705242
146,low - density lipoprotein cholesterol tx difference vs pbo,C0023824;C0041403;C1705241;C1705242
146,homajr tx difference vs pbo,C0041403;C1705241;C1705242
146,homa_ir tx difference vs pbo,C0022065;C0022071;C0041403;C1448132;C1705241;C1705242
146,homa_ % b tx difference vs pbo,C0041403;C1705241;C1705242
146,high - density lipoprotein cholesterol tx difference vs pbo,C0023822;C0041403;C1705241;C1705242
146,hbanmbrc tx difference vs pbo,C0019016;C0041403;C1705241;C1705242;C1825777;C3538758
146,hbalc tx difference vs pbo,C0041403;C1705241;C1705242
146,fpg tx difference vs pbo,C0041403;C1705241;C1705242
146,c - peptide tx difference vs pbo,C0006558;C0041403;C1705241;C1705242
146,apolipoprotein b tx difference vs pbo,C0003593;C0041403;C1705241;C1705242
145,no clinical or lesion rfs for st,C0205210
145,durable clinical responseg,C0205210
145,durable clinical remissionh,C0205210
145,clinical variables,C0205210;C0439828
145,clinical responsed,C0205210
145,clinical remissione,C0205210
145,clinical outcome,C0205210;C1274040
145,clinical or lesion rf for st,C0205210
145,clinical details,C0205210;C1522508
145,clinical criterianmbr,C0205210;C0243161
145,clinical copd phenotype^,C0024117;C0031437;C0205210;C1285572;C1412502;C3714496
145,clinical and patient reported outcomes,C0205210
145,clinical and laboratory measurements,C0205210
145,clinical ae,C0205210;C3887670
145,clinical,C0205210
145,any clinical or lesion rf for st,C0205210
145,any clinical ae,C0205210;C3887670
144,prior clinical fracture ( since age nmbr ),C0016658;C0205210;C0332152;C2826257
144,history of clinical fracture ( > nmbr years old ),C0205210;C0439234;C1272071
144,history of clinical fracture ( > nmbr years ),C0205210;C0439234;C1272071
144,clinical fracture,C0016658;C0205210
144,c clinical fractures ( fas ),C0016658;C0205210
143,patients with any clinical event,C0030705;C0205210;C0441471;C4019010
143,patients with any clinical,C0030705;C0205210
143,clinical and patient - reported characteristics at baseline and randomization,C0205210
142,taking calcium supplements at baseline,C0006675;C0006726;C1515187;C2936886;C3540037;C3714611
142,dense calcium,C0006675;C0006726;C0439794;C2936886;C3540037;C3714611
142,calcium supplements,C0006675;C0006726;C2936886;C3540037;C3714611
142,calcium channelantagonist,C0006675;C0006726;C2936886;C3540037;C3714611
142,calcium aniagonisi,C0006675;C0006726;C2936886;C3540037;C3714611
142,calcium ( mmol / l ),C0006675;C0006726;C1532563;C2936886;C3540037;C3714611
142,calcium,C0006675;C0006726;C2936886;C3540037;C3714611
141,ca - channel blockers,C0870261;C3887642
140,dihydropyridine calcium - channel blocker,C2945601
139,calcium channel,C0006685
139,calcium - channel inhibitor,C0006685;C1999216
139,calcium - channel blockersubgroup,C0006685
139,calcium - channel blockerf,C0006685
138,cbz - naive,C0006949
138,cbz - exposed,C0006949
138,carbamazepine,C0006949;C0006950;C0682993
137,nmbr chlorthalidone amlodipine,C0008294;C0051696
137,nmbr chlorthalidone ( n = nmbr ),C0008294
137,nmbr chlorthalidone,C0008294
137,nmbr amlodipine - chlorthalidone,C0008294;C0051696
137,favors amlodipine favors chlorthalidone,C0008294;C0051696;C0309049
137,chlorthalidone vs lisinopril,C0008294
137,chlorthalidone vs doxazosin,C0008294
137,chlorthalidone vs amlodipine,C0008294
137,chlorthalidone nmbr,C0008294
137,chlorthalidone group,C0008294;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
137,chlorthalidone - amlodipine - lisinopril,C0008294;C0051696;C0065374
137,chlorthalidone ( n = nmbr ),C0008294
137,chlorthalidone,C0008294
137,amlodipione - chlorthalidone,C0008294
137,amlodipine / chlorthalidone,C0008294;C0051696
136,renin - angiotensin - aldosterone system blocker,C0086907
135,non - biological systemic,C0205373;C0445097
134,“ on ” without troublesome dyskinesia,C0013384
134,“ on ” with troublesome dyskinesia,C0013384
133,no high - intensity statin,C0360714;C4081854
133,high ‐ intensity statins ‡,C0360714;C4081854
133,high intensity,C4081854
133,high - intensity statin vs medium - or low - intensity statin at randomization,C0360714;C4081854
133,high - intensity statin use,C0042153;C0360714;C0457083;C1947944;C4081854
133,high - intensity statin *,C0360714;C4081854
133,high - intensity statin,C0360714;C4081854
132,• hospitalization for unstable angina,C0002965;C0019993
132,unstable angina requiring hospitalization,C0002965;C0019993
132,previous hospitalization for unstable angina,C0002965;C0019993;C0205156;C1552607
132,no hospitalization in the past nmbr months prior to baseline ( ref ),C0019993;C4331910
132,hospitalization stratum,C0019993
132,hospitalization in the past nmbr months prior to baseline,C0019993;C4331910
132,hospitalization for unstable ap,C0002680;C0019993;C0443343;C1883468;C3887950
132,hospitalization for unstable angina,C0002965;C0019993
132,hospitalization for acute limb ischemia,C0019993;C0205178;C2945695
132,hospitalization for acs,C0019993;C0742343;C4318612
132,hospitalization for / due to,C0019993
132,hospitalisation for chf within nmbr years of randomisation,C0018802;C0019993
132,first hospitalization for chf or cv death,C0018802;C0019993;C0205435;C1279901
131,hospitalizations,C0019993
131,hospitalization for hf,C0018488;C0019993;C1313497;C1538440;C3273279
131,hospitalization for,C0019993
131,hospitalization,C0019993
131,hospitalisation,C0019993
131,hf hospitalizations,C0018488;C0019993;C1313497;C1538440;C3273279
131,hf hospitalization or cardiovascular death,C0018488;C0019993;C1313497;C1538440;C3273279
131,hf hospitalization n,C0018488;C0019993;C1313497;C1538440;C3273279
131,hf hospitalization,C0018488;C0019993;C1313497;C1538440;C3273279
131,hf hospitalisation,C0018488;C0019993;C1313497;C1538440;C3273279
130,hospitalization to enrollment,C0019993;C1516879;C1696073;C3888021
130,hospitalisation related to exacerbation,C0019993
130,enrollment strata : prior hospitalization,C0019993;C0332152;C1516879;C1696073;C2826257;C3888021
129,physician ' s judgment that vka inappropriate],C0022423;C0031831;C0804815
129,physician ' s judgment that vka inappropriate,C0022423;C0031831;C0804815
129,physician ' s judgment that vka,C0022423;C0031831;C0804815
129,physician ' s ga,C0016993;C0031831;C0804815
129,physician ' s assessment of disease activity ( vas ),C0031831;C0042815;C0804815;C1261322;C1292728;C1516048;C3536884;C3827561
129,physician,C0031831;C0804815
128,★ reported by physicians . tdata are median ( iqr ) . all data are mean ( sd ) or number ( % ) unless otherwise indicated .,C0031831;C1709908
128,* reported by physicians . † data are median ( iqr ) . all data are mean ( sd ) or number ( % ) unless otherwise indicated .,C0031831;C1511726;C1709908;C3245479;C3714741
127,no nadroparin ( n = nmbr ),C0206232
127,nadroparin vs control,C0206232
127,nadroparin ( n = nmbr ),C0206232
127,nadroparin,C0206232
126,non - dihydropyridine ccbs,C0006684;C0012315;C0220821;C1518422
126,dihydropyridine ccbs,C0006684;C0012315;C0220821
126,dihydropyridine,C0012315;C0220821
125,nmbr lisinopril,C0065374
125,lisinopril vs amlodipineb,C0065374
125,lisinopril cvd total,C0007222;C0065374;C0439175;C0439810
125,lisinopril ( n = nmbr ),C0065374
125,lisinopril,C0065374
125,ii lisinopril i,C0021966;C0065374;C0221138;C1710602;C4082587
125,ii lisinopril,C0065374;C1710602;C4082587
125,i lisinopril ( n = nmbr ),C0021966;C0065374;C0221138
124,nmbr lisinopril - chlorthalidone,C0008294;C0065374
124,lisinopril vs chlorthalidone overweight,C0065374
124,lisinopril vs chlorthalidone obese,C0065374
124,lisinopril vs chlorthalidone normal,C0065374
124,lisinopril vs chlorthalidone,C0065374
124,lisinopril / chlorthalidone,C0008294;C0065374
124,lisinopril - chlorthalidone,C0008294;C0065374
124,ii nmbr amlodipine - lisinopril - chlorthalidone chlorthalidone,C0008294;C0051696;C0065374;C1710602;C4082587
124,favors lisinopril favors chlorthalidone,C0008294;C0065374;C0309049
123,normal albuminuria ( uacr < nmbr ),C0001925;C0205307;C0231683;C0439166;C2347086;C4553972
123,macro - albuminuria,C0001925;C2984010
123,any albuminuria — no . ( % ),C0001925
123,any albuminuria,C0001925
123,albuminuria,C0001925
122,albuminuria < nmbr gram / gram cr,C0001925;C0201975;C1319635;C3539604;C3711669;C4084730;C4553336;C4553337
122,albuminuria ( g / g ),C0001925;C1319635
121,progression of albuminuria,C0001925;C0242656;C0449258
121,albuminuria progression,C0001925;C0242656;C0449258
121,albuminuria and previous maerovaseular disease without established renal disease,C0001925
121,albuminuria and previous maerovaseular disease plus established renal disease ( egfr nmbr - nmbr ml / min / lnmbr in - with an uacr > nmbr mg / g or egfr nmbr - < nmbr ml / inin / lnmbr in - with any uacr mg / g ),C0001925
120,traditional nsaid use,C0003211;C3536840;C3897349
120,traditional nsaid,C0003211;C0443324;C1548559;C3536840
120,prior nsaid use,C0003211;C0042153;C0332152;C0457083;C1947944;C2826257;C3536840
120,prior nsaid,C0003211;C0332152;C2826257;C3536840
120,postoperative nsaid or glucocorticoid use post - randomisation characteristic * *,C0003211;C0032790;C3536840
120,postoperative nsaid or glucocorticoid use,C0003211;C0032790;C3536840
120,other nsaids,C0003211
120,nsaid   at   least   once,C0003211;C3536840
120,nsaid use — no . / total no . ( % ),C0003211;C3536840
120,nsaid,C0003211;C3536840
120,non - steroidal anti - inflammatory drugs,C0003211
120,never nsaid,C0003211;C2003901;C3536840
120,cox - nmbr selective nsaid use,C0003211;C0036576;C0042153;C0457083;C1565830;C1707391;C1947944;C3536840
120,cox - nmbr selective nsaid,C0003211;C0036576;C1565830;C1707391;C3536840
120,chronic non - steroidal antiinflammatory drugs,C0003211;C0205191
120,bmi  body mass index  hrt  hormone replacement therapy  lvh  left ventricular hypertrophy  nsaids  nonsteroidal anti - inflammatory drugs  pvd  peripheral vascular disease  tia  transient ischemic attack . ahistory of and / or currently taking lipid - lowering or antidiabetic medications . bp < nmbr . nmbr for verapamil sustained - release ( sr ) vs . atenolol . chistory of or currently have elevated serum creatinine but less than nmbr mg / dl . dblood pressure control defined as < nmbr / nmbr or < nmbr / nmbr in patients with diabetes or a history of renal insufficiency .,C0003211;C0007787;C0085096;C0149721;C0282402;C1305855;C3536840
119,la grade b,C1881342
118,modi fied la grade *,C0023031;C0023749;C0230347;C0342276;C0441800;C0919553;C2346906;C3244287;C4553351
118,la grade a,C0023031;C0023749;C0230347;C2346906;C4553351
118,la diameter,C0023031;C0023749;C0230347;C1301886;C2346906;C4553351
117,angioedema present,C0002994;C0150312;C0449450
117,angioedema ( adjudicated ),C0002994
116,placebo - carisbamate nmbrmg - carisbamate nmbrmg,C0032042;C1319635;C1696465;C1706408;C1871983
116,carisbamate nmbr,C1871983
115,placebo - famotidine nmbr - famotidine nmbr,C0015620;C0032042;C1696465;C1706408
115,placebo - famotidine nmbr,C0015620;C0032042;C1696465;C1706408
115,famotidine nmbr - famotidine nmbr,C0015620
114,prior pacemaker,C0030163;C0332152;C0810633;C1546728;C2826257;C3275122;C3853703
114,pacemaker — no . ( % ),C0030163;C0810633;C1546728;C3275122;C3853703
114,pacemaker or icd,C0030163;C0810633;C1546728;C3275122;C3853703
114,pacemaker,C0030163;C0810633;C1546728;C3275122;C3853703
114,cardiac pacemaker — no . ( % ),C0030163;C0037189
113,parameter mean ± s . d .,C0444504;C0549193;C1704769;C2347634;C2348143;C2350001
113,parameter / variable,C0439828;C0549193;C1704769;C2350001;C4553760
113,parameter ( mg / dl ),C0439269;C0549193;C1704769;C2350001
113,parameter,C0549193;C1704769;C2350001
113,nmbr parameter,C0549193;C1704769;C2350001
112,secondary mace endpoint,C0349381;C0949745;C1445339;C4528314
112,primary mace endpoint,C0349381;C0949745;C1445339;C2986535
112,nmbr - polnt mace,C0349381;C0949745;C1445339
112,mace +,C0349381;C0949745;C1445339
112,mace,C0349381;C0949745;C1445339
112,hard mace,C0018599;C0349381;C0949745;C1445339
112,expanded mace,C0205229;C0349381;C0949745;C1445339
112,b mace,C0349381;C0949745;C1445339
112,adjudicated macenmbr,C0349381;C0949745;C1445339
111,£ nmbr . nmbr mmol / l,C1532563
111,tg ( mmol / l ) c,C0337445;C1532563
111,tg ( mmol / l ),C0337445;C1532563
111,tg ( mmol / l,C0337445;C1532563
111,serum hdl cholesterol ( mmol / l ),C0428472;C1532563
111,nmbr . nmbr - nmbr . nmbr mmol / l,C1532563
111,nmbr - nmbr mmol / l,C1532563
111,hbanmbrc — % cholesterol — mmol / l,C0008377;C0019016;C1532563;C1825777;C3538758
111,cholesterol ( mmol / l ),C0008377;C1532563
111,baseline tg > nmbr . nmbr mmol / l,C0168634;C0337445;C1442488;C1532563
111,baseline tg < nmbr . nmbr mmol / l,C0168634;C0337445;C1442488;C1532563
111,> nmbr mmol / l,C1532563
111,> nmbr . nmbr mmol / l,C1532563
111,> nmbr - nmbr mmol / l,C1532563
111,> nmbr + nmbr mmol / l,C1532563
111,> nmbr ' nmbr mmol / l,C1532563
111,< nmbr mmol / l,C1532563
111,< nmbr . nmbr mmol / l,C1532563
111,< nmbr - nmbr mmol / l,C1532563
110,tc ( mmol / l ),C0039411;C0040642;C0041405;C0041698;C1532563;C1824670;C3272447;C4522122
110,phosphate ( mmol / l ),C0031603;C0031701;C1532563;C1601799
110,na ( mmol / l ),C0597484;C1272460;C1532563;C1546968;C1879645;C4049872;C4552882
110,mmol / l [n],C1532563
110,mmol / l ),C1532563
110,mmol / l,C1532563
110,mdg ( mmol / l ),C0024443;C1417239;C1532563;C2986643
110,ldl - c   *   ( mmol / l ),C1532563
110,ldl - c < nmbr . nmbr mmol / l,C1532563
110,ldl - c * ( mmol / l ),C1532563
110,ldl - c ( mmol / l ),C1532563
110,ldl - c ( mmol / l,C1532563
110,ldl ( mmol / l ),C1532563
110,k ( mmol / l ),C0597277;C1532563;C1708601
110,hdl - c ( mmol / l ),C1532563;C3715113
110,hdl - c ( mmol / l,C1532563;C3715113
110,hdl ( mmol / l ),C1532563;C3715113
110,free fatty acids ( mmol / l ),C0015688;C1532563
110,fpg ( mmol / l ),C1532563
110,ffa ( mmol / l ),C0015688;C1532563
110,fbg ( mmol / l ),C1532563
110,[nmbr . nmbr mmol / l] ),C1532563
110,> nmbr . nmbrmmol / l ( n = nmbr ),C1532563
110,( mmol / l],C1532563
110,( mmol / l ),C1532563
110,( < nmbr . nmbr mmol / l ),C1532563
109,≥   nmbr   mmol / mol ( nmbr . nmbr % ),C3829066
109,≥ nmbr . nmbr % ( ≥ nmbr mmol / mol ),C3829066
109,≤   nmbr   mmol / mol ( nmbr . nmbr % ),C3829066
109,mmol / mol,C3829066
109,hbanmbrc   ( mmol / mol ),C0019016;C1825777;C3538758;C3829066
109,hbanmbrc nmbr . nmbr to < nmbr . nmbr % ( nmbr - nmbr mmol / mol ),C0019016;C1825777;C3538758;C3829066
109,hbanmbrc ( mmol / mol [se] ),C0019016;C0036919;C1825777;C3538758;C3829066
109,hbanmbrc ( mmol / mol ),C0019016;C1825777;C3538758;C3829066
109,hbanmbrc $ nmbr . nmbr % ( nmbr mmol / mol ),C0019016;C1825777;C3538758;C3829066
109,hbalc £ nmbr mmol / mol ( £ nmbr . nmbr % ) ( n = nmbr / nmbr ),C3829066
109,hbalc £ nmbr mmol / mol ( > nmbr . nmbr % ) ( n = nmbr / nmbr ),C3829066
109,hbalc £ nmbr mmol / mol ( < nmbr . nmbr % ) ( n = nmbr / nmbr ),C3829066
109,hbalc > nmbr mmol / mol ( > nmbr . nmbr % ) ( n = nmbr / nmbr ),C3829066
109,hbalc > nmbr - < nmbr mmol / mol ( > nmbr . nmbr - < nmbr . nmbr % ) ( n = nmbr / nmbr ),C3829066
109,hbalc < nmbr mmol / mol ( £ nmbr . nmbr % ) ( n = nmbr / nmbr ),C3829066
109,hbalc < nmbr mmol / mol ( < nmbr . nmbr % ) at week nmbr,C0332174;C0439230;C3829066
109,hbalc < nmbr mmol / mol ( < nmbr . nmbr % ) ( n = nmbr / nmbr ),C3829066
109,hbalc < nmbr % ( nmbr mmol / mol ),C3829066
109,hbalc < nmbr % ( < nmbr mmol / mol ),C3829066
109,hbalc ( mmol / mol ),C3829066
109,hbaj ( - ( %  mmol / mol ),C3829066
109,hba]c ( mmol / mol ),C0019016;C1825777;C3538758;C3829066
109,baseline hbanmbrc ≥ nmbr . nmbr % to < nmbr . nmbr % ( nmbr – nmbr mmol / mol ),C0019016;C0168634;C1442488;C1825777;C3538758;C3829066
109,anmbrc ( mmol / mol ),C3829066
109,alc ( mmol / mol ),C1424945;C3811058;C3829066
109,>   nmbr – <   nmbr   mmol / mol ( nmbr . nmbr – nmbr . nmbr % ),C3829066
109,> nmbr % ( > nmbr mmol / mol ),C3829066
109,> = nmbr % ( nmbr mmol / mol ),C3829066
109,< nmbr . nmbr % ( nmbr mmol / mol ),C3829066
109,< nmbr . nmbr % ( < nmbr mmol / mol ),C3829066
109,< nmbr % ( nmbr mmol / mol ),C3829066
109,< nmbr % ( < nmbr mmol / mol ),C3829066
109,% hbanmbrc ( mmol / mol ),C0019016;C1825777;C3538758;C3829066
108,nmbr . nmbr to < nmbr . nmbr % ( nmbr to < nmbr mmol / mol ),C0040363;C0041260;C1883351;C3829066
108,> nmbr % to < nmbr % ( > nmbr to nmbr mmol / mol ),C0040363;C0041260;C1883351;C3829066
108,> nmbr % to < nmbr % ( > nmbr to < nmbr mmol / mol ),C0040363;C0041260;C1883351;C3829066
108,> = nmbr . nmbr % ( > = nmbr mmol / mol ),C3829066
107,homa - ir ( mu / l^mmol / l ),C0022065;C0022071;C0439190;C0439342;C1448132
107,haemoglobin ( mmol / l ),C0019046;C0439190;C0635222;C1532563
107,fpg ( mmol / nmbr ),C0439190
107,> nmbr . nmbr to < nmbr . nmbr mu / l - mmol / l,C0439190;C0439342
107,> nmbr . nmbr to < nmbr . nmbr mu / l $ mmol / l,C0439190;C0439342
107,> nmbr . nmbr mu / l - mmol / l,C0439190;C0439342
107,> nmbr . nmbr mu / l $ mmol / l,C0439190;C0439342
107,< nmbr . nmbr mu / l - mmol / l,C0439190;C0439342
107,< nmbr . nmbr mu / l $ mmol / l,C0439190;C0439342
107,( mu / l $ mmol / l ) b,C0439190;C0439342
106,triglycerides — mmol / liter,C0041004;C0439190;C0475211
106,serum cholesterol — mmol / liter,C0439190;C0475211;C0587184
106,plasma glucose — mmol per liter,C0202042;C0439190;C0455280;C0475211
106,plasma glucose nmbr hr after glucose load — mmol / liter,C0202042;C0439190;C0455280;C0475211;C1550025;C1704782;C1708715
106,glucose — mmol / liter,C0017725;C0439190;C0475211
106,free fatty acids — mmol / liter,C0015688;C0439190;C0475211
106,fasting plasma glucose — mmol / liter,C0015663;C0202042;C0439190;C0455280;C0475211
106,fasting blood glucose — mmol / liter,C0428568;C0439190;C0475211;C1261430
106,> nmbr . nmbr mmol / liter,C0439190;C0475211
106,< nmbr . nmbr mmol / liter,C0439190;C0475211
105,urine acr ( mg / mmol ),C0042036;C0042037;C0567349;C1412134;C1515941;C2348885;C2963137
105,urinary acr ( mg / mmol ),C0042027;C0567349;C1412134;C1515941;C1524119;C2348885
105,uacr   ≥ nmbr   mg / mmol ∗,C0567349;C2348885
105,uacr   < nmbr   mg / mmol ∗,C0567349;C2348885
105,snmbr mg / mmol,C0565930;C0567349;C2348885;C2603362
105,snmbr . nmbr mg / mmol,C0565930;C0567349;C2348885;C2603362
105,nmbr . nmbr to # nmbr . nmbr mg / mmol,C0567349;C2348885
105,nmbr . nmbr - < nmbr . nmbr mg / mmol,C0567349;C2348885
105,mg / mmol,C0567349;C2348885
105,> nmbr . nmbr mg / mmol,C0567349;C2348885
105,< nmbr . nmbr mg / mmol,C0567349;C2348885
105,. nmbr . nmbr mg / mmol,C0567349;C2348885
104,nmbr tq - fi ' i,C0021966;C0221138;C3555502;C4050619
104,nmbr . nmbr ( fi . nmbr ),C4050619
103,≤ nmbr u / kg / day,C1532634
103,> nmbr u / kg / day,C1532634
102,( nmbr % ell ' ll,C1427925;C3273466
101,> nmbr / nmbr lung fields,C0225759
100,< nmbr . nmbr tng > cll,C0023434
99,no . copies glynmbr - glunmbr - nmbrc,C0068000;C1948062
98,fc - ldl - c,C2983605
98,baseline fc - ldl - c,C0168634;C1442488;C2983605
97,titre ( u / ml ) t,C0439340;C0475208;C1880521;C2945590
97,igelow ( < nmbrku / l  n = nmbr  nmbr ),C0439340
97,igelow ( < inmbrku / l  n = i  nmbr ),C0021966;C0221138;C0439340
97,igehigh ( > inmbrku / l  n = i  nmbr ),C0021966;C0221138;C0439340
97,ige ( ku / l ),C0439340
96,iee at baseline : < nmbriu / l,C0168634;C0439457;C1442488
96,> nmbr to < nmbr iu / l,C0439457
96,> nmbr iu / l,C0439457
95,£ nmbr m b ' m in,C1709500
95,. nmbr . nmbr ml / s / mnmbr ( nmbr ml / min / nmbr . nmbr mnmbr ),C0439390;C0702093;C1524029;C1709500;C3813700
94,> l : nmbrhrs : min ( n = nmbr ),C0439393;C1568891
94,> = nmbr l_ / min,C0439393
94,> = nmbr l / min,C0439393
94,< nmbr l / min,C0439393
93,≥ nmbr ng / ml,C0439275
93,wapnmbrc ( ng / ml ),C0439275
93,vegfr ( ng / ml ),C0439275;C1568520
93,troy ( ng / ml ),C0439275;C1420811;C1883402
93,tnmbr ( nmbr . nmbr - nmbr . nmbr ng / ml ),C0439275;C2603360
93,tertile nmbr ( < nmbr . nmbr ng / ml ) n - nmbr,C0439275
93,syndecan - nmbr ( ng / ml ),C0075691;C0439275;C1419891
93,sdc nmbr . nmbr - nmbr . nmbr ng / ml,C0439275;C1419891;C3273112
93,sdc ( nmbr . nmbr - nmbr . nmbr ng / ml ),C0439275;C1419891;C3273112
93,sdc ( ng / ml ),C0439275;C1419891;C3273112
93,rage ( ng / ml ),C0034634;C0439275;C3539760;C3815186
93,ptxnmbr ( ng / ml ),C0030899;C0439275
93,psap - b ( ng / ml ),C0439275;C1418975;C1420002;C1425004
93,procalcitonin ( ng / ml ),C0072027;C0439275
93,proadm ( ng / ml ),C0439275
93,pigr ( ng / ml ),C0439275;C1418569
93,pentraxin - nmbr ( ng / ml ),C0439275
93,osteopontin ( ng / ml ),C0069676;C0439275;C1420369;C1505427;C4084879
93,ntpro - cnp ( ng / ml ),C0439275;C3889729
93,nt probnp > nmbr ng / ml n ( % ) §,C0439275;C1317554;C2825907;C4284038
93,ngal ( ng / ml ),C0215955;C0439275;C1416806;C2346625
93,neuropilin ( ng / ml ),C0287275;C0439275
93,mpo ( ng / ml ),C0439275
93,mesothelin ( ng / ml ),C0380162;C0439275;C1334533
93,ltbr ( ng / ml ),C0439275;C1416931
93,gdf - nmbr ( ng / ml ),C0439275;C1418244
93,galectin - nmbr ( ng / ml ),C0439275;C0607430
93,esam ( ng / ml ),C0439275;C1424976
93,d - dimer ( ng / ml ),C0060323;C0439275
93,angiogenin ( ng / ml ),C0051844;C0439275;C1367482
93,> nmbr . nmbr ng / ml ( n = nmbr ),C0439275
93,> nmbr . nmbr ng / ml,C0439275
93,< nmbr ng / ml,C0439275
93,< nmbr . nmbr ng / ml ( n = nmbr ),C0439275
93,< nmbr . nmbr ng / ml,C0439275
92,sr ii b nmbr - cjl nmbr,C0753208;C1709991;C1710602;C3813610;C3890900;C3891546;C4082587
92,rerapamil - sr strategy ( n = nmbr ),C0679199;C0753208;C1709991;C3813610;C3890900;C3891546
91,risk ratio [nmbr % cl],C0028873;C0242492;C0596019
91,relative risk ® ( nmbr % cl ),C0242492;C0596019
91,relative risk ® ' ( nmbr % cl ),C0242492;C0596019
91,relative risk vs . placebo ( nmbr % cl ),C0242492
91,relative risk * ( nmbr % cl ),C0242492;C0596019
91,relative risk ( nmbr % cl ),C0242492;C0596019
90,insulin glargine - air insulin / insulin glargine,C0001861;C0907402;C3536832
90,air insulin - insulin glargine - air insulin / insulin glargine,C0001861;C0907402;C3536832
90,air insulin - air insulin / insulin glargine,C0001861;C0907402;C3536832
90,air + ig ( n = nmbr ),C0001861;C0021027;C0305052;C0360506;C3536832
90,air ( n = nmbr ),C0001861;C3536832
89,irr = nmbr . nmbr ( nmbr . nmbr – nmbr . nmbr ) nmbr . nmbr,C4082285
88,nmbrrd : nmbr . nmbr - nmbr . nmbr pmol / l,C0439284;C0694666;C4553350
88,nmbrnd : nmbr . nmbr - nmbr . nmbr pmol / l,C0439284
87,nmbr mg / nmbr wk ( n = nmbr ),C1881833
87,mtx ( mean dose : nmbr . nmbr mg / wk ),C0366550;C0444504;C1881833;C2347634;C2348143
86,normonatremic ( > nmbr meq / l ) at baseline,C0168634;C0439375;C1442488
86,hyponatremic ( < nmbr meq / l ) at baseline,C0168634;C0439375;C0857122;C1442488
86,elevated bun ( > nmbr . nmbr meq / l ),C0151539;C0439375
86,baseline : > nmbr . nmbr meq / l eos : > nmbr . nmbr meq / l,C0168634;C0439375;C1442488;C1623465;C1861303
86,baseline : > nmbr . nmbr meq / l eos : < nmbr . nmbr meq / l,C0168634;C0439375;C1442488;C1623465;C1861303
86,baseline : < nmbr . nmbr meq / l eos : > nmbr . nmbr or < nmbr . nmbr meq / l,C0168634;C0439375;C1442488;C1623465;C1861303
85,nmbr mq / kq *,C0024853
85,elevated creatine kinase mb ( > nmbr u / l ),C0010290;C0024853;C0151576;C0205250;C0439339;C0523584;C3163633
85,elevated creatine kinase - mb ( > nmbr u / l ),C0010290;C0024853;C0151576;C0205250;C0439339;C0523584;C3163633
84,alvmi ( per g / mnmbr ),C0456715
83,apo a - l ( g / l ),C0628062
82,anti - dsdna ( > nmbr iu / ml ),C0439458;C0741099
81,tnf - rnmbra ( ng / ml ),C1363984;C1706001
80,nmbr . nmbr ( g . l ),C0439294;C0456615
80,igg ( > nmbr . nmbr g / l ),C0439294;C0456615
80,hemoglobin ( g / l ),C0019046;C0439267;C0439294;C0456615;C0635222
80,haemoglobin ( g / l ),C0019046;C0439267;C0439294;C0456615;C0635222
80,apo b ( g / l ),C0003593;C0439294;C0456615;C3252643
80,> nmbr . nmbr - g / l,C0439294;C0456615
79,nmbr / nmbr mga ( n = nmbr ),C0065879
79,hscrp > nmbr . nmbr mga .,C0065879
79,hscrp < nmbr . nmbr mga . nmbr ( nmbr . nmbrxnmbr ( nmbr . nmbr ),C0065879
78,unbound pcsknmbr ( nmol / l ),C0439282
78,testosterone level ( nmol / l ),C0428412;C0439282;C0523912
78,testosterone ( tt ) ( nmol / l ),C0039601;C0439282;C1452561;C4554543
78,testosterone ( nmol / l ),C0039601;C0439282
78,hscrp ( nmol / l ),C0439282
78,cholesterol ( nmol / l ),C0008377;C0439282
77,nmbr - h postprandial proinsulin ( pmol / l ),C0033362;C0376674;C2827799;C3813208
77,fasting proinsulin ( pmol / l ),C0015663;C0033362;C0439284;C3813208
76,trigl yeerides * ( m mol / l ),C0027960;C0324740;C0347982;C0369637;C0439189;C0441923;C0456616;C1456781;C1824986;C3665593
76,epa ( mol % ),C0027960;C0324740;C0439189;C1456781;C1824986;C3665593
75,nmbr - h pmg ( mmol / l ),C2827804
75,nmbr - h pg ( mmol / l ),C0030827;C0072225;C0439190;C1266240;C2827798;C2827804
74,≤ nmbr mg / l,C0439268
74,upadacitinib nmbr mg ( n = lnmbr ),C0439268
74,serum cholesterol ( mg / l ) *,C0439268;C0587184
74,nmbr to nmbr mg / l ( n = nmbr ),C0439268
74,nmbr . nmbr - nmbr . nmbr mg / l,C0439268
74,hscrp > nmbr to < nmbr mg / l,C0439268
74,hscrp > nmbr mg / l,C0439268
74,hscrp > nmbr . nmbr mg / l,C0439268
74,hscrp < nmbr . nmbr mg / l,C0439268
74,hscrp ( mg / l ) c,C0439268
74,hscrp ( mg / l ),C0439268
74,hs - crp mg / l,C0439268;C3890735;C4048285
74,hs - crp jnmbr . nmbrmg / l,C0439268;C3890735;C4048285
74,hs - crp jnmbr . nmbr mg / l,C0439268;C3890735;C4048285
74,hs - crp _ = nmbr . nmbr mg / l,C0439268;C3890735;C4048285
74,hs - crp > nmbr . nmbr mg / l,C0439268;C3890735;C4048285
74,hs - crp < nmbr . nmbr mg / l,C0439268;C3890735;C4048285
74,hs - crp ( mg / l ),C0439268;C3890735;C4048285
74,hs - crp ( mg / l,C0439268;C3890735;C4048285
74,crp — mg / l,C0439268;C3890735;C4048285
74,crp [mg / l],C0439268;C3890735;C4048285
74,crp < nmbr mg / l,C0439268;C3890735;C4048285
74,crp ( mg / l ) [b],C0439268;C3890735;C4048285
74,crp ( mg / l ) : < nmbr,C0439268;C3890735;C4048285
74,crp ( mg / l ) ( cv ),C0439268;C3538987;C3890735;C4048285;C4048877;C4318503
74,crp ( mg / l ),C0439268;C3890735;C4048285
74,crp $ nmbr mg / l,C0439268;C3890735;C4048285
74,cld nmbr mg ( n = lnmbr ),C0439268
74,about nmbr mg / l or more,C0439268
74,about nmbr mg / l,C0439268
74,> nmbr mg / l ( n = nmbr ),C0439268
74,> nmbr mg / l,C0439268
74,> nmbr . nmbr mg / l,C0439268
74,< nmbr mg / l ( n = nmbr ),C0439268
74,< nmbr mg / l,C0439268
74,< nmbr . nmbrmg / l,C0439268
74,( ≥ nmbr mg / l ),C0439268
74,( < nmbr mg / l ),C0439268
73,troponin i ( pg / ml ),C0077401;C0439297
73,tnf - alpha ( pg / ml ),C0439297;C1448177;C1456820;C1522669
73,tertile nmbr ( nmbr . nmbr - nmbr . nmbr pg / ml ) n = nmbr,C0439297
73,tertile nmbr ( > nmbr . nmbr pg / ml ) n - nmbr,C0439297
73,kim nmbr ( pg / ml ),C0439297
73,interleukin nmbr ( pg / ml ),C0021764;C0439297;C1527200
73,interleukin - nmbr ( ng / l ),C0021764;C0439297;C1527200
73,il - nmbr ( pg / ml ),C0020898;C0021764;C0022271;C0439297
73,endothelin nmbr ( pg / ml ),C0079284;C0439297
73,> ulnand < nmbr ng / l,C0439297
72,avp pg / ml,C0439297;C1098706;C1568204;C1708407
72,> nmbr ng / l,C0439297
71,nptercilenmbr ( bnpnmbr - nmbr pg / ml,C0054015;C0439297;C1095989;C1417808;C2982014
71,np tercile nmbr ( bnp > nmbr pg / ml,C0054015;C0065827;C0439297;C1095989;C1417808;C1706141;C2982014;C3887659
71,np tercile nmbr ( bnp < nmbr pg / ml,C0054015;C0065827;C0439297;C1095989;C1417808;C1706141;C2982014;C3887659
71,nmbr . nmbr - < nmbr ng / l ( n = nmbr ),C0439297
71,nmbr - < nmbr ng / l ( n = nmbr ),C0439297
71,mean ( nmbrth tonmbrthquartile ) bnp ( pg / ml ),C0039725;C0039738;C0054015;C0439297;C0444504;C1095989;C1417808;C1420718;C2347634;C2348143;C2982014;C4282123;C4285344
71,elevated bnp ( nmbr pg / ml ),C0054015;C0205250;C0439297;C1095989;C1417808;C2982014;C3163633
71,bnp o nmbr pg / ml or nt pro - bnp o nmbr pg / ml,C0054015;C0439297;C1095989;C1417808;C2982014
71,bnp > nmbr pg / ml or nt pro - bnp > nmbr pg / ml,C0054015;C0439297;C1095989;C1417808;C2982014
71,b - natriuretic peptide . pg / ml,C0070338;C0439297;C0597421
71,> = nmbr to < nmbr ng / l ( n = nmbr ) n ( % ),C0439297
71,> = nmbr ng / l ( n = nmbr ) n ( % ),C0439297
71,> = nmbr ng / l ( n = nmbr ),C0439297
71,> = nmbr . nmbr to < nmbr ng / l ( n = nmbr ) n ( % ),C0439297
71,< nmbr . nmbr ng / l ( n = nmbr ) n ( % ),C0439297
71,< nmbr . nmbr ng / l ( n = nmbr ),C0439297
70,stage nmbr : nmbr - nmbr ml / min / nmbr . nmbr mnmbr,C0439445;C0456533
70,stage nmbr : > nmbr ml / min / nmbr . nmbr mnmbr,C0439445;C0456533
70,stage nmbr : < nmbr ml / min / nmbr . nmbr mnmbr,C0439445;C0456533
70,nmbr to < nmbr ml / min,C0439445
70,egfr ≥ nmbr ml / min / nmbr . nmbr mnmbr,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
70,egfr — ml / min / nmbr . nmbr mnmbr,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
70,egfr — ml / min / nmbr . nmbr m^,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
70,egfr — ml / min / nmbr . nmbr m * *,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
70,egfr £ nmbr ml / min / nmbr . nmbrmnmbr,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
70,egfr   ≥ nmbr   ml / min / nmbr . nmbr mnmbr,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
70,egfr   < nmbr   ml / min / nmbr . nmbr mnmbr,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
70,egfr via mdrd ( ml / min / nmbr . nmbrmnmbr ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682;C3839656
70,egfr snmbro ml / min / nmbr . nmbr m^,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
70,egfr snmbr ml / min / nmbr . nmbr m^,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
70,egfr nmbr – nmbr ml / min / nmbr . nmbr mnmbr,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
70,egfr nmbr to < nmbr ml / min / nmbr . nmbr m^,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
70,egfr nmbr to < nmbr ml / min / nmbr . nmbr m ’,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
70,egfr nmbr to < nmbr ml / min / nmbr . nmbr m *,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
70,egfr nmbr to < nmbr ml / min / nmbr . nmbr,C0439445;C1739039;C3811844;C3812682
70,egfr nmbr to < nmbr ml / min,C0439445;C1739039;C3811844;C3812682
70,egfr nmbr ml / min / nmbr . nmbr m^,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
70,egfr nmbr ml / min / nmbr . nmbr,C0439445;C1739039;C3811844;C3812682
70,egfr nmbr - nmbr ml / min / nmbr . nmbrmnmbr n = nmbr,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
70,egfr nmbr - nmbr ml / min / nmbr . nmbrmnmbr,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
70,egfr nmbr - nmbr ml / min / nmbr . nmbr mnmbr,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
70,egfr in ml / min / nmbr . nmbr m^,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
70,egfr crcl < nmbr ml / min / nmbr . nmbr mnmbr,C0369637;C0439445;C0441923;C1739039;C1846718;C3811844;C3812682
70,egfr category ( ml / min / nmbr . nmbr mnmbr ),C0369637;C0439445;C0441923;C0683312;C1739039;C3811844;C3812682;C3889287
70,egfr by cystatin c ( ml / min per nmbr · nmbrmnmbr,C0071744;C0439445;C1413772;C1739039;C3811844;C3812682
70,egfr by creatinine ( ml / min per nmbr · nmbr mnmbr ),C0010294;C0439445;C1561535;C1739039;C3811844;C3812682
70,egfr by creatinine ( ml / min per nmbr · nmbr mnmbr,C0010294;C0439445;C1561535;C1739039;C3811844;C3812682
70,egfr > nmbr ml / min / nmbr . nmbrmnmbr,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
70,egfr > nmbr ml / min / nmbr . nmbr mz,C0026655;C0439445;C1705291;C1739039;C3811844;C3812682
70,egfr > nmbr ml / min / nmbr . nmbr mnmbr,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
70,egfr > nmbr ml / min / nmbr . nmbr m^,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
70,egfr > nmbr ml / min / nmbr - nmbr mnmbr,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
70,egfr > nmbr ml / min,C0439445;C1739039;C3811844;C3812682
70,egfr > nmbr ( ml / min / nmbr . nmbr mnmbr ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
70,egfr > = nmbrml / min / nmbr . nmbrmnmbr n = nmbr,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
70,egfr < nmbr ml / min / nmbr . nmbrmnmbr,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
70,egfr < nmbr ml / min / nmbr . nmbr mz,C0026655;C0439445;C1705291;C1739039;C3811844;C3812682
70,egfr < nmbr ml / min / nmbr . nmbr mnmbr §,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
70,egfr < nmbr ml / min / nmbr . nmbr mnmbr *,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
70,egfr < nmbr ml / min / nmbr . nmbr mnmbr,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
70,egfr < nmbr ml / min / nmbr . nmbr m^,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
70,egfr < nmbr ml / min / nmbr . nmbr,C0439445;C1739039;C3811844;C3812682
70,egfr < nmbr ml / min / nmbr - nmbr mnmbr,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
70,egfr < nmbr ml / min,C0439445;C1739039;C3811844;C3812682
70,egfr < nmbr ( ml / min / nmbr . nmbr mnmbr ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
70,egfr ( ml / min / nmbr . nmbrmnmbr ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
70,egfr ( ml / min / nmbr . nmbr mnmbr ) §,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
70,egfr ( ml / min / nmbr . nmbr mnmbr ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
70,egfr ( ml / min / nmbr - nmbr mz ),C0026655;C0439445;C1705291;C1739039;C3811844;C3812682
70,egfr ( ml / min ),C0439445;C1739039;C3811844;C3812682
70,chronic kidney disease stage : egfr ( ml / min per nmbr . nmbr mnmbr ),C0007591;C0439445;C0456533;C1561643;C1739039;C3811844;C3812682;C4553188
70,> nmbr to < nmbr ml / min,C0439445
69,〉 nmbr ml / min per nmbr . nmbr mnmbr,C0369637;C0439445;C0441923
69,≥ nmbr ml / min / nmbr . nmbr mnmbr,C0369637;C0439445;C0441923
69,rate ( ml / min / nmbr . nmbrmnmbr ),C0369637;C0439445;C0441923;C0871208;C1521828
69,nmbr to nmbr ml / min per nmbr . nmbr mnmbr,C0369637;C0439445;C0441923
69,nmbr to < nmbr ml / min per nmbr . nmbr m^,C0369637;C0439445;C0441923
69,nmbr to < nmbr ml / min ( n = nmbr nmbr ),C0439445
69,nmbr - nmbr ml / min / nmbr . nmbrmnmbr,C0369637;C0439445;C0441923
69,nmbr - nmbr ml / min / nmbr . nmbr mnmbr,C0369637;C0439445;C0441923
69,gfr < nmbrml / min / nmbr . nmbr mnmbr,C0017654;C0369637;C0439445;C0441923;C1424601
69,egfrmdrd ， ml - min - nmbr - nmbr . nmbr m_nmbr,C0369637;C0439445;C0441923
69,egfrmdrd < nmbr ml - min - nmbr - nmbr . nmbr m - nmbr,C0369637;C0439445;C0441923
69,egfr ≥ nmbr ml / min per nmbr · nmbr mnmbr,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
69,egfr ≥ nmbr ml / min / nmbr . nmbr mnmbr ( n = nmbr ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
69,egfr ‡ ( ml / min per nmbr · nmbr mnmbr ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
69,egfr nmbr to < nmbr ml / min / nmbr . nmbr mnmbr ( n = nmbr ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
69,egfr nmbr - nmbr ml / min / nmbr . nmbrmnmbr n = nmbr ( nmbr . nmbr % ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
69,egfr nmbr - nmbr ml / min / nmbr . nmbr mnmbr ( n = nmbr,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
69,egfr crcl ml · min − nmbr · nmbr . nmbr m − nmbr,C0369637;C0439445;C0441923;C1739039;C1846718;C3811844;C3812682
69,egfr > nmbr ml / min per nmbr^nmbr m ',C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
69,egfr < nmbr ml / min per nmbr^nmbr m ',C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
69,egfr < nmbr ml / min per nmbr · nmbr mnmbr,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
69,egfr < nmbr ml / min / nmbr . nmbr mnmbr ( n = nmbr ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
69,egfr < nmbr ml / min / nmbr . nmbr mnmbr ( mdrd ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682;C3839656
69,egfr . nmbr ml / min / nmbr . nmbr mnmbr ( n = nmbr,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
69,egfr ( ml / min per nmbr^nmbr m ' ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
69,egfr ( ml / min per nmbr · nmbr mnmbr ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
69,egfr ( ml / min per nmbr . nmbr mnmbr ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
69,egfr ( ml / min per nmbr - nmbr mnmbr ) t,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
69,egfr ( ml / min per nmbr - nmbr mnmbr ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
69,egfr ( ml / min per nmbr - nmbr m^ ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
69,egfr ( ml / min per nmbr - nmbr m ’ ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
69,egfr ( ml / min per nmbr - nmbr m ' ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
69,egfr ( ml / min per nmbr + nmbr m ”,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
69,ecfr ( ml / min per nmbr - nmbr m ’ ),C0369637;C0439445;C0441923
69,> nmbrml / min / nmbr . nmbr,C0439445
69,> nmbr ml / min per nmbr . nmbr m^,C0369637;C0439445;C0441923
69,> nmbr ml / min per nmbr - nmbr mnmbr,C0369637;C0439445;C0441923
69,> nmbr ml / min / nmbr . nmbrmnmbr,C0369637;C0439445;C0441923
69,> nmbr ml / min / nmbr . nmbr mnmbr,C0369637;C0439445;C0441923
69,> nmbr ml / min / nmbr . nmbr m^,C0369637;C0439445;C0441923
69,> nmbr ml / min / nmbr . nmbr,C0439445
69,> nmbr ml / min ( n = nmbr ),C0439445
69,> = nmbr ml / min / nmbr . nmbrmnmbr,C0369637;C0439445;C0441923
69,< nmbr ml / min per nmbr . nmbr mnmbr,C0369637;C0439445;C0441923
69,< nmbr ml / min per nmbr - nmbr mnmbr,C0369637;C0439445;C0441923
69,< nmbr ml / min / nmbr . nmbrmnmbr,C0369637;C0439445;C0441923
69,< nmbr ml / min / nmbr . nmbr mnmbr,C0369637;C0439445;C0441923
69,< nmbr ml / min / nmbr . nmbr m^,C0369637;C0439445;C0441923
69,< nmbr ml / min ( n = nmbr ),C0439445
69,( nmbr - nmbr ml / min per nmbr . nmbr mnmbr ),C0369637;C0439445;C0441923
69,( $ nmbr ml / min per nmbr . nmbr mnmbr ),C0369637;C0439445;C0441923
68,≥ nmbr ml / min,C0439445
68,• ? sd ml / min,C0439445;C2699239
68,£ nmbr ml / min,C0439445
68,snmbr ml / min,C0439445;C0565930;C2603362
68,nmbr – ≤ nmbr ml / min,C0439445
68,nmbr – < nmbr ml / min,C0439445
68,nmbr to < nmbr ml / min / nmbr - nmbr,C0439445
68,nmbr to < nmbr ml / min / nmbr,C0439445
68,nmbr ml / min,C0439445
68,nmbr - nmbr ml min ) nmbr,C0439445
68,"nmbr - nmbr ml min "" nmbr",C0439445
68,nmbr - nmbr ml / min,C0439445
68,nmbr - nmbr ( < nmbr ml / min ),C0439445
68,nmbr - < nmbrml / min,C0439445
68,nmbr - < nmbr ml / min,C0439445
68,nmbr ( nmbr to < nmbr ml / min ),C0439445
68,nmbr ( $ nmbr ml / min ),C0439445
68,ecrcl < nmbr ml / min,C0439445
68,creat clearance > nmbr ml / min,C0201975;C0439445;C0449297;C1382187;C2825073;C4554548
68,creat clearance < nmbr ml / min,C0201975;C0439445;C0449297;C1382187;C2825073;C4554548
68,crcl of nmbr - nmbr ml min ',C0439445;C1846718
68,crcl > nmbrml / min,C0439445;C1846718
68,crcl > nmbr ml / min,C0439445;C1846718
68,crcl > nmbr - < nmbrml / min,C0439445;C1846718
68,crcl < nmbrml / min,C0439445;C1846718
68,crcl < nmbr ml / min,C0439445;C1846718
68,crcl ( sd ) ml / min,C0439445;C1846718;C2699239
68,crcl ( ml / min ),C0439445;C1846718
68,crcb - ( ml / min ),C0439445
68,^nmbr ml / min,C0439445
68,> nmbr ml min ) nmbr,C0439445
68,> nmbr ml / min,C0439445
68,< nmbr ml / min — %,C0439445
68,< nmbr ml / min / nmbr,C0439445
68,< nmbr ml / min,C0439445
68,< = nmbr ml / min,C0439445
67,ind / glyb n = nmbr,C1415124;C4049864
66,bud nmbr ptg n = nmbr,C0039512;C1418830;C2700462;C2945744
66,bud / fm nmbr / nmbr atg n = ^nmbr,C2700462;C2945744;C3540627;C3815109
65,≤ nmbr ug / g,C0439272
65,tcz nmbr mg / kg n = nmbr,C0439272
65,nmbr mg / kg ( n = nmbr ),C0439272
65,nmbr mg / kg,C0439272
65,abatacept ~ nmbr mg / kg ( n = nmbr ),C0439272;C1619966
65,abatacept nmbr mg / kg ( n = nmbr ),C0439272;C1619966
65,abatacept nmbr / — nmbr mg / kg ( n = nmbr ),C0439272;C1619966
65,> nmbr ug / g,C0439272
64,≥ nmbr to < nmbr mg / g,C1300563
64,≥ nmbr mg / g,C1300563
64,urine acr ( mg / g ),C0042036;C0042037;C1300563;C1412134;C1515941;C2963137
64,uacr — mg / g,C1300563
64,uacr *  mg / g ( qnmbr  qnmbr ),C1300563
64,uacr ( mg / g ),C1300563
64,uacr ( mg / g,C1300563
64,uac nmbr - nmbr mg / g,C1300563
64,uac > nmbr mg / g,C1300563
64,normoalbuminuria ( uacr < nmbr mg / g ),C1300563
64,nmbr − nmbr mg / g,C1300563
64,nmbr to nmbr mg / g,C1300563
64,nmbr mg / g,C1300563
64,nmbr - nmbr mg / g,C1300563
64,mg / g,C1300563
64,cohort nmbr ( uacr > nmbr . nmbr mg / g ),C0009247;C0599755;C1300563
64,cohort nmbr ( uacr < nmbr . nmbr mg / g ),C0009247;C0599755;C1300563
64,acr > nmbr mg / g,C1300563;C1412134;C1515941
64,acr ( mg / g ),C1300563;C1412134;C1515941
64,^nmbr mg / g,C1300563
64,> nmbr to nmbr mg / g,C1300563
64,> nmbr mg / g,C1300563
64,> = nmbr mg / g,C1300563
64,< nmbr mg / g,C1300563
63,wc ( cm ),C0013123;C2825512
62,fl ( nmbrb ),C1300812;C1708024
62,fl ( nmbr . nmbr ),C1300812;C1708024
61,imt ( nmbr ),C0334121;C1704614;C4318736
61,imt ( mm ),C0334121;C1704614;C4318736;C4330985;C4554674
60,europa ( n = nmbrlnmbr ),C0242751
59,tah ( n = nmbr ),C0404079
59,dmab ( n = nmbr ),C0012411
58,ivc ( n = nmbr ),C4085887
58,igm ( n = nmbr ),C1706005
58,igl ( n = nmbr ),C0021037;C0314619;C2247518
57,alive ( n = nmbr ),C2584946;C4551704
56,peace ( n = nmbr ),C0680443
55,t ( n = nmbr,C2986835
54,sal ( n   = nmbr,C0036140;C0037494;C0206136
54,sal ( n = nmbr ),C0036140;C0037494;C0206136
53,nmbr to < nmbr cel,C0208736;C0346421;C0439237;C1413336
52,jvp $ nmbr cm hnmbro,C0455483
52,jvd $ nmbr cm hnmbro,C0425687;C0455483
51,nmbr % c . i .,C1547546
50,ama 士 s . e .,C0002461;C0279755;C2825862
50,am △ 士 s . e .,C3813124;C3890196;C4520798
49,enmbr / snmbr vs snmbr,C3846405
49,enmbr / snmbr vs enmbr,C3846405
49,enmbr / snmbr ( n = nmbr ),C3846405
48,vi nmbr   µ g,C0205999;C0439267
48,vi nmbr % ( - nmbr %,C0205999
48,vi - nmbr % ( - nmbr %,C0205999
48,umec / vi nmbr . nmbr / nmbr ( n nmbr nmbr ),C0205999
48,umec / vi nmbr . nmbr / nmbr,C0205999
48,nmbr . nmbr % vi . nmbr . nmbr %,C0205999
48,nmbr . nmbr % vi,C0205999
48,ff / vi nmbr / nmbr pg od,C0030827;C0072225;C0205999;C0229089;C0439164;C1266240;C1512019;C3273373;C3665488;C4554348
48,ff / vi ( n   =   nmbr ),C0205999;C4554348
47,≥ nmbr kg / mnmbr,C1532718
47,£ nmbr kg / mnmbr,C1532718
47,snmbr kg / mnmbr,C0565930;C1532718;C2603362
47,snmbr kg / m^,C0565930;C1532718;C2603362
47,nmbr to < nmbr kg / mnmbr,C1532718
47,nmbr nmbr to < nmbr kg / mnmbr,C1532718
47,nmbr kg / mnmbr or more,C1532718
47,nmbr kg / mnmbr,C1532718
47,nmbr kg / m ’,C1532718
47,nmbr - nmbr kg / mnmbr,C1532718
47,nmbr - nmbr . nmbr kg / mnmbr,C1532718
47,nmbr - < nmbr kg / mnmbr,C1532718
47,kg / mnmbr ),C1532718
47,kg / mnmbr,C1532718
47,bmp kg - m “ nmbr,C0053932;C0279266;C1532718;C4281808
47,bmnmbr ( kg / mnmbr ),C0006416;C1532718
47,anmbr kg / mnmbr,C1532718
47,[kg / m^],C1532718
47,> nmbrkg / mnmbr,C1532718
47,> nmbr kg / mnmbr smokers,C0337664;C1532718
47,> nmbr kg / mnmbr,C1532718
47,> nmbr kg / m^,C1532718
47,> nmbr kg / m ’,C1532718
47,> nmbr . nmbr kg / mnmbr,C1532718
47,> nmbr - snmbr kg / m ’,C0565930;C1532718;C2603362
47,> nmbr - ^nmbr kg / m ’,C1532718
47,> nmbr - < snmbr kg / m ’,C0565930;C1532718;C2603362
47,> = nmbr kg / mnmbr,C1532718
47,< nmbrkg / mnmbr,C1532718
47,< nmbr kg / mnmbr,C1532718
47,< nmbr kg / m^,C1532718
47,< nmbr kg / m nmbr,C1532718
47,< nmbr . nmbr kg / mnmbr,C1532718
46,nmbr . nmbr - nmbr . nmbr kg / mnmbr,C1532718
46,mean bmi ( kg / mnmbr ) ( sd ),C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
46,low ( < nmbr kg / mnmbr ) baseline bmi,C0168634;C0205251;C0578022;C1442488;C1532718;C1550472;C3890211;C4048187;C4321351;C4522223
46,low ( < nmbr kg / m^ ) baseline bmi,C0168634;C0205251;C0578022;C1442488;C1532718;C1550472;C3890211;C4048187;C4321351;C4522223
46,high ( inmbr kg / mnmbr ) baseline bmi,C0021966;C0168634;C0205250;C0221138;C0578022;C1299351;C1442488;C1532718;C2700149;C3887512;C3889660;C4321237;C4522209
46,high ( > nmbr kg / m^ ) baseline bmi,C0168634;C0205250;C0578022;C1299351;C1442488;C1532718;C2700149;C3887512;C3889660;C4321237;C4522209
46,bmi £ nmbr kg / m * ( n = nmbr / nmbr ),C0578022;C1532718
46,bmi   kg · m − nmbr,C0578022;C1532718
46,bmi onmbr kg / mnmbr,C0578022;C1532718
46,bmi nmbr - < nmbr kg / m^ ( n = nmbr / nmbr ),C0578022;C1532718
46,bmi nmbr - < nmbr kg / m - ( n = nmbr / nmbr ),C0578022;C1532718
46,bmi nmbr - < nmbr kg / m * ( n = nmbr / nmbr ),C0578022;C1532718
46,"bmi nmbr - < nmbr kg / m "" ( n = nmbr / nmbr )",C0578022;C1532718
46,bmi kg · m − nmbr,C0578022;C1532718
46,bmi kg - m - nmbr,C0578022;C1532718
46,bmi in kg / mnmbr,C0578022;C1532718
46,bmi [kg / mnmbr],C0578022;C1532718
46,bmi > nmbrkg / mnmbr ( n = nmbr / nmbr ),C0578022;C1532718
46,bmi > nmbrkg / mnmbr,C0578022;C1532718
46,bmi > nmbrkg / m * ( n = nmbr / nmbr ),C0578022;C1532718
46,bmi > nmbr kg / mnmbr *,C0578022;C1532718
46,bmi > nmbr kg / mnmbr ( % ),C0578022;C1532718
46,bmi > nmbr kg / mnmbr,C0578022;C1532718
46,bmi > nmbr kg / m^ ( n = nmbr / nmbr ),C0578022;C1532718
46,bmi > = nmbrkg / mnmbr,C0578022;C1532718
46,bmi > = nmbr kg / mnmbr population ( n = nmbr ),C0032659;C0578022;C1257890;C1532718
46,bmi < nmbrkg / mnmbr,C0578022;C1532718
46,bmi < nmbr kg / mnmbr ( n = nmbr / nmbr ),C0578022;C1532718
46,bmi < nmbr kg / mnmbr,C0578022;C1532718
46,bmi < nmbr kg / m^ ( n = nmbr / nmbr ),C0578022;C1532718
46,bmi < nmbr kg / m * ( n = nmbr / nmbr ),C0578022;C1532718
46,"bmi < nmbr kg / m "" ( n = nmbr / nmbr )",C0578022;C1532718
46,bmi : > nmbr . nmbr kg / mnmbr,C0578022;C1532718
46,bmi : < nmbr . nmbr kg / mnmbr,C0578022;C1532718
46,bmi - kg / mnmbr,C0578022;C1532718
46,bmi * ( kg / mnmbr ),C0578022;C1532718
46,bmi ( kg = mnmbr ),C0578022;C1532718
46,bmi ( kg / mnmbr ) cardiovascular history,C0578022;C1532718;C1880008
46,bmi ( kg / mnmbr ) a,C0578022;C1532718
46,bmi ( kg / mnmbr ) < nmbr,C0578022;C1532718
46,bmi ( kg / mnmbr ) *,C0578022;C1532718
46,bmi ( kg / mnmbr ) ( sd ),C0578022;C1532718;C2699239
46,bmi ( kg / mnmbr ),C0578022;C1532718
46,bmi ( kg / m^ ),C0578022;C1532718
46,bmi ( kg / m ’ ),C0578022;C1532718
46,bmi ( kg / m nmbr ),C0578022;C1532718
46,bmi ( kg / m ),C0578022;C1532718
46,bmi ( kg / ( m ) nmbr ),C0578022;C1532718
46,bmi ( . kg / m - ) *,C0578022;C1532718
46,bmi # kg - m “ nmbr,C0578022;C1532718
46,baseline bmi nmbr to < nmbr kg / mnmbr,C0168634;C0578022;C1442488;C1532718
46,baseline bmi > nmbr kg / mnmbr,C0168634;C0578022;C1442488;C1532718
46,baseline bmi < nmbr kg / mnmbr,C0168634;C0578022;C1442488;C1532718
46,baseline bmi ( kg / mnmbr ),C0168634;C0578022;C1442488;C1532718
46,baseline bmi ( kg / m^ ),C0168634;C0578022;C1442488;C1532718
46,> nmbr kg / mnmbr ( n — nmbr ),C1532718
46,> nmbr kg / mnmbr ( n = nmbr ),C1532718
46,> nmbr - < nmbrkg / mnmbr ( n = nmbr ),C1532718
46,< nmbr kg / mnmbr ( n — nmbr ),C1532718
46,< nmbr kg / mnmbr ( n = nmbr ),C1532718
45,overweight ( nmbr to < nmbr kg / mnmbr ),C0497406;C1532718
45,obesity * ( bmnmbr > nmbr kg / mnmbr ),C0006416;C0028754;C1532718;C1963185
45,obesity ( body mass index > nmbr kg / mnmbr ),C0005893;C0028754;C0578022;C1305855;C1532718;C1963185
45,obesity ( bmi £ nmbr kg / mnmbr ),C0028754;C0578022;C1532718;C1963185
45,obesity ( bmi > nmbr kg / mnmbr ),C0028754;C0578022;C1532718;C1963185
45,obese ( bmi > nmbrkg / mnmbr ),C0028754;C0578022;C1532718
45,obese ( > nmbr kg / mnmbr ) b,C0028754;C1532718
45,obese ( > nmbr kg / mnmbr ),C0028754;C1532718
45,obese ( > nmbr kg / m^nmbr ),C0028754;C1532718
45,lean ( < nmbr kg / mnmbr ),C1532718
44,ssed as ls means,C0023668;C1704970
44,placebo ls means ( n ),C0023668;C0032042;C1696465;C1704970;C1706408
44,ls / ul nmbr nmbr,C0023668;C1300557
43,nmbr ( io - nmbr % ),C1046794;C3146236
43,inflotmas io mgluj versus piecew,C1046794;C3146236
42,eosinophil count ( cells / microlitre ),C0200638;C0439378;C0750879
42,> nmbr cells / ul,C0439378
42,< nmbr cells / ul nmbr nmbr,C0439378
41,white blood cell count,C0023508;C0427512
41,white - cell count — xnmbr_nmbr / liter,C0023508;C0427512;C0475211
40,nmbr to < nmbr cells,C0007584;C0007634
40,local eosinophil count ( cells per pl ) t,C0007584;C0007634;C0200638;C0205276;C0750879;C3897966;C4049765
40,eosinophil count ( cells per pl ),C0007584;C0007634;C0200638;C0750879;C3897966;C4049765
40,eosinophil count ( cells / pl ),C0007584;C0007634;C0200638;C0750879;C3897966;C4049765
40,eos count ( cells / pl ),C0007584;C0007634;C0750480;C1623465;C1705566;C1861303;C3897966;C4049765
40,central eosinophil count ( cells per pl ) t,C0007584;C0007634;C0200638;C0205099;C0750879;C1879652;C3897966;C4049765
40,central eosinophil count ( cells per pl ),C0007584;C0007634;C0200638;C0205099;C0750879;C1879652;C3897966;C4049765
39,ors ( nmbr % cis ) :,C0069590;C1963718
38,origin [n ( % ) ],C0079946;C0439659;C1550512
37,nmbrl . nmbr ( lnmbr . nmbrl ),C3539687
37,nmbrl . nmbr ( lnmbr . nmbr ),C3539687
37,nmbrl ( lnmbr ),C3539687
37,nmbr . nmbr ± l . l,C3539687
37,nmbr . nmbr ( nmbr l . l ),C3539687
37,nmbr . nmbr ( nmbr . nmbr - l . l ),C3539687
37,nmbr . l ( nmbrl . nmbr ),C3539687
37,nmbr . l ( nmbr . l ),C3539687
37,l . l ± nmbr . nmbr,C3539687
37,l ( < l ),C3539687
37,< nmbr . nmbr l - g / l,C0439267;C3539687
36,nmbr - nmbr ( snmbr - nmbr ) t,C0718146
35,snmbr ( n = nmbr ),C2986823
35,nmbr < nmbrs ) n nmbr ( nmbr . nmbr ),C2986823
34,[zi = nmbr] nmbr ( nmbr . nmbr ),C0043476
33,li nmbr ( nmbr . nmbr ),C0023617;C3495095
32,ibs ( nmbr . nmbr ),C0022104;C0432306
31,sun - nmbr ( nmbr ),C0038817;C0376223
30,avm ( n = nmbr ),C0003857;C0279476
30,avm % △ ( se ),C0003857;C0036919;C0279476
29,xho  p = o - nmbr,C4050013
28,nosnmbr nmbr c . t,C0326287;C1518425
28,nosnmbr nmbr a . g,C0326287;C1518425
27,hl 土 nmbr . nmbr,C1453952;C4085347
26,nmbr . nmbr ± nmbr . lf,C1416933;C2986618;C4554443
25,bl alc < nmbr . nmbr %,C0005918;C0006413;C1424945;C1552663;C2827109;C3811058
25,alc at weeko ( % ),C1424945;C3811058
25,alc at week nmbr ( % ),C0332174;C0439230;C1424945;C3811058
25,alc > nmbr . nmbr - nmbr . nmbr %,C1424945;C3811058
25,alc > = nmbr . nmbr %,C1424945;C3811058
25,alc < nmbr . nmbr %,C1424945;C3811058
25,alc ( % ),C1424945;C3811058
24,rrr ( nmbr % cl ),C0596019
24,rr ( nmbr % cl ) p value,C0596019;C1709380;C4554402
24,rr ( nmbr % cl ) [ / ’ value],C0596019;C1522609;C4554402
24,rr ( nmbr % cl ),C0596019;C4554402
24,rr ( cl ),C0596019;C4554402
24,ratet ( nmbr % cl ),C0596019
24,qrs < nmbr ms ( nmbr % cl ) ( n - nmbr,C0596019;C2349943;C3539704;C3713294
24,qrs $ nmbr ms ( nmbr % cl ) ( n - nmbr ),C0596019;C2349943;C3539704;C3713294
24,p ( nmbr % cl ),C0369773;C0596019;C2603361
24,orc ( nmbr % cl ),C0596019;C1167125
24,oradj ( nmbr % cl ),C0596019
24,nmbr cl ),C0596019
24,nmbr . nmbr ( nmbr % cl nmbr . nmbr to nmbr . nmbr ) p = nmbr . nmbr,C0596019
24,nmbr - nmbr ( nmbr % cl nmbr - nmbr to nmbr - nmbr ),C0596019
24,nmbr ( nmbr cl ),C0596019
24,nmbr ( nmbr % cl nmbr to nmbr ),C0596019
24,nmbr % cl,C0596019
24,lsm ( nmbr % cl ),C0596019
24,hr nmbr . nmbr ( nmbr % cl nmbr . nmbr,C0596019
24,hr nmbr - nmbr ( nmbr % cl nmbr - nmbr - nmbr - nmbr ),C0596019
24,hr nmbr - nmbr ( nmbr % cl nmbr - nmbr - nmbr ),C0596019
24,hr nmbr % cl,C0596019
24,hr ( nmbr % cl ) pvalue,C0596019
24,hr ( nmbr % cl ) = nmbr nmbr ( nmbr . nmbr . nmbr,C0596019
24,hr ( nmbr % cl ) = nmbr . nmbrb ( nmbr,C0596019
24,hr ( nmbr % cl ) = nmbr . nmbr ( nmbr nmbr,C0596019
24,hr ( nmbr % cl ) = nmbr . nmbr ( nmbr . nmbr,C0596019
24,hr ( nmbr % cl ) *,C0596019
24,hr ( nmbr % cl ),C0596019
24,cl nmbr %,C0596019
24,cl - nmbr],C0596019
24,arr ( nmbr % cl ),C0596019;C2170357;C4084934
24,adj . hr ( nmbr % cl ) a,C0001552;C0596019;C2826286
24,[nmbr % cl],C0596019
24,- nmbr - nmbr ( nmbr % cl - nmbr - nmbr to nmbr - nmbr ),C0596019
24,- nmbr - nmbr ( nmbr % cl - nmbr - nmbr to - nmbr - nmbr ),C0596019
24,( nmbr % cl ),C0596019
24, p = nmbr . nmbr,C0596019
24, ( nmbr % cl : nmbr . nmbr - nmbr . nmbr ) p = nmbr . nmbr,C0596019
23,risk reduction ( nmbr % cl ),C0596019;C1137094
23,relative risk reduction ( nmbr % cl ) percent,C0080103;C0205345;C0242492;C0301630;C0392756;C0439165;C0596019;C1137094;C1293152;C1547039;C4551656
23,relative risk reduction ( nmbr % cl ),C0080103;C0205345;C0242492;C0301630;C0392756;C0596019;C1137094;C1293152;C1547039;C4551656
23,% risk reduction ( nmbr % cl ),C0596019;C1137094
22,rib,C0035561
21,pi,C0122626;C0429863;C3537219;C3539772
20,pb,C1415801;C3819255
19,with placebo ( n nmbr nmbr ),C0032042;C1696465;C1706408
19,with placebo,C0032042;C1696465;C1706408
19,stent plus placebo,C0032042;C0038257;C0332287;C1696465;C1706408
19,rerandomization to placebo ( n = nmbr ) f,C0016327;C0032042;C1696465;C1706408
19,randomization to placebo or telmisartan,C0032042;C0034656;C1696465;C1706408
19,placebo §,C0032042;C1696465;C1706408
19,placebo |,C0032042;C1696465;C1706408
19,placebo to ustekinumab nmbr mgt,C0032042;C1608841;C1696465;C1706408
19,placebo secukinumab pooled,C0032042;C1696465;C1706408;C3179547
19,placebo secukinumab nmbr mg,C0024671;C0026410;C0032042;C0439269;C1696465;C1706408;C1960952;C2346927;C3179547;C4321396;C4521761
19,placebo r %,C0032042;C0205090;C0684010;C1696465;C1706408;C2603358
19,placebo pts / n ( % ),C0032042;C1419129;C1696465;C1706408;C2698747
19,placebo plus statin ( n = nmbr ),C0032042;C0332287;C0360714;C1696465;C1706408
19,placebo plus aspirin,C0004057;C0032042;C0332287;C1696465;C1706408
19,placebo patients with events / total,C0030705;C0032042;C0441471;C1696465;C1706408;C3541888
19,placebo patients with events,C0030705;C0032042;C0441471;C1696465;C1706408;C3541888
19,placebo patients / events n,C0030705;C0032042;C0441471;C1696465;C1706408;C3541888
19,placebo no diabetes n = nmbr,C0032042;C1696465;C1706408
19,placebo no . of events / total no . ( % ),C0032042;C1696465;C1706408
19,placebo no . of events / no .,C0032042;C1696465;C1706408
19,placebo no . / total no .,C0032042;C1696465;C1706408
19,placebo no . / total ( % ),C0032042;C1696465;C1706408
19,placebo no . ( nmbr - y km % ),C0032042;C1696465;C1706408
19,placebo nmbronmbr,C0032042;C1696465;C1706408
19,placebo nmbr yr km %,C0032042;C0439234;C1696465;C1706408;C3887676
19,placebo nmbr year km ( % ),C0032042;C0439234;C0439508;C1696465;C1706408;C3887676
19,placebo nmbr / nmbr,C0032042;C1696465;C1706408
19,placebo nmbr . nmbr pt yrs,C0032042;C0032743;C0699718;C1696465;C1706408
19,placebo nmbr . nmbr,C0032042;C1696465;C1706408
19,placebo nmbr,C0032042;C1696465;C1706408
19,placebo n[nmbr,C0032042;C1696465;C1706408
19,placebo n = nmbr subjects,C0032042;C1696465;C1706408
19,placebo n = nmbr n ( % ),C0032042;C1696465;C1706408
19,placebo n = nmbr,C0032042;C1696465;C1706408
19,placebo n / n ( % ),C0032042;C1696465;C1706408
19,placebo n / n,C0032042;C1696465;C1706408
19,placebo n ( rate ) nmbr,C0032042;C0871208;C1521828;C1696465;C1706408
19,placebo n ( rate ) *,C0032042;C0871208;C1521828;C1696465;C1706408
19,placebo n ( % ),C0032042;C1696465;C1706408
19,placebo n,C0032042;C1696465;C1706408
19,placebo mortality rate,C0026565;C0032042;C0205848;C1696465;C1706408
19,placebo monthly ( n = nmbr ),C0032042;C0332177;C1696465;C1706408
19,placebo mean ( n ),C0032042;C0444504;C1696465;C1706408;C2347634;C2348143
19,placebo mean,C0032042;C0444504;C1696465;C1706408;C2347634;C2348143
19,placebo mdi,C0032042;C0993596;C1696465;C1706408;C1839839;C4049613
19,placebo km %,C0032042;C1696465;C1706408;C3887676
19,placebo group ( n = nmbr ) ’ j ',C0032042;C0441844;C1696465;C1706408
19,placebo group ( n = nmbr ) f,C0016327;C0032042;C0441848;C1696465;C1706408
19,placebo group ( n = nmbr ),C0032042;C0441848;C1696465;C1706408
19,placebo group,C0032042;C0441833;C0687744;C1257890;C1519504;C1696465;C1705428;C1705429;C1706408
19,placebo every nmbr weeks ( n = nmbr ),C0032042;C1696465;C1706408
19,placebo events / patients ( % ),C0030705;C0032042;C0441471;C1696465;C1706408;C3541888
19,placebo events / patients (,C0030705;C0032042;C0441471;C1696465;C1706408;C3541888
19,placebo events / n ( % ),C0032042;C0441471;C1696465;C1706408;C3541888
19,placebo event rate ( n = nmbr ),C0032042;C0441471;C0871208;C1521828;C1696465;C1706408;C4019010
19,placebo estimated mean,C0032042;C1696465;C1706408
19,placebo dr = nmbr ),C0013014;C0031831;C0032042;C1696465;C1706408;C1707664;C2348314;C3540849
19,placebo dn = nmbr ),C0032042;C1333964;C1696465;C1706408;C1707618
19,placebo diabetes n = nmbr,C0011847;C0011849;C0032042;C1696465;C1706408
19,placebo croup,C0010380;C0032042;C1696465;C1706408
19,placebo arm,C0032042;C0446516;C1696465;C1706408;C3715044;C4553528
19,placebo analysed ( % ),C0032042;C1696465;C1706408
19,placebo allocation,C0032042;C1696465;C1706408;C1706778
19,placebo [n z nmbr],C0032042;C1696465;C1706408
19,placebo [n = nmbr],C0032042;C1696465;C1706408
19,placebo [n = nmbr |,C0032042;C1696465;C1706408
19,placebo / simvastatin,C0032042;C0074554;C1696465;C1706408
19,placebo / simva,C0032042;C1696465;C1706408
19,placebo / rosu vastatin,C0032042;C1099881;C1696465;C1706408
19,placebo /,C0032042;C1696465;C1706408
19,placebo - vonoprazan nmbr - vonoprazan nmbr,C0032042;C1696465;C1706408;C4080009
19,placebo - vonoprazan nmbr,C0032042;C1696465;C1706408;C4080009
19,placebo - dexlansoprazole,C0032042;C1696465;C1706408;C2348248
19,placebo - adjusted mean difference in % hbanmbrc ( nmbr % ci  [ p value] ),C0032042;C1696465;C1706408
19,placebo - abatacept nmbr / nmbr - abatacept nmbr / nmbr,C0032042;C1619966;C1696465;C1706408
19,placebo + statin ( n = nmbr,C0032042;C0360714;C1696465;C1706408
19,placebo + statin,C0032042;C0360714;C1696465;C1706408
19,placebo + pioglitazone ( n = nmbr ),C0032042;C0071097;C1696465;C1706408
19,placebo + mtx,C0025677;C0032042;C1417487;C1696465;C1706408
19,placebo + insulin glargine ( award - nmbr  n = nmbr ),C0004446;C0032042;C0907402;C1696465;C1706408
19,placebo * ( add on to basal insulin ),C0032042;C0650607;C1696465;C1706408;C1883712
19,placebo ( » = nmbr ),C0032042;C1696465;C1706408
19,placebo ( « = nmbr ),C0032042;C1696465;C1706408
19,placebo ( w = nmbr ),C0032042;C1696465;C1706408
19,placebo ( nmbr = nmbr ),C0032042;C1696465;C1706408
19,placebo ( nmbr,C0032042;C1696465;C1706408
19,placebo ( n[nmbr ),C0032042;C1696465;C1706408
19,placebo ( n — nmbr ),C0032042;C1696465;C1706408
19,placebo ( n   =   nmbr ) b,C0032042;C1696465;C1706408
19,placebo ( n   =   nmbr ) a,C0032042;C1696465;C1706408
19,placebo ( n   =   nmbr ),C0032042;C1696465;C1706408
19,placebo ( n   =   nmbr ),C0032042;C1696465;C1706408
19,placebo ( n   =   nmbr,C0032042;C1696465;C1706408
19,placebo ( n   = nmbr ),C0032042;C1696465;C1706408
19,placebo ( n   = nmbr,C0032042;C1696465;C1706408
19,placebo ( n z nmbr ),C0032042;C1696465;C1706408
19,placebo ( n nmbr nmbr ),C0032042;C1696465;C1706408
19,placebo ( n nmbr nmbr,C0032042;C1696465;C1706408
19,placebo ( n nmbr ),C0032042;C1696465;C1706408
19,placebo ( n [ nmbr ),C0032042;C1696465;C1706408
19,placebo ( n = nmbro ),C0032042;C1696465;C1706408
19,placebo ( n = nmbrl ),C0032042;C1696465;C1706408
19,placebo ( n = nmbrinmbr ),C0032042;C1696465;C1706408
19,placebo ( n = nmbr nmbr ),C0032042;C1696465;C1706408
19,placebo ( n = nmbr * ),C0032042;C1696465;C1706408
19,placebo ( n = nmbr ) †,C0032042;C1696465;C1706408
19,placebo ( n = nmbr ) nmbr . nmbr ± nmbr . nmbr,C0032042;C1696465;C1706408
19,placebo ( n = nmbr ) n ( % ),C0032042;C1696465;C1706408
19,placebo ( n = nmbr ) i -,C0032042;C1696465;C1706408
19,placebo ( n = nmbr ) ',C0032042;C1696465;C1706408
19,placebo ( n = nmbr ),C0032042;C1696465;C1706408
19,placebo ( n = nmbr,C0032042;C1696465;C1706408
19,placebo ( n = lnmbr ),C0032042;C1696465;C1706408
19,placebo ( n : nmbr ),C0032042;C1696465;C1706408
19,placebo ( n - nmbr . nmbr ),C0032042;C1696465;C1706408
19,placebo ( n - nmbr ),C0032042;C1696465;C1706408
19,placebo ( lsm ),C0032042;C1696465;C1706408
19,placebo ( events / n ( % ) ),C0032042;C0441471;C1696465;C1706408;C3541888
19,placebo ( dm - vs . dm + ),C0011816;C0032042;C1696465;C1706408;C3250443
19,placebo ( % ),C0032042;C1696465;C1706408
19,placebo %,C0032042;C1696465;C1706408
19,"placebo "" ( n = nmbr )",C0032042;C1696465;C1706408
19,placebo,C0032042;C1696465;C1706408
19,patients in the placebo group  nt - probnp values were reported for nmbr patients,C0030705;C0032042;C0042295;C0441833;C0669479;C0687744;C0754710;C1257890;C1519504;C1696465;C1705428;C1705429;C1706408
19,no . of patients ( indacaterol / placebo ),C0030705;C0032042;C1696465;C1706408;C1722260
19,nmbr placebo n = nmbr,C0032042;C1696465;C1706408
19,nmbr placebo ( n = nmbr nmbr ),C0032042;C1696465;C1706408
19,nmbr placebo,C0032042;C1696465;C1706408
19,n ( indacaterol nmbr ug / indacaterol nmbr ug / placebo ),C0032042;C0369718;C0441922;C1319635;C1696465;C1706408;C1722260
19,mtx plus placebo,C0025677;C0032042;C0332287;C1417487;C1696465;C1706408
19,losartan plus placebo ( n = nmbr ),C0032042;C0126174;C0332287;C1696465;C1706408
19,i placebo ( n = nmbr ),C0021966;C0032042;C0221138;C1696465;C1706408
19,i placebo,C0021966;C0032042;C0221138;C1696465;C1706408
19,feno placebo ( lsm ),C0032042;C1696465;C1706408
19,favors ffa / i favors placebo,C0015688;C0021966;C0032042;C0221138;C0309049;C1696465;C1706408
19,esrd on placebo ( % ),C0022661;C0032042;C0035078;C1696465;C1706408;C2316810
19,duration from clopidogrel / placebo to pci,C0032042;C0070166;C0449238;C1696465;C1706408;C2926735
19,dapagliflozin placebo no . of events / no . of patients,C0032042;C1696465;C1706408;C2353951
19,copd - placebo ( nmbr pt ) n . ( % ),C0024117;C0032042;C0032743;C0699718;C1412502;C1696465;C1706408;C3714496
19,copd - placebo ( n = nmbr ),C0024117;C0032042;C1412502;C1696465;C1706408;C3714496
19,comparison with placebo ( mean,C0032042;C0444504;C1696465;C1706408;C1707455;C2347634;C2348143
19,comparison with placebo,C0032042;C1696465;C1706408;C1707455
19,chf on placebo ( % ),C0018802;C0032042;C1696465;C1706408
19,baseline to eom placebo ( n = nmbr ),C0032042;C0168634;C0241886;C1442488;C1696465;C1706408
19,aspirin plus placebo ( n = nmbr ),C0004057;C0032042;C0332287;C1696465;C1706408
19,any placebo,C0032042;C1696465;C1706408
19,> = nmbr years ( placebo n = nmbr  nmbr  saxagliptin n = nmbr  nmbr ),C0032042;C0439234;C1611934;C1696465;C1706408
19,= placebo  eze = ezetimibe  erol  apo = apolipoprotein  metabolic syndrome  patients were eans and percentage changes are,C0003591;C0030705;C0032042;C0524620;C1142985;C1696465;C1706408
19,= placebo  eze : tes ( fc j > nmbr rr nmbr definition ) .,C0032042;C0076172;C1422793;C1550452;C1696465;C1704788;C1706408;C2983605;C3539107;C3888054;C4554402
19,< nmbr years ( placebo n = nmbr  nmbr  saxagliptin n = nmbr  nmbr ),C0032042;C0439234;C1611934;C1696465;C1706408
19,- nmbr placebo,C0032042;C1696465;C1706408
18,permanent users,C0205355;C1706077
18,permanent af,C0205355;C0344434;C4049859
18,permanent ( n,C0205355
18,permanent,C0205355
17,perianal or anus,C0442158
17,perianal gi tract,C0017189;C0442158
17,perianal,C0442158
16,peripheral vasodilators,C0724804
15,peripheral sensory neuropathy,C0151313;C4554142
14,peripheral neuropathy,C0031117
13,peripheral embolism,C0013922;C0205100;C1704212
13,peripheral,C0205100
12,bacterial pneumonia,C0004626
11,previous pneumonia,C0032285;C0205156;C1552607
11,pneumonia,C0032285
10,serum values^,C0042295;C0229671;C1546774;C1550100
10,serum values,C0042295;C0229671;C1546774;C1550100
10,serum urea nitrogen,C0028158;C0229671;C0600137;C0856666;C1291218;C1546774;C1550100;C1550581;C3683557
10,serum trap - nmbrb ( u / liter ),C0184047;C0229671;C0439148;C0475211;C1336677;C1546774;C1550100;C1566918;C1706005;C1710330;C3887583
10,serum pnmbrnp ( ^g / liter ),C0065827;C0229671;C0439267;C0475211;C1546774;C1550100;C1706141;C3887659
10,serum pepsinogen i / iit,C0077923;C0229671;C0523816;C1546774;C1550100
10,serum nmbr - hydroxyvitamin d,C0020337;C0229671;C1546774;C1550100
10,serum mg > nmbr . nmbr mmol / l ( normal mg / hvpermagnesemia ),C0205307;C0229671;C0231683;C0439166;C0439190;C1546774;C1550100;C2347086;C2827881;C4553972
10,serum mg < nmbr . nmbr mmol / l ( hypomagnesemia ),C0024671;C0026410;C0151723;C0229671;C0439190;C0439268;C0439269;C1532563;C1546774;C1550100;C1960952;C2346927;C4321396;C4521761;C4552839
10,serum gastrint,C0229671;C1546774;C1550100
10,serum fg,C0016703;C0229671;C0439214;C1546774;C1550100;C2348814
10,serum ctx i ( ng / ml ),C0229671;C0439275;C0631180;C1546774;C1550100
10,serum ctx - nmbr,C0010377;C0229671;C0631180;C1546774;C1550100;C3539598
10,serum ctx ( ng / ml ),C0010377;C0229671;C0439275;C0631180;C1546774;C1550100;C3539598
10,serum c - terminal telopeptide of,C0229671;C1546774;C1550100;C1707271
10,serum bone - specific alkaline,C0205369;C0229671;C0262950;C1546774;C1550100;C1552740;C1979842
10,serum,C0229671;C1546774;C1550100
10,patients with serum nmbr ( oh ) d ≥   nmbr . nmbr and <   nmbr   ng / ml,C0030705;C0220853;C0229671;C1546774;C1550100
9,serum uric acid ( mg / dl ),C0439269;C0455272;C0700634
9,serum uric acid,C0455272;C0700634
9,serum urate ( mg / dl ),C0439269;C0455272
8,serum triglycerides — pmol / liter,C0439192;C0475211;C0542495
8,serum triglycerides — mmol / liter,C0439190;C0475211;C0542495
8,serum triglycerides,C0542495
7,serum albumin concentration,C0001924;C0036773;C0086045;C0229671;C0486291;C0683149;C0728877;C1446561;C1546774;C1550100;C3827302
7,serum albumin - adjusted calcium ( mg / dl ),C0036773;C0728877
7,serum albumin,C0036773;C0728877
6,serum sodium — mmol / liter,C0439190;C0475211;C0523891
6,serum sodium — meq / liter,C0439152;C0475211;C0523891
6,serum sodium . meq / l,C0439375;C0523891
6,serum sodium,C0523891
5,serum calcium,C0036785;C0728876
5,baseline serum calcium level,C0036785;C0168634;C0728876;C1442488
4,selexipag vs placebo hazard ratio ( nmbr % cl ),C2000145
4,selexipag ( n = nmbr ),C2000145
4,selexipag,C2000145
3,febuxostat - febuxostat / lesinurad nmbr - febuxostat / lesinurad nmbr,C0249529;C3886073
3,febuxostat - febuxostat / lesinurad nmbr,C0249529;C3886073
3,completed prior febuxostat studya,C0205197;C0249529;C0332152;C2826257;C3854010
2,febuxostat nmbr mg n = nmbr,C0024671;C0026410;C0249529;C0439269;C1960952;C2346927;C4321396;C4521761
2,febuxostat nmbr mg daily n = nmbr n ( % ),C0024671;C0026410;C0249529;C0332173;C0439269;C1960952;C2346927;C4321396;C4521761
2,febuxostat nmbr mg daily n = nmbr % ( n / n ),C0024671;C0026410;C0249529;C0332173;C0439269;C1960952;C2346927;C4321396;C4521761
2,febuxostat nmbr mg daily n = nmbr,C0024671;C0026410;C0249529;C0332173;C0439269;C1960952;C2346927;C4321396;C4521761
2,febuxostat nmbr mg ( n = nmbr ),C0024671;C0026410;C0249529;C0439269;C1960952;C2346927;C4321396;C4521761
2,febuxostat nmbr mg,C0024671;C0026410;C0249529;C0439269;C1960952;C2346927;C4321396;C4521761
2,febuxostat,C0249529
1,之 nmbr,
1,≥ nmbr yearsa,
1,≥ nmbr teae,
1,≥ nmbr bpm ( n = nmbr ),
1,≥ nmbr . nmbr % and ≤ nmbr . nmbr %,
1,≥ nmbr . nmbr % and < nmbr . nmbr %,
1,≥ nmbr %,
1,≥ nmbr,
1,≤ nmbr . nmbr %,
1,≤ nmbr %,
1,≤ nmbr,
1,• j . the body - mass index is the weight in kilograms divided by the square of the,
1,“ off ”,
1,— no . ( % ),
1,β ‐ blocker,
1,β blockers,
1,β blocker,
1,β - blockers,
1,β - blocker,
1,» nmbry,
1,« nmbr - nmbr,
1,« = nmbr,
1,£ nmbr . nmbr yrs,
1,£ nmbr . nmbr % * *,
1,£ nmbr %,
1,£ nmbr,
1,| interactior nmbr p,
1,| ? > - blocker ( n,
1,| ? ) - blocker,
1,zt = nmbr,
1,zotarolimust,
1,z\tonastaiin,
1,ynmbr,
1,yearl,
1,yaa,
1,xnmbr = nmbr - nmbr  p = nmbr - nmbr,
1,xnmbr = nmbr - l  p = nmbr - nmbr,
1,xnmbr = nmbr  p = nmbr - nmbr,
1,xnmbr,
1,xanthinesg,
1,x ? = nmbr - nmbr  p = nmbr - nmbr,
1,x ? = nmbr - l  p = nmbr - nmbr,
1,x ? = l - nmbr  p = nmbr - nmbr,
1,x / n *,
1,x / n,
1,wssng,
1,woscops,
1,womens,
1,without revascularsation,
1,without antiplatelets,
1,without an sfua,
1,with rehospitalization,
1,with laba,
1,with antiplatelets,
1,with an sfua,
1,whiteb,
1,while ethnic origin,
1,while,
1,wegu,
1,we recorded no significant interactions for any subgroup analysis . pufa = polyunsaturated fatty acids . nyha = new york heart association . lvef = left ventricular ejection fraction . * nmbr % cl was calculated with a cox proportional hazards model . tmedian value . data for total cholesterol were available for nmbr patients ( nmbr n - nmbr pufa,
1,we recorded no significant interactions for any subgroup analysis . nyha = new york heart association . lvef = left ventricular ejection fraction . ' nmbr % cl was calculated by cox proportional hazards model . tmedian value . data for total cholesterol were available for nmbr patients ( nmbr rosuvastatin,
1,wafarin,
1,w hite,
1,w,
1,vs . warfarin,
1,vs . placebo,
1,vora,
1,vnmbr ( n = nmbr,
1,vldm n = nmbr,
1,vka naxve,
1,vka naive,
1,vka experienced,
1,vka ( n   = nmbr ),
1,vka,
1,vhd,
1,versus tiotropium nmbr pg tiotropium + olodaterol nmbr . nmbr / nmbr pg,
1,versus tiotropium nmbr pg tiotropium + olodaterol nmbr - nmbr / nmbr pg,
1,versus tiotropium nmbr pg,
1,versus tiotropium nmbr . nmbr pg,
1,versus tiotropium + olodaterol nmbr . nmbr / nmbr pg,
1,versus olodaterol nmbr pg,
1,veflonzumao,
1,vdz n = nmbr,
1,vdz n = \nmbr,
1,vdz / vdz [n = nmbr],
1,vdhmtss,
1,values expressed as mean sd or number ( percent ) . * two patients were missing values for body mass index .,
1,vadas score *,
1,v ( n = nmbr ),
1,ustekinu,
1,usteki,
1,useofmedical therapyathospitaldischarge,
1,us w = nmbr,
1,us,
1,urti,
1,ure,
1,upcr,
1,unstableangina,
1,unprovoked,
1,univariable or ( nmbr % ci ),
1,univariable,
1,uniti - nmbr and uniti - nmbr im - uniti,
1,uniti - nmbr,
1,unfractionated,
1,undeterminedc,
1,undergoing major vascular surgery,
1,uncover - nmbr,
1,uncodable,
1,uncerlain,
1,umied,
1,ulpasi nmbr,
1,uistekinumab,
1,ufh,
1,ucr,
1,ucl,
1,uc [gemini nmbr] ‘,
1,uc ( n   =   nmbr ),
1,uc,
1,uasnmbr {,
1,uasnmbr,
1,uacra,
1,uacr not available,
1,uacr ( mgg - nmbr ),
1,uacr,
1,uac =,
1,tzd,
1,tvr,
1,treated patients with baseline and nmbr post - baseline ef ﬁ cacy measurement  bp value for treatment group comparison ( proactive intervention vs usual care ) was calculated based on a nmbr - sample t test for continuous variables and chi - square test for categorical variables  cbp values were measured at baseline ( week nmbr )  whereas information on all of the other variables listed was collected during screening .,
1,transradial,
1,transfemoral,
1,tpasi nmbr,
1,toward,
1,totai mortaiity,
1,tolal choleslerol,
1,tnt and ideal ( pooled ),
1,tngtycerides a median,
1,tngtycerides < median,
1,tngtycendes a median,
1,tnglycendes < median,
1,tnfi naive,
1,tnfi exposed,
1,tnfi and other bdmardst,
1,tnfi - naive,
1,tnfi - exposed †,
1,tnfi ( no other bdmard taken ) t,
1,tjc ( nmbr - nmbr ),
1,tjc,
1,tiotropiumc,
1,tion — no . ( % ),
1,tio ( n nmbr nmbr ),
1,tio,
1,timi ≥ nmbr and spoke and time ≤ nmbr h,
1,timi ≥ nmbr and spoke,
1,timi ≥ nmbr,
1,timi score,
1,timi risk scoret,
1,timi minor,
1,timi major or minor bleeding,
1,timi major or,
1,timi major,
1,timi clinically significant,
1,timi - defined bleeding,
1,timi - bleeding major / minor,
1,ticlopidin,
1,thromboaspiration — no . ( % ),
1,thromboaspiration,
1,thiazolidinedionesc,
1,thiazolidinedioneb,
1,the plot shows hazard ratios and nmbr % confidence intervals for the primary outcome,
1,texcaps,
1,tertile nmbr : nmbr . nmbr ( nmbr . nmbr ),
1,tertile nmbr ( n = nmbr ),
1,tertile nmbr,
1,terlile nmbr,
1,teaes reported by ≥ nmbr % patients in the overall brv group,
1,teaes leading to discontinuation of study drug,
1,teaes,
1,tchdl - c,
1,tbp,
1,tamong those enrolling via bnp stratum . the study - qualifying bnp or,
1,symptomaticb,
1,sulfonylureasb,
1,sulfonylureaa,
1,subtrochanteric,
1,subscale  and nmbr to nmbr for the function subscale  normalized scores can range from nmbr to nmbr . scores for the health assessment question -,
1,subgroupt,
1,sua < nmbr . nmbr,
1,strokezsee,
1,stratum *,
1,stratum,
1,strata modelb hr,
1,still taking alendronate at study entry,
1,std n ( n / loopy ),
1,statisticd,
1,statini,
1,stalin,
1,sso - nmbr,
1,ssi - nmbr,
1,spoke,
1,spirono ( n = nmbr ),
1,spiralcomputedtomographyangiography,
1,spga > nmbr,
1,sonti amenca,
1,some walking,
1,some,
1,sokolow - lyon,
1,sokoiow - lyon voitage,
1,soe or sue,
1,socalone ( n = nmbr ),
1,soc,
1,smokingb,
1,smmse < nmbr,
1,smmse,
1,smi :,
1,sk . nmbr,
1,sjc ( nmbr - nmbr ),
1,sjc,
1,sita nmbr,
1,sirius,
1,since onset,
1,since diagnosis,
1,simva n = nmbr n ( % ),
1,simva ( „ = nmbr },
1,simva ( n = nmbr ),
1,simva ( % ),
1,simva,
1,shs,
1,sgrq scores,
1,sgrq score,
1,sgrq responder ( % ),
1,severitya,
1,sesbp,
1,sedbp,
1,scsbp,
1,scdbp,
1,scd ( % ),
1,saxagiiptin,
1,saxa + met n = nmbr,
1,saxa + dapa + met n = nmbr,
1,samac,
1,sack,
1,sabae,
1,sabaa,
1,saba §,
1,saba ( inhaled ),
1,saba,
1,saaca,
1,rvw,
1,rvfac ( % ),
1,rvalue,
1,rrr,
1,rronmbr ( nmbr . nmbr,
1,rro . nmbr ( nmbr . nmbr . nmbr . nmbr ),
1,rrnmbr . nmbr ( nmbr . nmbr . nmbr . nmbr ),
1,rrnmbr . nmbr ( nmbr - nmbr . nmbr . nmbr ) *,
1,rrnmbr . nmbr ( nmbr - nmbr,
1,rr nmbr . nmbr < nmbr . nmbr,
1,rr nmbr . nmbr ( nmbr . nmbr . nmbr . nmbr ),
1,rr nmbr . nmbr ( nmbr . nmbr,
1,rr nmbr . nmbr,
1,rr nmbr - nmbr ( nmbr . nmbr,
1,rr *,
1,rr,
1,rosigiitazone ± oad,
1,revive ii,
1,revive i,
1,resllzumab,
1,reqion,
1,remodeling,
1,reinfarction,
1,regiont,
1,reduction,
1,reduction,
1,redon,
1,recervng,
1,recervini },
1,rca,
1,ratet n ( % ),
1,ratet,
1,rarertd antocagibtcn before andorrtzafon,
1,ranozaline,
1,ranotazine vs . placebo km failure rate,
1,randomly assigned to diuretic,
1,randomly assigned to calcium channel blocker,
1,randomly assigned to ace,
1,randomize,
1,randomised to canakinumab nmbr mg,
1,raee,
1,racey,
1,racea,
1,qveral,
1,quicki,
1,qtc > nmbr n = nmbr,
1,qtc < nmbr n = nmbr,
1,qnmbrw ( n nmbr nmbr ),
1,qnmbrw ( n = nmbr ),
1,qnmbr - qnmbr,
1,qnmbr ( n   = nmbr ),
1,qmi,
1,qmax,
1,q ( q nmbr\,
1,pvaluefor any mi versus no mi,
1,pvalue ∗,
1,pvalue,
1,ptga ⁎ ⁎ ⁎,
1,ptga,
1,psychoactivesd,
1,psaqol,
1,prosthetic,
1,prosper,
1,priorother ( predefined ) medical conditions,
1,priorother ( not predefined ) medical conditions,
1,priorheartfailure,
1,previously taken tnfi,
1,previously taken methotrexate,
1,previously taken dmards other than methotrexate,
1,previously taken any other dmards,
1,previously failed anti - tnf treatment,
1,previously,
1,prediabeticb,
1,prediabetese,
1,ppci in - nmbr,
1,ppci ( n = nmbr ),
1,ppci,
1,postamendment,
1,poslmenopausal,
1,pollent s nmbr,
1,pollent < nmbr,
1,poci ( n = nmbr ),
1,poci,
1,poba,
1,pnorpci,
1,pnorcabg,
1,plus – minus values are means ± sd . cabg denotes coronary - artery by - pass graft  ptca percutaneous transluminal coronary angioplasty  and ace angiotensin - converting enzyme . hypertension and diabetes were de - fined by clinical history . a more complete list of base - line characteristics is given in rubins et al .,
1,plaeebo,
1,placeboa,
1,pinteraction = nmbr . nmbr,
1,pinteraction,
1,piacebo ( n = nmbr ) no . of participants with events ( % ),
1,piacebo,
1,phakic,
1,persisent,
1,pdq - nmbr,
1,pasia,
1,paod,
1,pacific,
1,overally,
1,overallb,
1,overaii ( n = nmbr ),
1,overaii,
1,otherz,
1,otherx,
1,othert,
1,othersc,
1,othernmbr,
1,otherj^ :,
1,otherf,
1,otherd,
1,otherc,
1,otherb,
1,othera,
1,other^,
1,other †,
1,other — no . ( % ),
1,other vasculars,
1,other uc - related gi surgical procedure,
1,other teaes,
1,other or missing data,
1,other bdmards ( no tnfi taken ) t,
1,other bdmard §,
1,other antiplatelet,
1,other : :,
1,other * ’,
1,other *,
1,other ',
1,other !,
1,other,
1,ornmbr_value,
1,ornmbr,
1,oretal,
1,oralb,
1,or_value,
1,or 、 ( nmbr % ci ),
1,or ulcerations,
1,or taking antihypertensive medication,
1,or severe,
1,or raloxifene,
1,or primary outcome,
1,or placebo treatment,
1,or no microalbuminuria or macroalbuminuria,
1,or nmbr % ci,
1,or morbidity and mortality,
1,or esrd,
1,or death,
1,or [nmbr % cl],
1,or [nmbr % ci],
1,or = nmbr . nmbr ( nmbr . nmbr – nmbr . nmbr ) nmbr . nmbr,
1,or = nmbr . nmbr ( nmbr . nmbr – nmbr . nmbr ) < nmbr . nmbr,
1,or : nmbr . nmbr ( nmbr . nmbr  nmbr . nmbr )  p = nmbr . nmbr,
1,or ( unadjusted ),
1,or ( nmbr % cl ) = nmbr nmbr ( nmbr . nmbr . nmbr nmbr ),
1,or ( nmbr % cl ) = nmbr nmbr ( nmbr . nmbr,
1,or ( nmbr % cl ) = nmbr . nmbr ( nmbr nmbr . nmbr . nmbr ),
1,or ( nmbr % cl ) = nmbr . nmbr ( nmbr . nmbr . nmbr . nmbr ),
1,or ( nmbr % cl ),
1,or ( nmbr % ci ) a,
1,or ( nmbr % ci ),
1,or ( itt ) ( n = nmbr ),
1,or,
1,op,
1,onsetofaf,
1,on or after e^andomization,
1,on omt ( n = nmbr ),
1,on omt,
1,on nmbr,
1,olaemia,
1,ol / l ),
1,off omt ( n = nmbr ),
1,off omt,
1,octi,
1,octave sustain,
1,ocs use,
1,ocs reduced / stopped,
1,ocs maintained / increased,
1,ocs,
1,obesityj,
1,oascvd,
1,oam,
1,oads,
1,oad,
1,oac experienced,
1,nyhaiiioriv,
1,nyhaii,
1,numbera,
1,numab,
1,ntbnp ( n = nmbr ),
1,nsteacs,
1,nothfref,
1,northamerica,
1,normoalbuminuria — no . / total no . ( % ),
1,normoalbuminuria — no . ( % ),
1,normoalbuminuria §,
1,normoalbuminuria or microalbuminuria,
1,normoalbuminuria,
1,normalfunction or mild impairment,
1,normai fasting giucose levei ( n = nmbr ),
1,noppi,
1,nonwhite race — no . ( % ) ejection fraction,
1,nonwhite,
1,nonvertebral,
1,nonuser,
1,nonreversible,
1,nonischemic,
1,noninducing,
1,nonfatal,
1,noneh,
1,none 一 no . ( % ),
1,none or seldom,
1,none or diet,
1,none ( cdmard - naive or past use at baseline ),
1,none,
1,nondisabling,
1,nondiabetic,
1,nondiabetes,
1,noncaucasian,
1,noncardiovascular,
1,nonblack race — no . ( % ) f,
1,nonblack race — no . ( % ) - j -,
1,nonblack ( n = nmbr ),
1,nonblack,
1,nonanterior,
1,nominal p vs placebo,
1,noliecervrig,
1,noirecerving,
1,no vhd,
1,no ststm,
1,no or unknown,
1,no op,
1,no ocs use,
1,no ocs,
1,no oam,
1,no nmbr,
1,no laba  no ics ( tiotropium n = nmbr  placebo n = nmbr ),
1,no laba,
1,no ipst ( n = nmbr,
1,no ipst,
1,no immomtedion,
1,no ?,
1,no . of tnfi among non - tnfi naive,
1,no . of panents . total no . nmbr % ),
1,no . of,
1,no . needed to treat ( nmbr % cl ) *,
1,no . evenls,
1,no . a,
1,no . *,
1,no . ( % ) nmbr ( nmbr ),
1,no . ( % ) *,
1,no . ( % ) ',
1,no . ( % ),
1,no .,
1,no *,
1,no ( nmbr . nmbr ),
1,no ( % ),
1,no,
1,nmbry,
1,nmbrtol ( n = nmbr ),
1,nmbrtcz,
1,nmbrs = scandinavian simvastatin survival study . nmbr woscops = west of scotland coronary prevention study . nmbr care = cholesterol and recurrent events . nmbr post - cabg = post - coronary artery bypass graft . nmbr afcaps / texcaps = air force / texas coronary atherosclerosis prevention study . nmbr lipid = long - term intervention with pravastatin in ischaemic disease . nmbr gissi prevention = gruppo italiano per lo studio della sopravvivenza nell ’ infarto miocardico . nmbr lips = lescol intervention prevention study . nmbr hps = heart protection study . nmbr prosper = prospective study of pravastatin in the elderly at risk . nmbr allhat - llt = antihypertensive and lipid - lowering treatment to prevent heart attack trial . nmbr ascot - lla = anglo - scandinavian cardiac outcomes trial - lipid lowering arm . nmbr alert = assessment of lescol in renal transplantation . nmbr cards = collaborative atorvastatin diabetes study . nmbr s = simvastatin .,
1,nmbrrrmnl ),
1,nmbrqnmbrw ( n = nmbr ),
1,nmbrornmbr,
1,nmbrnd > nmbr . nmbr / < nmbr . nmbr,
1,nmbrmwd,
1,nmbrii ( nmbr . nmbr ),
1,nmbrenmbr,
1,nmbre < nmbr %,
1,nmbrb ( nmbrb to nmbra ),
1,nmbrb ( nmbrb to > nmbra ),
1,nmbr — nmbr nlmw,
1,nmbr — em,
1,nmbr — < nmbr,
1,nmbr ± ll,
1,nmbr §,
1,nmbr yrs or more,
1,nmbr yrs l,
1,nmbr yrs,
1,nmbr to nmbr y ( n = nmbr,
1,nmbr to nmbr y,
1,nmbr to < nmbr — no . { % ),
1,nmbr to < nmbr mumin,
1,nmbr to < nmbr hr,
1,nmbr or nmbr — no . / total no . ( % ),
1,nmbr or nmbr step,
1,nmbr or nmbr high cardiovascular risk categories,
1,nmbr or nmbr high - risk categories,
1,nmbr or nmbr days,
1,nmbr or nmbr d / wk,
1,nmbr or nmbr d / mo,
1,nmbr or nmbr,
1,nmbr or more,
1,nmbr or greater,
1,nmbr oam,
1,nmbr oads,
1,nmbr oad,
1,nmbr nmbr fo nmbr - nmbr nmbr ),
1,nmbr nmbr ( nmbr . nmbr ),
1,nmbr nmbr,
1,nmbr mortis,
1,nmbr montlts,
1,nmbr mgrdl,
1,nmbr mentis,
1,nmbr is ( nmbr . nmbr ),
1,nmbr c . t,
1,nmbr blockers,
1,nmbr blocker,
1,nmbr < - nmbr,
1,nmbr / nmbr ( nmbr . nmbr ),
1,nmbr / nmbr ( nmbr ),
1,nmbr / nmbr,
1,nmbr . nmbr ± ii . nmbr,
1,nmbr . nmbr ± b . b,
1,nmbr . nmbr { nmbr . nmbr,
1,nmbr . nmbr yrs,
1,nmbr . nmbr vs nmbr . nmbr,
1,nmbr . nmbr per nmbr pyr,
1,nmbr . nmbr per nmbr nmbr . nmbr per nmbr pyr pyr,
1,nmbr . nmbr or more,
1,nmbr . nmbr - nmbr . nmbr,
1,nmbr . nmbr - < nmbr . nmbr %,
1,nmbr . nmbr - < nmbr . nmbr,
1,nmbr . nmbr - < nmbr,
1,nmbr . nmbr + nmbr . nmbr,
1,nmbr . nmbr ( nmbr nmbr . nmbr ),
1,nmbr . nmbr ( nmbr . nmbr – nmbr . nmbr ),
1,nmbr . nmbr ( nmbr . nmbr . nmbr . nmbr ),
1,nmbr . nmbr ( nmbr . nmbr - nmbr . nmbr ),
1,nmbr . nmbr ( nmbr . nmbr ),
1,nmbr . nmbr ( nmbr . nmbr,
1,nmbr . nmbr ( ll . nmbr ),
1,nmbr . nmbr % vs . nmbr . nmbr %,
1,nmbr . nmbr % or more,
1,nmbr . nmbr % - nmbr . nmbr %,
1,nmbr . nmbr % ( nmbr ),
1,nmbr . nmbr %,
1,nmbr . nmbr,
1,nmbr - up and / or aza at baseline,
1,nmbr - nmbr — no . ( % ),
1,nmbr - nmbr yrs,
1,nmbr - nmbr y,
1,nmbr - nmbr hr,
1,nmbr - nmbr fo - nmbr nmbr - nmbr^,
1,nmbr - nmbr . nmbr,
1,nmbr - nmbr - nmbr - nmbr,
1,nmbr - nmbr - nmbr,
1,nmbr - nmbr,
1,nmbr - blocker,
1,nmbr - < nmbr yrs,
1,nmbr - < nmbr y,
1,nmbr - < nmbr mvmin,
1,nmbr - < nmbr . nmbr,
1,nmbr - < nmbr ( % ),
1,nmbr - < nmbr %,
1,nmbr - < nmbr,
1,nmbr +,
1,nmbr ( or nmbr,
1,nmbr ( oonmbr - o . nmbr ),
1,nmbr ( nmbrj ) znmbr ( nmbr . e,
1,nmbr ( nmbre < nmbr % ),
1,nmbr ( nmbr si,
1,nmbr ( nmbr . nmbr ) / nmbrz ( nmbrze ),
1,nmbr ( nmbr . nmbr ),
1,nmbr ( nmbr . nmbr % ),
1,nmbr ( nmbr % ),
1,nmbr ( nmbr,
1,nmbr ( > nmbr % ),
1,nmbr ( < nmbr % ),
1,nmbr % nmbr,
1,nmbr % - nmbr %,
1,nmbr % ( oto nmbr ),
1,nmbr %,
1,nmbr,
1,nkf stage,
1,nitratesf,
1,niacini,
1,nerd,
1,neohrodathv . and all - cause mortalitv,
1,neither uh or lmw heparin,
1,neither,
1,nd not due to swelling or ich,
1,nd,
1,nctnmbr,
1,nbp,
1,napsit,
1,napsi score ( nmbr - nmbr ) of target fingernail,
1,naive : no,
1,naive ( no treatment for current flare ),
1,naive ( n = nmbr ),
1,naive,
1,naire can range from nmbr to nmbr for the alternative disability portion and from nmbr to nmbr for the pain portion . scores for the medical outcomes,
1,myopathyt,
1,myoclonic,
1,multivariable or ( nmbr % ci ),
1,multivariable,
1,mucocutaneous,
1,mtss at,
1,mtss ( nmbr - nmbr ),
1,mtss,
1,mssbp / msdbp,
1,mssbp,
1,msfc timed nmbr - foot walk test .,
1,msfc timed nmbr - foot walk test,
1,msdbp,
1,msasss,
1,monteiukast vs placebo,
1,monteiukast ( n = nmbr ),
1,monteiukast,
1,monotherapynmbr,
1,monotherapy,
1,moderatez,
1,moderatey,
1,moderatex,
1,mnapsi,
1,mmrm estimates,
1,mhi,
1,mfns ( n = nmbr ),
1,metsyn,
1,metrex modified intention - to - treat population with an eosinophilic phenotypey,
1,metforminmonotherapy,
1,merformin,
1,mepo ( n = nmbr ),
1,mensa,
1,mellitus,
1,mcs score ( nmbr – nmbr scale ),
1,mcs score,
1,mbesc,
1,mbesb,
1,mbes / crbesc,
1,mbes / crbesb,
1,mases ( nmbr - nmbr ),
1,mafcaiancy at randorrtzaton,
1,maf,
1,macroalbuminuriaf,
1,macroalbuminuria — no . / total no . ( % ),
1,macroalbuminuria — no . ( % ) drug therapy — no . ( % ),
1,macroalbuminuria ( uacr > nmbr ),
1,macroalbuminuria,
1,macce ( % ),
1,macce,
1,lvmi ( nmbr,
1,lunchb,
1,lntensityd,
1,llpasi nmbr,
1,llnmbr ( nmbr ),
1,lleocolon,
1,ll ( nmbr ),
1,ll,
1,lixi,
1,lithe,
1,lisrs,
1,lgm ( n = nmbr ),
1,leader,
1,ldu - c,
1,ldlnmbr - c,
1,ldl cholesterolt,
1,ldl choleslerol,
1,ldl cholesicrol ( minol / l ),
1,ldl - csmedian,
1,ldl - cihdl - c,
1,ldl - c ( measured ) *,
1,ldl - c ( measured ),
1,ldl - c ( calculated ) *,
1,ldl - c ( calculated ),
1,ldl - c,
1,ldl *,
1,ldl,
1,ldinmbr,
1,ldi - b > nmbr ( n = nmbr ),
1,ldi,
1,lcznmbr ( n = nmbr ),
1,lcznmbr,
1,lc,
1,lb,
1,lavolta nmbr,
1,latin and north america,
1,latin ameriea,
1,latin,
1,lamad,
1,lad,
1,labaa,
1,laba or lamab n = nmbr,
1,laba or lama ’ versus ind / gly lsm difference ( nmbr % cl ),
1,laba or lama ’,
1,laba or lama,
1,laba alone,
1,laba - inhaled glucocorticoid use at screening,
1,laba ( inhaled ),
1,laba ',
1,laba,
1,laaca,
1,laa,
1,killip ciass,
1,kellgren and lawrence radiographic reading grade nmbr — no . ( % ),
1,jvp > nmbrcm,
1,jvp ( 〉 nmbr cm ),
1,jvp,
1,jsn,
1,jnmbr - blocker,
1,ization — no . ( % ),
1,ixeqnmbrw,
1,itt,
1,itherchdt,
1,ith vs . without ),
1,it nmbr . nmbr,
1,islander,
1,ish,
1,is only,
1,is domain luts severity ( % ),
1,irofiban,
1,iqr,
1,ipst ( n = nmbr ),
1,ipst,
1,iorii ( n z nmbr ),
1,interact !,
1,intensified ( n 二 nmbr ),
1,insulina,
1,insuiin giargine ± oad,
1,inhixanab nmbr mgikg versus piacom,
1,inhaledb,
1,indzgly,
1,incidencea,
1,in thirds,
1,in,
1,immobazaton,
1,im use : no,
1,im or cs use : no,
1,im on]y,
1,im and cs use : no,
1,im - uniti,
1,ileocolonic ( both ileum and colon ),
1,ileocolon,
1,ijb^,
1,iinmbr ± nmbr,
1,iiiv,
1,ii or iii,
1,ii = nmbr,
1,ii . nmbr ( nmbr . nmbr ) nmbr,
1,ii ( nmbr ),
1,ii,
1,igt or ifg,
1,igm,
1,iglarlixi ( n   =   nmbr ),
1,iglarlixi,
1,iglar ( n   =   nmbr ),
1,iglar,
1,igelow ( n = nmbr,
1,idr,
1,idiopathica,
1,idegasp – biasp nmbr,
1,idegasp bid,
1,ideg,
1,icsusers atbaseline,
1,icsf,
1,icsa,
1,ibdq score |,
1,ibdq score,
1,ibdq,
1,hypoglycemiat,
1,hypoglycaemiad,
1,hypertensiont,
1,hyperlipidmemia,
1,hyperlension,
1,hyperkalemiab,
1,hypercholesterolemiat,
1,hydochlorothiazide ( n = nmbr ),
1,hvpertension,
1,hvpercholesterolemia,
1,hvookalemia,
1,hscrp §,
1,hscrp,
1,hrnmbr and nmbr % cl,
1,hr ‡,
1,hr vs placebo ( nmbr % ci ),
1,hr vs control ( nmbr % cl ) *,
1,hr vs . warfarin ( nmbr % ci ),
1,hr nmbr . nmbr,
1,hr is < nmbr if pravastatin is better than diet alone,
1,hr and nmbr % ci *,
1,hr : nmbr . nmbr,
1,hr : nmbr . nmbr,
1,hr * or rr † ( nmbr % ci ) ,
1,hr * or rr †,
1,hr ( nmbrs % a ),
1,hr ( nmbr % c ! ),
1,hr ( enl vs lcz ) ( nmbr % cl ),
1,hr ( bpm ),
1,hr ( adjusteda ),
1,hr,
1,hosji fcrhypoglycemia,
1,hordic,
1,homa_ % b,
1,homa . % b,
1,homa - p,
1,homa - b,
1,homa,
1,highjj,
1,hhf ( n = nmbr ),
1,hfref ( n = nmbr ),
1,hfref,
1,hfpef ( ef n nmbr ),
1,hdm n = nmbr,
1,hdlcholesterol,
1,hd ( n = nmbr ),
1,hcru ( a ),
1,"hbau  % """,
1,hbalc in %,
1,hbalc anmbr mmol / mol ( > nmbr . nmbr % ) ( n = nmbr / nmbr ),
1,hbalc > nmbr %,
1,hbalc > = nmbr % ( n - nmbr ),
1,hbalc < nmbr %,
1,hbalc < medan,
1,hbalc ( % ),
1,hbalc,
1,hbaie ( % ),
1,hbaie,
1,hbaic — %,
1,hbaic ( % ),
1,hbai,
1,has - bledo,
1,has - blednmbr - nmbr,
1,has - bled score ’,
1,has - bled score > nmbr,
1,has - bled score,
1,has - bled nmbr - nmbr,
1,has - bled > nmbr,
1,handihaler and diskus,
1,hale,
1,gusto severe or,
1,gusto severe,
1,gusto moderate or severe bleeding,
1,gusto moderate or severe,
1,gusto moderate / severe bleeding,
1,gusto moderate / severe bleed,
1,gusto moderate / severe,
1,gusto moderate,
1,gusto - defined bleeding,
1,gusto - bleeding severe / moderate,
1,granulating,
1,golden - nmbr and - nmbr,
1,golden - nmbr,
1,glulisine monotherapy,
1,glulisine + oad,
1,glacialnmbr,
1,giimepiride ± oad,
1,giargine,
1,getgoal - s,
1,gertder,
1,gentype,
1,gendar,
1,fsg,
1,fpi,
1,fpg,
1,fpci vs . ppci in women,
1,fpci vs . ppci in men,
1,figure nmbr least squares ( ls ) mean differences between ro ﬂ umilast and placebo in ( a ) pre - and ( b ) postbronchodilator fevnmbr in the itt population and subpopulations . copd  chronic obstructive pulmonary disease  fevnmbr  forced expiratory volume in nmbr s  ics  inhaled corticosteroid  itt  intent to treat  laba  long - acting bnmbr - agonist .,
1,fibrofatty,
1,fibrinolysist,
1,fibrate or other lipid - lowering agent,
1,fibrate,
1,fh nmbr,
1,fevj % predicted !,
1,fenofibric,
1,feno + eze,
1,feno,
1,femoralneck t - scorebybaselinevfxstatus,
1,femalesex,
1,femaleb,
1,femaie,
1,fcal,
1,fbg,
1,fas,
1,eze / simva ( „ = nmbr },
1,eze / simva ( n = nmbr ),
1,eze / simva,
1,eze,
1,extenswe,
1,evomab + soc,
1,evomab ( n = nmbr ),
1,evomab,
1,ever smoked ( current / former ),
1,ever been on a vka,
1,ever,
1,evenls per nmbr,
1,ethnieity,
1,erd *,
1,epa ( n = nmbr ),
1,epa,
1,enrope + sonth afriea,
1,enmbr + anmbr -,
1,enmbr + anmbr,
1,enmbr ( n = nmbr ),
1,endpointc,
1,enact - nmbr trial rerandomization to natalizumab ( n = nmbr ),
1,enact - nmbr trial,
1,empagllflozln,
1,empagllflozin,
1,egfrmdrd,
1,ef nmbr - nmbr . nmbr % ( n nmbr nmbr ),
1,ef nmbr - nmbr % hfmref ( n = nmbr,
1,ef nmbr - nmbr %,
1,ef b nmbr %,
1,ef > nmbr % n = nmbr,
1,ef > nmbr % hfpef ( n = nmbr,
1,ef > nmbr % ( n nmbr nmbr ),
1,ef > nmbr % ( n = nmbr,
1,ef > nmbr %,
1,ef < nmbr % n = nmbr,
1,ef < nmbr % hfref ( n = nmbr,
1,ef < nmbr % ( n nmbr nmbr ),
1,ef < nmbr % ( n = nmbr,
1,ef < nmbr %,
1,ef ( % ),
1,ef,
1,educ ssy,
1,educ nmbr - nmbry,
1,educ > nmbry,
1,edo,
1,ecrcl,
1,ecfr,
1,e / e ' ( septal ),
1,e,
1,dyslipidaemiat,
1,dyslipidaemiaj,
1,dupiiumab,
1,dosing,
1,diureties,
1,diureticff,
1,diurciic,
1,discontinu - ation,
1,disabling or fatal stroke,
1,disabling or fatal,
1,differencevs . pbof,
1,diff_measure,
1,did not meet atopy and igenmbr - nmbrku / lcriteriaa ( n = nmbr,
1,did not enrol into osler,
1,diabeticb,
1,diabetesz,
1,diabetesf,
1,diabetese,
1,diabetesduration,
1,diabetesc,
1,denotes angiotensin - converting enzyme .,
1,deathsb,
1,dcct anmbrc,
1,data represent number of patients ( % ) or mean ( standard deviation )  unless otherwise indicated . a self - reported information . bc physician - diagnosed diabetes or fasting plasma glucose ≥ nmbr mg / dl or hemoglobin anmbrc ≥ nmbr . nmbr % . d physician - diagnosed hypertension or systolic blood pressure ≥ nmbr mmhg or diastolic blood pressure ≥ nmbr mmhg .,
1,data are presented as mean sd . * n nmbr for ldl cholesterol .,
1,data are mean ( sd ) or number ( % ) . bmi = body - mass index . sbp = systolic blood pressure . dbp = diastolic blood pressure . lvef = left ventricular ejection fraction .,
1,data are mean ( sd ) or n ( % ) . ace = angiotensin - converting enzyme  arb = angiotensin - receptor blocker .,
1,data are expressed as n / total ( % ) unless otherwise speci ﬁ ed . systeme international unit conversion : to convert creatinine clearance to ml / s  multiply by nmbr . nmbr . * estimated with cockroft - gault equation  † at discharge .,
1,dapagliflozint,
1,dapaglifloz . in,
1,dapaglifloiin,
1,dapa + met n = nmbr,
1,dabetes,
1,cwt,
1,cvdeath,
1,currentd,
1,csii,
1,cse] +,
1,crude,
1,crt - p + d,
1,crt - p,
1,crt - d,
1,crt,
1,crpnonr ?,
1,crj,
1,crci > nmbr - < nmbr,
1,crci > nmbr,
1,covariates,
1,covariate,
1,corticosteroidsa,
1,controlld,
1,continuation ( n = nmbr ),
1,continuation,
1,conservative,
1,conieosieroids and / or nmbr - mp,
1,comorbidites,
1,combo vs . primary,
1,combinationf,
1,coexisting conditions — no . ( % ),
1,cm,
1,clopiodogrel,
1,clonic,
1,ckdc,
1,cigarettesmoking,
1,ciass ll - iv,
1,chda,
1,charlson,
1,characteristicsa,
1,characteristica,
1,chajdsrvasc nmbr - nmbr,
1,chajdsj - vasc nmbr - nmbr,
1,chajdsj - vasc > nmbr,
1,chajdsa - vasc nmbr - nmbr,
1,chadsj > nmbr,
1,chadsj < nmbr,
1,chadsa < nmbr,
1,cgfr,
1,cerebral,
1,cdmard,
1,ccq score § §,
1,cclear nmbr - nmbr,
1,cclear nmbr +,
1,cclear < nmbr,
1,causaslan,
1,caucasiana ( % ),
1,catscorecategory,
1,cardiovasculardeath,
1,cardiovascuiar mortaiity,
1,cardioembolism,
1,cardioembolic,
1,cancert,
1,canagiiflozin,
1,caleitonin,
1,cabgorptca,
1,c,
1,bun,
1,bsa involved,
1,bsa affected,
1,bsa > nmbr %,
1,bsa ( % ),
1,bsa,
1,breakfastb,
1,brandomization was stratified by diabetic status .,
1,bp : blood pressure  ci : confidence interval  esrd : end - stage renal disease  hr  hazard ratio .,
1,both ( % ),
1,both,
1,bms,
1,bmit,
1,bmij,
1,bmia,
1,blockers,
1,blocker,
1,blaic > nmbr . nmbr %,
1,blaic < nmbr . nmbr %,
1,blaek / afriean - ameriean,
1,blaek,
1,biolimus anmbr - eluting stent ¶,
1,bilag a,
1,bid,
1,biasp nmbr bid,
1,biasp nmbr,
1,biack non - hispanic,
1,biack,
1,bi ( nmbr . nmbr ),
1,bempedoic,
1,bdmard - naive,
1,basmi ( linear ),
1,basfi *,
1,basfi,
1,baselinec,
1,baselineb,
1,baseiine diuretic,
1,barc nmbr - nmbr,
1,b pooled new and worsened vertebral fractures ( mfas ),
1,b includes both ex - smokers and nonsmokers .,
1,b - blockers,
1,b - blocker,
1,b + a ( n = nmbr ),
1,b ) those on inhaled corticosteroids and long - acting bronchodilators as previous treatment use .,
1,b,
1,austrafca and new zealand,
1,attain,
1,atorvastatinb,
1,atenoioi ( n = nmbr ),
1,at or above the median,
1,at or above median,
1,at least nmbr flare,
1,at,
1,asui score,
1,associatedproximaldeep - veinthrombosisatdiagnosis,
1,assoc,
1,asqol,
1,aslan,
1,as,
1,arvfac ( per nmbr % ),
1,arteriai access,
1,aqe ^nmbr,
1,aqe < nmbr,
1,aqc < nmbr,
1,apolipoproiein b ( mij / nmbr ),
1,apolipoproiein anmbr ( tng / nmbr ),
1,apobe,
1,apoal,
1,apo bt,
1,ap = nmbr . nmbr  bp nmbr . nmbr  cp = nmbr . nmbr . * the study - speci ﬁ c bp targets were sbp nmbr mm hg and dbp nmbr mm hg ( or sbp nmbr mm hg and dbp nmbr mm hg in those with dm ) . the ldl - c target was nmbr mg / dl or nmbr mg / dl  depending on risk factor status at baseline in accordance with ncep atp iii guidelines . odds ratio and p value calculated based on generalized linear mixed model with generalized estimating equations method that includes compound symmetry covariance matrix for subjects from the same site . an interaction between treatment effect and dm status was observed for bp goal attainment ( p = nmbr . nmbr ) and dual bp / ldl - c goal attainment ( p = nmbr . nmbr ) among patients with or without dm calculated based on a mixed - effects linear model ( not adjusted for differences in baseline values ) .,
1,any timi bleeding,
1,any teaes,
1,any teae,
1,any other llts ( other than statin ),
1,any other lipid ‐ lowering therapy,
1,any other antihyperglycaemic drugs,
1,any bleeding,
1,any ( including corticosteroid ),
1,any,
1,antithrombotic and anticoagulant medications,
1,antithrombotic,
1,antiplateletsa,
1,antiplatelets or anticoagulants,
1,antiplatelets,
1,antiplatelet — no . / total no . ( % ),
1,antiplatelet — no . ( % ),
1,antiplatelet or anticoagulant therapy,
1,antiplatelet or anticoagulant,
1,antiplatelet or anti - inflammatory drugs,
1,antiplatelet,
1,antihyperglycemictherapies,
1,anti - pnmbr,
1,anthropometrics,
1,annt or bnnh ( nmbr % ci ),
1,anmbrc > s . nmbr - s . nmbr %,
1,anmbrc > nmbr . nmbr - nmbr . nmbr %,
1,anmbrc > nmbr . nmbr %,
1,anmbrc < nmbr . nmbr %,
1,anmbrc ( % ),
1,anmbrc,
1,anmbr vs placebo,
1,anmbr . nmbr ± nmbra . nmbr,
1,anmbr + ezio anmbr ( n = nmbr ) ( n = nmbr ),
1,anmbr,
1,aniagonisi,
1,anesthesiad,
1,and vfx status,
1,and physical examination,
1,and microalbuminuria or macroalbuminuria,
1,and infusion,
1,and either an ace inhibitor or angiotension receptor blocker,
1,and / or discharge,
1,and / or aza at baseline,
1,amputationsa,
1,ampdnmbr,
1,am_delta,
1,am_ % delta,
1,am pef ( sd ),
1,alvef ( per nmbr % ),
1,allopurinolt,
1,allogliptin,
1,all teaes *,
1,all teaes,
1,all subjects - n,
1,all subjects,
1,all strokes *,
1,all strokes,
1,all rosuva,
1,all responders,
1,all randomly assigned,
1,all randomized all - cause mortality or hospitalization for worsening hf^,
1,all randomized all - cause mortality,
1,all randomized,
1,all patientsb,
1,all participantst ( n = nmbr / nmbr ),
1,all participantsa,
1,all other,
1,all noncompleters,
1,all itt sutajects,
1,all grafts,
1,all diabetesd,
1,all completers ( n nmbr nmbr ),
1,all completers,
1,all bleeding,
1,all bleed,
1,all,
1,ali,
1,alathosterol ( % ),
1,aiorvasiaiin,
1,aiirocumab ( n = nmbr ),
1,aiirocumab,
1,aget,
1,ageadj,
1,agea,
1,afcaps /,
1,adverse eventy,
1,adjustedb,
1,adjustedaor,
1,adjustedahr,
1,acholesterol ( % ),
1,acenocoumaroi,
1,aceis,
1,acei vs . non - acei,
1,acei use,
1,acei or arb pre - randomisation,
1,acei or arb post - randomisation,
1,acei or arb,
1,acei and / or arb,
1,acei,
1,acecoumarol,
1,absolutedifferenceestimate vs placebo ( nmbr % ci ),
1,abbreviations : egfr = estimated glomerular filtration rate  imt = intimal medial thickness  lv = left ventricular .,
1,aabnmbr ( % ),
1,a vs . c,
1,a from baselineb,
1,a excludes two randomized patients with unknown diabetes status at baseline .,
1,a a ( nmbr ( % ),
1,a / c,
1,a . beuralizuinab nmbr ing qnmbrw,
1,a - blockers,
1,a - blocker,
1,a ) those receiving no inhaled pre - treatment maintenance medication,
1,a,
1,^nmbr y,
1,^nmbr - nmbr,
1,^nmbr,
1,^ - blockers,
1,^ - blocker,
1,\nmbr %,
1,\nmbr,
1,[ } ifrerence vs . placebo,
1,> nmbryearstos is years,
1,> nmbry,
1,> nmbrnd and < nmbrrd quartile,
1,> nmbrb ( nmbrb to nmbra ),
1,> nmbr   vs .   ≤   nmbr,
1,> nmbr — no . { % ),
1,> nmbr yrs,
1,> nmbr y . n ( % ),
1,> nmbr y ( n = nmbr ),
1,> nmbr y ( n = nmbr,
1,> nmbr y,
1,> nmbr to   ≤   nmbr   vs .   ≤   nmbr,
1,> nmbr or incident vitrectomy or photocoagulation,
1,> nmbr oads,
1,> nmbr nmbr,
1,> nmbr mon ( n = nmbr ),
1,> nmbr mlymin,
1,> nmbr microg / l,
1,> nmbr lb,
1,> nmbr ky / nr,
1,> nmbr hr,
1,> nmbr enroll,
1,> nmbr cm,
1,> nmbr but < nmbr mg / dl,
1,> nmbr bpm ( n = nmbrlnmbr ),
1,> nmbr bpm ( n = nmbr ),
1,> nmbr beats / min,
1,> nmbr and   ≤   nmbr   vs   ≤   nmbr,
1,> nmbr and   ≤   nmbr   vs .   ≤   nmbr,
1,> nmbr and < nmbr years,
1,> nmbr and < nmbr mg / dl,
1,> nmbr and < nmbr %,
1,> nmbr and < nmbr,
1,> nmbr and / or > nmbr moderate or severe deformity,
1,> nmbr < nmbr,
1,> nmbr . nmbr   vs .   >   nmbr . nmbr and   ≤   nmbr . nmbr,
1,> nmbr . nmbr   vs . nmbr . nmbr to   ≤   nmbr . nmbr,
1,> nmbr . nmbr yrs,
1,> nmbr . nmbr bpm,
1,> nmbr . nmbr - < nmbr . nmbr,
1,> nmbr . nmbr ( % ),
1,> nmbr . nmbr % and ≤ nmbr . nmbr %,
1,> nmbr . nmbr %,
1,> nmbr . nmbr,
1,> nmbr - nmbr cm,
1,> nmbr - nmbr - nmbr - nmbr,
1,> nmbr - nmbr - nmbr,
1,> nmbr - nmbr,
1,> nmbr - < nmbr,
1,> nmbr ( % ),
1,> nmbr % nmbr,
1,> nmbr % and < nmbr % predicted arr ( n = nmbr,
1,> nmbr % and < nmbr %,
1,> nmbr %,
1,> nmbr,
1,> lto < nmbr ( n = nmbr ),
1,> is years,
1,> ii,
1,> = nmbry,
1,> = nmbr yea ' s,
1,> = nmbr y,
1,> = nmbr mmhq,
1,> = nmbr . nmbr,
1,> = nmbr * ( % ),
1,> = nmbr ( % ),
1,> = nmbr % and < nmbr % ( > = nmbrand < nmbr mmol / mol ),
1,> = nmbr,
1,> - nmbr cm,
1,> - nmbr . nmbr and < - nmbr . nmbr,
1,> - nmbr . nmbr - vfx,
1,> - nmbr . nmbr + vfx,
1,> - nmbr . nmbr,
1,= nmbr ’ ),
1,= nmbr,
1,< nmbry,
1,< nmbrxuln,
1,< nmbrnwrrtn,
1,< nmbrmlmin ) nmbr,
1,< nmbr — no . { % ),
1,< nmbr — no . ( % ),
1,< nmbr » < nmbry,
1,< nmbr { % ),
1,< nmbr yrs,
1,< nmbr yea ' s,
1,< nmbr y ( n = nmbr ),
1,< nmbr y ( n = nmbr,
1,< nmbr y,
1,< nmbr no . ( % ),
1,< nmbr mon ( n = nmbr ),
1,< nmbr mlymin,
1,< nmbr microg / l,
1,< nmbr lb,
1,< nmbr ky / nr,
1,< nmbr hr,
1,< nmbr enroll,
1,< nmbr cm,
1,< nmbr bpm ( n = nmbr ),
1,< nmbr beats / min,
1,< nmbr and no moderate or severe deformity ( n = nmbr ),
1,< nmbr . nmbr yrs,
1,< nmbr . nmbr bpm,
1,< nmbr . nmbr ( % ),
1,< nmbr . nmbr %,
1,< nmbr . nmbr,
1,< nmbr - nmbr,
1,< nmbr ( % ),
1,< nmbr %,
1,< nmbr,
1,< = nmbr . nmbr %,
1,< = nmbr %,
1,< = nmbr,
1,< - nmbr . nmbr cm,
1,< - nmbr . nmbr - vfx,
1,< - nmbr . nmbr + vfx,
1,< - nmbr . nmbr,
1,/ nmbr - blockers,
1,/ nmbr - blocker,
1,/ j - valuc ! l,
1,. nmbr,
1,- ° - nmbr  wom -,
1,- nmbr . nmbr ± lno^,
1,- nmbr . nmbr to - nmbr cm,
1,- nmbr . nmbr ( nmbr . nmbr ) * ll,
1,- nmbr . nmbr ( - nmbr . nmbr,
1,- nmbr - nmbr ( - nmbr - nmbrtoo nmbr ),
1,- bi -,
1,* risk reduction  nmbr percent confidence interval ( ci )  and p value are derived from cox models .,
1,* nmbr to < nmbry,
1,( sem ),
1,( ofl ),
1,( nmbr blocker,
1,( nmbr - blockers,
1,( nmbr - blocker,
1,( iqr ),
1,( e - blocker,
1,( cm ),
1,( a blocker,
1,( : > blockers,
1,( % ) nmbr - nmbr,
1,( % ) ( nmbr . nmbr ),
1,( % ) ( nmbr - nmbr ),
1,( % ),
1,( %,
1,(,
1,% phg,
1,% nmbr - nmbr,
1,% fhg,
1,%,
1,$ nmbrand,
1,$ nmbr %,
1,$ nmbr,
1, ‡,
1, ‡,
1, †,
1, †,
1, ¶,
1, §,
1, §,
1, two - sample comparison t - tests were calculated based on log - transformed variables .,
1, signi ﬁ cantly different from baseline values by repeated measures ( analysis of variance )  p nmbr . nmbr .,
1, signi ﬁ cantly different from baseline values by repeated measures ( analysis of variance )  p nmbr . nmbr .,
1, other forms of atherosclerosis are peripheral arterial disease  abdom - inal aortic aneurysm  symptomatic carotid artery disease  transient isch - emic attack  and stroke .,
1, nmbr,
1, n nmbr for ldl cholesterol .,
1, in risk,
1, in risk,
1, for risk reductions  negative numbers indicate an increase in risk . † diabetes and hypertension were defined by clinical history . ‡ a family history was defined as having one or more first - degree relatives with either myocardial infarction or sudden death before the age of nmbr . § hdl cholesterol levels are shown according to the median value ( nmbr . nmbr mg per deciliter [nmbr . nmbr mmol per liter] ) . ¶ triglyceride levels are shown according to the median value ( nmbr mg per deciliter [nmbr . nmbr mmol per liter] ) .,
1, family history of premature chd de ﬁ ned as chd in male ﬁ rst - degree relative aged nmbr years or female ﬁ rst - degree relative nmbr years .,
1, event : no . of patients with esrd  rate : event rate per nmbr years of follow - up  pre - specified : a cox model with treatment group and region as covariates and baseline proteinuria level ( o or xnmbr g / g ) as strata  adjusted : a multivariate cox model with treatment group  time - varying systolic and diastolic bp as covariates .,
1, all patients ( except patients with other race ) were included with missing covariates imputed .,
1, * *,
1, *,
1, ( nmbr % cl : nmbr . nmbr - nmbr . nmbr ),
1,,
